aspirin

Research Excerpts

Overview

Aspirin is an anti-inflammatory drug commonly used as an analgesic and in cardiovascular disorders. Aspirin (ASA) is a proven chemoprotective agent for colorectal cancer, though mechanisms underlying these effects are incompletely understood.

Excerpt	Reference	Relevance
"Aspirin is a common antipyretic, analgesic, and anti-inflammatory drug, which has been reported to extend life in animal models and application in the treatment of aging-related diseases. "	( Characterization of transcriptional landscape in bone marrow-derived mesenchymal stromal cells treated with aspirin by RNA-seq. Da, J; Jin, H; Li, Y; Liu, L; Liu, X; Liu, Z; Wang, J; Xu, W; Zhan, Y; Zhang, B; Zhang, K; Zhang, X, 2022)	2.38
"Aspirin is a cornerstone of preventive treatment for stroke recurrence, but during the last few years the role of dual antiplatelet therapy (DAPT) is much more emerging."	( P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis. Bellesini, M; Galli, E; Maroni, L; Pomero, F; Squizzato, A, 2022)	2.48
"Aspirin is an effective antiplatelet agent for the treatment of carotid atherosclerosis. "	( Dengzhan Shengmai capsule versus Aspirin in the treatment of carotid atherosclerotic plaque: A single-centre, non-inferiority, prospective, randomised controlled trial. Jin, J; Liu, Y; Qu, L; Shen, X; Wu, J; Zou, S, 2022)	2.45
"Aspirin is a common drug for the treatment of pre-eclampsia. "	( Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome. Chen, D; Ding, J; Song, L; Yang, S; Zhang, J; Zhang, Y, 2022)	2.47
"Aspirin is an anti-inflammatory drug commonly used as an analgesic and in cardiovascular disorders. "	( Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer. Bhatia, A; Dahiya, D; Saha, L; Thakur, B, 2023)	2.76
"Aspirin (ASA) is a proven chemoprotective agent for colorectal cancer, though mechanisms underlying these effects are incompletely understood. "	( Genomic and epigenomic responses to aspirin in human colonic organoids. Bielski, MC; Kupfer, SS; Lawrence, KM; Li, J; Mendoza, IN; Usman, H; Witonsky, D, 2023)	2.63
"Aspirin is an essential drug in the prevention of atherosclerotic cardiovascular disease (ASCVD). "	( Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study. Basaran, O; Celik, O; Cil, C; Demirci, E; Dogan, V; Kaya, C; Kırıs, T; Memic Sancar, K; Orscelik, O; Resulzade, MM; Tanık, VO, 2023)	2.68
"Aspirin is a well-known non-steroid anti-inflammatory drug."	( Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner. Hu, LP; Huang, S; Huang, WQ; Ji, J; Jiang, SH; Li, DX; Li, J; Sundquist, J; Sundquist, K; Xing, X; Xu, CJ; Yao, LL; Zhang, NQ; Zhang, XL; Zhang, ZG, 2023)	1.89
"Aspirin is a commonly used antipyretic, analgesic, and anti-inflammatory drug. "	( Aspirin prevents estrogen deficiency-induced bone loss by inhibiting osteoclastogenesis and promoting osteogenesis. Chang, Y; Hu, Y; Kong, K; Li, H; Qiao, H; Tong, Z; Xia, R; Zhai, Z; Zhang, J, 2023)	3.8
"Aspirin is an analgesic and antiapoptotic drug used in combination with morphine as an adjuvant in diabetic neuropathy."	( Aspirin attenuates morphine antinociceptive tolerance in rats with diabetic neuropathy by inhibiting apoptosis in the dorsal root ganglia. Avcı, O; Gunes, H; Gursoy, S; Inan, ZDS; Ozdemir, E; Taskiran, AS, 2023)	3.07
"Aspirin (ASA) is a popular nonsteroidal anti-inflammatory drug (NSAID), which exerts its therapeutic properties through the inhibition of cyclooxygenase (COX) isoform 2 (COX-2), while the inhibition of COX-1 by ASA results in the formation of gastrointestinal side effects. "	( Acetylsalicylic Acid Supplementation Affects the Neurochemical Phenotyping of Porcine Duodenal Neurons. Brzozowska, M; Całka, J, 2023)	2.35
"Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. "	( Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries. Aryal, KK; Atun, R; Azangou-Khyavy, M; Bahendeka, SK; Bärnighausen, T; Brant, LCC; Chung, GS; Cífková, R; Damasceno, A; Davies, JI; Farzadfar, F; Flood, D; Geldsetzer, P; Gurung, MS; Guwatudde, D; Haghshenas, R; Houehanou, C; Huffman, MD; Karki, KB; Lunet, N; Manne-Goehler, J; Marcus, ME; Martins, J; Mwangi, JK; Norov, B; Rohloff, P; Saeedi Moghaddam, S; Sibai, AM; Singh, K; Sturua, L; Sussman, JB; Theilmann, M; Vollmer, S; Yoo, SGK, 2023)	3.8
"Aspirin is a prevalent over-the-counter medicine that has been categorized as an emerging contaminant due to its danger to both living things and the environment. "	( Spent tea waste extract as a green modifying agent of chitosan for aspirin adsorption: Fixed-bed column, modeling and toxicity studies. Nabgan, W; Ngadi, N; Noralidin, NA; Nordin, AH; Nordin, ML; Osman, AY; Shaari, R, 2023)	2.59
"Aspirin is a well-known anti-platelet drug widely used for the prevention of cardiovascular events and systematic reviews suggest a possible benefit of low-dose aspirin (LDA) use in the prevention and treatment of ARDS in patients with COVID-19 infection."	( Low dose aspirin and clinical outcomes in patients with SARS-CoV-2 pneumonia: a propensity score-matched cohort analysis from the National SIMI‑COVID‑19 Registry. Cimellaro, A; Daidone, M; Dalbeni, A; Giontella, A; Pietrangelo, A; Rossi, I; Sesti, G; Susca, N; Talerico, G; Villani, R; Zaccone, V, 2023)	2.05
"Aspirin is a widely used drug throughout the world and recent studies have identified a new function of this drug."	( PPARα Between Aspirin and Plaque Clearance. Chandra, S; Pahan, K; Patel, DR; Roy, A, 2019)	1.6
"Aspirin is a drug that has been found to be useful in reducing the incidence of infarctions. "	( Role of Aspirin in Tuberculous Meningitis: A Systematic Review and Meta-analysis. Garg, RK; Kumar, N; Malhotra, HS; Rizvi, I; Uniyal, R, )	2.01
"Aspirin is a nonsteroidal anti-inflammatory drug that effectively inhibits inflammation and oxidative stress and has been widely used for the treatment of back pain."	( Aspirin-Mediated Attenuation of Intervertebral Disc Degeneration by Ameliorating Reactive Oxygen Species Bai, J; Chen, Z; Geng, D; Guo, X; Lin, J; Liu, Y; Mao, H; Shen, J; Sun, H; Wu, X; Yang, H; Yu, B, 2019)	2.68
"Aspirin is a nonsteroidal anti-inflammatory drug that is very effective in the treatment of inflammation and other health conditions, however, it causes gastric irritation. "	( Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles. Akpa, PA; Attama, AA; Chime, SA; Ugwuanyi, CC, 2020)	2.25
"Aspirin is a widely used drug with anti-coagulating and anti-inflammatory effects on atherosclerotic vascular disease. "	( Differential expression of microRNA and arachidonic acid metabolism in aspirin-treated human cardiac and peri-cardiac fat-derived mesenchymal stem cells. Gao, S; Geng, YJ; King, B; Ruan, DT; Shelat, H, 2020)	2.23
"Aspirin is a widely used medicine for a variety of indications. "	( True or false? Challenges and recent highlights in the development of aspirin prodrugs. Foley, DW; Willetts, S, 2020)	2.23
"Aspirin is a non-steroidal anti-inflammatory drug used to relieve both inflammatory symptoms and pain."	( Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-κB pathway. Duan, L; Jia, Y; Liu, Y; Lu, Y; Nong, L; Tan, A; Zhao, J, 2020)	2.72
"Aspirin is a classic anti-inflammatory drug and its anticancer effect has been previously explored in many types of cancer including colorectal cancer therapy. "	( Aspirin-targeted PD-L1 in lung cancer growth inhibition. Dong, Y; Lv, C; Yang, Q; Zhang, Y, 2020)	3.44
"Aspirin is a chemopreventive agent against several types of cancer."	( Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth. Chiu, HH; Hsieh, CC; Kuo, CH; Wang, CH, 2020)	2.72
"Aspirin is a drug with well-accepted safety profile, and its use and our preliminary observation and outcome of the use of aspirin in VA shunt are promising."	( Should not we be using aspirin in patients with a ventriculoatrial shunt? Borrowing a leaf from other specialities: a case for surrogate evidence. Kumar, S; Udayakumaran, S, 2021)	2.37
"Aspirin is a safe treatment for patients with concurrent small UIAs and ICVD. "	( Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms. Cao, Y; Du, X; Fu, WL; Huo, R; Jiao, YM; Li, H; Wang, J; Wang, S; Weng, JC; Xu, HY; Yan, ZH; Zhao, JZ, 2021)	2.47
"Aspirin is a commonly used medication with anti-inflammatory and analgesic properties, and it is widely used to reduce the risk of ischaemic heart disease-related events and/or cerebrovascular accidents. "	( The multiple effects of aspirin in prostate cancer patients. Bryant, RJ; Joshi, SN; Murphy, EA; Olaniyi, P, 2021)	2.37
"Aspirin is a relatively safe and effective choice for VTE prophylaxis in low-risk patients undergoing THR. "	( Incidence and risk factors associated with venous thromboembolism following primary total hip arthroplasty in low-risk patients when using aspirin for prophylaxis. Clement, ND; Howard, TA; Judd, CS; Lambert, RJ; Snowden, GT, 2022)	2.37
"Aspirin is an old drug extracted from willow bark and is widely used for the prevention and treatment of cardiovascular diseases. "	( Mechanisms of the antiangiogenic effects of aspirin in cancer. Huang, Y; Wang, Y; Xie, S; Yang, B, 2021)	2.33
"The ASPIRIN LAAO study is a prospective, multicentre, randomised, double-blinded, placebo-controlled non-inferiority trial. "	( Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial. Chen, M; Chen, TZ; Li, W; Li, YG; Mo, BF; Sun, J; Tang, X; Wang, Q; Zhang, PP, 2021)	1.4
"Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression. "	( Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. Brennan, CA; Chan, AT; Drew, DA; Gallini Comeau, CA; Garrett, WS; Glickman, JN; Nakatsu, G; Schoen, RE, 2021)	3.51
"Aspirin is a desired leaving group in prodrugs aimed at treatment of neurodegeneration and other conditions. "	( Identification of a potent Nrf2 displacement activator among aspirin-containing prodrugs. Ahuja, M; Ammal Kaidery, N; Gaisin, AM; Gaisina, IN; Gazaryan, IG; Hushpulian, DM; Kazakov, EH; Poloznikov, AA; Thatcher, GRJ; Thomas, B, 2021)	2.31
"Aspirin is a prototypic cyclooxygenase inhibitor with a variety of beneficial effects on human health. "	( Aspirin increases metabolism through germline signalling to extend the lifespan of Caenorhabditis elegans. He, XM; Huang, XB; Luo, HR; Mu, XH; Wan, QL; Wu, GS, 2017)	3.34
"Aspirin is a promising medical therapy for the prevention of intracranial aneurysm (IA) rupture. "	( Sex Differential in 15-Hydroxyprostaglandin Dehydrogenase Levels in the Lumen of Human Intracranial Aneurysms. Chalouhi, N; Hasan, DM; Jabbour, P; Nakagawa, D; Starke, RM; Torner, J; Zanaty, M, 2017)	1.9
"Aspirin is a cornerstone antiplatelet drug that has substantial interpatient variability in pharmacodynamic response and a number of reports have demonstrated that obesity is a risk factor for a reduced aspirin pharmacodynamic response."	( Obesity and Altered Aspirin Pharmacology. Norgard, NB, 2018)	1.53
"Aspirin is a commonly used medicine for primary and secondary prevention of cardiovascular diseases. "	( Aspirin is associated with low oral pH levels and antacid helps to increase oral pH. Dilina, N; Ediriweera, DS; Fernando, D; Fernando, I; Kurera, J; Kurukulasuriya, B; Saparamadu, V, 2018)	3.37
"Aspirin is a cornerstone in the antiplatelet therapy for acute coronary syndromes. "	( Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers. Bartko, J; Hobl, EL; Jilma, B; Kubica, J; Schoergenhofer, C; Schwameis, M; Wadowski, P, 2018)	2.22
"Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA). "	( Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018)	2.34
"Aspirin is a novel chemopreventive agent against malignancy. "	( Aspirin restores ABT-737-mediated apoptosis in human renal carcinoma cells. Chen, CJ; Chen, WY; Kuan, YH; Li, JR; Liao, SL; Lu, HC; Ou, YC; Wang, JD; Yang, CP, 2018)	3.37
"Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. "	( Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. Abhayaratna, WP; Beilin, LJ; Brauer, D; Cloud, G; Donnan, GA; Eaton, CB; Ernst, ME; Fitzgerald, SM; Grimm, R; Jelinek, M; Johnston, CI; Kirpach, B; Lockery, JE; Mahady, SE; Malik, M; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Satterfield, S; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Wood, EM; Woods, RL, 2018)	2.33
"Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established."	( AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II pilot randomised controlled trial. Bland, M; Buckley, H; Chetter, I; Clark, L; Cook, L; Dumville, J; Fenner, C; Forsythe, R; Gabe, R; Harding, K; Hinchliffe, R; Layton, A; Lindsay, E; McDaid, C; Moffatt, C; Rolfe, D; Sbizzera, I; Stansby, G; Tilbrook, H; Torgerson, D; Vowden, P; Williams, L, 2018)	1.66
"Aspirin is a commonly prescribed non steroidal anti-inflammatory drug, but its prolonged use injures the gastric mucosa. "	( Spirulina ameliorates aspirin-induced gastric ulcer in albino mice by alleviating oxidative stress and inflammation. Abd El-Ghffar, EA; Mahmoud, YI, 2019)	2.27
"Aspirin is a widely used platelet inhibitor to prevent thrombotic events. "	( Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort. Binderup, HG; Brasen, CL; Houlind, K; Madsen, JS, 2019)	2.29
"Aspirin is an effective, low cost option to reduce cardiovascular events."	( Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs. Duval, S; Eder, M; Jones, C; Luepker, RV; Misialek, JR; Oldenburg, NC; Van't Hof, JR, 2019)	2.68
"Aspirin is a widely used anti-inflammatory and antithrombotic drug also known in recent years for its promising chemopreventive antineoplastic properties, thought to be mediated in part by its ability to induce apoptotic cell death. "	( Aspirin impairs acetyl-coenzyme A metabolism in redox-compromised yeast cells. Azzopardi, M; Balzan, R; Benes, V; Borg, J; Eisenberg, T; Farrugia, G; Grech, G; Gross, AS; Madeo, F; Pistolic, J; Saliba, C; Vassallo, N, 2019)	3.4
"Aspirin is a widely available pain reliever that is showing promise beyond its known pain-relieving capacity."	( Aspirin up-regulates suppressor of cytokine signaling 3 in glial cells via PPARα. Chakrabarti, S; Dasarathi, S; Pahan, K; Patel, D; Prorok, T; Roy, A, 2019)	2.68
"Aspirin is a salicylate drug that is widely used, and recently it has been shown to influence the development of various types of cancers. "	( Impact of acetylsalicylic acid on tumor angiogenesis and lymphangiogenesis through inhibition of VEGF signaling in a murine sarcoma model. Jia, Q; Wang, Z; Wu, L; Zhang, W; Zhang, X; Zhang, Y, 2013)	1.83
"Aspirin is a non-steroidal anti-inflammatory drug that is an irreversible inhibitor of both cyclooxygenase (COX)-1 and COX-2, It stimulates endogenous production of anti-inflammatory regulatory 'braking signals', including lipoxins, which dampen the inflammatory response and reduce levels of inflammatory biomarkers, including C-reactive protein, tumor necrosis factor-α and interleukin (IL)--6, but not negative immunoregulatory cytokines, such as IL-4 and IL-10."	( Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. Berk, M; Davey, CG; Dean, O; Drexhage, H; Maes, M; McNeil, JJ; Moylan, S; O'Neil, A; Sanna, L, 2013)	2.55
"Aspirin is an effective antiplatelet drug for preventing thrombo-embolic vascular events. "	( Aspirin resistance: Where are we now? Abacı, O; Kılıçkesmez, KO, 2013)	3.28
"Aspirin 1000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 mg or 100 mg."	( Aspirin with or without an antiemetic for acute migraine headaches in adults. Derry, S; Kirthi, V; Moore, RA, 2013)	2.55
"Aspirin is an important antiplatelet agent in the treatment of cardiovascular disease. "	( Cardiovascular prophylaxis and aspirin "allergy". Simon, RA; Woessner, KM, 2013)	2.12
"Aspirin is an antiplatelet agent commonly used in treatment of patients with high risk to develop stroke and myocardial infarction. "	( The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin. Al-Azzam, SI; Al-Azzeh, O; Alzoubi, KH; Khabour, OF; Tawalbeh, D, 2013)	2.03
"Aspirin (ASA) is a non-selective cyclooxygenase (COX) inhibitor that contributes to the treatment of inflammatory conditions such as RA."	( Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells. Chang, HY; Chang, PY; Chen, TL; Cheng, AL; Chuang, SE; Hsieh, MC; Lai, GM; Lee, LM; Yan, KH; Yan, MD; Yao, CJ, 2013)	2.55
"Aspirin is an effective treatment option for these patients."	( Aspirin resistance in systemic lupus erythematosus. A pilot study. Akdogan, A; Akman, U; Bilgen, SA; Buyukasik, Y; Dogan, I; Ertenli, I; Karadag, O; Kilic, L; Kiraz, S, 2013)	2.55
"Aspirin is a cornerstone of therapy in the treatment of patients with acute coronary syndromes (ACS). "	( Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Dinicolantonio, JJ; Norgard, NB, 2013)	1.83
"Aspirin is a safe and effective modality to provide thromboprophylaxis in patients undergoing hip-preservation surgery. "	( Prevention of venous thromboembolic events following femoroacetabular osteoplasty: aspirin is enough for most. Diaz-Ledezma, C; Parvizi, J; Ponzio, DY; Tischler, EH, )	1.8
"Aspirin is a cornerstone in prevention of cardiovascular events and modulates both platelet aggregation and fibrin clot formation. "	( Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. Ajjan, R; Grove, EL; Hess, K; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2013)	2.07
"Aspirin is an essential component of peri-PCI pharmacotherapy. "	( The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. Aronow, HD; Gurm, HS; Kenaan, M; Seth, M; Share, D; Wohns, D, 2013)	2.05
"Aspirin is an antiplatelet drug which is commonly used in secondary prevention in ischemic heart disease and cerebrovascular events, and in newly diagnosed myocardial infarction. "	( Dose-dependent effect of aspirin on the level of sphingolipids in human blood. Baranowski, M; Knapp, M; Knapp, P; Lisowska, A, 2013)	2.14
"Aspirin is a widely used medication for primary and secondary prevention of cardiovascular and cerebrovascular events. "	( The prevalence of gastroduodenal mucosal injuries in aspirin users. Thongbai, T, 2013)	2.08
"Aspirin is a cornerstone in the prevention of ischemic events and guidelines usually recommend a once-daily dosing. "	( [Aspirin: once or twice a day?]. Boehlen, F; Casini, A; Fontana, P; Reny, JL, 2014)	2.76
"Aspirin is an irreversible cyclooxygenase inhibitor anti-inflammatory drug."	( Hydrogen sulfide releasing aspirin, ACS14, attenuates high glucose-induced increased methylglyoxal and oxidative stress in cultured vascular smooth muscle cells. Del Soldato, P; Desai, K; Huang, Q; Sparatore, A; Wu, L, 2014)	1.42
"Aspirin (ASA) is a commonly used nonsteroidal anti-inflammatory drug (NSAID), which exerts its therapeutic effects through inhibition of cyclooxygenase (COX) isoform 2 (COX-2), while the inhibition of COX-1 by ASA leads to apparent side effects. "	( A computational prospect to aspirin side effects: aspirin and COX-1 interaction analysis based on non-synonymous SNPs. Hamzeh, MT; Marjan, MN; Rahman, E; Sadeq, V, 2014)	2.14
"Aspirin is an effective, safe, and inexpensive early treatment of acute myocardial infarction (AMI) with few barriers to administration, even in countries with limited healthcare resources. "	( Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study. Desai, NR; Gao, Y; Hu, S; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Zhang, H, 2014)	2.19
"Aspirin is a non-steroidal anti-inflammatory drug which is currently used as an anticoagulant, antinociceptive, antipyretic, and anti-inflammatory drug."	( Feasibility of clinoptilolite application as a microporous carrier for pH-controlled oral delivery of aspirin. Parsa, MJ; Sharifi, AM; Shetab-Boushehri, SV; Tondar, M; Yousefpour, Y, 2014)	1.34
"Aspirin is a paradigmatic example, as it is used for the primary and secondary prevention of cardiovascular disease and appears to have a beneficial impact on cancer risk."	( Aspirin underuse, non-compliance or cessation: definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease. Abbate, A; Agostoni, P; Biondi-Zoccai, G; Frati, G; Serrano, CV; Wu, Y, 2015)	2.58
"Aspirin is an important part of primary cardiovascular disease prevention, but little is known about aspirin use patterns in regional health care systems. "	( Identifying opportunities to improve aspirin utilization for the primary prevention of cardiovascular disease in a regional health care system. Miller, AW; Rezkalla, H; VanWormer, JJ, 2014)	2.12
"Aspirin is an important drug in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). "	( Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin. Kafkas, NV; Liakos, CI; Mouzarou, AG, 2015)	2.06
"Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke. "	( Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. Cho, KH; Choi, KH; Choi, MJ; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, JS; Lee, SH; Nam, TS; Park, MS, 2015)	3.3
"Aspirin is a potent inhibitor of cyclooxygenase-2 (COX), which plays a critical role in the expression of immune modulators known to contribute to cerebral aneurysm formation and rupture."	( Potential role of aspirin in the prevention of aneurysmal subarachnoid hemorrhage. Chalouhi, N; Ding, D; Hasan, DM; Starke, RM, 2015)	1.47
"Aspirin is a cornerstone in management of coronary artery disease (CAD). "	( Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2015)	2.12
"Aspirin is a promising agent for chemoprevention of lung cancer. "	( Meta-analysis of aspirin use and risk of lung cancer shows notable results. Hochmuth, F; Jochem, M; Schlattmann, P, 2016)	2.22
"Aspirin is an unique compound because it bears two active moieties within one and the same molecule: a reactive acetyl group and the salicylate metabolite. "	( Aspirin and lipid mediators in the cardiovascular system. Rauch, BH; Schrör, K, 2015)	3.3
"Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established."	( Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial. Bland, M; Buckley, H; Chetter, I; Clark, L; Cook, L; Dumville, J; Forsythe, RO; Gabe, R; Harding, K; Hinchliffe, RJ; Layton, A; Lindsay, E; McDaid, C; Moffatt, C; Phillips, C; Rolfe, D; Stansby, G; Tilbrook, H; Torgerson, D; Vowden, P; Williams, L, 2015)	2.58
"Aspirin is a widely used medication and has become a cornerstone for treating cardiovascular disease. "	( Aspirin resistance and other aspirin-related concerns. Cai, G; Chen, P; Fu, Y; Lu, Y; Lu, Z; Zhou, W, 2016)	3.32
"Aspirin use is an effective strategy for the chemoprevention of colorectal cancer, even at low doses. "	( Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial. Botma, A; Habermann, N; Klika, KD; Lampe, JW; Liesenfeld, DB; Popanda, O; Potter, JD; Toth, R; Ulrich, CM; Weigel, C, 2016)	3.32
"Aspirin is a well-known analgesic, anti-inflammatory and antipyretic drug and is recognised as a chemopreventative agent in cardiovascular disease and, more recently, in colorectal cancer. "	( Decreased sensitivity to aspirin is associated with altered polyamine metabolism in human prostate cancer cells. Cameron, GA; Li, J; Wallace, HM, 2016)	2.18
"Aspirin is known to be a salicylate drug widely used as an analgesic, antipyretic and anti-inflammatory drug."	( Sol-gel approach for extracting highly versatile aspirin and its metabolites using MISPE followed by GC-MS/MS analysis. Bhatia, T; Chauhan, A; Gupta, MK; Mudiam, MK; Saxena, PN; Singh, P, 2016)	2.13
"Aspirin is a widely used drug for prevention of thrombotic events in cardiovascular patients, but approximately 25% of patients experience insufficient platelet inhibition due to aspirin, and remain in risk of cardiovascular events. "	( Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. Binderup, HG; Brasen, CL; Houlind, K; Madsen, JS, 2016)	3.32
"The Aspirin-Guide is a clinical decision making support tool (app for mobile devices) with internal risk calculators to help clinicians with this dual assessment by calculating the ASCVD risk and the bleeding risk in the individual patient, and incorporating age- and sex-specific guidance based on randomized trial results."	( Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. Manson, JE; Mora, S, 2016)	2.36
"Aspirin is a key player in the management and prevention of stroke and myocardial infarction in patients with atherothrombosis. "	( A study into the genetic basis of aspirin resistance in Pakistani patients with coronary artery disease. Akhtar, N; Junaid, A; Mohyuddin, A; Mukarram, O, 2016)	2.16
"Aspirin is a commonly used medicine as an effective antipyretic, analgesic and anti-inflammatory drug. "	( Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells. Fan, Y; Li, Y; Liu, B; Sang, HX; Yang, C; Yang, HJ; Zeng, YP, 2016)	3.32
"Aspirin is a commonly used over-the-counter (OTC) agent for the symptomatic treatment of acute pain, fever, or the common cold, but data regarding safety in this context are limited. "	( Gastrointestinal Safety of Aspirin for a High-Dose, Multiple-Day Treatment Regimen: A Meta-Analysis of Three Randomized Controlled Trials. Forder, S; Lanas, A; Voelker, M, 2016)	2.17
"Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts. "	( ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Berkman, L; Cafferty, FH; Cameron, D; Coyle, C; Gilbert, D; Gupta, S; Kynaston, H; Langley, RE; MacKenzie, M; Pramesh, CS; Ring, A; Rowley, S; Wilson, RH, 2016)	1.55
"Aspirin therapy is a unique treatment consideration for patients with AERD."	( Aspirin-Exacerbated Respiratory Disease. Hwang, PH; Walgama, ES, 2017)	2.62
"Aspirin is a very common anti-inflammatory medication to relieve aches and pains."	( Aspirin-Based Carbon Dots, a Good Biocompatibility of Material Applied for Bioimaging and Anti-Inflammation. Bu, W; Chang, B; Gu, Z; Li, C; Lin, C; Shen, Y; Sun, H; Xu, X; Yang, B; Zhang, K; Zhao, L; Zheng, C, 2016)	2.6
"Aspirin is a generally well-tolerated drug that is now widely used in aged patients for its antithrombotic action. "	( Aspirin treatment for chronic wounds: Potential beneficial and inhibitory effects. Darby, IA; Weller, CD, 2017)	3.34
"Aspirin is an effective analgesic and antiplatelet drug that in addition to its ability to reduce pain, inflammation and fever, appears to have efficacy in the prevention/treatment of a range of diseases including heart disease, numerous cancers and Alzheimer's. "	( Bioavailability of aspirin in rats comparing the drug's uptake into gastrointestinal tissue and vascular and lymphatic systems: implications on aspirin's chemopreventive action. Dial, EJ; Edler, S; Fang, D; Li-Geng, T; Lichtenberger, LM; Phan, T; Philip, J, 2016)	2.21
"Aspirin is a safe and effective prophylaxis for the prevention of venous thromboembolism following total joint arthroplasty. "	( Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. Austin, MS; Chen, AF; Hozack, WJ; Huang, R; Lonner, JH; Parvizi, J; Restrepo, C, 2017)	2.31
"NOSH-aspirin is a potent anti-inflammatory, preferentially affecting cancer cells and targets parameters important in determining cellular mass."	( Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents. Kashfi, K, 2015)	0.93
"Aspirin is a common, chronically administered preventive treatment for cardiovascular disease, but is often discontinued prior to invasive dental procedures because of concern for bleeding complications. "	( Aspirin use and post-operative bleeding from dental extractions. Brennan, MT; Fox, PC; Kent, ML; Lockhart, PB; Napeñas, JJ; Noll, JL; Sasser, HC; Valerin, MA, 2008)	3.23
"Aspirin 'resistance' is a widely used term for hyporesponsiveness to aspirin in a platelet function test. "	( Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. Barnard, MR; Fox, ML; Frelinger, AL; Li, Y; Linden, MD; Michelson, AD; Tarnow, I, 2008)	3.23
"Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke. "	( ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Cha, JK; Jeon, HW; Kang, MJ, 2008)	2.02
"Aspirin is a well-known nonsteroidal anti-inflammatory drug (NSAID) that may potentiate some acute allergies and causes adverse immunological reactions collectively referred to as aspirin intolerance. "	( Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca(2+) influx. Inoue, T; Ochiai, T; Ra, C; Suzuki, Y; Terui, T; Togo, K; Yoshimaru, T, 2009)	3.24
"Aspirin alone is a relatively weak antiplatelet agent because it inhibits only one of many paths to platelet activation."	( Variability in responsiveness to oral antiplatelet therapy. Angiolillo, DJ, 2009)	1.07
"Aspirin resistance is an emerging clinical entity. "	( Report: frequency of aspirin resistance in patients with coronory artery disease in Pakistan. Ahmed, W; Akhtar, N; Junaid, A; Khalid, A; Rahman, H; Shah, MA, 2009)	2.11
"Aspirin is an anti-inflammatory drug, and has been widely used for the prevention of cardio-cerebrovascular events. "	( Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages. Jie, X; Keping, Z; Meilin, X; Yiqin, Y, 2009)	3.24
"Aspirin is a unique nonsteroidal anti-inflammatory drug; at high doses (aspirin(high), 1g), it is anti-inflammatory stemming from the inhibition of cyclooxygenase and proinflammatory signaling pathways including NF-kappaB, but is cardioprotective at lower doses (aspirin(low), 75 mg). "	( Effects of low-dose aspirin on acute inflammatory responses in humans. Bellingan, G; Colville-Nash, P; de Souza, P; Gilroy, DW; Hobbs, A; Morris, T; Newson, J; Stables, M; Warner, T, 2009)	2.12
"Aspirin resistance is a transient phenomenon present in the majority of patients undergoing CABG. "	( Postoperative development of aspirin resistance following coronary artery bypass. Anger, K; Dhein, S; Garbade, J; Kempfert, J; Krabbes, S; Lehmann, S; Mohr, FW; Rastan, A; Sauer, M; Walther, T, 2009)	2.09
"Aspirin is an important antithrombotic agent. "	( [Research advances in aspirin resistance]. Si, XY; Zhao, YQ, 2009)	2.11
"Aspirin resistance is a major problem and its incidence and clinical significance in Indian patients with documented coronary artery disease are not known."	( Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. George, P; John, B; Jose, J; Joseph, G; Thomson, VS, )	3.02
"Aspirin 1000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 mg or 100 mg. "	( Aspirin with or without an antiemetic for acute migraine headaches in adults. Derry, S; Kirthi, V; McQuay, HJ; Moore, RA, 2010)	3.25
"Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular diseases. "	( Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan. Horiuchi, H; Ikeda, T; Kawato, M; Kimura, T; Kita, T; Kondo, H; Shirakawa, R; Tabuchi, A; Takahashi, K; Tamura, T; Taniguchi, R; Toma, M; Watanabe, H; Watanabe, S; Yamane, K; Yoshikawa, Y, 2010)	2.06
"Aspirin (ASA) is an effective antiplatelet drug that reduces the risk of myocardial infarction, stroke, or death by approximately 25% in patients who are at increased risk of cardiovascular events. "	( Factors responsible for "aspirin resistance" - can we identify them? Filipiak, KJ; Huczek, Z; Kosior, D; Opolski, G; Postuła, M; Serafin, A; Tarchalska-Kryńska, B, 2010)	2.11
"Aspirin (ASA) is a unique non-steroidal anti-inflammatory drug, which switches AA metabolism from prostaglandin E₂ (PGE₂) and thromboxane B₂ (TXB₂) to lipoxin A₄ (LXA₄) and 15-epi-LXA₄."	( Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites. Basselin, M; Chen, M; Ramadan, E; Rapoport, SI, 2011)	1.36
"Aspirin is a proven antiplatelet agent in acute ischemic stroke, and there are no current guidelines for other antiplatelet treatments. "	( Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011)	1.81
"Aspirin resistance is a transient phenomenon during the early postoperative period in approximately 30% of patients undergoing OPCAB."	( Aspirin resistance in off-pump coronary artery bypass grafting. Gao, F; Men, J; Modi, P; Ren, J; Wang, Z; Wei, M, 2012)	3.26
"Aspirin is a kind of anti-inflammatory drug and may be used to reverse hyperglycemia, hyperinsulinemia, and dyslipidemia by improving insulin resistance. "	( Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats. Han, F; Han, L; Sun, X; Wang, B; Yi, J, 2011)	2.21
"Aspirin is an organic anion and could be a substrate for MRP4."	( Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. Barbarulo, A; Felli, MP; Frati, L; Gaudio, C; Gazzaniga, P; Guerriero, R; Lotti, LV; Mattiello, T; Pucci, B; Pulcinelli, FM; Trifirò, E, 2011)	2.53
"Aspirin is a substrate for MRP4 and can be extruded from platelet through its transportation. "	( Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. Barbarulo, A; Felli, MP; Frati, L; Gaudio, C; Gazzaniga, P; Guerriero, R; Lotti, LV; Mattiello, T; Pucci, B; Pulcinelli, FM; Trifirò, E, 2011)	3.25
"Aspirin is a relatively weak anti platelet agent."	( Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds. Bett, JH; Syed, FA; Walters, DL, 2011)	1.09
"Aspirin is a well-known trigger for anaphylaxis in patients with FDEIA."	( Limited influence of aspirin intake on mast cell activation in patients with food-dependent exercise-induced anaphylaxis: comparison using skin prick and histamine release tests. Fukunaga, A; Horikawa, T; Kikuzawa, A; Nishigori, C; Sekimukai, A; Shimizu, H; Tanaka, M; Tsujimoto, M; Yamashita, J, 2012)	1.42
"Aspirin is a prototypic non-steroidal anti-inflammatory drug, which is now being regarded as a life-saver in variety of atherosclerotic cardiovascular complications."	( Aspirin may do wonders by the induction of immunological self-tolerance against autoimmune atherosclerosis. Ashraf, M; Hussain, M; Javeed, A; Mushtaq, MH; Riaz, A, 2012)	2.54
"Aspirin is an anti-inflammatory drug demonstrated to possess a tremendous anticancer potential. "	( Gender-specific antitumor action of aspirin in a murine model of a T-cell lymphoma bearing host. Bharti, AC; Kumar, A; Singh, SM; Vishvakarma, NK, 2012)	2.1
"Aspirin is a widely used NSAID that has been extensively studied in numerous conditions. "	( Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension-type headache and postoperative dental pain. Fisher, M; Gatoulis, SC; Voelker, M, 2012)	2.07
"Aspirin is an irreversible inhibitor of platelet prostaglandin synthase activity, and is the most widely prescribed drug for the secondary prevention of cardiovascular disease. "	( A contemporary viewpoint on 'aspirin resistance'. Blann, A; Kuzniatsova, N; Lip, GY; Shantsila, E, 2012)	2.11
"Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism. "	( Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Alessi, DR; Din, FV; Dunlop, MG; Green, KA; Houde, VP; Sakamoto, K; Valanciute, A; Zibrova, D, 2012)	3.26
"Aspirin triad is a subclass of chronic sinusitis characterized by nasal polyposis, nonallergic induced asthma, and aspirin sensitivity. "	( Immunomodulatory treatments for aspirin exacerbated respiratory disease. Han, JK; Moebus, RG, )	1.86
"Aspirin is an effective analgesic for acute pain of moderate to severe intensity. "	( Single dose oral aspirin for acute postoperative pain in adults. Derry, S; Moore, RA, 2012)	2.16
"Aspirin is an antiplatelet drug, inhibiting the cyclooxygenase activity of platelet prostaglandin H synthase-1 and almost complete suppressing platelet capacity to generate the prothrombotic and proatherogenic thromboxane A2. "	( Clinical use of aspirin in ischemic heart disease: past, present and future. De Caterina, R; Renda, G, 2012)	2.17
"Aspirin is a cornerstone in secondary cardiovascular prevention and has been thoroughly investigated."	( Pharmacogenetics of the antiplatelet effect of aspirin. Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2012)	1.36
"Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular disease; however, it is known to increase bleeding events. "	( Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. Higashi, T; Horiuchi, H; Ikeda, T; Kawato, M; Kimura, T; Kita, T; Kondo, H; Shirakawa, R; Tabuchi, A; Takahashi, K; Tamura, T; Taniguchi, R; Toma, M; Watanabe, H; Watanabe, S; Yamane, K; Yoshikawa, Y, 2012)	2.02
"Aspirin is a key drug used in treating patients with a high risk to develop stroke, myocardial infarction and other cardiovascular events. "	( The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Al-Azzam, SI; Alowidi, A; Alzoubi, KH; Khabour, O; Tawalbeh, D, 2012)	2.08
"Aspirin acts as an acetylating agent in which its acetyl group is covalently attached to a serine residue (S530) in the active site of the cyclooxygenase-1 enzyme."	( Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. Komáromi, I; Muszbek, L; Tóth, L, 2013)	1.35
"Aspirin (ASA) is an important cause of asthma so that ASA induced asthma (AIA) is considered a disease. "	( [Asthma and aspirin]. Frati, F; Gani, F; Marcucci, F; Schiappoli, M; Senna, G, 2003)	2.14
"Aspirin is an independent risk factor for UGI tract injury, even at the low doses used for cardiovascular prophylaxis."	( Challenges in managing NSAID-associated gastrointestinal tract injury. Goldstein, JL, 2004)	1.04
"Aspirin is an effective antithrombotic agent for many patients. "	( [Aspirin resistance]. Balbay, Y; Korkmaz, S; Yilmaz, MB, 2004)	2.68
"Aspirin is a common antiplatelet drug used in the prevention of ischemic stroke due to its inhibitory effect on platelet cyclooxygenase-1 (Cox-1). "	( Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Hillarp, A; Lethagen, S; Mattiasson, I; Palmqvist, B; Villoutreix, BO, 2003)	2.02
"With aspirin there is a 1.5 fold increase of hemorrhagic stroke and a 2 fold increase of gastrointestinal hemorrhage."	( [Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or vitamins?]. Martin-Du Pan, RC, 2003)	1.02
"Aspirin is a safe, inexpensive, and readily available therapy that is effective for preventing cardiovascular disease, and patients with type 2 DM are particularly likely to benefit from such preventive therapy. "	( Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. Guirguis, LM; Johnson, JA; Klinke, JA; Lee, TK; Lewanczuk, RZ; Majumdar, SR; Toth, EL, 2004)	2.15
"Aspirin is an effective antiplatelet agent with proven benefit in the prevention of atherothrombotic complications of cardiovascular disease. "	( Aspirin resistance: current concepts. Freedman, JE; Jacobs, AK; Mason, PJ, 2004)	3.21
"Aspirin is a very useful medication for the prevention of cardiovascular thrombotic events in patients with or those at risk for cardiovascular disease (CVD). "	( Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Kimmey, MB, 2004)	2.01
"Aspirin is a widely administered, cheap, anti-inflammatory, and antioxidant compound that has a variety of positive effects on the immune system and cardiovascular health."	( Lifelong aspirin supplementation as a means to extending life span. Leeuwenburgh, C; Phillips, T, 2004)	1.46
"Aspirin is a well-established medication in the treatment of atherothrombotic vascular disease. "	( Aspirin resistance in stroke: 2004. Sas, K; Sztriha, LK; Vecsei, L, 2005)	3.21
"Aspirin (ASA) is a widely used oral analgesic which acts as an inhibitor of cyclooxygenase. "	( Effect of aspirin and acetaminophen on proinflammatory cytokine-induced pain behavior in mice. Choi, SS; Kwon, MS; Lee, HK; Lee, JY; Seo, YJ; Shim, EJ; Suh, HW, 2005)	2.17
"Aspirin is an effective and generally accepted treatment drug during the acute stage of ischemic brain infarction. "	( The significance of prestroke aspirin dosage in fatal outcome of acute stroke. Boaz, M; Lampl, Y; Sadeh, M, )	1.86
"Aspirin is an antiplatelet agent that acetylates cyclo-oxygenase and decreases the products of arachidonic acid metabolism, including thromboxane and prostacyclin."	( Effects of clopidogrel and high dose aspirin on survival of skin flaps in rats. Akan, M; Aköz, T; Cakir, B; Misirlioğlu, A; Taylan, G; Yildirim, S, 2005)	1.32
"Aspirin is a popular nonsteroidal anti-inflammatory drug, but some patients suffer from hypersensitivity to it. "	( Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Cheon, MS; Choi, S; Lee, K; Park, HS, )	1.8
"Aspirin resistance is a poorly characterized phenomenon, whereby certain patients do not benefit from the antithrombotic effect of aspirin. "	( Aspirin resistance: an evaluation of current evidence and measurement methods. Martin, CP; Talbert, RL, 2005)	3.21
"Aspirin is a potent antioxidative agent that reduces vascular production of superoxide, prevents angiotensin II-induced hypertension, and induces NO release. "	( Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Ayala, DE; Calvo, C; Fernández, JR; Hermida, RC; López, JE; Mojón, A; Rodríguez, M, 2005)	2.02
"Aspirin is an established therapy for primary and secondary prevention of CVD that may be underutilized in hemodialysis patients."	( Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease. Dempster, DW; DeVita, MV; Michelis, MF; Panagopoulos, G; Rosenstock, JL; Schwimmer, JA, 2005)	1.37
"Aspirin is an aryl ester with a short plasma half life."	( Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Parthasarathy, S; Santanam, N, 2007)	2.5
"Aspirin is an anti-inflammatory drug and a main source of protein acetylation that can alter enzymatic activity and protein functions. "	( Aspirin interaction with ribonuclease A. Neault, JF; Novetta-Dellen, A; Ragi, C; Tajmir-Riahi, HA, 2006)	3.22
"Aspirin is a powerful anti-platelet drug widely used in patients with coronary atherosclerosis, but its side effects and especially its toxicity for gastrointestinal tract limit its usefulness in specific groups of patients. "	( Nitric oxide-releasing aspirin: will it say NO to atherothrombosis? Antoniades, C; Stefanadis, C; Tousoulis, D, 2007)	2.09
"Aspirin was found to be a potent inhibitor of the UPS in some tumour studies; however, its effect on AS remains to be demonstrated in vivo."	( Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis. Huang, W; Li, Y; Pan, H; Tan, C; Tan, X, 2006)	1.06
"Aspirin will continue to be an important therapeutic agent and to generate considerable interest among the research community for the foreseeable future."	( The established and emerging uses of aspirin. Morgan, G, 2006)	1.33
"Aspirin is a mainstay in the prevention of vascular complications of atherosclerosis."	( Effects of aspirin on atherosclerosis and the cyclooxygenase-2 expression in atherosclerotic rabbits. Guo, Y; Jiang, X; Li, FM; Ma, KF; Tang, BS; Wang, L; Wang, QZ; Zuo, YF, 2006)	1.45
"Aspirin is an effective antithrombocyte agent, the efficiency and safety of which has been demonstrated by numerous studies."	( [The modern view on the use of aspirin for the primary prophylaxis of cardiovascular diseases in women]. Arablinskiĭ, AV; Zakharov, OV, 2006)	1.34
"Aspirin therapy is a cornerstone in the prevention of atherothrombotic events, but recurrent vascular events are estimated to occur in 8-18% of patients taking aspirin for secondary prevention after 2 years. "	( Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Colby, E; Dorsch, MP; Dunn, SP; Lee, JS; Lynch, DR; Montague, D; Rodgers, JE; Schwartz, T; Smyth, SS, 2007)	3.23
"Aspirin is a frequently prescribed drug for primary and secondary prevention of myocardial infarction, stroke and cardiovascular death. "	( Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Chen, BL; Fan, L; Ji, W; Lei, HP; Li, Q; Liu, J; Mao, YM; Ozdemir, V; Wang, LC; Zhang, W; Zhou, HH, 2007)	1.99
"Aspirin resistance is a well-documented laboratory finding, but the effects of clinical aspirin (ASA) failure on patients with acute coronary syndrome (ACS) have been debated. "	( Dual antiplatelet agent failure: a new syndrome or clinical nonentity? Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A, 2007)	1.78
"Aspirin is a common preventative therapy in patients at risk for cardiovascular diseases, yet little is known about how aspirin protects the vasculature in hypercholesterolemia. "	( Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. Granger, DN; Specian, RD; Tailor, A; Wallace, JL; Wood, KC, 2007)	1.78
"Aspirin is a less effective alternative, and any benefit of aspirin might be due to its favourable effects on arterial thrombosis caused by vascular disease."	( Atrial fibrillation and stroke prevention. Lim, HS; Lip, GY, 2007)	1.06
"Aspirin is a cornerstone of treatment in cardiovascular disease. "	( Antiplatelet effects of licking an aspirin tablet can be detected by thrombelastography. Curzen, NP; Dawkins, KD; Hobson, AR, 2008)	2.07
"Aspirin is an efficacious drug with increasing therapeutic use."	( Aspirin and allergic diseases: a review. Settipane, GA, 1983)	2.43
"Aspirin is an effective antiinflammatory and analgesic agent. "	( Other NSAIDs of choice for rheumatoid arthritis. Ehrlich, GE, 1984)	1.71
"Aspirin is a known gastric mucosal barrier breaker and it produces a significant increase of the ulcer index in the restraint rat model."	( The effect of 3-methoxy-5,7,3',4'-tetrahydroxyflavan on the restraint induced gastric ulceration augmented by aspirin, a gastric mucosal barrier breaker. Hennings, G; Parmar, NS, 1983)	1.2
"Aspirin, today, is an established drug in the regime for the prevention of myocardial infarction, especially in high-risk groups. "	( The mechanism of action of aspirin--is there anything beyond cyclo-oxygenase? Ghooi, RB; Joshi, PS; Thatte, SM, 1995)	2.03
"Aspirin acts as a potent stimulator of IL-3 through its ability to raise leukotriene production, which induces production of IL-3 both in vitro and in vivo."	( Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. Falach-Vaknin, E; Fishman, P; Meroni, PL; Rudniki, C; Shoenfeld, Y; Sredni, B, 1995)	3.18
"Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients."	( Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. , 1993)	1.01
"Aspirin is a widely used over-the-counter drug in our society which has wide therapeutic value, yet not all of the behavioral side effects have been studied. "	( Aspirin (acetylsalicylic acid) effects on behavioral thermoregulation with microwave radiation. Agnew, AC; DePace, AN; Henderson, ME; Holland, BE; Laconsay, KL; Quinn, JM; Vitulli, WF, 1993)	3.17
"Aspirin (ASA) is an alternative, but there are no controlled trials on its efficacy."	( Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome. Brus, F; Elzenga, NJ; Okken, A; Schasfoort, M; van Acker, KJ; van der Auwera, JC; van Overmeire, B, 1995)	2.46
"Aspirin is a widely used drug for its analgetic, antiinflamatory and antipyretic effects as well as for prophylactic effect in cardiovascular diseases. "	( Aspirin, a silent risk factor in urology. Davidsen, MB; Meyhoff, HH; Zhu, JP, 1995)	3.18
"Aspirin is an approximately 150- to 200-fold more potent inhibitor of the (constitutive) isoform of the platelet enzyme (COX-1) than the (inducible) isoform (COX-2) which is expressed by cytokines, inflammatory stimuli, and some growth factors."	( Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Schrör, K, 1997)	2.46
"Aspirin is a widely used and effective antithrombotic agent. "	( Aspirin therapy for cardiovascular disease. Goodnight, SH, 1996)	3.18
"Aspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. "	( New antiplatelet agents. Ellis, CJ; French, JK; White, HD, 1998)	1.74
"Aspirin therapy is an essential part of the drug regimen for patients with acute myocardial infarction (MI), unstable angina, or after coronary angioplasty and coronary stenting. "	( Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding time. Gantt, AJ; Gantt, S, 1998)	2.03
"Aspirin is a lower-risk alternative to warfarin but is also less effective."	( Antithrombotic therapy for stroke prevention among Medicare beneficiaries hospitalized in Alaska with atrial fibrillation. Gordian, ME; Mustin, HD, )	0.85
"Aspirin is an established treatment for the prevention of cerebrovascular accidents (CVA) in patients with transitory ischemic attacks (TIA) or minor CVA. "	( [Antiaggregant treatment: present and future]. Kase, CS, )	1.57
"Aspirin is a commonly used drug with a wide pharmacological spectrum including antiplatelet, anti-inflammatory, and neuroprotective actions. "	( Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Berkane, N; Blandin, V; Breittmayer, JP; Ferrari, E; Frelin, C; Talbodec, A; Vigne, P, 2000)	3.19
"Aspirin is an effective analgesic for acute pain of moderate to severe intensity with a clear dose-response. "	( Single dose oral aspirin for acute pain. Carroll, D; Collins, SL; Edwards, JE; McQuay, HJ; Moore, RA; Oldman, A; Smith, L; Wiffen, PJ, 2000)	2.09
"Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects."	( The thienopyridines in coronary artery disease. Berger, PB, 1999)	1.02
"Aspirin is a widely used drug and perceived by most physicians to be inexpensive. "	( The real cost of aspirin. Brooks, NH; Burgess, MI; Densem, CG; Lee, HS; Levy, RD, 2000)	2.09
"Aspirin is a platelet inhibitor that works by inhibiting platelet cyclooxygenase, which reduces the production of thromboxane A2. "	( Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Hilleman, DE; Lenz, TL, 2000)	2.02
"Aspirin is a cyclooxygenase (COX) inhibitor."	( Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Jiang, MC; Lee, PH; Liao, CF, 2001)	2.47
"Aspirin is a more potent inhibitor of Cox-1 than of Cox-2, unlike other non-steroidal anti-inflammatory drugs (NSAIDs), which have limited selectivity."	( Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Catella-Lawson, F, 2001)	1.27
"Aspirin is a relatively inexpensive and effective agent for secondary stroke prevention, and lower doses of aspirin appear as effective as higher doses. "	( Antiplatelet agents for secondary prevention of ischemic stroke. Delanty, N; Kantor, J; Majid, A, 2001)	1.75
"'Aspirin resistance' is a poorly defined term to describe the inability of aspirin to protect individuals from thrombotic complications and there are conflicting reports on incidence rates and clinical relevance of this phenomenon. "	( Towards a definition of aspirin resistance: a typological approach. Hohlfeld, T; Przytulski, B; Schanz, A; Schrör, K; Weber, AA, 2002)	1.53
"Aspirin is a potent inhibitor of the platelet release reaction and the accompanying second phase of platelet aggregation. "	( Effect of oral aspirin on "ecto-ATPase" activity of washed human platelets. Davis, JW; Yue, KT, 1978)	2.05
"Aspirin is a promising antithrombogenic agent. "	( Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. Buchanan, MR; Carter, CJ; Hirsh, J; Kelton, JG, 1978)	1.98
"Aspirin therapy is a reasonable alternative for those subjects at relatively lower risk of thromboembolism, especially subjects who are not suitable candidates for anticoagulation."	( Rationale for antithrombotic therapy in atrial fibrillation. Kelley, RE, 1992)	1
"Aspirin is a regulator of TXB2 synthesis by inhibition of cyclooxygenase; ouabain and nifedipine are regulators of [Ca++]i."	( The relationship between thromboxane and cytosolic calcium modifiers in rat platelets. Dupont, J; Krumhardt, B, 1991)	1
"Aspirin is a safe and inexpensive agent for prevention of HO after THA."	( The use of aspirin to prevent heterotopic ossification after total hip arthroplasty. A preliminary report. Cantor, R; Freiberg, AA; Freiberg, RA, 1991)	1.39
"Aspirin, which is an effective anti-platelet agent, given in the low dosage of 60 to 100 mg per day appears to be beneficial for patients with a history of unstable angina, myocardial infarction, transient ischaemic attacks and stroke."	( Aspirin and coronary heart disease. Clinical applications. Koutts, J, 1990)	3.16
"Thus aspirin is a potent agent in preventing rethrombosis after thrombolytic recanalization of prosthetic grafts."	( Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator. Bush, HL; Curl, GR; Deykin, D; Jakubowski, JA, 1986)	1.05
"Aspirin is an important drug in the treatment of numerous disorders, especially rheumatic diseases. "	( Alteration of uptake and distribution of eicosanoid precursor fatty acids by aspirin. Alvarez, J; Bomalaski, JS; Touchstone, J; Zurier, RB, 1987)	1.94
"Aspirin is an inhibitor of prostaglandin H synthase and has been shown to inhibit FANFT-induced bladder carcinogenesis when coadministered in the diet."	( Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cohen, SM; Hasegawa, R; Johansson, SL; Sakata, T; Zenser, TV, 1986)	1.35
"Aspirin is a possible cofactor with influenza B virus in Reye's syndrome. "	( Influenza B virus model of Reye's syndrome in mice: the effect of aspirin. Davis, LE; Green, CL; Wallace, JM, 1985)	1.95

Effects

Aspirin has a significant effect on hemostasis, so it is often recommended that patients taking aspirin discontinue treatment before elective surgery. Aspirin plus ER-DP has a greater bleeding rate than clopidogrel.

Aspirin resistance has been shown to be a significant risk factor for recurrent cardiovascular ischaemic events. Aspirin therapy has modest efficacy in reducing stroke risk, but is much less effective than warfarin.

Excerpt	Reference	Relevance
"Aspirin counseling has a lower health impact (2,200 QALYs) but is found to be cost saving ($31 saved per person)."	( Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017)	1.39
"Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making."	( Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018)	1.44
"Aspirin sensitivity has a highly significant association with AFRS."	( Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018)	1.52
"Aspirin has a protective role against endothelial dysfunction and atherosclerosis, whease all non-steroidal anti-inflammatory drugs (NSAIDs) are known for their anti-inflammatory properties."	( Association between use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs and erectile dysfunction: A systematic review. Fu, F; Li, T; Qin, F; Wei, Q; Wu, C; Yuan, J, 2018)	1.5
"Aspirin has a well-established history of safety and efficacy in management of secondary cardiovascular protection in ischemic heart disease patients. "	( Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review. Bhupathi, V; Shanker, A, 2019)	1.96
"Aspirin probably has a preventive effect on metastasis."	( [Aspirin and cancer: evidence of a prophylactic effect]. Algra, AM; Nortier, JW, 2013)	2.02
"Aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease. "	( Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events. Bavry, AA; Park, K, 2013)	3.28
"Aspirin has a range of antineoplastic properties linked to inhibition of cyclooxygenase enzymes in tumor cells, platelet inhibition and to inhibition of angiogenesis. "	( Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Holmes, CE; Jasielec, J; Levis, JE; Muss, HB; Skelly, J, 2013)	2.19
"Aspirin has a proven role in preventing thrombotic diseases. "	( Does Early Post-operative Administration of Aspirin Influence the Risk of Bleeding After Coronary Artery Bypass Graft Surgery? A Prospective Observational Study. Emami Zeydi, A; Gholipour Baradari, A; Nouraei, SM, 2015)	2.12
"Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events. "	( Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016)	2.08
"Aspirin has a clear anti-inflammatory effect and is used as an anti-inflammatory agent for both acute and long-term inflammation. "	( Aspirin Protects against Acinar Cells Necrosis in Severe Acute Pancreatitis in Mice. Ding, Y; Gao, L; Li, W; Liu, G; Liu, J; Lu, G; Pan, Y; Tong, Z; Tu, J; Wang, Y, 2016)	3.32
"Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone."	( Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009)	1.07
": Aspirin has a distinct depressant effect on human Ishikawa adenocarcinoma endometrium cell growth, and its effect may be realized by lowering Bcl-xl proteinum expression."	( Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. Hongwei, L; Shu, L; Xiaoxin, M; Yanxia, L; Yingnan, J; Yuanqi, H, 2009)	1.33
"Aspirin has an antithrombotic action at low dose and anti-ischemic and anti-inflammatory properties, which are dose-related."	( The role of aspirin in childhood tuberculous meningitis. Janse van Rensburg, A; Laubscher, JA; Schoeman, JF; Springer, P, 2011)	1.47
"Aspirin has a beneficial role in prevention of cardiovascular and thromboembolic events. "	( High frequency of aspirin resistance in patients with nephrotic syndrome. Agbaht, K; Akoglu, H; Dede, F; Falay, MY; Odabas, AR; Ozet, G; Piskinpasa, S, 2012)	2.16
"Aspirin has a central role in preventing thromboembolic complications in atherosclerotic conditions."	( [The effect of platelet transfusion on traumatic intracranial hemorrhage among patients treated with aspirin]. Bental, O; Cohen, ZR; Jonas-Kimchi, T; Margalit, N; Patal, R; Ram, Z; Roth, J, 2012)	1.32
"Aspirin has a role in the prevention of cardiovascular and cerebrovascular disease, Alzheimer's dementia and several cancers. "	( Review article: the ageing bowel and intolerance to aspirin. Johns, CE; May, FE; Newton, JL, 2004)	2.02
"Aspirin treatment has an undoubted beneficial impact on the progression of cardiovascular diseases. "	( Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Grotz, W; Olschewski, M; Peter, K; Siebig, S; Strey, CW, 2004)	2.18
"Aspirin has a significant effect on hemostasis, so it is often recommended that patients taking aspirin discontinue treatment before elective surgery. "	( Duration of increased bleeding tendency after cessation of aspirin therapy. Cahill, MR; Cahill, RA; Crowe, BH; Manning, BJ; McGreal, GT; Redmond, HP; Ryan, DA, 2005)	2.01
"Aspirin has a direct impact in the LX circuit by triggering the biosynthesis of endogenous epimers of LX, termed the aspirin-triggered 15-epi-LX, that share the potent anti-inflammatory actions of LX."	( Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Serhan, CN, )	1.22
"Oral aspirin has a repertoire of gastrointestinal side effects even at low doses and requires high frequent dosing because it undergoes extensive presystemic metabolism."	( Design of a transdermal delivery system for aspirin as an antithrombotic drug. Ammar, HO; El-Nahhas, SA; Ghorab, M; Kamel, R, 2006)	1.05
"Aspirin has a similar effect upon the endothelial cyclo-oxygenase, but in contrast to that of the platelet, it is less sensitive and has the capacity to generate new cyclo-oxygenase activity if aspirin is removed from the system."	( Mechanisms of action: aspirin. Hoak, JC, 1983)	1.3
"Aspirin has an established benefit in reducing the incidence of coronary events and vein graft occlusion. "	( Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. Bevan, DH; Cowans, D; Kallis, P; Talbot, S; Tooze, JA; Treasure, T, 1994)	2.09
"Aspirin has a well established role in the prevention of arterial thrombosis. "	( Aspirin in essential thrombocythemia: status quo and quo vadis. Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997)	3.18
"Aspirin has a modest effect on reducing stroke (about 20% risk reduction)."	( Prevention of stroke in patients with nonvalvular atrial fibrillation. Cairns, JA; Easton, JD; Hart, RG; Sherman, DG, 1998)	1.02
"Aspirin has a role in secondary prevention of coronary artery disease; among patients who are allergic to or intolerant of aspirin, ticlopidine has a role in patients with unstable angina and clopidogrel has a potential role in patients with ischemic heart or vascular disease."	( Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. Tisdale, JE, 1998)	1.02
"Aspirin has a modest effect on reducing stroke."	( [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation]. Kitabatake, A; Kohya, T; Tomita, F, 2000)	1.03
"Aspirin (400 ppm) has a similar impact on reducing prostaglandin levels, but in contrast to indomethacin, is uneffective in reducing the tumor load."	( Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. Chiu, CH; McEntee, MF; Whelan, J, 2000)	1.35
"Aspirin has a marked effect on the positive staining pattern of scleral collagen."	( Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking. Hadley, J; Malik, N; Meek, K, 2001)	1.28
"Aspirin has a well established role in the prevention of arterial thrombosis. "	( Time related neutralization of two doses acetyl salicylic acid. Aguejouf, O; Belon, P; Doutremepuich, C; Malfatti, E, 2000)	1.75
"Aspirin has an anticoagulant effect due to its action on Cyclo-oxygenase and vitamin K dependent coagulation factors."	( Fetal intracranial hemorrhage due to antenatal low dose aspirin intake. Kutty, PM; Sajith, N; Sasidharan, CK, 2001)	1.28
"Aspirin has an essential place formally demonstrated in ISIS 2."	( [Fibrinolysis in myocardial infarction with EKG elevation. Optimization of myocardial reperfusion by treatment with antithrombotic agents]. Coste, P; Jaïs, C; Labèque, JN; Lafitte, S; Perron, JM; Roudaut, R; Zabsonré, P, 2001)	1.03
"Aspirin also has an antiplatelet effect."	( The bleeding time effects of a single dose of aspirin in subjects receiving omega-3 fatty acid dietary supplementation. Mueller, BA; Prihoda, TJ; Talbert, RL; Tegeler, CH, 1991)	1.26
"Aspirin has a membrane-stabilizing effect and it is used locally for the treatment of post- herpetic neuralgia."	( [Remarks on some analgesics used in the pain clinic]. Yamamura, H, 1989)	1
"Aspirin has a similar effect in vivo on both atrophic cartilage and osteoarthritic cartilage in the dog, although no in vivo effect of salicylate on normal joint cartilage has been observed."	( Nonsteroidal antiinflammatory drugs and articular cartilage. Brandt, KD, 1987)	0.99
"Aspirin has been suggested as a potential therapeutic strategy to prevent the growth and rupture of unruptured intracranial aneurysms (UIAs), but there is still controversy. "	( Aspirin and growth, rupture of unruptured intracranial aneurysms: A systematic review and meta-analysis. Guo, XM; Guo, Y; Yang, MF; Zhao, K, 2021)	3.51
"Aspirin use has been shown to be associated with reduced risk of aggressive prostate cancer, although the mechanisms are not fully understood."	( Aspirin use and prostate tumor angiogenesis. Clinton, SK; Fu, BC; Giovannucci, EL; Mucci, LA; Wang, K, 2022)	3.61
"Aspirin has known effects beyond inhibiting platelet cyclooxygenase-1 (COX-1) that have been incompletely characterized. "	( Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. Dave, S; Ginsburg, GS; Myers, RA; Ortel, TL; Voora, D; Waldrop, A, 2022)	3.61
"Aspirin and curcumin have been reported to be beneficial to anti-aging in a variety of biological models. "	( Curcumin Acetylsalicylate Extends the Lifespan of Bu, LL; Cheng, SW; Liao, DF; Liu, J; Zheng, XL; Zhou, L, 2021)	2.06
"Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. "	( Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. , 2022)	3.61
"Aspirin has become the main agent for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA). "	( Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty. Chisari, E; Ludwick, L; Parvizi, J; Shohat, N; Sutton, R, 2022)	3.61
"Aspirin has anti-inflammatory and antiplatelet activities and directly inhibits bacterial growth. "	( Association Between Aspirin Use and Sepsis Outcomes: A National Cohort Study. Chang, IJ; Dao, QL; Hsu, TC; Hsu, WT; Lee, CC; Porta, L; Tehrani, BM, 2022)	2.49
"Aspirin has protective effects on people with chronic liver disease (OR, 0.46; 95% CI: 0.31-0.67) and on the general population (OR, 0.65; 95% CI: 0.54-0.79)."	( Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis. Dang, S; Liu, C; Shi, J; Wang, M; Wang, W; Wang, Y, 2022)	2.89
"Aspirin intake has been shown to lead to significant protection against colorectal cancer, for example with an up to twofold reduction in colorectal adenoma incidence rates at higher doses. "	( Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study. Boland, CR; Goel, A; Komarova, NL; Wang, Y; Wodarz, D, 2022)	3.61
"Aspirin has been found to induce reprogramming factors of mesenchymal-to-epithelial transition in breast cancer cells."	( A novel role for aspirin in enhancing the reprogramming function of miR-302/367 cluster and breast tumor suppression. Ardekani, AM; Eghtedari, A; Javeri, A; Rezania, MA; Taha, MF, 2022)	1.78
"Aspirin has been reported to promote apoptosis, inhibit proliferation, stemness, angiogenesis, cancer-associated inflammation and migration in NSCLC."	( Aspirin blocks AMPK/SIRT3-mediated glycolysis to inhibit NSCLC cell proliferation. Li, G; Ma, Y; Ren, G; Wang, X; Zheng, Z, 2022)	2.89
"Aspirin has been shown in numerous studies to affect bone metabolism."	( Low dose aspirin associated with greater bone mineral density in older adults. Liu, H; Shi, Q; Tang, X; Tian, Y; Xiao, X, 2022)	1.86
"Aspirin has been shown to prevent the onset of colorectal adenoma and cancer. "	( Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake. Goto, C; Ishikawa, H; Itoh, Y; Matsuda, T; Mutoh, M; Otani, T; Sano, Y; Suzuki, S; Takeuchi, Y; Yoshida, N, 2022)	3.61
"Aspirin has been shown to prevent the onset of colorectal adenoma and cancer, and its effect modifications have been analyzed. "	( Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake. Goto, C; Ishikawa, H; Itoh, Y; Matsuda, T; Mutoh, M; Otani, T; Sano, Y; Suzuki, S; Takeuchi, Y; Yoshida, N, 2022)	3.61
"Aspirin has recently been attracting attention as a cancer preventive drug, and its inhibitory effects on the development of various cancers have been reported in several large prospective studies."	( Salicylic acid directly binds to ribosomal protein S3 and suppresses CDK4 expression in colorectal cancer cells. Aono, Y; Horinaka, M; Iizumi, Y; Imai, A; Ishikawa, H; Mutoh, M; Nishimoto, E; Ono, H; Sakai, T; Takakura, H; Taniguchi, K; Yasuda, S, 2022)	1.44
"Aspirin has been suggested to reduce the risk of cancer. "	( Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis. Bentley, R; Feng, L; Gao, J; Jiang, Y; Kim, NH; Li, N; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Q; Zhu, Y, 2023)	2.87
"Aspirin has been reported to reduce bone fragility and slow bone loss."	( Daily Low-Dose Aspirin and Risk of Serious Falls and Fractures in Healthy Older People: A Substudy of the ASPREE Randomized Clinical Trial. Barker, AL; Cumming, RG; Ebeling, PR; Hussain, SM; Khosla, S; McNeil, JJ; Morello, R; Newman, AB; Pasco, JA; Ronaldson, K; Sanders, KM; Seeman, E; Thao, LTP; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2022)	1.8
"Aspirin has been shown to be effective at reducing rates of VTE."	( Aspirin Thromboprophylaxis Following Primary Total Knee Arthroplasty Is Associated With a Lower Rate of Early Prosthetic Joint Infection Compared With Other Agents. Aggarwal, VK; Anil, U; Kirschner, N; Long, WJ; Lygrisse, KA; Schwarzkopf, R; Sicat, CS; Teo, GM, 2023)	3.07
"Aspirin use has been associated with reduced ovarian cancer risk, yet the underlying biological mechanisms are not fully understood. "	( Associations between prediagnostic aspirin use and ovarian tumor gene expression. Cleveland, JL; Conejo-Garcia, J; Fridley, BL; Hecht, JL; Sasamoto, N; Stewart, PA; Terry, KL; Thompson, ZJ; Tworoger, SS; Wang, T; Yoder, SJ, 2023)	2.63
"Aspirin has been demonstrated to have a clear benefit in secondary prevention of cardiovascular disease, but recent primary prevention trials have at best demonstrated a small benefit. "	( Aspirin and lipoprotein(a) in primary prevention. Bhatia, HS, 2023)	3.8
"Aspirin has been reported to have neuroprotective effects and may be effective against neurodegenerative diseases."	( Multi-omics reveals aspirin eugenol ester alleviates neurological disease. Bai, LX; Ge, BW; Li, JY; Li, SH; Liu, XW; Lu, XR; Qin, Z; Tao, Q; Yang, YJ; Zhang, ZD, 2023)	1.96
"Aspirin has also been associated with decreased VS growth in animal studies."	( Metformin Reduces Tumor Growth in a Murine Flank Schwannoma Model. Burns, A; Hartman, Y; Hunter, JB; Killeen, DE; Lora Gonzalez, MA; Manickavel, S; Walsh, E; Warram, J, 2023)	1.63
"Aspirin has been suggested to reduce the risk of cancer. "	( Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies. Feng, L; Gao, J; Guo, X; Jiang, Y; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Z, 2023)	2.76
"Aspirin (ASP), which has the activity of anti-metastasis and enhancing T cells infiltration in tumors, is encapsulated into the HS-DTX micelle."	( In Vivo Environment-Adaptive Nanocomplex with Tumor Cell-Specific Cytotoxicity Enhances T Cells Infiltration and Improves Cancer Therapy. Cheng, H; Huang, X; Lang, T; Li, Y; Liu, Y; Wang, G; Yin, Q; Zheng, Z, 2019)	1.24
"Aspirin, in 2017, has celebrated its 120th birthday. "	( Aspirin in primary prevention: the triumph of clinical judgement over complex equations. Santilli, F; Simeone, P, 2019)	3.4
"Aspirin has been commonly used for the primary and secondary prevention of ASCVD for decades and is an easily accessible therapeutic option."	( Aspirin for the Primary Prevention of Cardiovascular Disease: A Review of the Literature and Considerations for Clinical Practice. Cicci, JD; Clarke, MM; Iyer, P; Mazzella, AJ, )	2.3
"Aspirin has been the cornerstone of antiplatelet therapy in patients with acute coronary syndromes and is well accepted and recommended by several major healthcare organizations. "	( Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome. Magrum, BG; Pickworth, KK, 2020)	3.44
"Aspirin use has been associated with reduced risk of cancer mortality, particularly of the colorectum. "	( Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cao, Y; Chan, AT; Loomans-Kropp, HA; Pinsky, P; Umar, A, 2019)	2.31
"Aspirin has been demonstrated to promote osteoblast-mediated bone formation and inhibit osteoclast (OC)-mediated bone resorption. "	( Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation. Bai, Y; Du, J; Guo, L; Jia, L; Jiang, Y; Liu, Y; Luo, Z; Wu, L, 2019)	3.4
"Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis."	( Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. Afshar, Y; Bromley, B; Caughey, AB; Chescheir, N; Copel, JA; Grechukhina, O; Grobman, W; Han, CS; Hobbins, JC; Mallampati, D; Nicolaides, K; Pettker, C; Platt, LD; Saade, G; Sibai, B; Simhan, H; Sonek, J; Werner, E, 2020)	1.28
"Aspirin has been found to lower the occurrence rates of some cancers through the inhibition of the cyclooxygenase enzyme. "	( Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. Hsu, CY; Hsu, RJ; Hsu, WL; Huang, SY; Liao, YH; Liu, DW; Su, YC; Wang, TH; Wu, CT, 2020)	3.44
"Aspirin therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. "	( Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. Choi, DH; Kim, JH; Kim, TS; Lee, HW; Lee, M; Lee, SH; Lee, W; Park, MS; Park, S; Shin, S, 2020)	3.44
"Aspirin has been widely prescribed over the last several decades as part of primary CAD prevention strategy."	( Aspirin for Primary Prevention of Coronary Artery Disease. Aronow, WS; Bandyopadhyay, D; Deedwania, P; Ghosh, RK; Gupta, M; Jain, V; Kapadia, S; Lavie, CJ; Qamar, A; Ujjawal, A, 2021)	2.79
"Aspirin has been associated with a reduced risk of colorectal cancer, and possibly of a few other digestive tract cancers. "	( Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Bosetti, C; Gallus, S; La Vecchia, C; Martinetti, M; Santucci, C, 2020)	3.44
"Aspirin therapy has been associated with reduced risk of colon cancer, but there is only limited evidence for its effects on risk of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). "	( Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection. Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS, 2020)	2.32
"Aspirin has long had a role in the primary prevention of atherosclerotic cardiovascular disease (ASCVD); however, recent randomized controlled trials (RCTs) have challenged this practice. "	( Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis. Cooper, J; Foy, AJ; Ghahramani, M; Mandrola, J; Nudy, M; Ruzieh, M, 2020)	3.44
"Aspirin has demonstrated a clear benefit in secondary prevention of coronary syndrome, while aspirin's effect in primary prevention is unclear. "	( Aspirin in Primary Prevention of Cardiovascular Events. Rezkalla, SH; Soodi, D; VanWormer, JJ, 2020)	3.44
"Aspirin has been used in the management of postpartum perineal pain, and its effectiveness and safety should be assessed."	( Aspirin (single dose) for perineal pain in the early postpartum period. Grivell, RM; Shepherd, E, 2020)	2.72
"Aspirin has been shown to decrease cancer incidence and improve outcomes in various malignancies."	( Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Fang, B; He, Y; Heymach, JV; Hong, L; Hubert, SM; Jack Lee, J; Le, X; Lewis, J; Liu, X; Nilsson, M; Rinsurongkawong, W; Roth, J; Spelman, A; Swisher, S; Wu, S; Zhang, J, 2020)	1.61
"Aspirin has been associated with a reduced risk of colorectal and other selected digestive tract cancers, but the evidence for other neoplasms is still controversial. "	( Aspirin and the risk of nondigestive tract cancers: An updated meta-analysis to 2019. Bosetti, C; Gallus, S; La Vecchia, C; Martinetti, M; Santucci, C, 2021)	3.51
"Aspirin use has been suggested to reduce cancer risk. "	( Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis. Li, X; Liu, L; Yu, Y, 2021)	2.43
"Aspirin has emerged as a promising intervention in cancer in the past decade. "	( Current Studies of Aspirin as an Anticancer Agent and Strategies to Strengthen its Therapeutic Application in Cancer. Lee, BJ; Tran, PHL; Tran, TTD, 2021)	2.39
"Aspirin has been the mainstay of both secondary and primary prevention of cardiovascular disease for half a century. "	( Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. Dasa, O; Pearson, TA; Pepine, CJ, 2021)	3.51
"Aspirin (ASA) has attracted wide interest of numerous scientists worldwide thanks to its chemopreventive and chemotherapeutic effects, particularly in colorectal cancer (CRC). "	( New Formulation of a Methylseleno-Aspirin Analog with Anticancer Activity towards Colon Cancer. Aydillo, C; Encío, I; González-Gaitano, G; Plano, D; Ruberte, AC; Sanmartín, C; Sharma, AK, 2020)	2.28
"Aspirin has been associated with a decreasing risk of subarachnoid hemorrhage due to its anti-inflammatory mechanism of action and potential protective properties against aneurysm growth."	( Relationship between aspirin use and subarachnoid hemorrhage: A systematic Review and meta-analysis. Florez, WA; García-Ballestas, E; Joaquim, A; Maeda, F; Martinez-Perez, R; Moscote-Salazar, LR; Pavlov, O; Tsimpas, A, 2021)	2.38
"Aspirin has long been an inexpensive cornerstone of arterial vascular disease therapy, but its role in the primary or secondary prophylaxis of VTE has been debated."	( Does aspirin prevent venous thromboembolism? Diep, R; Garcia, D, 2020)	1.79
"Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)."	( Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021)	2.58
"Aspirin has demonstrated safety and efficacy for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA); however, inconsistent dose regimens have been reported in the literature. "	( Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. Cao, SL; Feng, B; Li, Z; Luo, T; Ren, Y; Weng, XS, 2021)	2.35
"Aspirin has become a new focus of cancer prevention and treatment research so far; clinical studies, however, found conflicting conclusions of its anti-cancer characteristics."	( Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. Bhan, C; Cao, C; Cheng, C; Guo, Z; Han, T; Ji, Z; Ma, S; Qu, G; Sun, C; Yan, Y; Yang, H; Zhang, H; Zhou, Q, 2021)	1.86
"Aspirin (ASA) has historically been one of the most important drugs in cardiology and has long been the cornerstone of antiplatelet therapy. "	( Overview of Aspirin and Platelet Biology. Badimon, J; Santos-Gallego, CG, 2021)	2.44
"Aspirin has shown life-extending effects in numerous model organisms."	( Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence. Bubalo, V; Kindrat, I; Koliada, A; Lushchak, O; Piskovatska, V; Stefanyshyn, N; Storey, KB; Strilbytska, O; Vaiserman, A, 2021)	2.79
"Aspirin has become a new focus of cancer prevention and treatment research at present, however, clinical studies found conflicting conclusions of its anticancer characteristics."	( Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019. Guo, C; Han, T; Jiang, Y; Ma, S; Qu, G; Sun, C; Sun, Y; Zhang, H; Zhou, Q, 2021)	2.79
"Aspirin has anti-inflammatory effects, antiplatelet aggregation, anticoagulant properties as well as pleiotropic effects on endothelial function."	( Rationales and uncertainties for aspirin use in COVID-19: a narrative review. Aiash, H; Amin, H; Darling, E; Goweda, RA; Habeb, H; Ismail, M; Joudeh, AI; Merrell, E; Nieman, GF; Riley, JB; Sayed Ahmed, HA; Shawkat, A; Shehata, MH, 2021)	1.62
"Aspirin has long been recommended to reduce cardiovascular events."	( Low-dose aspirin for primary prevention of cardiovascular disease: Trends in use patterns among African American adults in Minnesota, 2015-2019. Duval, S; Eder, MM; Finnegan, JR; Jones, C; Luepker, RV; Misialek, JR; Oldenburg, NC; Van't Hof, JR, 2021)	1.76
"Aspirin has traditionally been used as an analgesic and anti-inflammatory drug; however, low-dose aspirin is known to increase the risk of gastrointestinal and intracranial hemorrhage. "	( Big Data Analysis of the Risk of Intracranial Hemorrhage in Korean Populations Taking Low-Dose Aspirin. Kim, TG; Yu, S, 2021)	2.28
"Aspirin and statins have been suggested to prevent hepatocellular carcinoma (HCC). "	( Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Choi, SH; Choi, WM; Han, S; Jo, AJ; Kim, HJ; Ko, MJ; Lim, YS, 2021)	2.42
"Aspirin has been the mainstay of prophylactic anticoagulation for shunt-dependent patients with several reports of prevalent aspirin resistance, especially in neonates."	( Aspirin resistance in infants with shunt-dependent congenital heart disease. Cooper, DS; Henry, B; Koh, W; Nebbia, A; Rodts, M; Sawyer, J, 2022)	2.89
"Aspirin counseling has a lower health impact (2,200 QALYs) but is found to be cost saving ($31 saved per person)."	( Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017)	1.39
"Aspirin has antipyretic and anti-inflammatory properties and is frequently used by pregnant and lactating women. "	( Transfer of Low Dose Aspirin Into Human Milk. Baker, T; Datta, P; Hale, TW; Kallem, RR; Rewers-Felkins, K, 2017)	2.22
"Aspirin has been shown to have many health benefits since its discovery as a nonsteroidal anti-inflammatory drug (NSAID) to treat pain and inflammation."	( Metabolome analysis of effect of aspirin on Drosophila lifespan extension. Fan, X; Gao, Y; Gaur, U; Qi, J; Song, C; Wu, Q; Yang, D; Yang, M; Zhang, Z; Zhu, C, 2017)	1.46
"Aspirin has been implicated in the postoperative management of moyamoya disease (MMD) in order to avoid bypass failure and decrease the incidence of subsequent stroke. "	( Effect of Aspirin in Postoperative Management of Adult Ischemic Moyamoya Disease. Zhang, D; Zhang, Q; Zhao, Y, 2017)	2.3
"Aspirin has been shown to trigger the synthesis of specialized pro-resolving lipid mediators from arachidonic acid and omega-3 fatty acids."	( Aspirin and blood pressure: Effects when used alone or in combination with antihypertensive drugs. Albino-Teixeira, A; Costa, AC; Reina-Couto, M; Sousa, T, )	2.3
"Aspirin has been the mainstay for secondary prevention of coronary artery disease to decrease early recurrence and severity of recurrent cardiovascular events. "	( Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease. Haseeb, S; Kagolanu, D; Lam, P; Munnangi, S; Sayedy, N; Shah, S; Stephenson, K; Viswanathan, P, 2017)	1.9
"Aspirin has been confirmed as an effective antitumor drug in various cancers. "	( Aspirin inhibits the proliferation of human uterine leiomyoma cells by downregulation of K‑Ras‑p110α interaction. Cai, JR; Gao, M; Guo, KM; Ma, MM; Wei, YM; Xia, TT; Ye, QJ, 2017)	3.34
"Aspirin has been widely used as an antipyretic analgesic drug. "	( The anti-tumor effect of aspirin: What we know and what we expect. Cai, Z; Liu, X; Ma, J; Wei, H; Zhang, T; Zhao, Q, 2017)	2.2
"Aspirin has been reported to modulate heat shock response in different organisms through increased induction of HSPs and is also known to exert antioxidative and radical scavenging effects in diabetes."	( Physiological and pharmacological inductors of HSP70 enhance the antioxidative defense mechanisms of the liver and pancreas in diabetic rats. Cipanovska, N; Dervisevik, M; Dimitrovska, M; Dinevska-Kjovkarovska, S; Gerazova, K; Miova, B, 2018)	1.2
"Aspirin has been shown to minimise gentamicin-induced ototoxicity."	( COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Abab, J; Bayne, M; Chester, J; Crabb, SJ; Davies, J; Ellis, M; Galanopoulou, A; Geldart, T; Hartley, A; Huddart, R; Joffe, JK; King, E; Lamb, C; Lineton, B; Maishman, T; Martin, K; Moody, R; Nutting, C; Ottensmeier, C; Popat, S; Ratcliffe, I; Stanton, L; Thomas, G; Thornton, R, 2017)	1.44
"Aspirin has been widely prescribed since the 1980's to prevent pre-eclampsia, intra-uterine growth retardation and fetal death of vascular origin."	( [Aspirin: Indications and use during pregnancy]. Belhomme, N; Doudnikoff, C; Henriot, B; Isly, H; Jego, P; Polard, E, 2017)	2.09
"Aspirin has been identified as a protective factor against the apparition of colorectal cancer."	( [Aspirin and colorectal cancer]. Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018)	2.11
"Aspirin has been shown to reduce cancer risk and mortality, particularly in colorectal cancer."	( Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer. Cheng, W; Cui, B; Dong, L; Fan, W; Gong, Y; Hou, Z; Kamran, M; Kang, Z; Li, J; Li, M; Li, S; Liu, B; Liu, Q; Luo, Y; Ren, Y; Tian, P; Wang, C; Wang, H; Wang, J; Wang, L; Wen, Q; Xu, J; Xu, L; Xue, X; Yang, M, 2017)	1.43
"Aspirin has been shown to exert several pharmacological effects by inducing the expression of the heme oxygenase-1 (HO-1) protein."	( Aspirin suppresses neuronal apoptosis, reduces tissue inflammation, and restrains astrocyte activation by activating the Nrf2/HO-1 signaling pathway. Chang, L; Hongliang, D; Hongyu, W; Kang, Z; Mei, X; Shurui, C; Wei, W; Yuanlong, L; Yue, G; Zhaoliang, S; Zipeng, Z, 2018)	2.64
"Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making."	( Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018)	1.44
"Aspirin has positive effects on bone marrow mesenchymal stem cells (BMSCs) osteogenic differentiation. "	( Aspirin-induced attenuation of adipogenic differentiation of bone marrow mesenchymal stem cells is accompanied by the disturbed epigenetic modification. Cao, X; He, Z; Jin, H; Li, Y; Lin, F; Liu, X; Liu, Z; Miao, N; Mu, H; Mu, S; Xu, W; Yuan, M; Zhan, Y; Zhang, B, 2018)	3.37
"Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC). "	( Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study. Cardwell, CR; Coleman, HG; Gray, RT; Hughes, C; Murray, LJ, 2018)	2.34
"Aspirin has cyclooxygenase-2 (COX2)-mediated anti-inflammatory and anti-coagulant properties that may confer a positive effect in preventing and limiting the progression of prostate cancer. "	( Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe? Marignol, L; Mascan, B, 2018)	3.37
"Aspirin has proved its efficacy in primary and secondary pre-eclampsia prevention, especially when it is given at 150mg per day bedtime before 15 weeks of gestation to high-risk women."	( [Pre-eclampsia prevention in 2018 in general population and in lupic women: At the dawn of a personalized medicine?] de Moreuil, C; Fauchais, AL; Lacut, K; Le Moigne, E; Merviel, P; Pan-Petesch, B; Pasquier, E; Tremouilhac, C, 2018)	1.2
"Aspirin has been regarded as the drug of first choice in the prevention of thromboembolic diseases."	( Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome. Velázquez de Campos, O, 2017)	1.42
"Aspirin sensitivity has a highly significant association with AFRS."	( Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018)	1.52
"Aspirin has a protective role against endothelial dysfunction and atherosclerosis, whease all non-steroidal anti-inflammatory drugs (NSAIDs) are known for their anti-inflammatory properties."	( Association between use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs and erectile dysfunction: A systematic review. Fu, F; Li, T; Qin, F; Wei, Q; Wu, C; Yuan, J, 2018)	1.5
"Aspirin resistance has been often considered a guilty actor, although many mechanisms have been mistaken for true aspirin resistance, such as patient poor compliance, inadequate dosing, drug interactions, and high-platelet turnover."	( Aspirin in primary prevention for patients with diabetes: Still a matter of debate. Bonaventura, A; Liberale, L; Montecucco, F, 2018)	2.64
"Aspirin has been demonstrated to enhance the regeneration of bone marrow mesenchymal stem cells (MSCs); however, the impact of aspirin on the osteogenic differentiation of hDPSCs remains unknown."	( Aspirin promotes osteogenic differentiation of human dental pulp stem cells. Hu, W; Jin, H; Li, Y; Miao, N; Xie, X; Yuan, M; Zhan, Y; Zhang, B, 2018)	2.64
"Aspirin has been incorporated into clinical practice for over 100 years at a low cost, making it particularly attractive as a potential agent in breast cancer prevention and as an adjunct treatment to endocrine therapy in the prophylaxis of cardiovascular complications."	( Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review. Jorge, AJL; Leite, AM; Macedo, AVS; Martins, WA, 2018)	1.2
"Aspirin has been found to diminish hypertriglyceridemia and hyperglycemia in both obese rodents and patients with type 2 diabetes mellitus. "	( Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019)	2.21
"Aspirin has been shown to prevent preeclampsia. "	( Aspirin use during pregnancy and hypoxia-related placental pathology. Chen, C; Chen, Y; Feng, L; Ye, J; Ye, W; Zhang, J; Zhu, J; Zhu, X, 2018)	3.37
"Aspirin use in COPD has been associated with reduced all-cause mortality in meta-regression analysis with few equivocal studies. "	( Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study. Aaron, CP; Barr, RG; Bowler, RP; Comellas, AP; Cooper, CB; Dransfield, MT; Fawzy, A; Han, MK; Hansel, NN; Hoffman, EA; Kanner, RE; Krishnan, JA; Labaki, WW; Paine, R; Paulin, LM; Peters, SP; Putcha, N; Wise, R, 2019)	3.4
"Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0.57%) and DVT (0.1%-0.35%) with low-dose aspirin for prophylaxis after THA."	( Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020)	1.52
"Aspirin has been found to inhibit cancer cell viability and promote CRC cell apoptosis.Similarly, aspirin has also been found to increase pro-apoptotic protein Bax's expression."	( Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway. Du, Y; Duan, X; Li, H; Liu, J; Ma, B; Su, C; Yang, S; Yang, X; Zhang, D; Zhou, Q, 2019)	1.69
"Aspirin has been studied as a primary prevention method for multiple diseases, mainly cardiovascular disease and various forms of cancer."	( Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials. Bachuwa, G; Barbarawi, M; Chahine, A; Dhillon, H; Goranta, S; Haykal, T; Katato, K; Kerbage, J; Kheiri, B; Samji, V; Yelangi, A; Zayed, Y, 2019)	1.55
"Aspirin has a well-established history of safety and efficacy in management of secondary cardiovascular protection in ischemic heart disease patients. "	( Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review. Bhupathi, V; Shanker, A, 2019)	1.96
"Aspirin has potential benefits in cardiovascular primary prevention in diabetes. "	( Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Buring, JE; Gaziano, JM; Khunti, K; Kunutsor, SK; Roncaglioni, MC; Seidu, S; Sesso, HD, 2019)	3.4
"Aspirin has both the anti-platelet and anti-inflammatory effects, and decreases several cytokines production."	( Suppressive Effects of Aspirin for Postthoracotomy Pleural Adhesion in Rats. Inoue, M; Ishihara, S; Ito, K; Okada, S; Shimada, J; Shimomura, M; Yamaguchi, T, 2019)	1.55
"Aspirin has been used for decades for the primary prevention of cardiovascular disease. "	( Aspirin for primary prevention of cardiovascular disease: is it time to move on? Knickelbine, T; Miedema, MD, 2019)	3.4
"Aspirin has been widely used for the prevention of cardiovascular diseases, but its antiplatelet efficiency varies between individuals. "	( miR-34b-3p May Promote Antiplatelet Efficiency of Aspirin by Inhibiting Thromboxane Synthase Expression. Chen, XH; Fu, SW; Liu, ML; Liu, WW; Wang, H, 2019)	2.21
"Aspirin has been shown to be a safe and cost-effective thromboprophylaxis agent with equivalent preventive efficacy to warfarin and fewer side-effects. "	( Aspirin Thromboprophylaxis Confers No Increased Risk for Aseptic Loosening Following Cementless Primary Hip Arthroplasty. Courtney, PM; Goswami, K; Rondon, AJ; Schlitt, PK; Shohat, N; Tan, TL; Yayac, M, 2019)	3.4
"Aspirin has antiplatelet and immunomodulatory properties."	( Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. Aberg, JA; Berger, JS; Bhardwaj, N; Cavanagh, K; Gettenberg, G; Hu, L; Merolla, M; Montenont, E; Nardi, MA; O'Brien, M; Valdes, V, 2013)	2.55
"Aspirin has been revealed to have many beneficial effects for health since it was discovered as a nonsteroidal anti-inflammatory drug (NSAID) to treat pain and inflammation. "	( Aspirin extends the lifespan of Caenorhabditis elegans via AMPK and DAF-16/FOXO in dietary restriction pathway. Luo, HR; Wan, QL; Wu, GS; Zheng, SQ, 2013)	3.28
"Aspirin probably has a preventive effect on metastasis."	( [Aspirin and cancer: evidence of a prophylactic effect]. Algra, AM; Nortier, JW, 2013)	2.02
"Aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease. "	( Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events. Bavry, AA; Park, K, 2013)	3.28
"Aspirin has opposite effects on the absorption of larger and smaller probes, influencing the outcome of the test."	( Differential trafficking of saccharidic probes following aspirin in clinical tests of intestinal permeability in young healthy women. Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2014)	1.37
"Aspirin has a range of antineoplastic properties linked to inhibition of cyclooxygenase enzymes in tumor cells, platelet inhibition and to inhibition of angiogenesis. "	( Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Holmes, CE; Jasielec, J; Levis, JE; Muss, HB; Skelly, J, 2013)	2.19
"Aspirin has been demonstrated to be effective in inhibiting COX-2 and PGE(2) in Alveolar macrophages (AMs). "	( Aspirin inhibits lipopolysaccharide-induced COX-2 expression and PGE2 production in porcine alveolar macrophages by modulating protein kinase C and protein tyrosine phosphatase activity. Chen, F; Chen, Z; Duan, Y; Sun, J; Xie, Q; Zhang, A; Zhu, B, 2014)	3.29
"Aspirin intake has also been associated with a statistically significant improvement in patient survival after curative resection of colorectal cancer in large observational studies."	( Aspirin and colorectal cancer: back to the future. Manthravadi, S; Sha, D; Sinicrope, FA; Tougeron, D, 2014)	2.57
"Aspirin has been recommended for primary prevention of cardiovascular disease (CVD) and cancer, but overall benefits are unclear. "	( Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. Clarke, A; Connock, M; Freeman, K; Grove, A; Gurung, B; Gurung, T; Johnson, S; Morrow, S; Ngianga-Bakwin, K; Stranges, S; Sutcliffe, P, 2013)	3.28
"Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some studies. "	( A cohort study investigating aspirin use and survival in men with prostate cancer. Barron, TI; Bennett, K; Flahavan, EM; Sharp, L, 2014)	2.14
"Aspirin therapy has proven clinical effectiveness in the prevention and treatment of CVD and is one of the most widely used drugs nationwide."	( Aspirin for cardioprotection and strategies to improve patient adherence. Duffy, D; Kelly, E; Mills, G; Trang, A; Whellan, D, 2014)	2.57
"Aspirin and heparin have been shown to have potentially beneficial effects on trophoblast implantation."	( Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. Adam, I; Ashur, BM; Elbareg, AM; Elmahashi, MO; Essadi, FM, 2014)	1.54
"Aspirin has been associated to a reduced risk of colorectal, and possibly of other cancers. "	( Aspirin and prostate cancer prevention. Bosetti, C; Gallus, S; La Vecchia, C; Rosato, V, 2014)	3.29
"Aspirin has been used for a long time as an analgesic and anti-pyretic drug. "	( Amelioration of aspirin induced oxidative impairment and apoptotic cell death by a novel antioxidant protein molecule isolated from the herb Phyllanthus niruri. Bhattacharyya, S; Ghosh, S; Sil, PC, 2014)	2.19
"Aspirin has been widely used as analgesic, antipyretic and anti-inflammatory medicine for long. "	( Aspirin augments the expression of Adenomatous Polyposis Coli protein by suppression of IKKβ. Ashida, N; Kamei, K; Kimura, T; Kishihata, M; Tien, DN; Yokode, M, 2014)	3.29
"Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus. "	( Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014)	2.25
"Aspirin (ASA) has been frequently used for thromboprophylaxis in patients with multiple myeloma (MM) when treated with thalidomide or lenalidomide. "	( Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF. Chen, GA; Ding, JH; Huang, RB; Yuan, LY, 2014)	3.29
"Aspirin (ASA) use has been associated with improved breast cancer survival in several prospective studies."	( Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden. Adami, HO; Andersson, TM; Askling, J; Holm, J; Holmes, MD; Lundholm, C; Olsson, H; Pawitan, Y; Smedby, KE, 2014)	3.29
"Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. "	( Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Fraser, DM; McCowan, C; Sullivan, FM; Thompson, AM, 2014)	3.29
"Aspirin use has been shown to be an effective tool in cardiovascular disease (CVD) prevention among high-risk patients. "	( Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. Limacher, MC; Mainous, AG; Shorr, RI; Tanner, RJ, 2014)	2.3
"Aspirin has been shown to have effects on the immune-mediated inflammation in GCA, hence it may reduce damage caused in the arterial wall."	( Aspirin as adjunctive treatment for giant cell arteritis. Burdon, MA; Denniston, AK; Mollan, SP; Sharrack, N, 2014)	2.57
"Aspirin has been used and studied for over a century but has only recently been shown to have an additional polymorphic form, known as form II. "	( Role of dispersion interactions in the polymorphism and entropic stabilization of the aspirin crystal. Reilly, AM; Tkatchenko, A, 2014)	2.07
"Aspirin has been shown to prevent this process in a few reference proteins, but how the two post-translational modifications (PTMs) of aspirin-mediated acetylation and protein glycation interact with each other remains poorly investigated."	( Characterisation of the influences of aspirin-acetylation and glycation on human plasma proteins. Finamore, F; Fontana, P; Nolli, S; Priego-Capote, F; Sanchez, JC; Zufferey, A, 2015)	1.41
"Aspirin has been shown to partition into the lipid head groups, thereby increasing membrane fluidity."	( Aspirin inhibits formation of cholesterol rafts in fluid lipid membranes. Alsop, RJ; Harroun, TA; Kučerka, N; Marquardt, D; Rheinstädter, MC; Toppozini, L, 2015)	2.58
"Aspirin has higher side effect risks and requires a longer time to achieve benefit."	( Primary prevention: do the very elderly require a different approach? Schwartz, JB, 2015)	1.14
"Aspirin has been reported to regulate lipid metabolism. "	( Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. Cai, Y; Duan, W; Feng, Y; He, Z; Hu, T; Li, G; Peng, Y; Tian, Y; Zhang, J, 2015)	3.3
"Aspirin use has been associated with significant reductions in breast cancer-related mortality in some observational studies. "	( De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer. Barron, TI; Bennett, K; Brown, C; Murphy, LM; Sharp, L; Visvanathan, K, 2015)	2.17
"Aspirin therapy has recently been shown to reduce the risk of developing ARDS, but the effect of aspirin on established ARDS is unknown."	( Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Boyle, AJ; Cross, LJ; Di Gangi, S; Hamid, UI; McAuley, DF; McNamee, JJ; McNamee, L; Mottram, LJ; O'Kane, CM; White, G, 2015)	2.58
"Aspirin has the potential to ameliorate the disease process in multiple sclerosis (for example, by limiting some components of inflammation), but aspirin also has the potential to inhibit mitochondrial complex I activity, which is already reduced in multiple sclerosis."	( Aspirin and multiple sclerosis. Emerson, MR; LeVine, SM; Lynch, SG; Tsau, S, 2015)	2.58
"Aspirin has been used in many clinical and experimental trials for the prevention of diabetes and associated complications."	( Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats. Adeghate, E; Amiri, L; Howarth, FC; Jayaprakash, P; John, A; Raza, H; Shafarin, J; Yasin, J, 2015)	1.37
"Aspirin has recently been reported to reduce both the incidence and the risk of metastasis in colon cancer. "	( Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-κB Pathway. Duan, T; Hu, K; Kang, T; Liao, D; Lv, X; Wang, G; Wang, X; Zhang, RH; Zhong, L, 2015)	3.3
"Aspirin has many properties including anti-inflammation and anti-cancer."	( Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma. Aukkanimart, R; Boonmars, T; Jiraporn, S; Loilome, W; Nadchanan, W; Namwat, N; Ruangjirachuporn, W; Sriraj, P; Sudsarn, P, 2016)	1.44
"Aspirin has previously been reported to inhibit hepatitis C virus (HCV) replication. "	( Aspirin inhibits hepatitis C virus entry by downregulating claudin-1. Yin, P; Zhang, L, 2016)	3.32
"Aspirin has been shown to protect against colorectal neoplasms; however, the optimal chemopreventive dose and underlying mechanisms are unclear. "	( Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). Ahnen, DJ; Baron, JA; Barry, EL; Bradshaw, PT; Bresalier, RS; Fedirko, V; Figueiredo, JC; Milne, GL; Sandler, RS, 2015)	2.08
"Aspirin has been in use for prevention and management of cardiovascular diseases for several decades. "	( Aspirin dosing in cardiovascular disease prevention and management: an update. Becker, RC; Ganjehei, L, 2015)	3.3
"Aspirin nanoemulsion has less toxic effect on the gastric mucosa compared to ordinary aspirin. "	( The effect of aspirin nanoemulsion on TNFα and iNOS in gastric tissue in comparison with conventional aspirin. Elkelawy, AM; Hashem, KS; Mahmoud, FA, 2015)	2.22
"Aspirin has been shown to have relative beneficial effects in preventing a first myocardial infarction, but not stroke."	( Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? Nansseu, JR; Noubiap, JJ, 2015)	1.4
"Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease. "	( Can We Select Patients for Colorectal Cancer Prevention with Aspirin? Arber, N; Kraus, S; Sion, D, 2015)	2.1
"Aspirin has been one of the most widely used medications since its first synthesis more than 100 years ago. "	( Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence. Huang, WK; See, LC; Tu, HT, 2015)	3.3
"Aspirin has been a cornerstone of cardiovascular disease prevention since the late 1980s. "	( Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. Becker, RC; Kim, J, 2016)	3.32
"Aspirin therapy has been shown to reduce morbidity and mortality in patients with coronary artery disease."	( Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes. Cook, KA; White, AA, 2016)	1.64
"Aspirin has a proven role in preventing thrombotic diseases. "	( Does Early Post-operative Administration of Aspirin Influence the Risk of Bleeding After Coronary Artery Bypass Graft Surgery? A Prospective Observational Study. Emami Zeydi, A; Gholipour Baradari, A; Nouraei, SM, 2015)	2.12
"Aspirin has been the cornerstone of therapy for the secondary prevention treatment of patients with cardiovascular disease since landmark trials were completed in the late 1970s and early 1980s that demonstrated the efficacy of aspirin for reducing the risk of ischemic events. "	( Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. Fanaroff, AC; Roe, MT, 2016)	2.13
"Aspirin use has been shown to lower incidence and mortality in cancer patients. "	( The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients. Bastiaannet, E; de Steur, WO; Frouws, M; Hartgrink, HH; Lemmens, V; Liefers, GJ; Reimers, M; van de Velde, CJ; van Herk-Sukel, MP; van Staalduinen, J, 2016)	2.24
"Aspirin use has been shown to be safe for patients undergoing certain diagnostic bronchoscopy procedures such as transbronchial biopsies and endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration. "	( Aspirin use and the risk of bleeding complications after therapeutic bronchoscopy. Alraiyes, AH; Attwood, K; Dhillon, SS; Harris, K; Kebbe, J; Kumar, A; Modi, K, 2016)	3.32
"Aspirin has been the bedrock of antiplatelet treatment strategies for the secondary prevention of recurrent cardiovascular and cerebrovascular events for the last 3 decades. "	( Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Bliden, KP; Byun, S; Chaudhary, R; Gurbel, PA; Tantry, US, 2016)	1.88
"Aspirin previously has been found to be associated with reduced carcinogenesis of prostate cells."	( The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey. Erickson, SR; Hansen, RA; Huang, WT; Wu, CH, 2016)	1.42
"Aspirin has been used for the secondary prevention and treatment of cardiovascular disease for several decades. "	( Activation of activator protein 2 alpha by aspirin alleviates atherosclerotic plaque growth and instability in vivo. Chen, Y; Li, P; Li, QZ; Liang, WJ; Ma, H; Ma, ZM; Peng, QS; Wang, F; Wang, SX; Yang, JJ; Zhang, Y, 2016)	2.14
"Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD."	( The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Hernandez, AF; Johnston, A; Jones, WS, 2016)	1.46
"Aspirin has been used in the treatment and chemoprevention of many malignant cancers. "	( Anti-cancer activity and potential mechanism of a novel aspirin derivative. Bai, YH; Fan, DD; Li, L; Li, S; Lin, S; Ma, XL; Qiu, WH; Song, YP; Wang, ZY; Zong, M, 2016)	2.12
"Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events. "	( Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016)	2.08
"Aspirin has been associated with reduced incidence and mortality of colorectal and a few other cancers. "	( Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy. Barchielli, A; Manneschi, G; Mantellini, P; Miccinesi, G; Orso, F; Puliti, D; Ventura, L; Zappa, M, 2018)	2.28
"Aspirin has been shown to lower the incidence and the mortality of vascular disease and cancer but its wider adoption appears to be seriously impeded by concerns about gastrointestinal (GI) bleeding. "	( Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. Chia, JW; Dolwani, S; Elwood, PC; Galante, J; Graziano, JM; Kelson, M; Lanas, A; Longley, M; Morgan, G; Morris, D; Phillips, CJ; Pickering, J; Roberts, SE; Soon, SS; Steward, W; Weightman, AL, 2016)	2.08
"Aspirin has a clear anti-inflammatory effect and is used as an anti-inflammatory agent for both acute and long-term inflammation. "	( Aspirin Protects against Acinar Cells Necrosis in Severe Acute Pancreatitis in Mice. Ding, Y; Gao, L; Li, W; Liu, G; Liu, J; Lu, G; Pan, Y; Tong, Z; Tu, J; Wang, Y, 2016)	3.32
"Aspirin has been used in the management of postpartum perineal pain and its effectiveness and safety should be assessed."	( Aspirin (single dose) for perineal pain in the early postpartum period. Grivell, RM; Molakatalla, S; Shepherd, E, 2017)	2.62
"Aspirin has been demonstrated to possess potent chemopreventive and anticancer effects on prostate cancer. "	( Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator. Cao, J; Chen, X; Feng, Y; Liu, B; Shi, C; Zhang, N, 2017)	3.34
"Aspirin has been shown to inhibit atherosclerosis in mouse models."	( Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. Garelnabi, M; Jaichander, P; Parthasarathy, S; Selvarajan, K, 2008)	1.3
"Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness."	( Acute and long-term antiplatelet therapy. Goudevenos, JA; Mikhailidis, DP; Papathanasiou, AI; Tselepis, AD, 2008)	1.07
"Aspirin has proven beneficial in the primary prevention of CHD, but is clearly underutilized in this role. "	( Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic. Dela Rosa, KM; Linz, PE; Romero, SC, 2008)	3.23
"Aspirin has been used as an analgesic from time immemorial. "	( A study on the modification of anti-inflammatory and analgesic action of aspirin by nifedipine. Patowary, S, )	1.81
"Aspirin resistance has been defined as inability of aspirin to protect individuals from thrombotic complications or to produce an anticipated effect from laboratory tests of platelet function. "	( Aspirin non-responders in Thai ischemic stroke/TIA patients. Dharmasaroja, P, 2008)	3.23
"Aspirin resistance has been shown to be a significant risk factor for recurrent cardiovascular ischaemic events. "	( A pilot study of resistance to aspirin in stroke patients. Bennett, D; Davis, SM; Eccleston, D; Macgregor, L; Yan, B, 2008)	2.07
"Aspirin has been proposed as a possible chemopreventive agent. "	( Damage to cellular and isolated DNA induced by a metabolite of aspirin. Isono, Y; Kawanishi, S; Kobayashi, H; Oikawa, S; Tada-Oikawa, S, 2009)	2.04
"Aspirin therapy has modest efficacy in reducing stroke risk, but is much less effective than warfarin."	( Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. Fang, MC, 2009)	1.07
"Aspirin and selenium have been shown in vitro and in vivo to inhibit HIV production through inhibition of the transcription factor, the nuclear factor kappa binding (NF-eB). "	( Selenium and aspirin in people living with HIV and AIDS in Nigeria. Adediran, IA; Akinola, NO; Armistead, H; Durosinmi, MA; Elujoba, AA; Falola, OL; Irinoye, O; Muraina, HA; Odusoga, OL; Ogun, SA; Olasode, OA; Onayemi, O, 2008)	2.16
"Aspirin has been associated with a reduced risk of colorectal cancer and--based on limited evidence--to cancers of the oesophagus, stomach, breast, ovary and lung. "	( Aspirin and cancer risk: a summary review to 2007. Bosetti, C; Gallus, S; La Vecchia, C, 2009)	3.24
"Aspirin has been a commercial drug for over a century, although for most of this history, an understanding of its mechanism of action, as an inhibitor of cyclooxygenase (COX) activity and thus of prostanoid synthesis, was lacking. "	( Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Baigent, C; Patrono, C, 2009)	2.21
"Aspirin resistance has been associated with an adverse long-term outcome in patients with atherosclerotic coronary artery disease, but more studies are needed."	( The impact of aspirin resistance on the long-term cardiovascular mortality in patients with non-ST segment elevation acute coronary syndromes. Adamopoulou, EN; Argyrakis, SK; Foussas, SG; Makrygiannis, SS; Mytas, DZ; Patsourakos, NG; Perdiou, AJ; Prekates, AA; Tsirimpis, VG; Tsoukanas, VK; Zairis, MN, 2009)	2.16
"Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone."	( Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009)	1.07
"Aspirin has been shown to attenuate the adrenocorticotropic hormone (ACTH) and cortisol response to physiological challenge suggesting its potential to act as an augmenting agent in depression."	( Effect of aspirin on hypothalamic-pituitary-adrenal function and on neuropsychological performance in healthy adults: a pilot study. Bulmer, S; Carlile, J; Corcoran, C; Ferrier, IN; Gallagher, P; Horton, K; Watson, S, 2009)	1.48
"Aspirin has been found to prevent angiotensin II-induced hypertension and to induce nitric oxide (NO) release from vascular endothelium. "	( Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Ayala, DE; Fernández, JR; Hermida, RC; Mojón, A, 2009)	2.05
"Aspirin has emerged as the most likely NSAID for use in chemoprevention because of its known cardiovascular benefit and available safety and efficacy data."	( Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Baron, JA; Brown, PH; Burn, J; Cuzick, J; Greenwald, P; Jankowski, J; La Vecchia, C; Meyskens, F; Otto, F; Senn, HJ; Thun, M, 2009)	2.52
"Aspirin has been reported to induce apoptosis in various cancer cell lines. "	( Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Bae, MK; Bae, SK; Kim, JY; Kim, SR; Wee, HJ; Yoo, MA, 2009)	3.24
": Aspirin has a distinct depressant effect on human Ishikawa adenocarcinoma endometrium cell growth, and its effect may be realized by lowering Bcl-xl proteinum expression."	( Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. Hongwei, L; Shu, L; Xiaoxin, M; Yanxia, L; Yingnan, J; Yuanqi, H, 2009)	1.33
"Only aspirin has been shown to be safe and effective in large randomized trials in the first 48 hours after ischemic stroke."	( Antiplatelet agents in stroke prevention: acute and long-term treatment strategies. Diener, HC; Weber, R; Weimar, C, 2009)	0.81
"Aspirin has traditionally been used."	( Gastrointestinal bleed with clopidogrel and aspirin. Choudhary, S; Joshi, R; Kohli, V; Sibal, A, 2010)	1.34
"Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone."	( Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. Fung, K; Simmons, BB; Yeo, A, 2010)	1.08
"Aspirin has shown efficacy in preventing PE with a 10 % incidence reduction. "	( [Prevention of preeclampsia]. Coutty, N; Deruelle, P; Girard, JM; Subtil, D, 2010)	1.8
"Aspirin has been proven to reduce cardiovascular mortality as a secondary prophylactic agent, but not as a primary agent."	( Aspirin and non-small cell lung cancer resections: effect on long-term survival. Carr, M; Fontaine, E; McShane, J; Mediratta, N; Page, R; Poullis, M; Shackcloth, M; Soorae, A, 2010)	2.52
"Aspirin has been proven to prevent ischemic stroke in a variety of settings."	( Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010)	2.52
"Aspirin has not yet been proven effective for primary prevention of strokes in men, and a minimum dose for these patients cannot be determined from the available data."	( Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010)	2.52
""Aspirin resistance" has been defined as the occurrence of cardiovascular events despite regular intake of aspirin. "	( Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". Gurbel, PA; Hebert, PR; Hennekens, CH; Schneider, WR; Tantry, US, 2010)	1.47
"Aspirin has been shown to be cytotoxic to colorectal cancer cells in vitro."	( Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. Brown, JE; Dibra, HK; Hooley, P; Nicholl, ID, 2010)	2.52
"With aspirin, however, it has long been believed that it is difficult to induce any damage in the intestinal mucosa of laboratory animals."	( New method of inducing intestinal lesions in rats by intraduodenal administration of aspirin. Amagase, K; Nakagawa, K; Nakamura, M; Nonoyama, K; Okabe, S; Takeuchi, K, 2010)	1.04
"Aspirin, which has both anti-inflammatory and anti-thrombotic effects, has the potential to influence CRP release."	( The effect of aspirin on C-reactive protein in hypertensive patients. Chung, WY; Kim, CJ; Kim, MA; Kim, SH; Rho, EY; Seo, JB; Shin, S; Yoon, JH; Zo, JH, 2011)	1.45
"Aspirin resistance has been associated with a higher incidence of ischemic events after percutaneous coronary intervention (PCI)."	( A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention. El-Atat, F; Jakkulla, M; Karajgikar, R; Kini, A; Kodali, V; Mares, A; Sarkar, K; Sharma, S, 2011)	1.33
"Aspirin (ASA) has been shown to reduce postoperative coronary artery bypass grafting (CABG) mortality and ischemic events; however, the timing of chronic ASA discontinuation before surgery is controversial because of concern about postoperative bleeding. "	( Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Blackstone, E; Cho, L; Jacob, M; Smedira, N; Williams, S, 2011)	2.08
"Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. "	( Aspirin use and risk for lung cancer: a meta-analysis. Kwon, HT; Lee, CM; Myung, SK; Oh, SW; Park, JY, 2011)	3.25
"Aspirin has been recommended for the prevention of major adverse cardiovascular events (MACE, composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) in diabetic patients without previous cardiovascular disease. "	( Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Butalia, S; Ghali, WA; Leung, AA; Rabi, DM, 2011)	3.25
"Aspirin has been reported to be less effective for secondary vascular prevention in patients with ischaemic stroke, compared with other high-risk populations. "	( Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. Dinneen, SF; Eikelboom, JW; McGrath, E; O'Conghaile, A; O'Donnell, MJ; Oczkowski, C, 2011)	2.03
"Aspirin has an antithrombotic action at low dose and anti-ischemic and anti-inflammatory properties, which are dose-related."	( The role of aspirin in childhood tuberculous meningitis. Janse van Rensburg, A; Laubscher, JA; Schoeman, JF; Springer, P, 2011)	1.47
"Aspirin has been shown to decrease cardiovascular (CV) events by ∼25%. "	( Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. Auer, J; Berent, R; Franklin, B; Schmid, P; von Duvillard, SP, 2011)	2.13
"Aspirin has detrimental effects on the gastrointestinal tract mucosa and may play a role in the aetiology of inflammatory bowel disease."	( Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Bergmann, MM; Boeing, H; Chan, SS; Hart, AR; Kaaks, R; Kennedy, H; Khaw, KT; Luben, R; Olsen, A; Overvad, K; Riboli, E; Tjonneland, A, 2011)	3.25
"Aspirin has several additional mechanisms of action that may contribute to its anti-cancer effect."	( Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Burdett, S; Cafferty, F; Langley, RE; Parmar, MK; Tierney, JF; Venning, G, 2011)	2.53
"Aspirin has a beneficial role in prevention of cardiovascular and thromboembolic events. "	( High frequency of aspirin resistance in patients with nephrotic syndrome. Agbaht, K; Akoglu, H; Dede, F; Falay, MY; Odabas, AR; Ozet, G; Piskinpasa, S, 2012)	2.16
"Aspirin has been advocated as a primary prevention measure for myocardial infarction (MI) for more than 2 decades. "	( Aspirin for primary prevention of myocardial infarction: what is the evidence? Amsterdam, E; Kappagoda, T, )	3.02
"Aspirin has also been shown to be beneficial in a clinical trial of patients with Lynch syndrome, a hereditary CRC syndrome; in those treated with aspirin for at least two years, there was a 50% or more reduction in the risk of CRC commencing five years after randomization and after aspirin had been discontinued."	( Aspirin in the chemoprevention of colorectal neoplasia: an overview. Arber, N; Baron, JA; Burn, J; Chan, AT; Chia, WK; Elwood, P; Hull, MA; Logan, RF; Rothwell, PM; Schrör, K, 2012)	2.54
"Aspirin has been shown to decrease postoperative CABG mortality and ischemic events."	( Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in patients having combined coronary artery bypass grafting and valve surgery. Blackstone, E; Cho, L; Jacob, M; Smedira, N; Williams, S, 2012)	1.37
"Aspirin has antithrombotic activity and is commonly used to protect patients from cardiovascular disease attacks. "	( Aspirin inhibits the production of reactive oxygen species by downregulating Nox4 and inducible nitric oxide synthase in human endothelial cells exposed to oxidized low-density lipoprotein. Chen, B; Qi, R; Wu, W; Zhang, S; Zhao, J, 2012)	3.26
"Aspirin has been associated with a reduced risk of colorectal cancer. "	( Aspirin and urologic cancer risk: an update. Bosetti, C; Gallus, S; La Vecchia, C; Rosato, V, 2012)	3.26
"Aspirin has been found to improve outcomes in an animal model of transfusion-related acute lung injury. "	( The effect of aspirin in transfusion-related acute lung injury in critically ill patients. Binnenkade, JM; Juffermans, NP; Tuinman, PR; Vlaar, AP, 2012)	2.18
"Aspirin and statins have been integral in the prevention of atherosclerotic disease. "	( Do aspirin and statins prevent severe sepsis? O'Neal, HR; Sanchez, MA; Thomas, CB, 2012)	2.44
"Aspirin has been known for many years to be an effective analgesic for many different pain conditions."	( Single dose oral aspirin for acute postoperative pain in adults. Derry, S; Moore, RA, 2012)	1.44
"Aspirin has been associated to a reduced risk of colorectal and possibly of a few other common cancers."	( Aspirin and cancer risk: a quantitative review to 2011. Bosetti, C; Cuzick, J; Gallus, S; La Vecchia, C; Rosato, V, 2012)	3.26
"Aspirin has been increasingly recognised as an inferior choice for stroke prevention, and may not be any safer than warfarin in terms of major bleeding, especially in the elderly."	( What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? Lip, GY, 2012)	1.1
"Aspirin, which has been shown to reduce the local production of gall bladder mucins (mucosal or parietal factors of gallstone formation) in animal experimental models, does not appear to reduce the risk of symptomatic gallstones disease when tested alone."	( Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. Cariati, A; Piromalli, E, 2012)	1.35
"Aspirin has a central role in preventing thromboembolic complications in atherosclerotic conditions."	( [The effect of platelet transfusion on traumatic intracranial hemorrhage among patients treated with aspirin]. Bental, O; Cohen, ZR; Jonas-Kimchi, T; Margalit, N; Patal, R; Ram, Z; Roth, J, 2012)	1.32
"Aspirin resistance has been defined by clinical and/or laboratory criteria; however, detection by laboratory methods prior to experiencing a clinical event will likely provide the greatest opportunity for intervention."	( Antiplatelet therapy: aspirin resistance and all that jazz! Borhani-Haghighi, A; Divani, AA; Rao, GH; Zantek, ND, )	1.17
"Aspirin resistance has been described in some patient populations such as those with an acute coronary syndrome, ischemic stroke, percutaneous coronary intervention with drug-eluting stent, stent re-stenosis, and diabetes mellitus (DM)."	( Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus. Ariturk, Z; Cil, H; Elbey, MA; Gündüz, E; Islamoglu, Y; Kaya, H; Soydinc, S; Tekbas, E; Yavuz, C, 2012)	1.38
"As aspirin has both anti-inflammatory properties and interferes with platelet aggregation, we hypothesized that ongoing anti-platelet therapy with aspirin may impact clinical and echocardiographic manifestations of CIED infection."	( Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Anavekar, NS; Baddour, LM; Friedman, PA; Habib, A; Hayes, DL; Irfan, M; Le, KY; Lohse, CM; Sohail, MR; Steckelberg, JM; Wilson, WR, 2013)	1.25
"Aspirin has been widely reported to reduce the incidence of colorectal cancer. "	( Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Card, TR; Grainge, MJ; Walker, AJ, 2012)	3.26
"Aspirin has been used for the prevention and treatment of cardiovascular disease (CVD) for several decades. "	( Aspirin for primary prevention of cardiovascular disease events. Morbitzer, KA; Moser, LR; Nemerovski, CW; Salinitri, FD, 2012)	3.26
"Aspirin resistance has been well reported in CVD."	( Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. Cao, J; Fan, L; Hu, G; Hu, Y; Li, X; Liu, L; Zhu, B, 2013)	1.33
"Aspirin has been reported to trigger apoptosis in various cancer cell lines. "	( Direct regulation of caspase‑3 by the transcription factor AP‑2α is involved in aspirin‑induced apoptosis in MDA‑MB‑453 breast cancer cells. Ding, X; He, Q; Hu, X; Li, L; Li, W; Wei, K; Xiang, S; Yan, F; Zhang, J; Zhong, Y, 2013)	2.05
"Aspirin has shown promise as an anticonvulsant drug in animal models. "	( Does aspirin use make it harder to collect seizures during elective video-EEG telemetry? Caylor, LM; Doherty, MJ; Godfred, RM; Haltiner, AM; Parikh, MS; Sepkuty, JP, 2013)	2.35
"Aspirin has been shown to be beneficial in the secondary prevention of AMI. "	( Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective. Goldberg, RJ; Gore, JM; Jackson, EA; Lessard, D; Sivasubramian, R; Spencer, FA; Yarzebski, J, 2002)	2.04
"Aspirin prodrugs have been intensively investigated in an effort to produce compounds with lower gastric toxicity, greater stability or enhanced percutaneous absorption, relative to aspirin. "	( Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate. Clancy, JM; Gilmer, JF; Lally, MN; Moriarty, LM, 2002)	2.1
"Aspirin resistance has been reported in patients with cardiovascular, cerebrovascular, and peripheral vascular disease. "	( Aspirin resistance. Howard, PA, 2002)	3.2
"Aspirin has been used for more than 100 years, but its mechanisms of action have only been understood in the past 20 years. "	( Aspirin in the prophylaxis of coronary artery disease. Mehta, P, 2002)	3.2
"Aspirin has been shown to reduce the risk of myocardial infarction and stroke. "	( Effect of increasing doses of aspirin on platelet aggregation among stroke patients. Bitanga, ES; Florento, L; Gan, R; Teleg, RA, 2002)	2.05
"Aspirin has been reported to induce apoptosis in a variety of cell lines. "	( Aspirin and sodium salicylate inhibit proliferation and induce apoptosis in rheumatoid synovial cells. Hashimoto, S; Kawai, S; Kusunoki, N; Matsuzaki, T; Yamazaki, R, 2002)	3.2
"Aspirin has nonplatelet-mediated effects that contribute to its efficacy in the primary and secondary prevention of coronary events. "	( Nonplatelet-mediated effects of aspirin. Aude, YW; Mehta, JL, 2002)	2.04
"Aspirin has proven benefits in primary and secondary prevention of coronary artery disease."	( Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Badimon, JJ; Bhatt, DL; Corti, R; Francis, GS; Fuster, V; Jneid, H, 2003)	2.48
"Aspirin consumption has been reported to be able to reduce colorectal cancer risk in humans and in animal models of colon carcinogenesis. "	( Prostaglandin-independent effects of aspirin on cell cycle and putrescine synthesis in human colon carcinoma cells. Andriamihaja, M; Blachier, F; Camous, S; Charpigny, G; Eklou-Kalonji, E; Mayeur, C; Reinaud, P; Robert, V, 2003)	2.03
"Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment."	( NCX4016: a novel antithrombotic agent. Gresele, P; Mezzasoma, AM; Momi, S, 2003)	0.77
"Aspirin also has been studied and is effective, but with a more modest benefit (relative risk reduction of 22%)."	( Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. Connolly, SJ, 2003)	1.04
"Aspirin that has been chemically combined with a nitric oxide (NO) donor (NCX-4016) has been shown to inhibit cyclooxygenase and prostaglandin generation while maintaining the inhibitory effects of aspirin. "	( Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheek pouch microcirculation. Bertuglia, S; Del Soldato, P; Giusti, A, 2004)	2.03
"Aspirin has been studied and used most extensively."	( Role of antiplatelet drugs in the prevention of cardiovascular events. Tendera, M; Wojakowski, W, 2003)	1.04
"Aspirin has been the first-line agent for stroke prevention for a long time."	( Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke. Redman, AR; Ryan, GJ, 2004)	1.04
"Aspirin has a role in the prevention of cardiovascular and cerebrovascular disease, Alzheimer's dementia and several cancers. "	( Review article: the ageing bowel and intolerance to aspirin. Johns, CE; May, FE; Newton, JL, 2004)	2.02
"Aspirin has been widely studied to prevent, and also treat, PE."	( [Prevention of deep vein thrombosis and preeclampsia. Therapeutic possibilities]. Daigremont-Botmans, C; Palot, M; Visseaux, H, )	0.85
"Aspirin resistance has been defined in patients with cardiovascular, cerebrovascular, and peripheral vascular disease."	( [Aspirin resistance]. Balbay, Y; Korkmaz, S; Yilmaz, MB, 2004)	1.96
"Aspirin has also been used but is less effective."	( Warfarin for atrial fibrillation: the end of an era? Chambers, BR; Dewey, HM; Donnan, GA, 2004)	1.04
"Aspirin use has become increasingly common in the prevention of cerebrovascular and cardiovascular diseases."	( The effect of aspirin intake on bleeding on probing in patients with gingivitis. Badovinac, RL; Fiorellini, J; Goodson, M; Howell, H; Karimbux, N; Recio, L; Royzman, D, 2004)	1.41
"Aspirin treatment has an undoubted beneficial impact on the progression of cardiovascular diseases. "	( Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Grotz, W; Olschewski, M; Peter, K; Siebig, S; Strey, CW, 2004)	2.18
"Aspirin has potent antiinflammatory properties and attenuates atherosclerosis in apolipoprotein-E-deficient mice fed a high-fat, high-cholesterol diet. "	( Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. Camps, J; Ferré, N; Joven, J; Riu, F; Tous, M; Vilella, E, 2004)	3.21
"Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience."	( Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. Kerr, JL; Oppelt, TF; Rowen, RC, 2004)	1.04
"Aspirin resistance has been reported to occur in 5% to 45% of the general population; therefore, its detection is potentially of clinical importance."	( Aspirin resistance: current concepts. Freedman, JE; Jacobs, AK; Mason, PJ, 2004)	2.49
"Aspirin has the largest and most persuasive body of randomized trial evidence to support its use in secondary prevention for cardiovascular disease (CVD) and primary prevention for myocardial infarction."	( Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. Buring, JE; Gaziano, JM; Hennekens, CH; Kurth, T, 2004)	2.49
"Aspirin has been indicated to maintain venous graft patency in the post-operative period."	( Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Ayaz, S; Balbay, Y; Caldir, V; Guray, U; Guray, Y; Korkmaz, S; Yilmaz, MB, 2005)	1.27
"Aspirin has been shown to be as effective as warfarin in the prevention of noncardioembolic ischaemic stroke, with significantly fewer bleeding complications."	( Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Weinberger, J, 2005)	1.05
"Aspirin has a significant effect on hemostasis, so it is often recommended that patients taking aspirin discontinue treatment before elective surgery. "	( Duration of increased bleeding tendency after cessation of aspirin therapy. Cahill, MR; Cahill, RA; Crowe, BH; Manning, BJ; McGreal, GT; Redmond, HP; Ryan, DA, 2005)	2.01
"Aspirin resistance has been recognised to occur in patients with cardiovascular disease and is associated with poor clinical prognosis. "	( Prevalence of aspirin resistance in patients with type 2 diabetes. Bocksch, W; Cabeza, N; Dietz, R; Ersel, S; Fateh-Moghadam, S; Gawaz, M; Htun, P; Plöckinger, U; Reuter, T, 2005)	2.13
"Aspirin has always remained an enigmatic drug. "	( New insights into the anti-inflammatory actions of aspirin-induction of nitric oxide through the generation of epi-lipoxins. Gilroy, DW, 2005)	2.02
"Aspirin has a direct impact in the LX circuit by triggering the biosynthesis of endogenous epimers of LX, termed the aspirin-triggered 15-epi-LX, that share the potent anti-inflammatory actions of LX."	( Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Serhan, CN, )	1.22
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke."	( Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. , 2005)	1.06
"Aspirin (ASA) has unquestioned benefit to patients with cardiac ischemia. "	( Treatment of suspected cardiac ischemia with aspirin by paramedics in an urban emergency medical services system. Colwell, CB; Macht, M; McVaney, KE; Pons, PT, )	1.83
"Aspirin, which has been shown to block phosphorylation of the IkappaB component of the cytoplasmic NF-kappaB complex, significantly suppressed glutamate-induced cell death, whereas the NF-kappaB decoy oligonucleotide potentiated it."	( Distinct nuclear factor-kappaB/Rel proteins have opposing modulatory effects in glutamate-induced cell death in HT22 cells. Arakawa, M; Ishige, K; Ito, Y; Saito, H; Tanaka, M, 2005)	1.05
"Aspirin has potential in the prevention or treatment of oesophageal cancer, the seventh most common cancer in the world, but its mechanism of action is still not certain."	( Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2. Drew, PA; Jamieson, GG; Liu, JF; Shan, BE; Wang, QZ; Zhang, SW; Zhu, GJ; Zhu, TN, 2005)	3.21
"Aspirin has been shown to be associated with reduced risk of developing colorectal carcinoma and other cancers."	( Regular aspirin use and esophageal cancer risk. Baker, JA; Javle, MM; Jayaprakash, V; McCann, SE; Menezes, RJ; Moysich, KB; Natarajan, N; Reid, ME, 2006)	1.49
"Aspirin has been shown to reduce cardiovascular morbidity and mortality following percutaneous coronary intervention (PCI). "	( Impact of aspirin treatment on long-term outcome (over 10 years) after percutaneous coronary intervention. Akimoto, Y; Daida, H; Kasai, T; Kojima, T; Kurata, T; Miyauchi, K; Njaman, W; Ohta, H; Okazaki, S; Satoh, H; Yokoyama, K, 2006)	2.18
"Aspirin has been shown to exhibit neuroprotective properties."	( Therapeutic potentials of aspirin in glaucomatous optic neuropathy. Attarzadeh, A; Hosseini, H; Nowroozizadeh, S, 2006)	1.36
"Aspirin has been associated to a reduced risk of colorectal, and possibly of a few other common cancers. "	( Aspirin and cancer risk: an updated quantitative review to 2005. Bosetti, C; Gallus, S; La Vecchia, C, 2006)	3.22
"Aspirin has been associated with adverse heart failure outcomes, probably because of a blunting interaction with angiotensin-converting enzyme (ACE) inhibitors. "	( Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. Jug, B; Keber, I; Sabovic, M; Sebestjen, M, 2006)	2
"Aspirin has become the gold standard to which newer antiplatelet drugs are compared for reducing risks of cardiovascular diseases, while keeping low cost. "	( Design of a transdermal delivery system for aspirin as an antithrombotic drug. Ammar, HO; El-Nahhas, SA; Ghorab, M; Kamel, R, 2006)	2.04
"Aspirin has been known to be an enhancer to wheat allergy, including wheat-dependent, exercise-induced anaphylaxis."	( [Enhancement of nonsteroidal, anti-inflammatory drugs and preventive effect of antihistamines and disodium cromoglycate on wheat allergy]. Fujita, H; Ikezawa, Z; Inomata, N; Nakamura, K; Osuna, H; Sugawara, M; Takakura, M; Yamane, Y, 2006)	1.78
"Aspirin has been shown to slightly increase survival duration in multiple myeloma."	( Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha. Kast, RE, 2006)	2.5
"Aspirin resistance has to be defined by its inability to inhibit COX-1."	( Aspirin resistance: does it exist? Michiels, JJ; Rao, GH, 2007)	2.5
"Aspirin has reduced the risk of cardiovascular events by 25%."	( [Pathogenesis and prevention tactics of aspirin resistance]. Zhang, JP; Zhang, RG, 2007)	1.33
"Aspirin has long been established as a useful analgesic and antipyretic. "	( The discovery of aspirin's antithrombotic effects. Hoffhines, A; Miner, J, 2007)	2.12
"Aspirin has the potential to influence C-reactive protein (CRP) levels, an inflammatory marker, by its anti-inflammatory activity. "	( C-reactive protein levels increase after exercise testing in patients with increased platelet reactivity. Aydinalp, A; Bal, U; Demir, O; Ertan, C; Gulmez, O; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2007)	1.78
"Aspirin and sulindac have been shown to be effective in selecting for cells with reduced microsatellite instability (MSI) that is inherent in mismatch repair (MMR)-deficient hereditary nonpolyposis colorectal cancer (HNPCC) cells."	( Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Burkholder, S; Fishel, R; Kopelovich, L; McIlhatton, MA; Rigas, B; Ruschoff, J; Tyler, J, 2007)	1.38
"Aspirin has potential risks."	( Aspirin and reproductive outcomes. Brancazio, LR; James, AH; Price, T, 2008)	2.51
"Aspirin use has been shown to be effective in reducing the number of nonfatal myocardial infarction (MI) and fatal CHD, though studies of aspirin effects in women have found a significant reduction in ischemic stroke but no significant effect on fatal or nonfatal MI or CVD death."	( Aspirin use in the prevention of cardiovascular events. Crutcher, JM; Daniels, C; Mallonee, S, 2007)	2.5
"Aspirin has anti-inflammatory and antineoplastic activity."	( Effects of aspirin on the development of Helicobacter pylori-induced gastric inflammation and heterotopic proliferative glands in Mongolian gerbils. Chan, AO; Chen, MH; Cho, CH; Gu, Q; Hu, PJ; Li, GQ; Liang, YJ; Lin, HL; Qiao, L; So, WH; Tatematsu, M; Tsukamoto, T; Wong, BC; Xia, HH; Yuen, MF, 2008)	1.46
"Aspirin has become the antiplatelet treatment standard against which several other antiplatelet agents have been shown to be more effective."	( Antithrombotic and thrombolytic therapy for ischemic stroke. Cornett, O; Malhotra, S; Ocava, LC; Rosenbaum, DM; Singh, M, 2008)	1.07
"Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease. "	( Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008)	2.18
"Aspirin has been shown in clinical trials to be an effective agent in treating transient ischemic attacks and preventing infarction."	( Aspirin for prevention of stroke: a review. Fields, WS, 1983)	2.43
"Aspirin has a similar effect upon the endothelial cyclo-oxygenase, but in contrast to that of the platelet, it is less sensitive and has the capacity to generate new cyclo-oxygenase activity if aspirin is removed from the system."	( Mechanisms of action: aspirin. Hoak, JC, 1983)	1.3
"Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA."	( Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. Turpie, AG, 1982)	0.99
"Aspirin has been demonstrated to be an effective prophylactic agent against postoperative venous thromboembolic disease, but the optimum dosage is unknown. "	( High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement. Athanasoulis, CA; Harris, WH; Salzman, EW; Waltman, AC, 1982)	2.04
"Aspirin has been shown to raise serum digoxin levels in the dog."	( Kinetics of the digoxin-aspirin combination. Comess, KA; Fenster, PE; Finley, PR; Hanson, CD, 1982)	1.29
"Like aspirin, zomepirac has anti-inflammatory and antipyretic actions and inhibits the synthesis of prostaglandins."	( Zomepirac sodium. A new nonaddicting analgesic. Lewis, JR, )	0.59
"Aspirin has been used for the prevention of platelet thrombi, both prophylactically and therapeutically, in a wide variety of conditions. "	( Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo. Kajiwara, Y; Quattrociocchi-Longe, T; Shanberge, JN, 1995)	2.14
"Aspirin (100 uM) has suppressant effects (p < 0.05) on the normal contractility while the adrenaline stimulated contractility is not suppressed by aspirin and indomethacin significantly."	( The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the spontaneously beating isolated auricles of the rabbit heart. Bhatti, AS, 1994)	1.01
"Aspirin has an established benefit in reducing the incidence of coronary events and vein graft occlusion. "	( Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. Bevan, DH; Cowans, D; Kallis, P; Talbot, S; Tooze, JA; Treasure, T, 1994)	2.09
"Aspirin has many uses in cardiovascular disease. "	( The use of aspirin in cardiovascular disease. Byers, JF, 1993)	2.12
"Aspirin has no effect on stone formation, nor does it prevent the decrease in contractility despite a profound decrease in endogenous gallbladder prostanoid synthesis."	( Gallbladder contractility in aspirin- and cholesterol-fed prairie dogs. Li, YF; Moody, FG; Myers, SI; Russell, DH; Weisbrodt, NW, 1994)	2.02
"Aspirin therapy has been largely superseded by prescription nonsteroidal anti-inflammatory drug (NSAID) therapy in rheumatoid arthritis, in part because of premarketing studies suggesting lesser toxic effects for NSAIDs than for aspirin. "	( A reevaluation of aspirin therapy in rheumatoid arthritis. Bloch, DA; Fries, JF; Morfeld, D; Ramey, DR; Raynauld, JP; Singh, G, 1993)	2.06
"Aspirin has the potential to attenuate these effects."	( Aspirin increases tissue oedema after skeletal muscle ischaemia and reperfusion. Braithwaite, BD; Earnshaw, JJ; Gelabert, H; Moore, WS; Petrik, PV; Pollen, DN; Quinones-Baldrich, WJ, 1996)	2.46
"Aspirin sensitivity has not frequently been described in younger age groups. "	( Acetaminophen anaphylaxis with aspirin and sodium salicylate sensitivity: a case report. Ham Pong, A; Schwarz, N, 1996)	2.02
"Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction."	( [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. Canaple, S; Rosa, A, 1996)	0.75
"Aspirin has proved useful in further reducing thromboembolic events when added to oral anticoagulants."	( Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. Fondevila, CG; Frontroth, J; Lazzari, MA; Meschengieser, SS; Santarelli, MT, 1997)	1.27
"Aspirin (ASA) has become a well-documented therapeutic adjunct in patients with coronary heart disease."	( Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) Aursnes, I; Kjekshus, J; Nguyen, KN, 1997)	1.3
"Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy. "	( Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Schafer, AI, 1997)	1.74
"Aspirin has a well established role in the prevention of arterial thrombosis. "	( Aspirin in essential thrombocythemia: status quo and quo vadis. Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997)	3.18
"Aspirin has been reported to inhibit the activation of nuclear factor-kappaB (NF-kappaB) through stabilization of inhibitor kappaB (IkappaB). "	( Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. Adams, DO; Alford, PB; Pizzo, S; Shackelford, RE; Thai, SF; Xue, Y, 1997)	3.18
"Aspirin has also been shown to inhibit cell proliferation in human tumor cell lines and to induce apoptosis in colonic mucosa of familial polyposis patients."	( Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Acquaviva, AM; Apicella, A; Di Popolo, A; Memoli, A; Pignata, S; Ricchi, P; Zarrilli, R, 1997)	1.42
"Aspirin has been used to prevent this complication but may increase procedure-related and gastrointestinal bleeding."	( Low-dose aspirin therapy is associated with few side effects but does not prevent hepatic artery thrombosis in liver transplant recipients. Birnbaum, A; Boccagni, P; Bodenheimer, HC; Chodoff, L; Freni, MA; Miller, CM; Mor, E; Schwartz, ME; Wolf, DC, 1997)	1.44
"Aspirin has been identified as one factor contributing to the metabolic disorder that occurs."	( Reye's syndrome: an update. Ward, MR, 1997)	1.02
"Aspirin has recently been shown to increase endothelial resistance to oxidative damage. "	( Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Abate, A; Oberle, S; Podhaisky, HP; Polte, T; Schröder, H, 1998)	3.19
"Aspirin has proven clinical efficacy in limiting the thrombotic complications of atherosclerotic vascular disease but its mechanism of action remains unclear. "	( The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils. Hung, J; Ilton, MK; Misso, NL; Taylor, ML; Thompson, PJ; Watkins, DN, 1998)	2.1
"Aspirin has a modest effect on reducing stroke (about 20% risk reduction)."	( Prevention of stroke in patients with nonvalvular atrial fibrillation. Cairns, JA; Easton, JD; Hart, RG; Sherman, DG, 1998)	1.02
"Aspirin has a role in secondary prevention of coronary artery disease; among patients who are allergic to or intolerant of aspirin, ticlopidine has a role in patients with unstable angina and clopidogrel has a potential role in patients with ischemic heart or vascular disease."	( Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. Tisdale, JE, 1998)	1.02
"Aspirin has remained the pharmacologic foundation of stroke prevention, primarily because of its low cost."	( Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease. Harbison, JW, 1998)	1.02
"Aspirin has been shown to be effective in reducing the associated risk of myocardial infarction and stroke."	( Management of peripheral arterial disease. Hilleman, DE, 1998)	1.02
"As Aspirin (ASA) has proven efficacy in preventing patients with CAD from complications related to cardiovascular diseases, most patients scheduled for CABG are treated with ASA therapy. "	( Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin. Beckmann, H; Dauben, HP; Elert, O; Gams, E; Keith, PR; Klein, M; Mayer, G; Schulte, HD, 1998)	1.13
"Aspirin has been widely used to prevent myocardial infarction and ischemic stroke but some studies have suggested it increases risk of hemorrhagic stroke."	( Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. He, J; Klag, MJ; Vu, B; Whelton, PK, 1998)	3.19
"Aspirin has been well known for its anti-pyretic and anti-inflammatory action over the past century. "	( Aspirin induced apoptosis in gastric cancer cells. Lam, SK; Wong, BC; Zhu, GH, 1999)	3.19
"Aspirin has been found to reduce the incidence and death rate of cardiovascular and cerebrovascular events and is nowadays the cornerstone of any secondary prevention in vascular diseases."	( [Aspirin]. Reinhart, WH, 1999)	1.93
"Aspirin has been evaluated in primary prevention, with interesting results in high-risk patients."	( [Aspirin and prevention of cardiovascular risk]. Gabriel Steg, P; Karila-Cohen, D, 2000)	1.94
"Aspirin has been known to be an effective analgesic for many years and is commonly used throughout the world for many different pain conditions. "	( Single dose oral aspirin for acute pain. Carroll, D; Collins, SL; Edwards, JE; McQuay, HJ; Moore, RA; Oldman, A; Smith, L; Wiffen, PJ, 2000)	2.09
"Aspirin has been widely used as analgesic and anti-inflammatory drug. "	( Synthesis and biological activity of aspirin derivatives. Cha, BC; Lee, SB, 2000)	2.02
"Aspirin renography has been proposed as a useful test for evaluation of unilateral renal artery stenoses of moderate degree."	( Aspirin renography in the diagnosis of renovascular hypertension: a comparative study with captopril renography. Gambhir, S; Kher, V; Maini, A; Singhal, M, 2000)	2.47
"Aspirin has a modest effect on reducing stroke."	( [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation]. Kitabatake, A; Kohya, T; Tomita, F, 2000)	1.03
"Aspirin (400 ppm) has a similar impact on reducing prostaglandin levels, but in contrast to indomethacin, is uneffective in reducing the tumor load."	( Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. Chiu, CH; McEntee, MF; Whelan, J, 2000)	1.35
"Aspirin has been shown to be a powerful inhibitor of post-Amadori Maillard reactions, although the exact mechanism of this action remains unclear. "	( Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking. Hadley, J; Malik, N; Meek, K, 2001)	2
"(2) Aspirin has essentially gastrointestinal adverse effects, whose incidence can be limited by prescribing a daily dose below 350 mg."	( Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account. , 2000)	0.79
"Aspirin has a well established role in the prevention of arterial thrombosis. "	( Time related neutralization of two doses acetyl salicylic acid. Aguejouf, O; Belon, P; Doutremepuich, C; Malfatti, E, 2000)	1.75
"Aspirin has been the mainstay of antiplatelet therapy in stroke prevention for 30 years. "	( Newer antiplatelet therapies in stroke prevention. Davis, SM; Donnan, GA, 2001)	1.75
"Aspirin has the potential to influence CRP release, either by its anti-inflammatory activity or by reducing myocardial necrosis."	( The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. Clarke, H; Cooper, J; Kennon, S; Mills, PG; Price, CP; Ranjadayalan, K; Timmis, AD, 2001)	1.39
"Aspirin has been shown to be beneficial after a myocardial infarction and for other acute coronary syndromes. "	( Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics? Elwood, P; Smith, A; Woollard, M, 2001)	2.12
"Aspirin has also demonstrated a potential ability to reduce the risk of deep venous thrombosis and pulmonary embolism."	( An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I. Moyad, MA, 2001)	1.36
"Aspirin has an anticoagulant effect due to its action on Cyclo-oxygenase and vitamin K dependent coagulation factors."	( Fetal intracranial hemorrhage due to antenatal low dose aspirin intake. Kutty, PM; Sajith, N; Sasidharan, CK, 2001)	1.28
"Aspirin has an essential place formally demonstrated in ISIS 2."	( [Fibrinolysis in myocardial infarction with EKG elevation. Optimization of myocardial reperfusion by treatment with antithrombotic agents]. Coste, P; Jaïs, C; Labèque, JN; Lafitte, S; Perron, JM; Roudaut, R; Zabsonré, P, 2001)	1.03
"Aspirin treatment has been shown to improve allergic diseases, especially asthma, and the decreased use of aspirin has been hypothesized to contribute to the increase in childhood asthma."	( Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. Keegan, AD; Melo, M; Perez-G, M; Zamorano, J, 2002)	2.48
"Aspirin has been reported to counteract the effects of ACE inhibitors in patients with heart failure."	( Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. Davie, AP; McMurray, JJ, 2002)	1.44
"Aspirin has no effect on the vasodilator response to bradykinin and substance P in patients with heart failure treated with an ACE inhibitor. "	( Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. Davie, AP; McMurray, JJ, 2002)	2.16
"Aspirin has been shown to inhibit prostaglandin synthetase and this could lead to functional impairment of the tissue."	( Aspirin, protein transacetylation and inhibition of prostaglandin synthetase in the kidney. Caterson, RJ; Duggin, GG; Horvath, J; Mohandas, J; Tiller, D, 1978)	2.42
"Aspirin has some advantage over acetaminophen for analgesia."	( Aspirin and acetaminophen: a comparative view of their antipyretic and analgesic activity. Lovejoy, FH, 1978)	2.42
"Aspirin has no effect on the course of glomerulonephritis in children."	( Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders. Breddin, K, 1977)	0.98
"Aspirin has been shown to acutely block the natriuretic effect of spironolactone in the mineralocorticoid-treated normal rat, dog, and man. "	( Failure of aspirin to antagonize the antihypertensive effect of spironolactone in low-renin hypertension. Hollifield, JW, 1976)	2.09
"Aspirin ototoxicity has been studied on guinea pigs by shiver-audiometry and histological investigation of the cochlear duct. "	( Aspirin ototoxicity in the guinea pig. Crifò, S, 1975)	3.14
"Aspirin has been recommended previously for persons at risk for cardiovascular disease."	( Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992)	2.45
"Aspirin also has an antiplatelet effect."	( The bleeding time effects of a single dose of aspirin in subjects receiving omega-3 fatty acid dietary supplementation. Mueller, BA; Prihoda, TJ; Talbert, RL; Tegeler, CH, 1991)	1.26
"Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated."	( Aspirin in the prevention of thrombosis. Bell, WR; Lekstrom, JA, 1991)	2.45
"Aspirin has been shown to be beneficial in the prophylaxis of arterial thromboembolic disease. "	( Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. Bucchi, F; Cerletti, C; Davies, JA; de Gaetano, G; Donati, MB; Hampton, KK; Loizou, LA; Prentice, CR, 1990)	1.95
"An aspirin test has been performed in 100 asthma patients. "	( [Bronchoconstrictive and bronchodilating effects of acetylsalicylic acid in patients with bronchial asthma]. Didkovskiĭ, NA; Evseev, NG; Treskunov, VK; Zakharzhevskaia, TV, 1990)	0.9
"Aspirin has been successfully used in the secondary prophylaxis of myocardial infarction, cerebral vascular events and peripheral arterial disease. "	( [Aspirin against aging? For whom and how much?]. Meier, PJ; Oelz, O, 1990)	2.63
"Aspirin has been tested for its benefit in preventing cardiovascular disease in randomized trials in three categories of patients. "	( Prevention of cardiovascular disease: risks and benefits of aspirin. Buring, JE; Hennekens, CH, )	1.82
"Aspirin intolerance has become increasingly important in clinical dermatology during the past decade, especially as a diagnostic aid in chronic urticaria. "	( [Clinical and pathogenetic aspects of aspirin intolerance]. Voigtländer, V, 1986)	1.98
"Aspirin has been disappointing."	( Deep venous thrombosis and pulmonary emboli: etiology, medical treatment, and prophylaxis. Coffman, JD, 1989)	1
"Aspirin has been convincingly shown to reduce the incidence of vascular occlusive events in a wide range of patients at risk of thrombotic complications. "	( Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Patrono, C, 1989)	3.16
"Aspirin has a membrane-stabilizing effect and it is used locally for the treatment of post- herpetic neuralgia."	( [Remarks on some analgesics used in the pain clinic]. Yamamura, H, 1989)	1
"Aspirin has antisecretory and ulcerogenic properties in the gastrointestinal tract. "	( Effects of acetylsalicylic acid on electromechanical activity of in vivo rabbit ileum. Dwyer, A; Koch, KL, 1988)	1.72
"Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis. "	( Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Harker, LA, 1986)	1.71
"Aspirin has significantly reduced both the occurrence of myocardial infarction and mortality rate in patients with unstable angina and/or previous myocardial infarction; it has also proved beneficial in cerebrovascular disease."	( Current issues in thrombosis prevention with antiplatelet drugs. Cerletti, C; de Gaetano, G; Dejana, E; Vermylen, J, 1986)	0.99
"Aspirin has a similar effect in vivo on both atrophic cartilage and osteoarthritic cartilage in the dog, although no in vivo effect of salicylate on normal joint cartilage has been observed."	( Nonsteroidal antiinflammatory drugs and articular cartilage. Brandt, KD, 1987)	0.99
"Aspirin has been reported to induce the adult respiratory distress syndrome (ARDS) in humans. "	( Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress syndrome. Krieger, BP; Suarez, M, 1986)	1.99
"Aspirin has been proven to inhibit PGs liberation."	( [Prostaglandins]. , 1973)	0.87

Actions

Aspirin was found to inhibit platelet thrombosis by thrombin in low doses (optimum dose 2.5 mg/kg body weight) Aspirin may cause a transient shedding of renal tubular cells, alterations in urate excretion, and inhibition of spironolactone action.

Excerpt	Reference	Relevance
"Aspirin is known to cause mucosal injury leading to increased gut permeability and tight junction damage and can be used as a model to study leaky gut in cattle."	( Effect of aspirin to intentionally induce leaky gut on performance, inflammation, and carcass characteristics of feedlot cattle. Briggs, NG; Godoi, LA; Schoonmaker, JP; Silva, BC, 2021)	1.75
"aspirin 81 mg) and an increase in expression of platelet proteins corresponding to ARS genes."	( An antiplatelet response gene expression signature is associated with bleeding. Friede, KA; Gales, J; Ginsburg, GS; Kraus, WE; Myers, RA; Ortel, TL; Shah, SH; Voora, D; Zhbannikov, I, 2023)	1.63
"Aspirin did not increase bleeding in SA positive patients."	( Staphylococcus aureus increases platelet reactivity in patients with infective endocarditis. Akhyari, P; Barth, M; Dannenberg, L; Helten, C; Hoffmann, T; Hohlfeld, T; Huhn, R; Kelm, M; Levkau, B; Lichtenberg, A; M'Pembele, R; Mourikis, P; Naguib, D; Petzold, T; Polzin, A; Sixt, S; Zako, S; Zeus, T, 2022)	1.44
"Aspirin can inhibit the malignant behavior of ESCC cells by downregulating ATAD2 and KIF4A."	( Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A. Liu, C; Liu, H; Ren, Z; Wang, X; Zhang, M; Zhao, J; Zheng, Z, 2022)	2.89
"Aspirin and dapsone inhibit the activation of both IFN-1 and NF-κB by targeting cGAS."	( COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs. Altschuler, EL; Balentine, J; Bourbeau, J; Coleman, M; Kanwar, B; Kast, RE; Khattak, A; Lee, CJ; Lee, JH; Nguyen, NH; Nguyen, TNM; Oh, S; Sergi, CM; Sohn, MG, 2022)	1.44
"Aspirin plays a key role in the treatment and prognosis of BC."	( Low-dose aspirin can inhibit exosomal release induced by radiotherapy in breast cancer and attenuate its inhibitory effect on NK cell proliferation. Chen, C; Chen, T; Hu, Z; Li, W; Wang, L; Yang, Z; Yao, Z, 2023)	2.05
"Aspirin did not produce a statistically significant reduction in the incidence of ischemic stroke (hazard ratio [HR], 0.89; 95% CI, 0.71-1.11)."	( Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial. Cloud, GC; Donnan, GA; Eaton, CB; Fitzgerald, SM; Lockery, J; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Reid, CM; Shah, RC; Thao, LTP; Tran, C; Williamson, JD; Wolfe, R; Woods, RL, 2023)	2.05
"Aspirin can inhibit the proliferation activity of myeloma cells by down-regulating Blimp1 expression in myeloma cells and up-regulating ATF4 and CHOP expression, therefore plays an anti-tumor rote."	( [Expression of Blimp1、ATF4 and CHOP in Multiple Myeloma Cells and Effect of Aspirin on Their Expression]. Geng, J; Li, J; Liu, HC; Liu, JW; Pei, L; Ren, ZZ; Xiong, C, 2020)	1.51
"Aspirin may increase the risk of lower gastrointestinal bleeding (LGIB) from precursors of colorectal cancer (CRC). "	( Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study. Erichsen, R; Farkas, DK; Sørensen, HT; Troelsen, FS, 2020)	2.22
"Aspirin could inhibit NLRP1 inflammasome in endothelial cells, and clopidogrel could also provoke a reduction in vascular inflammation."	( Effect of clopidogrel vs. aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells. ECLOAS study. Acin, F; Bleda, S; de Haro, J; Laime, I; Sánchez, I, )	1.15
"Aspirin tended to increase jejunal CLDN-1 mRNA expression (P = 0.10) but did not affect the mRNA expression of other genes regulating tight junction function (P ≥ 0.20)."	( Use of aspirin to intentionally induce gastrointestinal tract barrier dysfunction in feedlot cattle. Brennan, KM; Briggs, NG; Funnell, BJ; Nicholls, GT; Schoonmaker, JP, 2020)	1.73
"Aspirin cannot cause major haemorrhage, but in the elderly it can cause gastrointestinal bleeding via ulceration of the gastrointestinal mucosa."	( Additive effect of dabigatran and high-dose aspirin in the development of haemorrhagic pleural effusion in a patient with tuberculous pleuritis. Barış, VÖ; Karagül, DA; Karnak, D, 2020)	1.54
"Aspirin is able to inhibit the growth of cancers through targeting nuclear factor κB (NF-κB)."	( Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling. Feng, J; Liu, Y; Wang, T; Wang, Y; Yang, G; Ye, L; Zhang, X; Zhao, M, 2017)	2.62
"Aspirin dose increase in unresponsive patients is associated with reduced risk of thrombosis."	( Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery. DiNardo, JA; Emani, S; Emani, SM; Mulone, M; Trenor, CC; Zurakowski, D, 2017)	1.48
"Aspirin plays a crucial role in the prevention of cardiovascular diseases. "	( Aspirin Inhibits Platelet-Derived Sphingosine-1-Phosphate Induced Endothelial Cell Migration. Böhm, A; Dannenberg, L; Kelm, M; Knoop, B; Levkau, B; Polzin, A; Rauch, BH; Zeus, T; Zurek, M, 2018)	3.37
"Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity."	( [Aspirin and colorectal cancer]. Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018)	2.11
"Aspirin plays a pivotal role in the management of patients with Coronary Artery Disease (CAD) with well-recognised benefits of reducing recurrent myocardial infarction and minimising the risk of stent thrombosis for those undergoing Percutaneous Coronary Intervention (PCI). "	( Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing? Alexopoulos, D; Kassimis, G; Raina, T, 2019)	3.4
"Aspirin users had a lower incidence rate of total AECOPD (adjusted incidence rate ratio [IRR], 0.78; 95% CI, 0.65-0.94), with similar effect for moderate but not severe AECOPD (IRR, 0.86; 95% CI, 0.63-1.18)."	( Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study. Aaron, CP; Barr, RG; Bowler, RP; Comellas, AP; Cooper, CB; Dransfield, MT; Fawzy, A; Han, MK; Hansel, NN; Hoffman, EA; Kanner, RE; Krishnan, JA; Labaki, WW; Paine, R; Paulin, LM; Peters, SP; Putcha, N; Wise, R, 2019)	2.68
"Aspirin plays a well-established role in this setting, and for a long time, clopidogrel use has been restricted to patients allergic to aspirin."	( Dual platelet antiaggregation therapy after myocardial revascularization surgery. Batista, DV; Feitosa, MPM; Lima, EG; Linhares Filho, JPP; Lobo Filho, HG; Serrano Júnior, CV; Soffiatti, CD, 2019)	1.24
"Aspirin plays an important role in the prevention and therapy of pre-eclampsia."	( Ameliorative effects of pre-eclampsia by quercetin supplement to aspirin in a rat model induced by L-NAME. Ma, Y; Shi, X; Song, L; Yang, S; Zhao, N, 2019)	1.47
"Aspirin did not inhibit the proliferation of HCC cells, but it decreased the invasiveness of HCC with lower expression of HTATIP2 and increased expression of a set of markers, indicating a mesenchymal-to-epithelial transition in tumor cells."	( Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013)	2.55
"Aspirin may cause teratogenicity and fetal toxicity, and perinatal mortality is increased."	( Antithrombotic therapy for pregnant women. Toyoda, K, 2013)	1.11
"Aspirin users had a lower lymphadenectomy rate in comparison with patients in the control group (p = .001)."	( Safety of perioperative aspirin therapy in minimally invasive endometrial cancer staging. Bogani, G; Casarin, J; Cromi, A; Ghezzi, F; Pinelli, C; Serati, M; Uccella, S, )	1.16
"The aspirin-dependent increase of netrin-1 in ApoE(-/-) mice exerts anti-atherogenic effects by preventing arterial accumulation of monocytes."	( Aspirin-induced histone acetylation in endothelial cells enhances synthesis of the secreted isoform of netrin-1 thus inhibiting monocyte vascular infiltration. Alfieri, A; Andia, ME; Botnar, RM; Cooper, M; Ferro, A; Lavin, B; Passacquale, G; Phinikaridou, A; Warboys, C, 2015)	2.34
"Aspirin did, however, increase the risk of major bleeding."	( Role of aspirin for prevention and treatment of perioperative cardiovascular events. Devereaux, PJ; Duceppe, E; Mrkobrada, M; Thomas, S, 2015)	1.57
"Aspirin plays a key role in preventing IPS."	( In-Pipeline Stenosis: Incidence, Predictors, and Clinical Outcomes. Barros, G; Chalouhi, N; Daou, B; Gonzalez, LF; Hasan, D; Jabbour, P; Judy, B; Kung, D; Polifka, A; Rosenwasser, RH; Starke, RM; Tjoumakaris, S, 2015)	1.14
"Aspirin's ability to inhibit cell proliferation and induce apoptosis in cancer cell lines is considered to be an important mechanism for its anti-cancer effects. "	( Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53. Ai, G; Alfonso, LF; Bhat, GJ; Dachineni, R; Kumar, DR; Marimuthu, S, 2016)	3.32
"Aspirin is likely to increase the risk of major bleeding events."	( Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Brunskill, NJ; Dawson, S; Gray, LJ; Major, RW; Oozeerally, I; Riddleston, H, 2016)	2.6
"Aspirin benefits increase with duration of treatment, especially after 10years of treatment."	( Aspirin, platelets, and cancer: The point of view of the internist. Boccatonda, A; Davì, G; Santilli, F, 2016)	2.6
"Aspirin treatment may inhibit the progression of ovarian cancer in the hen and egg production may be used to identify hens with early stages of the disease."	( Dietary aspirin decreases the stage of ovarian cancer in the hen. Giles, JR; Johnson, PA; Urick, ME, 2009)	2.23
"Aspirin is known to cause a multitude of pharmacologic actions through inhibition of cyclooxygenase(s) and reduced formation of prostaglandins. "	( Nitric oxide and aspirin: a new mediator for an old drug. Schröder, H, )	1.91
"Aspirin can inhibit the cell growth and suppress the protein level of cyclin D(1) after CSE affected EC109 cell line."	( Influence of aspirin and cigarette smoke extract on the expression of cyclin D1 and effects of cell cycle in esophageal squamous cell carcinoma cell line. Hu, H; Zhang, S; Zhu, S, 2009)	1.44
"Aspirin is known to suppress platelet function markedly. "	( Augmentation of U46619 induced human platelet aggregation by aspirin. Jin, J; Kim, JM; Koo, YK; Lee, YY; Park, S; Yun-Choi, HS, 2009)	2.04
"Aspirin did not inhibit and did not interfere with the effects of clopidogrel or cangrelor using this test."	( Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Fox, SC; Heptinstall, S; May, JA; Neubert, U; Shah, A, 2009)	1.28
"Aspirin may inhibit hypoxic hypercapnia pulmonary hypertension and pulmonary vessel remodeling."	( [Effect of aspirin on pulmonary hypertension in rat during chronic hypoxia and hypercapnia]. Chen, SX; Fan, XF; Wang, LX; Wang, MS; Zeng, HH, 2003)	2.15
"Aspirin does not increase bleeding or increase the need for allogeneic blood transfusion in coronary artery surgery."	( Aspirin does not increase bleeding and allogeneic blood transfusion in coronary artery surgery. Hijazi, E, 2011)	3.25
"Aspirin reduced all-cause mortality (RR 0.94; 95% CI, 0.88-1.00), myocardial infarction (RR 0.83; 95% CI, 0.69-1.00), ischemic stroke (RR 0.86; 95% CI, 0.75-0.98), and the composite of myocardial infarction, stroke, or cardiovascular death (RR 0.88; 95% CI, 0.83-0.94), but did not reduce cardiovascular mortality (RR 0.96; 95% CI, 0.84-1.09)."	( Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Eikelboom, J; Hirsh, J; O'Donnell, M; Raju, N; Sobieraj-Teague, M, 2011)	1.49
"Aspirin and NSAIDs inhibit COX-2."	( COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Chen, WY; Colditz, GA; Collins, L; Hankinson, SE; Holmes, MD; Schnitt, SJ; Tamimi, RM, 2011)	1.31
"Aspirin seems to produce these effects through its antioxidative properties, since it was found to prevent the increase in aortic O2- production observed in chronically glucose-fed rats."	( Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. de Champlain, J; El Midaoui, A; Wu, R, 2002)	1.27
"Aspirin reduced all-cause mortality by 18%. "	( Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Graham, DY; Weisman, SM, 2002)	2.01
"Aspirin is known to inhibit vascular smooth muscle cell proliferation and to produce an endothelial stabilizing effect."	( Nonplatelet-mediated effects of aspirin. Aude, YW; Mehta, JL, 2002)	1.32
"Aspirin could inhibit the AP-1 binding activation stimulated by fetal calf serum."	( [Inhibition effect of aspirin on the growth of gastric cancer and the mechanism there-in involved]. Tang, C; Wang, C, 2003)	1.35
"Aspirin at the lower dose (30 mg/kg) protects the endothelium against damages elicited by LDL in vivo, and the protective effect of aspirin on endothelium is related to reduction of ADMA concentration by increasing DDAH activity."	( Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Deng, HD; Deng, PY; Deng, S; Jiang, JL; Li, YJ; Yang, TL; Ye, F; Yu, J, 2004)	3.21
"Aspirin was found to cause severe haemorrhagic lesions mainly through oxidative damage of the mucosa as indicated by increased lipid peroxidation, conjugated diene, protein carbonyl content, decreased levels of antioxidant defense enzymes and alteration in the lipid levels."	( Effect of ambrex (an amber based formulation) on gastric mucosal damage: role of antioxidant enzymes and lipid profile. Devi, CS; Jainu, M, 2004)	1.04
"Aspirin produces an increase of CD36 expression in THP-1 macrophages by a PGE(2)-dependent mechanism. "	( Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Alegret, M; Bermúdez, I; Laguna, JC; Llaverias, G; Sanchez, RM; Vázquez-Carrera, M; Viñals, M, 2005)	3.21
"Aspirin is known to produce severe adverse gastrointestinal effects, such as bleeding and perforation."	( Minidose aspirin and gastrointestinal bleeding--a retrospective, case-control study in hospitalized patients. Eliakim, R; Fishman, M; Hershkovici, M; Niv, Y; Sapoznikov, B; Vilkin, A, 2005)	1.47
"Aspirin use was lower among African Americans and Hispanics than Whites (28.6% and 28.7% vs 37.1%, respectively)."	( Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. Brown, DW; Croft, JB; Giles, WH; Greenlund, KJ; Shepard, D, 2005)	1.33
"Aspirin can inhibit inflammatory reactions and platelet aggregation, but little is known about the effects of the combination of aspirin plus clopidogrel, a new antiplatelet agent, on inflammation. "	( Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chen, YG; Ji, QS; Li, RJ; Lü, RJ; Sun, Y; Xu, F; Zhang, Y, 2006)	2.18
"Aspirin was shown to increase oxygen affinity of hemoglobin via acetylating lysine residues and its general acetylating activity on proteins such as histones makes it also an interesting candidate to activate fetal hemoglobin."	( Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale. Altinoz, MA; Carin, MN; Gedikoglu, G; Ozdilli, K, 2007)	1.33
"Aspirin and ibuprofen enhance the effect of pyrazinamide during the initial phase of tuberculosis treatment in the mouse model. "	( Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. Byrne, ST; Denkin, SM; Zhang, Y, 2007)	3.23
"Aspirin enhance the recurrence of gastric ulcer. "	( Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. Guo, CJ; Huang, GP; Jia, BB; Wang, GZ; Wang, JF; Xie, CG; Yin, GL; Zhou, G, 2007)	3.23
"Aspirin's ability to suppress platelet function varies widely among individuals and lesser suppression of platelet function is associated with increased risk of myocardial infarction, stroke and cardiovascular death."	( Pharmacogenomics of platelet responsiveness to aspirin. Becker, DM; Becker, LC; Faraday, N, 2007)	1.32
"Aspirin could inhibit the proliferation of cell lines EC109 and EC9706, pretreated with EE for 5 hours, in a dose-dependent manner."	( Aspirin inhibits the proliferation of tobacco-related esophageal squamous carcinomas cell lines through cyclooxygenase 2 pathway. Ding, XC; Li, P; Liu, HB; Yu, ZL; Zhang, ST; Zhou, QZ, 2007)	2.5
"Aspirin can inhibit the proliferation of ESCC cell lines induced by EE, which suggests it may be advantageous in the chemoprevention and therapy of human tobacco-related ESCC."	( Aspirin inhibits the proliferation of tobacco-related esophageal squamous carcinomas cell lines through cyclooxygenase 2 pathway. Ding, XC; Li, P; Liu, HB; Yu, ZL; Zhang, ST; Zhou, QZ, 2007)	2.5
"Aspirin can cause bronchoconstriction in some asthmatic patients through increased production of proinflammatory mediators, particularly leukotrienes. "	( Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma. Hopkinson, P; Lipworth, BJ; Meldrum, KT; Menzies, D; Nair, A, 2008)	2.19
"Aspirin plays a key role in the secondary prevention of atherothrombotic events and thrombotic complications after stent implantation."	( Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Angiolillo, DJ; Bass, TA; Gavazzi, A; Invernizzi, P; Mihalcsik, L; Musumeci, G; Rossini, R; Scuri, P, 2008)	2.51
"2 Aspirin-like drugs inhibit prostaglandins I2 and E2, synthesis, which explains their anti-algic effect."	( Peripheral analgesia: mechanism of the analgesic action of aspirin-like drugs and opiate-antagonists. Ferreira, SH, 1980)	1.06
"Aspirin, known to inhibit platelet function markedly, seems to have little effect on isolated vascular smooth muscle."	( Cerebral vasospasm: effects of prostaglandin synthetase inhibitors in vitro. Chapleau, CE; Robertson, JT; White, RP, 1980)	0.98
"Aspirin is known to produce a reversible loss of hearing that can be as great as 40 dB, depending upon the dose and the individual subject. "	( Aspirin can potentiate the temporary hearing loss induced by intense sounds. McFadden, D; Plattsmier, HS, 1983)	3.15
"Thus aspirin does not inhibit the hydroperoxidase component of prostaglandin endoperoxide synthetase, and co-oxidation of acetaminophen and benzidine may proceed in the presence of aspirin."	( Effect of aspirin on metabolism of acetaminophen and benzidine by renal inner medulla prostaglandin hydroperoxidase. Davis, BB; Mattammal, MB; Rapp, NS; Zenser, TV, 1983)	1.12
"Aspirin may cause a transient shedding of renal tubular cells, alterations in urate excretion, inhibition of spironolactone action, and, in certain clinical settings, a reversible decline in renal function manifested as a fall in glomerular filtration that may be accompanied by mild water, sodium, and potassium retention."	( Acute effects of aspirin and acetaminophen on renal function. Kimberly, RP; Plotz, PH, 1981)	1.32
"Aspirin was found to inhibit platelet thrombosis by thrombin in low doses (optimum dose 2.5 mg/kg body weight), but at higher doses the aspirin was less effective."	( Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo. Kajiwara, Y; Quattrociocchi-Longe, T; Shanberge, JN, 1995)	1.41
"Nonaspirin NSAIDs inhibit cyclooxygenase reversibly and, therefore, the duration of their action depends on specific drug dose, serum level, and half-life."	( Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. Schafer, AI, 1995)	0.81
"The aspirin-induced increase in PMN adherence to HUVEC was significantly reduced by monoclonal antibodies against CD18, CD11b, CD11a, and intercellular adhesion molecule 1."	( Molecular determinants of aspirin-induced neutrophil adherence to endothelial cells. Anderson, DC; Granger, DN; Kvietys, PR; McIntire, LV; Takemura, T; Wolf, RE; Yoshida, N, 1993)	1.07
"Aspirin may directly increase cholesterol transport into bile or have cell membrane effects which alter cholesterol transport."	( Oral acetylsalicylic acid induces biliary cholesterol secretion in the rat. Gebhard, RL; Prigge, WF, 1997)	1.02
"Aspirin may suppress tumour incidence via salicylate by enhancing apoptosis in carcinogen-initiated cells."	( Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Barnes, CJ; Cameron, IL; Hardman, WE; Lee, M, 1998)	1.02
"Aspirin use was lower among older patients (P = 0.02) but did not differ by gender or type of insurance plan."	( Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated? Hill, JW; Roglieri, JL; Warburton, SW, 1998)	2.46
"Aspirin is known to cause adverse effects, including gastric mucosal injury, and to retard gastric wound healing. "	( Effects of growth factors on aspirin-induced inhibition of wound repair in a rabbit gastric epithelial cell model. Hirose, M; Kitamura, T; Miwa, H; Miyazaki, A; Ogihara, T; Oide, H; Osada, T; Sato, K; Sato, N; Takei, Y; Watanabe, S; Yamamoto, J; Yoshizawa, T, 2000)	2.04
"Aspirin is known to cause gastric injury and to delay ulcer healing. "	( Aspirin effects on gastric epithelial cell proliferation and cytokine expression. Becker, JC; Domschke, W; Konturek, JW; Lügering, N; Markmann, A; Pauels, HG; Pohle, T, 2001)	3.2
"The aspirin-induced increase in collateral flow was confined to epicardium (12 +/- 4% of normal zone flow at 5 minutes to 23 +/- 4% at 4 hours after occlusion)."	( Aspirin-induced increase in collateral flow after acute coronary occlusion in dogs. Aamodt, R; Capurro, NL; Epstein, SE; Goldstein, RE; Marr, KC, 1979)	2.18
"Aspirin did not inhibit white body formation but another non-steroid anti-inflammatory agent, flurbiprofen was able to do so, as was the anti-gout agent, sulphinpyrazone."	( The effect of agents which modify platelet behaviour and of magnesium ions on thrombus formation in vivo. Adams, JH; Mitchell, JR, 1979)	0.98
"Aspirin-induced increase in the mast cell population of the stomach was also prevented."	( Inhibition of mast cell population by L-glutamine in aspirin-induced ulceration in rat stomach. Mitra, R; Pal, SP, )	1.1
"Aspirin-like drugs inhibit the biosynthesis of prostaglandins in all tissues and species so far studied. "	( The mode of action of aspirin and similar compounds. Vane, JR, 1976)	2.01
"Aspirin may produce these actions by two mechanisms, one of them like that of indomethacin which is dependent on the inhibition of biosynthesis of prostaglandins, and another possible mechanism that is not related to the inhibition of prostaglandin biosynthesis."	( Effect of aspirin and indomethacin on the serum and urinary calcium, magnesium and phosphate. Ghaneimah, SA; Gomaa, AA; Hassan, HA, )	1.26
"Aspirin did not fully inhibit the collagen stimulated IP formation either in vitro or in vivo, and the response to thrombin was unaffected."	( Dose-dependent inhibition of phosphoinositide metabolism in human platelets by aspirin in vitro and in vivo. Bochner, F; Godfrey, PP; Grahame-Smith, DG, 1986)	1.22
"Aspirin did not cause any change in either the BUN concentration, its 15N enrichment, or any of the plasma amino acids."	( The effect of aspirin on protein breakdown in septic man. Marino, PL; Miccolo, M; Novick, WM; Stein, TP, 1986)	1.35
"Both aspirin (ASA) and TR inhibit platelet cyclooxygenase but the effects of these drugs are different."	( Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxygenase in rats. Albors, M; De Castellarnau, C; Rutllant, ML; Sancho, MJ; Vila, L, 1988)	0.73
"Aspirin given in a lower dose (20 mg/kg) did not show significant difference from the vehicle group."	( Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. Hulsman, LO; Kort, WJ; van Schalkwijk, WP; Weijma, IM; Westbroek, DL; Zondervan, PE, 1986)	1.32
"Thus aspirin can produce occult gastrointestinal blood loss by a mechanism unrelated to hydrochloric acid."	( Influence of achlorhydria on aspirin-induced occult gastrointestinal blood loss: studies in Addisonian pernicious anaemia. John, DJ; McDermott, FT, 1970)	0.99

Treatment

Aspirin and/or CLOP treatment prior to TBI is a double-edged sword that exerts a dual effect post-injury. Aspirin treatment appears to be a reasonable choice for thrombocytopenic (> 30 × 109/l) patients with acute coronary syndrome.

Excerpt	Reference	Relevance
"Aspirin treatment after desensitization (ATAD) represents an effective therapeutic option suitable for NSAID-exacerbated respiratory disease (N-ERD) patients with recalcitrant disease. "	( A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease. Andrews, PJ; Pendolino, AL; Scadding, GK; Scarpa, B, 2022)	2.4
"Aspirin co-treatment rescued DNMTs activation and BDNF IV hypermethylation, and mitigated the recession in BDNF mRNA and protein induced by B[a]P treatment."	( Aspirin ameliorates the cognition impairment in mice following benzo[a]pyrene treatment via down-regulating BDNF IV methylation. Bai, J; Cao, J; Hao, Z; Li, H; Li, X; Li, Y; Liu, A; Wang, Z; Xia, N; Zhang, H; Zhang, Z, 2022)	2.89
"Aspirin and/or CLOP treatment prior to TBI is a double-edged sword that exerts a dual effect post-injury."	( The effect of clopidogrel and aspirin on the severity of traumatic brain injury in a rat model. Dakroub, F; Dalloul, Z; Darwish, H; El-Achkar, GA; Habib, A; Hamade, E; Kobeissy, F; Mallah, K; Mallah, Z; Mohamed, W; Mondello, S; Nasrallah, L; Nasser, M; Ramadan, N; Zibara, K, 2022)	1.73
"Aspirin treatment appears to be a reasonable choice for thrombocytopenic (> 30 × 109/l) patients with acute coronary syndrome."	( [Which anticoagulant or antiplatelet treatment for cancer patients with thrombocytopenia ?] Azizi, MA; Efthymiou, A; Paoletti, M, 2023)	1.63
"Aspirin treatment in ICU patients, especially in nonseptic patients, was associated with a lower 28-day all-cause mortality on multivariate Cox analysis (eICU-CRD, hazard ratio [HR] = 0.81, [95% CI, 0.75-0.87]; MIMIC-III, HR = 0.72 [95% CI, 0.68-0.76])."	( Aspirin Therapy and 28-Day Mortality in ICU Patients: A Retrospective Observational Study From Two Large Databases. Guan, X; Li, B; Liu, Y; Liu, Z; Nie, Y; Pei, F; Wang, L; Wu, J; Zuo, L, 2023)	3.07
"Aspirin treatment during the ICU stay was associated with a significantly reduced 28-day all-cause mortality, particularly in patients with SIRS symptoms but without sepsis. "	( Aspirin Therapy and 28-Day Mortality in ICU Patients: A Retrospective Observational Study From Two Large Databases. Guan, X; Li, B; Liu, Y; Liu, Z; Nie, Y; Pei, F; Wang, L; Wu, J; Zuo, L, 2023)	3.8
"Aspirin treatment was associated with a 20% reduction in colorectal polyp number at BCSP surveillance colonoscopy 12 months later."	( Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use. Brown, LC; Downing, A; Fenton, H; Hull, MA; Loadman, PM; Morris, EJA; Nickerson, C; Rees, CJ; Williams, EA, 2023)	1.83
"In aspirin-treated CAD patients, the laboratory aspirin resistance predicts all-cause death and TVR."	( Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. Bai, J; Chen, J; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Wang, F; Wang, J; Xu, K; Zhou, Y, 2019)	1.27
"Aspirin treatment also had favorable therapeutic effects on bone regeneration in the bone defect model, and the number of osteoclasts was decreased."	( Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation. Bai, Y; Du, J; Guo, L; Jia, L; Jiang, Y; Liu, Y; Luo, Z; Wu, L, 2019)	2.68
"Aspirin treatment promoted bone regeneration by inhibiting DDOC activation in the early stages of inflammation in a rat mandibular bone defect model."	( Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation. Bai, Y; Du, J; Guo, L; Jia, L; Jiang, Y; Liu, Y; Luo, Z; Wu, L, 2019)	2.68
"Aspirin treatment should be considered only when the CV risk is very high and the bleeding risk is low, after taking into account the patient's preferences."	( Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. Aimo, A; De Caterina, R, 2020)	2.72
"Aspirin treatment reduced AA-induced platelet aggregation in both HTx groups, but HTx patients with CAV had higher platelet aggregation on-aspirin than HTx patients without CAV (p < 0.05)."	( Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy. Berg, K; Bjerre, KP; Clemmensen, TS; Eiskjær, H; Grove, EL; Hvas, AM; Jakobsen, L; Kristensen, SD; Løgstrup, BB; Poulsen, SH; Thim, T, 2020)	1.55
"Aspirin treatment during pregnancy seemed to reduce the incidence of hs-PDA in preterm infant and to increase infant responsiveness to postnatal medical treatment of PDA."	( Effects of maternal aspirin treatment on hemodynamically significant patent ductus arteriosus in preterm infants - pilot study. Beer, G; Fridman, E; Kapusta, L; Mandel, D; Mangel, L; Marom, R, 2022)	2.49
"Aspirin treatment for two weeks showed no hyperuricaemic effect in people over 60."	( Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial. Chen, XH; Liang, WY; Liu, ML; Liu, WW; Wang, H; Zhang, P, 2020)	1.61
"Aspirin treatment modified metabolites involved in suppressing lipogenesis, oxidative stress, and neoplastic formation."	( Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth. Chiu, HH; Hsieh, CC; Kuo, CH; Wang, CH, 2020)	2.72
"In aspirin-treated patients with high levels of MRP4, reduced SNP inhibition was found compared to those with low levels of MRP4."	( MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation. Alemanno, L; Angiolillo, DJ; Conti, L; Guarino, ML; Massimi, I; Pulcinelli, FM, 2021)	1.14
"Aspirin is a safe treatment for patients with concurrent small UIAs and ICVD. "	( Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms. Cao, Y; Du, X; Fu, WL; Huo, R; Jiao, YM; Li, H; Wang, J; Wang, S; Weng, JC; Xu, HY; Yan, ZH; Zhao, JZ, 2021)	2.47
"Aspirin treatment antagonized vascular stiffening and rivaroxaban treatment led to a positive trend towards reduced stiffening."	( Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery. Brouns, AE; Chayoua, W; Coenen, DM; Cosemans, JMEM; Debets, J; Heitmeier, S; Karel, MFA; Konings, J; Korsten, EIJ; Kuijpers, MJE; Leenders, PJA; Mastenbroek, TG; Nagy, M; Spronk, HM; van Essen, H; van Oerle, R, 2020)	1.57
"Aspirin co-treatment with levetiracetam did not result in a significant improvement."	( Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020)	1.57
"Aspirin is the key treatment in the secondary prevention of atherosclerotic cardiovascular disease. "	( Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease. Liang, W; Liu, M; Zhang, P, 2021)	2.3
"Aspirin treatment was started in 53 of the 286 patients (18.5%) due to arthritis."	( Aspirin-induced hepatotoxicity and anemia in children with acute rheumatic fever. Altay, D; Arslan, D; Baykan, A; Pamukçu, Ö; Üzüm, K, 2021)	2.79
"Aspirin treatment also increased the number of newborn neurons with anatomic integration through improving the survival of the newly generated cells."	( Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic mice. Hu, M; Liu, JX; Liu, Y; Yuan, B; Zhu, K, 2017)	2.62
"Aspirin treatment during the chronic stage of TLE could attenuate the spontaneous recurrent seizures in mice. "	( Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic mice. Hu, M; Liu, JX; Liu, Y; Yuan, B; Zhu, K, 2017)	3.34
"Aspirin treatment during the acute phase of infection reduced parasitemia (P<.05). "	( Myenteric neuroprotective role of aspirin in acute and chronic experimental infections with Trypanosoma cruzi. Araújo, EJA; Araújo, SM; Belém, MO; Buttow, NC; Carlos, TM; Gouveia, R; Luchetti, BFC; Massocatto, CL; Moreira, NM; Oda, JY; Pinge-Filho, P; Sant Ana, DMG, 2017)	2.18
"Aspirin treatment suppressed toll‑like receptor (TLR)4 and nuclear factor (NF)‑κB expression in cerebrovascular endothelial cells."	( Aspirin ameliorates cerebral infarction through regulation of TLR4/NF‑κB‑mediated endoplasmic reticulum stress in mouse model. Cui, X; Shen, B; Sun, D; Wang, X, 2018)	2.64
"Aspirin pretreatment prevented the diffuse thrombosis of cortical and subcortical vessels after aSDH."	( Direct visualization of microcirculation impairment after acute subdural hemorrhage in a novel animal model. Hsieh, ST; Huang, SJ; Lee, JE; Lin, WC; Po-Hao Huang, A; Tsai, JC; Wang, HC; Wang, KC, 2018)	1.2
"The Aspirin-Cardio treatment reduced the mean score of GI symptom severity from the questionnaire (1.4-1.6 times, р=0.001), requirement for proton pump inhibitors (р=0.002) and endoscopy during the ASA treatment the mean score of GI symptom questionnaire >3 predicted non-compliance or insufficient compliance with a diagnostic sensitivity of 58.9 % and specificity of 56.3 % (р=0.002), which makes this value a threshold for considering a modification of the treatment."	( [Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study]. Karpukhina, EV; Nekrasov, AA; Petelina, IS; Timoshchenko, ES, 2017)	1.01
"Aspirin treatment (100 mg/day) (n = 50) or usual therapy (n = 61). "	( Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E, 2018)	3.37
"Aspirin treatment decreased renal disease progression in a model adjusted for age, baseline kidney function, and diabetes mellitus (HR, 0.272; 95% CI, 0.077-0.955; p = 0.043) but did not when adjusted for albuminuria."	( Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E, 2018)	2.64
"Aspirin treatment significantly decreased the levels of pro-inflammatory cytokines in serum and placenta tissues of preeclampsia rats."	( Ameliorative effects of aspirin against lipopolysaccharide-induced preeclampsia-like symptoms in rats by inhibiting the pro-inflammatory pathway. Liu, F; Lu, X; Sun, J; Tang, D; Zhang, H, 2018)	1.51
"Aspirin treatment also increased the level of phospho-CREB in the nigra of C57/BL6 mice."	( Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease. Dasarathi, S; Jana, M; Pahan, K; Pahan, P; Rangasamy, SB, 2019)	1.65
"Aspirin treatment improves multiple functions of PE-DMSCs."	( Low-dose aspirin treatment enhances the adhesion of preeclamptic decidual mesenchymal stem/stromal cells and reduces their production of pro-inflammatory cytokines. Brennecke, SP; Georgiou, HM; Kalionis, B; Khanabdali, R; Murthi, P; Shakouri-Motlagh, A; Wilkinson, S, 2018)	1.62
"Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice."	( Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019)	1.49
"Aspirin treatment induced marginal improvements in ozone-induced uterine blood flow impairment."	( Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats. Dye, JA; Farraj, AK; Henriquez, AR; Jarrell, LT; Kodavanti, UP; Ledbetter, AD; Miller, CN; Richards, JH; Schaldweiler, M; Snow, SJ; Stewart, EJ, 2019)	2.68
"Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup."	( Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019)	1.65
"Aspirin may improve treatment outcomes and increase the survival of patients with prostate cancer, but the results remain controversial."	( Aspirin use improves the biochemical control of prostate cancer in Chinese men. Gong, H; Hao, Q; Huang, S; Wang, T; Zhang, Y; Zhou, Y; Zong, H, )	3.02
"Aspirin pretreatment of HP-diabetic animals is manifested with significantly lower blood and liver glucose, higher G6P concentration, lower G6P-ase and HK activity as well as higher Glk content and GPho-ase activity, compared both to diabetic and HP-diabetic animals."	( Heat preconditioning and aspirin treatment attenuate hepatic carbohydrate-related disturbances in diabetic rats. Cipanovska, N; Dervisevic, M; Dimitrovska, M; Dinevska-Kjovkarovska, S; Miova, B, 2019)	1.54
"Both aspirin-treated and naproxen-treated mice had normal forelimb use in the week after injury, whereas control mice favored the injured forelimb until day 7."	( Naproxen impairs load-induced bone formation, reduces bone toughness, and diminishes woven bone formation following stress fracture in mice. Fertala, A; Park, J; Tomlinson, RE, 2019)	0.97
"Aspirin pretreatment reduced the increase in the aforementioned parameters to a certain degree and partially improved the histopathological alterations caused by cerulein."	( Long-term aspirin pretreatment in the prevention of cerulein-induced acute pancreatitis in rats. Akyazi, I; Bala, DA; Cırakli, ZL; Ekiz, EE; Eraslan, E; Gülçubuk, A; Haktanir, D; Matur, E; Ozcan, M; Ozkurt, M, 2013)	1.51
"Aspirin treatment resulted in a non-significant reduction in polyp number and a significant reduction in polyp size among patients treated with aspirin for more than 1 year."	( Chemoprevention in Lynch syndrome. Bishop, DT; Burn, J; Mathers, JC, 2013)	1.11
"Aspirin treatment inhibited cell proliferation and caused early apoptosis in glioma, coupled with reduced S100A9 levels."	( Overexpression of S100A9 in human glioma and in-vitro inhibition by aspirin. Chen, S; Cheng, Y; Deng, J; Huang, N; Huang, Q; Liao, P; Wang, F, 2013)	1.35
"Aspirin pretreatment reduced the incidence and intensity of flushing without affecting GI events or the DR-DMF PK profile."	( Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Dawson, KT; Huang, R; Milne, GL; Nestorov, I; Novas, M; O'Gorman, J; Russell, H; Scannevin, RH; Sheikh, SI, 2013)	1.33
"Aspirin treatment led to a significant reduction in mortality (P<0.0001)."	( Aspirin reduces lung cancer metastasis to regional lymph nodes. Amano, H; Hosono, K; Ito, Y; Kitasato, H; Majima, M; Matsui, Y; Ogawa, F; Satoh, Y, 2014)	2.57
"Aspirin-treated patients were older than patients in the control group (71 [range, 50-85] vs."	( Safety of perioperative aspirin therapy in minimally invasive endometrial cancer staging. Bogani, G; Casarin, J; Cromi, A; Ghezzi, F; Pinelli, C; Serati, M; Uccella, S, )	1.16
"Aspirin treatment significantly enhanced the killing of KP-M1 by leukocytes (p < 0.01)."	( Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome. Chang, CC; Chen, RF; Lee, CH; Liu, JW; Su, LH; Yang, KD, 2014)	2.57
"In aspirin-treated patients, statin therapy was independently and inversely associated with inflammation in a dose-dependent manner."	( Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. Bliden, KP; Ens, G; Franzese, CJ; Gesheff, MG; Gurbel, PA; Guyer, K; Singh, M; Singla, A; Stapleton, D; Tabrizchi, A; Tantry, US; Toth, PP, 2014)	1.13
"Aspirin-treated animals displayed a decreased atherosclerotic lesion area compared to the untreated control mice, while meloxicam had a null effect on the extent of atherosclerosis in Apo E KO mice."	( Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. Afek, A; Arber, N; Aroch, I; Eisenberg, O; Finkelstein, A; George, J; Kazanov, D; Kraus, S; Naumov, I; Shapira, S, 2014)	3.29
"Aspirin-treated and COX-1 knockout (KO) mice showed significantly lower accumulation of PMN-MDSCs in the inflamed lung and immune organs accompanied by increased TH2 airway responses."	( Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice. Bao, Y; Funk, CD; Kong, D; Shen, Y; Shi, G; Shi, M; Tang, J; Wang, H; Wang, Q; Wang, T; Xiao, B; Yu, Y; Zhou, J; Zuo, C, 2014)	1.37
"In aspirin-treated ACS patients, MRP-8/14 and 11-dehydro-TXB2 were lower versus those not receiving aspirin (P<0.001) and still significantly correlated (r=0.528, P<0.001)."	( Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. Davì, G; Di Marco, M; Di Nicola, M; La Barba, S; Lattanzio, S; Liani, R; Mascellanti, M; Paloscia, L; Pascale, S; Santilli, F, 2014)	1.11
"Aspirin treatment for the period of initial hospitalization after acute stroke of undetermined etiology is predicted to decrease acute stroke-related mortality and in-hospital stroke recurrence even at the highest reported proportion of acute strokes due to ICH. "	( Aspirin for acute stroke of unknown etiology in resource-limited settings: a decision analysis. Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014)	3.29
"Aspirin-treated human platelets were found to be phagocytosed more efficiently by macrophages, associated with attenuation in platelet proteasomal activity and upregulation of conformationally active Bax, which were consistent with enhanced platelet apoptosis."	( Aspirin delimits platelet life span by proteasomal inhibition. Dash, A; Dash, D; Nayak, MK; Singh, N, 2014)	2.57
"Aspirin (ASA) treatment significantly reduced lung platelet sequestration and activation, NPA formation, and lung injury."	( Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice. Bins, A; Headley, M; Krummel, MF; Looney, MR; Mallavia, B; Ortiz-Muñoz, G, 2014)	2.57
"Aspirin-treated patients with MIs had higher serum TxB2 compared with those without MIs (p = 0.005)."	( Platelet activation is associated with myocardial infarction in patients with pneumonia. Bertazzoni, G; Bucci, T; Calabrese, CM; Calvieri, C; Cangemi, R; Casciaro, M; Falcone, M; Farcomeni, A; Grieco, S; Palange, P; Pignatelli, P; Rossi, E; Taliani, G; Violi, F, 2014)	1.12
"Aspirin is the key treatment in the secondary prevention of atherothrombosis. "	( Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy. Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S, 2015)	2.17
"Aspirin-treated rats exhibited a significant decrease in degradation of internal elastic lamina (IEL), medial layer thinning, CA size and macrophages infiltration with reduced expression of MMP-2 and 9 compared with rats in the CA group."	( Aspirin Inhibits Degenerative Changes of Aneurysmal Wall in a Rat Model. Dong, JF; Jiang, R; Li, S; Liu, L; Tian, Y; Wang, D; Wei, H; Zhang, J; Zhou, Z, 2015)	2.58
"Aspirin-pretreated patients (n = 236; 35%) were older and more likely to have known coronary disease than those without pretreatment (P≤.01 for all). "	( Effect of Prior Aspirin Treatment on Patients With Acute Coronary Syndromes: Insights From the PROSPECT Study. Brener, SJ; de Bruyne, B; Maehara, A; Mintz, GS; Serruys, PW; Stone, GW; Weisz, G, 2015)	2.21
"Aspirin pretreatment was not an independent predictor of MACE in ACS patients treated with an early invasive strategy."	( Effect of Prior Aspirin Treatment on Patients With Acute Coronary Syndromes: Insights From the PROSPECT Study. Brener, SJ; de Bruyne, B; Maehara, A; Mintz, GS; Serruys, PW; Stone, GW; Weisz, G, 2015)	1.48
"Aspirin-BMSC treatment has significantly decreased the concentration of TNF-α and IFN-γ (p < 0.05)."	( Aspirin promotes bone marrow mesenchymal stem cell-based calvarial bone regeneration in mini swine. Cao, Y; Liu, Y; Mei, S; Wang, F; Wang, S; Xiong, J; Zhao, Z, 2015)	2.58
"Aspirin pretreatment was associated with reduced 48-hour cardiac death (adjusted hazard ratio 0.50, 95% confidence interval 0.26-0.97; P=0.04) and 30-day death (adjusted hazard ratio 0.68, 95% confidence interval 0.49-0.94; P=0.04)."	( Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. Ayele, GM; Brener, SJ; Lansky, AJ; Mehran, R; Stone, GW, 2016)	1.49
"Aspirin treatment significantly inhibited the proliferation of 4T1 cells, and decreased the production of MCP-1 and PAI-1 in both the Ad-CM model and co-culture system."	( Aspirin Breaks the Crosstalk between 3T3-L1 Adipocytes and 4T1 Breast Cancer Cells by Regulating Cytokine Production. Hsieh, CC; Huang, YS, 2016)	2.6
"Aspirin treatment significantly prevented bone loss by increasing bone formation."	( Aspirin prevents bone loss with little mechanical improvement in high-fat-fed ovariectomized rats. Cui, L; Fu, Z; Huang, J; Huang, M; Lee, WYW; Li, G; Liang, Y; Lin, S; Suen, CW; Wu, H; Wu, T; Xu, L, 2016)	2.6
"Aspirin in vivo treatment enhances platelet MRP4 expression and MRP4 mediated transport inhibition reduces platelet function and delays thrombus formation."	( Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment. Calcagno, S; Frati, L; Lotti, LV; Mancone, M; Massimi, I; Pulcinelli, FM; Sardella, G; Temperilli, F; Turriziani, O, 2016)	1.37
"Aspirin treatment significantly resulted in reduction of matrix metalloproteinase-9 (MMP-9) and upregulation of tissue inhibitors of metalloproteinase-1 (TIMP-1) activity, which are the proteolytic enzymes contributing to the degradation of extracellular matrix and basement membrane in cell invasion and metastasis."	( Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator. Cao, J; Chen, X; Feng, Y; Liu, B; Shi, C; Zhang, N, 2017)	2.62
"Aspirin treatment affects the reproducibility of both PFA-100 and OPA. "	( Monitoring aspirin therapy with the Platelet Function Analyzer-100. Grove, EL; Hvas, AM; Kristensen, SD; Mortensen, J; Nielsen, HL; Pedersen, SB; Poulsen, TS; Refsgaard, J; Thygesen, SS, 2008)	2.18
"Aspirin (5 mM) treatment of MKN28 gastric epithelial monolayers significantly decreased transepithelial electrical resistance and increased dextran permeability."	( Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7. Joh, T; Miwa, H; Oshima, T, 2008)	2.51
"Aspirin treatment also restored endothelial function and beta(2)-adrenoceptor activity."	( Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats. Fahim, M; Shahid, M; Sharma, KK; Tauseef, M, 2008)	1.37
"Aspirin-pretreated macrophages potently induced IL-10 expression in the MCF-7 cells."	( Regulation of inflammation- and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages. Bremner, TA; Burnett, GT; Taylor, TE; Weathersby, DC, )	0.85
"Aspirin-treated patients showed a significant reduction of sP-selectin levels by 13% (p=0.021) which significantly correlated with collagen-induced lag-phase (p=0.005)."	( Soluble P-selectin as a marker of in vivo platelet activation. Ciatti, F; Ferroni, P; Guadagni, F; La Farina, F; Magnapera, A; Martini, F; Riondino, S, 2009)	1.07
"In aspirin-treated patients, urinary concentrations of 11-dehydro thromboxane B(2) are an externally valid and potentially modifiable determinant of stroke, myocardial infarction, or cardiovascular death in patients at risk for atherothrombotic events."	( Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Bhatt, DL; Easton, JD; Eikelboom, JW; Fox, KA; Hamm, C; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Montalescot, G; Steg, PG; Steinhubl, SR; Thom, J; Topol, EJ, 2008)	0.97
"Aspirin treatment decreased liver PGE(2) in treated hens as compared to control hens. "	( Dietary aspirin decreases the stage of ovarian cancer in the hen. Giles, JR; Johnson, PA; Urick, ME, 2009)	2.23
"Aspirin treatment may inhibit the progression of ovarian cancer in the hen and egg production may be used to identify hens with early stages of the disease."	( Dietary aspirin decreases the stage of ovarian cancer in the hen. Giles, JR; Johnson, PA; Urick, ME, 2009)	2.23
"Aspirin-treated subjects with coronary artery disease were randomized to double-blind treatment with clopidogrel 600 mg loading dose (LD) followed by daily 75 mg maintenance dose (MD) or prasugrel 60 mg LD and daily 10 mg MD for 28 days."	( Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE, 2008)	1.29
"Aspirin (30 mg/kg) treatment also reduced platelet aggregation."	( Aspirin attenuates cerebral ischemic injury in diabetic rats. Fu, FH; Han, B; Wang, T; Yu, X; Zhang, LM; Zhu, M, 2009)	2.52
"In aspirin-treated patients also fibrinogen levels increased with aging (p<0.001)."	( Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin- and thienopyridine-treated patients. Alexy, T; Feher, G; Horvath, B; Kenyeres, P; Kesmarky, G; Koltai, K; Lenart, I; Marton, Z; Toth, K, 2008)	1.09
"51 aspirin-treated (100 mg/day) patients participated. "	( Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor. Karhunen, PJ; Lassila, R; Lepäntalo, A; Mikkelsson, J; Reséndiz, JC; Viiri, LE; Virtanen, KS, 2009)	1.22
"Aspirin and placebo treatment were associated with elevated P-selectin expression, platelet-monocyte aggregation and reduced CD42b expression (p<0.05, Wilcoxon signed-rank test) post-exercise."	( Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. Ashour, H; Bhattacharya, V; Cleanthis, M; Smout, J; Stansby, G, 2009)	1.49
"Aspirin treatment enhanced LPS-stimulated TNFalpha production by PBML from controls but not cases."	( Effect of aspirin treatment on TNFalpha production by women with a history of preterm birth. Cooper, C; Esplin, MS; Faux, DS; Hamblin, SD; Peltier, MR; Silver, RM, 2009)	1.48
"Aspirin treatment did not prevent either CD62P or CD40L expression."	( Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. Chandler, AB; Earhart, AD; Hansen, J; Jennings, LK; Kueter, TJ; Speich, HE; White, MM, 2010)	1.08
"Aspirin treatment was continued throughout the first trimester of pregnancy."	( Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Groeneveld, E; Homburg, R; Hompes, PG; Hoozemans, DA; Lambalk, CB; Lambers, MJ; Schats, R, 2009)	1.29
"Aspirin-treated CT26 cells gave 5,15-diHETE as the most prominent product formed from 5S-HETE."	( Identification and absolute configuration of dihydroxy-arachidonic acids formed by oxygenation of 5S-HETE by native and aspirin-acetylated COX-2. Boeglin, WE; Griesser, M; Hernandez, NT; Mulugeta, S; Schneider, C; Suzuki, T, 2010)	1.29
"Aspirin pre-treatment at the dose tested did not influence either endothelial injury or platelet thrombus growth, while clopidogrel pretreatment significantly inhibited 3D growth and prolonged occlusion time up to 64.6+/-25.3 minutes (100 mg/kg)."	( Imaging of structural changes in endothelial cells and thrombus formation at the site of FeCl(3)-induced injuries in mice cremasteric arteries. Eguchi, Y; Goto, S; Ishida, H; Kawamura, Y; Takahari, Y; Tamura, N; Urano, T, 2009)	1.07
"Aspirin pre-treatment abolished the difference in response between oxygen breathing and air breathing [maximum: 1.03 (0.90-1.16) vs."	( Prostaglandins and radical oxygen species are involved in microvascular effects of hyperoxia. Henricson, J; Rousseau, A; Sjöberg, F; Tesselaar, E, 2010)	1.08
"Aspirin treatment given to healthy volunteers at a dose of 75 mg/day increased the susceptibility of their plasma LDL to oxidative modification ex vivo. "	( Aspirin promotes low density lipoprotein susceptibility to oxidative modification in healthy volunteers. Fuhrman, B; Hayek, T; Keidar, S; Waterman, M, 2009)	3.24
"In aspirin-treated DM patients the presence of moderate/severe CKD is associated with reduced clinical efficacy of adjunctive clopidogrel therapy."	( Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010)	0.87
"Aspirin treatment also led to a decrease in the microviscosity in the native as well as the benzyl alcohol treated membrane which might be due to the lipid peroxidative damage in the membrane."	( The effect of prostaglandin synthase inhibitor, aspirin on the rat intestinal membrane structure and function. Kaur, G; Kaur, J; Mittal, N; Nath Sanyal, S, )	1.11
"In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation. "	( [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. Husted, SE; Nielsen, HK, 2010)	0.98
"In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation. "	( [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. Husted, SE; Nielsen, HK, 2010)	0.98
"Aspirin treatment is essential in patients with acute myocardial infarction (AMI) to block platelet thromboxane (TXA)₂ synthesis. "	( Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction. Fuset, MP; Moscardó, A; Ruano, M; Santos, MT; Vallés, J, 2011)	2.04
"Aspirin treatment also reduced right ventricular hypertrophy and pulmonary arteriole proliferation in ASA-treated PAH model."	( Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. He, B; Pu, J; Shen, J; Shen, L, 2011)	2.53
"Aspirin treatment inhibited PrP (106-126)-induced neuronal cell death in SH-SY5Y neuroblastoma cells."	( Prion peptide-mediated cellular prion protein overexpression and neuronal cell death can be blocked by aspirin treatment. Jeong, JK; Lee, YJ; Moon, MH; Park, SY; Seo, JS; Seol, JW, 2011)	1.31
"Aspirin treatment led to the normalization of inflammation- and oxidative stress-related mRNA levels in treated MPS IIIA mouse brains."	( Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Arfi, A; Bonnefont-Rousselot, D; Gandolphe, C; Richard, M; Scherman, D; Thérond, P, 2011)	1.3
"Aspirin treatment reduces cardiovascular events and deaths in high-risk non-diabetic patients, but not in patients suffering from diabetes. "	( Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors. Kobzar, G; Mardla, V; Samel, N, 2011)	1.81
"All aspirin treated patients surviving 30 days after a first myocardial infarction from 1997 to 2006, with follow-up for one year. "	( Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011)	1.16
"Aspirin treatment reduced the basal superoxide production and blunted the oxidative and hypertensive effect of angiotensin II in wild type and cyclo-oxygenase-1 deficient mice whereas it lost completely its antioxidative property in angiotensin II-treated aortic smooth muscle cells isolated from cyclo-oxygenase-2 deficient mice."	( Cyclo-oxygenase-2 knockout genotype in mice is associated with blunted angiotensin II-induced oxidative stress and hypertension. De Champlain, J; Duchemin, S; Girouard, H; Laplante, MA; Wu, R, 2011)	1.09
"Aspirin treatment lowers inflammation via inhibition of NF-κB activity but also reduces hypertriglyceridemia in humans."	( Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. Berbée, JF; Havekes, LM; Rensen, PC; Romijn, JA; Shoelson, SE; van Diepen, JA; Voshol, PJ; Vroegrijk, IO, 2011)	2.53
"Aspirin-treated patients more frequently came from rural areas."	( [Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome]. Arauz, A; Artigas, C; Barinagarrementeria, F; Cantu-Brito, C; Hernandez, B; Marquez, JM; Merlos, M; Perez, A; Roa, LF, 2011)	2
"Aspirin treatment did not prevent the previously reported diabetes-induced marrow adiposity."	( Low dose aspirin therapy decreases blood glucose levels but does not prevent type i diabetes-induced bone loss. Coe, LM; Denison, JD; McCabe, LR, 2011)	1.51
"The aspirin-treated group was significantly older, with higher weight and poorer health state (higher incidence of ischemic heart disease, cerebral ischemia and diabetes). "	( [Low-dose aspirin doesn't increase surgical bleeding nor transfusion rate in total knee arthroplasty]. Bisbe Vives, E; Castillo Monsegur, J; López Bosque, R; Ruiz, A; Santiveri Papiol, X, 2012)	1.34
"Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopidogrel 75 mg daily for 7 days. "	( Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ, 2012)	2.04
"Aspirin treatment alone killed only 3% cells in culture."	( Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin. King, MR; Rana, K; Reinhart-King, CA, 2012)	1.34
"Aspirin treatment is associated with diminished endogenous oxidant stress and enhanced resistance to exogenous peroxide, both likely mediated by activation of antioxidant defenses. "	( Aspirin inhibits oxidant stress, reduces age-associated functional declines, and extends lifespan of Caenorhabditis elegans. Ayyadevara, S; Bharill, P; Dandapat, A; Hu, C; Khaidakov, M; Mehta, JL; Mitra, S; Shmookler Reis, RJ, 2013)	3.28
"Aspirin treatment of hPLTs in vitro abolished hPLT accumulation in the lung and protected mice from lung injury."	( Host platelets and, in part, neutrophils mediate lung accumulation of transfused UVB-irradiated human platelets in a mouse model of acute lung injury. Chi, X; Gelderman, MP; Vostal, JG; Zhi, L, 2012)	1.1
"Aspirin microsphere treatment induced slight apoptosis and modestly inhibited proliferation of LN229 and U87 cells in vitro and in vivo through inhibition of β-catenin transactivation. "	( Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation. Chen, LY; Han, L; Kang, CS; Liu, CY; Pu, PY; Qian, XM; Shi, ZD; Yuan, XB; Zhang, JX; Zhang, KL, 2013)	3.28
"Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia."	( Aspirin in the prophylaxis of coronary artery disease. Mehta, P, 2002)	2.48
"Aspirin treatment does not seem to protect against exercise-induced platelet activation in 22% of such patients, despite aspirin sensitivity at rest."	( Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Allal, J; Brizard, A; Christiaens, L; Coisne, D; Duplantier, C; Herpin, D; Macchi, L; Mauco, G, 2002)	1.4
"Aspirin treatment initiates biosynthesis of carbon 15 epimeric LXs, and both series of epimers (LX and aspirin-triggered 15-epi-LX) display counter-regulatory actions with neutrophils."	( Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. Arita, M; Bernasconi, G; Clish, CB; Colgan, SP; Fierro, IM; Petasis, NA; Serhan, CN, 2003)	1.39
"Aspirin treatment at stroke onset had a 97% risk reduction of early neurological deterioration, and this effect remained unchanged after a further adjustment for glutamate concentrations."	( Neuroprotective effects of aspirin in patients with acute cerebral infarction. Castillo, J; Dávalos, A; Leira, R; Lizasoain, I; Moro, MA; Serena, J, 2003)	1.34
"Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1.5%. "	( [Anticoagulation and antiaggregation in cardiac patients]. Meyer, BJ, 2003)	1.76
"Aspirin treatment reduced the development of atherosclerosis by approximately 47%."	( Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. Lee, P; Prasad, K, 2003)	1.26
"Aspirin pretreatment increased the tongue-bleeding time, whereas the addition of CRL42796 or enoxaparin did not prolong bleeding time to a further degree."	( Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, preven Driscoll, EM; Giboulot, TA; Hong, TT; Lucchesi, BR; Sherigill, A; White, AJ, 2003)	1.23
"Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal."	( Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Michiels, JJ, 2003)	1.26
"Both aspirin treatments produced a statistically significant decrease in serum TxB2 (P<0.0001) but did not have an effect on the metabolite of prostaglandin I2 (P=0.136)."	( Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Bergmann, JF; Caulin, C; Cohen-Solal, A; Habib, A; Jondeau, G; Kevorkian, JP; Knellwolf, AL; Lebret, M; Levy, B; Mahé, I; Meune, C; Mourad, JJ; Simoneau, G, 2003)	2.22
"Aspirin treatment (10 mg/kg of body weight per day) reduced eNOS expression, but failed to modify the expression of VEGF in the colonic tissue of azoxymethane-treated rats."	( Aspirin inhibits endothelial nitric oxide synthase (eNOS) and Flk-1 (vascular endothelial growth factor receptor-2) prior to rat colon tumour development. Abarrategui, C; Carrasco, C; Escribano, M; García-Mendez, A; López-Farré, A; Manzarbeitia, F; Martín, MJ; Molero, L; Porres Cubero, JC; Rico, L; Sánchez-Fayos, P; Vázquez, M, 2004)	2.49
"aspirin) in subjects treated with NCX-4016."	( Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. del Soldato, P; Fiorucci, S; Morelli, A; Romano, M; Santucci, L; Sardina, M; Wallace, JL, 2003)	1.28
"The aspirin treated group displayed a 52% reduction in dysplastic ACF although this difference was not statistically significant."	( Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Bernheim, J; Buklan, G; Freund, HR; Grankin, M; Klein, E; Neufeld, D; Nissan, A; Shpitz, B, 2003)	1.11
"Aspirin treatment did not significantly reduce the frequency of stroke progression. "	( Aspirin in the prevention of progressing stroke: a randomized controlled study. Britton, M; Leijd, B; Malmkvist, K; Rödén-Jüllig, A, 2003)	3.2
"Aspirin treatment significantly reduced the dilation to acetylcholine and sodium nitroprusside."	( Dietary L-arginine restores aspirin-induced endothelial dysfunction in rat aorta. Bilgen, I; Eren, E; Oner, G, 2003)	1.33
"Aspirin treated patients have lower Vascular Endothelial Growth Factor titer levels in the perioperative course. "	( Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Fogel, M; Gerrah, R; Gilon, D, 2004)	3.21
"The aspirin-treated group received an average of 0.5 units of blood more than the control group, postoperatively."	( Aspirin therapy and bleeding during proximal femoral fracture surgery. Anekstein, Y; Halperin, N; Mirovsky, Y; Tamir, E, 2004)	2.25
"Aspirin treatment prevents CTGF release, suggesting that clinical benefits of this drug may involve the inhibition of CTGF secretion."	( Activated human platelets release connective tissue growth factor. Cicha, I; Daniel, WG; Garlichs, CD; Goppelt-Struebe, M, 2004)	1.04
"Aspirin is the treatment of choice for stroke prevention in patients who do not require anticoagulation."	( Transient ischemic attacks: Part II. Treatment. Solenski, NJ, 2004)	1.04
"Aspirin-treated patients exhibited highly significant inhibition of epinephrine-induced aggregation (p=0.0001), prolongation of the closure time (p=0.03), and reduction of the aspirin reactive units (p=0.02) measured by the Ultegra device."	( Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Atar, D; Hennekens, CH; Malinin, AI; Oshrine, BR; Sane, DC; Serebruany, VL; Takserman, A, 2004)	1.04
"Aspirin (10 mm) treatment of the cells significantly reduced the VCAM-1 response to these APLA."	( Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies. Boehlen, F; de Moerloose, P; Dunoyer-Geindre, S; Kruithof, EK; Reber, G; Satta-Poschung, N, 2004)	2.49
"Aspirin treatment has an undoubted beneficial impact on the progression of cardiovascular diseases. "	( Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Grotz, W; Olschewski, M; Peter, K; Siebig, S; Strey, CW, 2004)	2.18
"Aspirin treatment impacts biosynthesis of these compounds and a related series by triggering endogenous formation of the 17R-D series Resolvins and docosatrienes."	( Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Arita, M; Gotlinger, K; Hong, S; Serhan, CN, 2004)	1.27
"Aspirin treatment initiates a related epimeric series by triggering endogenous formation of the 17R-D series resolvins and docosatrienes."	( Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Arita, M; Gotlinger, K; Hong, S; Serhan, CN, 2004)	1.26
"Aspirin-treated men had increased levels of alpha-tocopherol than controls (P<0.05)."	( Cyclooxygenase-mediated prostaglandin F2alpha is decreased in an elderly population treated with low-dose aspirin. Basu, S; Helmersson, J; Larsson, A; Vessby, B, 2005)	1.26
"Oral aspirin treatment (100mg/d) was started at day 1 after surgery."	( Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Gams, E; Hohlfeld, T; Kurt, M; Wenk, A; Winter, J; Zimmermann, N, 2005)	1.05
"Aspirin treatment is effective in diabetic patients with cardiovascular disease and it does not significantly increase the risk of retinal haemorrhage, gastrointestinal bleeding or hemorrhagic stroke."	( Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital. Bruno, A; Dani, F; Degiovanni, M; Grassi, G; Maghenzani, G; Pagano, G, 2005)	1.05
"In aspirin-treated cultures the mutation rate was 8.2 x 10(-4) +/- 1.3 x 10(-4) (121% of control)."	( Mesalazine improves replication fidelity in cultured colorectal cells. Boland, CR; Gasche, C; Goel, A; Natarajan, L, 2005)	0.84
"Aspirin treatment had no significant effect on the neointimal smooth muscle component, but partially inhibited macrophage infiltration, without inhibiting ICAM-1 expression."	( S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Berry, CL; Campbell, JH; Thomas, AC; Worth, NF, 2005)	1.05
"Thus aspirin pretreatment could be used to decrease CIV resulting from all-at-once and repeated cathodal application and facilitate the study of the specific vascular effect induced by the drug delivered."	( Cathodal current-induced vasodilation to single application and the amplified response to repeated application in humans rely on aspirin-sensitive mechanisms. Abraham, P; Bouyé, P; Jaquinandi, V; Koïtka, A; Saumet, JL; Tan, L; Tartas, M, 2005)	0.99
"Aspirin-treated vitiligo patients showed significant decrease in serum V-IgG activity and sIL-2R concentration (0.32 +/- 0.08 O.D., 756 +/- 216 pg/ml) compared with that of placebo-treated patients (0.83 +/- 0.19 O.D., 1327 +/- 392 pg/ml; p<0.01)."	( Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients. Zailaie, MZ, 2005)	2.49
"Aspirin pretreatment revealed no beneficial effects and resulted in increased postoperative bleeding and requirement for blood product transfusions after coronary artery bypass grafting in patients with stable angina."	( Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. Bochenek, A; Cisowski, M; Dropinski, J; Morawski, W; Sanak, M; Szczeklik, M; Szczeklik, W; Ulczok, R; Waclawczyk, T, 2005)	1.26
"Aspirin treatment led to the activation of NF-kappaB signalling and increased binding at these NF-kappaB sites in the SSAT promoter, hence providing a potential mechanism for the induction of SSAT by aspirin in these cells."	( Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Babbar, N; Casero, RA; Gerner, EW, 2006)	1.29
"In aspirin-treated patients with STEMI who are treated with thrombolysis, intravenous UFH has not been shown to prevent reinfarction or death. "	( Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Eikelboom, JW; Mehta, SR; Menown, IB; Quinlan, DJ; Turpie, AG; Yusuf, S, 2005)	1.18
"Aspirin treated pts with NSTEACS (<48 hours from pain onset, Braunwald class IIIb) were included into 2 consecutive studies: 37 pts receiving unfractionated heparin (UFH) were randomized to open TIC (n=19, 500 mg BID for 2 days and 250 mg BID for subsequent 5 days) or no TIC (n=18); 19 pts receiving enoxaparin were randomized to CL (n=10, 300 mg on day 1 and 75 mg/day for subsequent 6 days) or no CL (n=9). "	( [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005)	1.77
"Aspirin treatment eliminated all oxygenase activity in the Y348F/Y504F double mutant, with no indication of the lipoxygenase activity observed in aspirin-treated wild-type PGHS-2."	( Role of Tyr348 in Tyr385 radical dynamics and cyclooxygenase inhibitor interactions in prostaglandin H synthase-2. Ho, B; Kulmacz, RJ; Liu, W; Rogge, CE; Tsai, AL, 2006)	1.06
"Aspirin treatment increased the risk of bleeding in women (OR, 1.68; 95% CI, 1.13-2.52; P = .01) and in men (OR, 1.72; 95% CI, 1.35-2.20; P<.001)."	( Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. Avanzini, F; Berger, JS; Brown, DL; Pangrazzi, I; Roncaglioni, MC; Tognoni, G, 2006)	2.5
"Aspirin treatment at the time of PCI significantly reduced the risk of death from any cause and cardiac death."	( Impact of aspirin treatment on long-term outcome (over 10 years) after percutaneous coronary intervention. Akimoto, Y; Daida, H; Kasai, T; Kojima, T; Kurata, T; Miyauchi, K; Njaman, W; Ohta, H; Okazaki, S; Satoh, H; Yokoyama, K, 2006)	1.46
"Aspirin treatment was dominant."	( [Economic evaluation of the treatment with aspirin plus esomeprazole compared to clopidogrel in gastrointestinal bleeding prevention]. Piñol, C, )	1.12
"Aspirin treatment reduced PGI-M already at the lowest dosage (by approximately 25%), but PGI-M excretion and platelet aggregability were not correlated."	( Dose- and time-dependent antiplatelet effects of aspirin. Fitzgerald, D; Hjemdahl, P; Perneby, C; Rooney, C; Wallén, NH, 2006)	1.31
"Non-aspirin antiplatelet treatment (clopidogrel/ticlopidine) had a similar risk of UGIB (adj RR 2.8; 95% CI 1.9 to 4.2) to cardioprotective aspirin at a dose of 100 mg/day (adj RR 2.7; 95% CI 2.0 to 3.6) or anticoagulants (adj RR 2.8; 95% CI 2.1 to 3.7)."	( Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Arroyo, MT; Bástida, G; Borda, F; de Argila, CM; Feu, F; García-Rodríguez, LA; Gomollón, F; González-Pérez, A; Güell, M; Lanas, A; Piqué, JM; Quintero, E; Rodrigo, L; Santolaria, S; Zapata, E, 2006)	1.02
"Aspirin treatment resulted in the inhibition of collagen-induced platelet aggregation, particularly the transition from small to large platelet aggregates."	( Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. Kobayashi, Y; Madoiwa, S; Mimuro, J; Nonaka, T; Ohmori, T; Ozaki, Y; Sakata, Y; Yatomi, Y, 2006)	2.5
"Aspirin treatment did not increase lipoxygenase-type catalysis by either trout enzyme."	( Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. Cao, D; Kulmacz, RJ; Liu, W; Oh, SF; Serhan, CN, 2006)	1.06
"Aspirin treatment prevented the symptoms."	( Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Rodriguez, M; Wingerchuk, DM, 2006)	1.27
"Aspirin-treated DCs are partially resistant to phenotypic changes following maturational stimuli, such as lipopolysaccharide (LPS) or TNFalpha, IL-1alpha and PGE2."	( Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Buckland, M; Fazekasova, H; George, AJ; Jago, CB; Lechler, R; Lombardi, G; Scott, K; Tan, PH, 2006)	2.5
"Aspirin treatment with 300 mg o.d. "	( Aspirin reduces anticardiolipin antibodies in patients with coronary artery disease. Andreotti, F; Ikonomidis, I; Kremastinos, DT; Lekakis, J; Loizou, S; Nihoyannopoulos, P; Revela, I; Vamvakou, G, 2006)	3.22
"Some aspirin-treated patients experience thromboembolic events, a phenomenon termed 'aspirin resistance', which may be clinical or biochemical by definition. "	( Assessment of biochemical aspirin resistance at rest and immediately after exercise testing. Atar, I; Aydinalp, A; Bal, U; Demir, O; Ertan, C; Gulmez, O; Konas, ND; Muderrisoglu, H; Ozin, B; Yildirir, A, 2007)	1.15
"Aspirin pretreatment had no effect on plasma ATP concentrations. "	( Human plasma ATP concentration. Buffington, CW; Feigl, EO; Gorman, MW, 2007)	1.78
"Aspirin treatment prevented the rise in blood pressure, heart rate and significantly improved baroreflex sensitivity in hypercholesterolemic rats."	( Aspirin restores normal baroreflex function in hypercholesterolemic rats by its antioxidative action. Fahim, M; Sharma, KK; Tauseef, M, 2007)	2.5
"Aspirin-treated DCs demonstrate the characteristics of a potential immunotherapy for controlling unwanted immune-responses such as the indirect pathway of allo-recognition that drives chronic allograft rejection."	( Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. Buckland, M; Fazekesova, H; George, A; Jago, C; Lechler, R; Lombardi, G, 2006)	2.5
"Aspirin co-treatment suppressed effectively the genotoxicity of MMC in a dose-dependent manner and the sex ratio at a dose of aspirin 10mg/bottle elevated from 0.01 (without aspirin) to 0.65 at sc z(1) w(+(TE)) mei-9(a) mei-41(D5)/-C(1)DX, y f [mei-9 mei-41, Rec(-) male.Rec(+) female] consists of DNA repair-deficient (Rec(-)) males and -proficient (Rec(+)) females."	( Effect of aspirin on DNA damage induced by MMC in Drosophila. Nagase, H; Niikawa, M, 2007)	1.46
"Aspirin pretreatment can inhibit TNF-alpha-induced activation of NF-kappaB in a dose-dependent manner by preventing the phosphorylation and degradation of IkappaBalpha and nuclear translocation of NF-kappaB."	( Abnormal nuclear factor (NF)-kappaB signal pathway and aspirin inhibits tumor necrosis factor alpha-induced NF-kappaB activation in keloid fibroblasts. Cai, J; Xu, B; Zhang, J; Zhao, Y; Zhu, G, 2007)	1.31
"Aspirin treatment involved one drop (100 microl) of 30 mg/ml lysine-aspirin solution to each nostril, initially daily, increased every two or three days up to a maximal of 18 drops (54 mg lysine-aspirin) a day."	( Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. Darby, Y; Ogata, N; Scadding, G, 2007)	1.39
"Aspirin treatment of wild-type mice causes similar effects, while the thromboxane A(2) analogue U46619 was borderline effective in suppressing the embolisation in alpha2-null mice."	( Role of murine integrin alpha2beta1 in thrombus stabilization and embolization: contribution of thromboxane A2. Cosemans, JM; Eckes, B; Heemskerk, JW; Kuijpers, MJ; Munnix, IC; Nieswandt, B; Pozgajova, M, 2007)	1.06
"Aspirin treated hypertensives showed a significant reduction of sP-selectin (-26%, p<0.01) and VEGF (-33%, p<0.01) levels."	( In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. Basili, S; D'Alessandro, R; Davì, G; Ferroni, P; Guadagni, F; Magnapera, A; Martini, F; Raparelli, V; Scarno, A, 2008)	1.07
"In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite."	( Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008)	1.16
"Aspirin treatment decreased 8-OHdG levels (P < 0.05), but no significant effect on intima/media thickness ratio was observed."	( Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. Boulanger, E; Bulckaen, H; Corman, B; Creusy, C; Garçon, G; Gaxatte, C; Gosset, P; Prévost, G; Puisieux, F; Robitaille, G; Roquet, V; Shirali, P, 2008)	1.48
"Aspirin treatment led to G1 cell cycle arrest and a robust reduction in the levels of the antiapoptotic protein survivin by inducing its proteasomal degradation, but did not affect the levels of many other apoptosis regulators."	( Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Bosman, J; Chen, F; Cryns, VL; Jordan, VC; Kwan, T; Lu, M; Strohecker, A, 2008)	2.51
"Aspirin treatment for primary prevention is cost-effective for men with a 10-year cardiovascular disease risk of >10% and for women with a risk of >15%. "	( Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Algra, A; Buskens, E; Greving, JP; Koffijberg, H, 2008)	2.1
"Aspirin pretreatment had no significant effect on responses to BHT 920; thus, prostanoid formation does not appear to be an important mechanism contributing to postsynaptic alpha 2-adrenoceptor activation."	( Pretreatment with aspirin does not influence the pressor response to alpha 2-adrenoceptor agonists in conscious rabbits. Hamilton, CA; Hannah, JA; Reid, JL, 1984)	1.32
"Aspirin treated patients and platelets incubated with aspirin in vitro both showed increased platelet EPM."	( Role of surface negative charge in platelet function related to the hyperreactive state in estrogen-treated prostatic carcinoma. Isohisa, I; Jung, SM; Kinoshita, K; Tanoue, K; Yamazaki, H, 1982)	0.99
"In aspirin-treated umbilical vein segments dipyridamole treatment did not cause PGI2 release as in the untreated segments."	( Dipyridamole and aspirin in relation to platelet aggregation and vessel wall prostaglandin generation. Mehta, J; Mehta, P, )	0.98
"Aspirin pre-treatment (2 X 25-40 mg kg-1 orally) had no effect on the renin, arterial pressure or renal blood flow responses to renal artery pressure reduction (n = 7)."	( Comparison of aspirin and indomethacin pre-treatments on the responses to reduced renal artery pressure in conscious dogs. Anderson, WP; Bartley, PJ; Casley, DJ; Selig, SE, 1983)	1.35
"Aspirin-treated two-kidney rats developed significantly higher blood pressures than vehicle-treated controls, but the blood pressures of aspirin-treated one-kidney rats increased less after clipping than those of vehicle-treated controls."	( Differences in arachidonic acid metabolism and effects of aspirin between one- and two-kidney Goldblatt hypertensive rats. Doyle, AE; Drysdale, T; Dusting, GJ; Veroni, M, )	1.1
"Aspirin pretreatment (150 mg/kg subcutaneously) significantly reduced the number of malformed pups and prevented the increase in prenatal mortality produced by alcohol."	( Aspirin reduces alcohol-induced prenatal mortality and malformations in mice. Anton, RF; Randall, CL, )	2.3
"In aspirin-treated platelets, this agonist activity peaked at 1 to 4 min and thereafter decayed rapidly with a time course that was both worm and arachidonic acid dependent."	( Thromboxane A2 generation by the larval cestode, Taenia taeniaeformis. Leid, RW; McConnell, LA, 1983)	0.78
"Aspirin pretreatment of the rabbits inhibited the formation of AA metabolites in the lungs of their fetuses."	( Maternal aspirin administration inhibits pulmonary arachidonic acid metabolism in fetal rabbits. Simberg, N, 1984)	1.41
"Aspirin (100 mg/kg) treatment, which reduced 6-keto PGF1 alpha to a lesser degree without altering PGE2 excretion, had no significant effect on the blood pressure fall."	( Role of prostaglandins during reversal of one-kidney, one-clip hypertension in the rat. Barden, A; O'Dwyer, J; Vandongen, R, )	0.85
"Aspirin pretreatment significantly reduced the hypotensive effect of clonidine."	( Effect of aspirin treatment on the hypotensive effect of clonidine in rats. Barber, ND; Griffiths, RJ; Moore, PK; Twohig, B, 1983)	1.39
"Aspirin treatment however may be a precipitating factor when associated with other abnormalities of platelet function."	( Bleeding time in rats: a comparison of different experimental conditions. de Gaetano, G; Dejana, E; Villa, S, 1982)	0.99
"Aspirin treatment completely inhibited metabolism of arachidonic acid by medullary microsomes."	( Effect of aspirin on metabolism of acetaminophen and benzidine by renal inner medulla prostaglandin hydroperoxidase. Davis, BB; Mattammal, MB; Rapp, NS; Zenser, TV, 1983)	1.39
"The aspirin treatment group defervesced more rapidly (10.3 h versus 21.5 h and 23.6 h; P less than 0.01), but by the second daily follow-up visit, both groups of amantadine recipients exhibited greater symptomatic improvement."	( Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Betts, RF; Douglas, RG; Roth, FK; Younkin, SW, 1983)	0.96
"The aspirin-treated dogs had greater resolution of pulmonary arterial proliferative disease, and prednisolone-treated dogs had the lesser resolution."	( Pulmonary thromboembolism during therapy of dirofilariasis with thiacetarsamide: modification with aspirin or prednisolone. Keith, JC; Rawlings, CA; Schaub, RG, 1983)	0.96
"Aspirin treatment drastically reduced TxB2 levels in all groups but did not alter the incidence of NE."	( Effects of vitamin E and aspirin on the incidence of encephalomalacia, fatty acid status and serum thromboxane levels in chicks. Bruckner, G; Combs, GF; Infante, J; Kinsella, JE, 1983)	1.29
"Aspirin pretreatment, however, caused a marked inhibition in both magnitude and duration of the hypotensive effect of bradykinin without altering that of eledoisine, isoprenaline, papaverine and prostacyclin."	( Inhibition by nicotine of the vasodilator effect of bradykinin: evidence for a prostacyclin-dependent mechanism. Ercan, ZS; Ersoy, A; Türker, RK; Zengil, H, 1982)	0.99
"Aspirin pretreatment resulted in smaller delta MTCIs at the higher doses of nicotinic acid."	( Aspirin blocks nicotinic acid-induced flushing. Buckner, J; Chernosky, ME; Donachie, R; Kapp, R; Wilkin, JK; Wilkin, O, 1982)	2.43
"Aspirin (0.9 g) pretreatment reduced the generation of both spasmogen and anti-aggregatory substance when blood was withdrawn 1 h but not 24 h after drug treatment."	( Release of biologically active substances from non-aggregating human platelets. Lofts, FJ; Moore, PK, 1982)	0.99
"Aspirin treatment did not influence the alterations in creatinine clearance, urine volume, osmolar clearance, and/or sodium and potassium excretion seen with exercise."	( Effects of aspirin treatment on kidney function in exercising man. Ciccone, CD; Rofrano, TA; Zambraski, EJ, 1982)	1.38
"Aspirin-treated embryos removed on day 12 exhibited a unique pattern of preaxial mesodermal cell death in the hindlimb buds."	( Aspirin-induced teratogenesis: a unique pattern of cell death and subsequent polydactyly in the rat. Klein, KL; Scott, WJ; Wilson, JG, 1981)	2.43
"Aspirin treatment did not influence patency."	( Delayed thrombosis of synthetic microvascular bypass grafts. Brittain, F; Reinert, RL; Weinstein, PR, 1981)	0.98
"Aspirin treated dogs had enhanced platelet adhesion to damaged arteries."	( Effect of long-term aspirin treatment on platelet adhesion to chronically damaged canine pulmonary arteries. Keith, JC; Rawlings, CA; Schaub, RG, 1981)	1.31
"Aspirin-treated dogs did not differ from control dogs in percent ventricle at risk (mean +/- standard error 37 +/- 2 versus 40 +/- 2), percent infarct weight/left ventricle (29 +/- 3 versus 31 +/- 2) or percent infarct weight/weight of ventricle at risk (78 +/- 4 versus 77 +/- 3)."	( Lack of effect of aspirin on myocardial infarct size in the dog. Bonow, RO; Capurro, NL; Epstein, SE; Goldstein, RE; Isner, JM; Lipson, LC; Roberts, WC; Sheehan, FH, 1981)	1.32
"In aspirin-treated platelets, the aggregation capacity induced by adenosine diphosphate was inhibited before the operation (p < 0.05) and showed substantial recovery during the operation (p < 0.05)."	( Hemostatic function of aspirin-treated platelets vulnerable to cardiopulmonary bypass. Altered shear-induced pathway. Eijsman, L; Huet, RC; Sturk, A; Tabuchi, N; Wildevuur, CR, 1995)	1.12
"The aspirin-treated group had thicker infarcts compared with the placebo-treated group (0.8 +/- 0.1 versus 0.5 +/- 0.1 mm, P < .05) and less expanded infarcts (expansion index, 1.2 +/- 0.1 versus 2.0 +/- 0.2, P < .05)."	( Aspirin enhances the benefits of late reperfusion on infarct shape. A possible mechanism of the beneficial effects of aspirin on survival after acute myocardial infarction. Alhaddad, IA; Brown, EJ; Mir, R; Siddiqui, F; Tkaczevski, L, 1995)	2.21
"Aspirin treatment is recognized as an advantageous adjunct to thrombolytic agents in myocardial infarct patients. "	( Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis. Bednar, MM; Bennett, WF; Errett, CJ; Gross, CE; Thibodeaux, H; Thomas, GR, 1995)	2.11
"The aspirin treated group showed increased mean gestational age at termination 39.4 +/- 2.6 weeks as against 38.2 +/- 3.4, increased foetal weight 2860 +/- 552 g as against 2540 +/- 720 g."	( A study of use of low dose aspirin in prevention of pregnancy induced hypertension. Pan, S; Roy, UK, 1994)	1.07
"The aspirin treatment induced a significant increase of 18:0 and arachidonic acid (20: 4n-6) and a decrease of 18: 1n-9 in the liver."	( Aspirin toxicity in chicks given diets deficient in linoleic acid. Furuse, M; Murai, A; Okumura, J, 1994)	2.21
"In aspirin-treated platelets the thrombin-induced increase of cytosolic Ca2+ ([Ca2+]i) associated with the release from the intracellular stores is followed by a decrease to the baseline which is largely dependent on the re-uptake into the stores. "	( Ca2+ influx in platelets: activation by thrombin and by the depletion of the stores. Effect of cyclic nucleotides. Alexandre, A; Cavallini, L; Doni, MG, 1994)	0.91
"Aspirin treatment in combination with neutropenia produced a 50% reduction in whole blood platelet aggregation, resulted in a significant inhibition of platelet deposition to deeply injured arteries, and decreased vasoconstriction by 66% to 15.6 +/- 3.0% (P < .05 versus control and neutropenic)."	( Neutrophil implications in platelet deposition and vasoconstriction after deep arterial injury by angioplasty in pigs. Lacoste, LL; Lam, JY; Merhi, Y, 1994)	1.01
"Aspirin treatment did not affect the relation between the Doppler indices and these outcomes in the logistic regression model."	( The predictive value of umbilical artery Doppler studies for preeclampsia or fetal growth retardation in a preeclampsia prevention trial. Atkinson, MW; Copper, RL; Goldenberg, RL; Hauth, JC; Maher, JE; Owen, J, 1994)	1.01
"Aspirin treatment of hPGHS-2 produced an enzyme which retained oxygenase activity but formed exclusively 15-hydroxy-5,8,11,13-eicosatetraenoic acid (15-HETE) instead of PGH2."	( Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. DeWitt, DL; Ji, C; Laneuville, O; Lecomte, M; Smith, WL, 1994)	1.24
"Aspirin pretreatment (500 mg orally 12 hours earlier) reduced the excretion of 11-dehydrothromboxane B2 by 62 +/- 5% (P < .001) and attenuated platelet aggregability at rest (P < .05) but not the effect of norepinephrine infusion on platelet aggregability."	( Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Hjemdahl, P; Larsson, PT; Wallén, NH, 1994)	1.23
"Aspirin-treated dogs were not different from vehicle."	( Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis. Cohen, DS; Dotson, R; Mathis, J; Olson, RW; Webb, RL, 1993)	1.01
"Aspirin-treated subjects had a significant decrease in mean hemoglobin levels of 0.33 gm/dl during the 12-month study period, which was significantly greater than the decrease in the placebo-treated group (0.11 gm/dl; p < 0.05)."	( Adverse effects of low-dose aspirin in a healthy elderly population. Campion, K; Donnan, GA; McNeil, JJ; Silagy, CA; Tonkin, AM; Worsam, B, 1993)	1.3
"Aspirin treatment also abolished (p < 0.05) platelet-mediated constriction of the de-endothelialized rings."	( Verapamil and aspirin modulate platelet-mediated vasomotion in arterial segments with intact or disrupted endothelium. Behrens, P; Lawson, D; Mehta, JL; Nicolini, F; Raymenants, E; Yang, B, 1993)	1.37
"Aspirin treatment is found to counteract the effect of isoproterenol on lipid and lipid peroxide formation and associated enzyme changes in heart mitochondria."	( Effect of aspirin on mitochondrial lipids in experimental myocardial infarction in rats. Devi, CS; Manjula, TS, 1993)	1.41
"Aspirin pretreatment significantly increased the ACTH response to naloxone [mean peak increase from basal, 8.3 +/- 1.2 vs."	( Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation. Crosbie, GV; Grice, JE; Hockings, GI; Jackson, AJ; Jackson, RV; Walters, MM, 1993)	2.45
"Aspirin treatment could restore the enzyme activity to near normal and also reduce the level of lipid peroxides."	( Effect of aspirin on isoproterenol induced changes in lipid metabolism in rats. Devi, CS; Manjula, TS, 1993)	1.41
"The aspirin treated group had evidence of intercellular oedema, widening of capillary fenestrae, rupturing of apical membranes, and dilatation of endoplasmic reticulum and mitochondria after one hour; these changes were more marked at five hours."	( Early ultrastructural changes of antral mucosa with aspirin in the absence of Helicobacter pylori. McCarthy, CJ; O'Morain, C; Sweeney, E, 1995)	1.02
"The aspirin and warfarin treatment groups were compared by size and location of venographically revealed clots and changes in ventilation perfusion scans."	( Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Ecker, ML; Keenan, AM; Kelley, MA; Lotke, PA; Meranze, S; Palevsky, H; Steinberg, ME, 1996)	2.22
"Aspirin pretreatment significantly lowered seminal PGE2 levels (from 86 +/- 5 before to 11 +/- 2 micrograms/mL [corrected] after drug administration; P < 0.001) without affecting testosterone concentrations."	( Aspirin inhibition of naloxone-induced luteinizing hormone secretion in man. Conte, D; De Giorgio, G; Fillo, S; Isidori, A; Nordio, M; Romanelli, F, 1996)	2.46
"Aspirin treatment compared with untreated control groups led to a significant reduction of preeclampsia in 5 small-scale studies."	( -Is prevention of pre-eclampsia with low dosage aspirin possible? Critical assessment of available studies-. Lippert, TH; Mück, AO, 1996)	1.27
"Aspirin-treated or untreated cells were incubated in the absence or presence of SC58125 and stimulated by thrombin, the ionophore A23187, or exogenous arachidonic acid."	( Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. Habib, A; Karim, S; Lévy-Toledano, S; Maclouf, J, 1996)	1.02
"Aspirin treatment significantly lowered plasma prostaglandin F2 alpha concentration, but did not affect liver lipid concentrations."	( Involvement of (n-6) essential fatty acids and prostaglandins in liver lipid accumulation in Japanese quail. Furuse, M; Murai, A; Okumura, J, 1996)	1.02
"Aspirin treatment did not abolish alpha granule release."	( Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase. Christiansen, I; Frandsen, NJ; McNair, P; Pedersen, F; Winther, K, 1996)	1.02
"Aspirin-treated rat aortic rings alone inhibited the AA-induced platelet aggregation by 7%."	( Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings. Imura, Y; Nishikawa, K; Terashita, Z, 1996)	1.02
"Aspirin treatment failed to suppress urinary levels of 8-epi-PGF2 alpha despite a significant reduction in urinary 11-dehydro-TxB2 production and suppression of 8-epi-PGF2 alpha and TxB2 in serum."	( Modulation of oxidant stress in vivo in chronic cigarette smokers. Delanty, N; FitzGerald, GA; Lawson, JA; Reilly, M, 1996)	1.02
"When aspirin-treated PGH2 synthase II was reacted with EtOOH, a normal peroxidase cycle occurred with compound I and compound II formation occurring over 10 s."	( Detection of an Fe2+-protoporphyrin-IX intermediate during aspirin-treated prostaglandin H2 synthase II catalysis of arachidonic acid to 15-HETE. Copeland, RA; Penning, TM; Tang, MS, 1997)	1
"Aspirin treatment did not alter hsp70 protein expression in the absence of heat."	( Potentiation of heat stress-induced hsp70 expression in vivo by aspirin. Fawcett, TW; Holbrook, NJ; Xu, Q, 1997)	1.26
"Aspirin treatment caused an increase of both the template bleeding time (61%) and the closure time of the PFA-100 (79%) when compared with the effects of placebo."	( A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Armstrong, J; Dixon, RM; Growcott, JW; Marshall, PW; Moores, J; Warburton, S; Williams, AJ, 1997)	1.3
"Aspirin-treated and non-aspirin-treated patients did not differ in stroke severity."	( Does daily aspirin diminish severity of first-ever stroke? Bornstein, NM; Hass, Y; Karepov, V; Korczyn, AD, 1997)	1.41
"If aspirin-treated platelets were incubated with endothelial cells, methacholine did not increase the production of [3H]TXB2."	( Methacholine-induced contraction of rabbit pulmonary artery: role of platelet-endothelial transcellular thromboxane synthesis. Campbell, WB; Deinhart, DD; Pfister, SL, 1998)	0.81
"Aspirin treatment again has similar benefits to those in non-diabetic subjects, and should be administered at presentation."	( Managing the diabetic patient with acute myocardial infarction. Yudkin, JS, 1998)	1.02
"The aspirin-treated patients exhibited a mild but consistent reduction of platelet activity which reached significance for 5 microM (p = 0.02), and 10 microM (p = 0.01) adenosine diphosphate induced aggregation."	( Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. Bahr, RD; Gurbel, PA; Lowry, DR; O'Connor, CM; Serebruany, VL, 1998)	1.17
"Aspirin treatment failed to decrease urinary levels of iPF2alpha-III (102 +/- 8 versus 99.2 +/- 7.3 pmol/ mmol creatinine), whereas 11-dehydro TxB2 was significantly reduced (695 +/- 74 versus 95 +/- 10 pmol/mmol creatinine) (p < 0.0001)."	( Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Basili, S; Cordova, C; Fitzgerald, GA; Praticò, D; Vieri, M; Violi, F, 1998)	1.02
"Aspirin treatment without repeated blood withdrawal had no effect."	( Influence of aspirin on platelet count and volume in humans. Beer, JH; Erhart, S; Reinhart, WH, 1999)	1.39
"Aspirin-treated blood perfused under normoxic conditions showed a marked decrease in thrombus with a concomitant increase in both platelet adhesion and covered surface percentages."	( Impaired antiplatelet effects of aspirin associated with hypoxia and ATP release from erythrocytes. Studies in a system with flowing human blood. Bozzo, J; Escolar, G; Galán, AM; Heras, M; Hernández, MR; Ordinas, A, 1999)	1.31
"Aspirin treatment attenuated certain signs of platelet activity in vivo at rest and fMLP-induced neutrophil activation in vitro, but it did not attenuate the prothrombotic effects of exercise."	( Evidence for prothrombotic effects of exercise and limited protection by aspirin. Hjemdahl, P; Li, N; Wallén, NH, 1999)	1.26
"Aspirin-treated P cows had longer PP intervals than either control P, control M, or aspirin-treated M cows."	( The effect of aspirin administration and parity on plasma salicylate concentrations and postpartum reproductive parameters in Brahman cows. Neuendorff, DA; Randel, RD; Stahringer, RC, 1999)	1.39
"Aspirin treatment of cyclooxygenase-2 is known to acetylate an active site serine, block prostaglandin biosynthesis, and give 15R-hydroxyeicosatetraenoic acid (15R-HETE) as the only product."	( Stereospecificity of hydrogen abstraction in the conversion of arachidonic acid to 15R-HETE by aspirin-treated cyclooxygenase-2. Implications for the alignment of substrate in the active site. Brash, AR; Schneider, C, 2000)	1.25
"In aspirin-treated patients with acute coronary syndrome without ST elevation, short-term unfractionated heparin or LMWH halves the risk of myocardial infarction or death. "	( Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Anand, SS; Eikelboom, JW; Ginsberg, JS; Malmberg, K; Weitz, JI; Yusuf, S, 2000)	0.93
"Aspirin treatment attenuated smoking-induced changes in plaque composition."	( Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Cercek, B; Chyu, KY; Dimayuga, P; Fishbein, MC; Kangavari, S; Matetzky, S; Shah, PK; Tani, S; Xu, H; Yano, J, 2000)	1.03
"Aspirin is the treatment of first choice for long-term secondary prevention of vascular events in patients with confirmed non-cardioembolic ischaemic stroke or TIA. "	( Prevention of ischaemic stroke--antiplatelets. Brown, MM; McCabe, DJ, 2000)	1.75
"Aspirin treatment appears to be strongly indicated."	( Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. Bhatt, DL; Kapadia, SR; Topol, EJ; Yadav, JS, 2000)	1.03
"Aspirin-treated patients had a lower incidence of chronic allograft nephropathy at 1 year than controls although this did not reach statistical significance (16 versus 26 per cent; P = 0.075)."	( Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. Metcalfe, M; Murphy, GJ; Nicholson, ML; Taha, R; Windmill, DC, 2001)	1.4
"Aspirin treatment for primary prevention is safe and worthwhile at coronary event risk >/= 1.5%/year; safe but of limited value at coronary risk 1%/year; and unsafe at coronary event risk 0.5%/year. "	( Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001)	3.2
"Aspirin treatment did not alter cyclooxygenase-1 protein expression."	( Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Bailey, J; Boland, CR; Brenner, DE; Burney, K; Krishnan, K; Normolle, D; Peters-Golden, M; Rock, CL; Ruffin, MT; Shureiqi, I, 2001)	1.26
"Aspirin treatment at a dose of 81 mg reduces colorectal mucosal prostaglandin E2 concentration after 28 daily doses. "	( Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Bailey, J; Boland, CR; Brenner, DE; Burney, K; Krishnan, K; Normolle, D; Peters-Golden, M; Rock, CL; Ruffin, MT; Shureiqi, I, 2001)	1.98
"Aspirin treatment improved survival ratio and stroke index, and decreased ischemically injured cell numbers in cortex."	( Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. Hosomi, N; Kohno, M; Mizushige, K; Ohyama, H; Takahashi, T, 2001)	1.03
"Aspirin-treated DC were highly efficient at Ag capture, via both mannose receptor-mediated endocytosis and macropinocytosis."	( Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. Falo, LD; Ganster, RW; Hackstein, H; Larregina, AT; Logar, AJ; Morelli, AE; Papworth, GD; Thomson, AW; Watkins, SC, 2001)	2.47
"Aspirin treatment also increased the production of the cell adhesion molecule, E-cadherin, in Hep G2 cancer cells."	( Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Jiang, MC; Lee, PH; Liao, CF, 2001)	2.47
"Aspirin-treated arthritic animals exhibited significantly less mechanical hyperalgesia and knee joint inflammation compared with vehicle treated arthritic animals."	( A comparison of chronic aspartame exposure to aspirin on inflammation, hyperalgesia and open field activity following carrageenan-induced monoarthritis. Fuchs, PN; LaBuda, CJ, 2001)	1.29
"The aspirin treatment increased the bleeding time from 1.7 +/- 0.3 minutes to 3.3 +/- 0.1 minutes."	( Aspirin treatment improves bladder function after outlet obstruction in rabbits. Kogan, BA; Levin, RM; Longhurst, PA; Schröder, A, 2001)	2.23
"oral aspirin). Treatment tolerance was excellent in both groups."	( A randomized parallel trial of topical aspirin-moisturizer solution vs. oral aspirin for acute herpetic neuralgia. Balakrishnan, S; Bhargava, VK; Bhushan, K; Pandhi, P, 2001)	1.04
"Aspirin treatment has been shown to improve allergic diseases, especially asthma, and the decreased use of aspirin has been hypothesized to contribute to the increase in childhood asthma."	( Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. Keegan, AD; Melo, M; Perez-G, M; Zamorano, J, 2002)	2.48
"In aspirin-treated patients, urinary concentrations of 11-dehydro thromboxane B2 predict the future risk of myocardial infarction or cardiovascular death. "	( Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002)	2.38
"Aspirin treatment significantly increased activity during the first and second dark cycles after surgery, whereas buprenorphine significantly increased activity during the second dark cycle only."	( Oral buprenorphine and aspirin analgesia in rats undergoing liver transplantation. Howden, BO; Jablonski, P, 2002)	1.35
"Aspirin treatment also resulted in a approximately 20% reduction in basal rates of hepatic glucose production and a approximately 20% improvement in insulin-stimulated peripheral glucose uptake under matched plasma insulin concentrations during the clamp."	( Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Hundal, RS; Inzucchi, S; Mayerson, AB; Petersen, KF; Randhawa, PS; Shoelson, SE; Shulman, GI, 2002)	1.33
"Aspirin treatment prevented vaccine-induced elevation of interleukin-1 receptor antagonist but enhanced the generation of tumor necrosis factor-alpha compared with placebo."	( Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Allen, M; Hingorani, AD; Kharbanda, RK; Klein, N; MacAllister, RJ; Vallance, P; Walton, B, 2002)	1.25
"Aspirin treatment did not affect this response and nor did it affect other manifestations of the syndrome."	( Effect of Sar1-ala8-angiotensin II on blood pressure and renin in Bartter's syndrome, before and after treatment with prostaglandin synthetase inhibitors. Aurell, M; Hansson, L; Rudin, A; Westberg, G, 1979)	0.98
"Aspirin treatment did not alter the rates of infection or illness but was associated with a moderate reduction in the frequency or severity of some symptoms."	( Increased virus shedding with aspirin treatment of rhinovirus infection. Dirda, V; Jackson, GG; Panusarn, C; Rubenis, M; Stanley, ED, 1975)	1.26
"Aspirin treatment of cultured endothelial cells from the umbilical vein increased the adherence of 51Cr-platelets when thrombin was present. "	( Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence. Czervionke, RL; Fry, GL; Haycraft, DL; Hoak, JC; Smith, JB, 1979)	1.94
"Aspirin treatment of the vessel wall was used to block PGI2 production; platelet adherence to the surface of the 'undamaged' aorta and the subendothelium was studied following this treatment."	( Platelet interactions with the endothelium and the subendothelium: the role of thrombin and prostacyclin. Cazenave, JP; Dejana, E; Kinlough-Rathbone, R; Mustard, JF; Packham, MA, 1979)	0.98
"Aspirin treatment prevented thrombocytosis and formation of platelet aggregates."	( Thrombocytosis and platelet aggregates in the circulation of adjuvant arthritic rats. Görög, P; Kovács, IB, 1978)	0.98
"The aspirin-treated group did not have a significantly lower incidence of coronary lesions compared with the group treated with an antibiotic alone."	( Kawasaki disease: effect of treatment on coronary artery involvement. Kato, H; Koike, S; Yokoyama, T, 1979)	0.74
"The aspirin-treated group had only 69% as much area under the radioactivity curve as the control group."	( Effects of aspirin on 14C-pirprofen disposition in rats. Borman, CH; Goodblatt, RS; Roth, WJ; Thompson, TA, 1979)	1.13
"Aspirin treatment causes a decrease in Leydig cell function, change in Sertoli cell morphology and a subsequent decrease in Spermatid count. "	( Antispermatogenic effect of aspirin and its prevention by prostaglandin E2. Biswas, NM; Patra, PB; Sanyal, S, )	1.87
"Aspirin treatment led to an increased PGF production by brain slices from rats on either diet and not subjected to an immunochallenge."	( Incidence and severity of experimental allergic encephalomyelitis and cerebral prostaglandin synthesis in essential fatty acid deficient and aspirin-treated rats. Johnston, PV; Weston, PG, 1978)	1.18
"Aspirin pretreatment prevented the ocular response following the intravenous injection of 10 mug per kilogram of endotoxin, but had no effect following 100 mug per kilogram."	( The effects of aspirin and indomethacin on the ocular response to circulating bacterial endotoxin in the rabbit. Howes, EL; McKay, DG, 1976)	1.33
"The aspirin-pretreated animals showed less inflammatory reaction after cryotherapy and significantly less protein in the aqueous humor than did the control animals (P less than .01)."	( Experimental inhibition of prostaglandin-like inflammatory response after cryotherapy. Chavis, RM; Vygantas, A; Vygantas, CM, 1976)	0.74
"Aspirin treatment, 150 mg/kg twice daily, inhibited growth of a transplantable mast-cell ascites tumor (P815) by 39-43% (p less than 0.001) and of a s.c."	( Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Beaven, MA; Hial, V; Horakova, Z; Shaff, FE, 1976)	1.27
"Aspirin-pretreated animals possessed higher 14C blood levels than controls."	( Effect of aspirin on fate of 14C-acetaminophen in guinea pigs. Paul, CJ; Thomas, BH; Whitehouse, LW, 1975)	1.38
"Aspirin treatment did not effect the length of pseudopregnancy."	( Effects of hysterectomy, administration of uterine extract, posterior pituitary extract and aspirin on the length of pseudopregnancy in rats. Fariduddin, KM; Uddin Kabiraj, M, 1975)	1.1
"Aspirin pretreatment before third ventricle instillation of arachidonic acid blocked the increases of intraocular pressure and temperature."	( Increased intraocular pressure after third ventricle injections of prostaglandin E1 and arachidonic acid. Becker, B; Krupin, T; Oestrich, C; Podos, SM, 1976)	0.98
"Aspirin treatment is found to counteract the effect of isoproterenol on lipid peroxide formation and associated enzyme changes in serum and heart."	( Effect of aspirin on isoproterenol induced myocardial infarction--a pilot study. Devi, CS; Geetha, A; Manjula, TS, 1992)	1.41
"Aspirin treated rats showed marked reversal of these metabolic changes."	( Effect of aspirin on serum lipoprotein profile in rats subjected to myocardial stress by isoproterenol. Devi, CS; Manjula, TS; Prema, A, 1992)	1.41
"Aspirin treatment also reduced the slope of the aggregation curve and increased the lag time (the period between the addition of collagen and the start of irreversible aggregation) significantly more in control than in diabetic platelets."	( Differential effect of aspirin on platelet aggregation in IDDM. Burke, V; Douglas, AJ; McCulloch, RK; Mori, TA; Vandongen, R, 1992)	1.32
"Aspirin treatment of the vessel (to prevent PGI2 formation) or endothelial stripping (to remove the ability to produce nitric oxide) had no effect on the degree of inhibition."	( Delivery of passivating proteins to sutures during passage through the vessel wall reduces subsequent platelet deposition by blocking fibrinogen adsorption. Brash, JL; Cornelius, RM; Garrett, KO; Johnson, PC; Kaplan, SS; Warty, V, 1992)	1
"Aspirin-ethanol pretreatment also did not alter the morphologic severity of pancreatitis."	( Effects of hemorrhagic shock, aspirin, and ethanol on secretagogue-induced experimental pancreatitis. Leli, U; Printz, H; Saluja, A; Sengupta, A; Steer, M, 1990)	1.29
"Aspirin-treated platelets alone (58 x 10(6)) were fully aggregated by thrombin at 0.05 U/mL or more."	( Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: blockade of aggregation and secretion by an aspirin-insensitive mechanism. Broekman, MJ; Eiroa, AM; Marcus, AJ, 1991)	1.19
"Aspirin treatment was instituted the night before surgery and continued for two weeks, except in 13 patients (7%) who had to stop treatment because of gastrointestinal symptoms."	( The use of aspirin to prevent heterotopic ossification after total hip arthroplasty. A preliminary report. Cantor, R; Freiberg, AA; Freiberg, RA, 1991)	1.39
"Aspirin treatment inhibited the PGI2 biosynthesis induced by GSH in the arsenic trioxide-induced cell injury, and significantly reduced the cytoprotective effect induced by GSH."	( Cytoprotective effect of reduced glutathione in arsenical-induced endothelial cell injury. Chang, WC; Chen, SH; Morita, I; Murota, S; Shi, GY; Wu, HL, 1991)	1
"Aspirin-treated lesions (n = 163) had lost 16 +/- 22% (mean +/- standard deviation) of lumen and placebo-treated lesions 22 +/- 25% of lumen (n = 134) at angiography (p less than 0.01)."	( Effects of low-dose aspirin on restenosis after coronary angioplasty. Cope, GD; Cumpston, GN; Gibbons, FA; Luke, P; Mews, GC; Taylor, RR, 1991)	1.33
"Aspirin treatment was associated with a 65 percent reduction in bone PGE and a 13 percent bone mass sparing effect."	( Immobilization increases bone prostaglandin E. Effect of acetylsalicylic acid on disuse osteoporosis studied in dogs. Caywood, DD; Hodgson, SF; Trachte, GJ; Turner, RT; Waters, DJ, 1991)	1
"Aspirin treatment did not alter the course of diabetic retinopathy in patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS). "	( Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. , 1991)	2.11
"Aspirin treated platelets aggregated with thrombin demonstrated no thromboxane B2 production and no glutathione disulfide generation."	( Glutathione disulfide production during arachidonic acid oxygenation in human platelets. Burch, JW; Burch, PT, 1990)	1
"Aspirin is the basic treatment for Kawasaki disease, however its optimal dose is controversial. "	( A study on the optimal dose of aspirin therapy in Kawasaki disease--clinical evaluation and arachidonic acid metabolism. Akagi, T; Inoue, O; Kato, H; Sato, N, 1990)	2.01
"Aspirin treatment started 24 hours before, and heparin 6 hours and phenprocoumon 2 days after surgery."	( Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion. Buchwalsky, R; Fassbender, D; Hahalis, G; Hasford, J; Langbehn, AF; Seggewiss, H; Taillens, C; Theisen, K; Weber, MA; Zitzmann, A, 1990)	1.42
"Aspirin treatment failed in 21 patients with severe carotid stenosis (greater than 75% stenosis)."	( Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease. Chen, TL; Chyatte, D, 1990)	1.31
"Aspirin-treated ECs also produced a marked reduction in platelet disposition (0.71 +/- 0.24 x 10 platelets/cm; p = 0.007 compared with EAS without ECs) that was equivalent to the effect of non-aspirin-treated ECs (p greater than 0.5)."	( Aspirin-independent antithrombotic effects of acutely attached cultured endothelial cells on endarterectomized arteries. Anderson, JS; Bass, A; Harker, LA; Kelly, AB; Krupski, WC, 1990)	2.44
"Aspirin treated rats showed lower mortality rate and smaller changes in the myocardium on histopathological examination when compared to corresponding animals given isoproterenol alone."	( Protective action of aspirin in experimental myocardial infarction induced by isoproterenol in rats and its effect on lipid peroxidation. Menon, VP; Muraleedharan, D; Sushama Kumari, S; Varghese, A, 1990)	1.32
"Aspirin treatment of platelets markedly potentiated the ability of t-PA to induce disaggregation."	( Tissue plasminogen activator promotes platelet disaggregation in plasma. Loscalzo, J; Vaughan, DE, 1987)	0.99
"Aspirin treatment failed to suppress plasma levels of both proteins when measured a month and then a year after initiation of treatment."	( Platelet alpha granule secretion in cerebral ischemia: effect of short and long term low dose aspirin treatment. Cananzi, AR; D'Andrea, G; Ferro-Milone, F; Grunfeld, S; Joseph, R; Toldo, M; Welch, MA, )	1.07
"Aspirin (100 mg/day)-treated and nontreated rats were fed for 7 days, a mixed diet of 2.5% safflower oil and 7.5% hydrogenated coconut oil (SFO/HCO) or 7.5% fish oil (SFO/FO), or 2.5% gamma-linolenate concentrate and 7.5% fish oil (GLA/FO)."	( Fatty acid changes in liver choline and ethanolamine glycerophospholipids in aspirin-treated rats fed linoleate, gamma-linolenate and fish oil. Horrobin, DF; Huang, YS; Simmons, V; Watanabe, Y, 1989)	1.23
"Aspirin/dipyridamole-treated patients failed to show suppression of platelet activating factor-induced platelet aggregation even though collagen-induced activation was inhibited, suggesting that platelet activating factor acts by cyclooxygenase-independent mechanisms."	( Effect of therapy on platelet activating factor-induced aggregation in acute stroke. D'Andrea, G; Joseph, R; Welch, KM, 1989)	1
"Aspirin pretreatment (10 mg/kg, i.v.) attenuated the return of airways responsiveness to prechallenge levels."	( Lipoxygenase metabolites mediate increased airways responsiveness to histamine after acute platelet activating factor exposure in the guinea-pig. Anderson, GP; Fennessy, MR, 1988)	1
"Aspirin-treated cells recovered within 2 h by a process that was blocked by cycloheximide but not by actinomycin D, and that required a serum component identified as epidermal growth factor (EGF)."	( Inhibition by corticosteroids of epidermal growth factor-induced recovery of cyclooxygenase after aspirin inactivation. Bailey, JM; Pash, JM, 1988)	1.21
"The aspirin-treated LDL was less efficiently recognized than native LDL by the apo B/E receptor of fibroblasts."	( Aspirin induces alterations in low-density lipoprotein and decreases its catabolism by cultured human fibroblasts. Goldstein, S; Mazière, C; Mazière, JC; Moreau, M; Polonovski, J, 1987)	2.2
"Aspirin pre-treatment studies and the use of [acetyl-14C]aspirin showed that IL-1 increased PGE2 production through the induction of cyclo-oxygenase."	( Induction of cyclo-oxygenase by interleukin-1 in rheumatoid synovial cells. Barrett, ML; Lewis, GP; O'Neill, LA, 1987)	0.99
"Aspirin treatment caused a rise in total proteoglycan content over degraded controls (p less than 0.002), however, this increase was not associated with increased [35S]sulfate incorporation into glycosaminoglycans."	( Effects of anti-inflammatory drugs on cartilage recovery from catabolin-induced degradation. Gorski, JP; Strathy, GM, 1987)	0.99
"Aspirin-treated platelets aggregated in response to PAF-acether and to 0.25 U/ml thrombin as much as control platelets in absence of detectable thromboxane A2, and were less responsive to 0.05-0.1 U/ml."	( Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets. Adnot, S; Joseph, D; Vargaftig, BB, 1987)	1.21
"In aspirin treated animals, a putative lipoxygenase inhibitor NDGA (10 mg/kg, i.v.)."	( Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites. Anderson, GP; Fennessy, MR; White, HL, 1988)	0.79
"Aspirin treatment reduced baseline [Cai2+] as well as thrombin- and collagen-induced [Cai2+] changes."	( Baseline and activated platelet cytoplasmic ionized calcium in acute ischemic stroke. Effect of aspirin. D'Andrea, G; Grunfeld, S; Joseph, R; Oster, SB; Welch, KM, 1988)	1.21
"Aspirin-treated EC when co-cultured with SMC did not stimulate CE hydrolytic activity in SMC, as was the case with non-aspirin-treated EC, suggesting a role of eicosanoids in the regulation of cholesterol metabolism."	( Interactions of arterial cells. Studies on the mechanisms of endothelial cell modulation of cholesterol metabolism in co-cultured smooth muscle cells. Hajjar, DP; Hajjar, KA; Marcus, AJ, 1987)	0.99
"Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent)."	( Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. Appelrouth, DJ; Baim, S; Chang, RW; Cohen, MH; Englund, DW; Germain, BF; Hartman, SS; Jaffer, A; Mullen, BJ; Smith, FE, 1987)	1.24
"Aspirin treatment was associated with increased lymphocyte thymidine uptake for blastogenesis in pregnant rats fed the normal protein control diet and their offspring."	( Effects of aspirin-like drugs on mitogen-stimulated DNA synthesis of lymphocytes from pregnant rats and offspring. Ewii, MC; Hyde, BP; Knight, EM; Millis, RM; Offiah, GU, 1988)	1.39
"Aspirin treatment increased serum globulin levels and decreased serum albumin-globulin ratios in off-spring of dams fed the low-protein diet."	( The effects of aspirin-like drugs on the nutritional status of pregnant rats and offspring. Ewii, MC; Hyde, BP; Knight, EM; Millis, RM; Offiah, GU, 1988)	1.35
"Aspirin treatment significantly enhanced platelet adhesion to the exposed vascular surface."	( Influence of anti-platelet drugs on platelet-vessel wall interactions. Rao, GH, 1987)	0.99
"In aspirin treated subjects both mucosal generation and luminal release of prostaglandins and thromboxane B2 were greatly suppressed although sucralfate treatment did not influence these prostaglandins in spite of the reduction in mucosal damage."	( Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man. Konturek, SJ; Kopp, B; Kwiecień, N; Obtułowicz, W; Oleksy, J, 1986)	0.99
"Aspirin treatment (3, 20, or 40 min) resulted in alterations in tight junction complex morphology and permeability."	( Effects of aspirin on tight junction structure of the canine gastric mucosa. McGinley, D; Meyer, RA; Posalaky, Z, 1986)	1.38
"Aspirin treatment significantly reduced platelet thrombi on exposed subendothelium."	( Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions. Escolar, G; Rao, GH; White, JG, 1986)	1.25
"Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary PGE2 remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0.05)."	( Salicylate nephropathy in the Gunn rat: potential role of prostaglandins. Janis, R; Mittman, N; Schlondorff, D, 1985)	0.99
"The aspirin-treated group reported the greatest number of adverse reactions, but the differences between the four groups were not statistically significant."	( Efficacy of fenoprofen in the treatment of primary dysmenorrhea. Burt, RA; Caldwell, BV; Kaul, AF; Naftolin, F; Osathanondh, R; Scavone, JM; Sokoloff, BJ; White, RM, 1985)	0.75
"Aspirin pretreatment consistently resulted in a decrease in the I50 for 15-HETE from an average of 21.5 microM to only 5.2 +/- 1.5 microM, indicating a probable interaction between the cyclooxygenase and lipoxygenase pathways."	( Aspirin enhances the sensitivity of human platelet 12-lipoxygenase to inhibition by 15-HETE, an endogenous regulator. Bailey, JM; Bryant, RW; Fletcher-Cieutat, M; Vanderhoek, JY, 1985)	2.43
"Aspirin treatment suppressed urinary 2,3-dinor-TxB2 excretion by 80%."	( Estimated rate of thromboxane secretion into the circulation of normal humans. Blair, IA; Ciabattoni, G; FitzGerald, GA; Patrono, C; Pierucci, A; Pugliese, F, 1986)	0.99
"The aspirin-treated subjects had significantly decreased uric acid levels (p = 0.006) and a significantly higher incidence of tinnitus (p = 0.04) compared with the flurbiprofen treatment groups."	( Effects of flurbiprofen and aspirin on the gastric and duodenal mucosa. An endoscopic comparison. Gernaat, CM; Lanza, FL; Nelson, RS; Rack, MF; Royer, GL; Schwartz, JH; Seckman, CE, 1986)	1.05
"Pretreatment with aspirin, anticoagulant and statin therapy is of key importance in the preprocedural phase, while pretreating with an oral P2Y"	( Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Angiolillo, DJ; Capodanno, D; Finocchiaro, S; Greco, A, 2023)	1.23
"Treatment with aspirin (4 mM) induced remarkable ferroptosis in HepG2 and Huh7 cells, which was enhanced by the ferroptosis inducer erastin (10 μM)."	( Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-κB p65-activated SLC7A11 transcription. Feng, JY; Geng, Y; Hou, CY; Wang, GW; Wang, YF; Wei, XF; Yang, G; Yuan, HF; Zhang, HH; Zhang, XD; Zhao, LN; Zhao, M, 2023)	2.69
"Treatment with aspirin during pregnancy was also recorded."	( Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain. Adiego, B; Carrillo, MP; Cuenca-Gómez, D; de Paco Matallana, C; Delgado, JL; Gil, MM; Mendoza, M; Molina, FS; Revello, R; Rolle, V; Santacruz, B; Valiño, N; Wright, A, 2023)	1.25
"Treatment with aspirin inhibited miR-20b-5p levels, thus restoring primary cilia formation and trophoblast invasion."	( Upregulation of miR-20b-5p inhibits trophoblast invasion by blocking autophagy in recurrent miscarriage. Chao, YY; Lin, RC; Su, MT; Tsai, HL; Tsai, PY; Wang, CY, 2024)	1.78
"Treatment of aspirin-exacerbated respiratory disease (AERD) includes endoscopic sinus surgery (ESS) and aspirin desensitization (AD) with aspirin therapy after desensitization (ATAD). "	( Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease. Adappa, ND; Bosso, JV; Civantos, AM; Corr, AM; Gleeson, PK; Ig-Izevbekhai, KI; Kohanski, MA; Kumar, A; Lin, TC; Locke, TB; Palmer, JN; Sweis, AM, 2021)	1.3
"Treatment with aspirin, a prostaglandin (PG) biosynthesis inhibitor, suppressed the induction of Se-Mucin1 expression during early adult stage and impaired egg development."	( An ovary-specific mucin is associated with choriogenesis mediated by prostaglandin signaling in Spodoptera exigua. Ahmed, S; Kim, Y; Seo, K, 2021)	0.96
"Treatment with aspirin did not aggravate the impairment of intestinal barrier in T2DM patients."	( Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, Zonulin, and IFABP. Chen, GC; Chen, QK; Huang, CL; Li, JY; Xie, QS; Yu, T; Yuan, JH, 2021)	0.96
"Treatment with aspirin 250 mg daily and intravenous iloprost 0.5 mL/h was initiated with a poor clinical response at day 4."	( Frostbite and Cold Agglutinin Disease: Coexistence of Two Entities Leading to Poor Clinical Outcomes. Andres, E; Cattelan, J; Guerrero-Niño, J; Jannot, X; Ledoux, MP; Lorenzo-Villalba, N; Nasco, E, 2021)	0.96
"Treatment with aspirin-clopidogrel led to more major bleedings (0.9%–1.7% per year), than reduction in ischemic events (ranging from 0.4% to 0.9/1.0% per year) across all quintiles."	( Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021)	0.96
"When treatment with aspirin was indicated, providers were notified with patient-specific messages."	( Primary prevention aspirin use in high-risk patients: A pharmacist intervention and comparison of risk stratification tools. Brooks, AD; Coon, SA; Wolff, SE, )	0.77
"Thus treatment with aspirin in the chronic phase of Chagas' disease changes the natural history of the disease and raises the possibility of using it as a new therapeutic approach to the treatment of this aspect of Chagas' disease pathology."	( Treatment with low doses of aspirin during chronic phase of experimental Chagas' disease increases oesophageal nitrergic neuronal subpopulation in mice. de Almeida Araújo, EJ; de Mello Gonçales Sant'ana, D; Marques de Araújo, S; Martins Moreira, N; Massocatto, CL; Muniz, E; Pinge-Filho, P; Rossi, RM, 2017)	1.06
"Treatment with aspirin or cilostazol was started 1 day after aneurysm induction."	( Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model. Hiramatsu, H; Hokamura, K; Kamio, Y; Kimura, T; Makino, H; Namba, H; Suzuki, T; Umemura, K; Yamasaki, T, 2018)	0.82
"Pretreatment of aspirin at non-toxic dose 0.3 mM significantly suppressed in vitro cord formation, adhesion, and the migration abilities of the HMVEC-dLy cells."	( Aspirin suppresses components of lymphangiogenesis and lymphatic vessel remodeling by inhibiting the NF-κB/VCAM-1 pathway in human lymphatic endothelial cells. Jantaree, P; Koizumi, K; Lirdprapamongkol, K; Ngiwsara, L; Prangsaengtong, O; Svasti, J, 2018)	2.26
"Treatment with aspirin and atorvastatin prevented an increase in the expression of Cx43 and PKCε without change in the miR-1 levels."	( Irradiation-Induced Cardiac Connexin-43 and miR-21 Responses Are Hampered by Treatment with Atorvastatin and Aspirin. Egan Benova, T; Kukreja, RC; Kura, B; Slezak, J; Szeiffova Bacova, B; Tribulova, N; Viczenczova, C; Yin, C, 2018)	1.03
"Treatment with aspirin alone ranked with high values both for primary and secondary endpoints (surface under the cumulative ranking curve of 70% and 82%, respectively)."	( Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis. Agostoni, E; Consoli, A; Consoli, D; Grampa, G; Vidale, S, 2019)	0.85
"Co-treatment of aspirin and NLCs did not improve the outcome."	( Neural like cells and acetyl-salicylic acid alter rat brain structure and function following transient middle cerebral artery occlusion. Asadi-Shekaari, M; Nematollahi-Mahani, SN; Shamsara, A; Sheibani, V, 2018)	0.81
"Pretreatment with aspirin or other prostaglandin inhibitors has demonstrated significant reductions in niacin-induced flushing (NIF), but other treatment options are needed."	( Apple pectin for the reduction of niacin-induced flushing. Backes, J; Dutton, JA; He, J; Moriarty, PM; Ruisinger, JF; Schmelzle, K, )	0.45
"Pretreatment with aspirin had no effect on the primary PK parameters, AUC0-10h, or Cmax."	( Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Dawson, KT; Huang, R; Milne, GL; Nestorov, I; Novas, M; O'Gorman, J; Russell, H; Scannevin, RH; Sheikh, SI, 2013)	0.93
"Treatment with aspirin suppressed the viability/proliferation of BON1, NCI-H727 and GOT1 cells in a time- and dose-dependent manner. "	( Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. Auernhammer, CJ; Göke, B; Maurer, J; Spampatti, M; Spöttl, G; Vlotides, G, 2014)	2.2
"Treatment with aspirin and new P2Y12 receptor blockers has further reduced the rate of cardiovascular death, myocardial infarction or stroke after ACS compared with aspirin and clopidogrel."	( Dual antiplatelet therapy for coronary artery disease. Lee, CW, 2015)	0.76
"Treatment with aspirin and intravenous immunoglobulins (IVIG) are first-line therapies."	( Kawasaki disease: an evolving paradigm. de Vincentiis, M; De Virgilio, A; Fusconi, M; Gallo, A; Greco, A; Martellucci, S; Pagliuca, G; Rizzo, MI; Ruoppolo, G; Tombolini, M, 2015)	0.76
"Treatment with aspirin also resulted in decreased expression of COX-2 within leukocytes within aneurysms as compared to peripheral blood samples."	( Potential role of aspirin in the prevention of aneurysmal subarachnoid hemorrhage. Chalouhi, N; Ding, D; Hasan, DM; Starke, RM, 2015)	1.09
"Treatment with aspirin was found to decrease induced SSAT activity in these cells."	( Decreased sensitivity to aspirin is associated with altered polyamine metabolism in human prostate cancer cells. Cameron, GA; Li, J; Wallace, HM, 2016)	1.08
"Treatment with aspirin prior to stroke did not predict severe stroke compared with no antiplatelet treatment (RR 1.24, 95% CI 0.51-2.98, p = NS)."	( Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016)	0.77
"Treatment with aspirin prior to chemotherapy suppressed the acquisition of chemoresistance by perturbing the nuclear translocation of NFκB in preexisting CSCs."	( Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. Das, T; De, S; Jana, D; Kajal, K; Khan, P; Manna, A; Mazumdar, M; Mukherjee, S; Saha, S; Sarkar, DK, 2016)	2.22
"Dual treatment with aspirin (5 mg kg(-1) ) and clopidogel (0.3 mg kg(-1) ) resulted in significant reductions in cerebral MESs (P < 0.05) as compared with monotherapy with either agent."	( A rabbit model of cerebral microembolic signals for translational research: preclinical validation for aspirin and clopidogrel. Chu, L; Desai, K; Gutstein, DE; Kurowski, S; Seiffert, D; Wang, X; Wu, W; Zhou, X, 2016)	0.96
"Treatment with aspirin alone after TAVI had greater safety benefits and was associated with similar valve function as DAPT. "	( Clinical Outcomes and Bioprosthetic Valve Function After Transcatheter Aortic Valve Implantation Under Dual Antiplatelet Therapy vs. Aspirin Alone. Ichibori, Y; Kuratani, T; Maeda, K; Mizote, I; Nakatani, S; Ohtani, T; Onishi, T; Sakata, Y; Sawa, Y; Torikai, K; Yamaguchi, O, 2017)	1.01
"Treatment with aspirin alone [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.55-0.70; P < 0.001), treatment with statins alone (HR, 0.48; 95% CI, 0.41-0.57; P < 0.001), and combined treatment (HR, 0.43; 95% CI, 0.34-0.55; P < 0.001) were independently associated with reductions in all-cause mortality. "	( Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study. Choi, D; Kang, SM; Kim, HC; Lee, CJ; Lee, SH; Oh, J; Park, S, 2017)	1.19
"Mice treated with aspirin also showed a 2-fold increase in plasma PON1 activity and a significant induction of both PON1 and apoA-I gene expression in the liver."	( Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. Garelnabi, M; Jaichander, P; Parthasarathy, S; Selvarajan, K, 2008)	0.9
"Pretreatment with aspirin and nimesulide inhibited EC9706 and EC109 cell growth in a time and dose-dependent manner, accompanied with a decrease of prostaglandin E2 production."	( Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells. Cho, CH; Li, P; Liu, X; Wu, YD; Xu, CM; Yu, ZL; Zhang, ST, 2009)	0.68
"Treatment with aspirin resulted in normalization of 11beta-PGF(2)(alpha) excretion in the 2 patients with elevated baseline levels and in prevention of symptoms in all 4 patients."	( Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Butterfield, JH; Weiler, CR, 2008)	0.69
"Treatment with aspirin was associated with a fall in total cholesterol, LDL-C and VLDL-C, and a significant rise in serum HDL-C."	( Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats. Fahim, M; Shahid, M; Sharma, KK; Tauseef, M, 2008)	0.99
"Treatment with aspirin (200 mg/kg, p.o.) or diclofenac (20 mg/kg im.) was conducted one hour before the challenge with carrageenan."	( Influence of protein malnutrition on induction and treatment of inflammation in mice. Bassiouny, K; Hamed, MR; Hassanein, NM; Talaat, RM, 2006)	0.67
"Treatment with aspirin did not decrease ovarian cancer incidence."	( Dietary aspirin decreases the stage of ovarian cancer in the hen. Giles, JR; Johnson, PA; Urick, ME, 2009)	1.13
"Treatment with aspirin and LMWH is associated with improved outcomes for women with previous late fetal loss or early delivery due to placental dysfunction (Group 2)."	( Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Bewley, S; Bramham, K; Calatayud, I; Germain, S; Hunt, BJ; Khamashta, M; Nelson-Piercy, C, 2010)	0.7
"Pretreatment with aspirin enhanced the SPT reactions to wheat and gluten in both patients."	( Two cases of wheat-dependent anaphylaxis induced by aspirin administration but not by exercise. Aihara, M; Ikezawa, Z; Inoue, Y; Kambara, T; Kunimi, Y; Matsuki, M; Matsukura, S; Sugawara, M, 2010)	0.93
"Treatment of aspirin-resistant patients by adding omega-3 fatty acids or increasing the aspirin dose seems to improve response to aspirin and effectively reduces platelet reactivity."	( Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. Assali, A; Battler, A; Brosh, D; Harel, N; Kleiman, NS; Kornowski, R; Lev, EI; Mager, A; Roller, M; Solodky, A, 2010)	1.1
"Treatment with aspirin resulted in a 7.2% absolute risk reduction [95% confidence interval (CI), 1.3-13%] for postoperative MACE."	( To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Darvish, B; Eintrei, C; Fredrikson, M; Gupta, A; Järhult, J; Krook, H; Nyström, M; Oscarsson, A; Pettersson, E; Swahn, E, 2010)	1
"Treatment of aspirin significantly prevented the progression of nephropathy and inhibited the augmented COX-2, NFkappaB (p65 levels), TNFalpha, and TGFbeta-smad expression."	( Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Gaikwad, AB; Mulay, SR; Tikoo, K, 2010)	1.07
"Pretreatment with aspirin, despite full inhibition of platelet COX-1, did not prevent it (-12.7 +/- 6.9 s, NS vs."	( Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Bolli, GB; Giannini, S; Gresele, P; Guglielmini, G; Lucidi, P; Marzotti, S; Minuz, P; Momi, S, 2010)	0.91
"Treatment with aspirin significantly promoted CRC cell apoptosis in AOM/DSS-induced CRC mice in vivo. "	( Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Chen, H; Gao, W; Mao, X; Ren, C; Song, T; Tian, Y; Wang, D; Ye, Y, 2011)	2.16
"A treatment with aspirin in the human bronchial epithelial cells increased the mRNA expression level of KIF3A compared to that of the untreated control (P ≤ 0.01), and nasal polyp epithelia from aspirin-intolerant asthma (AIA) patients also showed a higher expression of KIF3A protein than aspirin-tolerant asthma controls. "	( KIF3A, a cilia structural gene on chromosome 5q31, and its polymorphisms show an association with aspirin hypersensitivity in asthma. Bae, JS; Cha, JY; Cheong, HS; Cho, SH; Choi, IS; Jang, AS; Kim, JH; Kim, MK; Park, BL; Park, CS; Park, JS; Shin, HD; Uh, ST, 2011)	0.93
"When treated with aspirin, the patients showed a 49% reduction in the generation of CD34+/KDR+ cells, indicating that the level of circulating CD34+/KDR+ cells also relates to in vivo platelet activation."	( Human CD34+/KDR+ cells are generated from circulating CD34+ cells after immobilization on activated platelets. de Boer, HC; de Koning, EJ; Hovens, MM; Huisman, MV; Rabelink, AJ; Snoep, JD; Tamsma, JT; van Oeveren-Rietdijk, AM; van Zonneveld, AJ, 2011)	0.69
"Treatment with aspirin for CHD prevention is less costly and more effective than no treatment in men older than 45 years with greater than 10-year, 10% CHD risks. "	( Cost-utility of aspirin and proton pump inhibitors for primary prevention. Earnshaw, SR; Fendrick, AM; McDade, C; Pignone, M; Scheiman, J, 2011)	1.07
"Treatment with aspirin and heparin decreases the risk of miscarriages in APS. "	( Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). Burmester, GR; Dörner, T; Hoppe, B, 2011)	1.11
"Pretreatment with aspirin, however, exerted significant cytoprotective effects in a dose-dependent manner (P < .05)."	( Aspirin prevents resistin-induced endothelial dysfunction by modulating AMPK, ROS, and Akt/eNOS signaling. Chen, JF; Lee, WJ; Ou, HC; Sheu, WH; Wu, CM, 2012)	2.15
"Pretreatment with aspirin or RGDS did not affect 2017-78-induced Erk2 phosphorylation or desphosphorylation but both inhibited the rephosphorylation phase."	( Platelet activation by Streptococcus sanguinis is accompanied by MAP kinase phosphorylation. Abdulrehman, AY; Jackson, EC; McNicol, A, 2013)	0.71
"The treatment with aspirin inhibited excess methyl L-DOPA-induced quinoprotein formation and cell death."	( Cyclooxygenase-independent neuroprotective effects of aspirin against dopamine quinone-induced neurotoxicity. Asanuma, M; Kikkawa, Y; Kimoto, N; Miyazaki, I; Miyoshi, K; Murakami, S; Takeshima, M, 2012)	0.95
"Treatment with aspirin and clopidogrel during the chronic phase of the disease diminished the number of intrahepatic HBV-specific CD8(+) T cells and HBV-nonspecific inflammatory cells, the severity of liver fibrosis, and the development of HCC."	( Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Aiolfi, R; Chisari, FV; Di Lucia, P; Esposito, A; Fiocchi, A; Guidotti, LG; Iannacone, M; Mainetti, M; Mingozzi, F; Ruggeri, ZM; Sitia, G, 2012)	0.72
"Treatment with aspirin starting at 3h or 24h after SE also suppressed the development of mossy fiber sprouting."	( Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats. Cui, XL; Jiang, W; Li, XW; Ma, L; Wang, Y; Wei, D; Yang, F, 2012)	2.16
"Rats treated with aspirin showed intestinal barrier dysfunction; high contents of the specific antigen were absorbed into the lamina propria. "	( Oral antigens induce rheumatoid arthritis-like inflammation in a rat model. Chen, X; Hu, D; Huang, Z; Liu, X; Liu, Z; Su, H; Wu, D; Yang, PC; Zhang, H, 2013)	0.72
"Pretreatment of aspirin followed by irradiation also elevated the population of apoptotic cells."	( The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Jeon, GA; Kim, KY; Nam, MJ; Seol, JY, 2003)	0.95
"Pretreatment with aspirin or bilirubin at low micromolar concentrations protected endothelial cells from hydrogen peroxide-mediated toxicity."	( Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Abate, A; Becker, JC; Dennery, PA; Grosser, N; Oberle, S; Pohle, T; Schröder, H; Seidman, DS; Vreman, HJ, 2003)	0.88
"Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). "	( Efficacy and safety of low-dose aspirin in polycythemia vera. Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004)	0.96
"Treatment with aspirin+heparin alone reduced thrombus weight by 37+/-25% (18.9+/-6.1 to 11.8+/-7.7 mg, p<0.0001)."	( Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study. Atar, S; Birnbaum, Y; Horzewski, M; Kaul, S; Kobal, S; Luo, H; Miyamoto, T; Neuman, Y; Rukshin, V; Siegel, RJ; Thompson, T; Tsang, V, 2003)	0.88
"Treatment with aspirin or clopidogrel did not influence predictive effects by leukocytes."	( Leukocyte count as an independent predictor of recurrent ischemic events. Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004)	0.66
"Treatment with aspirin was initiated, with resolution of the bacteremia and a gradual decrease in vegetation size."	( Aspirin treatment for neonatal infectious endocarditis. Adler, A; Bauer, S; Dolfin, T; Litmanovitz, I, )	1.91
"Men treated with aspirin had decreased levels of urinary 15-keto-dihydro-PGF2alpha than controls (P<0.01), independent of possible cardiovascular risk factors."	( Cyclooxygenase-mediated prostaglandin F2alpha is decreased in an elderly population treated with low-dose aspirin. Basu, S; Helmersson, J; Larsson, A; Vessby, B, 2005)	0.87
"Treatment with aspirin and ceftriaxone followed by trimethoprim-sulfamethoxazole resulted in a good neurological recovery and complete remission of the malabsorption syndrome."	( A patient with cerebral Whipple's disease and a stroke-like syndrome. De Simone, C; Famularo, G; Minisola, G, 2005)	0.67
"On treatment with aspirin, which inhibited the cell-cell contact and network-like structure formation, there was no down regulation of MMPs and cells continued to produce MMP-2 and MMP-9."	( Temporal relationship between MMP production and angiogenic process in HUVECs. Kiran, MS; Sameer Kumar, VB; Sudhakaran, PR; Viji, RI, 2006)	0.66
"Treatment with aspirin lead to a dose- and time-dependent decrease in proteasome activity and an increase in the accumulation of ubiquitylated proteins in the cells, which correlated with its effect on cell death."	( Aspirin induces apoptosis through the inhibition of proteasome function. Chatterjee, M; Dikshit, P; Goswami, A; Jana, NR; Mishra, A, 2006)	2.12
"Pretreatment with aspirin (10 - 60 mg/kg, i.v.) one hour before an i.v."	( Aspirin may exert its antipyresis by inhibiting the N-methyl-D-aspartate receptor-dependent hydroxyl radical pathways in the hypothalamus. Chang, CP; Huang, WT; Kao, TY; Lin, MT, 2007)	2.11
"Treatment with aspirin is underused for PP in patients with diabetes mellitus in Primary Care. "	( Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. Fernández-de-Bobadilla, J; Frías-Garrido, X; Navarro-Artieda, R; Rejas-Gutiérrez, J; Ruiz-Riera, R; Sicras-Mainar, A, 2007)	1.15
"Treatment with aspirin and statin for every patient with diabetes has been postulated."	( Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? Stirban, AO; Tschoepe, D, 2008)	0.9
"Treatment with aspirin did not alter the relaxant effect of ADP, adenosine and adenine, suggesting that the release of vasoactive prostaglandins is not involved."	( Responses to adenine nucleotides and related compounds of isolated dog cerebral, coronary and mesenteric arteries. Miyazaki, M; Okunishi, H; Taniyama, K; Toda, N, 1982)	0.6
"Treatment with aspirin and indomethacin reduced urinary PGE excretion and was associated with a decrease in daily calcium excretion."	( Idiopathic hypercalciuria associated with hyperreninemia and high urinary prostaglandin E. Davidman, M; Fish, A; Houser, M; Sinaiko, A; Smith, C; Zimmerman, B, 1984)	0.61
"Pretreatment with aspirin (80 mg X kg -1 iv) did not prevent the bronchoconstriction caused by PAF-acether, and intravenous or intratracheal arachidonic acid caused no bronchial response."	( Acute effects of intratracheal administration of platelet-activating factor in baboons. Arnoux, B; Benveniste, J; Denjean, A; Lockhart, A; Masse, R, 1983)	0.59
"Pretreatment with aspirin (10 mg/kg) protected sheep against the pulmonary vascular response and completely blocked thromboxane synthesis."	( Thromboxane synthesis by sources other than platelets in association with complement-induced pulmonary leukostasis and pulmonary hypertension in sheep. Ali, M; Cooper, JD; McDonald, JW; Morgan, E; Townsend, ER, 1983)	0.59
"Pretreatment with aspirin (15 or 100 mg/kg) 30 minutes prior to endotoxin also significantly (p less than 0.001) decreased the endotoxin-induced elevations in plasma levels of immunoreactive thromboxane B2, a stable metabolite of thromboxane A2, and immunoreactive 6-keto prostaglandin F1 alpha, a stable metabolite of prostacyclin."	( Studies on the beneficial effects of aspirin in endotoxic shock. Relationship to inhibition of arachidonic acid metabolism. Cook, JA; Halushka, PV; Wise, WC, 1983)	0.86
"Pretreatment with aspirin (15 or 100 mg/kg) 30 min before endotoxin significantly (P less than .001) decreased the endotoxin-induced elevations in plasma levels of immunoreactive (i) TXB2, a stable metabolite of TXA2, i6-keto PGF1 alpha, a stable metabolite of PGI2 and significantly (P less than .05) inhibited thrombin-induced in vitro platelet iTXB2 synthesis."	( Protective effects of aspirin in endotoxic shock. Cook, JA; Halushka, PV; Wise, WC, 1981)	0.9
"Pretreatment with aspirin resulted in a significant inhibitory effect in the male but not the female animals (p less than 0.05)."	( Sex related differences in platelet function: the effect of aspirin. Carter, CJ; Hirsh, J; Kelton, JG; Santos, A, 1982)	0.83
"Pretreatment with aspirin, which uniformly inhibited platelet aggregation, was associated with a reduced incidence of sudden death (25%), but the difference between aspirin-treated and control animals lacked statistical significance."	( Effect of inhibition of platelet function with carbenicillin or aspirin on experimental canine sudden death. Franciosa, J; Heckel, R; Johnson, GJ; Leis, LA, 1981)	0.82
"Pretreatment with aspirin significantly augmented alcohol-induced resorption, IUGR, cleft palate and digital malformations associated with haematomas."	( Aspirin-alcohol interaction in the production of cleft palate and limb malformations in the TO mouse. Padmanabhan, R; Pallot, DJ, 1995)	2.06
"Treatment with aspirin led to a significant decrease in membrane fluidity in both patients and old controls, but had no apparent effect on the platelet membrane fluidity of younger controls.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Aspirin-induced conformational changes in platelet membrane in subjects with stroke. Hasan, M; Jackson, SK; Sinclair, AJ, 1995)	2.07
"Treatment with aspirin and prednisone in one patient."	( Anterior ischemic optic neuropathy secondary to interferon alfa. Purvin, VA, 1995)	0.64
"Treatment with aspirin for 2 or 7 days had no effect on the constrictive responses at the injured site 1 month after injury or on those at the noninjured site at all times examined."	( Inhibitory effects of aspirin on coronary hyperreactivity to autacoids after arterial balloon injury in miniature pigs. Ibayashi, S; Kuga, T; Ohara, Y; Shimokawa, H; Takeshita, A; Tomoike, H, 1995)	0.95
"Treatment with aspirin leads to substantial and significant reductions in rates of mortality, reinfarction and stroke in patients with acute myocardial infarction, and the benefits are additive with those of thrombolytic therapy."	( Antithrombotic therapy for acute myocardial infarction. Hebert, PR; Hennekens, CH; O'Donnell, CJ; Ridker, PM, 1995)	0.63
"Pre-treatment with aspirin (both 150 and 200 mg/kg) on day 8 of gestation resulted in a numerical, though not statistically significant increase in alcohol-induced exencephaly."	( Effect of pre-treatment with aspirin on alcohol-induced neural tube defects in the TO mouse fetuses. Craigmyle, MB; Padmanabhan, R; Wasfi, IA, 1994)	0.9
"Pretreatment with aspirin reduced the mean integrated ACTH response to naloxone by 33% (P < 0.05)."	( Paradoxical inhibition by aspirin of naloxone-induced adrenocorticotropin secretion in myotonic dystrophy. Crosbie, GV; Grice, JE; Hockings, GI; Jackson, AJ; Jackson, RV; Torpy, DJ; Walters, MM, 1994)	0.91
"Treatment with aspirin, heparin, or the combination of aspirin plus heparin was ineffective for the prevention of carotid artery thrombosis in this model."	( Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Cunningham, MR; Lucchesi, BR; Manley, PJ; Mu, DX; Nedelman, MA; Rote, WE; Weisman, H, 1994)	0.63
"Dogs treated with aspirin developed NSAID-induced gastropathy (including gastric ulceration), and the degree of endoscopically detectable damage correlated well with sucrose permeability."	( Noninvasive detection of nonsteroidal anti-inflammatory drug-induced gastropathy in dogs. Kirk, D; Meddings, JB; Olson, ME, 1995)	0.61
"Treatment with aspirin inhibited spontaneous platelet aggregation but had little effect on the activated platelet profile."	( Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. Bihour, C; Nurden, AT; Nurden, P; Raymond, JM; Smith, M, 1996)	0.63
"Pretreatment with aspirin (75 or 150 mg/kg, i.v.) reduced the number of Fos-LI neurones induced by carrageenin-inflammation (28 +/- 2% and 45 +/- 1% reduction, respectively; P < 0.001 for both)."	( Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Besson, JM; Buritova, J; Honoré, P, 1995)	2.06
"Treatment with aspirin induced a high aggregation rate, with or without exposure to flow conditions."	( Red blood cell aggregability is increased by aspirin and flow stress, whereas dipyridamole induces cell shape alterations: measurements by digital image analysis. Bozzo, J; Del Giorgio, A; Hernández, MR; Ordinas, A, 1996)	0.89
"Treatment with aspirin emerged as an independent predictor of reduced cardiovascular (RR = 0.61, 95% confidence interval [CI] 0.38 to 0.97) and all cause (RR = 0.66, 95% CI 0.47 to 0.93) mortality after multiple adjustment for possible confounders such as age, history of myocardial infarction, systemic hypertension, diabetes mellitus, peripheral vascular disease, current smoking, New York Heart Association classification, and concomitant treatment with digitalis."	( Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group. Behar, S; Benderly, M; Goldbourt, U; Harpaz, D; Kishon, Y, 1996)	1.04
"Treatment with aspirin plus dipyridamole caused an inhibition of the platelet production of thromboxane B2 and a decrease in the vascular synthesis of prostacyclin."	( Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. De la Cruz, JP; García Campos, JM; Moreno, A; Muñoz, M; Sánchez de la Cuesta, F, 1997)	1.04
"Treatment with aspirin and heparin leads to a significantly higher rate of live births in women with a history of recurrent miscarriage associated with phospholipid antibodies than that achieved with aspirin alone."	( Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) Cohen, H; Dave, M; Rai, R; Regan, L, 1997)	0.94
"Treatment with aspirin inhibited NF-kappaB nuclear translocation and binding and was associated with reduction of ICAM-1 expression, SMC proliferation and neointimal thickening following balloon injury."	( Nuclear factor-kappaB activity and arterial response to balloon injury. Cercek, B; Dimayuga, P; Fishbein, MC; Kaul, S; Nilsson, J; Regnstrom, J; Shah, PK; Yamashita, M; Zhu, J, 1997)	0.64
"Treatment with aspirin, beta blockers, and angiotensin converting enzyme inhibitors. "	( Secondary prevention in coronary heart disease: baseline survey of provision in general practice. Campbell, NC; Deans, HG; Rawles, JM; Ritchie, LD; Thain, J, 1998)	0.65
"Pretreatment with aspirin and/or fraxiparine in the presence of ionic contrast media showed antithrombotic activities equal to those obtained when they were tested alone (p<0.05), while in the presence of nonionic contrast media, these drugs only neutralised the prothrombotic effects."	( Aspirin and fraxiparine in the prevention of laser induced thrombosis in the presence of iodinated contrast media. Aguejouf, O; Belougne Malfatti, E; Doutremepuich, C; Doutremepuich, F, 1998)	2.07
"Pretreatment with aspirin or ticlopidine alone does not decrease the thrombogenic potential of RF ablation. "	( Pretreatment with antithrombotic agents during radiofrequency catheter ablation: a randomized comparison of aspirin versus ticlopidine. Cokkinos, DV; Manolis, AS; Maounis, T; Melita-Manolis, H; Psarros, L; Terzoglou, G; Vassilikos, V, 1998)	0.85
"Treatment with aspirin was associated with a significant reduction in cardiac and total mortality among non-insulin-dependent diabetic patients with coronary artery disease. "	( Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Behar, S; Boyko, V; Gottlieb, S; Graff, E; Harpaz, D; Kishon, Y, 1998)	1.04
"Pretreatment with aspirin did not change the vasodilator responses in any group."	( Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Montagne, O; Sediame, S, 1999)	0.63
"Pretreatment with aspirin had little or no effect on the response to smoking (n = 9)."	( A single high dose of vitamin C counteracts the acute negative effect on microcirculation induced by smoking a cigarette. Björkhem, I; Henriksson, P; Kallner, A; Lu, Q; Xiu, RJ; Ying, X; Zhang, J, 1999)	0.63
"Treatment with aspirin or sodium salicylate inhibited invasiveness of the LMP1-expressing C33A cells (P < 0.03) and suppressed both the LMP1-induced MMP-9 expression in zymographic analyses and LMP1-induced MMP-9 promoter activity in CAT reporter assays (P < 0.01)."	( Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Furukawa, M; Murono, S; Pagano, JS; Sato, H; Takeshita, H; Yoshizaki, T, 2000)	2.09
"Treatment with aspirin may reduce TF expression."	( Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Cercek, B; Chyu, KY; Dimayuga, P; Fishbein, MC; Kangavari, S; Matetzky, S; Shah, PK; Tani, S; Xu, H; Yano, J, 2000)	0.65
"Pre-treatment with aspirin lessened the number of CFRs but did not reduce platelet accumulation in LAD myocardium (483+/-148%)."	( Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization. Barrabés, JA; Garcia-Dorado, D; Garcia-Lafuente, A; Puigfel, Y; Solares, J; Soler-Soler, J; Soriano, B; Trobo, L, 2000)	0.63
"Treatment with aspirin resulted in an increase in nitric oxide production. "	( Nitric oxide mediated effect of cyclo-oxygenase inhibitors. Ashfaq, MK; Mahmood, M; Zuberi, HS, 2001)	0.66
"Pretreatment with aspirin significantly increased the number of laser spots needed to produce a complete RVO (P =.002)."	( Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. Arroyo, JG; Dastgheib, K; Hatchell, DL, )	0.45
"The treatment with aspirin, clopidogrel (including loading-dose) for a treatment period of 3-12 months and anticoagulation for 2 days can be considered the new standard of treatment in patients with acute coronary syndromes (unstable angina, non-ST-segment elevation, myocardial infarction)."	( [Modern therapy in acute coronary syndrome]. Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ, 2002)	0.63
"Pretreatment with aspirin and/or a loading dose of 1.5 mg roxifiban had no significant effect on the pharmacokinetics and pharmacologic response of XV459."	( Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. Cain, VA; Ebling, W; Fossler, MJ; Kornhauser, DM; Ma, S; Mondick, JT; Pieniaszek, HJ; Sy, SK, 2002)	0.64
"Treatment with aspirin or indomethacin abolished PGE2 production but did not affect collagenase levels."	( Collagenase production by synovial fibroblasts treated with phorbol myristate acetate. Brinckerhoff, CE; Fahey, JV; Harris, ED; McMillan, RM, 1979)	0.6
"Pretreatment with aspirin or indomethacin virtually abolished the increase in intraocular pressure and elevation of prostaglandin-like activity in the aqueous humor following a 20 mul burn."	( Prostaglandin-like activity in the aqueous humor following alkali burns. Paterson, CA; Pfister, RR, 1975)	0.58
"Pretreatment with aspirin plus iridectomy virtually eliminates the elevation of intraocular pressure consequent to paracentesis."	( Increased pressure after paracentesis of the rabbit eye is completely accounted for by prostaglandin synthesis and release plus pupillary block. Al-Ghadyan, A; Mead, A; Sears, M, 1979)	0.58
"Pretreatment with aspirin significantly decreased this trauma-induced, probably prostaglandin-mediated, disruption of the blood-aqueous barrier."	( Aspirin stabilization of the blood-aqueous barrier in the human eye. Gravenstein, N; Kaufman, HE; Sugar, A; Zimmerman, TJ, 1975)	2.02
"Pretreatment with aspirin and intraoperative heparin irrigation of the vessel lumen were not beneficial in altering the quantity of thrombus."	( Thrombus formation and endothelial alterations in microarterial anastomoses. Rosenbaum, TJ; Sundt, TM, 1977)	0.58
"Pretreatment with aspirin tended to reduce the rate and extent of acetaminophen absorption and altered the percentage of the dose excreted in the urine as sulfate, mercapturate, glucuronide, and cysteine."	( Effect of aspirin on a subtoxic dose of 14C-acetaminophen in mice. Paul, CJ; Thomas, BH; Whitehouse, LW; Wong, LT, 1977)	0.98
"Treatment with aspirin reduced urinary excretion of 5-hydroxy indole acetic acid--presumably by inhibiting in vivo platelet release of serotonin, reduced postoperative consumption of platelets, and reduced the mean corpuscular volume of the platelet population."	( The influence of aspirin on postoperative platelet kinetics and venous thrombosis. Clagett, GP; Rosoff, CB; Salzman, EW; Schneider, P, 1975)	0.93
"Pretreatment with aspirin rectal suppositories had no effect on the third ventricle responses induced by prostaglandin E1."	( Increased intraocular pressure after third ventricle injections of prostaglandin E1 and arachidonic acid. Becker, B; Krupin, T; Oestrich, C; Podos, SM, 1976)	0.58
"Treatment with aspirin led to a significant reduction in mucus biosynthesis by the gall bladder mucosa."	( Inhibition of human gall bladder mucus synthesis in patients undergoing cholecystectomy. Allen, A; Dowling, RH; Lennard, TW; Murphy, G; Rhodes, M, 1992)	0.62
"Pretreatment with aspirin and Y-20811, a thromboxane synthetase inhibitor, significantly prolonged the time required for occlusion in the guinea-pigs, while these drugs were ineffective in the rats."	( Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Hirata, Y; Nakashima, M; Takiguchi, Y; Wada, K, 1992)	0.61
"Pretreatment with aspirin significantly attenuated the effects of interleukin-1 beta on both the vasopressin and oxytocin levels."	( Effects of interleukins on plasma arginine vasopressin and oxytocin levels in conscious, freely moving rats. Ebisui, O; Fukata, J; Imura, H; Kasting, NW; Mori, K; Murakami, N; Naito, Y; Nakai, Y; Shindo, K; Tominaga, T, 1991)	0.6
"Pretreatment with aspirin at low concentrations (0.1-1 micrograms/ml) inhibited more than 60% of the enzyme mass and also the cyclooxygenase activity in IL-1-induced cells with only minimal effects on the basal level of the synthase enzyme in cells without IL-1."	( Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Ferhanoglu, B; Loose-Mitchell, DS; Sanduja, R; Tsai, AL; Wu, KK, 1991)	2.05
"Treatment with aspirin abolished the CFRs in all dogs and concomitantly reduced the ex vivo thrombus volume by 84% (p less than 0.01) without affecting platelet adhesion and fibrin deposition."	( Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models. Baumgartner, HR; Roux, SP; Sakariassen, KS; Turitto, VT, )	0.87
"Treatment with aspirin and a residual stenosis of 25-49% immediately after successful PTCA were the only variables associated with restenosis (P less than 0.05), otherwise the clinical and angiographic characteristics were similar with and without restenosis."	( Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. Emanuelsson, H; Hjalmarson, A; Johansson, SR; Karlsson, T; Wiklund, O, 1991)	0.62
"Treatment with aspirin (75 mg/day) should be recommended to all men for greater than or equal to 3 months after an episode of unstable coronary artery disease."	( Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Wallentin, LC, 1991)	2.06
"Pretreatment with aspirin abolished completely the increased PG secretion elicited by ET and potentiated the ET-induced reduction renal blood flow."	( Renal and femoral vascular responses to endothelin-1 in dogs: role of prostaglandins. Imanishi, M; Miura, K; Okumura, M; Shimmen, T; Yamamoto, K; Yamanaka, S; Yamashita, Y; Yukimura, T, 1991)	0.6
"Pretreatment with aspirin DL-lysine (25 mg/kg) or diphenhydramine (1 mg/kg) significantly attenuated the responses of MAP (P less than 0.05 in both) and plasma 6-keto-PGF1 alpha level (P less than 0.01 for aspirin group, P less than 0.05 for diphenhydramine group)."	( Contribution of prostacyclin to D-tubocurarine-induced hypotension in humans. Arai, T; Hatano, Y; Komatsu, K; Mori, K; Nakajima, Y; Noda, J; Sawada, M; Shinkura, R, 1990)	0.6
"Pre-treatment with aspirin (5 mg/kg), which inhibits the platelet-release reaction, also prevented the tachypnoeic response to both emboli and antiserum, although it did not prevent the fall in platelet count which following injection of antiserum."	( The role of platelets in the reflex tachypnoeic response to miliary pulmonary embolism in anaesthetized rabbits. Armstrong, DJ; Miller, SA, 1990)	0.6
"Pretreatment with aspirin did not prevent this decrease in vascular conductance during maximal vasodilation."	( No reflow and extent of infarction during maximal vasodilation in the porcine heart. Anselone, CG; Bristow, JD; Johnson, WB; Malone, SA; Pantely, GA, 1988)	0.6
"Pretreatment with aspirin (10 mg/kg) protected the sheep against the pulmonary vascular response to 20 micrograms of PAF and blocked completely the thromboxane synthesis."	( Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep. McDonald, JW; Smallbone, BW; Taylor, NE, 1987)	0.6
"Treatment with aspirin (IV perfusion-2 mg/kg/min) promoted profound depression of PLA in both segments while t-PA remained unchanged."	( Local plasminogen activator and prostacyclin-like activity after partial venous occlusion--an experimental study in the dog. Adolfo, A; Andrade, JA; Cabral, JM; Monteiro, AC, 1988)	0.61
"Pretreatment with aspirin resulted in a dose-dependent and parallel decrease in TXB2 and 6-keto PGF1 alpha production."	( Effect of single-dose aspirin on TXA2 and PGI2 cyclooxygenases in vivo. Le Breton, GC; Zaragoza, R, 1987)	0.91
"Pretreatment with aspirin reduces the levels of cyclooxygenase metabolites in nasal secretions without affecting the immediate physiologic response to antigen or the expected increase in the levels of histamine, N-alpha-tosyl-L-arginine methyl ester-esterase activity, and leukotriene C4."	( Experimentally induced nasal allergic responses. Adkinson, NF; Bascom, R; Kagey-Sobotka, A; Lichtenstein, LM; Naclerio, RM; Proud, D; Walden, SM, 1988)	0.6
"Treatment with aspirin-dipyridamole was without effect."	( Renal scintigraphy and survival of indium-111-labelled platelets in patients with diabetic nephropathy. Barker, MJ; Davies, JA; Hooper, AH; Spencer, AA; Stainton, C; Tindall, H, 1986)	0.61
"The treatment with aspirin, nitrendipine or nicardipine did not counteract the fall in circulating platelets counted 1 min after the aggregation challenge, but at 3 min platelet count was significantly higher in aspirin-treated mice than in animals given either Ca++ channel blocker."	( Mouse antithrombotic assay: the effects of Ca++ channel blockers are platelet-independent. Cerletti, C; de Gaetano, G; de Marchi, F; Guarneri, L; Molinari, A; Pacei, E, 1987)	0.59
"Pretreatment with aspirin (6 mg/kg i.v.; n = 5) was without any influence on these reactions."	( Cardiac sympathetic nerve activity and progressive vasoconstriction distal to coronary stenoses: feed-back aggravation of myocardial ischemia. Deussen, A; Heusch, G; Thämer, V, 1985)	0.59
"Treatment with aspirin prolonged induction-abortion time by about 9 hours and treatment with indomethacin by 30 hours."	( Letter to the editor: Non steroid anti-inflammatory drugs and pregnancy. Tricomi, V; Waltman, R, 1974)	0.59

Toxicity

Aspirin alone at the low dose of 100 mg administered or the combination of coumadin and aspirin after high-pressure coronary stenting does not prevent adverse clinical events. Adverse effects led to suspension of treatment in 6% (5% with aspirin and acenocumarol, 17% with ticlopidine)

Excerpt	Reference	Relevance
"A case of aspirin hepatotoxicity in a 46-year-old male with rheumatoid arthritis is discussed, and this adverse reaction is reviewed."	( Aspirin hepatotoxicity. Hindin, BI; Kanada, SA; Kolling, WM, 1978)	2.1
" In animals pretreated by anti-inflammatory drugs in toxic doses an earlier development of ulceration was observed by distention with acid."	( Distention ulcer as a model for testing of drugs for ulcerogenic side effects. Szelenyi, I; Thiemer, K, 1978)	0.26
" This case suggests that disseminated intravascular coagulation, and its rare association with hepatotoxicity, is a potentially fatal side effect of aspirin therapy."	( Aspirin hepatotoxicity and disseminated intravascular coagulation. Bennett, RM; Sbarbaro, JA, 1977)	1.9
"We prospectively analyzed adverse effects of aspirin in a multicentered cooperative study undertaken to determine the role of endarterectomy in the treatment of asymptomatic carotid artery stenosis."	( Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis. The VA Cooperative Asymptomatic Carotid Artery Stenosis Study Group. Corson, JD; Hobson, RW; Krupski, WC; Rapp, JH; Weiss, DG, 1992)	0.87
" The most common adverse effects that occurred were related to the gastrointestinal tract, nervous system, skin, and special senses."	( Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. Fleischmann, RM, 1992)	0.28
"Data from 58 premarketing studies of the nonsteroidal antiinflammatory drug flurbiprofen were pooled for analyses of adverse drug reactions (ADRs)."	( Clinical safety of flurbiprofen. Assenzo, JR; Brooks, CD; Defesche, CL; Johnson, JH; Linet, OI; Schellenberg, D; Teoh, KW; Turner, LF, 1990)	0.28
" The results indicated that FS 205-397, administered in single doses of either 500 or 250 mg, is a safe and effective analgesic for the relief of pain following dental surgery, and may offer particular advantages in terms of onset of effects."	( A single-dose study of the efficacy and safety of FS 205-397 (250 mg or 500 mg) versus aspirin and placebo in the treatment of postsurgery dental pain. Mazza, FA; Mehlisch, DR; Singer, JM; Sterling, WR, 1990)	0.5
" There was statistical evidence for greater adverse effects of aspirin/codeine on mood and mental alertness in comparison to ibuprofen/codeine and placebo."	( Multiple-dose safety study of ibuprofen/codeine and aspirin/codeine combinations. Friedman, H; Oster, H; Royer, G; Seckman, C; Stubbs, C, 1990)	0.77
"The hepatotoxicity of acetaminophen (APAP) overdose depends on metabolic activation to a toxic reactive metabolite via hepatic mixed function oxidase."	( Acetaminophen hepatotoxicity: is there a role for prostaglandin synthesis? Ben-Zvi, Z; Danon, A; Katz, S; Weissman-Teitellman, B, 1990)	0.28
" Hetastarch had no effect on blood loss and was not associated with any adverse clinical reactions."	( Platelet inhibitors and hydroxyethyl starch: safe and cost-effective interventions in coronary artery surgery. DeWeese, JA; Hicks, GL; Jensen, LA; Norsen, LH; Quinn, JR; Stewart, SS, 1985)	0.27
" Ototoxicity is a common and troublesome side-effect of high-dose aspirin treatment but there has been little previous study of the relationships between the degree of ototoxicity and the plasma concentrations of salicylate."	( Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Bieri, D; Brown, M; Cairns, D; Day, RO; Graham, GG; Harris, G; Hounsell, J; Platt-Hepworth, S; Reeve, R; Sambrook, PN, 1989)	0.51
" The oral LD50 value of S-01 was more than 10,000 mg/kg in mice and rats of both sexes."	( [Pharmacological study of kako-bushi-matsu: analgesic action and acute toxicity]. Murayama, M; Namiki, Y, 1989)	0.28
"A comparison was made among phenylpropanolamine, aspirin, acetaminophen and ibuprofen in terms of their relative safety, as measured by adverse reaction reports published since 1980, the five semiannual reports published by the Drug Abuse Warning Network during 1984-1986 and annual reports from Poison Control Centers from 1983-1986."	( A comparison of the relative safety of phenylpropanolamine, acetaminophen, ibuprofen and aspirin as measured by three compendia. Winick, C, 1989)	0.75
" Three patients (one on ketorolac, two on Doleron) withdrew because of adverse events (vomiting)."	( Analgesic efficacy and safety comparison of ketorolac tromethamine and Doleron for the alleviation of orthopaedic post-operative pain. Johansson, S; Josefsson, G; Lindstrand, A; Malstam, J; Stenstroem, A, )	0.13
" Previous studies have indicated that pregnant animals treated acutely with toxic levels of a variety of pharmacologically unrelated chemicals produced litters without a recognizable syndrome of defects, except for an increased incidence of supernumerary ribs (SNR)."	( The potential relationship of maternal toxicity, general stress, and fetal outcome. Beyer, PE; Chernoff, N; Kavlock, RJ; Miller, D, 1987)	0.27
" No serious drug-related adverse events or abnormal biochemistry or haematology were observed in either group."	( A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. Berry, H; Hutchinson, DR, )	0.13
"Despite the adverse effects of aspirin, many physicians still consider it to be the drug of choice for initial treatment of arthritic disorders."	( Salicylates in the treatment of arthritic disease. How safe and effective? Altman, RD, 1988)	0.56
" The percentage of aspirin-treated patients who withdrew from the study due to adverse experiences was greater (60 percent versus 20 percent), as was the number with at least one treatment-related adverse experience (19, or 95 percent, versus 11, or 55 percent)."	( Results of a six-month study comparing the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis. Mullen, BJ, 1987)	0.83
" Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent)."	( Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. Appelrouth, DJ; Baim, S; Chang, RW; Cohen, MH; Englund, DW; Germain, BF; Hartman, SS; Jaffer, A; Mullen, BJ; Smith, FE, 1987)	1.43
" Documentation is derived from clinical trials, post-marketing surveillance, special studies, and spontaneous reports of adverse drug reactions from foreign countries."	( Worldwide safety experience with diclofenac. Catalano, MA, 1986)	0.27
" None of the changes led to adverse clinical consequences."	( Renal safety of two analgesics used over the counter: ibuprofen and aspirin. Bonney, SL; Hedrich, DA; Northington, RS; Walker, BR, 1986)	0.51
" The most common type of adverse reaction to all medications (isoxicam, aspirin, and indomethacin) was gastrointestinal: 22."	( Evaluation of the safety of isoxicam. Burch, FX, 1985)	0.5
" Adverse experiences were infrequent and generally mild or transient."	( Worldwide clinical safety experience with diclofenac. Willkens, RF, 1985)	0.27
"EGTA-treated rat serum was added to the culture medium and tested the toxic effect of EGTA on development of embryo using 11."	( Embryotoxic effects of EGTA-induced hypocalcemic condition on cultured rat embryos. Eto, K; Igarashi, T; Kitagawa, H; Ueno, K; Yokoyama, A, 1985)	0.27
"Cardiac side effects from aspirin are uncommon; however, severe acid-base imbalance, pulmonary edema, ventricular ectopic activity and cardiopulmonary arrest have been reported in patients with toxic serum salicylate concentrations."	( Cardiac conduction abnormalities and atrial arrhythmias associated with salicylate toxicity. Alpert, MA; Beach, CL; Flaker, GC; Mukerji, V; Weber, RD, )	0.43
" Combination with ASA potentiated the toxic effect of the aminoglycoside after 10 but not after 5 days of treatment."	( Prostaglandins and aminoglycoside nephrotoxicity. Assael, BM; Bamonte, F; Chiabrando, C; Gagliardi, L; Noseda, A; Salmona, M, 1985)	0.27
"Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever."	( Safety profile: fifteen years of clinical experience with ibuprofen. Royer, GL; Seckman, CE; Welshman, IR, 1984)	0.27
" Suprofen was generally found to be at least as safe and as well tolerated as reference drugs of aspirin, propoxyphene and propoxyphene combination."	( Suprofen. An overview of long-term safety. Gardner, MC; Milak, DM; Raina, M; Smith, KE; Yeadon, A, 1983)	0.48
" In addition to gastrointestinal intolerance, photosensitivity and onycholysis are the most frequent adverse effects encountered."	( Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen. Dahl, SL; Ward, JR, )	0.13
" It was found that compounds with polar substituents at the 2 or 3 position of the ring system are less acutely toxic while maintaining antiinflammatory activity."	( Effect of structural change on acute toxicity and antiinflammatory activity in a series of imidazothiazoles and thiazolobenzimidazoles. Ariyan, ZS; Fogt, SW; Heilman, RD; Matthews, RJ; Powers, LJ; Rippin, DJ, 1981)	0.26
" In this long-term safety study, patients treated with zomepirac had significantly fewer adverse reactions and fewer limiting adverse reactions than did patients treated with aspirin."	( Long-term safety of zomepirac: a double-blind comparison with aspirin in patients with osteoarthritis. Andelman, SY; Cannella, JJ; Ruoff, GE, )	0.56
" 6 Following overdosage of paracetamol, a toxic intermediate metabolite causes acute hepatic necrosis which may be fatal."	( Hepatotoxicity of mild analgesics. Prescott, LF, 1980)	0.26
" The incidence of adverse events during each period did not seem to depend either on the treatment being given during that period or on the previous one."	( Double-blind cross-over investigation of the effectiveness and safety of two doses of indoprofen compared with an ASA preparation and placebo in patients suffering from osteoarthritis. Bergamini, N; Groppi, W; Mandelli, V; Valtonen, E, 1981)	0.26
" Discontinuation due to lack of efficacy or adverse effects was substantially lower for benoxaprofen than for aspirin or ibuprofen."	( An update on long-term efficacy and safety with benoxaprofen. Mikulaschek, WM, 1982)	0.48
" We used a tertiary referral clinic population to estimate safe exposure doses for epidemiological studies."	( Aspirin, salicylate, sulfite and tartrazine induced bronchoconstriction. Safe doses and case definition in epidemiological studies. Buckley, CE; Corder, EH, 1995)	1.73
"In women assigned to low-dose aspirin there were no adverse effects related to epidural anesthesia."	( Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. Caritis, SN; McNellis, D; Shaw, K; Sibai, BM; Thom, E, 1995)	1
" Microscopic hematuria was the most frequent (20%) adverse clinical event, but was unrelated to the INR."	( Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Comp, PC; Durica, SS; Goodman, SG; Gray, RJ; Hall, JH; Hua, TA; Kelley, RP; Langer, A; Lee, RJ; Raskob, GE, 1994)	0.52
"Our data suggest that combination antithrombotic therapy is safe in a controlled, inpatient setting."	( Safety of combination aspirin and anticoagulation in acute ischemic stroke. Fagan, SC; Kertland, HR; Tietjen, GE, 1994)	0.6
"The adverse effects of low-dose aspirin (100 mg daily) in the elderly were studied over a 12-month period in a double-blind, randomized, placebo-controlled trial of 400 subjects who were 70 years of age or older and had no preexisting major vascular diseases at the time of entry."	( Adverse effects of low-dose aspirin in a healthy elderly population. Campion, K; Donnan, GA; McNeil, JJ; Silagy, CA; Tonkin, AM; Worsam, B, 1993)	0.86
" Among the documented adverse effects of aspirin is the potential for ototoxicity."	( Ototoxicity associated with salicylates. A brief review. Brien, JA, 1993)	0.55
"048), and the frequency of adverse events was not significantly different between the two treatment groups."	( The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Weisberg, LA, 1993)	0.55
"The main adverse effects of tamoxifen, aspirin, oral contraceptives (OCs) and retinoids used as chemopreventive agents in humans are reviewed and quantified here."	( Adverse effects of preventive therapy in humans. Garattini, S; La Vecchia, C; Tavani, A, 1996)	0.56
"There were no serious adverse events associated with diaspirin cross-linked hemoglobin solution infusion."	( Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Bounds, MJ; Colburn, WA; Daily, EK; Kisicki, JC; Mattia-Goldberg, C; Przybelski, RJ, 1996)	0.78
" Although our data need confirmation in prospective clinical trials, they suggest that aspirin, particularly in lower doses (100 mg/d), may be a safe antithrombotic agent in ET with an acceptable risk for bleeding, if applied to patients with a platelet count <1000 x 10(9)/l and/or absence of a bleeding history."	( Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Michiels, JJ; Mulder, PG; van de Moesdijk, D; van Genderen, PJ; Waleboer, M, 1997)	0.73
"Reduced anticoagulation with antiplatelet therapy alone after coronary stenting, despite infrequent use of intravascular ultrasound, is an effective and safe strategy with a low rate of vascular complications, a relatively short hospital stay and a low incidence of clinical manifestations of stent thrombosis."	( Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. Buller, CE; Chauhan, A; Moscovich, MD; Penn, IM; Ricci, DR; Zubaid, M, 1997)	0.3
" In contrast to arachidonic acid, oleic acid was not toxic to the Hep G2-MV2E1-9 cells."	( Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. Cederbaum, AI; Chen, Q; Galleano, M, 1997)	0.3
" The free acid compounds were less toxic than their corresponding salts."	( Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines. Dierickx, PJ; Janssen, L; Noble, E, 1997)	0.3
" When used long term, aspirin has significant adverse effects and is poorly tolerated."	( Use and safety of aspirin in the chemoprevention of colorectal cancer. Singh, AK; Trotman, BW, 1998)	0.95
"The goals of stable angina pectoris treatment are: (i) symptom relief and increase in angina-free walking time; and (ii) reduction of mortality and adverse outcome."	( Choosing the most appropriate treatment for stable angina. Safety considerations. Asirvatham, S; Sebastian, C; Thadani, U, 1998)	0.3
"SC-58635 achieves analgesic and antiinflammatory efficacy in arthritis through selective COX-2 inhibition, without showing any evidence of 2 of the toxic effects of COX-1 inhibition associated with nonsteroidal antiinflammatory drugs."	( Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Geis, GS; Hubbard, RC; Isakson, PC; Lanza, FL; Lipsky, PE; Schwartz, BD; Simon, LS; Talwalker, S, 1998)	0.3
" The global incidence of adverse events was 45% higher with EC, though not significant (32 vs."	( Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Geraud, G; Gómez, JP; Henry, P; Joffroy, A; Lainez, JM; Le Jeunne, C; Liaño, H; Pradalier, A; Titus i Albareda, F, 1999)	0.3
" These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis."	( Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Creager, MA, 1998)	0.76
" Such aggressive antihypertensive treatment was safe and well tolerated, and did result in fewer cardiovascular events in the subset of patients with diabetes."	( Aggressive blood pressure lowering is safe, but benefit is still hard to prove. Pohl, MA; Vidt, DG, 1999)	0.3
" We identified epidemiologic studies, published from January 1970 to December 1995, that investigated the association of serious adverse effects with aspirin, diclofenac, acetaminophen, and dipyrone to determine and compare the excess mortality associated with short-term drug use."	( Comparative safety evaluation of non-narcotic analgesics. Andrade, SE; Martinez, C; Walker, AM, 1998)	0.5
" Two patients in the 100 mg/kg group had adverse events that were possibly drug related: one suffered fatal brain and pulmonary edema, the other transient renal and pancreatic insufficiency."	( Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Carton, H; Hacke, W; Kaste, M; Koudstaal, PJ; Przybelski, RJ; Saxena, R; Stern, KN; Wijnhoud, AD, 1999)	0.3
"Outcome scale scores were worse in the DCLHb group, and more serious adverse events and deaths occurred in DCLHb-treated patients than in control patients."	( Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Carton, H; Hacke, W; Kaste, M; Koudstaal, PJ; Przybelski, RJ; Saxena, R; Stern, KN; Wijnhoud, AD, 1999)	0.3
"Danaparoid sodium appears to be an efficient and safe treatment in critically ill patients with HIT."	( Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Guyotat, D; Mahul, P; Mazet, E; Mismetti, P; Reynaud, J; Tardy, B; Tardy-Poncet, B, 1999)	0.3
" Sumatriptan is more effective, but resulted in more adverse events."	( Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St Diener, HC, 1999)	0.3
"Aspirin alone at the low dose of 100 mg administered or the combination of coumadin and aspirin after high-pressure coronary stenting does not prevent adverse clinical events when ultrasound guidance is not used."	( Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study. Barmeyer, J; Germing, A; Jäger, D; Lange, S; Lemke, B; Machraoui, A; von Dryander, S, 1999)	2.01
" The incidence of early permanent discontinuations of the study drug due to adverse events was almost identical in both treatment groups (11."	( Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999)	0.55
" No in-hospital adverse cardiac events occurred."	( beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. Coen, VL; den Boer, A; Gijzel, AL; Kay, IP; Levendag, PC; Ligthart, JM; Sabaté, M; Serruys, PW; van Der Giessen, WJ; Wardeh, AJ, 1999)	0.3
"5 microCi is safe and feasible."	( beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. Coen, VL; den Boer, A; Gijzel, AL; Kay, IP; Levendag, PC; Ligthart, JM; Sabaté, M; Serruys, PW; van Der Giessen, WJ; Wardeh, AJ, 1999)	0.3
"To determine the incidence of adverse effects of antithrombotic drugs (platelet anti-aggregants and anticoagulants) in patients with transient ischemic attacks (TIA) and mild ischemic strokes (IL)."	( [Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease]. Cabezas, C; Clavería, LE; Duarte, J; Ferrero, M; Guerrero, P; Sempere, AP; Tabernero, C; Tahoces, ML, )	0.13
" Adverse effects which led to suspension of treatment or were a potential danger for the patient's life were recorded."	( [Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease]. Cabezas, C; Clavería, LE; Duarte, J; Ferrero, M; Guerrero, P; Sempere, AP; Tabernero, C; Tahoces, ML, )	0.13
" Adverse effects led to suspension of treatment in 6% (5% with aspirin and acenocumarol, 17% with ticlopidine)."	( [Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease]. Cabezas, C; Clavería, LE; Duarte, J; Ferrero, M; Guerrero, P; Sempere, AP; Tabernero, C; Tahoces, ML, )	0.37
" Vital signs, laboratory assessments, blood and fluid administration, complications, and adverse events were recorded at various times from the end of infusion through 72 hours after infusion."	( A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of hemorrhagic, hypovolemic shock. Bickell, WH; Cohn, SM; Corne, L; Daily, EK; Harviel, JD; Koenigsberg, MD; Micheels, J; Mols, P; Przybelski, RJ; Sloan, E; Thompson, DR, )	0.43
" Adverse events were experienced by 61% of patients in the DCLHb group and 53% of patients in the saline group; serious adverse events occurred in 28% of DCLHb-treated patients and 30% of saline-treated patients."	( A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of hemorrhagic, hypovolemic shock. Bickell, WH; Cohn, SM; Corne, L; Daily, EK; Harviel, JD; Koenigsberg, MD; Micheels, J; Mols, P; Przybelski, RJ; Sloan, E; Thompson, DR, )	0.43
"Administration of 50 to 200 mL of DCLHb to patients in hemorrhagic, hypovolemic shock was not associated with evidence of end organ toxicity or significant adverse events."	( A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of hemorrhagic, hypovolemic shock. Bickell, WH; Cohn, SM; Corne, L; Daily, EK; Harviel, JD; Koenigsberg, MD; Micheels, J; Mols, P; Przybelski, RJ; Sloan, E; Thompson, DR, )	0.43
" The primary end point consisted of major peripheral or bleeding complications, neutropenia, thrombocytopenia, or early discontinuation of study drug as the result of a noncardiac adverse event during the study-drug treatment period."	( Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLAS Bertrand, ME; Gershlick, AH; Rupprecht, HJ; Urban, P, 2000)	0.52
"Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1."	( Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)	0.31
"To determine whether celecoxib, a COX-2-specific inhibitor, is associated with a lower incidence of significant upper GI toxic effects and other adverse effects compared with conventional NSAIDs."	( Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)	0.31
"Incidence of prospectively defined symptomatic upper GI ulcers and ulcer complications (bleeding, perforation, and obstruction) and other adverse effects during the 6-month treatment period."	( Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)	0.31
"In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages."	( Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)	0.31
"We compared the gastric toxic effect of aspirin (ASA) in both normal and diabetic rats, with that of NCX-4016, a derivative of ASA with nitric oxide (NO) releasing moiety."	( Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. Fujita, A; Takeuchi, K; Tashima, K; Umeda, M, 2000)	0.83
" They differ mainly in their adverse effects and costs."	( Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account. , 2000)	0.31
" Overall, compliance was high and few adverse effects were reported."	( Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Applegate, WB; Crouse, JR; Davis, KB; Egan, D; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Johnson, WC; Kennedy, JW; Kostis, JB; Sheps, DS, 2000)	0.31
"ADMIT demonstrates that it is both feasible and safe to modify multiple atherosclerotic disease risk factors effectively with intensive combination therapy in patients with PAD."	( Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Applegate, WB; Crouse, JR; Davis, KB; Egan, D; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Johnson, WC; Kennedy, JW; Kostis, JB; Sheps, DS, 2000)	0.31
"To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile."	( Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001)	1.99
"The above discussion on the interaction of aspirin and ACE inhibitors seems to suggest that aspirin in high doses may have adverse interaction with ACE inhibitors in patients with heart failure but the data obtained is not sufficient or conclusive to recommended omission of aspirin in patients with heart failure."	( Combining aspirin with angiotensin converting enzyme inhibitors in heart failure: how safe is it? Bansal, N; Mahajan, A; Mehta, H; Pathak, L; Vaidya, S, 1998)	0.97
" A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis."	( A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000)	0.57
" At least 2 weeks after completion of the study, all patients received on an open basis 25 mg rofecoxib without any adverse effects."	( Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Bochenek, G; Mejza, F; Nagraba, K; Nizankowska, E; Swierczynska, M; Szczeklik, A, 2001)	0.58
" There were no deaths at 30 days and no serious adverse events attributed to AR-C69931MX."	( Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Oldroyd, KG; Storey, RF; Wilcox, RG, 2001)	0.31
" Monotherapy with ticlopidine is as safe and effective as a combined regimen of ticlopidine plus aspirin after coronary artery stenting in an unselected patient population."	( Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study. Barmeyer, J; Bojara, W; Deneke, T; Germing, A; Grewe, P; Jaeger, D; Lawo, T; Lemke, B; Lindstaedt, M; Machraoui, A; von Dryander, S, 2001)	0.76
"Clinical examination and histology revealed no adverse effects or signs of toxicity."	( Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. Hamasaki, D; Kieselbach, GF; Kralinger, MT; Parel, JM; Voigt, M, 2001)	0.31
"AS delivery by intravitreal administration of loaded silicone oil is a safe method and results in high concentrations of salicylic acid in the posterior segment of the eye while maintaining low blood levels."	( Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. Hamasaki, D; Kieselbach, GF; Kralinger, MT; Parel, JM; Voigt, M, 2001)	0.31
" All medications including placebo were almost equally safe and well tolerated."	( Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cámara, J; Cornet, ME; Despuig, J; Díez-Tejedor, E; Fragoso, YD; Leira, R; Liaño, H; Martínez-Martín, P; Ortiz, P; Peil, H; Raffaelli, E; Titus, F; van Toor, BS; Vix, JM, 2001)	0.31
"The gastric toxic effects of aspirin (ASA) and NCX-4016, a nitric oxide (NO)-releasing ASA, were compared in normal, cirrhotic, and arthritic rats."	( Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis. Kato, S; Komoike, Y; Suzuki, K; Takeuchi, K; Ukawa, H, 2001)	0.86
" Patients with GI adverse events during coxib therapy require co-therapy with acid suppression or prostaglandin analogue."	( [Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors]. Prónai, L, 2001)	0.31
"Ticlopidine reduces stent thrombosis and other adverse events among patients receiving coronary stents."	( Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001)	0.31
" Patients treated with aspirin and ticlopidine had more adverse angiographic and procedural characteristics, including longer lesions and treatment lengths."	( Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001)	0.62
"After balloon angioplasty of a subtotal or total coronary occlusion, no reduction in adverse events was observed among patients in whom ticlopidine was added to aspirin, even after adjustment for clinical and lesion characteristics."	( Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001)	0.51
"Determination of potential drug toxicity and side effect in early stages of drug development is important in reducing the cost and time of drug discovery."	( Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. Chen, YZ; Ung, CY, 2001)	0.31
"Adverse reactions to non-steroidal anti-inflammatory drugs (NSAID)s are frequent, and the need to identify a safe alternative drug is a common problem in clinical practice."	( Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Barbagallo, M; Biasi, D; Corrocher, R; Di Lorenzo, G; Pacor, ML, 2002)	0.54
" Rofecoxib is a safe alternative in subjects with previous adverse cutaneous reaction to NSAIDs."	( Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Barbagallo, M; Biasi, D; Corrocher, R; Di Lorenzo, G; Pacor, ML, 2002)	0.54
" Tolerability: withdrawal rates for adverse effects."	( Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Bradley, MD; Deeks, JJ; Smith, LA, 2002)	0.31
" Compared with those taking other NSAIDs, in patients taking celecoxib the rate of withdrawals due to adverse gastrointestinal events was 46% lower (95% confidence interval 29% to 58%; NNT 35 at three months), the incidence of ulcers detectable by endoscopy was 71% lower (59% to 79%; NNT 6 at three months), and the incidence of symptoms of ulcers, perforations, bleeds, and obstructions was 39% lower (4% to 61%; NNT 208 at six months)."	( Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Bradley, MD; Deeks, JJ; Smith, LA, 2002)	0.31
" The risk of ulcer complications can however be reduced, and perhaps completely removed, by using the lowest dose of the least toxic member of the class."	( Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Langman, MJ, 2003)	0.32
" Major adverse cardiac events (death, myocardial infarction, target lesion revascularization, and coronary artery bypass grafting) were observed at 30 days in 5 of 200 (2."	( Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. Ashby, DT; Aymong, ED; Fischell, T; Lansky, AJ; Leon, MB; Mehran, R; Narasimaiah, R; Siegel, R; Thomas, W; Whitworth, H; Wong, SC, 2003)	0.69
"The BX VELOCITY stent with HEPACOAT and aspirin alone after the procedure was safe in select patients with de novo or restenotic lesions in native coronary arteries."	( Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. Ashby, DT; Aymong, ED; Fischell, T; Lansky, AJ; Leon, MB; Mehran, R; Narasimaiah, R; Siegel, R; Thomas, W; Whitworth, H; Wong, SC, 2003)	0.96
"COX-2 inhibitors provide a potentially safe alternative for treatment of inflammatory conditions in patients with AERD."	( Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. Fernández, C; West, PM, 2003)	0.57
"The relative influence of various risk factors for adverse events (AE) in analgesics users have never been precisely quantified."	( Risk factors for adverse events in analgesic drug users: results from the PAIN study. Charlesworth, A; Jones, JK; LeParc, JM; Moore, N; Schneid, H; Van Ganse, E; Verrière, F; Wall, R, )	0.13
"Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT."	( A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. Benhameid, O; Endo, M; Shennib, H, 2003)	0.79
" Serious adverse events were uncommon but despite this aspirin cost the NHS between 6 and 25 times the cost of aspirin tablets due to dispensing costs and the cost of managing adverse effects."	( Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Cleland, JG; Davey, PG; MacDonald, TM; McMahon, AD; Morant, SV, 2004)	0.85
" Unlike selective COX-2 inhibitors, coadministration of licofelone and aspirin does not appear to be associated with an increase in gastrointestinal adverse events, at least under experimental conditions."	( Safety of anti-inflammatory treatment--new ways of thinking. Brune, K, 2004)	0.56
" Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) do not cross the placenta and are safe for the fetus, but long-term treatment with UFH is problematic because of its inconvenient administration, the need to monitor anticoagulant activity and because of its potential side effects, such as heparin-induced thrombocytopenia and osteoporosis."	( The safety of antithrombotic therapy during pregnancy. Ageno, W; Crotti, S; Turpie, AG, 2004)	0.32
" One hundred twenty-seven subjects with history of adverse reaction to ASA/NSAIDs received oral challenges with nimesulide, 61 subjects were challenged with meloxicam, 51 subjects were challenged with rofecoxib, and 37 subjects were challenged with all three drugs."	( Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004)	0.59
" All patients with asthma tolerated rofecoxib without any adverse effects."	( Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004)	0.59
" The primary outcome measure was bleeding time; secondary outcome measures were vital signs, adverse events, physical examinations, 12-lead electrocardiograms (ECG) and laboratory safety tests."	( Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study. Anderson, D; Engert, D; Ilgenfritz, J; Kato, N; Onomichi, K; Shelley, S; Uchida, H, 2004)	0.55
" The most common adverse events were dry mouth, epistaxis, gingival bleeding and abdominal pain."	( Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study. Anderson, D; Engert, D; Ilgenfritz, J; Kato, N; Onomichi, K; Shelley, S; Uchida, H, 2004)	0.55
"AT-1015 was safe and well-tolerated in healthy male volunteers when taken in combination with high-dose aspirin, and did not significantly prolong bleeding time compared with aspirin alone."	( Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study. Anderson, D; Engert, D; Ilgenfritz, J; Kato, N; Onomichi, K; Shelley, S; Uchida, H, 2004)	0.77
" Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting."	( Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004)	0.54
" While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol."	( Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004)	0.53
" There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO."	( Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004)	0.32
"Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0."	( Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004)	0.32
"In this exploratory analysis, the presence of PFO in the younger cryptogenic stroke patients did not increase the risk of adverse events."	( Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004)	0.32
" It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors."	( Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004)	0.52
"6 x 10(3) mg l(-1)) that was non-toxic for bioassays based on fish (Carassius auratus gibelio) and hydra (Hydra attenuata) and acutely toxic for bioassays with ceriodaphnia (Ceriodaphnia affinis) and onion (Allium cepa)."	( Use of a complex approach for assessment of metamizole sodium and acetylsalicylic acid toxicity, genotoxicity and cytotoxicity. Arkhipchuk, VV; Chernykh, VP; Goncharuk, VV; Gritsenko, IS; Maloshtan, LN, )	0.13
"Both COX inhibitors were toxic to dams in the highest doses evaluated, which caused a significantly greater incidence of intrauterine growth retardation and developmental variations."	( Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats. Burdan, F, 2004)	0.32
" Five hundred thirty-five adverse effects were reported after the use of 22,697 sachets."	( Safety and efficacy of combined lysine acetylsalicylate and metoclopramide: repeated intakes in migraine attacks. Baudesson, G; Chabriat, H; Danchot, J; Joire, JE; Pradalier, A, 1999)	0.3
" Few studies have addressed the incidence of adverse effects associated with prehospital administration of aspirin."	( Prehospital use of aspirin rarely is associated with adverse events. Clark, B; Gallagher, JV; LoVecchio, F; Quan, D, )	0.67
"To determine the incidence of adverse events following the administration of aspirin by prehospital personnel."	( Prehospital use of aspirin rarely is associated with adverse events. Clark, B; Gallagher, JV; LoVecchio, F; Quan, D, )	0.69
" The major outcome was an adverse event following prehospital administration of aspirin."	( Prehospital use of aspirin rarely is associated with adverse events. Clark, B; Gallagher, JV; LoVecchio, F; Quan, D, )	0.69
" No patients had an adverse event during the EMS encounter."	( Prehospital use of aspirin rarely is associated with adverse events. Clark, B; Gallagher, JV; LoVecchio, F; Quan, D, )	0.46
"Aspirin is rarely associated with adverse events when administered by prehospital personnel for presumed coronary syndromes."	( Prehospital use of aspirin rarely is associated with adverse events. Clark, B; Gallagher, JV; LoVecchio, F; Quan, D, )	1.9
"Low-dose aspirin (acetylsalicylic acid) has been shown to be as effective as high-dose aspirin in the prevention of stroke, with fewer adverse bleeding events."	( Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Weinberger, J, 2005)	0.75
"Prospective, randomized, double-blind study (POLENOX) proved that administration of low molecular weight heparin (LMWH)--enoxaparin for elective percutaneous coronary interventions (PCI) is as safe and as effective like unfractionated heparin (UFH)."	( [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine]. Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Legutko, J; Rzeszutko, L, 2004)	0.53
" Unlike general toxicity data, their prenatal toxic effects were not extensively studied before."	( Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study. Burdan, F, 2005)	0.33
"Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose."	( Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study. Burdan, F, 2005)	0.33
" This article reviews the current state of selective COX-2 inhibitors, discusses the mechanistic evidence underlying the cardiovascular risk associated with selective COX-2 inhibition, outlines the pharmacodynamics of aspirin effects on platelets and the interference of propionic acid derivatives (ibuprofen and naproxen) with these effects, and poses that aspirin confounding may have led to the erroneous conclusion of naproxen-associated adverse cardiovascular outcomes in the ADAPT trial."	( The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. Konstantinopoulos, PA; Lehmann, DF, 2005)	0.72
"To report procedure-related complications and neurological adverse events of unprotected over-the-wire (OTW) and protected rapid exchange (RX) carotid artery stenting (CAS) in a single-center patient series during an 8-year period."	( Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series. Ahmadi, A; Amighi, J; Boltuch, J; Dick, P; Minar, E; Mlekusch, W; Sabeti, S; Schillinger, M; Schlager, O, 2005)	0.33
" This study suggests that short-term NG intubation is relatively safe and may be beneficial and indicated for acute GI bleeding after recent MI."	( Safety and efficacy of nasogastric intubation for gastrointestinal bleeding after myocardial infarction: an analysis of 125 patients at two tertiary cardiac referral hospitals. Cappell, MS, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" As determined by Toxilight-cytotoxicity assay, the drug was only toxic to the cancer cells at 100 microM."	( Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Chiu, LC; Ooi, VE; Tong, KF, 2005)	0.33
" An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations."	( Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006)	0.33
"We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib."	( Aspirin reduces adverse effects of gefitinib. Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K, 2006)	1.97
"Rofecoxib can be used as a safe alternative drug for ASA/NSAID intolerant patients."	( Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. Bavbek, S; Celik, G; Misirligil, Z; Pasaoglu, G, 2006)	0.33
"EUS-FNA or TCB is safe in patients taking aspirin or NSAIDS."	( A prospective control study of the safety and cellular yield of EUS-guided FNA or Trucut biopsy in patients taking aspirin, nonsteroidal anti-inflammatory drugs, or prophylactic low molecular weight heparin. Chang, F; Doig, L; Kien-Fong Vu, C; Meenan, J, 2006)	0.81
" The introduction of new classes of drugs has resulted in new adverse effects that require consideration in patients presenting with gastroenterological symptoms."	( Drug-induced side effects affecting the gastrointestinal tract. Chan, FK; Leong, RW, 2006)	0.33
" Under intensive monitoring, warfarin is effective and safe for the moderate to high risk atrial fibrillation patients."	( [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Hu, DY; Jiang, LQ; Sun, YH; Zhang, HP, 2006)	0.54
"This article reviews recent advances in the protection from the adverse auditory or vestibular side effects associated with antibacterial treatment with aminoglycoside antibiotics."	( Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Chen, Y; Huang, WG; Qiu, JH; Schacht, J; Sha, SH; Wang, JL; Zha, DJ, 2007)	1.78
" The review establishes that aspirin, paracetamol and ibuprofen are safe in OTC doses and that there is no evidence for any difference between the medicines as regards efficacy and safety for treatment of colds and flu (except in certain cases such as the use of aspirin in feverish children)."	( Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. Eccles, R, 2006)	0.63
"Despite the lack of clinical data on the safety and efficacy of analgesics for the treatment of colds and flu symptoms a case can be made that these medicines are safe and effective for treatment of these common illnesses."	( Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. Eccles, R, 2006)	0.33
"We performed a systematic review to define the relative and absolute risk of clinically relevant adverse events with the antiplatelet agents, aspirin and clopidogrel."	( Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Laine, L; McQuaid, KR, 2006)	0.77
" Etoricoxib was safe for treating inflammation in patients with AERD."	( Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S, 2006)	0.56
" All treatments were well tolerated; drug-related adverse events were mild and transient."	( Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. Becka, M; Kubitza, D; Mueck, W; Zuehlsdorf, M, 2006)	0.54
"5 mg of meloxicam is a safe alternative treatment for ASA-hypersensitive asthma and/or NP patients with proven hypersensitivity via oral ASA challenges."	( Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Bavbek, S; Dursun, AB; Dursun, E; Eryilmaz, A; Misirligil, Z, 2007)	0.65
" The use of a combination of inhaled corticosteroids, long-acting beta-agonists, systemic corticosteroids, and leukotriene modifier drugs stabilized underlying airways in preparation for a reasonably safe and accurate oral aspirin challenge."	( Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ludington, E; Mehra, P; Simon, RA; Stevenson, DD; White, A, 2006)	0.76
" Safety was evaluated based on the frequency of reported adverse events, and treatment with eASA was associated with lower incidence of adverse events than was with sumatriptan."	( Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. Diener, HC; Lampl, C; Voelker, M, 2007)	0.6
"0001), and major adverse cardiac events (8."	( Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007)	0.34
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."	( Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)	0.34
" However, the extent to which enhanced platelet function signals subsequent adverse clinical outcomes in patients with cardiovascular disease is unknown."	( Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Christie, DJ; Gorman, RT; Kottke-Marchant, K, 2008)	0.35
"The CCT appears to be relatively safe compared with other regimens."	( Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute. Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M, 2007)	0.34
" One major adverse clinical event (0."	( Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. Davis, KE; Denardo, SJ; Tcheng, JE, 2007)	0.34
" No mortality or extrathoracic bleeding occurred in either group, and there were no differences in the incidence of adverse myocardial events or hospital length of stay."	( Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery. Bourke, ME; Chan, V; Kulik, A; Mesana, TG; Ressler, L; Ruel, M, )	0.13
"Loading with 375 mg of clopidogrel and 325 mg of aspirin appears to be safe when administered up to 36 hours after stroke and transient ischemic attack onset in this pilot study."	( LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. Albright, KC; Allison, TA; Grotta, JC; Meyer, DM, )	0.64
" The indication, dosage, duration of therapy, and adverse events were examined."	( Safety and efficacy of clopidogrel in children with heart disease. Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008)	0.35
"Clopidogrel therapy in a pediatric population appears to be relatively safe and effective; however, randomized, controlled prospective studies are needed to determine the true efficacy and safety of clopidogrel in children."	( Safety and efficacy of clopidogrel in children with heart disease. Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008)	0.35
"Three toxic substances have been made into a mixture administered intravenously, similar to methcathinone."	( Neurotoxicity following chronic intravenous use of "Russian cocktail". Delipoyraz, I; Filiz, G; Gecim, NO; Tireli, H; Varlibas, F; Yuksel, G, 2009)	0.35
" The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0."	( A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008)	0.59
"Long term triple antiplatelet therapy was asociated with a significant increase in adverse events and bleeding rates, and their severity, and a trend to increased discontinuations."	( A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008)	0.59
"Transradial cardiac catheterization is a safe and effective approach to reduce vascular complications in high risk patients."	( [Transradial diagnostic and interventional cardiac catheterization in daily practice: advantages, efficacy and safety]. Feldman, A; Ilan-Bushari, L; Suleiman, K; Turgeman, Y, 2008)	0.35
"Medline search for articles published up to 2007, using the keywords acetylsalicylic acid, aspirin, NSAIDs, cyclooxygenase 2, adverse effects, ulcer, and cardiovascular."	( Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. van de Laar, MA; Vonkeman, HE, 2010)	0.58
" These adverse effects may be prevented by limiting NSAID dosage and duration and by performing individual risk assessments and treating patients accordingly."	( Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. van de Laar, MA; Vonkeman, HE, 2010)	0.36
" After 3 months, the patient is free from adverse events."	( Drug-eluting stents in a patient with favism: is the aspirin administration safe? Capoluongo, E; Di Russo, C; Ferraiuolo, G; Giardina, B; Loschiavo, P; Minucci, A; Rigattieri, S; Silvestri, P, 2008)	0.6
" ASA at 100 micromol/l was selectively toxic toward human melanocytic SK-MEL-28, MeWo, and SK-MEL-5 and murine melanocytic B16-F0 and B16-F10 melanoma cell lines."	( Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines. Moridani, MY; Vad, NM; Yount, G, 2008)	0.6
" Patients received a telephone call on days 7 and 14 to assess for adverse events, discontinuation, and recurrent stroke/TIA."	( Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke. Douen, AG; Medic, S; Pageau, N; Sabih, M; Shuaib, A, )	0.13
" Our study demonstrated that a combination of aspirin and gammaT, but not a combination of aspirin and alphaT, has some advantage over aspirin alone in terms of anti-inflammatory effects and attenuation of aspirin-induced adverse effects."	( A combination of aspirin and gamma-tocopherol is superior to that of aspirin and alpha-tocopherol in anti-inflammatory action and attenuation of aspirin-induced adverse effects. Ames, BN; Jiang, Q; Moreland, M; Yin, X, 2009)	0.95
"Multiple randomized clinical trials have demonstrated that drug eluting stents can significantly reduce the rates of restenosis and subsequent adverse events across lesion and patient."	( Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years. Chen, JL; Gao, RL; Hu, J; Qiao, SB; Qin, XW; Shen, WF; Xu, B; Yang, YJ; Zhang, JS; Zhang, Q; Zhang, RY, 2008)	0.35
" The occurrences of major adverse cardiac events (MACE) and Academic Research Consortium defined stent thrombosis (ST) were evaluated in patients with and without diabetes mellitus."	( Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years. Chen, JL; Gao, RL; Hu, J; Qiao, SB; Qin, XW; Shen, WF; Xu, B; Yang, YJ; Zhang, JS; Zhang, Q; Zhang, RY, 2008)	0.35
" DM patients had higher rates of adverse events and than non DM."	( Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years. Chen, JL; Gao, RL; Hu, J; Qiao, SB; Qin, XW; Shen, WF; Xu, B; Yang, YJ; Zhang, JS; Zhang, Q; Zhang, RY, 2008)	0.35
" One important example of this type of injury is acetaminophen-induced liver injury, in which the initial toxic injury is followed by innate immune activation."	( Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. Flavell, RA; Imaeda, AB; Mahmood, S; Mehal, WZ; Mohamadnejad, M; Sohail, MA; Sutterwala, FS; Watanabe, A, 2009)	0.35
"Combined carotid stenting and cardiac surgery, performed in the same operating room under only heparin and aspirin, seems a safe and effective strategy for the treatment of patients with concomitant carotid and cardiac disease."	( Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience. Capuano, F; Faraglia, V; Palombo, G; Rizzo, L; Sinatra, R; Stella, N; Taurino, M, 2009)	0.57
"If acetylsalicylic acid therapy is maintained, short-term discontinuation of a thienopyridine may be relatively safe in patients with drug-eluting stents."	( Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Eisenberg, MJ; Filion, KB; Libersan, D; Richard, PR, 2009)	0.35
"It has been hypothesized that persistent presence of polymer may compromise the safety of drug-eluting stents, and that therefore biodegradable polymer coatings might reduce late adverse events."	( Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009)	0.35
"This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting."	( Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009)	0.35
" For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important."	( Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. Spinler, SA, 2009)	0.35
" However, the use of ASA and, indeed, other non-steroidal anti-inflammatory drugs (NSAIDs) is limited by the incidence of adverse gastroduodenal events."	( Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs. Brailsford, W; Hawkey, CJ; Naesdal, J; Yeomans, ND, 2009)	0.35
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	( Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)	0.35
"We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)."	( Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010)	0.36
" Primary end point was the combined incidence of major adverse coronary events and major bleedings."	( Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010)	0.36
"Results of our cohort study suggest that use of DES associated with a treatment with clopidogrel only may be safe and significantly reduce the need for new revascularization in patients requiring chronic anticoagulation."	( Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010)	0.36
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months."	( Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)	0.36
" The incidence of major adverse cardiac events was collected at 4 years."	( Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)	0.36
" Clinical examination revealed no signs of local or systemic adverse effects."	( Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study. Binder, S; Egger, S; Haas, A; Kieselbach, GF; Kralinger, MT; Parel, JM; Stolba, U; Velikay, M; Wedrich, A, 2010)	0.36
"Aspirin delivery by intravitreal silicone oil in the human eye is safe and also may provide a delivery vehicle for other antiproliferative agents to the posterior pole."	( Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study. Binder, S; Egger, S; Haas, A; Kieselbach, GF; Kralinger, MT; Parel, JM; Stolba, U; Velikay, M; Wedrich, A, 2010)	1.8
"The continuing use of low-dose aspirin in patients undergoing extended prostatic biopsy is a relatively safe option since it does not increase the morbidity of the procedure."	( Safety of ultrasound-guided transrectal extended prostate biopsy in patients receiving low-dose aspirin. Delakas, D; Kariotis, I; Philippou, P; Serafetinides, E; Volanis, D, )	0.64
"Tirofiban is safe and effective in patients with ACS."	( Safety evaluation of tirofiban. Tebaldi, M; Valgimigli, M, 2010)	0.36
"5 mg meloxicam is a safe alternative for ASA/NSAID-intolerant UR/AE patients."	( Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. Aydin, O; Bavbek, S; Demirel, YS; Göksel, O; Misirligil, Z, 2010)	0.63
"Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern."	( National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010)	0.82
"To estimate the numbers and rates of emergency department (ED) visits for hemorrhage-related AEs (hemorrhage or evaluation for potential hemorrhage) from DAT in the United States and put them in the context of those from warfarin, we analyzed AEs from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project, 2006-2008, and outpatient prescribing from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, 2006-2007."	( National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010)	0.57
" In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis."	( [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010)	0.57
" The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications)."	( Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP, 2011)	0.37
"To evaluate the safety (primary outcome, defined as any bleeding complication or thrombocytopenia) and adverse outcomes (secondary outcomes, defined as death from cardiovascular causes, myocardial infarction or stroke) of clopidogrel therapy in patients aged ≥75 years with stable or unstable coronary artery disease undergoing PCI, and to compare these outcomes with those in younger controls."	( Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011)	0.37
" The rate of the first adverse (secondary) outcome of the composite of death from cardiovascular causes, myocardial infarction or stroke was higher in older patients (12."	( Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011)	0.37
"034), and major adverse cardiac events (2."	( Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. Cheng, JW; Dorsch, MP; Goldberg, T; Mohammad, RA, 2010)	0.36
" Cyclooxygenase 2 inhibitors are a safe alternative in patients with AERD."	( Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease. Bartra, J; Muñoz-Cano, R; Picado, C; Roca, J; Sánchez-López, J; Serrano, C; Valero, A, 2011)	0.63
"The drug was well tolerated by all patients, with no adverse reactions."	( Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease. Bartra, J; Muñoz-Cano, R; Picado, C; Roca, J; Sánchez-López, J; Serrano, C; Valero, A, 2011)	0.63
" The development of HBOCs was highlighted by crosslinking to minimize adverse effects."	( Crosslinked, polymerized, and PEG-conjugated hemoglobin-based oxygen carriers: clinical safety and efficacy of recent and current products. Akha, AS; Holtby, RJ; Jahr, JS, 2012)	0.38
" The objective was to assess side effect frequency, degree of bother, and impact on health-related quality of life (HRQoL)."	( Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. Ackerman, SJ; Anastassopoulos, KP; Benson, C; Chow, W; Kim, MS; Tapia, C, )	0.13
" This raises a question about the unmet need for pain medications with improved side effect profiles."	( Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. Ackerman, SJ; Anastassopoulos, KP; Benson, C; Chow, W; Kim, MS; Tapia, C, )	0.13
" The primary endpoints were patient-reported gastrointestinal (GI) adverse events (AEs); the secondary endpoints were the incidence of patient-reported non-GI AEs."	( Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011)	0.65
" Balloon angioplasty with, or without stent deployment appears to be a safe procedure with excellent primary success rate."	( [Percutaneous, endovascular treatment of innominate artery lesions is a safe and effective procedure]. Bérczi, V; Hüttl, K; Nemes, B; Paukovits, TM, 2011)	0.37
"Within a regional STEMI system of care, half-dose fibrinolysis combined with immediate transfer for PCI may be a safe and effective option for STEMI patients with expected delays due to long-distance transfer."	( Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK, 2012)	0.38
" We also handsearched the conference proceedings for the American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) (2008 to 2009) and checked the websites of regulatory agencies for reported adverse events, labels and warnings."	( Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Colebatch, AN; Edwards, CJ; Marks, JL, 2011)	0.61
" Two of these studies reported no evidence for increased risk of methotrexate-induced pulmonary disease; one study assessed the effect of concurrent NSAIDs on renal function and found no adverse effect; one study identified no adverse effect on liver function; three studies demonstrated no increase in methotrexate withdrawal; and one study showed no increase in all adverse events, including major toxic reactions."	( Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Colebatch, AN; Edwards, CJ; Marks, JL, 2011)	0.61
"In the management of rheumatoid arthritis, the concurrent use of NSAIDs with methotrexate appears to be safe provided appropriate monitoring is performed."	( Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Colebatch, AN; Edwards, CJ; Marks, JL, 2011)	0.61
"Even very short-term dual antiplatelet therapy seems safe after coronary stenting with Genous in de novo coronary artery lesions located in secondary branch vessels."	( Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM, 2011)	0.37
" Regarding safety, there were no statistically significant differences between treatment groups in the incidence of adverse events in the dental pain and tension-type headache studies."	( Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension-type headache and postoperative dental pain. Fisher, M; Gatoulis, SC; Voelker, M, 2012)	0.63
" These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke."	( Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011)	0.87
"High platelet reactivity (HPR) under treatment with clopidogrel or aspirin is associated with adverse outcome."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.82
" The rates of the composite of cardiac adverse events (acute coronary syndrome, stent thrombosis, stroke, death and revascularization) were recorded during 12-month follow-up."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.59
"The composite endpoint of cardiovascular adverse events occurred more often in patients with high platelet reactivity (HPR) to both agonists ADP and AA (37."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.59
"Dual low responsiveness to clopidogrel and aspirin is a strong predictor of cardiac adverse events, especially in patients with diabetes mellitus, which underlines the need for personalized antiplatelet treatment."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.85
" Therefore, it remains unclear how to best manipulate PARs for safe antithrombotic activity."	( Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012)	0.38
"Our results indicate that PAR antagonists used in combination with aspirin provide a potent yet safe antithrombotic strategy in mice and provide insights into the safety and efficacy of using PAR antagonists for the prevention of acute coronary syndromes in humans."	( Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012)	0.62
"We analyzed data from 31 627 patients treated with intravenous alteplase enrolled in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register."	( Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012)	0.38
" The challenge is defining patients who would best benefit from thromboprophylaxis, and how to deliver it in the most effective and safe way."	( What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? Lip, GY, 2012)	0.38
" We examined the possibility that concurrent blockade of free radicals and prostaglandin E(2) (PGE(2))-mediated inflammation might constitute a safe and effective therapeutic approach to ALS."	( Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. Cho, W; Gwag, BJ; Im, DS; Lee, JH; Lee, JK; Lee, YA; Lee, YB; Shin, JH; Springer, JE; Yun, BS, 2012)	0.38
"To clarify the frequency of Japanese patients who are resistant to antiplatelet agents, and then clarify correlations between resistance and thromboembolic adverse events in neurointervention."	( [Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention]. Asai, T; Haraguchi, K; Izumi, T; Matsubara, N; Miyachi, S; Naito, T; Wakabayashi, T; Yamanouchi, T, 2012)	0.38
" Thromboembolic adverse events occurred in 7 patients."	( [Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention]. Asai, T; Haraguchi, K; Izumi, T; Matsubara, N; Miyachi, S; Naito, T; Wakabayashi, T; Yamanouchi, T, 2012)	0.38
"In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation."	( Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013)	0.71
", drug-associated adverse events, including the proportional reporting ratio, the reporting odds ratio, the information component given by a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean."	( Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012)	1.82
", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma."	( Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012)	1.82
"Over-the-counter antipyretics (acetaminophen, aspirin, ibuprofen) and/or analgesics (acetaminophen, aspirin, diclofenac, ibuprofen, naproxen) are relatively safe for adults."	( [Developmental toxicity of the over-the-counter analgetics and antypiretics]. Burdan, F; Cendrowska-Pinkosz, M; Dworzańska, A; Dworzański, W; Kubiatowski, T; Starosławska, E; Szumiło, J; Urbańczyk-Zawadzka, M, 2012)	0.64
" The search aimed to identify studies describing adverse events (AE) with the concurrent use of paracetamol and/or NSAID in people taking MTX for IA."	( Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. Colebatch, AN; Edwards, CJ; Marks, JL; van der Heijde, DM, 2012)	0.38
" Of the studies examining concurrent use of MTX and NSAID, there were no reported adverse effects on lung, liver, or renal function, and no increase in MTX withdrawal or in major toxic reactions."	( Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. Colebatch, AN; Edwards, CJ; Marks, JL; van der Heijde, DM, 2012)	0.38
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."	( Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)	0.39
" The primary outcome was the rate of major adverse cardiac events (MACE), defined as a composite of cardiac death, non-fatal myocardial infarction (MI), and target lesion revascularization (TLR)."	( Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)	0.39
"Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported."	( Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Aralica, G; Brcic, L; Drmic, D; Dzidic, S; Ilic, S; Klicek, R; Kolenc, D; Radic, B; Rak, D; Rokotov, DS; Rucman, R; Safic, H; Sebecic, B; Seiwerth, S; Sever, M; Sikiric, P; Suran, J; Turkovic, B; Vrcic, H, 2013)	0.39
" In addition, the discussion here reviews select acute ischemic stroke intravenous thrombolytic studies, such as the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study and European Cooperative Acute Stroke Studies, select neuroprotectant and endovascular clot retrieval device studies, and large cooperative databases, such as the Virtual International Stroke Trials Archive and Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry, to explore relationships between baseline stroke severity and other possible factors associated with efficacy and safety outcomes."	( How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials. Gorelick, PB, 2012)	0.38
" This study aimed to determine if codeine could be recommended as a safe treatment option for NSAID-hypersensitive patients without the need for oral drug provocation testing."	( The safety of codeine in patients with non-steroidal anti-inflammatory drug hypersensitivity: a preliminary study. Celebioglu, E; Kalyoncu, AF; Karakaya, G, )	0.13
"COX-2 inhibitors are safe alternatives in patients with cross-reactive non-steroidal anti-inflammatory drug (NSAID) hypersensitivity."	( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity? Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z, )	0.13
"This study included the retrospective analysis of cases with cross-reactive NSAID hypersensitivity who underwent DPTs with COX-2 inhibitors in order to find safe alternatives."	( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity? Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z, )	0.13
"Our results suggest to follow the traditional DPT method to introduce COX-2 inhibitors for finding safe alternatives in all patients with cross-reactive NSAID hypersensitivity before prescription as uncertainty of any predictive factor for a positive response continues."	( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity? Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z, )	0.13
"Currently, the commercial formulations of the herbicide paraquat are highly toxic to humans, and no effective antidote is available for paraquat poisoning."	( New formulation of paraquat with lysine acetylsalicylate with low mammalian toxicity and effective herbicidal activity. Baltazar, MT; Bastos, Mde L; Carvalho, F; Dinis-Oliveira, RJ; Duarte, JA; Guilhermino, L, 2013)	0.39
" Multimodal thromboprophylaxis with aspirin given to the majority of patients at a low VTE risk is safe and effective in patients undergoing primary TKA."	( Safety and efficacy of multimodal thromboprophylaxis following total knee arthroplasty: a comparative study of preferential aspirin vs. routine coumadin chemoprophylaxis. Bartolomé García, S; Gesell, MW; González Della Valle, A; Haas, SB; Ma, Y; Memtsoudis, SG; Salvati, EA, 2013)	0.87
"To examine whether it is safe to continue low-dose (100 mg/day) aspirin perioperatively as a part of standard multimodal venous thromboembolic prophylaxis for total hip arthroplasty (THA) or total knee arthroplasty (TKA)."	( Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. Cossetto, DJ; Goudar, A; Parkinson, K, 2012)	0.9
"It is safe to continue low-dose (100 mg/day) aspirin in the perioperative period as a part of multimodal prophylaxis against deep vein thrombosis."	( Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. Cossetto, DJ; Goudar, A; Parkinson, K, 2012)	0.92
" This systematic review assesses the efficacy and safety of adjunctive cilostazol to DAT in combination with DAT on reducing clinical adverse events."	( Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. Ding, XL; Gao, J; Jiang, B; Miao, LY; Xie, C; Zhang, H; Zhang, JJ; Zhang, LL, 2013)	0.39
" The CP-load group experienced more in-hospital major adverse cardiac events (5."	( Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R, 2013)	0.39
" Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up."	( Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013)	0.39
" Acetylsalicylic acid (ASA) and sodium salicylate (SS) are considered safe for poultry and often used in avian medicine."	( Adverse effects associated with high-dose acetylsalicylic acid and sodium salicylate treatment in broilers. Bobrek, K; Dzimira, S; Graczyk, S; Poźniak, B; Switała, M, 2012)	0.38
" We will examine the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) in patients undergoing percutaneous coronary intervention with DES for the treatment of coronary lesions."	( Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013)	0.39
" In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization."	( Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013)	0.39
" To summarize the available data on this topic, we conducted a meta-analysis of the published clinical trial literature regarding the gastrointestinal adverse effects of short-term use of aspirin in comparison with placebo and other medications commonly used for the same purpose."	( Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Baron, JA; Brückner, A; Lanas, A; Laurora, I; McCarthy, D; Senn, S; Thielemann, W; Voelker, M, 2013)	0.84
"An extensive literature search identified 119,310 articles regarding possible adverse effects of aspirin, among which 23,131 appeared to possibly include relevant data."	( Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Baron, JA; Brückner, A; Lanas, A; Laurora, I; McCarthy, D; Senn, S; Thielemann, W; Voelker, M, 2013)	0.86
" Serious adverse events were not observed with aspirin or any of the comparators."	( Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Baron, JA; Brückner, A; Lanas, A; Laurora, I; McCarthy, D; Senn, S; Thielemann, W; Voelker, M, 2013)	0.9
"In selected low TE risk patients undergoing ablation for AF, a short period of periprocedural therapeutic anticoagulation with LMWH together with aspirin is an effective and safe strategy to prevent TE events."	( Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy. Acena, M; Berte, B; Bun, SS; De Meyer, G; Duytschaever, M; Tavernier, R; Van Heuverswyn, F; Vandekerckhove, Y, 2013)	0.59
"Though dextran 40 did not result in any significant adverse local or systemic complications, it is not useful as a postoperative antithrombotic agent in head and neck oncologic reconstruction with free tissue transfer."	( Safety and efficacy of low molecular weight dextran (dextran 40) in head and neck free flap reconstruction. Duraisamy, S; Iyer, S; Jayaprasad, K; Mathew, J; Paul, J; Rajan, S; Sharma, M; Thankappan, K, 2013)	0.39
"TAT could significantly reduce the rates of MACEs and cardiac death in comparison to DAT, but more attention should be paid to adverse side effects of the drugs."	( Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis. Fu, ZX; Li, J; Tang, HQ; Zhang, Y, 2013)	0.39
"Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA."	( Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014)	0.4
" We evaluated preoperative and perioperative parameters, functional outcomes, and adverse events up to 12 months postoperatively of patients on oral anticoagulation therapy undergoing PVP, and compared the results with patients who did not take anticoagulation therapy."	( The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia. Chang, PL; Chen, CL; Chen, SM; Hou, CP; Lin, YH; Shao, IH; Tsui, KH, 2013)	0.69
" The present study was aimed to assess the safety aspect of DLBS1033 in a preclinical setting, which included observation on toxic signs after acute and repeated administrations, and the drug's effect on prenatal development and drug interaction."	( Toxicity studies of a bioactive protein with antithrombotic-thrombolytic activity, DLBS1033. Adnyana, IK; Anggadireja, K; Sigit, JI; Sukandar, EY; Tjandrawinata, RR, 2014)	0.4
" However, the comparative risks of gastrointestinal (GI) adverse events during DAPT are not clear."	( Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL, 2013)	0.39
" The safety profile was evaluated by using adverse events (AEs), which were assessed by physical examination, vital signs, ECGs, clinical laboratory tests, and interviews."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
" Hence, aspirin plus dipyridamole combination therapy is effective and safe for the secondary prevention of stroke."	( The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. Li, X; Zhou, G; Zhou, S; Zhou, X, 2013)	1.12
" These data suggest that continuation of aspirin is safe and that the continuation of aspirin should be considered acceptable and preferable, particularly in patients with perceived substantial medical need for treatment with antiplatelet therapy."	( Safety of perioperative aspirin therapy in pancreatic operations. Gabale, SD; Irizarry, AM; Kennedy, EP; Lavu, H; McIntyre, CA; Pucci, MJ; Rosato, EL; Winter, JM; Wolf, AM; Yeo, CJ, 2014)	0.98
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."	( Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)	0.4
" Perioperative mortality, morbidity and the incidence of adverse events were balanced between the groups without statistical significance."	( [Effectiveness and safety of tranexamic acid in patients receiving on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation]. Li, LH; Shi, J; Wang, GY; Wang, YF; Xue, QH; Yuan, S, 2013)	0.59
" In the pooled analysis from all five studies, incidences of treatment-emergent adverse events (AEs) (including prespecified NSAID-associated upper GI AEs and cardiovascular AEs), serious AEs, and AE-related discontinuations were stratified by LDA subgroups."	( Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies. Angiolillo, DJ; Datto, C; Raines, S; Yeomans, ND, 2014)	0.69
"Antiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end-stage renal disease undergoing dialysis."	( Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014)	0.68
" Five adverse events (3."	( Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation. Cho, YK; Hur, SH; Jung, BC; Kim, H; Kim, KB; Kim, KS; Kim, W; Kim, YN; Lee, BR; Lee, JB; Lee, JH; Nam, CW; Park, HS; Park, JS; Yang, DH; Yoon, HJ, 2014)	0.4
" The primary outcome was death and secondary outcome measures were 6 month disability, repeat MRI changes and serious adverse events (SAEs)."	( Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial. Bhoi, SK; Kalita, J; Misra, UK; Prasad, S, 2014)	0.4
" The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke."	( Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)	0.4
" Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events."	( Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015)	0.42
" The development of NSAID formulations that offer effective pain control with fewer or less serious adverse effects due to interference with ASA would be a valuable medical advance."	( Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Lakkireddy, DR; Nalamachu, S; Pergolizzi, JV; Raffa, RB; Taylor, R, 2014)	0.66
" Firstly, PCIS were incubated with 0-200 μM diclofenac (DCF), one of the most intensively studied NSAIDs, to investigate whether they could correctly reflect the toxic mechanisms."	( Precision cut intestinal slices are an appropriate ex vivo model to study NSAID-induced intestinal toxicity in rats. de Graaf, IA; Groothuis, GM; Niu, X; van der Bij, HA, 2014)	0.4
" However, severe and numerous adverse events are associated with vismodegib use."	( Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety. Ash, MM; Jolly, PS, 2015)	0.66
"Herein, we describe a potential serious adverse effect associated with vismodegib use."	( Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety. Ash, MM; Jolly, PS, 2015)	0.66
" This study suggests that aspirin may be a beneficial treatment for VM, with a reduction in pain and soft tissue swelling and an acceptable side-effect profile, but the retrospective nature of the study and the small size of the cohort limited our conclusions."	( Aspirin therapy in venous malformation: a retrospective cohort study of benefits, side effects, and patient experiences. Dickman, M; Dowd, CF; Frieden, IJ; Hess, CP; Hoffman, WY; Koerper, MA; Nguyen, JT, )	1.87
"Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA₂DS₂-VASc score≥2."	( Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. Choi, KJ; Joung, B; Kim, YH; Lee, MH; Nam, GB; Pak, HN; Uhm, JS; Won, H, 2014)	0.97
" Gastrointestinal (GI) adverse effects with aspirin may lead to poor adherence and/or discontinuation of treatment."	( Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. Bliden, KP; Contino, CJ; Franzese, CJ; Gesheff, MG; Gurbel, PA; Rafeedheen, R; Tantry, US, 2014)	0.88
"This meta-analysis demonstrates that short-term combination of clopidogrel and aspirin is effective and safe for stroke prevention in high vascular risk patients."	( Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014)	0.89
" The MCCAD was cast and assembled in a standard laboratory without specialist equipment and demonstrated for performing quantitative cell-based cytotoxicity assays of pyocyanine on human breast cancer (MCF-7) cells and assessed for toxic effect on human hepatocyte carcinoma (HepG2) cells as an indicator for liver injury."	( Low cost microfluidic cell culture array using normally closed valves for cytotoxicity assay. Ali, Z; Bateson, S; Islam, M; O'Hare, L; Pasirayi, G; Scott, SM, 2014)	0.4
"In recent decades, numerous methods have been developed for data mining of large drug safety databases, such as Food and Drug Administration's (FDA's) Adverse Event Reporting System, where data matrices are formed by drugs such as columns and adverse events as rows."	( Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection. Huang, L; Tiwari, R; Zalkikar, J; Zheng, D, 2017)	0.46
"7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs."	( Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015)	0.42
"PCNL is safe in patients continuing aspirin perioperatively and does not result in more blood transfusions, angioembolization procedures, or complications."	( Continuing aspirin therapy during percutaneous nephrolithotomy: unsafe or under-utilized? Elsamra, SE; Hoenig, DM; Leavitt, DA; Moreira, DM; Okeke, Z; Smith, AD; Theckumparampil, N; Waingankar, N, 2014)	1.07
"Biodegradable-polymer drug-eluting stents (BP-DES) were developed to be as effective as second-generation durable-polymer drug-eluting stents (DP-DES) and as safe >1 year as bare-metal stents (BMS)."	( Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D, 2015)	0.42
" Vital signs, adverse events, and pain scores were assessed."	( The shortened infusion time of intravenous ibuprofen part 1: a multicenter, open-label, surveillance trial to evaluate safety and efficacy. Ayad, SS; Bergese, SD; Candiotti, K; Gan, TJ; Soghomonyan, S, 2015)	0.42
" The most common adverse events experienced by patients were infusion site pain in 22 of 150 patients (15%) and flatulence (8 of 150 [5%])."	( The shortened infusion time of intravenous ibuprofen part 1: a multicenter, open-label, surveillance trial to evaluate safety and efficacy. Ayad, SS; Bergese, SD; Candiotti, K; Gan, TJ; Soghomonyan, S, 2015)	0.42
" With the exception of CVA, all adverse events were significantly higher in positive Tn T group as compared to negative Tn T group."	( Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. Campo, G; Ceconi, C; Contoli, M; Guerzoni, F; Malagù, M; Napoli, N; Papi, A; Pavasini, R; Punzetti, S, 2015)	0.42
"NSTE-ACS management with DAPT and DES is probably safe and effective in class II G6PD-deficient patients."	( Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin. Kafkas, NV; Liakos, CI; Mouzarou, AG, 2015)	0.62
" However, NSAIDs are associated with a number of adverse effects, especially in patients with cardiovascular disease (CVD)."	( Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Cicci, JD; Danelich, IM; Lose, JM; Reed, BN; Tefft, BJ; Wright, SS, 2015)	0.42
" Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database."	( Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. Abe, J; Hara, H; Kinosada, Y; Miyamura, N; Nakamura, M; Nishibata, Y; Sekiya, Y; Suzuki, H; Suzuki, Y; Tsuchiya, T; Umetsu, R; Uranishi, H, 2015)	0.67
" We hypothesized that staged chemoprophylaxis using LMWH in hospital followed by aspirin after discharge was safe and effective for the prevention of venous thromboembolic events (VTE)."	( Staged venous thromboemolic events prophylaxis with low-molecular-weight heparin followed by aspirin is safe and effective after arthroplasty. Asopa, V; Bauze, A; Cobain, W; Keene, G; Martin, D, 2015)	0.86
"Staged chemoprophylaxis using LMWH followed by aspirin is a safe and effective thromboprophylactic regime that is associated with a very low rate of fatal PE and all-cause mortality."	( Staged venous thromboemolic events prophylaxis with low-molecular-weight heparin followed by aspirin is safe and effective after arthroplasty. Asopa, V; Bauze, A; Cobain, W; Keene, G; Martin, D, 2015)	0.89
"The main undesirable side effect of the aspirin is the damage to the gastrointestinal mucosa, leading to the formation of erosions, peptic ulcers, and as a result, bleeding."	( Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan. Borisov, SA; Chistyachenko, YS; Dushkin, AV; Khvostov, MV; Polyakov, NE; Tolstikova, TG; Zhukova, NA, 2016)	0.97
" Long-term introduction of the complex at doses of 250 and 500 mg/kg was safe for gastric mucosa, while ASA at the dose of 50 mg/kg showed a strong gastric mucosal damage."	( Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan. Borisov, SA; Chistyachenko, YS; Dushkin, AV; Khvostov, MV; Polyakov, NE; Tolstikova, TG; Zhukova, NA, 2016)	0.7
" The two NSAIDs proved to be safe and efficacious in the experimental model used."	( Selective inhibition by aspirin and naproxen of mainstream cigarette smoke-induced genotoxicity and lung tumors in female mice. Balansky, R; D'Oria, C; De Flora, S; Ganchev, G; Iltcheva, M; La Maestra, S; Micale, RT; Steele, VE, 2016)	0.74
"Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality."	( Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015)	0.42
"The aim of our study was to triage clinical and laboratory predictors of major adverse clinical events (MACE) following coronary stenting."	( Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015)	0.42
" However its potential adverse effects on the small and large intestine are less well known and under- researched."	( Aspirin Induced Adverse Effects on the Small and Large Intestine. Bjarnason, I; Pavlidis, P, 2015)	1.86
"Saccharomyces cerevisiae is the simplest and a favorite eukaryotic system that contains lysosome and thus, is a suitable organism for monitoring some toxic effects in environmental pollution."	( Toxicity detection using lysosomal enzymes, glycoamylase and thioredoxin fused with fluorescent protein in Saccharomyces cerevisiae. Kim, YH; Min, J; Nguyen, NT; Shin, HY, 2015)	0.42
" Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities."	( Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. Bundhun, PK; Chen, MH; Qin, T, 2015)	0.42
"Four studies including 1005 patients reporting the adverse clinical outcomes and six studies including 519 patients reporting the platelet activities, with a total of 1524 patients have been analyzed in this meta-analysis."	( Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. Bundhun, PK; Chen, MH; Qin, T, 2015)	0.42
" No significant difference in stent thrombosis and bleeding risks between these 2 groups shows TAPT to be almost as safe as DAPT in these diabetic patients."	( Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. Bundhun, PK; Chen, MH; Qin, T, 2015)	0.42
" Interestingly, the acute toxic death could not be reached at the maximum administrable dose (5 g/kg)."	( Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. Dong, H; Gao, Y; Jia, L; Li, T; Lu, Y; Ma, J; Shao, J; Tu, X; Wan, L; Wang, J; Xie, F; Xie, J; Xu, B; Xu, H; Zhang, T; Zhu, Y, 2015)	1.86
"Aspirin desensitization is effective and safe in unstable patients with acute coronary syndrome in both the short and long term."	( Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety. Barrionuevo-Sánchez, MI; Corbí-Pascual, M; Córdoba-Soriano, JG; Fuentes-Manso, R; Gallardo-López, A; Gómez-Pérez, A; Gutiérrez-Díez, A; Hidalgo-Olivares, V; Jiménez-Mazuecos, J; Lafuente-Gormaz, C; López-Neyra, I; Navarro-Cuartero, J; Prieto-Mateos, D, 2016)	2.36
" Adverse events (AEs) caused study withdrawal in 13."	( Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk. Cryer, BL; Eisen, GM; Fort, JG; Goldstein, JL; Lanas, A; Scheiman, JM; Whellan, DJ, 2016)	0.67
" Discharge from hospital with aspirin was the primary end point, whereas rates of adverse reactions being a secondary outcome."	( Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention: A Survey and Systematic Review. Bernardi, A; Bianco, M; Carini, G; Cerrato, E; D'Ascenzo, F; DiNicolantonio, JJ; Gaita, F; Montefusco, A; Moretti, C; Omedè, P; Pozzi, R; Varbella, F; Zoccai, GB, 2016)	0.98
"To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack."	( [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015)	0.88
"There was no identifiable adverse drug reaction, evidence of hemorrhage, significant prolongation of prothrombin time or activated partial thromboplastin time, or increase in transfusion requirements associated with RIV therapy compared to CL and LDA in dogs with pIMHA."	( Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia. Bianco, D; Morassi, A; Nakamura, RK; Park, E; White, GA, 2016)	0.43
"89 mg/kg by mouth once daily was safe and well tolerated in a small group of dogs with presumed pIMHA able to tolerate oral medications and treated with a standardized immunosuppressive treatment protocol."	( Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia. Bianco, D; Morassi, A; Nakamura, RK; Park, E; White, GA, 2016)	0.43
"There was no major adverse cardiac event (MACE) and pouch infection were observed among 3 groups in perioperation."	( [Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy]. Cong, H; Li, X; Li, Z; Wang, Z; Zhang, F; Zhang, L, 2016)	0.43
"Few large studies have evaluated the adverse events associated with therapeutic colonoscopy for colorectal neoplasia, including bleeding and bowel perforation."	( Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan. Fushimi, K; Hirata, Y; Koike, K; Matsui, H; Niikura, R; Yamada, A; Yasunaga, H, 2016)	0.43
"Although the incidence of adverse events after therapeutic colonoscopy was low, several patient-related factors were significantly associated with bleeding and bowel perforation."	( Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan. Fushimi, K; Hirata, Y; Koike, K; Matsui, H; Niikura, R; Yamada, A; Yasunaga, H, 2016)	0.43
" Adverse events (AEs) and abnormalities in blood, urine, liver, and kidney function were monitored."	( Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016)	0.43
" Vinpocetine could be an effective and safe component of treatment regimen for acute cerebral infarction."	( Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016)	0.43
" The secondary endpoints were 6-month major adverse cardiac events (MACE), which included cardiac death, nonfatal myocardial infarction, or ischemic symptoms driven target vessel revascularization."	( Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016)	0.43
" Major adverse cardiac events occurred in 4 (8."	( Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016)	0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" The endpoints were patient-reported adverse events (AEs) with an emphasis on the system organ class gastrointestinal system."	( Gastrointestinal Safety of Aspirin for a High-Dose, Multiple-Day Treatment Regimen: A Meta-Analysis of Three Randomized Controlled Trials. Forder, S; Lanas, A; Voelker, M, 2016)	0.73
"Nonsteroidal anti-inflammatory drugs (NSAIDs), which are globally prescribed, exhibit mainly anti-inflammatory and analgesic effects but also can cause adverse effects including gastrointestinal erosions, ulceration, bleeding, and perforation."	( (1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats. Choi, KH; Chung, MW; Lee, HJ; Park, JH; Um, SY, 2016)	0.43
" Hence, objective of the current study was to investigate the potential toxic effects of ACS c-SLN combined chemopreventive regimens following acute (3 days), subacute (28 days), and subchronic (90 days) administrations by oral gavage in BALB/c mice."	( Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Chenreddy, S; Khamas, W; Prabhu, S; Thakkar, A; Thio, A; Wang, J, 2016)	0.65
"5 mg group) experienced adverse events versus 51/195 (26."	( Safety and tolerability of extended-release acetylsalicylic acid capsules: a summary of double-blind comparative studies. Dillaha, L; Johnson, A; Patrick, J; Pennell, AT, 2016)	0.43
" In conclusion, DOACs are effective and safe for the extended treatment of VTE, and may reduce the risk of all-cause mortality."	( Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F, 2016)	0.43
" The primary efficacy endpoint was major adverse cardiac events (MACE), defined as the composite of cardiac death, myocardial infarction, or stent thrombosis."	( Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Abizaid, A; Bhatt, DL; Chieffo, A; Colombo, A; Costa, RA; Feres, F; Genereux, P; Gilard, M; Giustino, G; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Leon, MB; Morice, MC; Palmerini, T; Park, KW; Redfors, B; Sardella, G; Sawaya, F; Stone, GW; Valgimigli, M, 2016)	0.43
"Laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery is a safe and effective procedure for patients with severe obesity."	( Is Daily Low-Dose Aspirin Safe to Take Following Laparoscopic Roux-en-Y Gastric Bypass for Obesity Surgery? Amin, N; Anvari, M; Gmora, S; Hong, D; Kang, X; Tiboni, M, 2017)	0.79
"Polychlorinated dibenzo-p-dioxins and dibenzofurans (dioxins) are classed as persistent organic pollutants and have adverse effects on multiple functions within the body."	( Protective effects of levamisole, acetylsalicylic acid, and α-tocopherol against dioxin toxicity measured as the expression of AhR and COX-2 in a chicken embryo model. Całkosiński, I; Dobrzyński, M; Gamian, A; Gostomska-Pampuch, K; Kowalczyk, A; Kuropka, P; Ostrowska, A; Ziółkowski, P; Łukaszewicz, E, 2017)	0.46
" Further, patients were asked about use of over-the-counter analgesics, adverse effects and how the treatment affected their everyday life."	( Switching, Adverse Effects and Use of Over-the-Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy-based Survey. Grove, EL; Hellfritzsch, M; Hyllested, LMR; Meegaard, L; Pottegård, A; Wiberg-Hansen, A, 2017)	0.46
"Exploratory analyses of adverse event reports (AERs) from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database (2004-2012 periods) were conducted."	( Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events. Hansen, RA; Rahman, MM; Scalese, MJ, 2017)	0.46
" An understanding of stroke mechanisms and causes is important to deliver safe and efficacious treatments for early stroke prevention."	( Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017)	0.72
" Clopidogrel decreased the rates of major adverse cardiac event, recurrent myocardial infarction, and all-cause mortality compared with placebo."	( Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. Fan, TM; Hwang, I; Khouzam, RN; Rashid, A; Reed, GL; Shah, R, 2017)	0.46
" Other outcomes of interest were major adverse cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), stroke and intracranial hemorrhage."	( Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. Bavry, AA; Elgendy, AY; Elgendy, IY; Mahmoud, AN; Mahtta, D; Rambarat, C, 2017)	0.77
" Excluding patients who reached study endpoints, 21 (8%) patients in the celecoxib group and 17 (7%) patients in the naproxen group had adverse events leading to discontinuation of treatment."	( Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017)	0.46
" The treatment results and adverse events in each group were compared."	( The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. Arı, ME; Azak, E; Çetin, İİ; Çevik, BŞ; Ekici, F; Eminoğlu, S; Kibar, AE; Kocabaş, A; Orgun, A; Sürücü, M, 2016)	0.43
" However, enoxaparin was found to be as safe as aspirin with respect to bleeding, and fondaparinux was as safe as aspirin for risk of wound complications."	( Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017)	0.71
"89] and other adverse events."	( Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A Meta-Analysis of Randomized Controlled Trials. Anderson, BJ; Dahal, K; Kaur, J; Sharma, SP; Singh, G, )	0.37
"The PPI seems to be effective in preventing peptic ulcers and erosive esophagitis and in resolution of dyspeptic symptoms without increasing adverse events, cardiac risks or mortality in long-term aspirin users."	( Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A Meta-Analysis of Randomized Controlled Trials. Anderson, BJ; Dahal, K; Kaur, J; Sharma, SP; Singh, G, )	0.56
" The aim of this study was to analyse the safety profile of these drugs using data from spontaneous reporting of suspected adverse reactions (ADRs)."	( Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network. Benfatto, G; Drago, F; Gozzo, L; Longo, L; Mansueto, S; Navarria, A; Pani, L; Salomone, S; Sottosanti, L, 2017)	0.46
" However, administration of aspirin causes toxic effects, especially in the stomach and liver."	( Nullification of aspirin induced gastrotoxicity and hepatotoxicity by prior administration of wheat germ oil in Mus musculus: histopathological, ultrastructural and molecular studies. Hamad, SR; Mohamed, HRH, 2017)	1.09
" The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up."	( The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018)	0.72
"The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR."	( Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017)	0.7
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months."	( SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017)	0.46
" The primary outcome measured was the composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), or ischaemia-driven target lesion revascularisation at the 12-month follow-up."	( Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. Cho, DK; Choi, S; Hong, BK; Hong, MK; Jang, Y; Jeon, DW; Kang, TS; Kang, WC; Kim, BK; Kim, BO; Kim, JS; Kim, S; Kim, YH; Kwon, HM; Lee, BK; Lee, OH; Min, PK; Shin, DH; Woo, SI; Yoon, YW, 2018)	0.48
" Each case showed a marked platelet decrease, from values within normal limits at the time of delivery, with no severe adverse events."	( Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review. Hasegawa, M; Sakai, K; Ueda, A; Ueda, Y, 2018)	0.48
"We sought to investigate whether double antiplatelet therapy (DAPT) is safe in patients after LAAC."	( Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R, 2018)	0.48
"LAAC followed by DAPT seems to be a safe and efficient alternative for stroke prevention in patients with NVAF who have contraindications to anticoagulation therapy."	( Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R, 2018)	0.48
" Safety was evaluated via PLATO-defined bleeding events, adverse events (AEs), serious AEs, and laboratory measurements."	( Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018)	0.48
" As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies."	( Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. Liu, X; Zhang, JJ, 2018)	1.92
" Low-dose aspirin can be considered a safe and effective agent in the prevention of VTE after TKA."	( Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018)	1.3
" Outcomes included composite major adverse cardiovascular events, noncardiovascular death, gastrointestinal or renal events, and components of the composite."	( Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. Abdallah, MS; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Reed, GW; Shao, M; Solomon, DH; Wisniewski, L; Wolski, K; Yeomans, N, 2018)	0.88
" Efficacy outcomes included ischemic stroke, stent thrombosis, major adverse cardiovascular event (MACE), all-cause mortality and myocardial infarction (MI); safety outcome was major bleeding."	( Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. Huang, J; Liu, L; Tang, X; Zhang, X, 2018)	0.48
" Major adverse cardiac and cerebrovascular events (MACCE) [death, myocardial infarction (MI), stroke, and unplanned reintervention] and thrombolysis in myocardial infarction (TIMI) bleeding (major/minor) were registered during hospitalization and follow-up."	( Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T, 2018)	0.48
"TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis."	( The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019)	0.51
" Serious adverse events were reported in 12 (1·7%) of 724 patients treated with primary IVIG plus prednisolone; two of these patients had hypertension and bacteraemia that was probably related to prednisolone."	( Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Chiga, M; Hori, N; Kaneko, T; Komiyama, O; Matsushima, T; Misawa, M; Miura, M; Miyata, K; Morikawa, Y; Nakazawa, M; Obonai, T; Sakakibara, H; Takahashi, T; Tamame, T; Tsuchihashi, T; Yamagishi, H; Yamashita, Y, 2018)	0.48
" The aspirin analogues fumaryldiaspirin (PN517) and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more toxic against the OC cell lines than aspirin."	( The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer. Bashir, AIJ; Devitt, A; Kilari, RS; Nicholl, ID; Perry, CJ; Safrany, ST, 2019)	1.29
"A rapid aspirin desensitization protocol is safe and effective across a broad spectrum of hypersensitivity reactions and clinical presentations."	( Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience. Austin, D; Bolton, S; Callaghan, S; Carter, J; de Belder, MA; Hall, JA; Jackson, M; Muir, DF; Stapleton, J; Sutton, AGC; Swanson, N; Williams, PD; Wright, RA, 2019)	1.43
" The incidences of bleeding (TIMI major and minor) and major adverse cerebrocardiovascular events (MACCE; all-cause death, nonfatal myocardial infarction, stent thrombosis, unplanned revascularization, and stroke) were evaluated."	( Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention　- From the TWMU-AF PCI Registry. Arashi, H; Ebihara, S; Fujii, S; Hagiwara, N; Honda, A; Jujo, K; Kawamoto, T; Mori, F; Nakao, M; Ota, Y; Otsuki, H; Saito, K; Takagi, A; Tanaka, H; Tanaka, K; Yamaguchi, J; Yoshikawa, M, 2019)	0.75
" Moreover, using C+P did not lead to any serious adverse effects when compared to the treatment group."	( Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)	0.51
"While the addition of low dose chlorpromazine and promethazine to standard of care for acute ischemic stroke did not have any significant improvement in functional outcomes, there were no serious adverse effects."	( Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)	0.51
" Regarding antithrombotic prophylaxis, data are lacking on DOAC use in general surgical patients, while DOACs appear to be more effective than and as safe as LMWHs in VTE prophylaxis for major orthopedic surgical patients."	( Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Agnelli, G; Becattini, C; Franco, L; Giustozzi, M; Vedovati, MC, 2019)	0.51
" These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies."	( Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019)	0.72
"In a large placebo-controlled randomized trial, we found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections."	( Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019)	0.72
"In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier."	( Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019)	0.51
" However, the least side effect was observed in the tadalafil + aspirin group."	( Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study. Albayrak, S; Bayraktar, Z, 2019)	1
"7%, and the most common adverse events were gastrointestinal symptoms."	( Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. Li, R; Luo, F, 2020)	0.87
"Clearly, Aspirin desensitization and treatment are beneficial for AERD patients, with relief of nasal symptoms, improvement in asthma control, decrease in daily corticosteroid use, and no fatal adverse events."	( Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. Li, R; Luo, F, 2020)	1.29
"Clopidogrel combined with low-dose aspirin is safe and effective in antithrombotic therapy for children with KD complicated by CAA."	( [Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms]. Chen, TT; Guo, YH; Li, Y; Liu, YL; Lu, YH; Shi, K; Wang, XM, 2019)	1.04
"For patients with inguinal hernias, laparoscopic TAPP repair is completely safe to be performed on those taking low-dose acetylsalicylic acid when it was only ceased on the operation day, with intravenous salvianolate given after the operation instead."	( Continuation of low-dose acetylsalicylic acid during perioperative period of laparoscopic inguinal hernia repair is safe: results of a prospective clinical trial. Han, H; Liu, Y; Ruze, R; Wang, M; Xiong, Y; Yan, Z; Zhan, H; Zhang, G, 2019)	0.51
" In this work, we reported a novel kind of BiOI@CuS nanoparticle to achieve safe and effective therapy of lung cancer by co-loading hydrochloric acid doxorubicin (DOX) and aspirin phenacetin and caffeine (APC)."	( Construction of DOX/APC co-loaded BiOI@CuS NPs for safe and highly effective CT imaging and chemo-photothermal therapy of lung cancer. Cheng, J; He, D; Huang, G; Li, W; Wang, R; Zhang, Y; Zhu, J, 2019)	0.71
"Patients who are at increased risk for MI can be maintained on DAPT up to the time of CABG because surgery is safe when patients are offered PPT."	( Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe? Charif, F; El Zein, A; Hamdan, R; Issa, M; Jassar, Y; Saab, M; Younes, M; Youness, G, 2019)	0.51
" Aspirin alone appears to be safe for use in those patients."	( Clopidogrel plus Aspirin Use is Associated with Worse Long-Term Outcomes, but Aspirin Use Alone is Safe in Patients with Vasospastic Angina: Results from the VA-Korea Registry, A Prospective Multi-Center Cohort. Baek, SH; Cho, SS; Gwon, HC; Han, SH; Her, SH; Jo, SH; Kim, SE; Lee, BK; Lee, KY; Lee, MH; Park, KH; Rha, SW; Seo, WW; Suh, JW; Yang, TH, 2019)	1.76
" In conclusion, treatment with low-dose IC TNK appears safe and well tolerated during PPCI."	( Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). Bainey, KR; Devireddy, C; Gibson, CM; Gopalakrishnan, L; Grip, L; Guo, J; Kazziha, S; Kumar, V; Marshall, JJ; Mavromatis, K; Pinto, D; Singh, P; Stouffer, GA, 2020)	0.56
" Secondary outcomes were adverse events associated with therapy, including bleeding."	( Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Blom, AW; Judge, A; Kunutsor, SK; Matharu, GS; Whitehouse, MR, 2020)	0.83
" The risk of adverse events, including major bleeding, wound hematoma, and wound infection, was not statistically significantly different in patients receiving aspirin vs other anticoagulants."	( Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Blom, AW; Judge, A; Kunutsor, SK; Matharu, GS; Whitehouse, MR, 2020)	1.03
" Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters."	( Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)	1.03
" The aim of this study is to determine whether a protocol of 81-mg aspirin (ASA) bis in die (BID) is safe and/or effective in preventing VTE in patients undergoing rTHAs vs 325-mg ASA BID."	( Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Hip Arthroplasty: A Retrospective Cohort Study. Bosco, J; Iorio, R; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2020)	1.21
"Using a protocol of 81-mg of ASA BID is noninferior to 325-mg ASA BID and may be safe and effective in maintaining low rates of VTE in patients undergoing rTHA."	( Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Hip Arthroplasty: A Retrospective Cohort Study. Bosco, J; Iorio, R; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2020)	0.98
"Compared with ASA, DAPT showed a non-significant impact on long-term survival and demonstrated to be a safe option."	( Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes. Amorim, MJ; Barros, AS; Cerqueira, RJ; Ferreira, AF; Leite-Moreira, AF; Lourenço, AP; Moreira, R; Pinho, P; Rocha-Gomes, JN; Saraiva, FA, 2020)	0.83
" The endpoints were major adverse cardiac events (MACEs), death, stroke, myocardial infarction (MI), stent thrombosis, and bleeding events."	( Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Li, D; Li, X; Shen, S; Wu, H; Xiang, X, 2020)	0.56
" This is concerning since it's a frequently prescribed drug, not exempt from adverse events."	( Safety and Drugs: How Do We Record Medication Consumption and Prescription in Electronic Medical Records? A Look on Aspirin. Esteban, S; Terrasa, S; Volpi, M, 2020)	0.77
" In this work, we propose to infuse a competitor drug into the extracorporeal circuit that increases the free fraction of a toxic drug and thereby increases its dialytic removal."	( A model-based analysis of phenytoin and carbamazepine toxicity treatment using binding-competition during hemodialysis. Fuertinger, DH; Hoffman, RS; Kotanko, P; Maheshwari, V; Tao, X; Thijssen, S, 2020)	0.56
" Hence, whether ASA might be a safe and reasonable therapeutic candidate to be tested in clinical trials involving adults with COVID-19 deserves further attention."	( Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? Bianconi, V; Fallarino, F; Pignatelli, P; Pirro, M; Sahebkar, A; Violi, F, 2020)	0.56
" Data on adverse events (AEs) and composite events such as cardiovascular (CV) death, myocardial infarction (MI), and stroke were recorded and summarized to assess efficacy."	( Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. Choi, JH; Chon, MK; Chun, KJ; Hwang, KW; Jung, SM; Kim, JH; Kim, JS; Lee, SH; Lee, SY; Park, YH, 2020)	0.56
" Efficacy (major adverse cardiovascular events, acute or chronic limb ischaemia, vascular amputation, peripheral revascularisation) and safety (all-cause mortality and overall bleeding) outcomes were evaluated via Bayesian network meta-analyses."	( Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)	0.62
"98) significantly reduced major adverse cardiovascular events risk compared with aspirin."	( Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)	0.85
"This updated network meta-analysis confirms that clopidogrel significantly decreases the risk of major adverse cardiovascular events compared with aspirin, without increasing bleeding risk."	( Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)	0.82
"A post hoc design was used to examine predictors of hemorrhagic stroke for adults of age 65 years and older from the Food and Drug Administration Adverse Events Reporting System database."	( Predictors of hemorrhagic stroke in older persons taking nonsteroidal anti-inflammatory drugs: Results from the Food and Drug Administration Adverse Event Reporting System. McDonald, DD; Srisopa, P, 2020)	0.56
" The aim of this study was to determine whether a protocol of 81-mg aspirin (ASA) bis in die (BID) is safe and/or sufficient in preventing VTE in patients undergoing rTKAs versus 325-mg ASA BID."	( Low-Dose Aspirin is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Knee Arthroplasty: A Retrospective Cohort Study. Bosco, JA; Iorio, R; Schwarzkopf, R; Slover, JD; Tang, A; Waren, D; Zak, SG, 2022)	1.37
"We initiated a multicenter, prospective cohort study to test the hypothesis that aspirin is safe for patients with ischemic cerebrovascular disease (ICVD) harboring unruptured intracranial aneurysms (UIAs) <7 mm."	( Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms. Cao, Y; Du, X; Fu, WL; Huo, R; Jiao, YM; Li, H; Wang, J; Wang, S; Weng, JC; Xu, HY; Yan, ZH; Zhao, JZ, 2021)	1.25
"Aspirin is a safe treatment for patients with concurrent small UIAs and ICVD."	( Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms. Cao, Y; Du, X; Fu, WL; Huo, R; Jiao, YM; Li, H; Wang, J; Wang, S; Weng, JC; Xu, HY; Yan, ZH; Zhao, JZ, 2021)	2.47
"In the VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb events with an early benefit for acute limb ischemia regardless of clopidogrel use."	( Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Anand, SS; Bauersachs, R; Berkowitz, SD; Bonaca, MP; Brackin, T; Brasil, D; Capell, WH; Debus, ES; Haskell, L; Hess, CN; Hiatt, WR; Jaeger, N; Madaric, J; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR; Sillesen, H; Szalay, D, 2020)	1.17
"Magnesium sulfate combined with low-dose aspirin can significantly reduce adverse reactions and effectively lower blood pressure in patients with pregnancy induced hypertension, but the overall efficacy and safety of the combination of drugs are not clear."	( Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis. Chen, M; Chen, Y; He, G; Liu, X, 2020)	1.11
"After adjustment, 3-month DAPT was not inferior to longer DAPT after BP-SES implantation in terms of net adverse clinical events."	( 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y Ako, J; Hibi, K; Hioki, H; Hirohata, A; Ikari, Y; Ito, Y; Kinoshita, Y; Kozuma, K; Morino, Y; Nakagawa, Y; Nanasato, M; Shiode, N; Sonoda, S; Tanabe, K; Yamaguchi, J, 2020)	0.8
" The aim of this study is to determine if discontinued use of outpatient IPCDs is safe and does not increase the rate of VTE or any other related complications in patients following TKA."	( Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin. Lajam, C; Lygrisse, K; Macaulay, W; Meftah, M; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2022)	0.91
" However, there were no significant differences in the adverse drug reactions between the two groups."	( Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke. Chen, M; Dai, X; Deng, X; Fu, S; Gong, Q; He, W; Huang, L; Li, C; Luo, Q; Qiu, T; Wang, J; Wang, M; Xiao, H, 2021)	0.62
"The most efficacious strategy to manage pregnant patients with antiphospholipid syndrome (APS) refractory to conventional heparin/low-dose aspirin treatment or at high risk of adverse pregnancy outcomes has not been determined with any degree of certainty."	( The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. Calligaro, A; Del Ross, T; Favaro, M; Gervasi, MT; Hoxha, A; Ruffatti, A; Ruffatti, AT; Tonello, M, 2021)	0.82
" Researchers followed up with participants for one month after treatment to determine whether adverse events (AEs) or adverse drug reactions (ADRs) such as bleeding tendency occurred."	( Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y, 2021)	0.85
"SMDS combined with aspirin is a clinically effective and safe intervention to treat adults aged 35 and older with SAP."	( Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y, 2021)	1.17
" There was no difference between short and standard-duration dual antiplatelet therapy regarding efficacy outcomes (all- cause death, major adverse cardiovascular events, myocardial infarction, stroke, and stent thrombosis)."	( Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Al-Ali, MH; Al-Farhan, H; Al-Kenzawi, H; Al-Kinani, T; Al-Myahi, M; Al-Obaidi, FR; Al-Sudani, N; Alrubaiy, L; Hutchings, HA; Yong, ASC, 2021)	0.84
"ASA is safe for VTE prophylaxis after total joint arthroplasty in patients with history of GI issues and is not associated with an increased risk of postoperative GI bleeds."	( Aspirin Is Safe for Venous Thromboembolism Prophylaxis for Patients With a History of Gastrointestinal Issues. Austin, MS; Grosso, MJ; Kozaily, E; Parvizi, J, 2021)	2.06
"Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)."	( The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. Costa, G; Gonçalves, L; Teixeira, R, 2021)	0.86
" There was no statistically significant difference in the incidence of adverse reactions between the 2 groups (OR=0."	( Effectiveness and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome: a systematic review and meta-analysis. Su, F; Wang, M; Wang, Z; Yu, Q, 2021)	0.92
"Aspirin combined with letrozole in the treatment of PCOS is safe and effective."	( Effectiveness and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome: a systematic review and meta-analysis. Su, F; Wang, M; Wang, Z; Yu, Q, 2021)	2.36
" In this study, we aimed to assess whether aspirin improves STA-MCA bypass patency and is safe in patients with MMD."	( Effects and safety of aspirin use in patients after cerebrovascular bypass procedures. Chen, X; Lu, J; Shi, G; Wang, H; Wang, R; Zhang, D; Zhao, JZ; Zhao, Y, 2021)	1.2
"Current available therapies for pancreatic ductal adenocarcinoma (PDAC) provide minimal overall survival benefits and cause severe adverse effects."	( Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity. Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK, 2021)	0.99
" Intravenous (IV) tirofiban alone or combined with DAPT was shown to be safe and effectively improved clinical outcome in progressive ischemic stroke patients."	( Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients. Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021)	0.62
"Our study suggested that tirofiban use appears to be safe as monotherapy in AIS treatment compared with common dual antiplatelet therapy, however, no improvement in functional outcomes was found."	( Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke. Chen, C; Hu, W; Liu, D; Liu, J; Liu, T; Luo, W; Song, J; Tao, C; Yuan, X; Zhang, C; Zhu, Y, 2021)	0.62
" The endpoints of efficacy include major adverse cardiac events (MACEs), all-cause mortality, and the number of target vessel revascularization."	( Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI. Hu, H; Hu, X; Luo, S; Zhang, Q; Zhao, W, 2021)	0.93
" We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events."	( Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. Bousquet, J; Brignardello-Petersen, R; Chu, DK; Kennedy, DW; Oykhman, P; Paramo, FA, 2022)	0.96
" CONCLUSIONS Continuing anticoagulation or antiplatelet was safe in not increasing bleeding complications or perioperative transfusion requirements."	( Is Continuing Anticoagulation or Antiplatelet Therapy Safe Prior to Kidney Transplantation? Alonso-Escalante, JC; Machado, L; Tabar, KR; Thai, N; Tindall, R; Uemura, T, 2021)	0.62
" No adverse clinical reactions were noted following DAS administration and safety studies suggested DAS caused no inflammatory response or coagulation disturbance."	( Pharmacokinetics, pharmacodynamics and safety evaluation of 5,5'-methylenebis(2-acetoxybenzoic acid) in dogs following intravenous administration. Behling-Kelly, E; Campbell, CJ; Goggs, R; Kannampuzha-Francis, J; Moreau, JP, 2021)	0.62
" The Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial is a multi-center, double-blind, randomized, controlled trial enrolling patients who require cardiothoracic surgery on cardiopulmonary bypass (CPB) within 48 hours of last ticagrelor dose."	( Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelo Cutlip, DE; Deliargyris, EN; Doros, G; Gibson, CM; Kroger, H; Lee, VT; Mack, MJ; Ohman, EM; Schneider, DJ; Sellke, FW; Thourani, VH, 2022)	0.72
") 200 mg was effective and safe in preventing the developmentof colonic polyps."	( [Efficacy and safety of lyophilized concentrate purple corn (Zea mays L.) in preventing the formation of colonic polyps]. Frisancho V, O; Ichiyanagui R, C; Soriano A, C, )	0.13
" The primary endpoints were change in HbA1c versus baseline, and the incidence of gastrointestinal adverse events (AEs)."	( Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022)	0.92
" This study intends to carry out an evaluation of whether combining rivaroxaben with aspirin will be effective and safe in treating patients experiencing chronic CAD."	( Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis. Li, X; Wang, H; Wu, H; Wu, X; Xie, G, 2022)	1.18
" Cilostazol therapy significantly increased the risk of adverse events of headache (odds ratio, 12."	( Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials. Huang, T; Wan, H; Wu, Q; Wu, T; Yang, P; Zhang, H, 2022)	0.72
"Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events."	( The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. Alagna, G; Di Lisi, D; Madaudo, C; Novo, G; Rossetto, L; Santoro, M; Siragusa, S, 2022)	0.72
" Safety evaluations include liver function and kidney function, serum fibrinogen, adverse events, serious adverse events, and bleeding events."	( Efficacy and safety of lumbrokinase plus aspirin versus aspirin alone for acute ischemic stroke (LUCENT): study protocol for a multicenter randomized controlled trial. Chen, Y; Dai, H; Liu, Y; Shang, H; Yang, B; Zhang, J; Zhang, X; Zhou, K, 2022)	0.99
"OACs plus single antiplatelet therapy and dual antiplatelet therapy alone are both safe and efficacious management strategies after CVSS stent placement."	( Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting. Bai, C; Chen, Z; Ding, Y; Ilagan, R; Ji, X; Meng, R; Wu, X, 2022)	0.72
" Laparoscopic repair appears to be safe in patients receiving APT/ACT under current perioperative management patterns."	( Safety of laparoscopic inguinal hernia repair in the setting of antithrombotic therapy. Al-Mansour, MR; Balch, JA; Crippen, C; Johnson-Mann, CN; Loftus, TJ; Neal, D; Read, TE, 2022)	0.72
"Acetylsalicylic acid (ASA) is a non-steroidal anti-inflammatory drug used in the treatment of acute rheumatic fever (ARF) and it can cause serious adverse effects."	( The effectiveness and safety of ibuprofen and acetylsalicylic acid in acute rheumatic fever. Gürses, D; Tükenmez, G; Yılmaz, M, 2022)	0.72
"The results of this study suggest that ibuprofen can be a safe alternative in the treatment of ARF, especially in young children."	( The effectiveness and safety of ibuprofen and acetylsalicylic acid in acute rheumatic fever. Gürses, D; Tükenmez, G; Yılmaz, M, 2022)	0.72
"The aim of this study was to analyze the clinical characteristics of fatal adverse events (AEs) of rivaroxaban combined with aspirin and to underline the importance of the rational use of drugs."	( Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022)	1.18
"By January 19, 2020, 2309 fatal adverse event reports of rivaroxaban combined with aspirin from 21 countries were entered in VigiBase."	( Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022)	1.2
" The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months."	( Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study. Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C, 2022)	0.72
" Many randomized, double-blind, placebo-controlled, multicenter clinical trials suggest that NBP is a safe and effective treatment for ischemic stroke."	( Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet. Lv, J; Xie, Z; Zhao, D; Zhao, G, 2022)	0.72
"), and adverse events of patients in groups."	( Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet. Lv, J; Xie, Z; Zhao, D; Zhao, G, 2022)	0.72
" Effectiveness endpoints were evaluated by the major adverse cardiovascular events, encompassing all-cause death, non-fatal myocardial infarction, and clinically driven revascularization."	( Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022)	0.72
"Ticagrelor was associated with a lower incidence of major adverse cardiovascular events than clopidogrel at 12 months in elderly Chinese patients with coronary artery disease, without a significant increase of Bleeding Academic Research Consortium bleeding events."	( Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022)	0.72
" Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic."	( Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022)	0.72
" The purpose of this study is to quantify the complication rate associated with FICB in patients who are actively taking prescribed anticoagulant and/or antiplatelet medications prior to injury and identify factors that may predispose patients to an adverse event."	( The safety of continuous fascia iliaca block in patients with hip fracture taking pre-injury anticoagulant and/or antiplatelet medications. Barletta, JF; Dzandu, JK; Mangram, AJ; Montanarella, PD; Prokuski, LJ; Shirah, GR; Sucher, JF, 2022)	0.72
" In terms of cardiovascular and cerebrovascular adverse events, other 3 interventions were higher than L-DAPT (Std-DAPT [OR = 1."	( Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis. Feng, T; Li, D; Luo, L; Ran, J; Tang, K; Wang, D; Wang, S; Wu, J; Xu, L; Yang, X; Zhang, L; Zhao, D, 2022)	0.72
" In the outcome of MI, stent thrombosis, and cardiovascular and cerebrovascular adverse events, L-DAPT has the best efficacy."	( Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis. Feng, T; Li, D; Luo, L; Ran, J; Tang, K; Wang, D; Wang, S; Wu, J; Xu, L; Yang, X; Zhang, L; Zhao, D, 2022)	0.72
" A comparison of hemocompatibility-related adverse events (HRAEs), hemocompatibility score (HCS), and hemocoagulative laboratory markers, both qualitative and quantitative, between the 2 groups were performed."	( Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more. Bagozzi, L; Bottigliengo, D; Bottio, T; Fabozzo, A; Fagan, D; Gerosa, G; Gregori, D; Mastro, FR; Pagnin, C; Tarzia, V; Tessari, C, 2023)	0.91
"The first 3 months after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) is a high-risk period for adverse events, including ischemic and bleeding events, which decrease greatly with time."	( Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. Li, X; Lin, Y; Peng, W; Zhang, Y, 2023)	0.91
" Major adverse cardiovascular and cerebrovascular events (MACCE) were considered the primary end point, and major bleeding was considered the secondary end point."	( Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. Li, X; Lin, Y; Peng, W; Zhang, Y, 2023)	0.91
" There was no significant difference between the two groups regarding hemorrhagic adverse effects."	( A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. Aref, HM; El-Khawas, H; Elbassiouny, A; Roushdy, TM; Shokri, HM; Zeinhom, MG, 2023)	0.91
"4:1:1) to 3 treatment arms (1, standard of care [SOC]; 2, SOC + additional rifampicin [up to 35 mg/kg/d] + linezolid 1200 mg/d reducing after 28 days to 600 mg/d; 3, as per arm 2 + aspirin 1000 mg/d) for 56 days, when the primary outcome of adverse events of special interest (AESI) or death was assessed."	( A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial. Aziz, S; Banderker, IA; Black, J; Bremer, M; Candy, S; Crede, T; Daroowala, R; Davis, AG; Denti, P; Goliath, R; Jackson, A; Jason Liang, C; Kadernani, Y; Koekemoer, S; Lai Sai, L; Lai, RPJ; Maartens, G; Maxebengula, M; Meintjes, G; Moosa, MS; Naude, J; Offiah, C; Raubenheimer, P; Sihoyiya, T; Stegmann, S; Stek, C; Szymanski, P; Vallie, Y; Vorster, I; Wahl, G; Wasserman, S; Wilkinson, RJ, 2023)	1.31
"The purpose of this study was to compare the adverse event (AE) rates of percutaneous pediatric transplant liver biopsies in patients receiving periprocedural antithrombotic agents with those in patients not receiving them."	( Safety of Periprocedural Antithrombotics during Pediatric Transplant Liver Biopsies. Koo, KSH; Monroe, EJ; Reis, J; Shaw, DW; Shivaram, GM, 2023)	0.91
"Our aim was to test the assertion that in terms of rate or severity level, adverse events (AEs) after fine-needle aspiration biopsies (FNABs) of thyroid nodules are unfazed by daily low-dose (100 mg) aspirin (acetylsalicylic acid, ASA) intake."	( Adverse events unlikely after fine-needle aspiration biopsies of thyroid nodules in patients on low-dose aspirin: a prospective controlled systematic single center analysis. Cordes, M; Götz, TI; Kuwert, T; Schmidkonz, C, 2023)	1.31
" However, information on the potential toxic effects of aspirin on non-target aquatic invertebrates is limited."	( Assessment of ecotoxicity effects of aspirin on non-target organism (Daphnia magna) via analysis of the responses of oxidative stress, DNA methylation-related genes expressions and life traits changes. Cuiping, H; Limei, H; Na, Z; Tang, T; Xiangping, N; Yang, Y, 2023)	1.43
"The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up."	( Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023)	0.91
"Aspirin was found to be effective and safe for VTE prevention in primary total joint arthroplasty, including in patients considered higher risk for VTE."	( Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients. Kroger, EW; Prentice, HA; Singh, G; Winston, BA, 2023)	2.6
" The primary comprehensive endpoint was a major adverse cardiovascular event (MACE) composite of cardiovascular death, stroke, or myocardial infarction, while the secondary endpoints were cardiovascular death, all-cause stroke, ischemic stroke, myocardial infarction, and all-cause death."	( Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J, 2023)	0.91
" For the incidence of adverse events, there was no statistical difference."	( Efficacy and safety of low-dose aspirin on preventing transplant renal artery stenosis: a prospective randomized controlled trial. Cao, G; Cao, H; Duan, W; Gu, Y; Ji, B; Niu, X; Qin, T; Shao, F; Tian, X; Wang, Z; Wu, X; Yan, T; Zhang, C; Zhao, J, 2023)	1.19
"Clinical application of low-dose aspirin after renal transplant could prevent the development of TRAS with no significant increase in adverse effects."	( Efficacy and safety of low-dose aspirin on preventing transplant renal artery stenosis: a prospective randomized controlled trial. Cao, G; Cao, H; Duan, W; Gu, Y; Ji, B; Niu, X; Qin, T; Shao, F; Tian, X; Wang, Z; Wu, X; Yan, T; Zhang, C; Zhao, J, 2023)	1.48
" The secondary endpoint is a composite of major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemia-driven target vessel revascularization, and stroke."	( Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T, 2023)	1.15
"Our findings suggest that perioperative continuation of aspirin is relatively safe in the setting of endoscopic surgery for airway stenosis management."	( Assessing the safety of continued perioperative antithrombotic therapy in endoscopic airway surgery for laryngotracheal stenosis. Kohli, N; Reeder, A; Rohrbaugh, T; Shah, HP, )	0.38
" Our meta-analysis aimed to demonstrate whether intensified antithrombotic regimens with ticagrelor plus aspirin have more beneficial effects and fewer adverse events compared to those of clopidogrel plus aspirin in East Asian patients with ACS undergoing PCI."	( Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023)	1.12
" The primary endpoint was bleeding events, and the secondary endpoints were major adverse cardiovascular and cerebrovascular events (MACCEs, including cardiovascular death, nonfatal myocardial infarction [MI], and stroke), all-cause death, and definite/probable/possible stent thrombosis."	( Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023)	0.91
"Patients with CKD were more likely than those without CKD to have adverse cardiovascular events or death and were also more likely to have major bleeding requiring hospitalization."	( Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. Anderson, RD; Benziger, CP; Bradley, SM; DeWalt, DA; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kim, H; Knowlton, KU; Mehta, H; Muñoz, D; Pepine, CJ; Polonsky, TS; Rothman, RL; Stebbins, A; Whittle, J; Wruck, LM; Zhou, L, 2023)	1.17
"This real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel."	( Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. Je, NK; Lee, YJ, 2023)	0.91
" However, numerous adverse events (AEs) have been reported."	( A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database. Chen, M; Wang, Y; Zhang, X; Zhao, B, )	0.13
" Endpoints were adverse events (AEs) of any kind and, especially of gastrointestinal (GI) nature."	( Comparison of gastrointestinal adverse events between fast release tablets and regular acetylsalicylic acid (aspirin) galenics after short-term use: a meta-analysis of randomized clinical trials. Lanas, A; Mikhail, E; Werz, O, 2023)	1.12
" The chitosan-STWE adsorbent was determined to be non-toxic, thus safe to be used in wastewater treatment applications."	( Spent tea waste extract as a green modifying agent of chitosan for aspirin adsorption: Fixed-bed column, modeling and toxicity studies. Nabgan, W; Ngadi, N; Noralidin, NA; Nordin, AH; Nordin, ML; Osman, AY; Shaari, R, 2023)	1.15
" Outcomes included major adverse cardiovascular events, all cause death, major bleeding and myocardial infarction."	( Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Liu, C; Ma, L, 2023)	0.91
" In head-to-head comparison, no significant difference was observed between all antithrombotic treatment strategies with respect to primary endpoint of major adverse cardiovascular events."	( Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Liu, C; Ma, L, 2023)	0.91

Pharmacokinetics

Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease. A twice-daily, low-dose aspirin administration resulted in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays.

Excerpt	Reference	Relevance
" A plasma half-life of approximately 45 hours is observed, permitting the use of single daily doses in therapy."	( Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. Hobbs, DC; Twomey, TM, )	0.41
" It is proposed in general that pharmacokinetic parameters may vary in accord with the physiologic circadian phase at the time of drug challenge."	( Chronopharmacokinetics of ethanol. III. Variation in rate of ethanolemia decay in human subjects. Pauly, JE; Scheving, LE; Sturtevant, FM; Sturtevant, RP, 1978)	0.26
"The pharmacodynamic interaction between phenybutazone and aspirin was studied in 9 patients."	( [Interaction of salicyl compounds and other non-steroidal anti-inflammatory agents: pharmacokinetic study of phenylbutazone-aspirin combination in man]. Faure, G; Gaucher, A; Maillard, A; Netter, P; Pourel, J; Royer, RJ; Tamisier, JN, 1976)	0.71
"The applications of pharmacokinetic modeling to the prediction of tissue residues of drugs in food-producing animals are reviewed."	( Pharmacokinetic prediction of tissue residues. Dittert, LW, 1977)	0.26
" The results show that antacid affected the relative bioavailability of aspirin since the mean peak concentration (Cmax) of aspirin was significantly higher when antacid was given."	( The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers. Chaiyos, N; Itthipanichpong, C; Sirivongs, P; Wittayalertpunya, S, 1992)	0.82
"A single-blind, randomized, crossover pharmacokinetic study was carried out to investigate the bioavailability of a new oral buffered 325 mg acetylsalicylic acid (ASA) formulation (ASPIRINA 03) in comparison with a 325 mg plain tablet."	( Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. Garagiola, U; Gaspari, F; Viganò, G, 1991)	0.47
" Therefore, caffeine is maximally effective in potentiating the effect of analgesics at a dose of 10 mg/kg and this potentiation is not due to a pharmacokinetic interaction with the analgesic, and also not due to phosphodiesterase (PDE) inhibition."	( Determination of the optimal analgesia-potentiating dose of caffeine and a study of its effect on the pharmacokinetics of aspirin in mice. Gayawali, K; Pandhi, P; Sharma, PL, 1991)	0.49
" An analytical method was developed, which detects parent drugs and active metabolites, in order to compare the pharmacokinetic and metabolic behaviour of the two products."	( High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. Lucarelli, C; Marzo, A; Meroni, G; Quadro, G; Ripamonti, M; Treffner, E, 1990)	0.28
"The pharmacokinetic profile of this new preparation fits that proposed by others to produce a selective inhibition of thromboxane synthesis by platelets."	( [Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. Artaza, MA; Castel, JM; Laporte, JR, 1991)	0.28
" We assessed the effect of pentazocine and acetylsalicylic acid on these parameters in 14 human volunteers and related the effects to the pharmacokinetic parameters of the drugs measured at the same time."	( Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to pharmacokinetic parameters. Brune, K; Hummel, C; Kobal, G; Nuernberg, B, 1990)	0.28
" The marked variation in pharmacokinetic parameters observed suggested that therapeutic drug monitoring would be benefit in the control of canine inflammatory conditions using aspirin."	( Pharmacokinetics of aspirin and its application in canine veterinary medicine. Knottenbelt, DC; Morton, DJ, 1989)	0.79
" After intravenous injection mean (+/- SD) values of clearance, steady-state volume of distribution, and terminal half-life were 12."	( Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. Aarons, L; Brossel, S; Hopkins, K; Rowland, M; Thiercelin, JF, 1989)	0.51
"The pharmacokinetic profile of an innovative formulation of soluble aspirin (l-ornithine acetylsalicylate, ldB 1003) was compared with that of conventional tablets and two other soluble dosage forms (d, l-lysine acetylsalicylate and a buffered effervescent formulation of acetylsalicylic acid) after administration of single oral doses in six normal volunteers."	( Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Attardo Parrinello, G; Barzaghi, N; Gatti, G; Perucca, E; Vitiello, B, 1989)	0.75
" Other pharmacokinetic parameters of the salicylate remained unchanged."	( Effect of caffeine on the bioavailability and pharmacokinetics of aspirin. Thithapandha, A, 1989)	0.51
" The various pharmacokinetic parameters determined in the study were similar to those observed in other single dose salicylate studies amongst healthy volunteers but were not predictive of salicylate concentration in the chronic dose study."	( Salicylate pharmacokinetics in patients with rheumatoid arthritis. Francis, HW; Friesen, WT; Owen, SG; Roberts, MS, 1989)	0.28
" In this study, pharmacokinetic interactions between arbaprostil and aspirin were examined in humans after chronic doses of both drugs."	( Pharmacokinetic interactions between arbaprostil and aspirin in humans. Cox, JW; Euler, AR; Gee, WL; Hsyu, PH; Pullen, RH, )	0.62
" Therefore the possible pharmacokinetic interactions between these three drugs were studied after a single-dose in beagle dogs."	( Pharmacokinetic interaction in beagle dogs of antiplatelet drugs: acetylsalicylic acid, dipyridamole and calcium dobesilate. Asimakopoulos, G; Dontas, I; Gogas, J; Karayannacos, PE; Kotsarelis, D; Plessas, CT; Plessas, ST; Souras, S, )	0.13
" The main pharmacokinetic constants of acetylsalicylic acid in these experiments were found to be similar to those in humans."	( [Antiaggregation action and pharmacokinetics of lysine acetylsalicylate]. Chaĭka, LA; Khadzhaĭ, IaI; Kosheleva, LP; Libina, VV; Pichugin, VV, )	0.13
" The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng."	( Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Bochner, F; Lloyd, JV; Morris, PM; Siebert, DM; Williams, DB, 1988)	0.72
" dose the serum half-life of the O-sulphate was estimated to be 7 days."	( The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Ahnfelt, NO; Ryde, EM, 1988)	0.27
" Intravenous injection and oral administration of aspirin (200 mg/kg) showed that the drug is eliminated rapidly (total clearance approximately 45 ml/min/kg; half-life approximately 8 min), that only about one-fourth of the dose is absorbed intact, and that the systemic availability of the oral dose is highly variable (coefficient of variation approximately 60%)."	( Nonlinear pharmacokinetics of aspirin in rats. Levy, G; Wientjes, MG, 1988)	0.82
"05) in the elimination half-life of chloramphenicol was observed before and after dapsone treatment in leprotic patients as compared with the normal volunteers, while no significant difference was observed in any of the pharmacokinetic parameters with aspirin."	( Pharmacokinetics of aspirin and chloramphenicol in normal and leprotic patients before and after dapsone therapy. Bakaya, V; Garg, SK; Kaur, S; Kumar, B; Lal, R; Shukla, VK, 1988)	0.78
" We thus found no clinical manifestations of the pharmacokinetic interaction."	( A study to determine the clinical relevance of the pharmacokinetic interaction between aspirin and diclofenac. Bird, HA; Hill, J; Leatham, P; Wright, V, 1986)	0.49
" At the end of each 2-week dosage period, plasma and urine were collected over a dosage interval for the estimation of various pharmacokinetic parameters."	( Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. Bochner, F; Cleland, LG; Graham, GG; Imhoff, DM; Polverino, A; Rolan, PE; Tregenza, RA, 1987)	0.27
" It was found that neither the 24-hr plasma levels nor the pharmacokinetic parameters of norethindrone following intravenous dosing were significantly altered by aspirin."	( Influence of aspirin on the pharmacokinetics of norethindrone. Gomaa, AA; Makarm, MH, 1987)	0.84
" It is difficult, especially for ASA, to characterize the gastro-intestinal absorption with pharmacokinetic model parameters, because the first-pass effect is large and often elimination of ASA is faster than absorption."	( A pharmacokinetic approach to the establishment of biopharmaceutic characteristics of different acetylsalicylic acid formulations in man. Raghoebar, M; Van Ginneken, CA; Vrancx, F, )	0.13
" Pharmacokinetic studies in four volunteers showed that the plasma protein binding and renal clearance of acetazolamide were significantly reduced during chronic salicylate dosing."	( Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Brandt, JL; Chapron, DJ; Feig, PU; Gomolin, IH; Kramer, PA; Sweeney, KR, 1986)	0.27
" Drug absorption is rapid, drug disappearance half-life is independent of oral dose, and the area under the plasma drug concentration versus time curve increases with increasing oral dose."	( Pharmacokinetics of flurbiprofen. Brooks, CD; Kaiser, DG; Lomen, PL, 1986)	0.27
" Therefore, the possible pharmacokinetic interactions between these agents were assessed following single-dose exposures in 14 healthy volunteers."	( Pharmacokinetic interaction of acetylsalicylic acid and dipyridamole. Melander, A; Nitelius, E; Wåhlin-Boll, E, 1985)	0.27
" The nomograms are based on pharmacokinetic parameters of acetylsalicylic acid with regard to the age."	( [Utilization of the pharmacokinetic parameters of acetylsalicylic acid for optimizing its use with people of different ages]. Belyĭ, AA; Bezverkhaia, IS; Korkushko, OV; Zapadniuk, VI, )	0.13
" To test these possibilities we examined the sex-related differences in (1) vessel wall PGI2 release and its inhibition by and recovery from aspirin in rabbits; (2) the effects of aspirin on platelet aggregation, thromboxane B2 and beta-thromboglobulin (BTG) release in man, and (3) the pharmacokinetic characteristics of aspirin, in both rabbits and man."	( The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Buchanan, MR; Butt, R; Hirsh, J; Rischke, JA; Rosenfeld, J; Turpie, AG, 1983)	0.75
" In addition, ibuprofen can be combined with acetaminophen without altering the pharmacokinetic profile."	( Pharmacokinetics of ibuprofen. Albert, KS; Gernaat, CM, 1984)	0.27
" Salicylate levels were not sustained between doses and elimination rates and half-life were similar for both preparations."	( A pharmacokinetic comparison of choline magnesium trisalicylate and soluble aspirin. Berry, D; Gibson, T; Helliwell, M; Volans, G, 1984)	0.5
" Elimination of salicylate involves two saturable (nonlinear) major pathways and three apparently first-order (linear) minor pathways; these mixed order kinetics lead to somewhat complex mathematics affecting elimination half-life which, in turn, can have implications for anticipating side effects and toxicity."	( Pharmacokinetic considerations of common analgesics and antipyretics. Hartwig-Otto, H, 1983)	0.27
" Most of the pharmacokinetic parameters derived from these profiles were not significantly different between young subjects, elderly subjects and subjects with alcoholic liver disease."	( Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Brooks, PM; Roberts, MS; Rumble, RH; Thomas, D; Wanwimolruk, S, 1983)	0.59
" The plasma levels of the drug after oral administration of a solution best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model."	( Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies. Carmichael, RH; Nash, JF; Ridolfo, AS; Spradlin, CT, 1980)	0.26
"To clarify the question whether pharmacokinetic properties of tiaprofenic acid (presumable trade name Surgam) can be changed by simultaneous application of aluminum hydroxide or acetylsalicylic acid (ASA) a randomized study of 7 healthy volunteers was carried out."	( [On the pharmacokinetics of tiaprofenic acid and its possible interactions with acetylsalicylic acid and aluminum hydroxide (author's transl)]. Altmayer, P; Lücker, PW; Marećek, N; Penth, B; Wetzelsberger, K, 1981)	0.26
" Pharmacokinetic parameters obtained by this method after a single oral dose of 900 mg soluble, effervescent acetylsalicylic acid in normal healthy subjects suggest that absorption, distribution, and elimination of acetylsalicylic acid are rapidly occurring events."	( Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Bochner, F; Cham, BE; Imhoff, DM; Ross-Lee, L, 1980)	0.26
"To study the pharmacokinetic interactions between aspirin (250 mg/kg) and simultaneously administered oral acetaminophen (125 mg/kg) or caffeine (50 mg/kg) in male rats, noninterfering GLC assays for these drugs were developed."	( Interactions of aspirin with acetaminophen and caffeine in rat stomach: pharmacokinetics of absorption and accumulation in gastric mucosa. Jager, LP; Olling, M; Seegers, JM; Van Noordwijk, J, 1980)	0.86
"74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg."	( Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. Eppler, J; Fraga, C; Giesbrecht, E; Ito, S; Johnson, D; Rais, A; Verjee, Z; Wiggins, T, 1995)	0.52
" The results of the pharmacokinetic analyses from blood and urinary data indicated no significant differences in the disposition of ASA between CuD and CuS rats."	( Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. Bacolod, M; Dawson, C; Gonzales, C; Kishore, V; Lopez-Anaya, A, 1994)	0.51
" There was no effect of ASA, ibuprofen or paracetamol on the single-dose kinetics of ethanol, but concurrent intake of ethanol reduced the peak concentration of ASA by 25%."	( Pharmacokinetic interactions of alcohol and acetylsalicylic acid. Lidén, A; Melander, A; Melander, O, 1995)	0.29
" Individual pharmacokinetic parameters were estimated by compartmental modeling (ASA and SA) and by model-independent methods (SUA)."	( Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling. Dubovská, D; Gajdos, M; Krivosíková, Z; Piotrovskij, VK; Spustová, V; Trnovec, T, )	0.13
" Therefore this study evaluated potential pharmacokinetic interactions between ceftiofur sodium and aspirin."	( The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. Freeman, DA; Hanlon, D; Parton, K; Whittem, T, 1995)	0.71
" The pharmacokinetic characteristics of the different NSAIDs relevant to therapy in children are reviewed."	( Relevance of the pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) in children. Pons, G, )	0.13
" To explore possible pharmacokinetic contributions to this phenomenon, a randomized, two-period crossover investigation was performed in 24 healthy volunteers in which a single oral dose of 300 mg cyclosporine was administered alone and on day 10 of multiple oral dosing of aspirin 960 mg three times daily."	( Pharmacokinetics of cyclosporine and steady-state aspirin during coadministration. Gaber, M; Jähnchen, E; Johnston, A; Kovarik, JM; Mueller, EA, 1993)	0.72
" The study of possible pharmacokinetic and bacteriological interactions was performed in healthy volunteers who received in a crossover protocol each of the two antibiotics, either alone or combined with acetylsalicylic acid or lysine acetylsalicylate."	( Pharmacokinetic and bacteriological study of cefadroxil-salicylate and josamycin-salicylate drug regimens. Bernard, E; Dellamonica, P; Etesse-Carsenti, H; Garraffo, R; Mondain, V, 1993)	0.29
" Blood samples for pharmacokinetic determinations of ASA and its metabolite, salicylic acid (SA) and platelet aggregation studies were obtained at scheduled timepoints before and up to 24 hours after each dose."	( Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. Benedek, IH; Joshi, AS; King, SY; Kornhauser, DM; Pieniaszek, HJ, 1995)	0.53
" Ibuprofen administration resulted in a slight increase in mean glyburide free fraction, but no significant changes in glyburide pharmacokinetic parameters were observed."	( Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Antal, EJ; Juhl, RP; Kubacka, RT; Welshman, IR, 1996)	0.68
" Pharmacokinetic characteristics (AUC, Cmax, tmax, t1/2, MRT) were taken or calculated on the basis of plasma concentration/time profiles."	( Lack of influence of glycine on the single dose pharmacokinetics of acetylsalicylic acid in man. Bias-Imhoff, U; Riechers, AM; Schulz, HU; Schurer, M; Schwantes, U, 1996)	0.29
" The pharmacokinetic parameters were determined using the experimental data in the literature."	( Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice daily. Nia, B; Vergnaud, JM, )	0.13
" The plasma level-time curves were fitted according to one compartment open pharmacokinetic model."	( [The effect of exercise on the pharmacokinetics of acetaminophen and acetylsalicylic acid]. Sawrymowicz, M, 1997)	0.3
" The study illustrates the need for pharmacokinetic data to establish the individual doses of drugs, particularly in conditions that alter nutritional status."	( Influence of nutritional status on the pharmacokinetics of acetylsalicylic acid and its metabolites in children with autoimmune disease. Carbajal-Rodríguez, L; Flores-Pérez, J; Juárez-Olguín, H; Lares-Asseff, I; Loredo-Abdalá, A; Ramírez-Lacayo, M, 1999)	0.3
" The safety profiles of various GP IIb-IIIa inhibitors are largely a function of their pharmacokinetic and pharmacodynamic properties, most notably the reversibility of platelet inhibition and the rate of plasma clearance."	( Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Kleiman, NS, 1999)	0.3
"The addition of ticlopidine/aspirin to sibrafiban did not significantly alter the pharmacokinetic parameters of Ro 44-3888."	( Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Birnböck, H; Chung, J; Ensor, H; Ertel, SI; Lausecker, B; Machin, SJ; MacKie, IJ; Wittke, B, 2000)	0.82
"This study shows a significant pharmacodynamic interaction between sibrafiban and ticlopidine/aspirin."	( Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Birnböck, H; Chung, J; Ensor, H; Ertel, SI; Lausecker, B; Machin, SJ; MacKie, IJ; Wittke, B, 2000)	0.74
" No pharmacodynamic interaction was seen with coadministration of heparin."	( Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. Modi, NB; Novotny, W; Reimann, JD, 2000)	0.51
" Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20."	( The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. Balmer, TV; Boyle, J; MacHon, R; Parton, K; Whittem, T, 2000)	0.31
" An open, randomised, crossover study design was used to compare the pharmacokinetic parameters of soluble aspirin and solid paracetamol tablets in 16 healthy, male volunteers from the University of the Witwatersrand, South Africa, in both fed and fasted states."	( Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Chetty, M; Clinton, C; Havlik, I; Little, S; Moodley, I; Muir, N; Schall, R; Stillings, M, 2000)	0.77
" Pharmacokinetic evaluation was performed after a single intravenous bolus administration of DCLHb (400 mg kg(-1))."	( Pharmacokinetics of diaspirin cross-linked haemoglobin in a rat model of hepatic cirrhosis. Gulati, A; Kastrissios, H; Palaparthy, R, 2001)	0.63
"The relationship between anthropometric data and pharmacokinetic characteristics of acetylsalicylic acid (ASA) after administration of a single oral dose of 500 mg ASA, an oral and intravenous dose of 500 mg D,L-lysine-mono-acetylsalicylate (Lys-ASA) and an oral dose of 1,000 mg Lys-ASA were evaluated."	( Anthropometric data and acetylsalicylic acid pharmacokinetics. Koch, HJ; Raschka, C, 2002)	0.31
" Pharmacokinetic parameters were calculated based on a one-compartment model."	( [Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. Koch, HJ; Raschka, C, )	0.13
" The plasma and urine results demonstrated no pharmacokinetic interaction between oseltamivir and aspirin."	( Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin. Barrett, J; Dorr, A; Liu, B; Oo, C; Ward, P, 2002)	0.75
" Significant predictors of pharmacokinetic response included infusion dose and weight."	( First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Armstrong, PW; Becker, RC; Bovill, EG; Dyke, CK; Dzavik, V; Gardner, LH; Gerstenblith, G; Harrington, RA; Hasselblad, V; Hochman, JS; Kleiman, NS; Kunitada, S; Lincoff, AM; Robertson, TL; Shimoto, Y; Zillman, LA, 2002)	0.31
"The pharmacokinetic and pharmacodynamic profiles after enoxaparin administration are consistent across a broad range of patients with ACS."	( Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002)	0.31
" The aim of this open, randomized, three-factorial (three-treatment, three-period, six-sequence) Latin Square clinical study was to investigate if there were any pharmacokinetic interactions between ASA and PSE when given as fixed combination of 500 mg ASA/30 mg PSE."	( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers. Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003)	0.32
" The supplementary evaluation for the non-normalized original parameters AUC and Cmax also revealed bioequivalence."	( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers. Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003)	0.32
"This study compared some pharmacokinetic parameters of DL-lysine-acetyl salicylate administered intravenously (i."	( Comparative pharmacokinetics of salicylate in camels, sheep and goats. Ali, BH, )	0.13
" Pharmacokinetic analysis of this new product showed it to have a more consistent and reproducible absorption compared with immediate-release dipyridamole."	( Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Lenz, T; Wilson, A, 2003)	0.32
"To investigate the pharmacodynamic interaction of unfractionated heparin (UFH) and acetylic salicylic acid (ASA) on YM337, a monoclonal humanized antibody of the platelet GPIIb/IIIa receptor."	( Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans. Breddin, HK; Graff, J; Harder, S; Kirchmaier, CM; Klinkhardt, U; Westrup, D, 2003)	0.52
" The usual pharmacokinetic parameters were then derived."	( Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Cerletti, C; de Gaetano, G; Dell'Elba, G; Di Castelnuovo, A; Feliziani, V; Manarini, S; Pecce, R; Scorpiglione, N, 2003)	0.55
"The maximum plasma concentration, half-life time, area under the curve and the amount of salicylates excreted were statistically different between the JRA and the RF groups, as well as between the RF group and the controls, however, there were no significant differences between the JRA group and the controls."	( Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseases. Carbajal Rodríguez, L; Flores Pérez, J; Juárez Olguín, H; Lares Asseff, I; Loredo Abdalá, A, 2004)	0.32
" However, due to ample variability of pharmacokinetic parameters it is recommended that dose schemes are individualized on the type of autoimmune disease considered."	( Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseases. Carbajal Rodríguez, L; Flores Pérez, J; Juárez Olguín, H; Lares Asseff, I; Loredo Abdalá, A, 2004)	0.32
"The objective of this study was to determine pharmacokinetic differences of acetyl salicylic acid (ASA) and its metabolites: gentisic acid (GA), salicylic acid (SA) and salicyluric acid (SUA) between Otomies and Mesticians healthy subjects."	( Pharmacokinetics and metabolic rates of acetyl salicylic acid and its metabolites in an Otomi ethnic group of Mexico. Flores-Pérez, J; Guillé-Pérez, A; Juárez-Olguín, H; Lares-Asseff, I; Vargas, A, 2004)	0.32
" The lesser long-term pharmacodynamic potency of aspirin relative to clopidogrel raises the prospect of the need for more effective antiplatelet agents or a synergistic combination therapy for stroke prevention in the future."	( Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Chang, HW; Chang, YY; Chen, MC; Chen, SS; Chen, WH; Kao, YF; Lai, SL; Lan, MY; Liu, JS; Yip, HK, 2004)	0.58
"In pharmacodynamic studies with antiplatelet agents, platelets are usually activated in vitro with single agonists (e."	( Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators. Graff, J; Harder, S; Klinkhardt, U, 2004)	0.32
"Because a variety of different agonists influence platelet activation and its distinct functions at a time, investigations which regard the concert of these agonists might be closer to the in vivo situation and better reflect the pharmacodynamic profile of an antiplatelet agent than using one single inducing agent."	( Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators. Graff, J; Harder, S; Klinkhardt, U, 2004)	0.32
"Terbogrel is a potent agent having two distinct, complimentary pharmacodynamic actions, namely inhibition of thromboxane synthase and antagonism of the TxA2 receptor."	( Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. Guth, BD; Narjes, H; Nehmiz, G; Riedel, A; Schubert, HD; Tanswell, P, 2004)	0.32
"We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen."	( Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Capone, ML; Di Gregorio, P; Grana, M; Merciaro, G; Patrignani, P; Renda, G; Ricciotti, E; Sciulli, MG; Tacconelli, S, 2005)	0.8
" The pharmacodynamic interaction between the two drugs was then investigated in four healthy volunteers who received aspirin (100 mg daily) for 6 days and then the combination of aspirin and naproxen for further 6 days: aspirin 2 h before naproxen (500 mg, twice-daily dosing)."	( Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Capone, ML; Di Gregorio, P; Grana, M; Merciaro, G; Patrignani, P; Renda, G; Ricciotti, E; Sciulli, MG; Tacconelli, S, 2005)	0.79
" Moreover, the rapid recovery of platelet COX-1 activity and function supports the occurrence of a pharmacodynamic interaction between naproxen and aspirin."	( Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Capone, ML; Di Gregorio, P; Grana, M; Merciaro, G; Patrignani, P; Renda, G; Ricciotti, E; Sciulli, MG; Tacconelli, S, 2005)	0.78
" This pharmacodynamic interaction might undermine the sustained inhibition of platelet COX-1 that is necessary for aspirin's cardioprotective effects."	( Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Capone, ML; Di Gregorio, P; Grana, M; Merciaro, G; Patrignani, P; Renda, G; Ricciotti, E; Sciulli, MG; Tacconelli, S, 2005)	0.79
" Observations collected in two population pharmacokinetic studies, in preterm neonates, investigating amikacin and vancomycin were used to estimate: i) the impact of ibuprofen administration on the clearance of these drugs; and ii) the difference between prophylactic and therapeutic administration of ibuprofen on this clearance."	( Impact of ibuprofen administration on renal drug clearance in the first weeks of life. Allegaert, K; Anderson, BJ; Rayyan, M, 2006)	0.33
" Pharmacokinetic parameters for these groups were calculated and compared with one another."	( Interaction study of aspirin or clopidogrel on pharmacokinetics of donepezil hydrochloride in rats by HPLC-fluorescence detection. Aboul-Enein, HY; Nakashima, K; Nishiwaki, J; Ohwaki, Y; Wada, M; Yamane, T, 2007)	0.66
"We report microwave-assisted synthetic routes, the pharmacokinetic profile along with results from ulcerogenicity and mutagenicity studies of atenolol aspirinate, and an already described derivative, in which acetyl salicylic acid (aspirin) was connected to atenolol by an ester linkage."	( Pharmacokinetic profile of atenolol aspirinate. Alves, DP; Caliendo, G; de Nucci, G; Donato, JL; Fiorino, F; Lavecchia, A; Lilla, S; Mendes, GD; Montes-Gil, AC; Okuyama, CE; Perissutti, E; Priviero, FB; Santagada, V; Severino, B; Zanfolin, M, 2007)	0.81
"The objective of this study was to develop a mechanism-based pharmacodynamic model that characterizes the antiplatelet effects of aspirin (acetylsalicylic acid) and ibuprofen alone and in combination."	( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008)	0.82
" The final pharmacodynamic model was based on the turnover of cyclo-oxygenase-1 (COX-1) enzyme, and incorporated irreversible inhibition by aspirin and reversible binding and antiplatelet effects of ibuprofen."	( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008)	0.82
"A mechanism-based pharmacodynamic model has been developed that characterizes the antiplatelet effects of aspirin and ibuprofen, alone and concomitantly, and predicts a significant inhibition of aspirin antiplatelet effects in the presence of a typical ibuprofen dosing regimen."	( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008)	0.83
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"This study was aimed at determination of pharmacokinetic parameters of copper (II) acetylsalicylate (CAS)."	( Pharmacokinetic study of copper (II) acetylsalicylate. Iqbal, MS; Pervez, H; Saeed, M; Sher, M, 2008)	0.35
" There is, however, limited information on its pharmacokinetic and pharmacodynamic effects in vivo."	( Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats. Choi, CI; Gao, L; Joseph, S; Kopelovich, L; Patlolla, JM; Rao, CV; Rigas, B; Steele, VE, 2008)	0.59
" Therefore, more easily accessible plasma salicylate and thromboxane B(2) concentrations were representative of the salicylate exposure and prostaglandin E(2) pharmacodynamic biomarker in the target colon, respectively."	( Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. Bauer, KS; Kapetanovic, IM; Lindeblad, MO; Lubet, R; Lyubimov, A; Tessier, DM; Zakharov, AD, 2009)	0.59
" We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel."	( Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ, 2009)	0.56
" For prasugrel, there was no statistically significant difference in active metabolite exposure or pharmacodynamic response between CYP2C19 EM and RM."	( Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ, 2009)	0.56
" The method was successfully applied to study the pharmacokinetic of PVP-I in rabbits after vaginal administration."	( Optimization and validation of an ion-pair RP-HPLC-UV method for the determination of total free iodine in rabbit plasma: application to a pharmacokinetic study. Cui, L; Fan, G; Wang, S; Wen, J; Zhou, T, 2009)	0.35
"A comparative analysis of the concentrations of acetylsalicylic acid (ASA) and its metabolite, salicylic acid (SA), in the blood was performed and the other pharmacokinetic parameters were studied after conventional intragastric and transdermal administration in rabbits."	( [Experimental study of the pharmacokinetics of acetylsalicylic acid upon transdermal administration]. Basok, IuB; Polukhina, OS; Salomatina, LA; Sevast'ianov, VI, )	0.13
" The primary pharmacokinetic end points were steady-state area under the concentration-time curve (AUCtau) and observed maximum plasma concentration (Cmax) of ASA +/- esomeprazole."	( Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. Andersson, T; Naesdal, J; Nauclér, E; Niazi, M; Sundin, M, 2009)	0.35
"There was no pharmacokinetic interaction between esomeprazole (40 mg) and ASA (325 mg) during repeated co-administration in healthy volunteers."	( Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. Andersson, T; Naesdal, J; Nauclér, E; Niazi, M; Sundin, M, 2009)	0.35
"No clinically relevant changes were noted in the serum concentrations of tapentadol, and accordingly, no dosage adjustments with respect to the investigated pharmacokinetic mechanism of interaction are warranted for the administration of tapentadol given concomitantly with acetaminophen, naproxen, or acetylsalicylic acid."	( Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Mangold, B; Oh, C; Ravenstijn, PG; Rengelshausen, J; Smit, JW; Terlinden, R; Upmalis, D; Wang, SS, 2010)	0.36
"This report is the first to demonstrate the superior pharmacodynamic effect of ticagrelor compared with clopidogrel irrespective of CYP2C19 genotype."	( First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C, 2010)	0.36
" The plasma concentrations of its metabolites, aspirin (ASA), salicylic acid (SA) and gentisic acid (GA) were determined by LC-MS/MS method and the pharmacokinetic parameters were calculated by noncompartmental analysis."	( Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. Chen, DM; Huang, LL; Ihsan, A; Wang, X; Yuan, ZH, 2011)	0.63
" The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM."	( A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011)	0.37
"Patients with type 2 diabetes mellitus (T2DM) have reduced aspirin-induced pharmacodynamic effects."	( Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	0.89
" Pharmacodynamic assessments included light-transmittance aggregometry after arachidonic acid, collagen and adenosine diphosphate stimuli; VerifyNow-Aspirin assay; and serum thromboxane B(2) (TXB(2)) levels."	( Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	0.84
"Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels."	( Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	2.08
" In this contribution, we describe how a novel method can be used for coformer selection to enable the efficient and effective development of a pharmaceutical cocrystal with desired physicochemical and pharmacokinetic properties."	( Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. Cheney, ML; Hanna, M; Shan, N; Weyna, DR; Wojtas, L; Zaworotko, MJ, 2011)	0.59
" This article provides an overview on antiplatelet drug response variability, an update on definitions, including the role of pharmacodynamic testing, underlying mechanisms - with emphasis on recent understandings on pharmacogenetics and drug-drug interactions - and current and future perspectives on individualized antiplatelet therapy."	( Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Angiolillo, DJ; Tello-Montoliu, A; Ueno, M, 2011)	0.37
" The pharmacokinetic and pharmacodynamic effects of clopidogrel have been significantly influenced by the enzyme activity of the ABCB1 C3435T and the CYP2C19 system."	( Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy Accordin Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Yoon, SE, 2012)	0.38
"We simulated ex vivo platelet aggregation using a previously developed pharmacokinetic (PK)/pharmacodynamic (PD) model."	( Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. Awa, K; Hori, S; Satoh, H; Sawada, Y, 2012)	0.64
" However, if cilostazol exerts different pharmacodynamic (PD) effects according to levels of on-treatment platelet reactivity remains unknown."	( Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013)	0.39
" If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"A dose-response effect was observed for all pharmacodynamic parameters tested."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."	( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach. Kumar, M; Sinha, VR; Thareja, S, 2012)	0.38
"The absence of a pharmacokinetic interaction between the proton pump inhibitor esomeprazole (40 mg) and acetylsalicylic acid (aspirin, ASA; 325 mg) has previously been established."	( Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Andersson, T; Morrison, D; Nagy, P; Pisupati, J; Schettler, J; Warner, TD, 2012)	0.59
"This study set out to investigate the potential for pharmacodynamic interaction between low-dose ASA and esomeprazole in healthy volunteers, by measuring ASA antiplatelet activity."	( Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Andersson, T; Morrison, D; Nagy, P; Pisupati, J; Schettler, J; Warner, TD, 2012)	0.38
"A total of 29 volunteers (19 aged ≥50 years; 8 women; 21 men) were evaluable for pharmacodynamic analysis (per protocol)."	( Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Andersson, T; Morrison, D; Nagy, P; Pisupati, J; Schettler, J; Warner, TD, 2012)	0.38
"No pharmacodynamic interaction between low-dose ASA and esomeprazole was found with regard to platelet function."	( Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Andersson, T; Morrison, D; Nagy, P; Pisupati, J; Schettler, J; Warner, TD, 2012)	0.38
" The validated method was successfully applied to a pharmacokinetic study following co-administration of carisoprodol (250 mg) and aspirin (75 mg) tablets by oral route to human volunteers."	( Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography-tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. Babu, RV; Krishnaiah, A; Kumar, IJ; Pilli, NR; Ramesh, M; Sreenivasulu, V, 2013)	0.85
"This review explores the results of clinical studies on the influence of the combination esomeprazole (ESA) and ASA on pharmacokinetic (PK) parameters, and the role for such combination in prevention of CV events in patients at risk of gastric ulcers."	( Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. Bardou, M; Barkun, AN; Goirand, F; Hamza, S; Le Ray, I, 2012)	0.38
"Our animal study indicated that co-administration of DG with warfarin/aspirin can cause significant pharmacokinetic and pharmacodynamic herb-drug interactions in rat."	( Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin. Fung, KP; Lau, BS; Leung, PC; Wang, S; Zhang, Z; Zhou, L; Zuo, Z, 2012)	0.83
" The developed assay method was applied to an oral pharmacokinetic study in humans."	( Low dose aspirin estimation: an application to a human pharmacokinetic study. Hotha, KK; Kolagatla, PR; Venkateswarlu, V; Vijaya Bharathi, D, 2013)	0.81
" At steady-state ticagrelor (50 mg bid, or 200 mg bid), concomitant aspirin (300 mg qd) had no effect on mean maximum plasma concentration (Cmax), median time to Cmax (tmax), or mean area under the plasma concentration-time curve for the dosing interval (AUC0-τ) for ticagrelor and its primary metabolite, AR-C124910XX."	( Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Butler, K; Maya, J; Teng, R, 2013)	0.85
"This study aimed to determine whether the PPI omeprazole influences the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of ASA+ER-DP."	( Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole. Brickl, R; Ehrlich, J; Eisert, W; Offman, E; Schobelock, MJ; VanderMaelen, CP, 2013)	0.62
" Three studies were conducted to evaluate the pharmacokinetic and pharmacodynamic interactions of edoxaban 60 mg coadministered with low-dose (100 mg) ASA, high-dose (325 mg) ASA, or naproxen (500 mg) in healthy subjects (n = 126)."	( The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. Chen, S; Lee, F; Mendell, J; Samama, MM; Shi, M; Worland, V, 2013)	0.66
"This article is an overview of currently used antithrombotic therapies in the management of ischaemic stroke with special focus on their pharmacokinetic properties and how these properties may influence their clinical utility."	( Pharmacokinetic considerations for antithrombotic therapies in stroke. Apostolakis, S; Lip, GY; Shantsila, E, 2013)	0.39
"This study was designed to compare the pharmacokinetic properties and safety profile of a fixed-dose combination formulation of ASA and clopidogrel with concurrent administration of each agent in healthy male Korean volunteers."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
" Plasma drug concentrations were determined using high-performance liquid chromatography with ultraviolet detection and pharmacokinetic variables were calculated using a non-compartmental model."	( Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. Jaworski, K; Niewiński, P; Okoniewski, P; Poźniak, B; Świtała, M, 2013)	0.39
" However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation."	( Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014)	0.62
"The purpose of this study was to evaluate the tolerability and pharmacokinetic (PK) profile of DR-DMF with or without concomitant acetylsalicylic acid (aspirin), a cyclooxygenase inhibitor."	( Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Dawson, KT; Huang, R; Milne, GL; Nestorov, I; Novas, M; O'Gorman, J; Russell, H; Scannevin, RH; Sheikh, SI, 2013)	0.8
" To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted."	( Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers. Chen, H; Chen, K; He, XM; Jia, MM; Li, J; Li, SF; Li, WY; Liu, MZ; Wang, YH; Wu, SL; Zhou, Y, 2013)	0.39
"Increased body weight is independently associated with impaired clopidogrel pharmacodynamic (PD) response."	( Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014)	0.4
" This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI."	( Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014)	0.86
" We verified if the pharmacodynamic effects of CYP3A4-metabolized statins (atorvastatin) and non-CYP3A4-metabolized statins (pitavastatin) differ in patients with coronary artery disease (CAD) treated with DAPT."	( Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014)	0.4
"Smokers have a greater relative benefit of clopidogrel therapy compared with nonsmokers, likely attributed to its enhanced pharmacodynamic (PD) effects."	( Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; Darlington, A; Degroat, C; Desai, B; Ferrante, E; Ferreiro, J; Franchi, F; Guzman, LA; Muniz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2014)	0.66
" It was the study's objective to assess the pharmacodynamic effects of vorapaxar versus placebo that included aspirin or a thienopyridine or, frequently, a combination of both agents in NSTE-ACS patients."	( Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Becker, RC; Chen, E; Cornel, JH; Dery, JP; Harrington, RA; Hord, E; Huber, K; Jennings, LK; Judge, HM; Kotha, J; Mahaffey, KW; Moccetti, T; Moliterno, DJ; Rorick, TL; Smyth, SS; Storey, RF; Strony, J; Thomas, GS; Tricoci, P; Valgimigli, M, 2014)	0.61
" Pharmacokinetic effects were estimated by measuring active metabolite of clopidogrel, and pharmacodynamic effects by inhibition of adenosine diphosphate (ADP)-induced platelet aggregation."	( Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Andersson, T; Galbraith, H; Nagy, P; Niazi, M; Nylander, S; Ranjan, S; Wallentin, L, 2014)	0.4
" Colesevelam (3750mg once daily) was dosed throughout the pharmacokinetic sampling period."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.63
"For all six test drugs, 90% CIs for geometric least-squares mean ratios of AUC and Cmax for the measured analytes were within specified limits, indicating no interaction between the test drug and colesevelam."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.63
" Although the phenytoin study indicated no pharmacokinetic interaction, phenytoin should continue to be taken ≥4h before colesevelam in accordance with current prescribing information."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.63
" However, the many formulations available are characterized by differences in the pharmacokinetic profile that could affect therapy effectiveness."	( Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. D'Alonzo, L; Lecchi, M; Martelletti, P; Negro, A, 2014)	0.68
" The method was applicable for the quality control of the mentioned drugs in raw material, bulk drug and pharmaceutical formulations as well as in pharmacokinetic studies."	( Liquid Chromatographic Method for Simultaneous Quantitation of Clopidogrel, Aspirin and Atorvastatin in Rat Plasma and Its Application to the Pharmacokinetic Study. Akhalaque Ahmad, RA; Chatpalliwar, VA; Chhajed, SS; Porwal, PK, 2015)	0.65
" Vortioxetine had no effect on the steady-state pharmacokinetic parameters of aspirin or its metabolite salicylic acid, and no statistically significant effect on the inhibition of arachidonic acid-, adenosine-5'-diphosphate-, or collagen-induced platelet aggregation at any time points."	( Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. Chen, G; Serenko, M; Zhang, W, 2015)	0.86
" This review sought evidence from single dose pharmacokinetic studies on the extent and timing of peak plasma concentrations of analgesic drugs in the fed and fasting states."	( Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. Derry, S; Moore, RA; Straube, S; Wiffen, PJ, 2015)	0.65
" Food typically delayed absorption for all drugs where the fasting tmax was less than 4 h."	( Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. Derry, S; Moore, RA; Straube, S; Wiffen, PJ, 2015)	0.65
" We describe the unique pharmacokinetic and pharmacodynamic properties of this drug and the extensive data obtained by preclinical and Phase II and III clinical studies."	( Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R, 2015)	0.42
"Both formulations produced dose-dependent inhibition on all pharmacodynamic parameters."	( A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Armas, D; Dillaha, L; Patrick, J; Sessa, WC, 2015)	0.63
" The aim of this study was to investigate the pharmacokinetic and pharmacodynamic interactions between warfarin and aspirin in beagles after single and multiple doses."	( Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs. Hu, T; Huang, J; Huang, X; Li, J; Li, L; Pappoe, F; Shen, C; Tang, H; Zhang, P; Zhang, W, 2016)	0.89
"For SA, Tmax significantly decreased after RYGB, while both Cmax and AUC0-24 significantly increased."	( The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study. Mitrov-Winkelmolen, L; Overdiek, HWPM; Swank, DJ; Touw, DJ; van Buul-Gast, MW; van Schaik, RHN, 2016)	0.43
"This study sought to assess the pharmacodynamic (PD) effects of switching to ticagrelor patients who were treated with prasugrel after undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome."	( Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. Aggarwal, N; Angiolillo, DJ; Antoun, P; Bass, TA; Been, L; Cho, JR; Durairaj, A; Faz, GT; Franchi, F; Guzman, LA; Hu, J; Kureti, M; Park, Y; Rollini, F; Suryadevara, S; Thano, E; Zenni, MM, 2016)	0.43
"The aim of the study was to assess ticagrelor's effects on inhibition of platelet aggregation (IPA), P2Y12 reaction units (PRU, measure of platelet P2Y12 receptor blockade), pharmacokinetic (PK) parameters and safety in Chinese patients with stable coronary artery disease (CAD)."	( Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Carlson, GF; Guo, J; Li, H; Teng, R, 2016)	0.43
" 90 mg twice daily) in ticagrelor Cmax (616 [37] vs."	( Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Carlson, GF; Guo, J; Li, H; Teng, R, 2016)	0.43
" However, the mean pharmacodynamic differences between 45 and 60 mg doses were small."	( Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Carlson, GF; Guo, J; Li, H; Teng, R, 2016)	0.43
"In this review, we discuss the unique pharmacodynamic properties of several antiplatelet drugs with their possible potential molecular of mechanisms on inhibiting platelet aggregation."	( The pharmacodynamics of antiplatelet compounds in thrombosis treatment. Geraldine, P; Jayakumar, T; Sheu, JR; Yang, CH; Yen, TL, 2016)	0.43
"OM3-CA did not affect the pharmacokinetics or pharmacodynamics of warfarin or the pharmacodynamic effects of ASA."	( No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. Davidson, M; Nilsson, C; Offman, E, 2017)	0.46
" A ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed for the simultaneous determination of ginsenoside Rg1 (Rg1), ginsenoside Rd (Rd), notoginsenoside R1 (R1) and salicylic acid (SA) in rat plasma to investigate the pharmacokinetic interaction of XST and ASA in blood stasis model rats."	( Pharmacokinetic herb-drug interaction of Xuesaitong dispersible tablet and aspirin after oral administration in blood stasis model rats. Bai, X; Bai, Y; Dai, G; Jiang, Z; Ju, W; Pan, R; Zhang, Q; Zhu, L, 2017)	0.69
" This study indicates that co-administration of XST and ASA can cause an apparent herb-drug pharmacokinetic interaction in blood stasis model rats."	( Pharmacokinetic herb-drug interaction of Xuesaitong dispersible tablet and aspirin after oral administration in blood stasis model rats. Bai, X; Bai, Y; Dai, G; Jiang, Z; Ju, W; Pan, R; Zhang, Q; Zhu, L, 2017)	0.69
" This is coherent with the emergence of an uninhibited subpopulation of reticulated platelets during treatment with aspirin plus thienopyridine, explained by the short pharmacokinetic half-lives of these drugs."	( Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Armstrong, PC; Chan, MV; Ferreira, PM; Hayman, MA; Hoefer, T; Knowles, RB; Tucker, AT; Warner, TD, 2017)	0.66
" There is little data describing parachuting in terms of substances use, context of use and, most importantly, the motivations for using such wrappers, although some authors hypothesized that parachute could be used for pharmacokinetic reason."	( Parachuting psychoactive substances: Pharmacokinetic clues for harm reduction. Baumevieille, M; Daveluy, A; Géniaux, H; Guéroult, P; Haramburu, F; Lazès-Charmetant, A; Létinier, L; Matta, MN, 2018)	0.48
"This in-vitro study provides the first pharmacokinetic data for drugs wrapped in parachutes."	( Parachuting psychoactive substances: Pharmacokinetic clues for harm reduction. Baumevieille, M; Daveluy, A; Géniaux, H; Guéroult, P; Haramburu, F; Lazès-Charmetant, A; Létinier, L; Matta, MN, 2018)	0.48
" Pharmacokinetic values of area under the curve from time point 0 to 24 hours point of maximum concentration, time of maximum concentration, volume of distribution, clearance, and elimination half-life were analyzed for statistical significance with SPSS v25 software."	( A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. Chau, K; Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Münch, G; Shanmugalingam, R; Wang, X; Xu, B, 2019)	0.74
" Further pharmacodynamic and clinical studies are required to examine the clinical relevance of these pharmacokinetic findings."	( A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. Chau, K; Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Münch, G; Shanmugalingam, R; Wang, X; Xu, B, 2019)	0.74
" Here we describe the results of 3 studies that evaluated the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects."	( Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)	0.98
" More importantly, these changes in the intestinal microbiota led to increasing absorption of aspirin in the rats after rapidly ascent to the plateau, and a reduction in the pharmacodynamic index TXB2, which would possibly result in bleeding."	( Effects of intestinal flora on the pharmacokinetics and pharmacodynamics of aspirin in high-altitude hypoxia. Feng, Q; Li, W; Sun, Y; Wang, R; Zhang, J; Zhao, A, 2020)	1.01
" Therefore, the goal of this paper was to create a physiologically based pharmacokinetic (PBPK) model to offer a reasonable starting point for required total AT-RvD1 dosage to be administered in future mice and humans thereby eliminating the need for excessive use of animals and humans in preclinical and clinical trials, respectively."	( Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome. Baker, OJ; Yellepeddi, VK, 2020)	0.87
" Specifically, short-term utility of these pharmacokinetic modeling findings involves improved targeting of in vivo studies as well as longer term prospects for drug development and/or better designs for clinical trials."	( Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome. Baker, OJ; Yellepeddi, VK, 2020)	0.87
" This study was performed to determine whether the lipid excipients influence the pharmacodynamic effects of aspirin and whether the excipients directly affect platelet function."	( Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin. Deliargyris, EN; Prats, J; Schneider, DJ; Taatjes-Sommer, HS, 2021)	1.06
"This study aimed to investigate the pharmacodynamic effects of indobufen and low-dose aspirin in patients with coronary atherosclerosis."	( Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. Abdus, S; Bai, J; Eikelboom, JW; Gong, X; Gu, Q; Li, C; Lu, Y; Mei, L; Shi, L; Tan, C; Ullah, I; Wang, G; Yang, M; Ye, Z, 2021)	1.1
"This investigation was a substudy analysis conducted in selected cohorts of patients with stable atherosclerotic disease enrolled from a larger prospective, open-label, parallel-group pharmacodynamic (PD) study."	( Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. Angiolillo, DJ; Bass, TA; Been, L; Franchi, F; Galli, M; Geisler, T; Jaoude, PA; Jennings, LK; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X, 2022)	0.95
" We also discuss the available pharmacodynamic (PD) evidence and clinical implications with the use of DPI in patients with atherosclerotic disease."	( Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications. Angiolillo, DJ; D'Amario, D; De Caterina, R; Franchi, F; Galli, M; Gibson, CM; Mehran, R; Ortega-Paz, L; Rollini, F, 2023)	0.91

Compound-Compound Interactions

Meta-analyses revealed that aspirin in combination with FDD was significantly more effective at alleviating angina pectoris and improving electrocardiogram (ECG) results.

Excerpt	Reference	Relevance
") combined with aspirin."	( Comparision of low dose heparin and low dose heparin combined with aspirin in prevention of deep vein thrombosis after total hip replacement. Blery, M; Flicoteaux, H; Honnart, F; Jean, N; Judet, T; Kher, A; Pasteyer, J, 1977)	0.84
" The effect of combination with aspirin on the metabolic fate of chlormezanone was investigated in rats and mice."	( Biotransformation of chlormezanone, 2-(4-chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide, a muscle-relaxing and tranquillizing agent: the effect of combination with aspirin on its metabolic fate in rats and mice. Hakusui, H; Sano, M; Tachizawa, H, 1978)	0.74
"14C-Isoniazid (20 mg/kg po or iv) was administered alone or in combination with aspirin (100 mg/kg po), rifampin (30 mg/kg po), ethambutol (100 mg/kg po), or ethanol (3 g/kg po) to rats."	( Drug interactions with isoniazid metabolism in rats. Solomonraj, G; Thomas, BH, 1977)	0.48
"The efficacy and safety of thrombolysis with different dose regimens of recombinant tissue plasminogen activator (rt-PA) and its combination with aspirin was tested in an embolic stroke model."	( Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Boysen, G; Overgaard, K; Pedersen, H; Sereghy, T, 1992)	0.74
" Preclinical research provides additional evidence that viruses and chemicals may interact and produce illnesses in animals."	( Adverse virus-drug interactions. Amsel, Z; Drotman, DP; Haverkos, HW, )	0.13
" It cannot, however, be concluded from this study that 75 mg dipyridamole in combination with 100 mg ASA tid is more effective in preventing reocclusion after PTA than in combination with 330 mg ASA tid."	( Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Deichsel, G; Heiss, HW; Just, H; Middleton, D, 1990)	0.28
" It is concluded that aspirin concurrently administered with ranitidine is safe and does not delay the healing of uncomplicated duodenal ulcers."	( Aspirin concurrently administered with ranitidine does not delay healing of duodenal ulcer. Anand, BS; Kumar, N; Misra, SP, 1990)	2.04
"The effects of cryptolepine alone and in combination with other antiplatelet agents have been investigated using a mouse model of arterial thrombosis."	( Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis. Okafor, JP; Oyekan, AO, 1989)	0.28
"The effect of 7-mono-hydroxyethylrutoside and its combination with acetylsalicylic acid was evaluated in a controlled clinical trial, performed in 105 patients with obliterative atherosclerosis of the lower limbs, and using non-invasive measurement of peripheral haemodynamic parameters--blood flow during reactive hyperaemia and ankle systolic blood pressure."	( The effect of hydroxyethylrutoside and its combination with acetylsalicylic acid in patients with obliterative atherosclerosis. Linhart, J; Oliva, I; Prerovský, I; Roztocil, K, 1989)	0.28
"Cardiovascular responses to the calcium antagonist nifedipine, alone and combined with low dose acetylsalicyclic acid (ASA), were evaluated in a piglet model of endotoxin-induced pulmonary hypertension."	( The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet. Huth, RG; Jüngst, BK; Schranz, D; Stopfkuchen, H, 1988)	0.27
" Subjects were initially given a single dose of aspirin alone or in combination with sucralfate for 2 days."	( Evaluation of a potential drug interaction between sucralfate and aspirin. Chang, CW; Lau, AH; Schlesinger, PK, 1986)	0.76
" These effects, combined with the common use of cimetidine in clinical practice, make the risk of adverse drug interactions a relatively frequent risk in the clinical setting."	( Drug interactions involving cimetidine--mechanisms, documentation, implications. Greene, W, 1984)	0.27
" These occurred only in the groups given MNNG in combination with stress, aspirin, or sodium taurocholate, and did not occur in experimental groups given either MNNG, stress, aspirin, or sodium taurocholate alone, and did not occur in the control group."	( Experimental models for gastric leiomyosarcoma. The effects of N-methyl-N'-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate. Cohen, A; Geller, SA; Horowitz, I; Toth, LS; Werther, JL, 1984)	0.7
" We investigated whether salicylate and aspirin interact in platelets in humans at doses and plasma levels of clinical relevance."	( Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function. Bonati, M; Cerletti, C; de Gaetano, G; Dejana, E; del Maschio, A; Galletti, F; Tognoni, G, 1984)	0.82
" All these drugs therefore appear to interact with the same site on platelet cyclo-oxygenase."	( Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclo-oxygenase. Evidence from "in vivo" drug interaction studies in rats. Cerletti, C; De Gaetano, G; Livio, M, 1982)	0.26
" Brief information on the following reports of drug-drug interactions is given in this article with the intention of giving these reports wider publicity and, possibly, encouraging further observation and research to establish or disprove their validity in a larger and wider range of patients or volunteer subjects."	( Early reports on drug interactions. D'Arcy, PF, 1983)	0.27
"Oxaprozin, a new nonsteroidal antiinflammatory agent, was studied alone and in combination with aspirin for its effects on hemostasis and protein binding in 10 healthy adults."	( Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding. Hubsher, JA; Kahn, SB, 1983)	0.74
" Dose response curves were performed to delineate a suppressive (high) and nonsuppressive (low) dose of each drug prior to studying these doses in combination with aspirin."	( Assessment of nonsteroidal anti-inflammatory drug combinations by the polyurethane sponge implantation model in the rat. Brooks, PM; Garrett, R; Manthey, B; Vernon-Roberts, B, 1983)	0.46
"3 mg/kg) of dipyridamole alone, or 75 mg of dipyridamole in combination with 30 mg (0."	( Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum. Viinikka, L; Ylikorkala, O, 1981)	0.26
"The effect of a saline cathartic combined with activated charcoal or activated charcoal alone on aspirin bioavailability was characterized in six healthy volunteers."	( Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. Anderson, WH; Czajka, PA; Mowry, JB; Sketris, IS; Stafford, DT, 1982)	0.78
" Since anti-platelet therapy with ASA is often combined with dipyridamol, the influence of this drug was also examined."	( Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and slow-release formulations, and in combination with dipyridamol. Brantmark, B; Melander, A; Wåhlin-Boll, E, 1982)	0.26
"The influence of phospholipids and their combination with prothrombin and calcium on coagulation both normal and affected by acetylsalicylic acid (ASA) was investigated by determination of the bleeding time of mice, thrombelastographic (TEG) measurements and counting of thrombocytes of rabbits."	( [Influence of phospholipids and their combination with prothrombin complex and calcium ions on coagulation in mice and rabbits both normal and affected by acetylsalicylic acid (author's transl)]. Ronneberger, H; Schwinn, H, 1980)	0.26
"Only drug-drug interactions that are believed clinically important and that are primarily pharmacokinetic in nature are discussed in this article."	( Therapeutic implications of drug interactions with acetaminophen and aspirin. Hayes, AH, 1981)	0.5
"We studied the effect of heparin combined with aspirin on the development and course of experimental alloxan-induced diabetes mellitus."	( [Effect of heparin combined with aspirin upon intragastric administration on the state of the insulin system in animals with alloxan diabetes]. Liapina, LA; Tarasov, IuA; Ul'ianov, AM, )	0.67
" It is concluded that NO-donors in principle are compounds suitable for the combination with antithrombotic drugs of different mechanism of action."	( New no-donors with antithrombotic and vasodilating activities, X: Antiplatelet and antithrombotic effects of 3-methylsydnone-5-nitrosimine (RE 2047) in combination with ASA, pentoxifylline, and ticlopidine. Ciborski, T; Rehse, K, 1995)	0.29
" In conclusion, treatment with dihydropyridines alone or in combination with low-dose aspirin can prevent circadian increases in platelet activity in patients with essential hypertension."	( Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension. Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Ulicna, L, 1994)	0.76
" Diltiazem and nicardipine also exhibited a similar potentiation of the anti-platelet effect in combination with aspirin or ticlopidine."	( Inhibitory effect of clentiazem (TA-3090) on platelet aggregation--alone and in combination with aspirin or ticlopidine. Karasawa, T; Katoh, M; Odawara, A; Sasaki, Y; Tamura, K, 1994)	0.72
" Moreover, a significant increase in red cell deformability was observed when blood was treated with dipyridamole alone or combined with aspirin (0."	( Reduced red cell deformability associated with blood flow and platelet activation: improved by dipyridamole alone or combined with aspirin. Bozzo, J; Hernández, MR; Ordinas, A, 1995)	0.7
"5 X SCa was administered with ASA plus heparin, time to occlusion was >180 minutes [T=0]."	( The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Feigen, LP; Frederick, LG; King, LW; Nicholson, NS; Salyers, AK; Suleymanov, OD, 1996)	0.51
" The present article reviews the literature on oral anticoagulants combined with aspirin in the prevention and treatment of arterial thromboembolism and draws a comparison to oral anticoagulation alone and aspirin alone, respectively."	( Oral anticoagulation alone or in combination with aspirin: risks and benefits. Bounameaux, H; de Moerloose, P; Hafner, J, 1996)	0.77
"The analgesic drug combination Thomapyrin consisting of acetylsalicylic acid (CAS 50-78-2, ASA), paracetamol (CAS 103-90-2, NAPAP) and caffeine (CAS 58-08-2) in the ratio 5:4:1 was investigated for its chronic toxicity in rats."	( Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. Bauer, E; Bauer, M; Greischel, A; Hirsch, U; Lehmann, H; Schmid, J; Schneider, P, 1996)	0.29
"It was shown that in the case of regular intragastric introduction of heparin combined with aspirin to rats with insulin-dependent experimental diabetes, enzymatic and nonenzymatic fibrinolysis of blood plasma was enhanced."	( [Changes in the functional status of the hemostatic system with the administration of heparin combined with aspirin to animals with experimental diabetes]. Liapina, LA; Pastorova, VE; Tarasov, IuA; Ul'ianov, AM, )	0.56
"The effect of acetylsalicylic acid in combination with quercetin on blood serum biochemiluminescence in the hypoxic syndrome was studied."	( [A biochemiluminescent analysis of the pharmacotherapeutic activity of acetylsalicylic acid in combination with quercetin in a hypoxic syndrome]. Luk'ianchuk, VD; Savchenkova, LV; Semenova, IA, )	0.13
"5 g/day) in combination with low-dose heparin."	( Intravenously administered acetylsalicylic acid in combination with low-dose heparin in acute ischemic stroke: a safety analysis. Büttner, T; Hellwig, K; Kuhn, W; Müller, T, )	0.13
"Previous experiments have shown that a variety of agents that interfere with the activity of the transcription factor NF-kB significantly enhanced the differentiation of HL-60 leukemia cells when combined with low levels of the monocytic/macrophagic differentiating agent vitamin D3."	( Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3. Sartorelli, AC; Sokoloski, JA, 1998)	0.3
" The pathogenesis of cilioretinal arterial obstruction combined with central retinal venous occlusion is not established."	( Central retinal vein occlusion combined with occlusion of a cilioretinal artery. A case report. Wrigstad, A, 1998)	0.3
" Twenty-six patients with coagulation abnormalities: protein S-deficiency, activated protein C (APC) resistance and/or > or =15 ACA GPL and/or MPL had a subsequent pregnancy and were treated with aspirin in combination with LMWH."	( Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998)	0.75
" Six hundred eighty-seven APA+ women, who were younger than 40 years and who each, completed up to three consecutive IVF/embryo transfer cycles within a 12-month period, were given either H/A alone or H/A in combination with IVIg."	( The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Ching, W; Chong, P; Feinman, M; Maassarani, G; Matzner, W; Sher, G; Zouves, C, 1998)	0.59
" In phase III, 121 women who did not achieve live births after two consecutive IVF attempts in which H/A alone was administered received IVIg in combination with H/A during their third consecutive IVF cycle."	( The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Ching, W; Chong, P; Feinman, M; Maassarani, G; Matzner, W; Sher, G; Zouves, C, 1998)	0.59
"In a prospective randomized trial in 42 patients undergoing coronary artery bypass surgery, we analyzed the long term platelet inhibiting effects of 50 mg acetylsalicylic acid (ASA) by itself and in combination with dipyridamole (2 x 200 mg), in comparison with phenprocoumon."	( [Long term effects of 50 mg acetylsalicylic acid alone and in combination with dipyridamole on platelet function after coronary bypass surgery]. Hoffmann, MW; Rauhöft, C; Terres, W, 1998)	0.3
" Opioids should not be combined with alcohol, and meperidine must be avoided in the patient who has taken monoamine oxidase inhibitors in the previous 14 days."	( Adverse drug interactions in dental practice: interactions associated with analgesics, Part III in a series. Haas, DA, 1999)	0.3
" We compared the safety and efficacy of two different antiplatelet drugs, aspirin (asa) and picotamide (pico)--a dual antithromboxane agent--in combination with low-intensity oral anticoagulation with warfarin or acenocoumarol in acute myocardial infarction (AMI)."	( Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial. Corsini, G; Milani, M; Vetrano, A, 1999)	0.92
" Since antiaggregation treatment with acetylsalicylic acid is a complex part of obligatory therapy of these patients, the authors studied the influence of ciprofibrate on chosen lipid parameters, fibrinogen and thromboxane in monotherapy, and also in combination with acetylsalicylic acid (ASA) in patients with advanced atherosclerosis and hyperlipoproteinemia."	( [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999)	0.3
" Concentrations of the active metabolite of sibrafiban, Ro 44-3888, in plasma and urine were determined by column-switching liquid chromatography combined with tandem mass spectrometry."	( Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Birnböck, H; Chung, J; Ensor, H; Ertel, SI; Lausecker, B; Machin, SJ; MacKie, IJ; Wittke, B, 2000)	0.52
" Another drug whose mechanism of action is unknown is caffeine, which is often used in combination with other analgesics, augmenting their effect."	( Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E(2) synthesis in rat microglial cells. Aicher, B; Engelhardt, G; Fiebich, BL; Hüll, M; Lieb, K; Pairet, M; van Ryn, J, 2000)	0.31
" To clarify this matter the study investigated the effects of aspirin alone and in combination with caffeine on mood and cardiovascular parameters before, during, and after pain induction through mechanical stimulation."	( [Experimental study of the effect of acetylsalicylic acid combined with caffeine regarding possible abuse potential]. Hüppe, A; Janke, W, 2001)	0.55
"to investigate the effect of clopidogrel combined with aspirin or aspirin alone on fibromyointimal hyperplasia (FIMH) in a bypass model with native vein grafts (NVG) and biocompound grafts (BCG)."	( Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. Gutersohn, A; Hetzer, R; Mülling, C; Musci, M; Sänger, S; Schaffner, T; Wellnhofer, E; Zurbrügg, HR, 2001)	0.8
" Four variants of the course treatment were used: 1) monotherapy with enalapril maleate (2 mg twice a day); 2) enalapril maleate (5 mg twice a day) in combination with NSAID; 3) monotherapy with lisinopril (10 mg once a day); 4) lisinopril (10 mg once a day in combination with NSAID."	( [Antihypertensive effect of enalapril and lisinopril administered in combination with nonsteroid anti-inflammatory agents]. Brodskaia, SA; Ivanov, SN; Savenkov, MP, 2001)	0.31
"1, 1, 5 and 10 mg/ml), phenylbutazone (1000 microgram/ml) and acetylsalicylic acid (25, 250, 2500 microgram/ml) alone, and combined with 10 mg/ml of ofloxacin on the respiratory burst."	( [Effect of anti-inflammatory drugs, alone and combined with ofloxacin, on the respiratory burst of human polymorphonuclear leukocytes]. Cabrera, E; Cantón, E; Martínez, P; Orero, A; Velert, MM, 2001)	0.31
" Oral anticoagulant therapy (OAT) reducing thrombin activity has the potential to be beneficial when administered alone or in combination with aspirin after ACS."	( [Oral anticoagulants combined with aspirin in the prolonged treatment after acute coronary syndrome]. Biancoli, S; Cerè, E; Di Pasquale, G; Parlangeli, R, 2002)	0.79
"Clopidogrel in combination with aspirin, given before percutaneous coronary intervention, has become the standard for stent thrombosis prevention."	( The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. Dick, SE; Hongo, RH; Ley, J; Yee, RR, 2002)	0.86
"Clopidogrel in combination with aspirin before CABG is associated with higher postoperative bleeding and morbidity."	( The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. Dick, SE; Hongo, RH; Ley, J; Yee, RR, 2002)	0.86
" Among these patients, 106 (41%) were discharged with a total of 150 prescriptions for drugs that could interact with warfarin to increase the INR."	( The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Ellerbeck, EF; Engelman, KK; Howard, PA; Patterson, KL, )	0.13
"To explore the interaction of low-dosage aspirin combined with angiotensin-converting enzyme (ACE) inhibitors by prostacyclin (PGI2), thromboxone A2 (TXA2) and norepinephrine (NE)) levels in rabbits' blood."	( [Effect of low-dosage aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in rabbits' blood]. Fang, YX; Li, J; Zhuang, HP, 2002)	0.9
" The ratio of PGI2 to TXA2 increased, and NE levels decreased significantly during the administration of aspirin combined with ACE inhibitors."	( [Effect of low-dosage aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in rabbits' blood]. Fang, YX; Li, J; Zhuang, HP, 2002)	0.84
"Non-sustained VTs are only associated with poor prognosis if combined with frequent VPBs."	( Prognostic value of non-sustained ventricular tachycardias after acute myocardial infarction in the thrombolytic era: importance of combination with frequent ventricular premature beats. Drögemüller, A; Gitt, A; Gottwik, M; Poppe, C; Rettig-Stürmer, G; Schiele, R; Schneider, S; Seidl, K; Senges, J; von Leitner, ER, 2003)	0.32
"The antithrombotic effect of the glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist (2S)-2-[(2-naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino] propanoic acid dihydrochloride (CRL42796), administered alone, or in combination with aspirin, and/or enoxaparin, was examined in a canine left circumflex (LCX) coronary artery rethrombosis model."	( Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, preven Driscoll, EM; Giboulot, TA; Hong, TT; Lucchesi, BR; Sherigill, A; White, AJ, 2003)	0.68
"To explore the interactive effect of low-dosage aspirin (ASA) combined with perindopril (PER), on prostacyclin (PGI2), thromboxone A2 (TXA2), and norepinephrine (NE) in the blood of arteriosclerosis rabbit models and the cardiac function."	( [Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function]. Li, J; Liu, LH; Zhuang, HP, 2003)	0.96
"The ratio of PGI2 to TXA2 increased, and the NE levels decreased significantly; meanwhile, the heart rate decreased and the cardiac function improved during the administration of aspirin combined with perindopril in arteriosclerosis rabbit models."	( [Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function]. Li, J; Liu, LH; Zhuang, HP, 2003)	0.9
" Considering these mechanisms of the reproductive failure generation by APLs, the application of immune suppressive therapy in combination with anti-coagulation therapy should be reconsidered as a treatment option."	( Effect of sairei-to combined with aspirin and prednisolone on four recurrent reproductive failure women who are positive for anti-phospholipid antibodies. Adachi, H; Ishii, K; Kurabayasi, T; Kurata, H; Natsume, N; Takaki, Y; Takakuwa, K; Tamura, M; Tanaka, K, 2003)	0.6
" This study was designed to assess the antiepileptic activity of aspirin and to investigate the potentiation of its activity in combination with a subconvulsive dose of lamotrigine."	( Evaluation of antiepileptic activity of aspirin in combination with newer antiepileptic lamotrigine in mice. Anuradha, K; Pandhi, P; Tandon, M, 2003)	0.82
"02) effect on the time to clot assessed with the activated clotting time was demonstrated when either eptifibatide or tirofiban was combined with aspirin and enoxaparin plus rNAPc2."	( Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions. Schneider, DJ; Sobel, BE; Whitaker, DA, 2004)	0.52
"The lack of an exaggerated effect on clotting and platelet function when GP IIb-IIIa inhibitors were combined with rNAPc2, aspirin, and enoxaparin suggests that no substantial increment in the incidence of bleeding would be observed when concentrations of rNAPc2 up to 250 ng/ml were to be used in clinical studies."	( Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions. Schneider, DJ; Sobel, BE; Whitaker, DA, 2004)	0.53
"To assess the safety of AT-1015 in combination with high-dose aspirin (300 mg daily)."	( Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study. Anderson, D; Engert, D; Ilgenfritz, J; Kato, N; Onomichi, K; Shelley, S; Uchida, H, 2004)	0.79
"AT-1015 was safe and well-tolerated in healthy male volunteers when taken in combination with high-dose aspirin, and did not significantly prolong bleeding time compared with aspirin alone."	( Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study. Anderson, D; Engert, D; Ilgenfritz, J; Kato, N; Onomichi, K; Shelley, S; Uchida, H, 2004)	0.77
"To review systematically the clinical effectiveness and the cost-effectiveness of clopidogrel used in combination with standard therapy including aspirin, compared with standard therapy alone for the treatment of non-ST-segment elevation acute coronary syndromes (ACS)."	( Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004)	0.8
" The clinical effectiveness and cost-effectiveness of clopidogrel in combination with standard therapy compared with standard therapy alone were synthesised through a narrative review with full tabulation of the results of the included studies."	( Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004)	0.6
"The results of the CURE trial indicate that clopidogrel in combination with aspirin was significantly more effective than placebo combined with aspirin in a wide range of patients with ACS."	( Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004)	0.83
" Since the pathophysiology of acute ischemic cardiac diseases involves haemostatic impairment and the therapeutic regimen includes antithrombotic drugs, we investigated the effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with platelet aggregation inhibitors (aspirin, eptifibatide and tirofiban), unfractionated heparin, low molecular weight heparin (enoxaparin) or the recombinant fibrinolytic drug (alteplase), on various haemostatic parameters in vitro."	( In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Kecskés, M; Losonczy, H; Nagy, A; Pótó, L; Szabó, C; Tóth, O, 2006)	0.72
"To compare the effects of aspirin and rofecoxib when administered with esomeprazole on prostaglandin E(2) production, cyclo-oxygenase-2 expression and proliferating cell nuclear antigen expression in patients with Barrett's oesophagus."	( The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. Kaur, B; Levine, D; Sood, S; Traxler, B; Triadafilopoulos, G; Weston, A, 2006)	0.9
" The oral immunomodulatory drugs thalidomide and lenalidomide have produced major therapeutic responses in patients with MM when used in combination with oral steroids and chemotherapy, but a high incidence of VTE has been reported."	( Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Hussein, MA, 2006)	0.33
" To date, evidence supporting antiplatelet drug resistance are pharmacokinetic response variability, drug-drug interaction through competitive inhibition a specific enzymatic pathway, genetic variability, and variability in the induction of enzymatic pathway in metabolic activation of prodrugs, like clopidogrel."	( Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Gurbel, PA; Lau, WC, 2006)	0.33
" Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding."	( Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007)	0.81
" Aspirin in combination with a coxib retarded the healing of experimentally induced gastric ulcers, whereas healing rates of rats treated with celecoxib in combination with aspirin/PC were comparable to controls."	( Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Dial, EJ; Lichtenberger, LM; Romero, JJ, 2007)	1.45
"Aspirin's gastric toxicity in combination with a coxib can be dissociated from its ability to inhibit COX-1 and appears to be dependent, in part, on its ability to attenuate the stomach's surface hydrophobic barrier."	( Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Dial, EJ; Lichtenberger, LM; Romero, JJ, 2007)	1.99
" However, drug-drug interactions may lead to a greatly increased risk of gastrointestinal bleeding when these drugs are combined."	( Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Brophy, JM; Delaney, JA; Opatrny, L; Suissa, S, 2007)	0.34
"A number of case reports and well-controlled clinical trials were identified that provided evidence of the relatively well known drug-drug interactions between prescription/OTC NSAIDs and alcohol, antihypertensive drugs, high-dose methotrexate, and lithium, as well as between frequently prescribed narcotics and other central nervous system depressants."	( Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Hersh, EV; Moore, PA; Pinto, A, 2007)	0.34
"Considering the widespread use of analgesic agents, the overall incidence of serious drug-drug interactions involving these agents has been relatively low."	( Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Hersh, EV; Moore, PA; Pinto, A, 2007)	0.34
"To investigate the effect of removing phlegm and dispelling stasis method (RPDSM) combined with Western medicine for treatment of cerebrovascular stenosis."	( [Removing phlegm and dispelling stasis method combined with Western medicine for treatment of cerebrovascular stenosis]. Gao, L; Liu, Q; Wang, PP, 2008)	0.35
" We evaluated apixaban, a direct and highly selective factor Xa inhibitor, in combination with clinically relevant doses of aspirin and/or clopidogrel for prevention of arterial thrombosis in rabbits."	( Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Crain, EJ; Watson, CA; Wong, PC, 2008)	0.55
"To observe the clinical value of protoparaxotril saporlirs (PTS) combined with aspirin in the secondary prevention of cerebral infarction."	( [Clinical value of protoparaxotril saporlirs combined with aspirin in the secondary prevention of cerebral infarction]. Liu, ZF; Xu, ZQ; Zhou, BR, 2008)	0.82
" As used in combination with aspirin, it shows potential practical importance in the clinical secondary prevention of stroke."	( [Clinical value of protoparaxotril saporlirs combined with aspirin in the secondary prevention of cerebral infarction]. Liu, ZF; Xu, ZQ; Zhou, BR, 2008)	0.88
"We investigated whether clopidogrel combined with aspirin affects local thrombin formation and platelet activation triggered by vascular injury."	( Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009)	0.8
"Our study shows that clopidogrel combined with aspirin does not reduce thrombin formation following vascular injury, but attenuates platelet sCD40L and P-selectin release."	( Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009)	0.81
"Two randomized, open-label, crossover, drug-drug interaction studies."	( Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Mangold, B; Oh, C; Ravenstijn, PG; Rengelshausen, J; Smit, JW; Terlinden, R; Upmalis, D; Wang, SS, 2010)	0.36
" In the 2-way crossover study, tapentadol IR was also given with the fifth of seven doses of acetaminophen 1000 mg; in the 3-way crossover study, tapentadol IR was also given with the third of four doses of naproxen 500 mg and the second of two doses of acetylsalicylic acid 325 mg."	( Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Mangold, B; Oh, C; Ravenstijn, PG; Rengelshausen, J; Smit, JW; Terlinden, R; Upmalis, D; Wang, SS, 2010)	0.36
" In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)."	( [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009)	0.35
" However, studies have found decreased efficacy of clopidogrel when concurrently administered with a PPI."	( Drug interaction between clopidogrel and proton pump inhibitors. Jackevicius, CA; Liu, TJ, 2010)	0.36
"We evaluated the bioavailability of each ingredient of the Polycap and determined any drug-drug interactions relative to single component reference preparations."	( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010)	0.36
"Comparative bioavailability was computed and no drug-drug interactions and no difference in comparative bioavailability were concluded for each ingredient based on point estimates of the T/R ratio of the geometric means falling within 80-125% for peak plasma concentration (C(max)), area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC(t)), and AUC from time zero to infinity (AUC(infinity))."	( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010)	0.36
" The present study in healthy volunteers establishes that Polycap is safe (no serious adverse events) and well tolerated, and that there is no indication of pharmacokinetic drug-drug interactions for any of the ingredients, with their bioavailabilities being well preserved."	( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010)	0.36
" We hypothesize that antiplatelet therapy in combination with rt-PA thrombolysis will improve outcome by enhancing fibrinolysis and preventing re-occlusion."	( A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial. de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010)	0.36
"The purpose of this work was to assess synergistic inhibitory responses of a novel chemopreventive combination regimen of drugs namely, aspirin in combination with calcium and folic acid on two human colon cancer cell lines, HT-29 and SW-480."	( Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. Chaudhary, A; Kanthamneni, N; Prabhu, S; Wang, J, 2010)	0.56
" We conclude that ibuprofen is likely to interact with aspirin and reduce its anti-platelet action particularly in those patients who take ibuprofen chronically."	( Antiplatelet drug interactions. Coughtrie, MW; MacDonald, TM; Mackenzie, IS; Wei, L, 2010)	0.61
"This study evaluated the risk of upper gastrointestinal bleeding (UGIB) associated with use of low-dose acetylsalicylic acid (ASA) alone and in combination with other gastrotoxic medications."	( Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. García Rodríguez, LA; Hernández-Díaz, S; Johansson, S; Lin, KJ, 2011)	0.37
"Our results indicate that PAR antagonists used in combination with aspirin provide a potent yet safe antithrombotic strategy in mice and provide insights into the safety and efficacy of using PAR antagonists for the prevention of acute coronary syndromes in humans."	( Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012)	0.62
" Drug-drug interactions (DDIs) involving OAAs pose a major concern in oncology practice due to these drugs' narrow therapeutic indices and potential for compromised efficacy and fatal adverse events."	( Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Chan, A; Ko, Y; Lim, SW; Ng, RC; Salim, A; Tan, SL; Wong, YP; Yong, WP, 2012)	0.38
" The in vivo antithrombotic property of ibudilast (CAS 50847-11-5), a phosphodiesterase 4 (PDE4) inhibitor, was evaluated in a photochemically-induced guinea pig carotid artery thrombosis model in combination with low-dose ASA."	( Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin potently inhibits guinea pig carotid artery thrombosis without extending bleeding time and causing gastric mucosal injury. Hoshina, K; Manita, S; Matsuzawa, S; Miyata, Y; Ooie, T; Sasahara, T; Sueyoshi, S; Yasue, T, 2012)	0.61
"SilverHawk Plaque Excision combined with aggressive pharmacotherapy in this presented high-risk population is associated with promising long-term outcomes that compare favorably with accepted standards of care."	( Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013)	0.39
" This study assessed whether high-dose aspirin: a) provides additional anti-platelet efficacy, assessed in vivo and ex vivo, when combined with P2Y12 inhibition; and/or b) has a negative effect on vascular function."	( High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H, 2013)	1.06
" The administration of ASA before calving (even at a low dose) in combination with ω-3 FA did not exert any synergistic positive effect on inflammation and performance."	( Effects of the precalving administration of omega-3 fatty acids alone or in combination with acetylsalicylic acid in periparturient dairy cows. Bertoni, G; Cappelli, FP; Grossi, P; Trevisi, E, 2013)	0.39
"Clopidogrel and ticlopidine, sometimes in combination with ASA, are associated with a low risk of bleeding during renal transplantation and does not seem to be a contraindication for renal transplant surgery."	( Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study. Abramowicz, D; Benahmed, A; Broeders, N; Donckier, V; Ghisdal, L; Hoang, AD; Kianda, M; Le Moine, A; Lemy, A; Madhoun, P; Massart, A; Mikhalski, D; Racapé, J; Sadis, C; Wissing, M, 2014)	0.65
"A review of the literature was conducted to provide an overview of current issues surrounding the concomitant use of NSAIDs and LD-ASA, to explore potential mechanisms for this drug-drug interaction and to consider current and future treatment options that may mitigate the risk associated with their concomitant use."	( Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Lakkireddy, DR; Nalamachu, S; Pergolizzi, JV; Raffa, RB; Taylor, R, 2014)	0.66
" The purpose of this study was to evaluate the role of aspirin combined with mechanical measures in the prevention of VTE after total knee arthroplasty (TKA)."	( Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Du, H; Jiang, Y; Liu, J; Zhou, Y, 2014)	2.09
" To prevent VTE, patients in group A received aspirin combined with mechanical measures postoperatively, while patients in group B received low-molecular-weight heparin (LMWH) sodium and rivaroxaban sequentially in combination with mechanical measures postoperatively."	( Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Du, H; Jiang, Y; Liu, J; Zhou, Y, 2014)	2.1
"Aspirin combined with mechanical measures had a good effect on prevention of VTE after TKA and resulted in lower cost, less blood loss, and less subcutaneous ecchymosis."	( Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Du, H; Jiang, Y; Liu, J; Zhou, Y, 2014)	3.29
" Drug exposure was determined based on prescriptions of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin, alone and in combination with other drugs that affect the risk of UGIB."	( Risk of upper gastrointestinal bleeding from different drug combinations. Coloma, PM; de Ridder, M; Gini, R; Herings, R; Kuipers, EJ; Masclee, GM; Mazzaglia, G; Pedersen, L; Picelli, G; Romio, S; Schuemie, MJ; Scotti, L; Sturkenboom, MC; Valkhoff, VE; van der Lei, J, 2014)	0.62
" The effect of aspirin on early neurological deterioration (END) was explored as a post hoc analysis of the randomized Antiplatelet Therapy in Combination With Recombinant t-PA Thrombolysis in Ischemic Stroke (ARTIS) trial."	( Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial. Beenen, LF; de Haan, RJ; Majoie, CB; Marquering, HA; Roos, YB; Zinkstok, SM, 2014)	1.02
"Simvastatin given in combination with aspirin delayed the development of pathological changes in the myocardium, reduced vascular damage and prolonged the survival time of cardiac allograft."	( Simvastatin combined with aspirin increases the survival time of heart allograft by activating CD4(+)CD25(+) Treg cells and enhancing vascular endothelial cell protection. Gao, B; Zhu, J, )	0.7
" Metformin combined with aspirin significantly inhibited the phosphorylation of mTOR and STAT3, and induced apoptosis as measured by caspase-3 and PARP cleavage."	( Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Carpizo, D; DiPaola, RS; Huang, H; Lin, Y; Tan, XL; Xu, Q; Yang, CS; Yue, W; Zheng, X, 2015)	1.03
" Importantly, these drug-drug interactions have prognostic implications, since patients with high on-treatment platelet reactivity associated with reduced clopidogrel metabolism have an increased risk of ischemia."	( Drug-drug interactions between clopidogrel and novel cardiovascular drugs. Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F, 2015)	0.42
"Aspirin resistance can potentially be identified by miR-92a levels in plasma combined with PDW."	( Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. Binderup, HG; Brasen, CL; Houlind, K; Madsen, JS, 2016)	3.32
" The purpose of this study was to compare the efficacy and safety of clopidogrel combined with aspirin (CA) versus sarpogrelate combined with aspirin (SA) treatment in carotid endarterectomy (CEA) patients."	( Effects of Sarpogrelate Combined with Aspirin in Patients Undergoing Carotid Endarterectomy in China: A Single-Center Retrospective Study. Gu, Y; Guo, J; Guo, L; Qi, L; Tong, Z; Wang, Z; Yu, H; Zhang, J, 2016)	0.92
"Background Drug-drug interactions in patients taking warfarin may contribute to a higher risk of adverse events."	( Study of warfarin utilization in hospitalized patients: analysis of possible drug interactions. Camargo, HP; Girotto, E; Guidoni, CM; Obreli-Neto, PR; Pereira, LR, 2016)	0.43
"The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present."	( Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. Abu-Ghazaleh, D; Al-Ramahi, R; Bsharat, A; Raddad, AR; Rashed, AO; Shehab, O; Yasin, E, 2016)	0.43
" The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs."	( Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016)	0.43
"Our previous studies have established the efficacy of chemopreventive regimens of aspirin and curcumin (CUR) encapsulated within solid lipid nanoparticles (SLNs) in combination with free sulforaphane (ACS combination) to prevent or delay the initiation and progression of pancreatic cancer, classified as one of the deadliest diseases with very low chances of survival upon diagnosis."	( Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Chenreddy, S; Khamas, W; Prabhu, S; Thakkar, A; Thio, A; Wang, J, 2016)	0.88
"This phase 2, open-label, single-center study in healthy Japanese males evaluated drug-drug interactions between vonoprazan 40 mg and LDA (100 mg) or NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and vice versa."	( Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men. Horii, S; Nakamura, K; Nishimura, A; Okamoto, H; Sakata, Y; Sakurai, Y; Shiino, M, 2017)	0.69
" There were few differences in the pharmacokinetics of vonoprazan when administered with LDA or NSAIDs, and few differences in the pharmacokinetics of LDA or NSAIDs when administered with vonoprazan."	( Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men. Horii, S; Nakamura, K; Nishimura, A; Okamoto, H; Sakata, Y; Sakurai, Y; Shiino, M, 2017)	0.69
"No clinically meaningful drug-drug interactions were observed and vonoprazan was well tolerated when administered with LDA or NSAIDs."	( Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men. Horii, S; Nakamura, K; Nishimura, A; Okamoto, H; Sakata, Y; Sakurai, Y; Shiino, M, 2017)	0.69
"We evaluated the pharmacokinetics and pharmacodynamics of prasugrel used in combination with aspirin in healthy Japanese subjects."	( Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects. Ikeda, Y; Kondo, K; Matsushima, N; Umemura, K, 2017)	0.89
" Therefore, we investigated whether the more stable aspirin-triggered (AT) epimer, AT-RvD1, combined with reduced doses of DEX is effective in treating TNF-α-mediated disruption of polarized rat parotid gland (Par-C10) epithelial cell clusters."	( AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium. Baker, OJ; Easley, JT; Maruyama, CL; Wang, CS, 2016)	0.68
" Clinically-relevant drug-drug interactions (DDIs) are a major concern of regulatory agencies and practicing physicians."	( Aspirin, stroke and drug-drug interactions. Petrucci, G; Rocca, B; Russo, NW, 2016)	1.88
" There have been several studies comparing the effectiveness of aspirin alone and in combination with FDD to treat coronary artery disease; however, it remains unclear whether combined aspirin therapy is superior."	( Clinical Therapeutic Effects of Aspirin in Combination with Fufang Danshen Diwan, a Traditional Chinese Medicine Formula, on Coronary Heart Disease: A Systematic Review and Meta-Analysis. He, J; Huang, J; Kong, X; Tang, X; Ye, F, 2016)	0.96
"The present meta-analysis demonstrated that aspirin in combination with FDD was more effective than aspirin alone for treating coronary heart disease."	( Clinical Therapeutic Effects of Aspirin in Combination with Fufang Danshen Diwan, a Traditional Chinese Medicine Formula, on Coronary Heart Disease: A Systematic Review and Meta-Analysis. He, J; Huang, J; Kong, X; Tang, X; Ye, F, 2016)	0.98
"0) combined with ASA (mean dose ≥100 mg/day) and ASA."	( Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. Huang, X; Li, J; Li, L; Shen, C; Wu, C; Zhang, P; Zhang, W, 2017)	0.77
" Considering the drug-HSA binding property of the compounds in DHI may change during drug combination therapy, competitive binding assay was carried out to evaluate the influence of aspirin on the DHI-HSA binding."	( Drug-protein binding of Danhong injection and the potential influence of drug combination with aspirin: Insight by ultrafiltration LC-MS and molecular modeling. Chen, S; Huang, P; Wu, Y; Yi, X; Zhu, J, 2017)	0.87
"Biomolecular network analysis was used to predict the mechanism of Salvianolate injection combined with aspirin for the treatment of stable angina pectoris(SAP)."	( [Mechanism of Salvianolate injection combined with aspirin in treatment of stable angina pectoris based on biomolecules network]. Li, Y; Wang, LX; Xie, YM, 2016)	0.9
" They were often used in combination with antibiotics, blood-activating and stasis-dissolving prescription, and adrenal cortical hormone drugs."	( [Real world analysis to explore clinical features of Shenxiong glucose injection combined with other medications]. Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y, 2017)	0.46
"To investigate temporal trends in the use of non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and/or clopidogrel in patients with atrial fibrillation (AF) following acute myocardial infarction (MI) and/or percutaneous coronary intervention (PCI)."	( Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. Berger, JS; Bjerring Olesen, J; Gerds, TA; Gislason, GH; Hansen, ML; Lamberts, M; Langtved Pallisgaard, J; Nissen Bonde, A; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018)	0.68
"From 2011 to 2016, the use of NOAC in combination with antiplatelet(s) increased in patients with AF following MI/PCI and exceeded the use of VKA in combination with antiplatelet(s) by 2016."	( Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. Berger, JS; Bjerring Olesen, J; Gerds, TA; Gislason, GH; Hansen, ML; Lamberts, M; Langtved Pallisgaard, J; Nissen Bonde, A; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018)	0.48
"56%) was the most common triple Western medicine therapy, often combined with antibiotics and blood stasis drugs in use."	( [Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world]. Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y, 2017)	0.46
"To explore the preventive and therapeutic effects of Resveratrol combined with total flavones of hawthorn, compatibility of traditional Chinese medicines, on the endothelial cells injury after artery bypass graft surgery."	( Resveratrol combined with total flavones of hawthorn alleviate the endothelial cells injury after coronary bypass graft surgery. Feng, B; He, S; Su, Z; Zheng, G; Zhu, Y, 2018)	0.48
" After CABG surgery, the rabbits were administrated with saline (model group), aspirin (Aspirin group), resveratrol (Res group), total flavones of hawthorn (Haw group) and resveratrol combined with total flavones of hawthorn (Res+Haw group) once a day for eight weeks, respectively."	( Resveratrol combined with total flavones of hawthorn alleviate the endothelial cells injury after coronary bypass graft surgery. Feng, B; He, S; Su, Z; Zheng, G; Zhu, Y, 2018)	0.71
"Compared with the model group, the level of CECs density and the expressions of albumen and mRNA of ICAM-1 were significantly decreased in the aspirin,resveratrol,total flavones of hawthorn and resveratrol combined with total flavones of hawthorn groups (P < ."	( Resveratrol combined with total flavones of hawthorn alleviate the endothelial cells injury after coronary bypass graft surgery. Feng, B; He, S; Su, Z; Zheng, G; Zhu, Y, 2018)	0.68
"The Resveratrol combined with total flavones of hawthorn could protect the endothelial cells after coronary artery bypass graft."	( Resveratrol combined with total flavones of hawthorn alleviate the endothelial cells injury after coronary bypass graft surgery. Feng, B; He, S; Su, Z; Zheng, G; Zhu, Y, 2018)	0.48
"Previous studies have found that Panax quinquefolius saponins (PQS) combined with dual antiplatelet therapy (DAPT) of aspirin and clopidogrel enhances antithrombotic effects while reducing gastric mucosal injury induced by DAPT."	( Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction. Kou, N; Miao, Y; Qu, H; Shi, DZ; Wang, MM; Xue, M; Yang, B; Yang, L; Zang, MX, 2018)	0.69
"This trial has been designed as a multi-center, prospective, randomized controlled, evaluator-blinded trial with two parallel groups to determine whether IVIG alone as the primary therapy in acute-stage KD is as effective as IVIG combined with high-dose aspirin therapy."	( Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial. Guo, MM; Hsieh, KS; Huang, YH; Kuo, HC; Lo, MH, 2018)	0.88
"The aim of this study is to assess patterns of potential drug-drug interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient hospital setting."	( Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital. Karakas-Torgut, A; Mo, Y; Pham, AQ, 2020)	0.56
" Salvianolate can significantly inhibit the aggregation and activation of platelets in patients with CHD; however, its optimum combination with western medicine is not established or supported by clinical trial results."	( Research on the mechanism of drug-drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial. Cao, W; Gao, R; Li, R; Wang, S; Zhang, W; Zhu, B, 2018)	0.7
"Highly Active Metastasis Preventing Therapy (HAMPT) is a quardruple drug combination consisting of mifepristone, aspirin, lysine and doxycycline."	( HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept. Jia, L; Liu, J; Wan, L; Xu, H; Xu, J; Zheng, N, 2019)	0.72
"The present study demonstrated that HAMPT is a novel quadruple drug combination that can safely and effectively prevent cancer metastasis."	( HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept. Jia, L; Liu, J; Wan, L; Xu, H; Xu, J; Zheng, N, 2019)	0.51
"To explore the anti-platelet aggregation and anti-thrombotic mechanisms of Trichosanthis Fructus combined with aspirin based on network pharmacology and the validation of arteriovenous by pass model in rats."	( [Anti-platelet aggregation and anti-thrombotic mechanism of Trichosanthis Fructus combined with aspirin based on network pharmacology]. Bian, YY; Wang, LL; Yan, HY; Zou, CC, 2019)	0.94
"There is an increased risk of potential drug-drug interactions (pDDIs) in critically ill patients based on the number of drugs received."	( Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. Akerberg, H; Avramovska, S; Buckley, MS; Fitzmaurice, MG; Kane-Gill, SL; Smithburger, PL; Wong, A, 2019)	0.51
"The aim was to provide insight into important clinical issues and offer guidance on drug-drug interaction (DDI) surveillance through the performance of a systematic review."	( Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. Akerberg, H; Avramovska, S; Buckley, MS; Fitzmaurice, MG; Kane-Gill, SL; Smithburger, PL; Wong, A, 2019)	0.51
"To assess the safety and efficacy of Aspirin desensitization combined with long-term Aspirin therapy in patients with Aspirinexacerbated respiratory disease (AERD)."	( Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. Li, R; Luo, F, 2020)	1.14
"To study the clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA)."	( [Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms]. Chen, TT; Guo, YH; Li, Y; Liu, YL; Lu, YH; Shi, K; Wang, XM, 2019)	0.99
"Clopidogrel combined with low-dose aspirin is safe and effective in antithrombotic therapy for children with KD complicated by CAA."	( [Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms]. Chen, TT; Guo, YH; Li, Y; Liu, YL; Lu, YH; Shi, K; Wang, XM, 2019)	1.04
" The objective of this study is to investigate the efficacy and safety of ticagrelor combined with a lower dose of aspirin (50 mg) than that recommended by guidelines (75-100 mg)."	( Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P, 2020)	1.05
"The effects of antibiotics on the intestinal flora can create potential drug-drug interactions."	( Gut Microbiota-Mediated Drug-Drug Interaction between Amoxicillin and Aspirin. Sun, Y; Wang, R; Zhang, J, 2019)	0.75
" We found that more than half of patients prescribed with triple free drug combination therapy with ACEi plus CCB plus statin or ACEi plus statin plus low-dose aspirin, were found to be nonadherent to these treatments."	( Adherence to Triple-Free-Drug Combination Therapies Among Patients With Cardiovascular Disease. Bettiol, A; Crescioli, G; Cricelli, C; Lapi, F; Lombardi, N; Marconi, E; Parretti, D; Simonetti, M; Vannacci, A, 2020)	0.75
"This study aims to explore the clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and the effects on N terminal pro B type natriuretic peptide (NT-ProBNP) and creatine kinase-MB (CK-MB) levels."	( Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020)	1.05
"Ticagrelor combined with aspirin has definite therapeutic effect on patients with coronary heart disease angina pectoris, with low prevalence of adverse reactions."	( Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020)	1.12
"To compare the efficacy of heparin combined with aspirin and aspirin alone for URSA."	( Meta-analysis of heparin combined with aspirin versus aspirin alone for unexplained recurrent spontaneous abortion. Gao, YH; Li, J; Li, ZY; Xu, L, 2020)	1.08
"Among women with URSA, heparin combined with aspirin increased the live birth rate as compared with aspirin alone."	( Meta-analysis of heparin combined with aspirin versus aspirin alone for unexplained recurrent spontaneous abortion. Gao, YH; Li, J; Li, ZY; Xu, L, 2020)	1.09
"Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the only option for complete revascularization in some patients with diffuse coronary artery disease."	( Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H, 2020)	0.56
"Objectives A "potential drug-drug interaction" (pDDI) is the possibility one drug has to alter the effects of another when both are administered simultaneously."	( Potential drug-drug interactions in ICU patients: a retrospective study. Ali, I; Bazzar, A; Hussein, N; Sahhar, E, 2020)	0.56
"Apixaban, a direct oral anticoagulant, has emerged over the past few years because it is considered to have a low risk of drug-drug interactions compared to vitamin K antagonists."	( Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Fernandez, S; Lenoir, C; Rollason, V; Samer, C, 2020)	0.56
"To explore the real world clinical application characteristics and the drug combination regularity of Ciwujia Injection, 12 554 cases of patients with Ciwujia Injection were extracted from the information systems of 24 class Ⅲ grade A hospitals in China, and a standardized analysis was carried out."	( [Analysis of clinical application characteristics and drug combination of Ciwujia Injection in 12 554 cases in real world]. Li, YY; Liu, H; Sun, LX; Xie, YM; Zhuang, Y, 2020)	0.56
" Here, we confirmed the protective effect and mechanism of XST combined with DAPT (XST+ASA+CLP) on cerebral ischemia/reperfusion injury, exploring their better pharmacological action for clinical patients."	( Xuesaitong injection (lyophilized) combined with aspirin and clopidogrel protect against focal cerebral ischemic/reperfusion injury in rats by suppressing oxidative stress and inflammation and regulating the NOX2/IL-6/STAT3 pathway. Dong, DX; Meng, XB; Qu, MW; Sun, GB; Sun, XB; Zhao, LY; Zhu, T, 2021)	0.88
"Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS."	( Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke. Chen, M; Dai, X; Deng, X; Fu, S; Gong, Q; He, W; Huang, L; Li, C; Luo, Q; Qiu, T; Wang, J; Wang, M; Xiao, H, 2021)	0.62
" In 2005, China's FDA approved the use of SMDS for stable angina pectoris (SAP), but the evidence of SMDS combined with aspirin remains unclear."	( Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y, 2021)	1.05
"The aim of this study was to assess the clinical effectiveness and safety of SMDS combined with aspirin in patients with SAP."	( Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y, 2021)	1.06
" Participants who were randomly assigned to the combination group received SMDS combined with aspirin."	( Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y, 2021)	1.06
"SMDS combined with aspirin is a clinically effective and safe intervention to treat adults aged 35 and older with SAP."	( Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y, 2021)	1.17
"A pharmacokinetic drug-drug interaction was found in the aspirin and salvianolate combination."	( Drug-drug interactions between salvianolate injection and aspirin based on their metabolic enzymes. Cao, W; Gao, R; Guo, Z; Li, R; Wang, S; Wu, Y; Xu, Y; Yang, Q; Zhang, W; Zhao, Y, 2021)	1.11
"The study aimed to investigate the effect and mechanism of aspirin combined with vinorelbine on the proliferation and apoptosis of non-small cell lung cancer cells."	( [Effect and mechanism of aspirin combined with vinorelbine on non-small cell lung cancer]. Cui, L; Liu, Z; Qiu, YN; Teng, YO; Xu, Y; Yu, P, 2020)	1.1
" Our findings showed that antiplatelet therapies (aspirin/clopidogrel cocktail and atopaxar) combined with anastrozole failed to prevent hypercoagulation and induced evidence of a partial EMT."	( Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. Augustine, TN; Xulu, KR, 2021)	0.87
"Meta-analysis was used to evaluate the efficacy and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome (PCOS)."	( Effectiveness and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome: a systematic review and meta-analysis. Su, F; Wang, M; Wang, Z; Yu, Q, 2021)	1.16
"Through comprehensive searches of the China Knowledge Network (CNKI), the VIP database (VIP), the Wanfang database, the China Biomedical Database (CBM), PubMed, EMBASE, and the Cochrane Library, the clinical randomized controlled trials (RCTs) published on aspirin combined with letrozole in the treatment of PCOS were collected."	( Effectiveness and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome: a systematic review and meta-analysis. Su, F; Wang, M; Wang, Z; Yu, Q, 2021)	1.1
" Meta-analysis results showed that compared with letrozole monotherapy, aspirin combined with letrozole could significantly increase the thickness of the endometrium [MD=1."	( Effectiveness and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome: a systematic review and meta-analysis. Su, F; Wang, M; Wang, Z; Yu, Q, 2021)	1.15
"Aspirin combined with letrozole in the treatment of PCOS is safe and effective."	( Effectiveness and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome: a systematic review and meta-analysis. Su, F; Wang, M; Wang, Z; Yu, Q, 2021)	2.36
" Veverimer is not systemically absorbed, so potential drug-drug interactions (DDIs) are limited to effects on the absorption of other oral drugs through binding to veverimer in the gastrointestinal tract or increases in gastric pH caused by veverimer binding to hydrochloric acid."	( Assessment of the Potential for Veverimer Drug-Drug Interactions. Biyani, K; Guttendorf, R; Klaerner, G; Lee, A; Li, E; Mathur, V; Parsell, D; Shao, J; Stasiv, Y; Tabakman, S; Tsao, L; Wu, YS, 2021)	0.62
"This study assessed the efficacy and safety of tirofiban in combination with dual-antiplatelet therapy (DAPT) in progressive ischemic stroke."	( Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients. Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021)	0.62
" This study aimed to evaluate whether aspirin combined with low-molecular-weight heparin (LMWH) can improve the live birth rate in antiphospholipid syndrome and its correlation with D-dimer."	( Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. Diao, QZ; Gu, ZD; Shi, T, 2021)	1.23
" We collected data on randomized controlled trials of aspirin combined with LMWH in the treatment of pregnant women with APS."	( Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. Diao, QZ; Gu, ZD; Shi, T, 2021)	1.21
" The live birth rate in pregnant women with APS was higher on administration of aspirin combined with LMWH than with aspirin alone (RR = 1."	( Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. Diao, QZ; Gu, ZD; Shi, T, 2021)	1.19
"Aspirin combined with LMWH for APS may improve live birth rate, and detection of d-dimer levels in APS pregnant women may predict pregnancy complications and guide the use of anticoagulants."	( Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. Diao, QZ; Gu, ZD; Shi, T, 2021)	2.4
"To explore the clinical efficacy of tirofiban combined with ticagrelor and aspirin in acute myocardial infarction treatment by percutaneous coronary intervention and its effect on patients' cardiac function."	( The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function. Li, F; Peng, R, 2022)	1.19
" On the basis of conventional treatment, patients were separated into a joint group (tirofiban combined with ticagrelor and aspirin) comprising 55 cases and a control group (conventional ticagrelor and aspirin dual treatment) involving 47 cases."	( The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function. Li, F; Peng, R, 2022)	1.17
" The aim of the study is to investigate the role of Prunus dulcis oil alone and in combination with aspirin, as\ an anti-angiogenic."	( Antiangiogenic Activity of Sweet Almond (Prunus dulcis) Oil Alone and in Combination with Aspirin in both in vivo and in vitro Assays. Ali, ZK; Sahib, HB, 2022)	1.16
"Colorectal cancer (CRC) can be either prevented or alleviated using conventional drugs combined with natural treatments."	( Andean berry (Vaccinium meridionale Swartz) juice, in combination with Aspirin, displayed antiproliferative and pro-apoptotic mechanisms in vitro while exhibiting protective effects against AOM-induced colorectal cancer in vivo. Arango-Varela, SS; Luzardo-Ocampo, I; Maldonado-Celis, ME, 2022)	0.95
"To assess the clinical efficacy of intravenous immunoglobulin G (IVIG) administration combined with low-dose aspirin in women with unexplained recurrent pregnancy loss (RPL)."	( Outcomes of Empirical Treatment With Intravenous Immunoglobulin G Combined With Low-Dose Aspirin in Women With Unexplained Recurrent Pregnancy Loss. Chae, HD; Kim, JH; Kim, SH; Ko, Y; Lee, SR; Yang, N, 2022)	1.16
"IVIG combined with low-dose aspirin treatment showed favorable pregnancy outcomes regardless of the patient's NK cell counts (%)."	( Outcomes of Empirical Treatment With Intravenous Immunoglobulin G Combined With Low-Dose Aspirin in Women With Unexplained Recurrent Pregnancy Loss. Chae, HD; Kim, JH; Kim, SH; Ko, Y; Lee, SR; Yang, N, 2022)	1.24
"The aim of this study was to analyze the clinical characteristics of fatal adverse events (AEs) of rivaroxaban combined with aspirin and to underline the importance of the rational use of drugs."	( Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022)	1.18
"By January 19, 2020, 2309 fatal adverse event reports of rivaroxaban combined with aspirin from 21 countries were entered in VigiBase."	( Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022)	1.2
"Fatal AEs related to rivaroxaban combined with aspirin, including bleeding and ischemic events, have been reported mostly in the elderly, and sometimes involved medication errors."	( Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022)	1.23
" The aim of our study was to investigate if the Syk inhibitor fostamatinib could be repurposed as an antiplatelet drug, either alone or in combination with conventional antiplatelet therapy."	( Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. Alenazy, FO; Harbi, MH; Nicolson, PLR; Smith, CW; Thomas, MR; Tiwari, A; Watson, SP, 2022)	0.72
"To analyze the significance of ezetimibe in combination with low- to moderate-intensity atorvastatin adjuvant aspirin therapy for cerebrovascular disease."	( Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease. Tang, X; Wang, L, 2022)	1.15
"Ezetimibe combined with medium- and low-intensity atorvastatin with aspirin in the treatment of cerebrovascular diseases can effectively improve the coagulation function of patients, reduce the level of inflammatory factors in patients, and improve the level of blood lipids in patients, with high safety and worthy of clinical application."	( Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease. Tang, X; Wang, L, 2022)	1.18
"Our previous studies have confirmed that aspirin combined with Lipitor inhibited the development of prostate cancer (PCa), but the mechanisms need to be comprehensively expounded."	( Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Chen, M; Li, D; Liu, J; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, Y; Xu, X; Zhao, D; Zheng, X, 2022)	1.25
" The effects of silent DNA replication and sister chromatid cohesion 1 (siDSCC1) combined with Lipitor and aspirin on DSCC1 expression, viability, invasion and migration of PCa cells were detected by qRT-PCR, Wound healing and transwell assays."	( Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Chen, M; Li, D; Liu, J; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, Y; Xu, X; Zhao, D; Zheng, X, 2022)	1.2
"The enrichment pathways and targets of Lipitor combined with aspirin in PCa are discovered, and DSCC1 silencing can potentiate the effect of Lipitor combined with aspirin in the treatment of PCa."	( Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Chen, M; Li, D; Liu, J; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, Y; Xu, X; Zhao, D; Zheng, X, 2022)	1.23
"The objective of the study was to compare the efficacy of low-molecular weight heparin (LMWH) alone and use in the combination with aspirin in the treatment of fetal growth restriction (FGR) patients."	( Comparison of Low Molecular Weight Heparin Used alone or Combined with Aspirin in the Treatment of Fetal Growth Restriction. He, S; Liang, L, 2022)	1.16
" This research explored the effects of hydroxychloroquine combined with low-dose aspirin on maternal and infant outcomes and cytokines of pregnant women with SLE."	( Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023)	1.38
"Ninety pregnant women with SLE were divided into the hydroxychloroquine (HCQ) group (45 cases) and the hydroxychloroquine combined with low-dose aspirin (HCQASP) group (45 cases) by random number table."	( Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023)	1.36
"Hydroxychloroquine combined with low-dose aspirin can effectively improve the pregnancy outcomes of pregnant women with SLE by affecting the levels of T helper (Th) 2 and Th1 cytokines."	( Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023)	1.42
"This study aimed to estimate how prevalent potential drug-drug interactions (pDDIs) were in patients with cardiovascular diseases who were hospitalized for more than 24 hours, and to determine the risk factors associated with these pDDIs."	( Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital. Almaghaslah, D; Khaled, A; Makki, S; Nagib, R; Siddiqua, A, 2023)	0.91
" After adjusting for sociodemographic and common cardiovascular risk factors, we used multivariable logistic regression analysis to determine aspirin should be combined with which type of statin for better CVD preventive effects."	( Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population. Huangtao, Z; Li, B; Liu, T; Pan, Y; Sun, L; Wang, B; Wang, J; Wang, S; Zhu, Z; Zuo, R, 2023)	1.37
" Linear discriminant analysis effect size (LEfSe) analysis combined with receiver operating characteristic (ROC) curves revealed the marker bacteria associated with taking medication were g_Parabacteroides（AUC = 0."	( Effects of long-term regular oral aspirin combined with atorvastatin to prevent ischemic stroke on human gut microbiota. Chen, C; Chen, G; Cui, J; Liao, Y; Ming, J; Song, W; Wang, X; Wang, Z; Xu, K, 2023)	1.19
"The study aimed to evaluate the clinical efficacy of the Huo Xue Hua Yu method combined with aspirin in the treatment of patients with acute cerebral infarction (ACI)."	( Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023)	1.37
"13 articles that included 1,243 patients were identified; in 646 of them, the Huo Xue Hua Yu method combined with aspirin has been administered, while 597 have only been administered aspirin therapy."	( Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023)	1.36
"This systematic review and meta-analysis aimed to evaluate the clinical effectiveness of low-dose aspirin combined with calcium supplements for the prevention of preeclampsia."	( Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. Chen, WY; Sun, SF, 2023)	1.42
" Randomized controlled trials investigating the preventive use of aspirin in combination with calcium supplementation for preeclampsia in high-risk pregnant women were included."	( Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. Chen, WY; Sun, SF, 2023)	1.44
"Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth."	( Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. Chen, WY; Sun, SF, 2023)	1.56
"To assess the antiplatelet effect of cilostazol clinically, we compared the effects of cilostazol in combination with clopidogrel on various platelet function tests."	( Differential inhibition of platelet function by cilostazol in combination with clopidogrel. Dahlen, JR; Hosokawa, K; Kitagawa, K; Ohnishi, T; Shirai, Y; Yamazaki, M, 2023)	0.91
" One such approach is the use of omega-3 polyunsaturated fatty acids (PUFAs) in combination with low-dose aspirin."	( Adjunctive use of omega-3 fatty acids in combination with low-dose aspirin in periodontitis: Systematic review and meta-analysis. Kriventsov, MA; Neprelyuk, OA; Romanenko, IG; Zhad'ko, SI, 2023)	1.36

Bioavailability

Aspirin bioavailability was estimated from spectrophotometric assay of total 48-hour urinary salicylate recovery. The bioavailability of aspirin was compared in plain aspirin tablets, chewed tablets, effervescent tablets and Enteric-coated aspirin tablets.

Excerpt	Reference	Relevance
" Benorylate was well absorbed in rabbits, but more slowly than an equimolar mixture of aspirin and paracetamol."	( Comparative metabolism of benorylate and an equivalent mixture of aspirin and paracetamol in neonate and adult rabbits. Davison, C; Dorrbecker, BR; Edelson, J, 1977)	0.72
" In five healthy adult volunteers concomitant administration of antacid had no effect on the bioavailability of aspirin."	( Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. Garrettson, LK; Kamath, BL; Lampman, T; Levy, G, 1975)	0.47
" The bioavailability of the salicylate preparations was studied in seven of the 12 patients."	( The effects of enteric coating of aspirin tablets on occult gastrointestinal blood loss. Champion, GD; Corrigan, AB; Day, RO; Graham, GG; Haski, A; Hewson, J; Howe, GB; Paull, PD, 1977)	0.54
" When salicylate absorption from effervescent aspirin tablets was studied during migraine, the rate of absorption was found to be reduced relative to that found in non-migrainous volunteers and in the same patients when headache-free."	( Migraine and drug absorption. Volans, GN, )	0.39
" Two independent studies have shown that aspirin markedly reduces the bioavailability of diclofenac, as measured by "area under the curve"."	( Diclofenac sodium (Voltarol): drug interactions and special studies. Fowler, PD, 1979)	0.53
" This new dissolution tester possibly can be useful in determining drug release from solid dosage forms and correlating it with in vivo bioavailability because dissolution rate can be controlled easily with the adjustment of air pressure without complicated changes in the apparatus, there is no excessive settling of particles, and complete drug dissolution can be achieved with no clogging of the screen."	( New in vitro dissolution test apparatus. Nasir, SM; Nasir, SS; Wilken, LO, 1979)	0.26
" On the other hand, bioavailability varied little, as did metabolic clearance."	( Pharmacokinetics of salicylates in elderly. Cuny, G; Faure, G; Maillard, A; Mur, JM; Netter, P; Penin, F; Royer, RJ; Serot, JM, 1979)	0.26
" Aspirin bioavailability was estimated from spectrophotometric assay of total 48-hour urinary salicylate recovery."	( Comparison of kaolin-pectin and activated charcoal for inhibition of aspirin absorption. Juhl, RP, 1979)	1.4
"The influence of test meals and accompanying fluid volume on aspirin bioavailability from commercial tablets was determined following single oral doses to healthy male volunteers."	( Influence of food and fluid ingestion on aspirin bioavailability. Hallquist, SL; Koch, PA; Schultz, CA; Welling, PG; Wills, RJ, 1978)	0.77
" Bioavailability of acetylsalicylic acid was slightly lower after intramuscular application than after intravenous administration."	( Pharmacokinetic investigations in adult humans after parenteral administration of the lysine salt of acetyl-salicylic acid. Göbel, U; Petrich, C; Pütter, J; von Voss, H, 1978)	0.26
" When phenylbutazone was administered together with salicylates a decrease in the bioavailability of phenylbutazone was demonstrated, but there was no significant variation in the absorption and elimination constants or in the half-life."	( [Interaction of salicyl compounds and other non-steroidal anti-inflammatory agents: pharmacokinetic study of phenylbutazone-aspirin combination in man]. Faure, G; Gaucher, A; Maillard, A; Netter, P; Pourel, J; Royer, RJ; Tamisier, JN, 1976)	0.46
" A preliminary in vivo study also was conducted on the bioavailability of aspirin from separate and similar mixtures with gluconolactone, anhydrous lactose, and starch."	( Application of gluconolactone in direct tablet compression. Akhtar, B; Nasir, SS; Wilken, LO, 1977)	0.49
"The influence of food intake on the bioavailability of three analgesic compounds--propoxyphene chloride, acetyl salicylic acid and phenazone--in a combination tablet, Doleron, has been examined in eight healthy volunteers."	( Bioavailability of D-propoxyphene, acetyl salicylic acid, and phenazone in a combination tablet (Doleron): interindividual variation and influence of food intake. Berlin-Wahlén, A; Bodin, NO; Danielson, K; Gustafsson, B; Lindgren, S; Melander, A; Westerlund, D, 1977)	0.26
" There was no difference with either drug between the two age-groups in the mean absorption rate constant and the time at which maximum concentration in the plasma occurred."	( The effect of ageing on drug absorption from the gut. Castleden, CM; Raymond, K; Volans, CN, 1977)	0.26
"The bioavailability of a new enteric-coated tablet of aspirin (Ecotrin, Smith, Kline and French) was evaluated after single doses to eight volunteers."	( Single-dose evaluation of a new enteric-coated aspirin preparation. Champion, D; Day, R; Graham, G; Paull, P, 1976)	0.76
"A comparison of the bioavailability of salicylate from five brands of commercially available aspirin rectal suppositories in an adult panel is presented."	( Bioavailability of aspirin from commercial suppositories. Gibaldi, M; Grundhofer, B, 1975)	0.8
" In the bioavailability study, the diffusion equilibrium was attained at approximately 4-5 and 9-10 hr after the rectal administration of powdered aspirin and aspirin disks, respectively."	( Influence of particle size on rectal absorption of aspirin. Parrott, EL, 1975)	0.71
"The rate of release of acetylsalicylic acid (ASA) coated and uncoated from suppositories in vitro, and the bioavailability of ASA in vivo were examined."	( The study of the bioavailability of coated acetylsalicylic acid in suppositories after rectal administration. Stozek, T, )	0.13
" The bioavailability of plain ASA after oral administration amounts to 40-50% at therapeutic doses."	( [Clinical pharmacology of acetylsalicylic acid]. Schröder, H; Schrör, K, 1992)	0.28
"The effect of antacid on aspirin pharmacokinetics and bioavailability was determined in 10 healthy adult male and female volunteers, aged 20-45 years old."	( The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers. Chaiyos, N; Itthipanichpong, C; Sirivongs, P; Wittayalertpunya, S, 1992)	0.89
"Differences in bioavailability of many drugs from their various dosage forms have been shown to be relatively common in human medicine."	( Bioavailability and bioinequivalence of drug formulations in small animals. Watson, AD, 1992)	0.28
"Bioavailability studies have been performed with ten healthy volunteers on different dosage forms of acetylsalicylic acid (ASA) in order to assess the bioavailability of two different ASA gums compared with commercial ASA tablets."	( Bioavailability of two formulations of acetylsalicylic acid gums. Bianchi, A; Bonina, FP; Bousquet, E; Ciampini, N; Montenegro, L; Tirendi, S, 1992)	0.28
" We concluded that the dog is a better animal model for bioavailability studies under fasting conditions than the pig and the rabbit."	( Gastric emptying of tablets and granules in humans, dogs, pigs, and stomach-emptying-controlled rabbits. Aoyagi, N; Kaniwa, N; Ogata, H; Tanioka, Y; Uchiyama, M; Yasuda, Y, 1992)	0.28
" Aspirin was well absorbed following nasal administration of a neutralized, nonirritating solution containing triethanolamine."	( Absorption of acetylsalicylic acid from the rat nasal cavity. Dittert, LW; Hussain, AA; Iseki, K; Kagoshima, M, 1992)	1.19
" It can be concluded that aspirin granule prepared by GMS and GTL has a property of pancreatic lipase-sensitive dissolution, and its bioavailability is unaffected by food intake."	( Preparation and evaluation of oral dosage form using acylglycerols. II. Effect of food ingestion on dissolution and absorption of aspirin from the granules prepared by acylglycerols in human subjects. Matsumoto, M; Matsumoto, Y; Suda, M; Takayama, K; Watanabe, Y; Zhao, W, 1991)	0.79
"A single-blind, randomized, crossover pharmacokinetic study was carried out to investigate the bioavailability of a new oral buffered 325 mg acetylsalicylic acid (ASA) formulation (ASPIRINA 03) in comparison with a 325 mg plain tablet."	( Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. Garagiola, U; Gaspari, F; Viganò, G, 1991)	0.47
"5 mg daily or as 325 mg on alternate days, despite the minimal systemic bioavailability of controlled-release aspirin."	( Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. Clarke, RJ; FitzGerald, GA; Mayo, G; Price, P, 1991)	0.72
" The results of a comparative pharmacokinetic investigation of MR 897 and benorilate in the rat confirm higher bioavailability and a more favourable plasma level profile with MR 897."	( High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. Lucarelli, C; Marzo, A; Meroni, G; Quadro, G; Ripamonti, M; Treffner, E, 1990)	0.28
"Effect of chronic administration of aspirin, phenobarbitone and oxytetracycline under therapeutic doses on the bioavailability of vitamin A was determined in different groups of albino rats."	( Effect of chronic administration of aspirin, phenobarbitone and oxytetracycline on the plasma levels of vitamin A in albino rats. Hashmi, AS; Maqbool, T; Shah, BH, 1990)	0.83
" Thus, aspirin may increase the bioavailability of ingested ethanol in humans, possibly by reducing ethanol oxidation by gastric alcohol dehydrogenase."	( Aspirin increases blood alcohol concentrations in humans after ingestion of ethanol. Baraona, E; Gentry, RT; Hernández-Munõz, R; Lieber, CS; Roine, R, 1990)	2.18
"In preliminary investigation of the pharmacokinetics of aspirin in dogs it became apparent that the drug was well absorbed following oral ingestion with food."	( Pharmacokinetics of aspirin and its application in canine veterinary medicine. Knottenbelt, DC; Morton, DJ, 1989)	0.85
" Apart from the potential advantages in terms of improved gastric tolerability, the increased rate of absorption of aspirin solutions is therapeutically useful whenever a rapid onset of action is required."	( Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Attardo Parrinello, G; Barzaghi, N; Gatti, G; Perucca, E; Vitiello, B, 1989)	0.73
" Inhibition of the formation of the reactive metabolite of paracetamol or reduction of the absorption rate of paracetamol seem to be unlikely as mechanisms underlying the ASA-induced effect."	( Reduction by acetylsalicylic acid of paracetamol-induced hepatic glutathione depletion in rats treated with 4,4'-dichlorobiphenyl, phenobarbitone and pregnenolone-16-alpha-carbonitrile. De Vries, J; Groot, EJ; van Bree, L, 1989)	0.28
"The objective of this study was to determine the influence of caffeine on aspirin bioavailability and pharmacokinetics in man."	( Effect of caffeine on the bioavailability and pharmacokinetics of aspirin. Thithapandha, A, 1989)	0.74
"The aim of this study is to compare the bioavailability of acetylsalicylic acid administered rectally in suppositories form and orally in tablets form to the rabbit."	( [Bioavailability of acetylsalicylic acid administered orally or rectally in the rabbit]. Aiache, JM; Boukef, K; Fehri, B, )	0.13
"Absolute Bioavailability of a Special Acetylsalicylic Acid Sustained Release Formulation."	( [Absolute bioavailability of a special sustained-release acetylsalicylic acid formulation]. Lücker, PW; Swoboda, M; Wetzelsberger, N, 1989)	0.28
" However, concurrent DP or CaDb improved the bioavailability of ASA, particularly the increased Cmax and (AUC)."	( Pharmacokinetic interaction in beagle dogs of antiplatelet drugs: acetylsalicylic acid, dipyridamole and calcium dobesilate. Asimakopoulos, G; Dontas, I; Gogas, J; Karayannacos, PE; Kotsarelis, D; Plessas, CT; Plessas, ST; Souras, S, )	0.13
"In this work, we have studied in the rabbit, bioavailability of acetylsalicylic acid contained respectively in three forms of suppositories which are made as follows: for the first by only acetylsalicyclic acid (0."	( [The effect of certain active principles and excipients on the biodisposition of rectally administered acetylsalicylic acid in the rabbit]. Aiache, JM; Boukef, K; Fehri, B, )	0.13
" The increase in absorption of poorly absorbed drugs could be ascribed to the increased permeability of the blood-gastric epithelium barrier as was evidenced by leakage of Evans Blue."	( Characterization of mitomycin C-induced gastrointestinal damage: changes in the gastric absorption of drugs in rats. Hashida, M; Kawabata, S; Mizuno, M; Sezaki, H, 1986)	0.27
" ratios indicate that, relative to ranitidine, the bioavailability of AY-29,315 by the oral route was low, particularly in the dog."	( Antisecretory and antiulcer activities of a potent new histamine H2-receptor antagonist with an intermediate duration of action. Borella, L; Failli, A; Grimes, D; Mir, GN; Rimele, TJ; Russell, J, 1988)	0.27
" The present study was designed to investigate whether the abnormally prolonged post-ASA BT in uremia is due to different ASA pharmacokinetics and bioavailability that might be a consequence of uremic condition, platelet cyclooxygenase is peculiarly sensitive to ASA in uremia, and ASA affects primary hemostasis in uremia by a mechanism independent of cyclooxygenase inhibition."	( Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. Bonati, M; Gaspari, F; Livio, M; Orisio, S; Remuzzi, G; Viganò, G, 1987)	1.72
" Bioavailability of ASA at intramuscular administration to rabbits was close to that at intravenous injection and significantly higher as compared with intragastric administration."	( [Analgesic action and pharmacokinetics of lysine acetylsalicylate administered intramuscularly]. Chaĭka, LA; Khadzhaĭ, IaI; Kosheleva, LP; Libina, VV; Pichugin, VV, )	0.13
" The gastric emptying rates of dosage forms were extremely prolonged in beagle dogs after drug administration postprandially, and this restricted the use of beagle dogs as an animal model in bioavailability tests."	( Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates. Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1988)	0.27
" We have demonstrated that a 50 mg enteric-coated aspirin formulation (Astrix) which has an absorption rate much lower than soluble aspirin, is sufficient to inhibit platelet thromboxane synthesis while causing no major decrease in vascular prostacyclin synthesis."	( Effect of 50 mg enteric-coated aspirin (Astrix) on thromboxane and prostacyclin synthesis. Foreman, RK; James, MJ; Walsh, JA, 1987)	0.81
" The rate of absorption of ASA was faster and its peak plasma concentration was higher after the ingestion of CT."	( The absorption of acetylsalicylic acid from an enteric-coated formulation and the inhibition of thromboxane formation. Anttila, M; Kahela, P; Uotila, P, 1988)	0.27
" From the above results, it was concluded that this in situ experimental model of rectal absorption has advantages in that it can be used directly to measure the rectal absorption rate and to determine ratios of easily metabolized and poorly absorbed drugs."	( An in situ experimental model in rabbits for the study of rectal absorption. Hiura, M; Kasama, T; Mayuzumi, K; Minato, M; Minohara, K; Nakai, M; Ohshiro, K; Sakaguchi, Y, 1986)	0.27
" Bioavailability of aspirin from activated charcoal described by area under the curve was 19% of control."	( Reversible adsorption (desorption) of aspirin from activated charcoal. Filippone, GA; Fish, SS; Lacouture, PG; Lovejoy, FH; Scavone, JM, 1987)	0.87
"In an effort to improve the oral bioavailability of naltrexone [17-(cyclopropylmethyl)-4,5 alpha-epoxy-3,14-dihydroxymorphinan-6-one;1], a number of prodrug esters on the 3-hydroxyl group were prepared: the anthranilate (2), acetylsalicylate (3), benzoate (4), and pivalate (5)."	( Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach. Hussain, MA; Koval, CA; Myers, MJ; Shami, EG; Shefter, E, 1987)	0.27
"The effects of caffeine on the pharmacokinetics and bioavailability of aspirin were studied in 12 healthy adult male volunteers."	( Influence of caffeine on aspirin pharmacokinetics. Sriwatanakul, K; Thithapandha, A; Yoovathaworn, KC, )	0.67
"The bioavailability and pharmacokinetics of acetylsalicylic acid were studied in 6 volunteers, under a cross-over design, using plain compressed aspirin, two buffered preparations and an enteric-coated tablet."	( Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. Cerletti, C; de Gaetano, G; Dejana, E; Galletti, F; Latini, R; Marzot, M; Urso, R, 1986)	0.76
"The bioavailability of enteric coated and plain aspirin tablets was studied in four beagle dogs."	( Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. Amidon, GL; Fleisher, D; Lui, CY; Oberle, R, 1986)	0.74
" Administration of a tablet in a tablespoon of yoghurt is a good alternative, even though the bioavailability of certain preparations may be reduced."	( Alternatives to optimal administration of tablets. Hasselbalch, H; Hey, H; Jørgensen, F; Wamberg, T, 1985)	0.27
" Azapropazone has been found to be well absorbed, and benoxaprofen and fenclofenac somewhat more slowly, so for the latter two drugs their low rate of absorption might also be a factor in their reduced ulcerogenicity."	( Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs of varying ulcerogenicity. Rainsford, KD, 1986)	0.27
" Total urinary recovery, and recovery of salicyluric acid and the two SA glucuronides were not different, thus confirming the equivalent bioavailability and metabolite profile of the 2 ASA formulations."	( Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets. Montgomery, PR; Sitar, DS, )	0.13
" Following a single oral dose of 100 mg of flurbiprofen, drug bioavailability is equivalent using regimens of four 25-mg tablets, two 50-mg tablets, or one 100-mg tablet once daily."	( Pharmacokinetics of flurbiprofen. Brooks, CD; Kaiser, DG; Lomen, PL, 1986)	0.27
" Existing analytical methods do not permit determination of systemic bioavailability when low (less than 100 mg) doses of aspirin are administered."	( Preparation and analysis of deuterium-labeled aspirin: application to pharmacokinetic studies. FitzGerald, GA; Pedersen, AK, 1985)	0.74
" The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application."	( [The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. Altmayer, P; Cattarius-Korb, S; Krüger, B; Lang, E; Mutschler, E; Sörgel, F; Spahn, H, 1985)	0.27
" Phenylbutazone, aspirin and indomethacin were all well absorbed after oral administration, and the resultant plasma drug concentrations were closely similar to those produced when the drugs were administered intraperitoneally."	( Factors influencing the inhibitory action of anti-inflammatory drugs on carrageenin induced oedema. Green, AY; Green, D; Murray, PA; Wilson, AB, 1971)	0.59
" Bioavailability and pharmacokinetics of total serum ketoprofen studied in eight patients did not appear to be significantly modified by addition of aspirin."	( [Ketoprofen-aspirin interaction]. Chales, G; Flouvat, B; Louboutin, JY; Pawlotsky, Y; Roux, A, 1983)	0.84
"Recent studies evaluating the effect of slow releasing enteric-coated aspirin formulations have reported contradictory findings regarding the bioavailability of the active molecule in the circulating blood and the length of duration of the inhibitory effect on platelet function."	( Enteric-coated aspirin, platelet cyclooxygenase activity and function. Johnson, GJ; Radh, E; Rao, GH; White, JG, 1984)	0.85
"The 3 acetylsalicylic acid preparations showed at normal patients at the same elimination phase no significant differences concerning the bioavailability (comparison of the area under the concentration-time-curve)."	( [Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. Berlet, G; Chemnitius, KH; Schröber, R; Traeger, A; Zaumseil, J, 1984)	0.27
"When aspirin is administered by mouth in low doses, poor systemic bioavailability may contribute to its apparent dose-related "selective inhibition" of thromboxane A2 formation."	( Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. FitzGerald, GA; Pedersen, AK, 1984)	1.08
"Studies were performed in fasted rats to establish if the propensity of 4 non-steroidal anti-inflammatory (NSAI) drugs to elicit varying degrees of gastric mucosal damage following oral administration is related to their rate of absorption by the mucosal and subsequent inhibitory effects on prostaglandin (PG) production in vivo."	( Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructural integrity and prostaglandin levels in the rat gastric mucosa: relationship to drug uptake. Fox, SA; Osborne, DJ; Rainsford, KD, 1984)	0.27
" A significantly faster absorption rate was observed with the sodium bicarbonate-citrate buffer, when compared with the potassium bicarbonate-citrate buffer and the unbuffered tablets, which were equivalent."	( Comparative aspirin absorption kinetics after administration of sodium- and potassium-containing buffered solutions. Mason, WD, 1984)	0.65
" No significant difference was found in the bioavailability of either the aspirin or metoclopramide from the combination as compared to the individual components."	( The pharmacokinetics of the individual constituents of an aspirin-metoclopramide combination ('Migravess'). Dinneen, LC; Langemark, M; Manniche, PM, 1984)	0.74
" During the absorption phase isofezolac plasma levels were slightly decreased in association with isofezolac-aspirin, but bioavailability of isofezolac was not modified."	( The effect of antacid and aspirin on the bioavailability of isofezolac in man. Flouvat, B; Henry, JF; Rocher, I, 1984)	0.78
" When the drugs were taken on an empty stomach, activated charcoal given 5 min or 60 min afterwards reduced the bioavailability of the drugs by 75-98% or 10-60%, respectively."	( Do gastric contents modify antidotal efficacy of oral activated charcoal? Neuvonen, PJ; Olkkola, KT, 1984)	0.27
" This method has been applied to human bioavailability studies and the data are presented."	( Improved method for the determination of aspirin and its metabolites in biological fluids by high-performance liquid chromatography: applications to human and animal studies. Beach, CA; Bianchine, JR; Gerber, N; Kershaw, RA; Mays, DC; Sharp, DE, 1984)	0.53
" The bioavailability of meprobamate administered rectally to human volunteers as the marketed preparations DoloVisano Suppositories and Dolo-Visano Suppositories sine codeino, is similar to that observed following oral administration."	( The pharmacokinetics of meprobamate following its oral and rectal administration as a series of combinations with diphenhydramine, acetylsalicylic acid, codeine and pentaerythritol tetranitrate. Aylott, RI; Draffan, GH; Gilbert, JD; Sögtrop, HH, 1984)	0.27
" In both single and multiple dose studies significant sex differences were found in the plasma levels of SA, which were due, at least in part, to individual, sex-determined differences in the rate of absorption and elimination of SA; a slower absorption rate in men reduced the magnitude of the peak plasma levels of SA."	( Sex differences in the pharmacokinetics of salicylates. Trnavská, Z; Trnavský, K, 1983)	0.27
"The absorption and bioavailability of nabumetone, a novel anti-inflammatory drug, were investigated following administration of single oral doses alone, and with food, milk, antacids, and analgesics to healthy volunteers."	( Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Buscher, G; Dierdorf, D; Mügge, H; von Schrader, HW; Wolf, D, 1983)	0.27
" Butyric acid, by markedly reducing the absorption rate of aspirin, may be partially responsible for the unpredictable absorption of rectally administered aspirin."	( Colonic absorption of acetylsalicylic acid in the rat. Harmon, D; Hollander, D; Meshkinpour, H, 1984)	0.51
" after aspirin (1000 mg) and quinidine sulfate (200 mg), reduced their bioavailability by about 70% (aspirin) and 99% (quinidine)."	( Effect of ethanol and pH on the adsorption of drugs to activated charcoal: studies in vitro and in man. Alanen, T; Neuvonen, PJ; Olkkola, KT, 1984)	0.72
" Delayed treatment with ASA also reduced paracetamol-induced liver toxicity, suggesting that reduction of the absorption rate of paracetamol does not contribute essentially to the protection by ASA."	( Protection against paracetamol-induced hepatotoxicity by acetylsalicylic acid in rats. De Jong, J; De Vries, J; Lock, FM; Mullink, H; Van Bree, L; Veldhuizen, RW, 1984)	0.27
" The bioavailability of ascorbic acid during the first 400 min was reduced by half following simultaneous administration of aspirin."	( Impairment of absorption of ascorbic acid following ingestion of aspirin in guinea pigs. Basu, TK; Breacker, PJ; Ioannides, C; Stone, AN, 1982)	0.71
" After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy."	( Atenolol interaction with aspirin, allopurinol, and ampicillin. Axthelm, T; Kirch, W; Köhler, H; Mutschler, E; Schäfer-Korting, M, 1983)	0.57
" The results show that the bioavailability as well as the pharmacokinetic profile of orally administered tiaprofenic acid is not changed by the mentioned compounds."	( [On the pharmacokinetics of tiaprofenic acid and its possible interactions with acetylsalicylic acid and aluminum hydroxide (author's transl)]. Altmayer, P; Lücker, PW; Marećek, N; Penth, B; Wetzelsberger, K, 1981)	0.26
" Bioavailability studies carried out on 10 healthy male volunteers demonstrated that absorption from the enteric-coated pellet capsules was sustained and complete."	( Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability. Fleming, A; Graham, G; Portek, I, 1981)	0.56
"The effect of a saline cathartic combined with activated charcoal or activated charcoal alone on aspirin bioavailability was characterized in six healthy volunteers."	( Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. Anderson, WH; Czajka, PA; Mowry, JB; Sketris, IS; Stafford, DT, 1982)	0.78
" In order to compare the bioavailability of unchanged ASA from rapid- and slow-release formulations, the single-dose concentration profiles of ASA and SA were studied in healthy volunteers following intake of two different rapid-release (conventional and effervescent tablets) and three different slow-release (microencapsulated ASA in tablets and in capsules, and enteric-coated tablets) formulations of ASA, and of one slow-release formulation of sodium salicylate."	( Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and slow-release formulations, and in combination with dipyridamol. Brantmark, B; Melander, A; Wåhlin-Boll, E, 1982)	0.26
" These and control animals were sacrificed and, using inverted sacs, the rate of absorption of either dimethylnitrosamine and benzo(a)pyrene determined."	( Use of inverted intestinal sacs to assess the effect of gastrointestinal insult on carcinogen absorption. Capel, ID; Cosier, RS; Pinnock, MH; Williams, DC, 1981)	0.26
" Significant differences in the absorption rate were observed, with the solution having 16 mEQ of buffer being fastest, the solution having 34 mEq of buffer being intermediate, and the tablet being slowest."	( Kinetics of aspirin, salicylic acid, and salicyluric acid following oral administration of aspirin as a tablet and two buffered solutions. Mason, WD; Winer, N, 1981)	0.64
" There was no significant difference in the AUC-value between the two routes of administration, but a slower rate of absorption with no clear peak effect was found after rectal administration."	( Bioavailability of rectal aspirin in neurosurgical patients. Kanto, J; Klossner, J; Mäntylä, R; Yrjänä, T, 1981)	0.56
"The bioavailability of aspirin gum relative to unbuffered aspirin tablets was determined in six normal volunteers."	( Relative bioavailability of aspirin gum. Lesko, LJ; Woodford, DW, 1981)	0.87
"The bioavailability of aspirin from an aspirin aluminum tablet was compared with that from an aspirin tablet in humans by determining total salicylate excreted in the urine."	( The bioavailabilities of aspirin from an aspirin aluminum and an aspirin tablet and the effects of food and aluminum hydroxide gel. Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1981)	0.88
"A rapid simple and robust reversed-phase HPLC method was developed for rapid screening in bioavailability studies or comparative bioequivalence studies."	( Rapid high-performance liquid chromatographic determination of vancomycin in human plasma. Luksa, J; Marusic, A, 1995)	0.29
" Neither differences in bioavailability of ASA nor the formation of SA seems to contribute to the aspirin-elicited reactions."	( Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects. Anderson, P; Andersson, R; Boréus, LO; Dahlén, B; Zetterström, O, 1994)	0.75
" This open, randomized, crossover study was conducted to examine the effects of aspirin, the antacid Maalox (Rhone-Poulenc Rorer, Cologne, Germany), and cimetidine on the pharmacokinetics and bioavailability of a single oral dose of meloxicam 30 mg in healthy male volunteers."	( Interaction of meloxicam with cimetidine, Maalox, or aspirin. Busch, U; Heinzel, G; Narjes, H; Nehmiz, G, 1996)	0.77
" fruit extract incorporated in a traditional meal on the bioavailability of aspirin tablets 600 mg dose was studied in 6 healthy volunteers."	( Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. Aguye, IA; Mustapha, A; Yakasai, IA, )	0.61
" The bioavailability of these products was assessed in human subjects according to a cross-over design system."	( Discrepancy among dissolution rates of commercial tables as a function of the dissolution method. Part 7: Aspirin. Ammar, HA; el-Nahhas, SA; Emara, LH; Ghorab, MM; Salama, HA, 1997)	0.51
"In this study, the bioavailability of aspirin and paracetamol was compared in plain and soluble combination formulations in fasting, healthy volunteers."	( Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Muir, N; Nichols, JD; Stillings, MR; Sykes, J, 1997)	0.85
" In the present study, we evaluated the potential of omeprazole to interfere with the bioavailability of aspirin administered to rats either alone or complexed with the zwitterionic phospholipid, dipalmitoylphosphatidylcholine (DPPC)."	( Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Dial, EJ; Felder, TB; Giraud, MN; Illich, PA; Lichtenberger, LM; Sanduja, SK, 1997)	0.73
"Gastric absorption of aspirin and its relative bioavailability were reduced by an antisecretory dose of omeprazole; its inhibitory effect on gastric prostaglandin synthesis was consequently attenuated."	( Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Dial, EJ; Felder, TB; Giraud, MN; Illich, PA; Lichtenberger, LM; Sanduja, SK, 1997)	0.84
"To determine if treatment with low-dose aspirin (ASA) influences the bioavailability of orally administered alcohol and to assess whether this is caused by altered gastric emptying as measured by the paracetamol absorption test."	( Low-dose aspirin decreases blood alcohol concentrations by delaying gastric emptying. Carlsson, B; Jones, AW; Jönsson, KA; Kechagias, S; Norlander, B, 1997)	0.98
"Extent and rate of absorption of acetylsalicylic acid (ASA) from rapidly dispersing (Acesal Extra) and plain tablets (Acesal) relative to reference 1 (plain tablets, Aspirin) and from microcapsuled tablets (Micristin) relative to comparable listed tablets (reference 2, Colfarit) were assessed in 2 single-dose (0."	( Relative bioavailability of rapidly dispersing, plain, and microencapsuled acetylsalicylic acid tablets after single dose administration. Diedrich, F; Hoffmann, C; Krüger, WD; Sauter, R; Siegmund, W; Steinijans, VW; Zschiesche, M, 1998)	0.5
"The well-documented disadvantages of unfractionated heparin in the management of coronary syndromes, such as unpredictable bioavailability and maintenance of therapeutic range, has prompted several studies into the benefits of low-molecular-weight heparins (LMWHs)."	( Rationale for the management of coronary syndromes with low-molecular-weight heparins. Antman, E; Cohen, M; Fareed, J; Gurfinkel, E; Mautner, B, 1998)	0.3
" According to our results, omeprazole treatment did not influence the bioavailability from uncoated acetylsalicylic acid tablets but the absorption rate of salicylate from enteric-coated tablets was increased significantly."	( Interaction of omeprazole with enteric-coated salicylate tablets. Ayanoglu-Dülger, G; Imeryüz, N; Nefesoglu, FZ; Ulusoy, NB, 1998)	0.3
"Findings of the present study demonstrate that omeprazole treatment significantly increases the rate of absorption of single-unit enteric-coated medication."	( Interaction of omeprazole with enteric-coated salicylate tablets. Ayanoglu-Dülger, G; Imeryüz, N; Nefesoglu, FZ; Ulusoy, NB, 1998)	0.3
" The bioavailability of cutaneous aspirin was 4%-8% that of oral aspirin."	( Effects of cutaneous aspirin on the human stomach and duodenum. Cryer, B; Feldman, M; Kliewer, D; McAllister, L; Sie, H, )	0.73
" With a single administration of 100 mg/kg of the extract, aspirin blood levels remained unchanged, but salicylic acid bioavailability was reduced in 44% compared with control animals."	( Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. Castañeda-Hernández, G; Cruz, L; Navarrete, A, 1999)	0.55
" Despite a trend for slower gastric emptying with aspirin, the alcohol bioavailability increased and was associated with a 39% decrease in the first pass metabolism of alcohol (from 106+/-4 to 65+/-19 mg/kg, p<0."	( Mechanism of the aspirin-induced rise in blood alcohol levels. Amir, I; Baraona, E; Chayes, ZW; Gentry, RT; Lieber, CS; Roine, R; Sharma, R, 1999)	0.9
" In this study, the bioavailability of aspirin was compared in plain aspirin tablets, chewed tablets, effervescent tablets and Enteric-coated aspirin tablets."	( A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. Sagar, KA; Smyth, MR, 1999)	0.83
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
"The purpose of the present work was to study whether spinal cord injury (SCI) alters salicylate bioavailability after oral aspirin administration."	( Effect of experimental spinal cord injury on salicylate bioavailability after oral aspirin administration. Fuentes-Lara, G; García-López, P; Guízar-Sahagún, G, 1999)	0.74
"The bioavailability of salicylates on the healthy volunteers in this study was significantly affected by concomitant administration of 40 degrees alcohol (spirit), beer and milk."	( Influence of seven beverages on salicylate disposition in humans. Barthélémy, C; Odou, P; Robert, H, 2001)	0.31
" Based on the results obtained, it can be concluded that absorption of salicylate from the granules can be sufficiently described using a first-order linear model with an absorption rate constant of salicylate similar to that reported for an aqueous solution of aspirin administered orally to healthy subjects."	( Modeling drug absorption from enteric-coated granules. Dedík, L; Durisová, M, 2001)	0.49
"Endothelial dysfunction, defined as a deficit in the bioavailability of nitric oxide (NO), occurs as sequelae of many vascular diseases; however, the utility of supplementing NO to obviate the extent of disease is understudied."	( Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. Rudic, RD; Sessa, WC; Yu, J, 2002)	0.63
" Lack of interaction was assessed by determination of pharmacokinetic characteristics and relative bioavailability of both substances and salicylic acid (CAS 69-72-7, SA), administered in combination and as equally single dosed drugs."	( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers. Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003)	0.32
" The drug bioavailability (F) in camels, sheep and goats were 71."	( Comparative pharmacokinetics of salicylate in camels, sheep and goats. Ali, BH, )	0.13
" The rate of absorption of extended-release dipyridamole is considerably slower than that of immediate-release dipyridamole, while similar plasma concentrations are maintained to optimise antiplatelet efficacy."	( Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Lenz, T; Wilson, A, 2003)	0.32
" It is reported that the aspirin concentration in blood reaches its peak approximately 20 min after oral administration in healthy volunteers, but the absorption and bioavailability of aspirin in AMI may be quite different."	( Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement. Mohri, H; Niikawa, O; Nishiyama, A; Tsushima, M, 2003)	0.89
" The bioavailability of aspirin (based on salicylate concentrations) from the controlled-release formulation was approximately 90% relative to the solution, and drug release was not affected by co-administration of a standard breakfast."	( Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. Charman, SA; Charman, WN; Fitzgerald, GA; Frisbee, SE; Lockhart, EA; Monkhouse, DC; Weisman, S, 1993)	0.82
" Constitutive nitric oxide synthase (cNOS) is present in endothelial cells, platelets, leukocytes and neurons, yet no data are available on the effect of aspirin on cNOS and the bioavailability of NO produced by this enzyme."	( Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Korda, M; Madajka, M; Malinski, T; White, J, 2003)	0.92
" Therefore the bioavailability of NO increased only slightly in endothelium and did not reflect the increase in eNOS."	( Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Korda, M; Madajka, M; Malinski, T; White, J, 2003)	0.72
"Aspirin did not have a significant effect on the NO bioavailability in endothelial cells."	( Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Korda, M; Madajka, M; Malinski, T; White, J, 2003)	2.16
" The purpose of this open, randomized, three-factorial (three-treatment, three-period, six-sequence) Latin Square clinical study was to investigate the relative bioavailability of ASA and PSE as well as the establishment of bioequivalence after single administration of the fixed combination (final formulation for approval) of 500 mg ASA/30 mg PSE*HCl and the preliminary formulation of this combination."	( Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003)	0.32
" The relative bioavailability of salicylic acid was 105."	( [Study on relative bioavailability of aspirin in afenca tablet]. He, L; Jiang, X; Li, S; Lin, S; Yang, J; Zhou, J, 2003)	0.59
" Metastable and amorphous solids often display better solubility and bioavailability than the stable crystalline form of the API."	( Deposition and aggregation of aspirin molecules on a phospholipid bilayer pattern. Chen, D; Dong, W; Handa, H; Kurth, DG; Mao, G; Möhwald, H, 2005)	0.62
"Dipyridamole (DP) is an antiplatelet agent that shows decreased oral bioavailability with increased gastric pH that occurs with commonly prescribed antacids."	( Dipyridamole bioavailability in subjects with reduced gastric acidity. Brickl, RS; Derendorf, H; Eisert, W; MacGregor, TR; VanderMaelen, CP, 2005)	0.33
"We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals."	( Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. Conroy, RM; Cox, D; Crean, P; Curtin, RJ; Dooley, M; Fitzgerald, DJ; Maree, AO, 2005)	0.83
" Thirty-eight healthy volunteers and 38 type 2 diabetic patients were enrolled to test the hypothesis that the enhanced plasma degradation and lowered bioavailability of ASA in diabetic patients is associated with the attenuation of platelet response."	( Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. Bryszewska, M; Dolník, M; Gresner, P; Sikurová, L; Waczulíková, I; Watala, C, 2006)	0.33
"Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects."	( Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P, 2006)	0.33
" Lower bioavailability of these preparations and poor absorption from the higher pH environment of the small intestine may result in inadequate platelet inhibition, particularly in heavier subjects."	( Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Byrne, MF; Conroy, R; Cox, D; Dooley, M; Fitzgerald, DJ; Maree, AO, 2006)	0.57
" It is also possible that drug interactions with statins might reduce aspirin bioavailability and/or activity, thereby reducing platelet inhibition in aspirin-resistant patients."	( Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Alkonyi, B; Czopf, L; Feher, G; Kenyeres, P; Kesmarky, G; Koltai, K; Papp, E; Solyom, A; Toth, K, 2006)	2.01
" The pharmacokinetics of in vivo aspirin- and NO- released by NCX 4016, as well as the bioavailability of the two molecules, were not yet adequately studied."	( Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Gresele, P; Momi, S, 2006)	0.84
" Additionally, it increases NO bioavailability as a vascular level, and it may have the antiatherogenic properties of endogenously produced NO."	( Nitric oxide-releasing aspirin: will it say NO to atherothrombosis? Antoniades, C; Stefanadis, C; Tousoulis, D, 2007)	0.65
" However, the concomitant production of superoxide and other reactive oxygen species (ROS) during I/R may diminish the bioavailability of NO and hence compromise the beneficial effects."	( Prevention of postischemic myocardial reperfusion injury by the combined treatment of NCX-4016 and Tempol. Colantuono, G; Khan, M; Kumbala, D; Kuppusamy, P; Kutala, VK; Mandal, R; Potaraju, V, 2006)	0.33
" These include patients with poor bioavailability or noncompliance, an impaired platelet response to ASA in vitro and an increased, TX-independent hyperreactivity to collagen."	( Variable platelet response to aspirin in patients with ischemic stroke. Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007)	0.63
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" In contrast to aspirin, the response to clopidogrel is highly variable and reflects the bioavailability of the active metabolite and not "resistance" of the receptor to inhibition."	( Aspirin and clopidogrel resistance. Fitzgerald, DJ; Maree, A, 2007)	2.13
" There is a major thrust on the development of orally bioavailable anticoagulant drugs (anti-Xa and anti-IIa agents), which are slated to replace oral anticoagulants."	( Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Adiguzel, C; Bick, R; Clarke, M; Demir, M; Fareed, D; Fareed, J; Hoppensteadt, DA; Wahi, R, 2008)	0.6
" There is a major thrust on the development of orally bioavailable anti-Xa and IIa agents, which are slated to replace oral anticoagulants."	( Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Adiguzel, C; Bick, R; Clarke, M; Cunanan, J; Demir, M; Fareed, J; Iqbal, O; Wahi, R, 2008)	0.35
" However, the enzymes involved in this biosynthetic pathway, the bioavailability of the fatty acid substrate, and the occurrence of the reaction products (hydroperoxides and eight-carbon volatiles) are not fully understood."	( Influence of sporophore development, damage, storage, and tissue specificity on the enzymic formation of volatiles in mushrooms (Agaricus bisporus). Burton, KS; Combet, E; Eastwood, DC; Henderson, J, 2009)	0.35
"Oral triptans outperform oral ergotamine most because of the extremely low (< 1%) oral bioavailability of ergotamine."	( [Triptans versus other migraine medicine--secondary publication]. Tfelt-Hansen, P, 2009)	0.35
" Pharmacokinetic studies showed that montelukast bioavailability is not affected by food and did not interact with other drugs."	( Dose selection and dosing interval determination for LTRA use in asthma. Hendeles, L, 2000)	0.31
"We evaluated the bioavailability of each ingredient of the Polycap and determined any drug-drug interactions relative to single component reference preparations."	( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010)	0.36
"The bioavailability of the ingredients of the Polycap (T; test) when formulated as a single capsule was compared with that of identical capsules with each of its ingredients administered separately (R; reference) in a five-arm, randomized, single-dose, two-period, two-treatment, two-sequence, crossover trial with at least a 2-week washout period in a total of 195 healthy volunteers."	( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010)	0.36
"Comparative bioavailability was computed and no drug-drug interactions and no difference in comparative bioavailability were concluded for each ingredient based on point estimates of the T/R ratio of the geometric means falling within 80-125% for peak plasma concentration (C(max)), area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC(t)), and AUC from time zero to infinity (AUC(infinity))."	( Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010)	0.36
"Dispensing medicines into compliance aids is a common practice in pharmacy contrary to manufacturers' advice and studies have shown the appearance of light-sensitive tablets is compromised by such storage; we previously found evidence of reduced bioavailability at elevated temperature and humidity."	( Quality of medicines stored together in multi-compartment compliance aids. Donyai, P, 2010)	0.36
" The chemical stability of atenolol was not affected and we did not find evidence of changes to bioavailability with either make."	( Quality of medicines stored together in multi-compartment compliance aids. Donyai, P, 2010)	0.36
" In this study, we investigated the effects of iloprost infusion on urinary 11-dehydro-TXB₂ and 8-iso-PGF(₂α) excretion rate, as in vivo indexes of thromboxane-dependent platelet activation and lipid peroxidation, respectively, and on platelet-derived proinflammatory sCD40L and nitric oxide bioavailability in 44 patients with CLI while on chronic treatment with low-dose aspirin."	( Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. Cuccurullo, C; Davì, G; Di Iorio, P; Di Michele, D; Di Ruscio, P; Ferrante, E; Lattanzio, S; Laurora, G; Lessiani, G; Liani, R; Sgrò, G; Simeone, E; Vazzana, N, 2011)	0.78
" Response to aspirin was reassessed 1 month after hospital discharge and non-responders received a directly observed intake of aspirin to exclude any biological non-response due to bioavailability problems."	( Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. Bonnet, JL; Carrieri, P; Cohen, W; Cuisset, T; Fourcade, L; Fugon, L; Gaborit, B; Molines, L; Quilici, J; Roux, P, 2011)	1.08
"Most conventional ophthalmic dosage forms, though simplistic are limited by poor bioavailability in the posterior chamber of the eye."	( Protein based nanoparticles as platforms for aspirin delivery for ophthalmologic applications. Banerjee, R; Bellare, JR; Das, S, 2012)	0.64
" A low-dose, slow-release formulation of aspirin designed to inhibit platelets but to have little systemic bioavailability was as effective as higher doses."	( Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Belch, JF; Meade, TW; Mehta, Z; Price, JF; Rothwell, PM; Wilson, M, 2012)	0.99
"Human absorption studies are used to test new drug candidates for their bioavailability in different regions of the gastrointestinal tract."	( Magnetic Active Agent Release System (MAARS): evaluation of a new way for a reproducible, externally controlled drug release into the small intestine. Abert, S; Dietzel, CT; Hippius, M; Merkel, U; Richert, H; Stallmach, A, 2012)	0.38
" Hydrolytic effectiveness varies widely primarily from non-genetic variation of BChE activity that affects aspirin bioavailability in blood and the ability of aspirin to inhibit platelet aggregation."	( Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2). Allayee, H; Hartiala, J; Hazen, SL; Marathe, GK; McIntyre, TM; Tang, WH; Zhou, G, 2013)	2.05
"The present study evaluated the bioavailability and bioequivalence of fixed dose combination test formulation (atorvastatin 10 mg and aspirin 150 mg capsule) against marketed reference formulations (Lipitor® tablets 10 mg and Nu-Seals tablets 75 mg)."	( Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. Battula, R; Betha, MR; Cheerla, R; Gadiko, C; Khan, SM; Nakkawar, M; Thota, S; Tippabhotla, SK; Vobalaboina, V; Yergude, S, 2013)	0.83
" Clopidogrel resistance is likely to develop as a result of a decreased bioavailability of the active metabolite, due to genetic variation or concomitant drug treatment."	( Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part II: Potential causes and laboratory tests. Sas, K; Sztriha, LK; Vadász, D; Vécsei, L, 2013)	1.83
" The absorption rate of fluorescein isothiocyanate (FITC)-labeled lysozyme in the proximal intestine was higher than that for a marker of non-specific absorption, FD-10, and was suppressed by colchicine (endocytosis inhibitor)."	( Intestinal absorption of lysozyme, an egg-white allergen, in rats: kinetics and effect of NSAIDs. Hamura, K; Matsuo, H; Yokooji, T, 2013)	0.39
" The bioavailability of SS was complete and the maximal plasma concentration of SA (C max) after oral administration was 96."	( Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. Jaworski, K; Niewiński, P; Okoniewski, P; Poźniak, B; Świtała, M, 2013)	0.39
" The goals of the clinical development program were to demonstrate the following: improved gastrointestinal safety of PA relative to enteric-coated aspirin alone; bioequivalence and comparative bioavailability between the PA compounds and currently marketed enteric-coated aspirin; and long-term safety."	( PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. Bliden, KP; Brener, M; Franzese, CJ; Gesheff, MG; Gurbel, PA; Tabrizchi, A; Tantry, U, 2013)	0.85
" These findings indicate low-dose aspirin coadministration may decrease clopidogrel bioavailability but does not decrease its efficacy."	( Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. Cho, JY; Chu, K; Hong, KS; Jang, IJ; Ji, SC; Jung, KH; Lee, H; Lee, S; Lim, KS; Oh, J; Shin, D; Shin, KH; Yoon, SH; Yu, KS, 2014)	2.12
" In situ intestinal re-circulating perfusion experiments showed that the absorption rate of fluorescein isothiocyanate (FITC)-labeled OVA in the distal intestine was higher than that for a marker of non-specific absorption, FITC-dextran (FD-40), and that colchicine, a general endocytosis inhibitor, suppressed OVA absorption."	( Characterization of ovalbumin absorption pathways in the rat intestine, including the effects of aspirin. Matsuo, H; Nouma, H; Yokooji, T, 2014)	0.62
" While an aspirin prodrug exhibited comparable oral bioavailability and antiplatelet activity (i."	( Gastric-sparing nitric oxide-releasable 'true' prodrugs of aspirin and naproxen. Borhade, N; Burhan, A; Desai, DC; Dhiman, M; Gaikwad, P; Gund, M; Nemmani, KVS; Patil, M; Satyam, A; Sharma, A; Sharma, S; Sheikh, J; Thakre, G; Tipparam, SG, 2014)	1.05
" This is possibly due to decreased bioavailability of ASA caused by prolonged solvation and absorption of the enteric-coated formulations."	( Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid. Grønlykke, T; Haastrup, PF; Jarbøl, DE, 2015)	0.42
"The crystal structures of active pharmaceutical ingredients and excipients should be strictly controlled because they influence pharmaceutical properties of products which cause the change in the quality or the bioavailability of the products."	( The effect of microcrystalline cellulose crystallinity on the hydrophilic property of tablets and the hydrolysis of acetylsalicylic acid as active pharmaceutical ingredient inside tablets. Awa, K; Ozaki, Y; Shinzawa, H, 2015)	0.42
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."	( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. Bharate, SS; Vishwakarma, RA, 2015)	0.42
"New sources of dioxins and increased dioxin concentrations in the environment, coupled with their increased bioavailability along the food chain and accumulation in adipose tissues, contribute to various adverse long-term biological effects."	( Effect of tocopherol and acetylsalicylic acid on the biochemical indices of blood in dioxin-exposed rats. Całkosiński, I; Rosińczuk, J, 2015)	0.42
" However, these predictions are strongly affected by the highly variable first pass metabolism necessitating the evaluation of an absorption rate metric that is more independent of the first-pass effect."	( Toward Biopredictive Dissolution for Enteric Coated Dosage Forms. Al-Gousous, J; Amidon, GL; Langguth, P, 2016)	0.43
" For example, gastric ulcer has the potential to enhance absorption, bioavailability and therapeutic effects of aspirin, but this is rarely discussed in preference to the probability of gastro-intestinal bleeding side-effect."	( Drug-disease interactions: narrative review of aspirin in gastric ulcer. Nwose, EU; Yee, KC, 2016)	0.9
" It is important to understand the bioavailability of aspirin and its major metabolite, salicylic acid, since dosage and route of administration can vary for treating differing diseases, and the major side-effects of aspirin, upper gastrointestinal ulceration and bleeding, are dose-dependent."	( Bioavailability of aspirin in rats comparing the drug's uptake into gastrointestinal tissue and vascular and lymphatic systems: implications on aspirin's chemopreventive action. Dial, EJ; Edler, S; Fang, D; Li-Geng, T; Lichtenberger, LM; Phan, T; Philip, J, 2016)	1.01
"Resveratrol (RVT) is a stilbene with a protective effect on the cardiovascular system; however, drawbacks including low bioavailability and fast metabolism limit its efficacy."	( Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties. Chin, CM; Dos Santos, JL; Dutra, LA; Guanaes, JFO; Johmann, N; Lopes Pires, ME; Marcondes, S, 2017)	0.46
" However, obstacles to using phytochemicals for chemoprevention, including bioavailability and translational potential, must be resolved."	( Could Aspirin and Diets High in Fiber Act Synergistically to Reduce the Risk of Colon Cancer in Humans? Arnold, M; Huang, YW; Oshima, K; Pan, P; Wang, LS; Yearsley, M; Yu, J; Zhang, J, 2018)	0.96
" Lower ASA concentrations may be explained by reduced bioavailability associated with higher esterase activities."	( Investigation into the causes of aspirin resistance in healthy dogs. Court, MH; Haines, JM; Hegedus, RM; Hwang, JK; Lee, PM, 2019)	0.8
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Furthermore, the bioavailability of the APIs from the dosage form depends largely on these characteristics."	( Fiber-Array-Based Raman Hyperspectral Imaging for Simultaneous, Chemically-Selective Monitoring of Particle Size and Shape of Active Ingredients in Analgesic Tablets. Frosch, T; Popp, J; Wyrwich, E; Yan, D, 2019)	0.51
"The aim of this work was to formulate aspirin-loaded lipid based formulation in order to enhance oral bioavailability and inhibit gastric irritation."	( Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles. Akpa, PA; Attama, AA; Chime, SA; Ugwuanyi, CC, 2020)	1.08
" ASA treatment also evoked an increase in platelet and granulocyte counts and decreased systemic NO bioavailability along with increased markers of systemic oxidant stress such as higher GSSG/lower GSH concentrations in RBC."	( Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer. Berkowicz, P; Chlopicki, S; Derszniak, K; Jasztal, A; Kieronska-Rudek, A; Kij, A; Matyjaszczyk-Gwarda, K; Proniewski, B; Przyborowski, K; Smeda, M; Sternak, M; Stojak, M, 2020)	0.56
" Herein, we report application of a previously disclosed cyclic carbamate P1 linker which provided improved oral bioavailability in the imidazole-based 13-membered macrocycle to the 12-membered macrocycle."	( Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species. Arumugam, A; Bozarth, JM; Chacko, SA; Clark, CG; Corte, JR; Crain, EJ; Ewing, WR; Fang, T; Gilligan, PJ; Jeon, Y; Kaspady, M; Lai, A; Lam, PYS; Lou, Z; Luettgen, JM; Mathur, A; Myers, JE; Neithnadka, PR; Pabbisetty, KB; Raju, S; Rampulla, RA; Rossi, KA; Seiffert, DA; Sheriff, S; Wang, Y; Wexler, RR; Wong, PC; Wu, Y; Yang, W; Zheng, JJ, 2020)	0.56
"To perform a comparative bioavailability study between a test (re-formulation) and a reference acetylsalicylic acid formulation (Ecasil-81, 81 mg coated tablet) in healthy subjects under fed condition."	( Bioavailability study of two 81-mg coated tablet formulations of acetylsalicylic acid in fed healthy subjects . Antunes, NJ; Campos, R; Czezacki, AS; De Nucci, G; Dolores, RC; Mendes, GD; Moreno, RA; Previato, C, 2020)	0.56
"Agglomeration of active pharmaceutical ingredients (API) in tablets can lead to decreased bioavailability in some enabling formulations."	( Diagnosis of Agglomeration and Crystallinity of Active Pharmaceutical Ingredients in Over the Counter Headache Medication by Electrospray Laser Desorption Ionization Mass Spectrometry Imaging. Dimmitt, NH; Green, AM; Hubbard, ND; Khan, SM; McVey, PA; Taulbee-Cotton, BV; Van Meter, MI; Webster, GK, 2021)	0.62
" Panel members agreed to recognize polypill as effective in reducing cardiovascular events, blood pressure and lipids, cardiovascular risk and the weight of therapy, in therapeutic adherence improvement, in the absence of differences in bioavailability between drugs administered in fixed or free combinations and the better cost-effectiveness profile compared with standard care."	( The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus. Bianchi, S; Cafiero, D; Corona, T; Gambarelli, G; Izzi, C; Lopatriello, S; Menditto, E; Minghetti, P; Misciagna, V; Perrone-Filardi, P; Piccinocchi, G; Putignano, D; Scaglione, F; Trifirò, G, 2021)	0.62
" Furthermore, brain bioavailability of aspirin was determined by high performance liquid chromatography."	( Acetylsalicylic acid improves cognitive performance in sleep deprived adult Zebrafish ( Aslam, M; Bhat, A; Bishir, M; Chang, SL; Chidambaram, SB; Elumalai, P; Essa, MM; R, JP; Rashan, L; Ray, B; Sakharkar, MK; Yang, J, 2021)	0.89
" Here, a microstirring pill technology is reported with built-in mixing capability for oral drug delivery that greatly enhances bioavailability of its therapeutic payload."	( A Microstirring Pill Enhances Bioavailability of Orally Administered Drugs. Esteban-Fernández de Ávila, B; Fang, RH; Karshalev, E; Litvan, I; Mundaca-Uribe, R; Nguyen, B; Wang, J; Wei, X; Zhang, L, 2021)	0.62
" Our goal is to enhance the bioavailability and anticancer activity of aspirin and reduce its toxicity through successive generations of organoiron dendrimers."	( Aspirin-Based Organoiron Dendrimers as Promising Anti-Inflammatory, Anticancer, and Antimicrobial Drugs. Abd-El-Aziz, AS; Abdel-Rahman, LH; Abdelghani, AA; Benaaisha, MR; Bissessur, R; El-Ezz, DA; Fayez, AM, 2021)	2.3
"The therapeutic efficacy of clopidogrel as an antiplatelet drug varies among individuals, being the mainstream hypothesis that its bioavailability depends on the individual genetic background and/or interactions with other drugs."	( Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022)	0.72
" Importantly, cocrystallization simultaneously improves bioavailability of both parent drugs."	( Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization. Hao, Y; He, X; Sun, CC; Wang, C; Wang, K; Zhao, X, 2022)	0.93
" The metabolic details of GM on MSTG-A, MSTG-B and Gualtherin were clarified in this study, providing data support and basis for clinical development and bioavailability improvement."	( Biotransformation and metabolism of three methyl salicylate glycosides by gut microbiota in vitro. Chai, K; Deng, Q; Dong, Y; He, Y; Li, X; Lv, F; Ren, X; Shan, D; She, G; Song, R; Wang, X; Zhao, Y; Zheng, Y; Zhong, X, 2023)	0.91
" At 3 d and 7 d, the experimental group's absorption rate was higher than the control group, and the experimental group's hematoma absorption rate was faster than the control group."	( Clinical characteristics and dynamic evaluation of hematoma morphology in patients with aspirin-related intracerebral hemorrhage. Huang, W; Xu, LR; Zhao, Y, 2023)	1.13
" The use of nanoparticles may increase the bioavailability of aspirin, allowing it to be more efficiently absorbed by the body and produce a more significant analgesic effect."	( EVALUATION OF PAIN-KILLING ACTION OF ACETYLSALICYLIC ACID NANOPARTICLES ON THERMAL NOCICEPTION IN MICE. Al-Alsadoon, L; Al-Saffar, M; Taqa, G, 2023)	1.15

Dosage Studied

Aspirin, a widely used anti-thrombotic drug, achieved comparable activity in this model system at a dosage of ca. 300 mg/kg. The major side-effects of aspirin, upper gastrointestinal ulceration and bleeding, are dose-dependent.

Excerpt	Relevance	Reference
" Step 7 spermatids decreased significantly at both dosage levels of PGE2 and at the higher dosage level of PGE1."	( The effect of prostaglandins and prostaglandin inhibitors on spermatogenesis. Abbatiello, ER; Kaminsky, M; Weisbroth, S, 1975)	0.25
" Gastric mucosal lesions occurred in 50 to 70% of the animals in the various dosage groups, including deep ulcers in 20%."	( Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. Aures, D; Bugat, R; Grossman, MI; Thompson, MR, 1976)	0.5
"An oral dosing of either acetylsalicylic acid (ASA) or taurocholic acid (TCA) to pylorus-ligated rats subjected to water-immersion stress produced severe damage to the gastric musoca in contrast to the irritation observed in non-stressed ones."	( Effects of L-glutamine of acetylsalicylic acid or taurocholic acid-induced gastric lesions and secretory changes in pylorus-ligated rats under normal or stress conditions. Hung, CR; Okabe, S; Takagi, K; Takeuchi, K, 1976)	0.26
" Gross bleeding from the pouch treated with ASA was never observed with the concomitant dosing of ASA and L-glutamine 50 or 100 mM."	( Effects of L-glutamine on acetylsalycylic acid induced gastric lesions and acid back diffusion in dogs. Hung, CR; Murata, T; Okabe, S; Takagi, K; Takeuchi, K, 1976)	0.26
" Hence it might not be always necessary to take into consideration changes in the surface area as a function of dissolution rate, and the 1n W infinity/(W infinity) versus time plot devised by Kitazawa & others might be a useful and simple means of obtaining the dissolution rate constant of an active ingredient from a dosage form such as compressed tablet."	( Interpretation of dissolution rate data from in vitro testing of compressed tablets. Johno, I; Kitazawa, S; Minouchi, T; Okada, J, 1977)	0.26
"Male Wistar rats were dosed daily by gavage for 200 days with either (1) aspirin, 200 mg/kg; (2) acetaminophen, 200 mg/kg; (3) aspirin and acetaminophen, 200 mg/kg of each; (4) aspirin and acetaminophen, 100 mg/kg of each or (5) vehicle alone."	( Failure to observe pathology in the rat following chronic dosing with acetaminophen and acetylsalicylic acid. Nera, EA; Thomas, BH; Zeitz, W, 1977)	0.49
" Treatment at the same dosage for a period of 12 days produced a significant decrease in the mean numbers of preleptotene and pachytene spermatocytes and spermatids."	( A quantitative study of the effects of acetylsalicylic acid on spermatogenesis and organs of the rat. Persaud, TV; Scott, JE, 1978)	0.26
" Potencies of estrogens varied greatly, but all compounds tested prevented DIC at adequate dosage levels."	( Disseminated intravascular coagulation induced by progesterone in the pregnant rat. Prevention by estogens. Stamler, FW, 1977)	0.26
" Potencies of estrogens varied greatly, but all compounds tested prevented DIC at adequate dosage levels."	( Disseminated intravascular coagulation induced by progesterone in the pregnant rat. Prevention by estogens. Stamler, FW, 1977)	0.26
"Fifteen patients with seropositive rheumatoid arthritis were treated for 2-weeks periods with 150 mg flurbiprofen daily and with flubriprofen in the same dosage plus 3 g aspirin daily, the treatments being administered in random allocation."	( Flurbiprofen-aspirin interaction: a double-blind crossover study. Brooks, PM; Khong, TK, 1977)	0.82
" For each medicine the information is presented under four headings: nature and purpose of the drug, dosage and administration, unwanted effects, and keeping qualities."	( Minimun information for sensible use of self-prescribed medicines. An international consensus. , 1977)	0.26
"2 The acetyl-(14)C residue was bound to renal proteins in a linear manner in increasing amounts with increasing dosage up to 100 mg/kg."	( Aspirin, protein transacetylation and inhibition of prostaglandin synthetase in the kidney. Caterson, RJ; Duggin, GG; Horvath, J; Mohandas, J; Tiller, D, 1978)	1.7
" This dosage of aspirin does not affect the hypotensive activity of arachidonic acid nor the oedematous properties of carrageenan in the rat."	( [Role of platelets in arterial hypotension induced by arachidonic acid and in carrageenan induced edema in the rat]. Damas, J; Volon, G, 1979)	0.61
" Time-effect and dose-response curves were generated from the relief and change in pain-intensity scores."	( Comparative analgesic potency of aspirin and ibuprofen. Cooper, SA; Kruger, GO; Needle, SE, 1977)	0.54
" In addition, dose-response derived potencies show fenbufen more potent than aspirin and at least as potent as phenylbutazone in all five tests."	( Fenbufen, a new anti-inflammatory analgesic: synthesis and structure-activity relationships of analogs. Child, RG; Osterberg, AC; Sloboda, AE; Tomcufcik, AS, 1977)	0.49
" dosing caused a small significant drop, especially at trough level."	( Diflunisal, a new-acting analgesic and prostaglandin inhibitor: effect of concomitant acetylsalicylic acid therapy on ototoxicity and on disposition of both drugs. Ferber-Perret, F; Perrier, CV; Schulz, P; Steelman, SL; VandenHeuvel, WJ, 1979)	0.26
"To determine the feasibility of twice daily dosing of enteric-coated aspirin (EntrophenR), a preliminary trial on 10 patients with rheumatic diseases was conducted."	( Twice-daily dosing of enteric-coated aspirin in patients with rheumatic diseases. Bensen, WG; Fam, AG; Laskin, CA; Little, HA; Paton, TW, )	0.64
" During the dosing period, females received 300mg/kg of M73101 showed pronounced body weight depression and decrease in food and water intake."	( [Reproduction study of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101) in rabbits. Administration of M73101 during the period of major organogenesis (author's transl)]. Kosazuma, T; Obori, R; Tanaka, H; Tanigawa, H; Yoshida, J, 1979)	0.26
" The findings of this study are comparable to those of other studies and it is concluded that tolfenamic acid, in the relatively high dosage employed in this trial, is free from any irritant effect on the gastric mucosa."	( Comparative effects of tolfenamic acid and acetylsalicylic acid on human gastric mucosa. A double-blind crossover trial employing gastroscopy, extern gastrocamera and multiple biopsies. Axelsson, CK; Christiansen, LV; Johansen, A; Poulsen, PE, 1977)	0.26
" A twice day dosage schedule seems to be clinically adequate, 375 mg twice daily proving to be equally effective as glafenin 200 mg three times daily."	( Diflunisal: efficacy in postoperative pain. Rodda, B; Van Winzum, C, 1977)	0.26
" Papillitis of the renal system may result from a comparable dosage of aspirin compound mediates with phenacetin."	( Harmful effects of "aspirin compounds". Najjar, TA, 1977)	0.81
" Blood loss was significantly increased during dosage with all three salicylate preparations."	( The effects of enteric coating of aspirin tablets on occult gastrointestinal blood loss. Champion, GD; Corrigan, AB; Day, RO; Graham, GG; Haski, A; Hewson, J; Howe, GB; Paull, PD, 1977)	0.54
" Better results were produced with 1200 mg oxaproxin daily than with a 600 mg dosage level, suggesting that there is a close dose-response relationship."	( Oxaprozin versus aspirin in rheumatoid arthritis: a double-blind trial. Dequeker, J; Jamar, R, 1978)	0.6
" The intended dosage was 2 tablets every 4 hours as necessary for relief of menstrual pain."	( Ibuprofen therapy for dysmenorrhea. Bolognese, RJ; Corson, SL, 1978)	0.26
" The symptoms of salicylism correlated closely with serum salicylate levels, which, in turn, correlated well with the dosage in g/m2."	( Dosage of salicylates for children with juvenile rheumatoid arthritis. A prospective clinical trial with three different preparations of acetylsalicylic acid. Mäkela, AL; Mattila, M; Yrjänä, T, 1979)	0.26
" It is concluded that the arthralgia was often self-limiting, that aspirin had a small beneficial effect, that allopurinol, in the dosage studied, may have had a slightly deleterious effect, but that it would be worth studying larger dosages of allopurinol because the dosage studied did not affect the serum uric acid concentration."	( Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. Allan, WG; Fox, W; Girling, DJ; Horsfall, PA; Nunn, AJ; Plummer, J, 1979)	0.77
" Two dosage regimes were tested."	( The aspirin-ibuprofen interaction in rheumatoid arthritis. Ashworth, ME; Ferry, DG; Grennan, DM; Kenny, RE; Mackinnon, M, 1979)	0.82
" The investigation was carried out as a two-part, randomized cross-over trial, and with a test dosage of either 1 g X 4 or 2 g X 2 per day, given to 10 and 14 male students, respectively, during two 5-day periods separated by a one week interval."	( Gastrointestinal blood loss caused by controlled-release and conventional acetylsalicylic acid tablets. Brandslund, I; Klitgaard, NA; Rask, H, 1979)	0.26
" This new dissolution tester possibly can be useful in determining drug release from solid dosage forms and correlating it with in vivo bioavailability because dissolution rate can be controlled easily with the adjustment of air pressure without complicated changes in the apparatus, there is no excessive settling of particles, and complete drug dissolution can be achieved with no clogging of the screen."	( New in vitro dissolution test apparatus. Nasir, SM; Nasir, SS; Wilken, LO, 1979)	0.26
"The labeled dosage schedule that has long been on pediatric aspirin preparations is at variance with the recommendation in authoritative medical references, studies demonstrating antipyretic effectiveness in children, and the prescribing habits of pediatricians as revealed by a poll conducted by the authors."	( Aspirin dosage for infants and children. Clayton, JM; Done, AK; Yaffe, SJ, 1979)	1.94
"A dosage of 10 mg/kg body weight Na-salicylate has no depressive effect on uterine motility."	( [Influence of na-salicylate on uterine motility in labour (author's transl)]. Kunath, H; Michels, W; Möller, R; Seewald, HJ; Voigt, R; Zanke, S, 1979)	0.26
" It appears from this study that in these cases prophylaxis against venous thromboembolism using aspirin in a dosage of 600 mg bid is ineffective."	( Aspirin prophylaxis of venous thromboembolic disease following fracture of the upper femur. Channon, GM; Wiley, AM, 1979)	1.92
"Beagle bitches were administered aspirin at either 100 or 400 mg/kg/day between Days 15 and 22 or Days 23 and 30 postmating, and corresponding control groups were dosed with vehicle during one of these same time periods."	( Aspirin: teratogenic evaluation in the dog. Allen, HL; Bokelman, DL; Robertson, RT, 1979)	1.98
" The degree of gastric or intestinal irritation seen with dosing of other drugs was as follows; indomethacin greater than diclofenac Na greater than ibuprofen greater than aspirin greater than phenylbutazone or indomethacin greater than CH-800 = diclofenac Na greater than ibuprofen greater than phenylbutazone, respectively."	( [Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)]. Ohtsuki, H; Okabe, S; Tabata, K, 1979)	0.45
"Furosemide (20 mg) was administered intravenously to 7 healthy volunteers, before and after 4 days of oral administration of aspirin in uricosuric dosage (1 g daily)."	( Effect of combined administration of furosemide and aspirin on urinary urate excretion in man. Komninos, Z; Mayopoulou-Symvoulidou, D; Mountokalakis, T; Rallis, D, 1979)	0.72
" These results suggest that Y-8004 may make feasible a reduction in dosage or a withdrawal of the steroid prescription."	( [Pharmacological studies of 2-(5H-(1)benzopyrano[2,3-b]pyridin-7-yl)propionic acid (Y-8004). (3) Its interaction with anti-inflammatory agents]. Foto, K; Imayoshi, T; Kadobe, Y; Maruyama, Y, 1977)	0.26
" The dose-response curve of KC-6141 was parallel to that of aspirin, suggesting it is an aspirin-like compound."	( Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit platelet aggregation in vitro and rat platelet retention. Kato, T; Umetsu, T, 1978)	0.5
" These data do not provide pharmacokinetic support for a general reduction of the Doleron dosage in elderly subjects."	( Absorption and elimination of D-propoxyphene, acetyl salicylic acid, and phenazone in a combination tablet (Doleron): comparison between young and elderly subjects. Bodin, NO; Danielson, K; Gustafsson, B; Haglund, G; Melander, A; Westerlund, D, 1978)	0.26
" Increasing the heparin dosage postoperatively to 3 X 7500 IU/24 h effectively prevented the incidence of thrombosis by reducing it to 11% in these high-risk patients."	( [Heparin in the prevention of thromboembolism after elective hip-joint operations (author's transl)]. Schöndorf, TH, 1978)	0.26
" There are pronounced intersubject differences in salicylate elimination kinetics; dosage must be individualized on the basis of plasma concentration and clinical response."	( Clinical pharmacokinetics of aspirin. Levy, G, 1978)	0.55
" Both drugs were injected intraperitoneally at the dosage of 4 mg/kg body weight daily during a 6-day period into 40 rats rendered nephritic by rabbit nephrotoxic serum injection."	( Indomethacin and lysine acetylsalicylate in rats with autologous nephrotoxic serum nephritis. Biochemical and morphological studies. Cioffi, A; Conte, F; Di Belgiojoso, GB; Donati, MB; Saruggia, M; Sessa, A, 1978)	0.26
" At the dosage level employed, no significant differences were noted between the two anti-inflammatory agents in regard to efficacy."	( Fenoprofen in rheumatoid arthritis: a controlled crossover multi-centre study. Gum, OB, 1976)	0.26
" In constrast, 3H-indometacin injected like ASA and PBZ in subtherapeutic dosage diappeared from the blood in a threephasic process."	( [Antiphiogistic drugs. Sudies on the pharmocokinetics of anti-inflammatory agents]. Havemann, D, 1977)	0.26
" Increases in dosage of PGE2 produced a progressive reduction in mean blood pressures, heart, and kidney weights."	( Effects of prostaglandin E2 and prostaglandin inhibitors on adrenal regeneration hypertension. Eversole, WJ; Paulson, DJ, 1977)	0.26
" Tablets allowed to disintegrate spontaneously prior to dosing yielded aggregates of various sizes which failed to produce uniform patterns of antipyresis."	( Antipyretic testing of commercial aspirin formulations in rats. DePalma, PD; Eby, RZ; Loux, JJ; Yankell, SL, 1977)	0.54
"2 gm aspirin appears predictive of the success of long-term dosage of aspirin."	( Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Champion, GD; Day, RO; Graham, GG; Paull, PD, 1977)	0.77
" This method has provided us with an accurate evaluation of the corticosteroid dose-response curve and the effect of bases."	( Effect of bases and accelerants on the anti-inflammatory activity of topical corticosteroids. Gaylarde, PM; Sarkany, I, 1976)	0.26
" Because of variation in the levels reached using a fixed dosage schedule, treatment should be individualised."	( Salicylate therapy and drug interaction in rheumatoid arthritis. Barraclough, DR; Laby, B; Muirden, KD, 1975)	0.25
" Laboratories) were investigated following dosage with single tablets."	( Evaluation of an enteric coated aspirin preparation. Champion, GD; Day, RO; Graham, GG; Paull, PD, 1976)	0.54
" The very shallow dose-response curves for flurbiprofen compared with acetylsalicylic acid, especially in the mouse and the rat test systems, are not due to an unreliable or abnormal absorption, which suggests that in these species the mode of action of flurbiprofen is not identical with that of acetylsalicylic acid."	( Some biological properties of flurbiprofen, an anti-inflammatory, analgesic and antipyretic agent. Adams, SS; McCullough, KF; Nicholson, JS, 1975)	0.25
" The dosage of ASA was 1 g 3 times daily for 3 days."	( The effects of acetylsalicylic acid on the human gastric mucosa as revealed by gastrocamera. Edmar, D, 1975)	0.25
" For optimal therapeutic responses, individualization of aspirin dosage by following serum salicylate levels is recommended."	( Correlation of plateau serum salicylate level with rate of salicylate metabolism. Gupta, N; Paulus, HE; Sarkissian, E, 1975)	0.5
" Between the effects of this dosage of phenylbutazone and other non-steroidal antirheumatic drugs, however, no significant difference could be detected."	( [Clinical study on a new acetylsalicylic acid/paracetamol preparation with gastric acid resistant coating (Safapryn), and on two various phenylbutazone dosages in patients with primary chronic polyarthritis as based on a new evaluation method]. Anderson, JA; Bell, AM; Brooks, PM; Buchanan, WW; Fowler, PD; Lee, P; Walker, JJ, )	0.13
"An automated high-pressure liquid chromatographic (HPLC) method for the separation and determination of aspirin, phenacetin, and caffeine in pharmaceutical dosage forms is descreibed."	( Automated high-pressure liquid chromatographic analysis of aspirin, phenacetin, and caffeine. Ascione, PP; Chrekian, GP, 1975)	0.71
" Emesis occurred frequently after dosing at the rate of 50 mg/kg of body weight, a dosage that would be required for a convenient 12-hour dosing interval."	( Aspirin dosages for the dog. Brant, RJ; Yeary, RA, 1975)	1.7
"It is shown on the basis of pharmacokinetic simulations and experimental data that adequate evaluation of aspirin dosage forms with different absorption rates by urinary excretion measurements in man requires that such measurements be made during the first hour after drug administration."	( Assessment of aspirin absorption rate from urinary excretion rate measurements. Levy, G; Yacobi, A, 1975)	0.83
" The procedure was applied to commercial dosage forms."	( Differentiating nonaqueous titration of aspirin, acetaminophen, and salicylamide mixtures. Blake, MI; Bode, DW; DeNardo, JJ; Rhodes, HJ, 1975)	0.52
"Twelve healthy subjects were placed on aspirin in a dosage of 600 mg five times daily for 14 days."	( Aspirin and lymphocyte transformation. Davis, K; Hoth, M; Smith, MJ, 1975)	1.97
" The use of optimum concentration of polyethylene glycol 6000 in physical mixtures or coprecipitates would seem advantageous in the preparation of solid dosage forms containing acetylsalicylic acid."	( Dissolution of acetylsalicylic acid from acetylsalicylic acid-polyethylene glycol 6000 coprecipitates. Asker, AF; Whitworth, CW, 1975)	0.25
"91 hours) of orally administered aspirin and rapid elimination (biologic half-life, 32 minutes) of salicylates, oral dosage of 100 mg/kg every 12 hours maintained serum salicylate concentration greater than 30 mug/ml, which was considered to be therapeutically effective."	( Pharmacokinetics and dosage of aspirin in cattle. Baggot, JD; Gingerich, DA; Yeary, RA, 1975)	0.82
"The daily dosage of salicylates is traditionally very high for patients with juvenile rheumatoid arthritis."	( Dosage of salicylates for children with juvenile rheumatoid arthritis. A preliminary report. Haapasaari, J; Mäkelä, AL; Tryänä, T, 1975)	0.25
" Groups of homozygotes were dosed by gavage with aspirin, phenacetin and paracetamol for 4 weeks."	( The induction of renal papillary necrosis in Gunn rats by analgesics and analgesic mixtures. Axelsen, RA, 1975)	0.51
" Dosage of VK744 was 300 mg TID for 2 days before, 5 days during, 3 days after saturation dive."	( Hematology and blood chemistry in saturation diving: I. Antiplatelet drugs, aspirin, and VK744. Bishop, B; Francey, I; Freeman, D; Philp, RB, 1975)	0.48
" In the uncommon occurrence of asthma and diabetes in the same patient, insulin dosage should be considered as a factor in all such asthmatics who do not respond well to conventional therapy."	( Diabetes mellitus and insulin in an aspirin sensitive asthmatic. Caplin, I, 1976)	0.53
"The detection of a small amount of 13C labelled methyl benzoate and its metabolites in human urine dosed 13C labelled aspirin was carried out by a new mass fragmentographic technique."	( A new technique for the detection of metabolites labelled by the isotope 13C using mass fragmentography. Abe, H; Sano, M; Sasaki, S; Yotsui, Y, 1976)	0.46
" The dosage should also be adjusted with respect to the age, sex and individual sensitivity of the organism."	( Effect of continuous, long-term administrations of acetylsalicylic acid on hematological and hemocoagulation changes in the rat. Blehová, Z; Drbohlavová, H; Navrátil, L, 1992)	0.28
" The protective effect of inhibitors when administered before, but not after, 3MI dosing suggests it is the inhibition of PHS activity in activation of 3MI, not in production of prostanoids which prevented the disease process."	( The role of prostaglandin H synthase in 3-methylindole-induced pneumotoxicity in goat. Acton, KS; Boermans, HJ; Bray, TM, 1992)	0.28
" We have used dose-response curves to quantitate the potentiation of adenosine 5'-diphosphate (ADP)-induced aggregation and thromboxane (TXA2) generation by 5-hydroxytryptamine (5-HT) and adrenaline in human citrated platelet-rich plasma."	( Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. Bochner, F; Duncan, EM; Lloyd, JV; Rodgers, SE; Vanags, DM, 1992)	0.28
" Aspirin in either dosage did not appear to have any effect on the window vasculature when given immediately after light exposure."	( Effect of aspirin on photodynamic therapy utilizing chloroaluminum sulfonated phthalocyanine (CASP). Craig, JR; Flock, S; Small, S; Stern, SJ, 1992)	1.6
" Patients received prednisone, at a dosage of 40 mg/d, for 4 weeks."	( Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992)	0.51
" The volume of UNDW causing a 20% fall in FEV1 (UNDW PD20) was calculated by linear interpolation on the dose-response curve."	( Protective activity of inhaled nonsteroidal antiinflammatory drugs on bronchial responsiveness to ultrasonically nebulized water. Bianco, S; Pieroni, MG; Refini, RM; Robuschi, M; Sestini, P; Vaghi, A, 1992)	0.28
"Differences in bioavailability of many drugs from their various dosage forms have been shown to be relatively common in human medicine."	( Bioavailability and bioinequivalence of drug formulations in small animals. Watson, AD, 1992)	0.28
"Bioavailability studies have been performed with ten healthy volunteers on different dosage forms of acetylsalicylic acid (ASA) in order to assess the bioavailability of two different ASA gums compared with commercial ASA tablets."	( Bioavailability of two formulations of acetylsalicylic acid gums. Bianchi, A; Bonina, FP; Bousquet, E; Ciampini, N; Montenegro, L; Tirendi, S, 1992)	0.28
" Treated with a high dosage of aspirin, the patient is asymptomatic after a 7-month follow-up, with regression of coronary lesions."	( [Kawasaki disease in Pernambuco, Brazil. Considerations on a case seen in a general hospital]. Barros, GS; Brindeiro Filho, D; de França, NA; Pontes, GA; Saraiva, LR, 1992)	0.57
" A flexible treatment schedule was applied to the follow-up of all the pregnancies, and included low dose aspirin, steroids at medium-low dosage and, if needed, azathioprine (AZA) after 20 weeks of gestation."	( Systemic lupus erythematosus and pregnancy: a prospective study. Balestrieri, G; Cattaneo, R; Di Mario, C; Faden, D; Gastaldi, A; Lojacono, A; Spatola, L; Tanzi, P; Tarantini, M; Tincani, A, )	0.34
" Therefore, the authors recommend 50 mg/d as the optimal dosage for low dose aspirin therapy in geriatric patients."	( Optimal low dosage of acetylsalicylic acid (ASA) for the prevention and treatment of ischemic cerebrovascular disease in geriatric patients. Li, CF; Li, H; Luo, Y; Ma, ZZ; Tang, HC; Yin, ZJ, 1992)	0.51
" Women presenting with unstable angina or myocardial infarction should receive aspirin 325 mg as soon as the diagnosis is confirmed, and this dosage should be continued on a chronic basis."	( Aspirin for the prevention of vascular death in women. Corn, CR; Hamilton, SF; McAnally, LE, 1992)	1.95
" The rates of gastric emptying of both dosage forms in dogs tended to be faster than or similar to those in humans, whereas the rates in pigs were slower."	( Gastric emptying of tablets and granules in humans, dogs, pigs, and stomach-emptying-controlled rabbits. Aoyagi, N; Kaniwa, N; Ogata, H; Tanioka, Y; Uchiyama, M; Yasuda, Y, 1992)	0.28
"Daily administration of acetyl salicylic acid (ASA) and ibuprofen leads to an appreciable retardation in the process of retinal degeneration in the RCS rat which is dependent on the dosage given."	( [The effect of cyclooxygenase inhibitors on the course of hereditary retinal dystrophy in RCS rats]. el-Hifnawi, ES; Haug, H; Kühnel, W; Laqua, H; Orün, C, 1992)	0.28
"It is concluded that aspirin does affect the platelet response to shear forces, but this requires higher dosage (greater than 300 mg/day), suggesting a mechanism probably different from that of interference with thromboxane formation."	( High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Edmondson, SF; Kovacs, IB; Ratnatunga, CP; Rees, GM, 1992)	1
" The slope of the dose-response curve of bromfenac was significant."	( Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain. Beaver, WT; Edquist, IA; Forbes, JA; Gongloff, CM; Jones, KF; Schwartz, MK; Smith, FG; Smith, WK, 1992)	0.54
" To explain this phenomenon, 6-keto-PGF1 alpha and von Willebrand factor were dosed in the incubation media."	( In vitro platelets/endothelial cells interactions in presence of acetylsalicylic acid at various dosages. de Sèze, O; Doutremepuich, C; Lalanne, MC; Ramboer, I, 1992)	0.28
" There has been no recurrence of pain after stepwise reduction over one year of the steroid dosage until its discontinuation."	( [Giant-cell arteritis limited to the femoral arteries]. Baumann, G; Bogner, J; Haschka, C; Spengel, FA; Stautner-Brückmann, C, 1992)	0.28
" It is suggested that the effect of aspirin in low dosage on platelet aggregation might be ineffective in many patients without control of aspirin hydrolysis velocity in blood."	( Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis. Akopov, SS; Gabrielian, ES; Grigorian, GS, 1992)	0.91
" Maintenance therapy with the same dosage is also recommended."	( [Antiplatelet therapy in cardiac diseases]. Aosaki, M; Hosoda, S; Iwade, K; Kimata, S, 1992)	0.28
"5 to 5 x 10(4)IU/mL, approximately 1/100 the therapeutic dosage for humans) and interleukin-1 (IL-1) (1."	( Experimental study on Reye's syndrome: inhibitory effect of interferon alfa on acetylsalicylate-induced injury to rat liver mitochondria. Enzan, H; Kurashige, T; Miyahara, M; Takeda, K; Tomoda, T, 1992)	0.28
" No effect on APTT was detectable in this dosage after 3 h infusion."	( Reocclusion after thrombolysis: a problem solved by hirudin? Eschenfelder, V; Rübsamen, K, 1991)	0.28
" Additional administration of metoclopramide in combination with 100 mg ASA was more effective as compared to a single dosage of 1000 mg ASA."	( Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Grotemeyer, KH, 1991)	0.28
" For heartworm-negative dogs, mean (+/- SD) aspirin dosage that inhibited collagen-induced platelet reactivity by at least 50% was 6 (+/- 2) mg/kg of body weight given once daily."	( Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. Boudreaux, MK; Dillon, AR; Ravis, WR; Sartin, EA; Spano, JS, 1991)	0.84
" However, whether ASA may affect pain after exercise or whether other dosage intervals would be more beneficial needs further study."	( A double-blind, placebo-controlled study of acetylsalicylic acid (ASA) in trained runners. Fuchs, JE; Lisse, JR; MacDonald, K; Thurmond-Anderle, ME, 1991)	0.28
"The inhalation challenge with lysine-aspirin (L-ASA) using the dosimeter method allows the construction of a dose-response curve and the quantitative estimation of airway responsiveness to the drug."	( Aspirin-induced asthma and bronchial hyperresponsiveness. Cocco, G; Masi, C; Melillo, E; Melillo, G; Padovano, A, 1991)	2
" Six dogs were given cimetidine at dosage of 10 mg/kg orally every 8 hours, and 6 dogs were given omeprazole orally at dosage of 2 mumol/kg (0."	( Comparison of effects of cimetidine and omeprazole on mechanically created gastric ulceration and on aspirin-induced gastritis in dogs. Bright, RM; DeNovo, RC; Jenkins, CC; Patton, CS; Rohrbach, BW, 1991)	0.5
" Incidence of side effects and toxicity may be reduced by choice of drug and modification of dosing regimen."	( Nonnarcotic analgesics and tricyclic antidepressants for the treatment of chronic nonmalignant pain. Richlin, DM, 1991)	0.28
" The 5-lipoxygenase inhibitor diethylcarbamazine and the LTD4/LTE4 receptor antagonist LY 171883 markedly reduced mortality in dose-response fashion."	( Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis. Gross, NJ; Holloway, NO; Narine, KR, 1991)	0.28
"Maximal inhibition of platelet thromboxane A2 production was sustained during long-term dosing with controlled-release aspirin, whereas basal prostacyclin biosynthesis fell only slightly and systemic synthesis of prostacyclin stimulated by bradykinin was preserved."	( Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. Clarke, RJ; FitzGerald, GA; Mayo, G; Price, P, 1991)	0.71
" At 24 hours, 202 patients were randomized to continue intravenous heparin therapy (n = 99) in full dosage or to discontinue heparin therapy and begin an oral antiplatelet regimen of aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103)."	( A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Aylward, PE; Federman, J; Giles, RW; Harris, PJ; Hodge, RL; Nelson, GI; Thompson, PL; Thomson, A; Tonkin, AM; Walsh, WF, 1991)	0.72
" Newer dosing regimens for currently available thrombolytic agents, as well as new thrombolytic agents, are currently under active investigation and will be the subject of intense research over the next few years."	( Thrombolytic therapy: then and now. Cole, PL, 1991)	0.28
" While steroid dosage was gradually decreased, administration of acetylsalicylic acid (for three months 100 mg daily, then three times daily 100 mg) brought about complete disappearance of the visual signs."	( [The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities]. Berg, PA; Leo-Kottler, B; Weller, M; Wiethölter, H, 1991)	0.28
" There was disagreement concerning the dosage of heparin and the exact use of betablockers, aspirin, warfarin, ACE-inhibitors, magnesium and antiarrhythmics."	( [Drug therapy of acute coronary syndrome. Summary of a hearing arranged by the Norwegian Cardiologic Society and the Institute of pharmacotherapy]. Amlie, JP; Aursnes, I; Osnes, JB; Platou, ES; Smiseth, OA, 1990)	0.5
" These results demonstrate that high aspirin dosage does not reduce the restenosis rate more than low dosage."	( [Effects of high and low doses of acetylsalicylic acid on the restenosis rate after initially successful coronary angioplasty]. Grimme, M; Kochsiek, K; Schanzenbächer, P; Walter, U, 1991)	0.55
"Aspirin (acetylsalicyclic acid) was administered to rats intravenously, orally, and intraintestinally at different doses or in different dosage forms."	( The pharmacokinetics of aspirin in rats and the effect of buffer. Fu, CJ; Mason, WD; Melethil, S, 1991)	2.03
" Gastroduodenal mucosal damage was assessed 2 hours after aspirin dosage by video-endoscopic techniques."	( Age does not influence acute aspirin-induced gastric mucosal damage. Avots-Avotins, A; Bjorkman, DJ; Mitchell, MD; Moore, JG, 1991)	0.82
" All active treatments were significantly superior to placebo, and the slope of the dose-response curve for bromfenac was significant."	( Evaluation of bromfenac, aspirin, and ibuprofen in postoperative oral surgery pain. Beaver, WT; Edquist, IA; Forbes, JA; Schwartz, MK; Smith, FG, 1991)	0.58
" Whereas the death rate was nearly the same in all three former dosage groups the total reinfarction rate was higher (22."	( Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study. Förster, W; Handreg, W; Hoffmann, W; Kampe, W; Muche, J; Nitschke, M, 1991)	0.53
"The efficacy of aspirin for prevention of thrombotic graft occlusion after coronary artery bypass grafting (CABG) depends both on the dosage and time window of administration."	( Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Baron, DW; Gavaghan, TP; Gebski, V, 1991)	0.93
" Oral temperatures were recorded at 15 minute intervals from 30 minutes post dosing to 8 hours post endotoxin administration."	( Antipyretic activity of tebufelone (NE-11740) in man. Jain, AK; McMahon, FG; Meredith, MP; Powell, JH; Vargas, R, 1991)	0.28
" Based upon the results of the first two groups, the third group (adjusted aspirin group) of six cats was studied in which the aspirin dosage was adjusted in order to maintain an inhibition of in vitro platelet aggregation."	( Pulmonary arteriography and hemodynamics during feline heartworm disease. Effect of aspirin. Rawlings, CA, )	0.59
"5 mg of aspirin given twice a week, and the third group of six cats was given aspirin at a sufficient dosage to block in vitro platelet aggregation throughout the study."	( Morphologic changes in the lungs of cats experimentally infected with Dirofilaria immitis. Response to aspirin. Farrell, RL; Mahood, RM; Rawlings, CA, )	0.78
" We challenge these premises and discuss a number of technical errors that underlie Feinstein's writings: he generally ignores the tendency of nondifferential exposure misclassification to dilute associations; he inappropriately interchanges measure of disease occurrence, which leads him to erroneous assertions regarding differences among studies; and he asserts that absence of a dose-response gradient precludes causality, despite the fact that causal effects need not follow a monotonic dose-response curve over the entire range of exposure."	( Scientific standards of criticism: a reaction to "Scientific standards in epidemiologic studies of the menace of daily life," by A.R. Feinstein. Greenland, S; Kelsey, JL; Savitz, DA; Stolley, PD, 1990)	0.28
" Thus, in clinical use of aspirin or ticlopidine, it may be expected that the lower dosage of aspirin or ticlopidine with lower frequencies of side effects inhibits platelet aggregation effectively with the combination of trapidil rather than dipyridamole."	( Effect of the combination of antiplatelet agents in man: combination of aspirin, trapidil, ticlopidine and dipyridamole. Akedo, Y; Nagakawa, Y; Orimo, H; Yano, H, 1990)	0.81
" On the basis of earlier findings that aspirin is able to sensitize platelets to the action of PGI2 and produce beneficial changes in platelet sensitivity, we decided to treat this girl with a daily dosage of 20 mg aspirin orally."	( Successful therapy of the prostaglandin defect "Wien-Hietzing" (lack of platelet high-affinity binding sites for prostaglandin I2). Gludovacz, D; Kaliman, J; Sinzinger, H; Steurer, G, 1990)	0.55
" Platelet function and urinary prostaglandin production were assessed immediately before and on the seventh day of dosing in both studies and in the second study, repeated on the tenth day of dosing."	( Selective inhibition of platelet cyclooxygenase with controlled release, low-dose aspirin. McLeod, LJ; Roberts, MS; Seville, PR; Vial, JH, 1990)	0.5
" Clinical information is available in the literature concerning aspirin dosage and stroke prevention following transient ischemic attack (TIA)."	( Aspirin and stroke prevention: how much? Toffol, GJ, 1990)	1.96
" Our results demonstrate the efficacy of combined therapy, but the efficacy of acetylsalicylic acid or dipyridamole alone and the most effective acetylsalicylic acid dosage remain in question."	( European Stroke Prevention Study. ESPS Group. , 1990)	0.28
"Because intravenously administered immune globulin (IVIG) is effective in reducing the incidence of coronary artery aneurysms in Kawasaki syndrome when given at a dose of 400 mg/kg daily for 4 days, we undertook a multicenter clinical trial comparing two dosage regimens of IVIG."	( Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. Barron, KS; Cox, DG; Franklin, W; Goldberg, SJ; Higashino, SM; Lee, M; Murphy, DJ; Ruttenberg, HD; Silverman, ED; Wright, GB, 1990)	0.28
"Ninety-two children with juvenile rheumatoid arthritis were randomly assigned to treatment in a multicenter, double-blind, 12-week trial designed to compare the efficacy and safety of a liquid formulation of ibuprofen at a dosage of 30 to 40 mg/kg/day versus those of aspirin at a dosage of 60 to 80 mg/kg/day."	( Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. Bernstein, B; Brewer, EJ; Fink, CW; Giannini, EH; Gibbas, D; Hoyeraal, HM; Miller, ML; Passo, MH; Person, DA; Sawyer, LA, 1990)	0.46
" The second group also of 10 patients was treated with CBS 120 mg qid and after 2 days they received aspirin and CBS simultaneously in the dosage mentioned above for another 4 days."	( [Protective effect of colloidal bismuth subcitrate on gastric mucosal lesion induced by aspirin]. Chen, J; Chen, SP; Wen, SH, 1990)	0.72
" The risk of therapy with acetyl salicylic acid (ASS) in low dosage is significantly smaller."	( [Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct]. Dahn, G; Kothe, K, 1990)	0.28
" Dose-response to ADP was studied at three concentrations in 20 dogs."	( The validity of canine platelet aggregometry in predicting vascular graft patency. Cabusao, EA; Ellinger, J; Greisler, HP; Henderson, SC; Klosak, JJ; McGurrin, JF; Tattersall, CW, )	0.13
" Prior dosing with aspirin may increase acceptability of niceritrol and hence improve compliance."	( Effects of aspirin upon the flushing reaction induced by niceritrol. Betteridge, DJ; Dickson, AC; Jay, RH, 1990)	1
"Aspirin, which is an effective anti-platelet agent, given in the low dosage of 60 to 100 mg per day appears to be beneficial for patients with a history of unstable angina, myocardial infarction, transient ischaemic attacks and stroke."	( Aspirin and coronary heart disease. Clinical applications. Koutts, J, 1990)	3.16
" At the same time, the effects of oral dosage with aspirin, and the exchange of stimulated and non-stimulated plasma were investigated."	( Dietary polyenoic fatty acids change the response of cat blood platelets to inductions of aggregation by ADP. Davidson, BC; Haggan, J, 1990)	0.53
"Aspirin at very ultra low dosage was tested in healthy volunteers (n = 20) in a randomized, double-blind and placebo-controlled trial."	( Aspirin at very ultra low dosage in healthy volunteers: effects on bleeding time, platelet aggregation and coagulation. Anne, MC; de Sèze, O; Doutremepuich, C; Lalanne, MC; Le Roy, D, 1990)	3.16
", consistently produced a nearly maximal hypothermic response in non tolerant rats, whereas this dosage induced an elevation of body temperature in tolerant rats."	( Modification of rat thermal responses to morphine by alpha-FMH suggests a role for neural histamine in morphine tolerance. Arrigo-Reina, R; Spadaro, C, 1990)	0.28
"To evaluate the effectiveness of gammaglobulin in decreasing the incidence of coronary artery lesions in Kawasaki disease, a randomized controlled study in 136 patients was conducted using high doses of gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d (gammaglobulin group) and aspirin alone at the same dosage (aspirin group)."	( High-dose gammaglobulin therapy for Kawasaki disease. Matsuoka, H; Matsushima, M; Nagashima, M; Ogawa, A; Okumura, N, 1987)	0.45
" Multiple dosing appeared to lead to a substantial increase in half-life; a twice daily dosage regimen would, therefore, be adequate for maintenance of therapeutic levels in dogs."	( Pharmacokinetics of aspirin and its application in canine veterinary medicine. Knottenbelt, DC; Morton, DJ, 1989)	0.6
"The effects on platelet function of a four-week administration of aspirin at a low dosage (100 mg daily) were compared in two groups, 14 healthy young volunteers and 14 patients with coronary heart disease."	( [Effects of low-dose acetylsalicylic acid on thrombocytes in health subjects and in patients with coronary heart disease]. Bleifeld, W; Kupper, W; Schuster, O; Terres, W, 1989)	0.51
"The pharmacokinetic profile of an innovative formulation of soluble aspirin (l-ornithine acetylsalicylate, ldB 1003) was compared with that of conventional tablets and two other soluble dosage forms (d, l-lysine acetylsalicylate and a buffered effervescent formulation of acetylsalicylic acid) after administration of single oral doses in six normal volunteers."	( Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Attardo Parrinello, G; Barzaghi, N; Gatti, G; Perucca, E; Vitiello, B, 1989)	0.75
" Platelet accumulation at the PTA site occurred with both doses of aspirin, with no differences between the two dosage groups."	( Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries. Ahmadi, R; Dudczak, R; Ehringer, H; Jung, M; Koppensteiner, R; Leitha, T; Minar, E; Stümpflen, A, 1989)	0.51
" The time course and dose-response for the effect of PMA at 23 degrees C closely correlate with the phosphorylation of a set of relatively "slowly" phosphorylated proteins (P20, P35, P41, P60), but not the rapidly phosphorylated P47 protein."	( Synergistic release of arachidonic acid from platelets by activators of protein kinase C and Ca2+ ionophores. Evidence for the role of protein phosphorylation in the activation of phospholipase A2 and independence from the Na+/H+ exchanger. Banga, HS; Feinstein, MB; Halenda, SP; Lau, LF; Zavoico, GB, 1989)	0.28
" The use of 20% ethanol as a dosage vehicle enhanced the protective effects of all drugs tested and the ethanol vehicle alone provided 45% protection."	( Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis. Okafor, JP; Oyekan, AO, 1989)	0.28
" Male Wistar rats (n = 30) were starved for 24 h, then dosed orally with aspirin suspension (300 mg/kg body weight)."	( Gastric epithelial mucus--a densitometric histochemical study of aspirin-induced damage in the rat. Berrisford, RG; Dixon, MF; Wells, M, 1985)	0.74
" There was a dose-response effect for the indomethacin and aspirin groups, with higher doses having a greater inhibitory effect."	( The effect of indomethacin, aspirin, and ibuprofen on bone ingrowth into a porous-coated implant. Mills, W; Trancik, T; Vinson, N, 1989)	0.81
" During the chronic dosing study, there was a significant increase in the Vmax (total and unbound) for the formation of SU, whilst the Km and SU clearance remained constant."	( Salicylate pharmacokinetics in patients with rheumatoid arthritis. Francis, HW; Friesen, WT; Owen, SG; Roberts, MS, 1989)	0.28
" There was a significant dose-response regression between flurbiprofen 25 mg and both of the higher dosages."	( An evaluation of flurbiprofen, aspirin, and placebo in postoperative oral surgery pain. Beaver, WT; Forbes, JA; Rosenmertz, SK; Selinger, LR; Yorio, CC, 1989)	0.56
" The controversies of dosage high (= 1,500 mg/d) or low (= 20-30 mg/d) are opposed by the concept of the individual dosage via the ASA-test."	( [Anticoagulants and inhibitors of thrombocyte function in the long-term treatment of arteriosclerosis]. Heine, H; Norden, C, 1989)	0.28
" It was concluded that sucralfate lacks a mucosal protection capacity at the dosage studied in human subjects ingesting large doses of aspirin over a two-week period."	( Lack of gastric mucosal protection by sucralfate during long-term aspirin ingestion in humans. Sievert, W; Stern, AI; Ward, F, 1989)	0.72
" Plasma aspirin concentrations measured in blood obtained simultaneously from permanent catheters in a systemic artery and portal vein for 6 hours after dosage showed a large variation in the plasma aspirin concentration: time profile between pigs."	( Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Bochner, F; James, MJ; Lloyd, JV; McIntosh, GH; Rodgers, SE; Siebert, DM, 1989)	1.06
" This is probably best achieved by means of low oral dosage in the form of sustained-release ASA formulation where the inhibition of platelet function probably occurs mainly in the presystemic circulation."	( [Acetylsalicylic acid in the treatment of arterial thromboembolic diseases. 1. Pharmacologic aspects]. Faergeman, O; Husted, SE; Krusell, LR; Nielsen, HK, 1989)	0.28
" The dosage of ASA in the majority of works has been about 1,000 mg daily while isolated investigations have shown good effect from doses as low as 60 mg daily."	( [Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation]. Faergeman, O; Fasting, H; Husted, SE; Krusell, LR; Nielsen, HK, 1989)	0.28
" The observation of a dose-response relation between risk of Reye's syndrome and dose of aspirin ingested during the antecedent illness provides further supportive evidence for a causal link between Reye's syndrome and aspirin."	( Reye's syndrome. Hurwitz, ES, 1989)	0.5
" However, only marginal knowledge is available about the upper GI-tolerability of ASS in this dosage regiment."	( [Endoscopic studies of gastroduodenal tolerance of 100 mg versus 500 mg acetylsalicylic acid daily: a randomized double-blind study with healthy probands]. Dammann, HG; Marinis, E; Müller, P; Simon, B, 1989)	0.28
" The results showed that the tablets can be a suitable dosage form for pentaestergum-coated microcapsules to give a delayed drug release."	( Evaluation of compressibility of pentaestergum coated aspirin microcapsules. Dorle, AK; Pathak, YV, )	0.38
" There were eight rats in each dosage group."	( Sustained delivery of aspirin by means of ALCAP ceramics. Bajpai, PK; Muzina, DJ; Snow, KR, 1989)	0.59
" Flurbiprofen showed a linear dose-response relationship with respect to gastric injury and serum drug levels."	( The effects of flurbiprofen, aspirin, cimetidine, and antacids on the gastric and duodenal mucosa of normal volunteers. An endoscopic and photographic study. Friedman, H; Lanza, FL; Royer, GL; Schwartz, JH; Seckman, CE; Stubbs, CM, 1989)	0.57
" Neuropharmacological studies on anaesthetized rats showed that chemosensory discharge, recorded from a sectioned carotid nerve, increased in response to salicylate injections with a similar dose-response pattern to the hyperventilation."	( Arterial chemoreceptor involvement in salicylate-induced hyperventilation in rats. Birrell, GJ; McQueen, DS; Ritchie, IM, 1989)	0.28
" Increased dosage did not produce a proportional increase in the permeation and maximizing the skin-drug contact did not increase penetration: both factors indicate that absorption from deposited drug films was dissolution rate-limited."	( Absorption through human skin of ibuprofen and flurbiprofen; effect of dose variation, deposited drug films, occlusion and the penetration enhancer N-methyl-2-pyrrolidone. Akhter, SA; Barry, BW, 1985)	0.27
" Met (1 X 10(-6) M) increased the tension of both normal and diabetic atria, but in diabetic atria, the dose-response curve to Met was shifted to the left and the efficacy of Met was enhanced."	( Hypersensitivity to methoxamine in atria isolated from streptozotocin-induced diabetic rats. Canga, L; Sterin-Borda, L, 1986)	0.27
" The dose-response curves were obtained with good precision and allowed a discrimination between the teratogenetic and unspecific toxic effects and a comparison of the toxic potency of the six drugs."	( Routine teratogenicity test that uses chick embryos in vitro. Burnand, MB; Kucera, P, 1987)	0.27
"A 64-year-old woman, who was taking long-term enteric-coated aspirin therapy for rheumatoid arthritis, was prescribed approximately twice her normal dosage (7."	( Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated aspirin. Gay, RM; Hudson, P; Shkrum, MJ, 1989)	0.75
" A dose-response relationship was found for the three doses of etodolac, which was significant for summed pain relief scores for up to 8 hours."	( Relief of dental surgery pain: a controlled 12-hour comparison of etodolac, aspirin, and placebo. Bergman, SA; Nelson, SL, )	0.36
" A significant positive dose-response relationship was obtained for the three doses of etodolac."	( Comparison of etodolac, aspirin and placebo for pain after oral surgery. Frank, JE; Gaston, GW; Mallow, RD, )	0.44
" Failures (22%) were due to such factors as insufficient dosage at the very beginning of our experience or severe depressive syndrome."	( [Chronic refractory pain in cancer patients. Value of the spinal injection of lysine acetylsalicylate. 60 cases]. Abergel, A; Amiot, JF; Babinet, P; Boule, D; Glowinski, J; Hardy, F; Mechali, D; Palacci, JH; Pellerin, M; Wingtin, LN, 1987)	0.27
" Eight hours before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued."	( Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Aldridge, HE; Bonan, R; Bourassa, MG; David, PR; Henderson, M; Kazim, F; Lespérance, J; Salvatori, VA; Schwartz, L, 1988)	1.92
" The prolonged protection against aspirin-induced bleeding achieved with twice daily dosing with ranitidine has clinical potential in the management of patients taking anti-inflammatory drugs."	( Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine. Hawkey, CJ; Marshall, S; Somerville, KW, 1988)	0.91
" In the presence of 10(-4) acetylsalicylic acid (ASA), cumulative dose-response curves of phasic and tonic contractions for LTC4 were shifted to the right of controls, whereas curves of the phasic motility for LTD4 remained unaltered."	( On the inotropic effects of leukotrienes in the isolated urinary bladder of guinea pigs and rats. Chaud, MA; Gimeno, AL; Gimeno, MF; Viggiano, JM, 1985)	0.27
" Aspirin, at a dosage that almost completely inhibits both circulating cell and renal arachidonate metabolites, worsens the morphologic expression of rabbit nephrotoxic nephritis and negatively influences the clinical course of the disease."	( Effect of aspirin and sulindac in rabbit nephrotoxic nephritis. Benigni, A; Bertani, T; Carminati, C; Cutillo, F; Morelli, C; Remuzzi, G; Rocchi, G; Verroust, P, 1986)	1.58
" IC50 was calculated from dose-response curves of ADP-, adrenaline-, collagen- and arachidonic acid-induced aggregation."	( Effects of acetylsalicylic acid on platelet aggregation in male and female whole blood: an in vitro study. Bellido, I; Camara, S; de la Cruz, JP; Martos, F; Sanchez de la Cuesta, F, 1986)	0.27
" The inhibition was characterized by displacement of the dose-response to histamine to the right, in parallel, without depression of the maximum."	( Actions of nizatidine on the rat uterus, dog stomach and experimentally induced gastric lesions. Evans, DC; Lin, TM; Ruffolo, RR; Warrick, MW, 1986)	0.27
" We conclude that long-term dosing with 27 mg ECA three times daily results in profound inhibition of platelet TXA2 production, and diminished in vitro and in vivo platelet reactivity."	( Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. Deykin, D; Faigel, D; Jakubowski, JA; Stampfer, MJ; Vaillancourt, R, 1986)	0.58
" However, twice daily dosing with dazoxiben was effective."	( Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. Ambler, J; Butler, KD; Butler, PA; Shand, RA; Wallis, RB, 1987)	0.27
" The plasma concentration of fenflumizole reached a peak 2-3 hr after the dosing in non-fasted as well as fasted rats."	( Antithrombotic and ulcerogenic effects of fenflumizole, a new anti-inflammatory imidazole derivative, in rats. Nabata, H; Okazaki, A; Sakai, K; Uchino, M; Yamazaki, T, 1987)	0.27
"The aim of this study was to determine the effect of 1 week of antacid dosing on the aspirin-induced potential differences (PDs) across the gastric mucosa."	( Persistent gastric-protective effect of antacid evaluated by measurement of transmucosal gastric potential difference. Bergmann, JF; Caulin, C; Dorf, G; Segrestaa, JM; Simoneau, G, 1988)	0.5
" The volunteers also received 50 mg modified release capsules daily for 6 days to determine the effect on collagen, ADP and arachidonate induced platelet aggregation and thromboxane production, and to compare the pharmacokinetics after repeated dosing with the parameters obtained after the single dose."	( Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Bochner, F; Lloyd, JV; Morris, PM; Siebert, DM; Williams, DB, 1988)	0.5
" Possible explanations for these negative findings include inadequate dosage or form of omega-3 fatty acids and the antiplatelet drugs administered, excessive variability in graft response due to uncharacterized immunologic histocompatibility, and the possible influence of non-platelet-mediated mechanisms."	( Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts. DeCampli, WM; Handen, CE; Kosek, JC; Miller, DC; Mitchell, RS, 1988)	0.66
"The gastric emptying rates of oral dosage forms of different sizes were studied in humans and beagle dogs measuring of marker drugs such as acetaminophen, aspirin and pyridoxal phosphate in plasma or urine."	( Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates. Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1988)	0.47
"Enteric-coated granules with different densities and tablets of different sizes were prepared in order to study the effect of these physical properties of dosage forms on the gastric emptying rates in humans."	( Gastric emptying rates of drug preparations. II. Effects of size and density of enteric-coated drug preparations and food on gastric emptying rates in humans. Aoyagi, N; Ejima, A; Kaniwa, N; Motoyama, H; Ogata, H; Yasumi, H, 1988)	0.27
" The results allow the conclusion: --main antiphologistic effect of the combination is due to acetylsalicylic acid; --when combined with 250 mg DL-alpha-tocopherol/kg BW acetylsalicylic acid dosage can be reduced by one-third to 167 mg/kg BW and still have the same effect as ASS alone (250 mg/kg BW); --further reductions of ASS and/or DL-alpha-tocopherol dosage minimize the antiinflammatory effect."	( [Effect of various combinations of DL-alpha-tocopherol and acetylsalicylic acid on adjuvant arthritis in the rat]. Brandt, K; Elmadfa, I; Schlotzer, E; Sobirey, M, )	0.13
" Here we report on a study including 41 patients with peripheral arterial disease and/or coronary heart disease before treatment and after receiving ASA in an individually controlled dosage regimen."	( Individually controlled acetylsalicyclic acid (ASA) in the long-term treatment of patients with arteriosclerosis. Heine, H; Misselwitz, F; Norden, C, 1988)	0.27
" The majority of patients were given aspirin 1300 mg daily, but the optimum dosage was not properly evaluated."	( The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs. Goodman, DS, 1987)	0.55
" An initial dose-response study in 48 subjects showed that 200- and 400-mg doses of cimetidine conferred a sufficient reduction in gastric mucosal injury to warrant further study."	( Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine. Chapman, RC; Kimmey, MB; Saunders, DR; Silverstein, FE, 1987)	0.54
" Their occurrence varies, both qualitatively and quantitatively, and an attempt is made to assess these differences, although it may be that they are related directly to differences in dosage and therapeutic efficacy."	( Aspirin, paracetamol and non-steroidal anti-inflammatory drugs. A comparative review of side effects. Fowler, PD, )	1.57
" Medication was given as one dosage in the evening: 2-5 mg/kg KG ASS or 5-10 mg Flunarizine."	( [Prevention of migraine with flunarizine and acetylsalicylic acid. A double-blind study]. Pothmann, R, 1987)	0.27
" Total days of exposure was used as an index of dose, and no dose-response relationship between aspirin use and IQ was found."	( Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Berendes, HW; Klebanoff, MA, 1988)	1.94
"Steady-state serum salicylic acid (SA) concentrations and the formation rates of salicyluric acid (SU), salicylphenolic glucuronide (SPG), salicylacyl glucuronide (SAG), and gentistic acid (GA), and the excretion rate of unchanged SA were determined in three normal subjects following the administration of a single oral dose of acetylsalicylic acid (ASA) 37 mg kg-1 and during multiple dosing with ASA 56 mg kg-1 day-1."	( Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. Day, RO; Dromgoole, SH; Furst, DE; Paulus, HE, )	0.13
" A prevention of thromboembolic disease by individual dosage of heparin must be considered in patients at high risk for thromboembolic disease."	( [Mortality and morbidity of thromboembolism in drug prevention--5-year analysis]. Hopp, A; Hopp, H; Knispel, J, 1988)	0.27
"Buffered solid dosage forms containing aspirin, magnesium hydroxide, and aluminum hydroxide are blended with acidic ethanol to extract the aspirin and salicylic acid rapidly."	( Determination of aspirin and salicylic acid by reverse-phase liquid chromatography. Heidemann, DR; Schulenberg, ES; Smith, WH, )	0.74
" Moreover, it is worth recording the rapid remission in all subjects of the principal clinical and humoral systems following the treatment with ASA + high dosage Ig given via intravenous."	( [Clinical and therapeutic aspects of Kawasaki disease. Clinical contribution]. Alvano, L; De Vita, L; Di Luna, F; Fidelini, N; Massimo, L; Sottile, R, )	0.13
" Before the fertility experiments, the pharmacokinetics of the drugs were determined to find dosage regimens by which drug concentrations known as active from human anti-inflammatory therapy could be reached and maintained in the animals."	( Effect of non-steroidal anti-inflammatory drugs on fertility of male rats. Blazaki, D; Löscher, W, 1986)	0.27
" At the end of each dosing interval we measured platelet aggregation and thromboxane formation in response to four aggregating agents and to whole blood coagulation."	( A dose-ranging study of the antiplatelet effect of enteric coated aspirin in man. Bochner, F; Duncan, EM; Herd, CM; Lloyd, JV; Rodgers, SE; Tunbridge, LJ, 1987)	0.51
"Cumulative dose-response curves for histamine induced responses in mesometrial (ME) and antimesometrial (AME) regions of uterine horns isolated from rats at 7th, 16th and 22nd days of pregnancy, were constructed."	( Is there a prostaglandin involvement in the positive inotropic action of histamine in isolated pregnant rat uterus, apparently mediated via H1-receptors activation? Dveksler, G; Franchi, AM; Gimeno, AL; Gimeno, MF; Viggiano, M, 1987)	0.27
" This relationship may represent a dose-response curve relating amount of analgesic intake to prevalence of nephropathy."	( Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. Buckalew, VM; Schey, HM, 1986)	0.27
" This dose-response effect, evident in both endoscopic and microbleeding studies done after acute or short-term aspirin administration, is also associated with the risk of developing chronic gastric ulcer."	( Aspirin and the stomach. Graham, DY; Smith, JL, 1986)	1.92
" Our results suggested a positive dose-response relationship for ketorolac."	( Ketorolac versus aspirin for postpartum uterine pain. Barden, TP; Bloomfield, SS; Cissell, GB; Mitchell, J; Yee, JP, )	0.47
" The dosage of diflunisal could be increased to a maximum of 1 gm daily during the open-label phase."	( Comparison of diflunisal and aspirin in long-term treatment of patients with rheumatoid arthritis. Shackleford, RW; Turner, RA; Whipple, JP, 1986)	0.56
" Three weeks later these rats were orally dosed each day with aspirin (375 mg/kg) for six months."	( Molecular weight of gastric mucus glycoprotein is a determinant of the degree of subsequent aspirin induced chronic gastric ulceration in the rat. Bagshaw, PF; Munster, DJ; Wilson, JG, 1987)	0.73
"The pharmacokinetics of salicyl phenolic glucuronide (SPG) and other salicylic acid (SA) metabolites were studied at three aspirin dosage regimens in eight patients with rheumatoid arthritis."	( Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. Bochner, F; Cleland, LG; Graham, GG; Imhoff, DM; Polverino, A; Rolan, PE; Tregenza, RA, 1987)	0.48
"An 18-month-old child with Kawasaki syndrome twice developed severe recurrence of symptoms when the acetylsalicylic acid (Aspirin) dosage was decreased from 80 mg/kg/day."	( Relapsing Kawasaki's disease. Brady, S; Feild, C; Lowe, B, 1987)	0.48
" One-step extraction of UTXB2 with an octadecylsilyl-silica column was sufficient as pretreatment for TXB2 radioimmunoassay because recovery of UTXB2 was good, the eluate was parallel with the dose-response curve, and the value coincided with that obtained by the conventional method."	( Increased thromboxane B2 excretion in diabetes mellitus. Inaba, M; Ishii, J; Katayama, S; Kawazu, S; Maruno, Y; Omoto, A, 1987)	0.27
" Patients with this renal disorder require a permanent high dosed indomethacin therapy."	( [The significance of renal prostaglandins for kidney function in early childhood]. Seyberth, HW, 1987)	0.27
" Continuous dose-response and step-function parameterizations of aspirin exposure were both statistically significant and not clearly distinguishable from each other."	( Aspirin and acetaminophen use by pregnant women and subsequent child IQ and attention decrements. Barr, HM; Bleyer, WA; Martin, DC; Sampson, PD; Shepard, TH; Streissguth, AP; Treder, RP, 1987)	1.95
"025-16 micrograms/paw) were followed by a bell-shaped dose-response curve for oedema."	( Interactions between local inflammatory and systemic haematological effects of PAF-acether in the rat. Castro, HC; Cordeiro, RS; Lima, MC; Martins, MA; Neto, F; Silva, PM; Vargaftig, BB, 1987)	0.27
" A control group received no treatment, a second group was treated with a low, single daily dose of aspirin (12 mg), and a third group was given a higher dosage of aspirin (80 mg/day) combined with dipyridamole (50 mg/day) divided into two daily doses."	( Low-dose aspirin protects against lipid accumulation in primate vein bypass grafts. Boerboom, LE; Kissebah, AH; Montgomery, RR; Olinger, GN, 1987)	0.91
" 2 Dose-response studies were performed to delineate a suppressive (high) and non-suppressive (low) dose of isoxicam prior to studying these doses in combination with aspirin."	( The effect of isoxicam-aspirin combinations on the polyurethane sponge implantation model in the rat. Brooks, PM; Garrett, R; Manthey, B; Vernon-Roberts, B, 1986)	0.78
" Moreover, dose-response curves for added acetylcholine (ACh) were not modified by ASA."	( Cholinergic and non-cholinergic components of the inotropism evoked by electric field stimulation in the isolated rat urinary bladder. Influence of some eicosanoids. Dveksler, G; Gimeno, AL; Gimeno, MF, 1987)	0.27
" It was found that neither the 24-hr plasma levels nor the pharmacokinetic parameters of norethindrone following intravenous dosing were significantly altered by aspirin."	( Influence of aspirin on the pharmacokinetics of norethindrone. Gomaa, AA; Makarm, MH, 1987)	0.84
" In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market."	( A catch in the Reye. Gillis, J; Kilham, HA; Orlowski, JP, 1987)	0.54
" The data suggest normal single dosage for these drugs in acute viral hepatitis, and dosage modification only in severe cases."	( Reduction of paracetamol and aspirin metabolism during viral hepatitis. Beermann, B; Britton, S; Jorup-Rönström, C; Melander, A; Wåhlin-Boll, E, )	0.42
" The release of aspirin from its dosage form was detected by monitoring the change in intestinal pH."	( Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. Amidon, GL; Fleisher, D; Lui, CY; Oberle, R, 1986)	0.84
" The dogs were randomly allotted to 6 groups of 6 dogs each: group 1 was given plain aspirin at a dosage of 25 mg/kg of body weight: group 2 was given plain aspirin at a dosage of 10 mg/kg; group 3 was given buffered aspirin at a dosage of 25 mg/kg; group 4 was given enteric-coated aspirin at a dosage of 25 mg/kg; group 5 was given buffered aspirin at a dosage of 25 mg/kg; and, group 6 was given a placebo."	( Serum salicylate concentrations and endoscopic evaluation of the gastric mucosa in dogs after oral administration of aspirin-containing products. Boulay, JP; Klausner, JS; Lipowitz, AJ, 1986)	0.7
" During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight."	( Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. Abernethy, DR; Boxenbaum, HG; Greenblatt, DJ; Harmatz, JS; Matlis, R; Ochs, HR; Shader, RI, 1986)	0.49
" The drug dosing schedule was then reversed after 1 week."	( Evaluation of a potential drug interaction between sucralfate and aspirin. Chang, CW; Lau, AH; Schlesinger, PK, 1986)	0.51
"Two elderly patients, who were chronically receiving aspirin, developed lethargy, incontinence, and confusion after dosing with acetazolamide."	( Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Brandt, JL; Chapron, DJ; Feig, PU; Gomolin, IH; Kramer, PA; Sweeney, KR, 1986)	0.52
"The effect on platelet function of low-dose aspirin (ASA) and dipyridamole alone or in combination was evaluated after repeated dosing in 5 healthy volunteers."	( Effects of dipyridamole and low-dose aspirin therapy on platelet adhesion to vascular subendothelium. de Gaetano, G; Dejana, E; Lauri, D; Zanetti, A, 1986)	0.81
" In all dosage regimens the average temperature was significantly reduced in the time interval 1-6 h after drug administration; the antipyretic effect, however, was significantly greater with the 10 and 15 mg/kg doses."	( Correlation between dosage and antipyretic effect of aspirin in children. Biasini, GC; Cecchini, I; Dalla Villa, A; Principi, N; Vigano, A, 1986)	0.52
"Human fetal alcohol syndrome characteristics have been seen in the mouse fetus by several investigators who dosed the dam with only one or two doses of alcohol."	( Teratogenic effects on the CD-1 mouse embryo exposed to concurrent doses of ethanol and aspirin. Guy, JF; Sucheston, ME, 1986)	0.49
"Different dosages of aspirin were administered (by nasogastric tube) to 3 groups of 5 healthy adult horses to determine the minimal effective dosage needed to decrease serum thromboxane B2 (TxB2) concentrations and to determine the duration of this decrease."	( Effect of aspirin on ex vivo generation of thromboxane in healthy horses. Baxter, GM; Moore, JN, 1987)	0.99
" Naf shows a significant antithrombotic property, beginning with a dosage of 1 mg/kg which further increases relative to the dosage, and the stability of thrombi decreased."	( Antithrombotic efficacy and its time course after application of naftidrofuryl in vivo. Grosse-Heitmeyer, A; Herrmann, KS; Kreuzer, H, 1986)	0.27
" Patients showed significantly better compliance with a once daily dosage regimen."	( A double blind comparison of piroxicam and enteric coated ASA in rheumatoid arthritis. A Cooperative Multicenter Canadian trial. , 1985)	0.27
" Drug intervention should be on a regular schedule--avoid prn dosage of pain medications."	( Dilemmas in managing prostate carcinoma (Part II): Metastatic disease. Ahmann, FR, 1985)	0.27
" However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis."	( Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Boey, J; Chan, TK; Cheung, KL; Chow, J; Lee, PK; Mok, CK; Ng, RP; Tse, TF; Wang, R, 1985)	0.56
" We report here that an oral dose of aspirin (600 mg) causes rapid and substantial inhibition of bradykinin-stimulated PGI2 production, but recovery occurs within 6 hours; this implies that endothelial PGI2 synthesis would be spared most of the time during dosing once daily with even this relatively large dose of aspirin."	( Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man. Barrow, SE; Heavey, DJ; Hickling, NE; Ritter, JM, )	1.85
"6 percent with isoxicam, at a dosage greater than 200 mg per day; 14."	( Evaluation of the safety of isoxicam. Burch, FX, 1985)	0.27
" When this type of drug fails to provide relief for a woman suffering from primary dysmenorrhea, switching to another NSAID may be more appropriate than increasing the dosage and the probability of dosage-related side effects."	( Efficacy of fenoprofen in the treatment of primary dysmenorrhea. Burt, RA; Caldwell, BV; Kaul, AF; Naftolin, F; Osathanondh, R; Scavone, JM; Sokoloff, BJ; White, RM, 1985)	0.27
" In addition, because frequent repeated and synchronous dosing of aspirin was necessary, aspirin's potentiating effects appear to be produced by mechanism(s) unrelated to its potent, irreversible inhibition of platelet cyclooxygenase."	( Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. Bjornsson, TD; Hanson, SR; Harker, LA, 1985)	0.74
" When cells were pretreated with ibuprofen, aspirin, or indomethacin to block prostaglandin synthesis and then exposed to 20:4, the dose-response effect was shifted to the left."	( Morphological alterations in cultured endothelial cells induced by arachidonic acid. Bar, RS; Dolash, S; Kaduce, TL; Marshall, SJ; Sandra, A; Spector, AA, 1985)	0.53
" Acetylsalicylic acid inhibition, calculated as IC50 by a dose-response curve, is more than ten fold higher for leukocytes vs platelets."	( Differential effects of aspirin and indomethacin on platelet and leukocyte thromboxane A2 formation. Colli, S; Maderna, P; Morazzoni, G; Stragliotto, E; Tremoli, E, 1985)	0.58
" The dosage of 25 mg/kg (single and repeated) consistently inhibited platelet function, and the effects lasted 3 to 5 days."	( Effects of aspirin and propranolol on feline platelet aggregation. Greene, CE, 1985)	0.66
" These results suggest that modulation of leukotaxis by NSAIDs may reflect a differential dose-response sensitivity of lipoxygenase and cycloxygenase pathways."	( In vivo modulation of leukotaxis by non-steroidal anti-inflammatory drugs. diZerega, GS; Nakamura, RM; Shimanuki, T, 1985)	0.27
" Many flurbiprofen-treated patients (46 percent) completing the trial followed a relatively low dosage regimen of 50 mg twice daily for more than half the study."	( Treatment of osteoarthritis of the knee. A comparison of flurbiprofen and aspirin. Brinn, EL; Lamborn, KR; Lomen, PL; Porter, GH; Turner, LF, 1986)	0.5
"We tested the antiplatelet effects of low-dose aspirin in patients with occlusive cerebrovascular disease, because conventional dosage aspirin inhibits vascular synthesis of prostacyclin at the same time that it inhibits platelets."	( Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Kent, JL; Levy, DE; Rudolph, D; Scherer, PB; Weksler, BB, )	0.71
" The quantitative morphometric method was sufficiently sensitive to demonstrate a dose-response effect of ethanol and aspirin."	( A quantitative method for assessing the extent of experimental gastric erosions and ulcers. Bradford, JC; Brown, A; Homan, HD; Schnoor, J; Szabo, S; Trier, JS, 1985)	0.48
" It was concluded that aspirin alone at the recommended dosage of one-quarter of a 5-grain tablet (1."	( Effects of aspirin and propranolol alone and in combination on hemostatic determinants in the healthy cat. Allen, DG; Crane, S; Johnstone, IB, 1985)	0.97
" But to objectify the mode of action, or to measure dose-response functions, to evaluate the optimal therapeutic dosage, or to compare the relative efficacy of the drug tested with known substances--all these investigations can best be performed in a sample of healthy, informed, intelligent and cooperative volunteers, as homogenous as possible."	( Modern techniques to measure pain in healthy man. Bromm, B, 1985)	0.27
"A high unit dose (15 grain/975 mg) enteric coated aspirin preparation was studied in normal individuals and patients with arthritis to determine how readily well tolerated, therapeutic (150-300 micrograms/ml) salicylate (SA) levels could be achieved using a twice daily dosing regimen."	( Aspirin dosing using 15 grain enteric coated tablets. Feigal, D; Jang, H; Pollet, S; White, RH; Yim, CW, 1985)	1.97
" While using the nomograms one should be guided by the known therapeutic dose and the dosage intervals or by the therapeutic or maximal allowable dose."	( [Utilization of the pharmacokinetic parameters of acetylsalicylic acid for optimizing its use with people of different ages]. Belyĭ, AA; Bezverkhaia, IS; Korkushko, OV; Zapadniuk, VI, )	0.13
" The absence of any effects of a 2-mg/kg dose of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol and the severe side effects produced by 10 mg/kg prevented determination of its dose-response relationship."	( Shock titration in the rhesus monkey: effects of opiate and nonopiate analgesics. Bloss, JL; Hammond, DL, 1985)	0.27
" Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months."	( Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin. Balme, HW; Berry, H; Hart, FD; Huskisson, EC; Scott, J; Wojtulewski, JA, 1974)	0.76
" Several ways of administration, vaginal, intraamniotic, and intrauterine, as well as several modes of dosage have been tried to eliminate the side effects of PGs."	( [Prostaglandins]. , 1973)	0.25
" A starting dose of 200 mg/kg/day should be used, and the salicylate level checked at seven days and the dosage adjusted to give an anti-inflammatory effect-that is, a blood salicylate level of between 25 and 30 mg/100 ml."	( Benorylate in management of Still's disease. Ansell, BM; Powell, RH, 1974)	0.25
" At a dosage of 30 mg per kilogram it caused a lowering of body temperature in the intact preparations, but again an increase in decapitate preparations."	( Hyperpyrexia and antipyresis owing to sodium acetylsalicylate in intact and decapitate cats. Lloyd, DP, 1969)	0.25
" However, because of the inability to augment iron absorption to compensate for blood loss, it would be inadvisable for the patient with a partial gastrectomy to take a high dosage of aspirin for long periods of time, unless aspirin-induced blood loss is measured and shown to be very low."	( Role of occult blood loss in anaemia after partial gastrectomy. Baird, IM; Nasser, SS; St John, DJ, 1970)	0.44
" Dose-response curves in fasted and fed rats indicated that the fed rat was about eight times more susceptible to aspirin-induced intestinal damage than was the fasted rat, while the fasted rat was about 13 times more susceptible to aspirin-induced gastric damage than was the fed rat."	( Aspirin: intestinal damage in rats. Brodie, DA; Hooke, KF; Tate, CL, 1970)	1.9
"Gastric mucosal lesions were produced in rats by dosing orally with aspirin, 300 mg/kg."	( H2-receptor antagonists protect against aspirin-induced gastric lesions in the rat. Bunce, KT; Daly, MJ; Humphray, JM; Stables, R, 1981)	0.77
" On the other hand, in the presence of prostaglandin (PG)-inhibitors the dose-response curve of acetylcholine shifts to the right."	( In vitro effect of acetylcholine and bethanechol on the contractions of the human detrusor muscle. Influence of prostaglandins. Borda, E; Contreras-Ortiz, N; Gimeno, MF; Gutnisky, R, 1982)	0.26
" A reliable dose-response and time-response relations were observed for both groups of analgesics."	( A new method for the rapid measurement of analgesic activity in rabbits. Ayhan, IH; Melli, M; Türker, RK, 1983)	0.27
" The side effects of antihistamines are minor, and the dosage of corticosteroid used and length of time it is given are small enough to avoid major side effects."	( Chronic urticaria. Possible causes, suggested treatment alternatives. Kaplan, AP, 1983)	0.27
" Inhibition of LTB4-formation and cell migration by BW755C was dose-related, but the two dose-response curves were not parallel."	( The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation. Moncada, S; Salmon, JA; Simmons, PM, 1983)	0.27
" The reduced toxicity with full efficacy favours a low and infrequent dosage of aspirin."	( Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Kotzur, J; Lorenz, RL; Meister, W; Reichardt, B; Schacky, CV; Theisen, K; Weber, M; Weber, PC, 1984)	0.75
" The time-dependent increase of TAA after administration of 100 mg/kg acetylsalicylic acid is demonstrated; the dosage finally delayed TAA to longer than 360 seconds."	( Platelet aggregation induced in the hamster cheek pouch by a photochemical process with excited fluorescein isothiocyanate-dextran. Herrmann, KS, 1983)	0.27
" Animals were treated with a dosage regimen of aspirin which inhibited PES but had no effect on the cytochrome P-450-dependent oxidation of 7,8-dihydrodihydroxybenzo(a)pyrene."	( Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. Adriaenssens, PI; Anderson, MW; Boorman, GA; Eling, TE; Sivarajah, K, 1983)	0.93
" Plasma concentrations of tilcotil showed that the drug's half-life was approximately 50 hours, compatible with once daily dosage, and steady state concentrations on multiple dosing were reached after 10 to 12 days."	( Gastro-intestinal blood loss with high dose tilcotil (Ro 12-0068) and aspirin: an open crossover clinical trial and pharmacokinetic assessment in normal volunteers. Bird, HA; Galloway, DB; Lowe, JR; McEvoy, M; Pickup, ME; Taylor, P; Wright, V, 1983)	0.5
" Data are presented in 46 patients who took aspirin continuously for 10 or more years (mean total dosage 35 kg) in whom there was no evidence of significant renal dysfunction."	( Aspirin and renal disease. Emkey, RD, 1983)	1.97
" The pharmacokinetics of ASA is affected by the dosage form used and the presence of food."	( Aspirin: plasma concentration and effects. Thiessen, JJ, 1983)	1.71
" The optimal optimal dosage in influencing vascular haemostatic regulation is still an open question in the literature."	( [Venous prostacycline synthesis and plasma thromboxane B2 after low-dose aspirin]. Cromwell, M; Kaliman, J; Sinzinger, H, 1983)	0.5
" The teratogenic potential of a drug is related to dosage and time of administration."	( Analgesics during pregnancy. Niederhoff, H; Zahradnik, HP, 1983)	0.27
" A clinical dose-response relationship has been established, and time-effect curves indicate that the total threshold-raising effect depends on dosage frequency."	( Review of the comparative analgesic efficacy of salicylates, acetaminophen, and pyrazolones. Mehlisch, DR, 1983)	0.27
" Following an initial dose-response study, a double-blind crossover trial was performed using pretreatment with placebo or with 10-micrograms doses of 15-R-15 methyl prostaglandin E2 for 24 h before treatment with aspirin."	( Prevention of acute aspirin-induced gastric mucosal injury by 15-R-15 methyl prostaglandin E2: an endoscopic study. Bergman, D; Feld, AD; Gilbert, DA; Sanford, RL; Saunders, DR; Silverstein, FE; Surawicz, CM; Washington, P; Weinberg, CR, 1984)	0.78
"In a double-blind crossover study acetylsalicylic acid (ASA) in low (2 g daily) or high (4 g daily) dosage was tested against placebo in two groups of 20 patients who each underwent identical oral surgical procedures on two separate occasions."	( The effects of acetylsalicylic acid on swelling, pain and other events after surgery. Skjelbred, P, 1984)	0.27
" Some of the newer NSAIDs seem at normal dosage to be far less damaging than traditional ASA or indomethacin."	( Gastroduodenal damage due to drugs, alcohol and smoking. Domschke, S; Domschke, W, 1984)	0.27
"Soluble aspirin given by mouth in divided dosage decreased intestinal fluid loss in infants and young children with acute gastroenteritis."	( Aspirin in acute gastroenteritis: a clinical and microbiological study. Burke, V; Gracey, M; Phadke, MA; Raut, SK; Singh, B, 1984)	2.14
" In order to evaluate the role of arachidonic acid metabolites in the C3a response, dose-response curves for C3a-induced contractions of guinea pig lung strips were compared in the presence and absence of several inhibitors which block metabolism of arachidonic acid at relatively specific steps in the pathways."	( C3a-induced contraction of guinea pig lung parenchyma: role of cyclooxygenase metabolites. Bloor, CM; Hugli, TE; Stimler, NP, 1983)	0.27
" This action carried over to ex vivo situation following intraduodenal dosing as demonstrated in rabbits."	( Inhibition of platelet aggregation by a new agent, 2,2'-dithiobis-(N-2-hydroxypropyl benzamide) (KF4939). Nakamizo, N; Shuto, K; Yamada, K, 1983)	0.27
" Cumulative dose-response curves for isoproterenol, norepinephrine and methoxamine were made for the different groups."	( In vitro contractile responses of the uterus from 'restricted diet' rats to adrenoceptor agonists. Influence of cyclo-oxygenase inhibitors. Gimeno, AL; Gimeno, MA; Goldraij, A; Sterin, AB, 1983)	0.27
" In the presence of L (4 X 10(5) ml-1) the dose-response curve to NaA shifted to the left, the potency and the efficiency of NaA were enhanced and the chronotropic action was triggered."	( Lymphocytes sensitize rat isolated atria to the inotropic and chronotropic effects of sodium arachidonate. Borda, ES; de Bracco, MM; Finiasz, M; Sterin-Borda, L, 1984)	0.27
"The extent to which a controlled release acetylsalicylic acid (ASA) formulation inhibited platelet function has been evaluated in single and chronic dosing studies."	( Inhibition of platelet function by a controlled release acetylsalicylic acid formulation--single and chronic dosing studies. Cossum, PA; McLeod, LJ; Roberts, MS; Vial, JH, 1984)	0.27
") failed to elicit mucosal damage either ultrastructurally or even visually up to 23 h after dosing and did not affect the content of PG's even though the drug was present in the mucosa in sufficient concentration to elicit reduction in prostaglandin synthesis in vitro."	( Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructural integrity and prostaglandin levels in the rat gastric mucosa: relationship to drug uptake. Fox, SA; Osborne, DJ; Rainsford, KD, 1984)	0.27
"Claims that twice-daily dosage of choline magnesium trisalicylate (CMT) may alter salicylate disposal kinetics and result in sustained plasma levels were examined."	( A pharmacokinetic comparison of choline magnesium trisalicylate and soluble aspirin. Berry, D; Gibson, T; Helliwell, M; Volans, G, 1984)	0.5
" Desensitization, when essential, may be achieved for most drugs with graduated dosage schedules and maintained through continued administration of the drug."	( Management of adverse drug reactions. Pennoyer, DS; Sheffer, AL, 1984)	0.27
" These same dosage levels also caused a severe maternal hemolytic anemia following a dramatic decrease in erythrocyte ATP levels."	( Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits. Allen, HL; Bokelman, DL; Clark, RL; Cohen, SM; James, ML; Minsker, DH; Robertson, RT; Tocco, DJ, 1984)	0.27
" Thrombin, at a dosage producing a fibrinogen consumption of 70% within 4 h (1 unit/kg/min), failed to produce extrapulmonary microthrombi unless fibrinolysis inhibition (epsilon-aminocaproic acid-EACA) or alpha-adrenergic stimulation (norepinephrine) were provided simultaneously."	( Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits. Daoust-Fiorilli, J; Latour, JG; Léger-Gauthier, C, 1984)	0.27
" Available pharmacokinetic data can be used to predict plasma ASA and SA levels following different ASA dosing regimen."	( Relevance to redesigning aspirin therapeutic regimens. Thiessen, JJ, 1983)	0.57
" Cumulative dose-response curves for H, in strips isolated from proestrous rats, showed that the agonist inhibited, at all the concentrations tested, spontaneous myometrial contractions, evoking a maximum effect (100% inhibition) at 10(-5)M."	( Prostaglandins and ovarian factors as modulators of the negative inotropic action of histamine in the isolated rat uterus. Dveksler, G; Franchi, AM; Gimeno, AL; Gimeno, MF; Viggiano, M, 1984)	0.27
" The reduction in gastric bleeding with the 50-microgram dosage of misoprostol was directly related to the reduction in acid secretion."	( Effect of synthetic prostaglandin E1 analog on aspirin-induced gastric bleeding and secretion. Hunt, JN; Jiang, CL; Kessler, L; Smith, JL, 1983)	0.52
"01) differences in microbleeding between subjects given aspirin and those given either dosage of fenbufen or placebo."	( Comparative study of gastrointestinal microbleeding caused by aspirin, fenbufen, and placebo. Lebel, E; Lussier, A; Tétreault, L, 1983)	0.75
"Knowledge of pharmacokinetics (action of organisms on drugs) and pharmacodynamics (drug action on living organisms) allows for the proper assessment of the most suitable dose, dosing intervals, route of administration, as well as dose adjustment when clinically indicated."	( Pharmacokinetic considerations of common analgesics and antipyretics. Hartwig-Otto, H, 1983)	0.27
" The patient reacts to the need for pain relief and will take fewer aspirin than prescribed because the lower dosage is better tolerated and less expensive."	( Other NSAIDs of choice for rheumatoid arthritis. Ehrlich, GE, 1984)	0.5
" Non-steroidal anti-inflammatory drugs in full dosage should always be the first choice of treatment."	( Medical management of rheumatoid arthritis with emphasis on the Western Pacific Region. Muirden, KD, 1983)	0.27
" When steady state was achieved patients were hospitalized, and blood and urine specimens were obtained during three dosing intervals and during the washout period that followed."	( Availability of salicylate from salsalate and aspirin. Cassell, S; Dromgoole, SH; Furst, DE; Paulus, HE, 1983)	0.52
" Of the various solvent systems studied, aspirin was found most stable in water-polyethylene glycol (4:1, v/v),which provides an excellent medium for preparation of intravenous dosage forms."	( Stability of aspirin in different media. Bakar, SK; Niazi, S, 1983)	0.9
" A similar study was conducted with Dutch-Belted rabbits dosed po daily at 3, 10, 30, or 100 mg of o-toluenediamine/kg body wt/day from Days 6 through 18 of gestation."	( Teratogenesis study of o-toluenediamine in rats and rabbits. Barbee, SJ; Becci, PJ; Knickerbocker, MJ; Reagan, EL; Wedig, JH, 1983)	0.27
" The 0-24 h and the 0-72 h areas under the plasma level curves together with the maximum plasma concentration reached, correlated strongly with the dosage level used."	( Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Buscher, G; Dierdorf, D; Mügge, H; von Schrader, HW; Wolf, D, 1983)	0.27
"A simultaneous analysis of aspirin and nonaspirin salicylates in solid pharmaceutical dosage forms is described."	( Stabilized normal-phase high-performance liquid chromatographic analysis of aspirin and salicylic acid in solid pharmaceutical dosage forms. Galante, RN; Grim, WM; Visalli, AJ, 1984)	0.79
"Although it is widely accepted that aspirin inhibits platelet aggregation in arterial thrombosis, the appropriate dosage of aspirin remains quite controversial."	( Effect of different aspirin doses on arterial thrombosis after canine carotid endarterectomy: a scanning electron microscope and indium-111-labeled platelet study. Burke, JC; Chandler, WF; Ercius, MS; Ford, JW; Swanson, DP, 1984)	0.87
" Buffered aspirin in a dosage of 10-15 grains every 4 hours is prescribed both for its analgesic effect as well as for its antiinflammatory properties."	( The conservative treatment of sciatica. Bell, GR; Rothman, RH, )	0.53
"The qualitative changes of gastric mucus glycoproteins occurring after aspirin dosing in rats were further investigated."	( Changes of gastric mucus glycoproteins with aspirin administration in rats. Azuumi, Y; Goso, K; Hotta, K; Ishihara, K; Ohara, S, 1984)	0.76
" Each subject was examined in basal conditions and after dosing with carprofen and ASA in random sequence with a 10-day washout period between tests."	( Antiinflammatory drugs and gastric emptying. A comparison between acetylsalicylic acid and carprofen. Calbiani, B; Cisternino, M; Colombi-Zinelli, L; Papa, N; Rinetti, M; Ugolotti, G, 1982)	0.26
" Once daily dosing of 300-600 mg is effective for many patients."	( Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen. Dahl, SL; Ward, JR, )	0.13
"The pharmacology, pharmacokinetics, clinical studies, adverse reactions, and dosage of sucralfate (Carafate, Marion Laboratories), a unique drug for peptic-ulcer disease, are reviewed."	( Sucralfate--alternative therapy for peptic-ulcer disease. Garnett, WR, )	0.13
" The low toxicity and the absence of the side effects typical to narcotic analgesics suggest to study the analgesic effects of ASL with higher dosage schedules or different administrations in order to increase the analgesic potency of the drug in the post-operative period."	( [Lysine acetylsalicylate in the control of postoperative pain in surgery of the upper abdomen]. Andreoni, A; Cristofori, GB; Fochi, C; Sganzerla, E, 1981)	0.26
" Blood was drawn before the study started, 3-4 h after the initial dosage, 12 h after the 10th dosage on the 5th day, and 3-4 h after the 11th (final) dosage on the 6th day."	( The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man. Badenhorst, PN; Deckmyn, H; Vermylen, J, 1982)	0.26
" Dose-response platelet aggregometry detected no differences between groups in the sensitivity of platelets to adenosine diphosphate (ADP), collagen, and epinephrine."	( Etiologic factors for recurrent carotid artery stenosis. Clagett, GP; Hutton, JE; McDonald, PT; Olson, DW; Rich, NM; Salander, JM; Youkey, JR, 1983)	0.27
" Venous blood was drawn before and at 2, 4, 6, and 24 hr after ASA dosage to measure platelet aggregation in response to collagen and adenosine diphosphate and, at more frequent intervals, to characterize ASA kinetics."	( Aspirin kinetics and platelet aggregation in man. Bochner, F; Field, J; Gabb, BW; Imhoff, DM; Lloyd, JV; Siebert, DJ; Watts, S, 1983)	1.71
" These results suggest that ASA may be an effective antithrombotic agent in man if the dosage is based on pharmacological data."	( Anti-thrombotic effect of very low doses of acetyl salicylic acid in rats. Fournau, P; Granero, M; Paris, J; Viens, C, 1983)	0.27
"The suitability for multiple dosing of two acetylsalicylic acid (ASA) preparations was compared in 8 healthy volunteers."	( Decreasing serum salicylate concentrations during long-term administration of acetylsalicylic acid in healthy volunteers. Discussion of possible clinical implications. Olsson, B, 1983)	0.27
" Due to the long plasma half life, once daily dosing provides continuous exposure to drug, with concentrations fluctuating less than twofold."	( Pharmacokinetics of piroxicam in man. Hobbs, DC, 1983)	0.27
"In a controlled cross-over study comprising eight healthy subjects of effervescent acetylsalicylic acid (ASA) and an experimental ASA formulation were compared with unbuffered ASA and placebo concerning effects on the urinary pH within a dosage interval after 2 days' medication with 3 g ASA daily."	( Urinary pH and plasma levels of salicylate after administration of different buffered acetylsalicylic acid formulations. Bogentoft, C; Dahl, G; Magnusson, A, )	0.13
"After a standard meal, 12 normal volunteers received three aspirin dosage forms in a single-dose, complete crossover study."	( Influence of food on aspirin absorption from tablets and buffered solutions. Mason, WD; Winer, N, 1983)	0.83
" If preterm labour was stopped, the dosage had been reduced."	( [Clinical study of the labour inhibiting effects an side effects of acetylsalicylic acid (ASA) (author's transl)]. Berg, R; Bolte, A; Wolff, F, 1981)	0.26
" The plasma levels of the drug after oral administration of a solution best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model."	( Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies. Carmichael, RH; Nash, JF; Ridolfo, AS; Spradlin, CT, 1980)	0.26
" Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer."	( Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. Dixon, R; Gordon, R; Hamilton, R; Harvey, H; Heckard, R; Lipton, A; Ramsey, H; Scialla, S; Weltz, M; White, D, 1982)	1.45
" Each dosage level of proquazone and aspirin provided significant analgesia compared to placebo and was well tolerated."	( An evaluation of the analgesic efficacy of proquazone and aspirin in postoperative dental pain. Forbes, JA; Hughes, MK; White, EH; White, RW, 1980)	0.78
" The dosage of tolmetin sodium remained at 1600 mg daily for the 3-month duration of the study but side-effects necessitated the reduction of the dosage of aloxiprin in many patients and after 3-months' treatment the mean dosage was 4 g daily."	( Clinical experience with tolmetin sodium. Balme, HW; Huskisson, EC; Wojtulewski, JA, 1980)	0.26
"Aspirin administration, at a dosage producing plasma levels within the human therapeutic range, caused marked inhibition of production of both vascular prostacyclin (a vasodilator) and platelet thromboxane (a vasoconstrictor) in beagle puppies."	( Retrolental fibroplasia: evidence for a role of the prostaglandin cascade in the pathogenesis of oxygen-induced retinopathy in the newborn beagle. Blake, DA; Flower, RW, 1981)	1.71
" The ideal dosage to obtain a serum salicylate level of 20 mg/100 ml seems to lie between 3 and 4 g of salsalate a day."	( Comparison of serum salicylate levels and gastro-intestinal blood loss between salsalate (Disalcid)and other forms of salicylates. Mielants, H; Verbruggen, G; Veys, EM, 1981)	0.26
" Dose-response experiments performed with 2 to 90 per cent (v/v) zymosan-activated plasma showed a direct correlation between the rate of neutrophil influx and the degree of vascular permeability in blood flow."	( Vascular responses during acute neutrophilic inflammation. Their relationship to in vivo neutrophil emigration. Issekutz, AC, 1981)	0.26
" Each patient received IP 600 mg/day or ASA 2100 mg/day for a four-week period; after a one-week wash-out period, the same drug was given at a higher dosage (IP 800 or ASA 2800 mg/day) for another four weeks."	( Double-blind comparative trial of indoprofen and acetylsalicylic acid in osteoarthritis. Katona, G, 1981)	0.26
" Platelet survival in 27 insulin-dependent diabetic patients with severe retinopathy was studied in a double-blind cross-over trial using placebo, aspirin (990 mg/day) and a combination of dipyridamole (225 mg/day) with aspirin at two dosage levels (330 mg and 990 mg/day)."	( Aspirin, dipyridamole and platelet survival in patients with diabetes mellitus. McNicol, GP; Paton, RC; Tindall, H, 1982)	1.91
" Initial fenoprofen dosage was 900 mg/m2/d increased to 1800 mg/m2/d (3200 mg/d-max)."	( Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial. A segment II study. Baum, J; Bernstein, B; Brewer, EJ; Emery, HM; Fink, CW; Giannini, EH; Schaller, JG, )	1.57
" We conclude that aspirin in the dosage used in probably not different from oral anticoagulants in affecting mortality and morbidity after a myocardial infarction."	( A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. , 1982)	0.9
"Aspirin has been demonstrated to be an effective prophylactic agent against postoperative venous thromboembolic disease, but the optimum dosage is unknown."	( High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement. Athanasoulis, CA; Harris, WH; Salzman, EW; Waltman, AC, 1982)	2.04
" According to the delta MCTI method, flushing is quantitatively characterized as a nonquantal, dose-response reaction of variable intensity."	( Aspirin blocks nicotinic acid-induced flushing. Buckner, J; Chernosky, ME; Donachie, R; Kapp, R; Wilkin, JK; Wilkin, O, 1982)	1.71
"4), and no dose-response relationship was demonstrated."	( Analgesics and cancer of the renal pelvis in New South Wales. Ford, JM; McCredie, M; Stewart, JH; Taylor, JS, 1982)	0.26
"9 g/d of enteric-coated acetylsalicylic acid (ASA) (Entrophen) according to one of four dosing schedules: group 1 (n = 13), three 325-mg tablets four times daily; group 2 (n = 11), two 650-mg tablets three times daily; group 3 (n = 10), three 650-mg tablets twice daily; and group 4 (n = 6), two 975-mg tablets twice daily."	( Steady-state plasma levels of salicylate in patients with rheumatoid arthritis: effects of dosing interval and tablet strength. Goldsmith, CH; Keystone, EC; Littlejohn, G; Paton, TW; Piper, S; Verdejo, A; Wright, LA, 1982)	0.26
" In 87% of the cases receiving aspirin, their maximum daily dosage did not exceed recommended levels, but their doses were higher than those of controls receiving aspirin."	( Reye's syndrome and medication use. Campbell, RJ; Correa-Villaseñor, A; Hall, LJ; Halpin, TJ; Holtzhauer, FJ; Hurwitz, ES; Lanese, R; Rice, J, 1982)	0.55
" Optimum drug or combination of drugs and dosage are still controversial."	( [Inhibition of platelet function in pediatric medicine (author's transl)]. Schmidt, B, 1982)	0.26
" Patients given aspirin with oral metoclopramide tended to obtain better early pain relief than the other two treatment groups, though by one hour from dosage use of injected metoclopramide was also associated with better pain relief."	( Aspirin treatment of migraine attacks: plasma drug level data. Eadie, MJ; Heazlewood, V; Ross-Lee, L; Tyrer, JH, 1982)	2.05
" We conclude that no alteration is required in digoxin dosing when aspirin is used."	( Kinetics of the digoxin-aspirin combination. Comess, KA; Fenster, PE; Finley, PR; Hanson, CD, 1982)	0.81
" In addition, dose-response derived potencies show fenbufen more potent than ASA and at least as potent as phenylbutazone in all five tests."	( A new non-steroidal anti-inflammatory analgesic: gamma-oxo (1,1'-biphenyl)-4-butanoic acid (fenbufen). Chemistry and activity of analogs. Child, RG; Osterberg, AC; Sloboda, AE; Tomcufcik, AS, 1980)	0.26
" Steady state serum concentrations were reached within a week with multiple dosing regimens."	( Metabolic and pharmacokinetic studies with fenbufen in man. Chiccarelli, FS; Eisner, HJ; Van Lear, GE, 1980)	0.26
"The effect of different dosage regimens of aspirin was investigated in an experimental model of arterial thrombosis."	( Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis. Mörl, H; Thiessen, M; Walter, E; Zimmermann, R, 1980)	0.79
" The results of the study showed Diflunisal in an average dosage of 500 to 1000 mg per day to be a useful drug in the treatment of rheumatoid arthritis not least due to the negligible side effects."	( [Comparison of the efficacy of diflunisal and acetylsalicylic acid in rheumatoid arthritis (author's transl)]. Fasching, U, 1981)	0.26
" Laboratory determinations were used to directly evaluate therapeutic anticoagulant effects, and dosage regimens were adjusted to achieve desired anticoagulant levels."	( Case study: complications associated with anticoagulant therapy. Davis, GL; Mutnick, AH, 1981)	0.26
" Blood/tissue ratios of 14C from rats dosed with these 14C-labeled acids were highly correlated with the logarithm of the binding affinity constantsaffinity constants."	( In vitro binding of 14C-labeled acidic compounds to serum albumin and their tissue distribution in the rat. Fang, SC; Lindstrom, FT, 1980)	0.26
" In the light of a recently proposed critical balance of vascular antiaggregatory prostacyclin and platelet proaggregatory TXA2 very low dose ASA might offer advantages over conventional dosage of ASA and should be evaluated in thromboembolic disorders."	( Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man. Lorenz, R; Siess, W; Weber, PC, 1981)	0.26
"Twelve fasting normal volunteers received three aspirin dosage forms in a single-dose, complete crossover study; the plasma and urine levels of aspirin, salicylic acid, and salicyluric acid were measured for 10 hr."	( Kinetics of aspirin, salicylic acid, and salicyluric acid following oral administration of aspirin as a tablet and two buffered solutions. Mason, WD; Winer, N, 1981)	0.9
" Oral aspirin therapy was started at a dosage of 100 mg/kg/day, every six hours."	( Salicylate hepatitis: a complication of the treatment of Kawasaki's disease. Bertino, JS; Reed, MD; Speck, WT; Willis, ED, 1981)	0.74
" The recovery of the content of mucus glycoprotein in drug dosed rats occurred within 3 h after aspirin dosing and was nearly 90% of control at 5 h in all cases."	( Efficacy of anti-ulcer drugs on the recovery of gastric mucosal glycoproteins with aspirin-induced gastric damage in rat. Azuumi, Y; Hotta, K; Ishihara, K; Ohara, S; Okabe, H, 1981)	0.71
" Administration of DPY alone at a higher dosage increased the exercise duration and had a similar effect on platelet survival."	( Effect of platelet suppressant treatment with dipyridamole and aspirin on exercise performance and platelet survival time in coronary disease. Rainwater, J; Steele, P; Vogel, R, 1981)	0.5
"A sensitive, simple, and rapid method for the quantitation of salicylic acid in aspirin powders and its dosage forms was developed."	( High-pressure liquid chromatographic determination of salicylic acid in aspirin powder and pharmaceutical dosage forms. Das Gupta, V, 1980)	0.72
" Administration of aspirin decreased the gastric mucosal hexosamine and induced the onset of ulcer, while administration of proglumide suppressed the gastric lesions in proportion to dosage and correspondingly prevented a decrease of the hexosamine."	( The role of gastric mucosal hexosamine in aspirin-induced ulcers. Aono, M; Moriga, M; Murakami, M; Uchino, H, 1980)	0.85
" Additionally they began taking 325 mg aspirin per day, and after 6 and 8 mo aspirin dosage was increased to 650 mg per day."	( Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. Mathison, DA; Simon, RA; Stevenson, DD, 1980)	1.97
"We dosed eight normal volunteers with single doses of probenecid alone and with aspirin or ibuprofen."	( Effect of ibuprofen or aspirin on probenecid-induced uricosuria. Brooks, CD; Ulrich, JE, 1980)	0.8
" The metabolism of [14C]benzoate and of p-aminobenzoic acid in the neonatal marmoset was compared with that in similarly dosed neonatal rats."	( Some pathways of xenobiotic metabolism in the adult and neonatal marmoset (Callithrix jacchus). Hall, BE; James, SP, 1980)	0.26
" Dosage intervals of 8 or even 12 h are usually sufficient to maintain plasma salicylate concentrations in the anti-inflammatory concentration range."	( Clinical pharmacokinetics of salicylates: a re-assessment. Levy, G, 1980)	0.26
" We therefore investigated the relative dose-response relationship of aspirin on arachidonic acid-induced increments in coronary blood flow and on ADP-induced aggregation of platelets."	( Relative effects of aspirin on platelet aggregation and prostaglandin-mediated coronary vasodilatation in the dog. Bonow, RO; Capurro, NL; Epstein, SE; Goldstein, RE; Lipson, LC; Shulman, NR, 1980)	0.82
" After intravenous dosing both plasma levels and areas under curves were significantly reduced although none of the rate constants was affected."	( A study of the effect of aspirin on the pharmacokinetics of oral and intravenous diclofenac sodium. Jack, DB; Kendall, MJ; Willis, JV, 1980)	0.56
" These animals were then assigned randomly to dose groups (1, 2 or 4 mg/kg/day of indomethacin and 100, 200, or 300 mg/kg/day of aspirin) and were dosed for 21 days."	( Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat. Allen, HL; Bear, WT; Wase, A, 1980)	0.81
" It returned to normal after withdrawal of acetylsalicylic acid in 3 cases, after decrease of the dosage in 2 cases and on the same dosage in 1 case."	( [The value of serum salicylate determination in patients with rheumatoid arthritis (author's transl)]. Chen, HL; Han, SH; Lan, JL; Wang, WC; Wong, W; Wu, HS, 1980)	0.26
"Eighteen healthy volunteers were administered single doses of commercially available solid dosage forms of aspirin, magnesium salicylate (I), and choline magnesium trisalicylate (II), equivalent to approximately 500 mg of salicylic acid, in a randomized, complete crossover design."	( Comparative plasma salicylate and urine salicylurate levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate. Mason, WD, 1980)	0.7
" An overestimation of rare side-effects of drugs should not block the application of certain medicaments, however, they should be given only in such a high dosage as it is necessary."	( [Hematotoxic lesions caused by non-steroidal antirheumatic agents]. Hüge, W; Stobbe, H, 1980)	0.26
" We sought to determine (i) whether ASA dosage influences the development of vegetations and (ii) whether ASA given with antimicrobial therapy improves the treatment outcome of infective endocarditis."	( Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Marangos, MN; Nicolau, DP; Nightingale, CH; Quintiliani, R, 1995)	0.66
" Patients were randomized to placebo (n = 19) or to 1 of 4 integrelin dosing regimens (total n = 54) that were studied sequentially."	( Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Harrington, RA; Joseph, D; Kleiman, NS; Kottke-Marchant, K; Lincoff, AM; Rios, G; Rose, D; Sigmon, KN; Tcheng, JE; Trainor, K, 1995)	0.29
" Maximum plasma hemoglobin concentrations and terminal half-life values were calculated for each dosage group."	( Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Blue, J; Colburn, WA; Collins, AJ; Halstenson, CE; Przybelski, RJ; Swan, SK, 1995)	0.59
" Although the dosage used has also varied, it is now suggested that lower doses are as efficacious and probably safer than higher doses."	( Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo. Kajiwara, Y; Quattrociocchi-Longe, T; Shanberge, JN, 1995)	0.69
" A survey of the currently available blood conservation techniques reveals 5 that stand out as reliable methods: 1) high-dose aprotinin therapy, 2) preoperative erythropoietin therapy when time permits adequate dosage before operation, 3) hemodilution by harvest of whole blood immediately before cardiopulmonary bypass, 4) autologous predonation of blood, and 5) salvage of oxygenator blood after cardiopulmonary bypass."	( Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Ferraris, SP; Ferraris, VA, 1995)	0.29
"Influence of dosing time on pharmacological effects and toxicity of acetylsalicylic acid was investigated in ICR male mice under light-dark (12:12) cycle."	( Chronopharmacological study of acetylsalicylic acid in mice. Ogawa, N; Ohdo, S; Song, JG, 1995)	0.29
" These results suggest that while waiting for the technological advancements of stents, postprocedural treatment that includes a low dosage of ticlopidine, aspirin, and low-molecular-weight heparin is a very effective alternative to conventional poststenting therapy."	( Intracoronary stenting without coumadin: one month results of a French multicenter study. Benveniste, E; Biron, Y; Bourdonnec, C; Faivre, R; Fajadet, J; Gaspard, P; Glatt, B; Joly, P; Morice, MC; Zemour, G, 1995)	0.49
" The dosage of aspirin decreased from 500 mg and more per day in 1986 to a dosage of 250 mg or 100 mg per day in 1989."	( [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area]. Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Richard, JL; Ruidavets, JB, 1995)	0.98
" These findings confirm the claim that a dosage of 50 mg ASS administered daily as an enteric coated or uncoated tablet is sufficient to almost completely block platelet cyclooxygenase, while the respective vascular enzyme is only minimally affected."	( [Thrombocyte function of healthy probands taking 50 mg of acetylsalicylic acid per day]. Banyai, M; Karanikas, G; Kritz, H; Kurtaran, A; Peskar, BA; Pirich, C; Rehak, P; Sinzinger, H, 1995)	0.29
" The dosage of aspirin was 30 mg/kg orally during the acute febrile stage and 5-10 mg/kg orally after lysis of fever."	( Histopathologic and coronary angiographic assessment of effectiveness of aspirin or aspirin-and-gammaglobulin in Kawasaki disease. Haneda, N; Mori, C, 1993)	0.87
" Morphine can also be administered subcutaneously, intravenously, and rectally, which provides enhanced flexibility for dosing patients unable to take oral medications."	( Management of pain in the cancer patient. Skaer, TL, )	0.13
" The amount of radioactivity excreted in faeces was measured during a placebo baseline phase of three days, a treatment phase of five days with thrice daily dosing of ASA, ibuprofen or lysine clonixinate and a subsequent wash-out phase of five days."	( Gastrointestinal blood loss induced by three different non-steroidal anti-inflammatory drugs. Bidlingmaier, A; Hammermaier, A; Nagyiványi, P; Pabst, G; Waitzinger, J, 1995)	0.29
" The best single dose of aspirin is that which is adequate to relieve pain; the proper dosage interval is that which sustains relief without causing toxicity."	( Acetylsalicylic acid and acetaminophen. Kacso, G; Terézhalmy, GT, 1994)	0.59
" These studies suggest that during pregnancy changes of the uptake rate and distribution volume modulate the pharmacokinetics of ASA and that this drug given in low dosage to gravidae marginally alters their platelet function."	( Low-dose aspirin to pregnant women: single dose pharmacokinetics and influence of short term treatment on bleeding time. Berntorp, E; Gennser, G; Liedholm, H; Melander, A; Nordsjö, P; Rymark, P, 1994)	0.71
" The dosage of aspirin decreased from 500 mg or more per day in 1986 to a daily dose of approximately 250 mg in 1989."	( [Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne]. Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Ruidavets, JB, 1994)	0.89
" Further dosage adjustments are made in accordance with a set protocol."	( The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Hansson, L; Zanchetti, A, 1994)	0.29
"Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo."	( Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995)	0.84
" For all patients, a dose-response relation was not found with gastrointestinal hemorrhages and hemorrhagic stroke, but was found with gastrointestinal symptoms and withdrawals from side effects."	( Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995)	0.57
"Three dosage regimens of a new recombinant glycosylated prourokinase (A-74187) were evaluated by measuring coronary artery patency at 90 min in patients with acute myocardial infarction."	( New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group. Anderson, JL; Hartmann, JR; Reddy, PS; Sasahara, AA; Sobolski, JC; Weaver, WD, 1994)	0.29
" Initial doses were randomly assigned and dosing intervals were separated by 2 weeks."	( Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Dabaghi, SF; Kamat, SG; Kleiman, NS; Marks, GF; Payne, J; Roberts, R; Schafer, AI, 1994)	0.61
" Compression load and dose-response studies were conducted for a total duration of seven days."	( A ceramic system for continuous release of acetylsalicylic acid. Bajpai, PK; Moldovan, KM, 1994)	0.29
" Recombinant hirudin led to a profound inhibition of thrombus growth (PD, 30 +/- 12; FD, 109 +/- 21), which was significant compared with all groups, even the highest dosage of heparin (250 IU/kg per hour)."	( Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Badimon, JJ; Badimon, L; Chesebro, JH; Fernández-Ortiz, A; Fuster, V; Mailhac, A; Meyer, BJ, 1994)	0.29
" Heparin dose dependently reduces thrombus growth, but even the highest dosage is less effective than hirudin."	( Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Badimon, JJ; Badimon, L; Chesebro, JH; Fernández-Ortiz, A; Fuster, V; Mailhac, A; Meyer, BJ, 1994)	0.29
" In addition, patients randomly assigned to PTX and IVGG combination therapy groups received oral PTX at a dosage of 10 mg/kg per day (low-dose) or 20 mg/kg per day (high-dose), in three divided doses until the 30th day."	( Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Furukawa, S; Ino, T; Matsubara, T; Motohashi, T; Umezawa, Y; Yabuta, K, 1994)	0.29
" Of the 52 with partial inhibition at initial testing, 35 achieved complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or fluctuation of response at the same dosage, but 8 of those 35 (22."	( Development of aspirin resistance in persons with previous ischemic stroke. Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994)	0.64
" The mechanisms by which increased dosage requirement or ASA resistance develops and the clinical significance of this development are currently undefined."	( Development of aspirin resistance in persons with previous ischemic stroke. Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994)	0.64
" Swine were dosed (2 g/kg) with 10 g/dL DCLHb, infused intravenously at a rate of 1 mL/kg/min."	( Diaspirin crosslinked hemoglobin (DCLHb): bioanalytical studies in swine. Bush, S; Marshall, T; Nelson, D; Spicuzza, J, 1994)	1.01
" A single dose of aspirin was administered four hours after dosing and FEV1 was measured for six hours."	( Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Arm, JP; Bell, GS; Foster, S; Lee, TH; MacMillan, R; Nasser, SM; Spruce, KE; Williams, AJ, 1994)	0.88
" The serum levels of theophylline and salicylates were measured at 6:00 PM after dosing and at 6:00 AM the following day, at weekly intervals for 4 weeks."	( Investigation of the influence of acetylsalicylic acid on the steady state of long-term therapy with theophylline in elderly male patients with normal renal function. Daigneault, EA; Ferslew, KE; Hamdy, RC; Harvill, LM; Kalbfleisch, JH; Rice, PJ; Singh, J, 1994)	0.29
" Platelet function was assessed before, 4, 24, 48 and 72 h after dosing by urinary excretion of thromboxane B2, filtragometry and collagen-based whole blood aggregometry."	( Comparison of three independent methods as estimates of platelet inhibition after a single dose of acetylsalicylic acid. Chen, J; Egberg, N; Karlberg, KE; Nowak, J; Sylvén, C, 1993)	0.29
" In addition, the combination of a suboptimal dosage of interferon gamma with ASA resulted in a significantly higher survival rate compared to the untreated controls."	( Influence of acetylsalicylic acid on a Listeria monocytogenes infection. Hockertz, S; Paulini, I; Rogalla, K; Schettler, T, 1993)	0.29
"To determine whether anticoagulation practices have changed when heparin and warfarin are used to treat cerebrovascular disease, and to determine the dosage of aspirin used to treat carotid territory transient ischemic attacks (TIAs)."	( A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. Alberts, MJ; Dawson, DV; Massey, EW, 1994)	0.71
" We present simple methods for combining dose information from the study of interest with dose-response data from other epidemiologic studies or animal studies to derive plausible hypothesized effect levels."	( Resolving discrepancies among studies: the influence of dose on effect size. Hertz-Picciotto, I; Neutra, RR, 1994)	0.29
"To examine whether the dosage of a platelet-suppressive agent at which an antithrombotic effect is adequate and bleeding tendency is not increased can be found, the antithrombotic effects, antiplatelet effects and bleeding times of ticlopidine and aspirin were investigated in the rat experimental thrombus formation model."	( Correlation between bleeding time and antithrombotic effect of platelet-suppressive agents in rat experimental model. Kakishita, E; Oura, Y; Suehiro, A; Ueda, M, 1994)	0.47
" In cases with severe cardiac disease, however, a high dosage of ASA or anticoagulation therapy may be necessary to prevent further vascular events."	( [Low dose acetylsalicylic acid in secondary prevention of stroke]. Deecke, L; Zeiler, K, 1993)	0.29
" Predicted plasma salicylate concentration-time curves were constructed for various aspirin dosage regimens."	( Plasma salicylate concentrations in immature dogs following aspirin administration: comparison with adult dogs. Bill, RL; Bowers, LD; Caywood, DD; Cipolle, RJ; Waters, DJ, 1993)	0.75
" Unfortunately, dosing strategies and monitoring have not kept pace with the rest of the field."	( The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration. Becker, RC; Gore, JM, 1993)	0.29
"In study 1, compared with control Krebs-Ringer-bicarbonate perfusion, peroxide perfusion significantly increased, in a dose-response manner, placental lipid peroxide secretion."	( Secretion of lipid peroxides by the human placenta. Walsh, SW; Wang, Y, 1993)	0.29
"25 or 0h oral dosing of the 5-lipoxygenase inhibitor, MK-886, but not when only one of these doses was given."	( Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. Rainsford, KD, 1993)	0.29
" Under ASA treatment, neither TAI nor prolongation of SBT was dependent on dosage or time (Figs."	( [Prolongation and normalization of bleeding time during therapy with different doses of acetylsalicylic acid]. Epp, K; Nolte, H, 1993)	0.29
" IVGG was given in a dosage of 400 mg/kg/day for 4 consecutive days."	( Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome. Chen, MR; Hsu, CH; Hung, HY; Hwang, FY; Kao, HA, 1993)	0.29
" A therapeutic plasma salicylate concentration can be attained using enteric-coated aspirin tablets at a dosage of 25 mg/kg TID."	( [Analgesics; the use of aspirin in dogs; effects of tablet type and food intake on plasma salicylate level]. Breen, DJ; De Bruyne, JJ; Lam, TJ; Nap, RC; Peters, IO; Willemsen, A, 1993)	0.82
"Patients admitted to the coronary care unit who received both intravenous nitroglycerin and heparin were studied to evaluate heparin dosage requirements."	( Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease. Berk, SI; Bodenheimer, MM; Grunwald, A; Pal, S, 1993)	0.29
" The data indicate that ticlopidine is better tolerated by the gastroduodenal mucosa than low dosage aspirin."	( [A comparison of the gastroduodenal tolerance of ticlopidine and acetylsalicylic acid]. Kleinsorge, H; Müller, P; Simon, B, 1993)	0.5
"We compared the effect of different aspirin schedules, dosages, and formulations on various bleeding time parameters including bleeding time, plasma and total blood volume, and levels of the stable metabolites of thromboxane A2 (TXA2) and prostacyclin (PGI2) (respectively, TXB2 and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha)) to determine the optimal dosage and formulation of aspirin to inhibit TXA2 production while sparing PGI2."	( The effect of regular and enteric-coated aspirin on bleeding time, thromboxane, and prostacyclin. Ebbeling, L; Gerrard, JM; Gow, JA, 1993)	0.83
" To explore possible pharmacokinetic contributions to this phenomenon, a randomized, two-period crossover investigation was performed in 24 healthy volunteers in which a single oral dose of 300 mg cyclosporine was administered alone and on day 10 of multiple oral dosing of aspirin 960 mg three times daily."	( Pharmacokinetics of cyclosporine and steady-state aspirin during coadministration. Gaber, M; Jähnchen, E; Johnston, A; Kovarik, JM; Mueller, EA, 1993)	0.72
"To complete research in this type of coagulation and cancer, a multicentric randomized clinical trial was performed, including 303 patients with small cell lung cancer (SCLC), treated by the addition of aspirin at 1 g/day (a dosage at which aspirin is considered to be a platelet aggregation inhibitor) to combined chemotherapy."	( No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J, 1993)	0.73
" Aspirin did not influence the cortisol responses to synthetic ACTH administration given according to a dose-response protocol."	( Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation. Crosbie, GV; Grice, JE; Hockings, GI; Jackson, AJ; Jackson, RV; Walters, MM, 1993)	2.64
" There was a linear dose-response curve that was steeper in women than in men."	( Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Dobson, A; Henry, D; Turner, C, 1993)	0.52
" Unexpectedly, MISO increased the antiinflammatory effect of ASA at some dosage regimens."	( Acetylsalicylic acid and misoprostol combination in adjuvant arthritis of rats. Dizbay-Sak, S; Melli, M; Saray, A; Taşcilar, O, 1993)	0.29
"To determine the renovascular effects of nonprescription ibuprofen in the maximum labeled over-the-counter (OTC) dosage for 7 days, and to compare these effects with those of two other available OTC analgesics, aspirin and acetaminophen, we evaluated 25 elderly patients with mild thiazide-treated hypertension and mild renal insufficiency."	( Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Furey, SA; McMahon, FG; Vargas, R, )	0.32
" A low (100 mg) to medium (325 mg) daily aspirin dosage was more effective than a high dose (975 mg)."	( Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. Chen, E; Christakis, GT; Fremes, SE; Goldman, BS; Levinton, C; Naylor, CD, 1993)	0.55
" Other significant factors contributing to an increase in SGOT concentrations were duration of therapy and, perhaps, daily dosage (mg/lb)."	( Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. Anderson, W; Furst, DE, 1993)	0.56
" A dose-response relationship particularly between DG I and DG II, was also observed in the anti-thrombotic activity monitored by the aPTT."	( Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results. Bosma, AH; Hertzberger, DP; Kingma, JH; Laarman, GJ; Lok, DJ; Luz, CM; Molhoek, GP; Takens, LH; Van den Bos, AA; Zijnen, P, 1995)	0.29
" It was also demonstrable after subcutaneous dosing or when injury was measured by a change in mucosal potential difference."	( Gastric mucosal adaptation to diclofenac injury. Cook, GA; Elliott, SL; Giraud, AS; Skeljo, MV; Yeomans, ND, 1996)	0.29
" A challenge with IS was carried out in every patient in single-blind fashion, reaching a cumulative dosage of 1000 mg in the fourth session."	( Tolerability of imidazole salycilate in aspirin-sensitive patients. Andri, G; Andri, L; Dama, AR; Mezzelani, P; Senna, GE, )	0.4
"These findings indicated that this convolution method is useful for estimating the in vivo dissolution profile of drugs, when they are administered in an enteric-coated multiple unit type dosage form, because the gastric emptying process is a determinant process for the in vivo drug dissolution."	( New evaluation method for in vitro/in vivo correlation of enteric-coated multiple unit dosage forms. Hayashi, T; Ogura, T; Takagishi, Y, 1995)	0.29
"6 studies with a placebo-controlled, double blind, randomized protocol on the effect of acetylsalicylic acid (ASA) in a dosage of higher than 100 mg/day have been published."	( [High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia]. Hartmann, A, 1995)	0.29
" There is disagreement over the optimal dosage to prevent a stroke: earlier studies considered > or = 975 mg ASS per day, sometimes in combination with other substances, while more recently, lower dosages of about 300 mg per day or even as low as < or = 100 mg per day have been proposed."	( [Aspirin dosage for prevention of cerebral infarct: arguments for low dosage]. Hennerici, MG; Meairs, S, 1995)	1.2
"Controlled release dosage forms offer advantages over conventional dosage forms and a more constant and prolonged therapeutic effect."	( Numerical models for calculating the blood level of a drug with oral controlled release forms. Vergnaud, JM, 1995)	0.29
" Administration of ASA at a dosage of 10 and 25 mg/kg BW orally and intravenously yielded a plasma concentration of salicylic acid of 30-42 micrograms/ml (10 mg/kg BW) and 50-70 micrograms/ml (25 mg/kg BW)."	( [Effect of acetylsalicylic acid on platelet aggregation and capillary bleeding in healthy cats]. Deniz, A; Hart, S; Kietzmann, M; Nolte, I; Sommer, B, 1995)	0.29
" The risks, however, may be minimized by creation of anticoagulation clinics to ensure optimal dosing and follow-up."	( Stroke prevention: the emerging strategies. Matchar, DB; McCrory, DC, 1996)	0.29
" However, little is known about the dose-response relationship for salicylate-related effects on labor and gestation."	( Maternal reproductive effects of oral salicylic acid in Sprague-Dawley rats. Daston, GP; Davis, DP; Kraus, AL; Odio, MR; York, RG, 1996)	0.29
"This study establishes a rational and generally well tolerated dosing regimen for administration of tirofiban as adjunctive therapy in high risk angioplasty patients."	( Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Ambrose, J; Cohen, M; Fitzpatrick, V; Herrmann, HC; Kereiakes, DJ; Kleiman, NS; McKee, DB; Palabrica, T; Rodriguez, S; Sax, FL; Sutton, JM; Weaver, WD, 1996)	0.29
" The adherence rates for all dosing errors between self-report and Medication Event Monitoring System were significantly different (P = ."	( Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Brenner, DE; Burney, KD; Krishnan, K; Ruffin, MT; Zhang, D, 1996)	0.57
" A assessment of low-dose aspirin treatment is difficult, since no dose-response study was performed to determine the optimal dose; the duration of treatment--beginning and end--was not defined and the drug risk for mother and child was not documented in accordance with GCP guidelines."	( -Is prevention of pre-eclampsia with low dosage aspirin possible? Critical assessment of available studies-. Lippert, TH; Mück, AO, 1996)	0.85
" Dose-response analyses employing the fever model demonstrated that potency of aspirin to reduce fever was increased 5 to 10-fold when the aspirin was intragastrically administered in the lipid-associated state."	( Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. Dial, EJ; Illich, PA; Lichtenberger, LM; Romero, JJ; Ulloa, C; Vanous, AL; Walters, ET, 1996)	0.8
" Therapy should be initiated in all settings with the lowest possible dosage since the incidence of the major AEs is dose related."	( Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. Matzke, GR, 1996)	0.57
" Limited dose-response analyses found that the point estimate decreased with the frequency but not the duration of use of aspirin and other NSAIDs."	( Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Annegers, JF; Levin, B; Martínez, ME; McPherson, RS, )	1.78
" There are three main reasons for measuring drugs: to test patient compliance, to ensure that dosage is high enough to have therapeutic effect but sufficiently low to avoid toxicity and, finally, to identify drugs taken during deliberate or accidental overdose."	( Measurement of aspirin and paracetamol metabolites. Higgins, C, )	0.48
"8%), while, in Lille, only one out of 2 patients received this dosage (50."	( [Treatments of ischemic cardiopathies (IC) and modalities of prescription of aspirin in the three French MONICA centers in 1990]. Amouyel, P; Arveiler, D; Bingham, A; Cambou, JP; Ferrières, J; Haas, B; Lablache Combier, B; Montayé, M; Richard, JL; Ruidavets, JB, 1995)	0.52
"The process of in-vivo drug transfer is very complex in the case of oral dosage forms with controlled release."	( Prediction of in-vivo blood level with controlled-release dosage forms. Effect of the gastrointestinal tract time. Ouriemchi, IM; Vergnaud, JM, 1996)	0.29
" All patients undergoing PTCA should receive adequate antiplatelet therapy, including aspirin, and heparin with dosing monitored by activated clotting times (ACT)."	( Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. Barry, WH; Boston, DR; Malouf, A, 1996)	0.52
" Samples of venous blood were taken from all patients at the moment of hospitalization and after 2, 4, 6, 8, 10, 12 and 24 hours from the thrombolytic treatment (AMI + urokinase) or conventional therapy (AMI + nitroglycerin), for the dosage of creatinine kinase (CK) and adhesion molecules."	( Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. Altavilla, D; Campo, GM; Canale, P; Caputi, AP; Di Tano, G; Ioculano, M; Mazzu, A; Saitta, A; Squadrito, F; Squadrito, G, 1996)	0.29
" Similar, log-linear dose-response curves were found for both ASA and SA, significant in effect at 3 g/kg and higher drug contents and reaching saturation level at 15 or 30 g/kg, respectively, which, 20 min after application, caused a mean pain suppression of 95% using ASA and 80% using SA."	( Dose-dependent competitive block by topical acetylsalicylic and salicylic acid of low pH-induced cutaneous pain. Kreysel, HW; Reeh, PW; Steen, KH, 1996)	0.29
" Plasma concentrations were measured in four additional animals of all high dose groups after the last dosing at seven time points."	( Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. Bauer, E; Bauer, M; Greischel, A; Hirsch, U; Lehmann, H; Schmid, J; Schneider, P, 1996)	0.29
" Further observational studies and randomized controlled trials are needed to confirm the association, to quantify the dosage required for a protective effect, and to identify those patients most likely to benefit."	( Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. Forman, D; Weiss, HA, 1996)	1.74
" A dose-response relation was found between level of anger and overall CHD risk (P for trend, ."	( A prospective study of anger and coronary heart disease. The Normative Aging Study. Kawachi, I; Sparrow, D; Spiro, A; Vokonas, P; Weiss, ST, 1996)	0.29
" Twenty-six patients were dosed for 2 weeks, 300 mg aspirin once daily and then for 2 weeks, 250 mg ticlopidine twice daily."	( Asymptomatic circulating cerebral emboli and cerebral blood flow velocity under aspirin and ticlopidine in patients with cerebrovascular disease. Droste, DW; Kaps, M; Siemens, HJ; Sonne, M, 1996)	0.77
" Existing epidemiological studies are limited by a lack of information about dosage and duration of aspirin use."	( Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents. Baron, JA; Greenberg, ER, 1996)	1.95
" A metaanalysis of ten trials has shown a 25% decrease in vascular events in the long-term, irrespective of age, gender, blood pressure blood glucose level, and dosage whether low (75 to 160 mg) or moderate (160 to 325 mg/day)."	( [Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents]. Aumont, MC; Seknadji, P, 1996)	0.29
"We performed the following studies: (1) a cross-sectional comparison of smokers and control subjects, (2) an examination of the dose-response relationship, (3) an exploration of the effect of smoking cessation (3 weeks) and nicotine patch supplementation, (4) the effect of aspirin consumption, and (5) the effects of 5 days' dosing with vitamin E (100 and 800 U), vitamin C (2 g), and their combination."	( Modulation of oxidant stress in vivo in chronic cigarette smokers. Delanty, N; FitzGerald, GA; Lawson, JA; Reilly, M, 1996)	0.47
" In a dosage of 150-300 mg/kg they are severe, and above 500 mg/kg potentially fatal."	( [Successful therapy of salicylate poisoning using glycine and activated charcoal]. Conen, D; Mühlebach, S; Steger, P; Wyss, PA, 1996)	0.29
" Acetylsalicylic acid is the first choice medical treatment, but the optimal dosage is still a matter of debate."	( [Large trials in the secondary prevention of stroke]. Gensini, GF; Inzitari, D; Pantoni, L; Simone, I, 1996)	0.29
" A single intravenous injection of aspirin at a dose of 225 mg/kg caused a reduction in the amplitude of the ABR P1 wave evoked by a 2 kHz tone pip 1 and 24 hr after dosing at almost all sound intensity levels, while the P1 amplitude at 4 kHz was reduced mainly 1 hr after dosing, and the P1 amplitude at 8 kHz was not significantly affected at middle and high intensities even 1 hr after dosing."	( A characteristic of aspirin-induced hearing loss in auditory brainstem response of conscious rats. Kurata, K; Sato, S; Suzuki, T; Tsukuda, R; Yamamoto, M, 1997)	0.9
" The tablets complied with the requirements of the acid neutralizing capacity, uniformity of dosage units, disintegration and dissolution tests (USP XXIII) for buffered aspirin tablets."	( Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. al Gohary, OM; el Din, K; el Tahir, H, )	0.68
" However, they are not sensitive enough for the simultaneous determination of ASA and its major metabolites salicylic (SA) and salicyluric (SUA) acids at the low dosage schedules (30-100 mg ASA/d)."	( A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Dzúrik, R; Krivosíková, Z; Spustová, V, 1996)	0.29
" Oral provocation showed clear dose-response relationships."	( [Oral exposure testing in non-aspirin-induced analgesic intolerance]. Brasch, J; Christophers, E; Wiedow, O, 1996)	0.58
" Three h after dosing with 50 mg/kg acidified aspirin, there was superficial mucosal damage and decreased mucin content in the surface mucosal layer."	( Recovery of mucin content in surface layer of rat gastric mucosa after HCl-aspirin-induced mucosal damage. Hotta, K; Ishihara, K; Saigenji, K; Sakai, T, 1997)	0.79
" Tramadol showed a dose-response for analgesia in both postsurgical and dental pain patients."	( Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. McQuay, JH; Moore, AR, 1997)	0.3
" The dosage of ticlopidine is 2 tablets per day; that of aspirin is not well established (100 to 330 mg per day in a single dose)."	( [Antiplatelet agents (inhibitors of platelet function) orally administered. Bases for their practical use in coronary artery disease]. de Maistre, E; Lecompte, T, 1996)	0.54
" Data from trials with aspirin suggest that the beneficial effect of this drug is maintained in diabetic patients with acute MI, but the optimal dosage remains undefined."	( Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. Latini, R; Zuanetti, G, )	0.44
" Ten patients with aspirin-induced asthma underwent three bronchial challenges with a single dose of lysine acetylsalicylate (LASA) that caused a decrease in FEV1 of 25% or more in a preliminary dose-response test 30 min after inhalation of 4 mg nedocromil sodium, 10 mg sodium cromoglycate, or placebo."	( Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium. Bianco, S; Gambaro, G; Pieroni, MG; Refini, RM; Robuschi, M; Sestini, P; Vaghi, A, 1997)	0.98
" Further investigation to refine eptifibatide dosing during coronary intervention is warranted."	( Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. , 1997)	0.3
" These findings suggest that onset of analgesia should be more rapid following dosing with soluble aspirin, a conclusion supported by comparative efficacy studies conducted with differing formulations of aspirin."	( Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Muir, N; Nichols, JD; Stillings, MR; Sykes, J, 1997)	0.8
" This paper reviews the pattern of adverse reactions to AAS and their relationship to the dosage of ASS evaluated."	( [Secondary prevention of ischemic strokes: effect of dosage of aspirin]. Alvarez-Sabín, J; Calvo, G; Morros, R, 1997)	0.54
" The crude odds ratio for the different adverse reactions was calculated using three sub tests: AAS versus placebo; AAS < 330 mg/d versus AAS > 330 mg/d; and each dosage level versus a placebo."	( [Secondary prevention of ischemic strokes: effect of dosage of aspirin]. Alvarez-Sabín, J; Calvo, G; Morros, R, 1997)	0.54
"There seems to be a direct relationship between the dosage of AAS and the frequency with which adverse reactions occur, except in the case of intracerebral hemorrhage."	( [Secondary prevention of ischemic strokes: effect of dosage of aspirin]. Alvarez-Sabín, J; Calvo, G; Morros, R, 1997)	0.54
" These inhibitory effects were observed within 30 min and sustained for 24 h at a single dosage of 5 mg/kg of vapiprost."	( The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Hiraishi, S; Horie, S; Ishii, H; Kazama, M; Kizaki, K; Kurusu, O; Nakahara, T; Noritake, S; Satoh, M; Yamada, M, 1997)	0.3
" Tablets "Paravit" have mark, which allows exact dosing for children of different age."	( [The physiological properties of the action of a new analgesic and antipyretic preparation]. Chernykh, VP; Shapovalova, VO, 1997)	0.3
"Aspirin and dipyridamole in pure admixtures and in dosage forms have been estimated by spectrofluorometry."	( Spectrofluorometric estimation of aspirin and dipyridamole in pure admixtures and in dosage forms. Agarwal, V; Parimoo, P; Thomas, SK; Umapathi, P, 1997)	2.02
" Even when used according to manufacturer's dosing instructions alendronate should probably be used with caution."	( Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Goodgame, R; Graham, DY; Malaty, HM, 1997)	0.52
" This explains the different dosage requirements of aspirin as an antithrombotic (COX-1) and an anti-inflammatory drug (COX-2), respectively."	( Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Schrör, K, 1997)	1.99
" This study was aimed at: evaluating the magnitude and incidence of the inhibitory phenomenon; defining the minimal aspirin dosage that produces an antagonistic effect, as well as the possible reasons for a different individual susceptibility."	( [The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors]. Alimento, M; Campodonico, J; Celeste, F; Guazzi, M; Rossi, M; Santambrogio, G; Trabattoni, D, 1997)	0.8
" Blood samples were taken at frequent intervals for 24 hours after single dosing in 12 healthy volunteers and Tmax, Cmax and t1/2 measured."	( The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. Clifford, JM; Hoare, RC; Muir, N; Nichols, JD; Stillings, MR, 1997)	0.58
" There are doubts in case of emergency operations, especially in transplant patients, concerning dosage and change of medication."	( [Preoperative aspirin therapy--a contraindication for kidney transplantation?]. Schubert, J; Werner, W, 1997)	0.66
" The question of transplant suitability, dosage and haemostatic effects will be discussed in comparison to the literature."	( [Preoperative aspirin therapy--a contraindication for kidney transplantation?]. Schubert, J; Werner, W, 1997)	0.66
" Most of the transplantation centers accept a dosage of 100 mg ASA daily."	( [Preoperative aspirin therapy--a contraindication for kidney transplantation?]. Schubert, J; Werner, W, 1997)	0.66
"Correctly indicated ASA treatment (cardiac arrhythmia, patients with embolism or thrombosis) isn't a contraindication for renal transplantation (daily dosage up to 100 mg)."	( [Preoperative aspirin therapy--a contraindication for kidney transplantation?]. Schubert, J; Werner, W, 1997)	0.66
" A statistically significant increase in the threshold for 2 kHz was found 1 to 72 hr after dosing but not for 4, 8 and 10 kHz."	( Frequency selectivity on aspirin-induced hearing loss in rats with auditory stimulus-induced conditioned suppression. Kurata, K; Nishida, N; Sato, S; Suzuki, T; Tokuriki, M; Tsukuda, R, 1997)	0.6
" Urinary 8-epi-PGF2 alpha was unchanged after 2-week dosing with aspirin and indobufen despite complete suppression of TX metabolite excretion."	( In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Alessandrini, P; Bon, GB; Bucciarelli, T; Ciabattoni, G; Cipollone, F; Costantini, F; Davi, G; Mezzetti, A; Minotti, G; Patrono, C, 1997)	0.53
" This study was designed to evaluate the incidence of the counteractive phenomenon and to define minimal aspirin dosage that causes an antagonistic effect."	( Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Alimento, M; Campodonico, J; Celeste, F; Guazzi, M; Guazzi, MD; Rossi, M; Santambrogio, G; Trabattoni, D, 1998)	0.75
" The cardinal questions to be answered were: (1) the relationship between three targeted diastolic pressures (< or = 90, < or = 85 and < or = 80 mm Hg, respectively) and cardiovascular morbidity and mortality rates among hypertensives; and (2) the effect of low dosage aspirin (75 mg daily) on morbidity and mortality rates, compared with a placebo."	( [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age]. Kolloch, RE; Rahn, KH, 1998)	0.48
" Any necessary changes in dosage (step 4) were made according to a prescribed plan."	( [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age]. Kolloch, RE; Rahn, KH, 1998)	0.3
"Study of the tolerance and pharmacodynamic and pharmacokinetic characteristics of ascolong, a new buccal dosage form of aspirin containing a very low dose of acetylsalicylic acid (ASA): 12."	( [Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and antiaggregant]. Belolipetskaia, VG; Bochkareva, EV; Davydo, AB; Deev, AD; Demina, EG; Gorin, NN; Ionova, VG; Khromov, GL; Kokurina, EV; Kucheriaeva, NG; Metelitsa, VI; Rumiantsev, DO; Suslina, ZA; Tanashian, MM; Zidra, SI, 1998)	0.51
"The anti-inflammatory effects of therapeutic dosing of drugs with greater selectivity for the inhibition of the constitutive (COX-1) or inducible isoform (COX-2) of cyclooxygenase were assessed in a model of chronic inflammation."	( Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Gilroy, DW; Tomlinson, A; Willoughby, DA, 1998)	0.3
" There are doubts in emergency operations, especially in transplant patients, concerning dosage and change in medication."	( [Does treatment with thrombocyte aggregation inhibitors modify kidney transplantation surgery?]. Klemm, A; Schubert, J; Werner, W; Wunderlich, H, 1998)	0.3
"The objective of this study is to evaluate and compare the analgesic efficacy of Piroxicam Fast Dissolving Dosage Formulation (FDDF) administered sublingually either preoperatively or postoperatively with that of aspirin and placebo."	( Postoperative pain control by single doses of piroxicam administered sublingually and aspirin. Alpaslan, C; Alpaslan, G; Uğar, D, 1997)	0.71
" Because of the need for frequent anticoagulation monitoring and dosage adjustment, the use of heparin is limited to short-term treatment during the acute in-hospital phase."	( New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials. Cohen, M, 1998)	0.3
" NMDA shifted the dose-response curve of AA to the right."	( Further insights into the anti-aggregating activity of NMDA in human platelets. Alberti, L; De Montis, MG; Franconi, F; Miceli, M; Seghieri, G; Tagliamonte, A, 1998)	0.3
" Consequently, dosing regimens for this compound may not need to be altered in sepsis."	( Influence of sepsis on the plasma elimination pharmacokinetics of diaspirin crosslinked hemoglobin in rats. Chin-Yee, IH; d'Almeida, MS; Sibbald, WJ; White, M, 1998)	0.54
" The dosage of Coumadin was maintained constant regardless of the prothrombin time (PT) or cardiac rhythm."	( Aortic valve replacement with the St. Jude Medical prosthesis and fixed dose anticoagulation. Iscan, HZ; Katircioglu, SF; Mavitas, B; Tasdemir, O; Ulus, AT; Yamak, B, )	0.13
" In this study, we investigated the effect of a combination between a high and an ultra-low dosage (100 mg/kg+ 10(-30) mg/kg) on an arterial thrombosis induced by a laser beam."	( Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis. Aguejouf, O; Belon, P; Belougne-Malfatti, E; Doutremepuich, C; Doutremepuich, F, 1998)	0.3
"The 2 arthritis trials identified SC-58635 dosage levels that were consistently effective in treating the signs and symptoms of arthritis and were distinguished from placebo on standard arthritis scales."	( Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Geis, GS; Hubbard, RC; Isakson, PC; Lanza, FL; Lipsky, PE; Schwartz, BD; Simon, LS; Talwalker, S, 1998)	0.3
" NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform."	( Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Gilroy, DW; Tomlinson, A; Willoughby, DA, 1998)	0.3
" It appears that 325 mg of aspirin is sufficient to affect PGE2 production and that increasing the dosage to 650 mg daily provides an additional decrease in PGE2 synthesis."	( Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients. Dyavanapalli, M; Frommel, TO; Kazi, N; Liao, Y; Lietz, H; Mobarhan, S; Oldham, T, 1997)	1
" Finally, the role of LMWH and heparinoids and appropriate dosing have still to be determined."	( Use of antithrombotic agents during pregnancy. Ginsberg, JS; Hirsh, J, 1998)	0.3
" Aspirin at the dosage of 160-325 mg per day accomplishes a 21% reduction of the recurrences of vascular events (INR: 3-4)."	( [Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct]. Biancoli, S; Ceré, E; Di Pasquale, G; Lombardi, A; Ottani, F; Sassone, B, 1998)	1.21
"Prediction of the drug level in the volume of distribution was made using a numerical model taking into account the following facts: the kinetics of drug release out of the dosage form along the gastrointestinal tract, the kinetics of absorption in the blood compartment and the kinetics of elimination."	( Assessment of blood level with controlled-release dosage forms: effect of the rate constant of elimination of the drug. Aïnaoui, A; Vergnaud, JM, )	0.13
" The mean dosage of aspirin was 273 mg/d and mean duration of treatment was 37 months."	( Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. He, J; Klag, MJ; Vu, B; Whelton, PK, 1998)	2.07
" Further studies are underway to develop alternative heparin dosing strategies in an effort to reduce the occurrence of bleeding complications associated with c7E3 Fab administration and to assess the benefit of c7E3 Fab-mediated platelet inhibition in lower risk patient subgroups."	( Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results. Popma, JJ; Satler, LF, 1994)	0.29
"The dose-response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels."	( Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Conran, P; Hawk, EE; Kelloff, GJ; Kramer, PM; Li, H; Lubet, RA; Pereira, MA; Schut, HA; Steele, VE, 1999)	0.89
" Results indicate that only aspirin treatment throughout the entire carcinogenic period significantly reduced tumour incidence and volume whereas intermittent aspirin dosing increased tumour number and/or volume, suggesting that aspirin must be used for an extended period in order to gain any chemopreventive benefit."	( Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in rats. Barnes, CJ; Lee, M, 1999)	0.85
"5, 1, 2, 3 and 4 h after dosing to evaluate eight upper gastrointestinal symptoms, which were stomach pain, burning sensation, nausea, heartburn, gas, burping, indigestion and upset stomach."	( Subjective gastrointestinal tolerability of acetylsalicylic acid and paracetamol after single dose treatment. Amin, D; Elfström, C; Grahnén, A; Loose, I; Nilsson, LG; Rolfsen, W, 1999)	0.3
" Aspirin, from 3 to 100 mg/kg, showed no dose-response relation for either TTO or TW and did not significantly affect ex vivo platelet aggregation."	( Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. Kambayashi, J; Lockyer, S, 1999)	1.21
" Seventy-three patients on antiplatelet therapy were evaluated, using dosing criteria established through a literature review."	( Drug utilization review: dipyridamole plus aspirin antiplatelet therapy. Crisp, CB; Garrard, EA, 1985)	0.53
" Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine."	( Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999)	0.58
" Thrombin-stimulated platelets contained not only the three major proteins: actin (43 kDa), myosin (200 kDa) and an actin-binding protein (250 kDa), but three additional proteins of Mr56 kDa, 80 kDa and 85 kDa in the cytoskeleton, which were induced in by thrombin dose-response relationship."	( Cytoskeletal changes in platelets induced by thrombin and phorbol myristate acetate (PMA). Chen, R; Liang, N, 1998)	0.3
" Next, by drawing on data from the HOT trial, the mixture and dosage of drugs for each level of blood pressure control were estimated."	( Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD. , 1998)	0.3
" It was concluded that the ASA dosage of 1500 mg daily was too high, and produced severe side-effects, probably leading to insufficient patient compliance to therapy."	( Oral anticoagulation in peripheral vascular surgery: how intense, for how long, or at all? Hölzenbein, TJ; Kretschmer, G, 1999)	0.3
" This review article examines research on both monotherapy and combination antiplatelet therapy for secondary stroke prevention, with an emphasis on lessons learned about dosage schedules, treatment protocols, and side-effect profiles."	( Antiplatelet therapy for secondary stroke prevention. Forbes, CD, 1999)	0.3
" To evaluate the dose-response relationship, we conducted a metaregression analysis of study-specific risk ratios by means of weighted linear regression."	( A metaregression analysis of the dose-response effect of aspirin on stroke. Abebe, BL; Dicker, LW; Johnson, ES; Lanes, SF; Satterfield, MH; Wentworth, CE, 1999)	0.55
" The slope of the dose-response curve was virtually flat across a wide range of aspirin doses from 50 to 1500 mg/d (P = ."	( A metaregression analysis of the dose-response effect of aspirin on stroke. Abebe, BL; Dicker, LW; Johnson, ES; Lanes, SF; Satterfield, MH; Wentworth, CE, 1999)	0.78
" Blood samples were taken before and up to 6 h after dosing and the plasma obtained from it was tested for its ability to inhibit prostanoid formation in IL-1beta-treated A549 cells (COX-2 system) and human washed platelets (COX-1 system)."	( Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Giuliano, F; Warner, TD, 1999)	0.3
"There was a clear dose-response for pain relief with aspirin, even though these were single dose studies."	( Oral aspirin in postoperative pain: a quantitative systematic review. Carroll, D; Edwards, JE; McQuay, HJ; Moore, AR; Oldman, AD; Smith, LA; Wiffen, PJ, 1999)	1.07
"Study 1: In this double-blind study 18 volunteers received randomized dosing with either EC-ASA 100 mg or placebo for 15 days."	( Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Burkhardt, F; Dammann, HG; Wolf, N, 1999)	0.63
" BC2 extended aPTT to a maximum of 60 to 80 seconds at 100 to 1000 nmol/L in vitro (rat and human plasma, respectively) and ex vivo (rat) after dosing of rats up to 6 mg/kg in vivo."	( Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Baker, A; Blackburn, MN; Bugelski, P; Church, WR; Feuerstein, GZ; Koster, P; Nichols, AJ; Patel, A; Toomey, JR; Valocik, R, 1999)	0.3
" It is likely that proper selection of patients, as well as the timing and dosage of treatment, are key factors for its efficiency."	( [Arterial hypertension of the pregnant woman]. Beaufils, M, 1999)	0.3
"25 mg/kg) acelysine ensured chronometric and structural hypocoagulation as early as 1 h after dosed infusion and throughout the entire intervention, preventing thrombosis of microvascular anastomoses."	( [The prevention of thrombus formation and the improvement of the blood rheological properties during operations with a microsurgical technic. I. The possibilities for using acelysin--an acetylsalicylic acid derivative]. Mikhaĭlova, OM; Roĭtman, EV; Shibaev, EIu; Smirnova, LA; Svetlov, VA; Vabishchevich, AV, )	0.13
" The investigations were performed with different amounts of 4 different inducers (ADP, arachidonic acid, epinephrine and collagen) taking dose-response curves."	( [The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis]. Barczi, V; Blaskó, G; Dinnyés, J; Hamvas, J; Jáger, R; Kinczel, A; Pál, A; Poór, F; Salamon, A; Tarján, J, 1999)	0.3
" In the present study, we examined whether this deconvolution method is useful for evaluating oral dosage forms."	( Deconvolution analysis for absorption and metabolism of aspirin in microcapsules. Hashida, M; Wu, X; Yamashita, F, 1999)	0.55
"Mini-dose aspirin, even at a dosage of 75 mg/day, caused significant changes in renal function and UA handling within 1 week in a group of elderly inpatients, mainly in those with preexisting hypoalbuminemia."	( The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Caspi, D; Graff, E; Habot, B; Lubart, E; Segal, R; Yaron, M, 2000)	1.02
" 4) The pectin-induced increase of gastric lesions (number) showed a dose-response effect."	( Effects of pectin-induced passive linkage of gastric H+ on the gastric acid secretion on the development of ethanol- and salicylate-induced gastric mucosal lesions in rats. Figler, M; Mózsik, G; Szabó, I, 1999)	0.3
" However, it was not possible to generate dose-response curves whereas significant correlations of uptake values with T50 values were found."	( The effect of oxytocin, prostaglandin E2 and acetylsalicylic acid on flow distribution and on the transfer of alanine, glucose and water in isolated perfused guinea pig placentae. Goepel, E; Niemax, K; Rybakowski, C; Schröder, HJ, 2000)	0.31
"A multi-dimensional column chromatographic method employing UV spectrometric detection was optimised and successfully used in a comparative bio-availability study of aspirin obtained from different commercially available oral dosage forms."	( A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. Sagar, KA; Smyth, MR, 1999)	0.75
" Compared with Pl(A1,A1) platelets, Pl(A2)-positive platelets showed a gene dosage effect for significantly greater surface-expressed P-selectin, GP IIb/IIIa-bound fibrinogen, and activated GP IIb/IIIa in response to low-dose ADP."	( Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Barnard, MR; Bray, PF; Christie, DJ; Coleman, L; Furman, MI; Goldschmidt-Clermont, P; Hamlington, J; Hendrix, C; Kickler, T; Kundu, S; Mascelli, MA; Michelson, AD, 2000)	0.31
" Fifty-nine per cent were unaware that aspirin is an anti-inflammatory drug, 3 per cent thought that taking a double dosage on alternate days was safe, and 46 per cent that taking a stronger dose at the beginning of treatment was an efficient and safe procedure."	( [Awareness of 125 patients of the rules for using their non-steroidal anti-inflammatory agent]. Berthelot, JM; Chatelier, B; Maugars, Y; Millet, S; Prost, A; Ripoll, N, )	0.4
"All healthy volunteers (n = 10) received a fractionated infusion of L-aspirin to establish individual dose-response curves."	( Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Hergovich, N; Homoncik, M; Jilma, B; Panzer, S; Speiser, W; Stohlawetz, P, 2000)	0.9
"03) of the norepinephrine dose-response curve and a significant decrease in logED50 (P < ."	( Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin. Arnold, JM; Dzeka, TN; Kuzminski, P, 2000)	0.53
" Discrepancies seem largely related to either studying very low-risk populations, or strong differences in aspirin dosage and/or term of introduction."	( [Aspirin and prevention of pre-eclampsia]. Beaufils, M, 2000)	1.43
" Dosage was 40 mg/day in women with solitary defect and 80 mg/day in combined defects."	( Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000)	0.31
" Our data indicate that HemoSTATUS clot ratio values and heparin dose response values are not significantly affected after IV dosing of epsilon-aminocaproic acid."	( The effect of epsilon-aminocaproic acid on HemoSTATUS and kaolin-activated clotting time measurements. Bigham, M; Despotis, GJ; Saleem, R; Spitznagel, E, 2000)	0.31
" The differences between the doses of aspirin, the type and dosage of the converting enzyme inhibitors and neuro-hormonal activation of the patients could explain the discordant results."	( [Aspirin, angiotensin converting enzyme inhibitors and cardiac insufficiency]. Aumégeat, V; de Groote, P; Lablanche, JM; Lamblin, N; Meurice, T; Millaire, A, 2000)	1.49
" Additional trials are needed with different dosage regimens to determine the optimal combination of fibrinolytic agents and platelet glycoprotein IIb/IIIa receptor blockers."	( Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study. Altmann, E; Cuffie-Jackson, CA; Molhoek, PG; Neuhaus, KL; Ronner, E; Simoons, ML; van der Wieken, LR; van Kesteren, HA; Zijnen, P, 2000)	0.31
"Niacin increased HDL cholesterol levels by 30%, with the majority of effect achieved at a dosage of 500 mg twice daily."	( Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Applegate, WB; Crouse, JR; Davis, KB; Egan, D; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Johnson, WC; Kennedy, JW; Kostis, JB; Sheps, DS, 2000)	0.31
" Therefore, it is quite possible that both drugs produce adverse immunological effects in vivo in cases of high dosage or obstruction of elimination."	( [Effect of migraine medications on monocyte chemotaxis] . Krumholz, W; Menges, T; Ogal, H; Szalay, G, 2000)	0.31
" In addition, the dose-response relation of aspirin in reducing the risk of colorectal cancer has not been described."	( Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. García-Rodríguez, LA; Huerta-Alvarez, C, 2001)	0.82
" However, we know that ejection fraction and symptom class do not always match and that the regulation of warfarin dosing is more difficult in worsening heart failure."	( Anticoagulation and heart failure. Graham, SP, 2001)	0.31
" In contrast, GI toxicity of the drug does appear to be dose related, consistent with dose- and dosing interval-dependent inhibition of COX-1 activity in the nucleated lining cells of the GI mucosa."	( Aspirin: new cardiovascular uses for an old drug. Patrono, C, 2001)	1.75
" Interindividual variability is observed in the level of platelet inhibition achieved with use of the current abciximab dosing regimen (0."	( Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Berkowitz, SD; Christie, DJ; Glazer, S; Jennings, LK; Madan, M; Sigmon, KN; Smit, AC; Tcheng, JE, 2001)	0.31
" The result was supported a rational dose-response relationship for different doses of paracetamol and codeine in 17 additional trials with 1,195 patients."	( Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. Gavaghan, D; McQuay, HJ; Moore, RA; Smith, LA, 2001)	0.31
" The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks."	( [Prevention of cardiovascular diseases in type 2 diabetes with aspirin]. Duly-Bouhanick, B; Guilloteau, G; Hadjadj, S; Menard, S; Plun-Favreau, J; Soares-Barbosa, S, 2001)	0.55
"To review the efficacy and dosage of aspirin in stroke prevention, and to review the benefits and risks of the newer strategies, compared with aspirin."	( Newer antiplatelet therapies in stroke prevention. Davis, SM; Donnan, GA, 2001)	0.58
" It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease."	( [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. Scheen, AJ, 2001)	0.31
" heart failure, hypertension or ischaemic cardiopathy); and differences in the type and the dosage of each treatment (especially ACE inhibitors and aspirin since an interaction might occur more often with dosage of aspirin greater than 250mg)."	( Interaction between aspirin and ACE inhibitors in patients with heart failure. Bergmann, JF; Caulin, C; Diemer, M; Mahé, I; Meune, C, 2001)	0.83
" We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk."	( Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001)	0.31
" Kawasaki disease is treated with intravenous gamma--globulin therapy and high dosage acetylsalicylic acid at the beginning of the disease."	( [Kawasaki disease--personal observations]. Balcar-Boroń, A; Dylewska, K; Kojro-Wojcieszonek, A; Maćkowska, K; Masłowska, E, 2001)	0.31
"Ammonio methacrylate copolymer is a pharmaceutical excipient widely used as a coating material for encapsulation of pellet and tablet dosage forms."	( Transport properties of ionic drugs in the ammonio methacrylate copolymer membranes. Hsu, SC; Lai, JY; Sun, YM, 2001)	0.31
" Pranlukast inhibited the bronchial reaction and an increase in sputum ECP after threshold dosed of ASA, but failed to change aspirin-induced LT production in sputum and urine."	( Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients. Fukushima, C; Kawano, T; Kohno, S; Matsuse, H; Mitsuta, K; Obase, Y; Shimoda, T; Tomari, S, 2001)	0.82
" The observed increase in time to occlusion was abolished when celecoxib was administered to animals dosed with HDA-ER (80."	( Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Barrett, TD; Crofford, LJ; Driscoll, EM; Hennan, JK; Huang, J; Lucchesi, BR; Park, AM; Willens, DE, 2001)	0.31
"Intravenous ASA in a dosage of 100 mg did not completely prevent TXA(2) production in AMI patients treated with streptokinase."	( Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial. Husted, SE; Jensen, HK; Kristensen, SD; Nielsen, HK; Vissinger, H; Ziegler, BK, 2001)	0.31
" Arjunolic acid at an effective dosage of 15 mg/kg body wt."	( Experimental myocardial necrosis in rats: role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Arutselvan, N; Balakrishna, K; Kumar, DA; Manikandan, P; Manohar, BM; Puvanakrishnan, R; Sumitra, M, 2001)	0.31
" This article will address the safety and efficacy of acetaminophen, aspirin, and ibuprofen independently and in combination with currently available prescription dosage forms with a focus on pharmacology, pharmacotherapeutics, pharmacodynamics, and pharmacokinetics, including drug interactions at the CYP450 system."	( Acetaminophen, aspirin, or Ibuprofen in combination analgesic products. Barkin, RL, )	0.72
" Original studies found a dose-response relationship between UGIC and aspirin, although the risk was still elevated for doses lower or up to 300 mg day(-1)."	( Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. de Abajo, FJ; García Rodríguez, LA; Hernández-Díaz, S, 2001)	0.87
" Be familiar with accepted dosing levels for the three agents."	( Pharmacologic optimization of microsurgery in the new millennium. Adams, WP; Conrad, MH, 2001)	0.31
" Dosing should be [figure: see text] cautious in old patients, however, because of the ability of NSAIDs and coxibs to cause fluid retention, heart failure, and hypertension."	( Gastrointestinal safety of COX-2 specific inhibitors. Hawkey, CJ; Jones, JI, 2001)	0.31
" The challenge for researchers and clinicians is to further understand which NSAIDs and what dosage and duration may provide the optimal benefit (if any), and to accurately construe the available current data on these agents for patients inquiring about these compounds."	( An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II. Moyad, MA, 2001)	0.64
" Future studies are needed to investigate further the role of pharmacological therapy combined with hsp induction in improving skin flap survival and to delineate the dose-response relationship between aspirin and hsp."	( Heat shock protein and high-dose aspirin: effects on random skin flap survival in a rat model. Ghavami, A; Hardy, SP; Nutt, MP, 2002)	0.78
" There was no dose-response effect between the 3 aspirin dose groups and urinary 11-DTB2 (P=0."	( Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. Bang, NU; Bruno, A; Cohen, SN; Mansbach, HH; McConnell, JP; Tietjen, GE, 2002)	2.01
"In African American stroke patients, aspirin use is associated with significantly lower urinary 11-DTB2 independent of other vascular factors, and there does not appear to be a dose-response effect for aspirin doses of 325 to 1300 mg daily."	( Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. Bang, NU; Bruno, A; Cohen, SN; Mansbach, HH; McConnell, JP; Tietjen, GE, 2002)	2.03
" VOAspi-PbetaPL film inhibited cell proliferation in a dose-response manner and induced formation of approximately half of the thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation."	( A vanadium/aspirin complex controlled release using a poly(beta-propiolactone) film. Effects on osteosarcoma cells. Alessandrini, JL; Cortizo, AM; Cortizo, MS; Etcheverr, SB, 2001)	0.7
" Non-fractionated heparin has more complex effects and its administration protocol in association with fibrinolysis has recently been reviewed with a reduction in dosage because prolonged clotting times during fibrinolysis have provoked a distinct increase in the risk of intracranial haemorrhage."	( [Fibrinolysis in myocardial infarction with EKG elevation. Optimization of myocardial reperfusion by treatment with antithrombotic agents]. Coste, P; Jaïs, C; Labèque, JN; Lafitte, S; Perron, JM; Roudaut, R; Zabsonré, P, 2001)	0.31
"The dose-response curves of platelet aggregation, dense body secretion, phospholipase C activation and calcium mobilization were measured in aspirin-treated platelets with and without added vitamin E (50 and 100 M)."	( Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets. Celestini, A; Frati, G; Gazzaniga, PP; Lenti, L; Pignatelli, P; Pulcinelli, FM; Violi, F, 2002)	0.77
" Dose-response curves were compared by analysis of the area under the curve (AUC) using independent samples t test."	( Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. MacAllister, RJ; Prasad, S; Singer, DR; Singh, N, 2002)	0.31
"5 mg/kg intravenous (IV), and eptifibatide using the ESPIRIT dosing (180 g/kg bolus IV, immediately followed by a 2 g/kg/minute continuous IV infusion, and then a second 180 g/kg bolus IV ten minutes after the first bolus)."	( Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. Bertolet, BD; Gupta, A; Miller, L, 2002)	0.31
" Until more definitive data become available, when prescribing and dosing ASA for the prevention of MI or vascular ischemia, clinicians should identify possible risk factors for ASA resistance."	( Possible mechanisms of aspirin resistance. Cambria-Kiely, JA; Gandhi, PJ, 2002)	0.63
" These findings are likely to result, at least in part, from the antiplatelet action of naproxen, which has been shown to be potent and sustained during a typical dosing regimen (500 mg twice daily in VIGOR)."	( Current perspective on the cardiovascular effects of coxibs. Konstam, MA; Weir, MR, 2002)	0.31
" Measurable plasma concentrations of XV459 appeared rapidly and were sustained throughout the dosing interval of 24 hours."	( Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. Cain, VA; Ebling, W; Fossler, MJ; Kornhauser, DM; Ma, S; Mondick, JT; Pieniaszek, HJ; Sy, SK, 2002)	0.31
" In fact, even retrospective data on heparin provide miserably inadequate information for those making a decision on the correct dosing regimen."	( Anticoagulation during pregnancy. Foster, E; Naqvi, TZ, 2002)	0.31
" This work illustrates the potential for an artificial neural network, GRNN, to assist in development of extended-release dosage forms."	( The application of generalized regression neural network in the modeling and optimization of aspirin extended release tablets with Eudragit RS PO as matrix substance. Djurić, Z; Ibrić, S; Jovanović, M; Parojcić, J; Solomun, L, 2002)	0.53
" However, when we examined this relationship in terms of days of NSAID use per month, we did not observe a dose-response with increasing NSAID use."	( Aspirin, other NSAIDs, and ovarian cancer risk (United States). Colditz, GA; Fairfield, KM; Fuchs, CS; Hankinson, SE; Hunter, DJ, 2002)	1.76
" The studies to date have failed to demonstrate consistent relationships between aspirin's platelet-inhibiting effects, the impact of dosage escalation, and clinical outcomes."	( Aspirin resistance. Howard, PA, 2002)	1.98
" This may have implications regarding the need for separate heparin dosing algorithms for patients undergoing PCI in the setting of different GPIIb-IIIa inhibitors."	( Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention. Ball, SA; Dauerman, HL; Desourdy, MA; Furman, MI; Goldberg, RJ, 2002)	0.31
"05), suggesting a linear dose-response relationship."	( Effect of diaspirin cross-linked haemoglobin (DCLHb) on mean arterial pressure during cardiopulmonary bypass in swine. Burhop, K; Chiari, P; Ferrera, R; Hadour, G; Jegaden, O; Lehot, JJ; Montagna, P, 2002)	0.69
" The developed method is rapid and sensitive and therefore suitable for routine control of these drugs in dosage form."	( HPLC assay of acetylsalicylic acid, paracetamol, caffeine and phenobarbital in tablets. Agbaba, D; Aleksic, M; Eric, S; Franeta, JT; Pavkov, S; Vladimirov, S, 2002)	0.31
" This rabbit model with a high dosage of clopidogrel and aspirin, and a short-time exposure of the heart valve leaflets to rabbit blood under laminar flow, should be further evaluated with respect to whether it can give information about antithrombotic regimens in patients after mechanical heart valve replacement."	( Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Bickel, C; Buerke, M; Hauroeder, B; Hundt, F; Meyer, J; Peetz, D; Rupprecht, HJ; Schlitt, A; Victor, A, 2002)	0.82
" They analyze also the effect of dosage (benefit vs."	( [Acetylsalicylic acid (ASA)--is everything clear?]. Spinar, J; Vítovec, J, 2002)	0.31
" Nevertheless, none of these fibans was able to effectively block shear-induced platelet adhesion at targeted clinical dosing regimens except for abciximab."	( Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X, 2002)	0.31
" Combination therapy may produce synergic effects with better tumor inhibition as well as lower dosage or side affects."	( [Effects of combination of octreotide and aspirin on proliferation of human hepatocellular carcinoma]. Tang, CW; Tang, LP; Wang, CH, 2002)	0.58
" Although there was no clear evidence of a dose-response relationship, we observed risk reductions associated with greater frequency of use."	( Regular aspirin use and lung cancer risk. Bepler, G; Cummings, KM; Falkner, KL; Loewen, GM; Menezes, RJ; Moysich, KB; Reid, ME; Ronsani, A; Swede, H, 2002)	0.75
"Pharmacologic and clinical studies focusing on the dose-response relationship of aspirin therapy were reviewed."	( Aspirin dose for prevention of cardiovascular disease in diabetics. Jaber, LA; Nowak, SN, 2003)	1.99
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)."	( Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003)	0.56
"The discovery of a functional single-nucleotide polymorphism in the cyclooxygenase 1 locus may ultimately improve the safe and effective use of acetylsalicylic acid by better tailoring of dosage with an individual's genetic variation."	( Genetic variation in cyclooxygenase 1: effects on response to aspirin. Halushka, MK; Halushka, PV; Walker, LP, 2003)	0.56
" Daily dosage of ACE inhibitors and particularly of beta-blockers was on average below the recommended target dose."	( The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Aguilar, JC; Cleland, J; Cohen-Solal, A; Dietz, R; Eastaugh, J; Follath, F; Freemantle, N; Gavazzi, A; Hobbs, R; Komajda, M; Korewicki, J; Madeira, HC; Mason, J; Moiseyev, VS; Preda, I; Swedberg, K; Van Gilst, WH; Widimsky, J, 2003)	0.32
"Our results suggest that the prescription of recommended medications including ACE inhibitors and beta-blockers remains limited and that the daily dosage remains low, particularly for beta-blockers."	( The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Aguilar, JC; Cleland, J; Cohen-Solal, A; Dietz, R; Eastaugh, J; Follath, F; Freemantle, N; Gavazzi, A; Hobbs, R; Komajda, M; Korewicki, J; Madeira, HC; Mason, J; Moiseyev, VS; Preda, I; Swedberg, K; Van Gilst, WH; Widimsky, J, 2003)	0.32
" Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and improve clinical outcomes."	( Aspirin resistance and genetic polymorphisms. Cambria-Kiely, JA; Gandhi, PJ, 2002)	1.76
"), few studies have examined dosage and long-term compliance and persistence patterns for the use of these drugs after AMI."	( Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Beck, C; Eisenberg, MJ; Pilote, L; Richard, H; Simpson, E, 2003)	0.32
"In summary, an incremental dosage of aspirin (660 mg) shortens the bleeding time prolonged by daily low-dosage aspirin (81 mg) in healthy subjects."	( Aspirin reversal--an incremental administration of aspirin shortens the bleeding time prolonged by low-dose aspirin. Manabe, M; Nishiyama, T; Ueta, T; Yamasaki, F; Yamashita, K; Yokoyama, T, 2003)	2.03
"To determine whether urinary 11-dehydrothromboxane B2 (d-TXB2) is a marker of aspirin resistance and define the relationship between aspirin dosage and concentrations of this thromboxane metabolite."	( Aspirin dosage and thromboxane synthesis in patients with vascular disease. Bovill, E; Cornell, E; Feinberg, WM; Hart, RG; Leonard, AD; Pearce, LA; Talbert, RL, 2003)	1.99
" Lack of interaction was assessed by determination of pharmacokinetic characteristics and relative bioavailability of both substances and salicylic acid (CAS 69-72-7, SA), administered in combination and as equally single dosed drugs."	( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers. Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003)	0.32
" No interaction was found for AUCnorm and Cmax, norm between the fixed combination ASA/PSE and the equally single dosed drugs as reference."	( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers. Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003)	0.32
" Intravenous glycoprotein IIb/IIIa inhibitors effectively prevent periprocedural thrombotic complications, but their short duration of action and parenteral dosing don't allow for long-term protection."	( What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Berger, P; Steinhubl, S, 2003)	0.32
" There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17."	( Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms. Cook, JC; Gupta, U; Hurtt, ME; Tassinari, MS, 2003)	0.58
" The objectives of the current study were to comprehensively define the developmental toxicology profile of ASA in rabbits by using a dosing paradigm encompassing the period of organogenesis and to test the hypothesis that maternal gastrointestinal toxicity after repeated dose administrations hampers the detection of low-incidence malformations with ASA in rabbits by limiting ASA administration to sensitive windows for cardiovascular development and midline closure."	( Comparison of the developmental toxicity of aspirin in rabbits when administered throughout organogenesis or during sensitive windows of development. Cappon, GD; Cook, JC; Gupta, U; Hurtt, ME; Tassinari, MS, 2003)	0.58
" The appropriate dosage and duration of drug use and the ratios of risk to benefit are still unclear."	( Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Etminan, M; Gill, S; Samii, A, 2003)	0.32
" This work illustrates the potential for an artificial neural network, GRNN, to assist in development of extended release dosage forms."	( Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance. Djurić, Z; Ibrić, S; Jovanović, M; Parojcić, J; Petrović, SD; Solomun, L; Stupar, B, 2003)	0.56
" Study group 1 (10 healthy volunteers) received a DDAVP infusion to establish dose-response curves for the in vitro inhibition of platelet function by eptifibatide, abciximab, and tirofiban together with l-aspirin before and after DDAVP."	( Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blazicek, H; Domanovits, H; Galehr, E; Jilma, B; Jilma-Stohlawetz, P; Mayr, F; Reiter, RA, 2003)	0.72
"To prospectively examine the association between non-steroidal anti-inflammatory drugs (NSAIDs) use (including dose and dosage schedule) and the recurrence of colorectal adenomas among individuals who were diagnosed with an adenoma at entry into a clinical trial."	( Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Albert, PS; Burt, R; Caan, B; Corle, D; Hasson, M; Iber, F; Kikendall, JW; Lance, P; Lanza, E; Paskett, E; Schatzkin, A; Shike, M; Tangrea, JA; Weissfeld, J; Woodson, K, 2003)	0.32
" However, the optimal dosage still remains problematic, and a recent trial found aspirin 160 mg/day to be more effective than 80 mg/day for secondary prevention of ischaemic stroke."	( Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Cerletti, C; de Gaetano, G; Dell'Elba, G; Di Castelnuovo, A; Feliziani, V; Manarini, S; Pecce, R; Scorpiglione, N, 2003)	0.78
"Inhibition of serum TxB2 generation and of thromboxane metabolite urinary excretion by the lower dosage of aspirin, although substantial, still appeared incomplete."	( Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Cerletti, C; de Gaetano, G; Dell'Elba, G; Di Castelnuovo, A; Feliziani, V; Manarini, S; Pecce, R; Scorpiglione, N, 2003)	0.76
"On administration of low-molecular heparin, its dosage weight-adjusted, and 100 mg aspirin daily the discoloration of the finger quickly disappeared, but Raynaud's syndrome remained unchanged until she had stopped breast feeding (left breast only) after 8 months."	( [Repeated attacks of pain in the nipple of a pregnant woman. Unusual manifestation of Raynaud's phenomenon]. Diehm, C; Lawall, H; Stammler, F, 2003)	0.54
" Salicylate therapy in common dosage may therefore falsely elevate or depress serum uric acid levels."	( The effects of oral salicylate on serum uric acid levels. FORD, DK; PRICE, GE, 1963)	0.24
" Given the low rates of events, at low or intermittent dosage without concurrent treatment, these 3 analgesics cannot be distinguished from each other or from background rates of serious GI toxicity."	( Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. Bruce, B; Fries, JF, 2003)	0.32
" A time course analysis of RegI expression during the onset and offset of adaptation showed that mucosal RegI increased during the development of adaptation, was maintained during subsequent aspirin dosing, and returned to baseline levels once dosing had ceased and adaptation was lost-indicative of a causal role in the adaptation process."	( Insights into the mechanisms of gastric adaptation to aspirin-induced injury: a role for regenerating protein but not trefoil peptides. Alderman, BM; Giraud, AS; Howlett, M; Judd, LM; Parker, LM; Ulaganathan, M; Yeomans, ND, 2003)	0.76
" In the VIGOR gastrointestinal outcomes trial of >8000 patients, naproxen (an NSAID with aspirin-like sustained antiplatelet effects throughout its dosing interval) was associated with a significantly lower risk of CV events than was rofecoxib."	( Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR, 2003)	0.54
" The drug's effect as well as adverse effects should be actively sought, and dosage alterations made in order to enhance the drug's effect."	( Introduction to monitoring. What is what you prescribed actually doing? George, A; Shakib, S, 2003)	0.32
"To determine how to prepare high drug content particles using a Wurster fluidized bed to determine realizing the miniaturization of solid dosage forms, aspirin was selected as the model drug and granulated without any additive."	( Preparation and evaluation of high drug content particles. Cui, F; Sunada, H; Wang, X; Yonezawa, Y, 2003)	0.52
"The quality and performance of a solid oral dosage form depends on the choice of the solid phase, the formulation design, and the manufacturing process."	( Phase transformation considerations during process development and manufacture of solid oral dosage forms. Law, D; Qiu, Y; Schmitt, EA; Zhang, GG, 2004)	0.32
" Clinicians should ensure that patients at high risk of atherothrombosis (>3% risk over 5 years) are compliant with aspirin therapy and are taking the correct dosage (75-150 mg/day)."	( Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Eikelboom, JW; Hankey, GJ, 2004)	0.92
"3% (mean+/-SD), respectively, and of the urinary excretion of 11-dehydro-TXB2, an index of systemic biosynthesis of TXA2 in vivo, by 85+/-8% and 78+/-7%, respectively, that persisted throughout the dosing interval."	( Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Capone, ML; Di Gregorio, P; Grana, M; Merciaro, G; Minuz, P; Patrignani, P; Patrono, C; Ricciotti, E; Sciulli, MG; Tacconelli, S, 2004)	0.54
" Additional studies have been conducted on combination antibiotic therapy, duration of treatment, dosing of aminoglycosides, alternative agents for gram-positive organisms, aspirin therapy, and surgical interventions."	( Recent trends in infective endocarditis: influence of case definitions. Andrews, MM; Devlin, RK; von Reyn, CF, 2004)	0.52
" Antioxidant and anti-inflammatory mechanisms with different dose-response relationships may contribute to the clinical effect of aspirin in cardiovascular disease."	( Aspirin in cardiovascular disorders. What is the optimum dose? Kong, DF, 2004)	1.97
" These findings suggest that effect of NTG on nNOS at a high dosage may involve the cycloxygenase pathway and that activation of the peripheral 5-HT1B/D receptors is not able to modify this effect."	( Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Pardutz, A; Schoenen, J; Szatmári, E; Vecsei, L, 2004)	0.32
" An initial dose-response study using 12."	( Evaluation of Pongamia pinnata root extract on gastric ulcers and mucosal offensive and defensive factors in rats. Agrawal, VK; Dora Babu, M; Goel, RK; Prabha, T; Priyambada, S, 2003)	0.32
" A daily dosage of 75 to 150 mg is sufficient to reduce the rate of future cardiac events."	( [Risk management of coronary artery disease--pharmacological therapy]. Hofmann, T, 2004)	0.32
" Thus, bedtime, but not morning, dosing with cilnidipine significantly reduces nocturnal blood pressure."	( Chronotherapy of hypertension. Hermida, RC; Smolensky, MH, 2004)	0.32
" As active ingredients may also change their solid-state form during formulation processing or storage and as this can adversely affect the final dosage performance, monitoring of pharmaceutical ingredients is essential for a 'right-first-time' philosophy within the industry."	( Applications of terahertz spectroscopy to pharmaceutical sciences. Taday, PF, 2004)	0.32
" The women were randomized, using a random numbers table with blocks of 12, to receive either prophylactic dosing of dalteparin or UFH starting either preconceptionally or early in pregnancy."	( Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Ballem, PJ; Ensom, MH; Ensworth, S; Houlihan, E; Purkiss, S; Stephenson, MD; Tsang, P, 2004)	0.32
" Although leukotriene CysLT1-receptor antagonists improve lower airway outcomes in AIA, their effects and dose-response in the upper airway is less well documented."	( Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Haggart, K; Lee, DK; Lipworth, BJ; Robb, FM, 2004)	0.59
" In addition, obtaining a valid therapeutic activated partial thromboplastin time (aPTT) in cardiology patients is a major challenge, and dosing is complex."	( Unfractionated heparin in cardiology: redefining the standard of practice. Díez, J; Rihn, TL, 2004)	0.32
"Drugs were separately, orally dosed to pregnant rats triple daily 8 hr apart from day 8 to 21 (GD=1-plug day)."	( Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats. Burdan, F, 2004)	0.32
" This study was designed (1) to investigate the effects of microemulsion dosage form on the healing of gastric ulcers, and (2) to determine the relationship between oxidative mechanisms and TGF-alpha during ulcer healing."	( The role of transforming growth factor alpha formulation on aspirin-induced ulcer healing and oxidant stress in the gastric mucosa. Akbulut, KG; Celebi, N; Gönül, B; Ozer, C; Yetkin, G, 2004)	0.57
" Its transnasal dosage form, which may be self-administered when the use of an opioid analgesic is appropriate, was previously shown to provide rapid relief of migraine pain."	( Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Davidson, WJ; Diamond, S; Gawel, MJ; Goldstein, J; Reich, L; Sussman, NM; Winner, P, )	0.13
" Moreover, ximelagatran has rapid onset and offset of action, fixed oral dosing without the need for anticoagulation monitoring, low potential for food and drug interactions, and a therapeutic margin wider than that of warfarin."	( New possibilities in anticoagulant management of atrial fibrillation. Waldo, AL, 2004)	0.32
" The Efficacy and Safety of the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Recent and Myocardial Damage (ESTEEM) trial, a placebo-controlled, double-blind study of post-MI patients, evaluated 4 dosing regimens of ximelagatran versus placebo in the initial months following an ACS and found an encouraging reduction in the end points of death, MI, and stroke with the use of an oral direct thrombin inhibitor."	( Reducing cardiac events after acute coronary syndromes. Granger, CB; Weaver, WD, 2004)	0.32
" If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used."	( [Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005)	0.33
" An increase in the dosage of aspirin or conversion to clopidogrel or clopidogrel plus aspirin might be beneficial in the management of those patients who are aspirin resistant."	( Aspirin resistance in stroke: 2004. Sas, K; Sztriha, LK; Vecsei, L, 2005)	2.06
" Hence, increased platelet turnover after CPB seems to contribute to aspirin resistance, since an increased number of platelets might be competent to form thromboxane within the dosing intervals."	( Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Gams, E; Hohlfeld, T; Kurt, M; Wenk, A; Winter, J; Zimmermann, N, 2005)	0.83
" In the present investigation, the effect of roxifiban (class I) on ex vivo clot dynamics using recalcified blood was tested in normal, healthy volunteers (n = 7) dosed with 1 mg BID roxifiban for 9 days."	( Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Bozarth, JM; Feuerstein, GZ; Mousa, SA; Seiffert, D, 2005)	0.33
" The association between the pretreatment aspirin dosage and fatal outcome among these treated patient groups has not been analyzed previously."	( The significance of prestroke aspirin dosage in fatal outcome of acute stroke. Boaz, M; Lampl, Y; Sadeh, M, )	0.68
"Of the limited number of epidemiological investigations on aspirin (and other nonsteroidal anti-inflammatory drugs) and breast cancer, the majority observe a protective role, yet only a few report dose-response effects for frequency or duration of use."	( Association of regular aspirin use and breast cancer risk. Menezes, RJ; Mirand, AL; Moysich, KB; Swede, H, 2005)	0.88
" Aspirin was significantly more effective than placebo for pain reduction beginning 1 hour after dosing (P<."	( Aspirin is efficacious for the treatment of acute migraine. Baggish, JS; Goldstein, J; Lipton, RB; Quiring, JN; Sorrentino, JV; Yataco, AR, 2005)	2.68
" As well, we highlight current research around optimal dosage and other issues related to aspirin administration."	( What every emergency nurse needs to know about aspirin. Smith, S; Turris, SA, 2005)	0.81
"Drugs were separately, orally once daily dosed to pregnant rats from day 8 to 21 (GD1=plug day)."	( Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study. Burdan, F, 2005)	0.33
" Regardless of the accumulated evidence on the molecular mechanisms of aspirin's action, the rationale of the appropriate dosing and monitoring of aspirin therapy and prophylaxis remains obscure."	( [Aspirin--the prodigious panacea? Molecular mechanisms of the action of acetylsalicylic acid in the organism]. Czyz, M; Watała, C, 2005)	1.47
" Also, the use of ASA as an elicitor resulted in the inhibition of biomass growth and an increase in total ginseng saponin content at every elicitor dosage (0."	( Production of antioxidant compounds by culture of Panax ginseng C.A. Meyer hairy roots: I. Enhanced production of secondary metabolite in hairy root cultures by elicitation. Hwang, B; Jeong, GT; Kim, D; Kim, SW; Park, DH; Ryu, HW; Woo, JC, 2005)	0.33
" Prospective randomized studies are warranted to elucidate the optimal aspirin dosage for preventing ischemic complications of atherothrombotic disease."	( Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Chen, WH; Cheng, X; Kwok, JY; Lau, CP; Lee, PY; Ng, W; Tse, HF, 2005)	0.98
"Helicobacter pylori (H pylori) infection and the use of non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin at any dosage and formulation represent well-established risk factors for the development of uncomplicated and complicated peptic ulcer disease accounting for the majority of such cases."	( Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. Archimandritis, AJ; Papatheodoridis, GV, 2005)	0.8
" The results of the proposed method were in excellent agreement with those obtained from PLS and HPLC methods and can be satisfactorily used for routine analysis of multicomponent dosage forms."	( Content uniformity and dissolution tests of triplicate mixtures by a double divisor-ratio spectra derivative method. Koundourellis, JE; Malliou, ET; Markopoulou, CK, 2005)	0.33
" The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient."	( Antiplatelet therapy in ischemic stroke. Káposzta, Z; Pongrácz, E, 2005)	0.33
" A similar dose-response relationship was found for nonaspirin NSAIDs (P = ."	( Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Chan, AT; Curhan, GC; Fuchs, CS; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES, 2005)	0.92
" The intensity of other symptoms of URTI was rated by patients at baseline and at 2, 4, and 6 hours after dosing (scale from 0 = none to 10 = severe)."	( Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging st Bachert, C; Chuchalin, AG; Eisebitt, R; Netayzhenko, VZ; Voelker, M, 2005)	1.77
" The present study was performed to extend the dose-response curve for effects of ASA on fibrinogen clotting properties and to examine the variability of these effects during a 24-h dose interval."	( Marked increase of fibrin gel permeability with very low dose ASA treatment. Antovic, A; Blombäck, M; Ekman, GJ; He, S; Hjemdahl, P; Perneby, C; Wallen, HN, 2005)	0.33
" The dose-response study of AA and IDM demonstrated that the concentration of intracellular AA accumulated by IDM is less than 100 nm."	( Enhancement of Ca2+-regulated exocytosis by indomethacin in guinea-pig antral mucous cells: arachidonic acid accumulation. Fujiwara, S; Kato, M; Katsu, K; Nakahari, T; Nakanishi, Y; Shimamoto, C, 2006)	0.33
" In this survey, 30% believed there was less risk with OTC analgesics, and 44% consumed more than the recommended dosage on the label."	( Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. Cryer, B; Triadafilopoulos, G; Wilcox, CM, 2005)	0.33
" Binary mixtures of a drug, acetylsalicylic acid, or fluoxetine hydrochloride, and of excipients commonly used in solid dosage forms were prepared at a ratio of approximately 1:100 in 96-well microtiter plates."	( Drug-excipient compatibility testing using a high-throughput approach and statistical design. Alsenz, J; Birringer, C; Kuentz, M; Wyttenbach, N, 2005)	0.33
"Pemetrexed (500 mg/m(2)) with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin (in patients with CrCl > or =60 mL/min) or ibuprofen (in patients with CrCl > or =80 mL/min)."	( Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Baker, SD; Battiato, L; Chaudhary, AK; Chaudhuri, T; Cleverly, A; Fife, K; Krull, JH; Latz, JE; Mita, AC; Murry, DJ; Rowinsky, EK; Sandler, A; Sweeney, CJ; Takimoto, CH, 2006)	0.75
" The mean aspirin dosage was 81 mg/day over a period of 6-288 weeks (mean: 86."	( [Significance of the stool occult blood test in patients with thrombotic disease under treatment with low dose aspirin]. Hayashi, S; Wakizaka, A, 2005)	0.94
" Furthermore, (i) the optimal dosage of aspirin for complete inhibition of platelet aggregation by physiological agonists (i."	( Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Christiaens, L; Macchi, L; Sorel, N, 2006)	2.04
" AZD6140 (100 and 200 mg bid, 400 mg qd) rapidly and nearly completely inhibited ADP-induced platelet aggregation after initial dosing (day 1) and at day 28."	( Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M, 2006)	0.55
" Changes in total thrombus area (TTA) under low shear rate (LSR; 212 s(-1)) and high shear rate (HSR; 1690 s(-1)) conditions were measured, using the ex vivo Badimon perfusion chamber model pre-dose and 2 and 5 hours after dosing on Day 6, and capillary bleeding times (CBT) were determined."	( Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Badimon, JJ; Bylock, A; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Kalies, I; Nyström, P; Sarich, TC; Wåhlander, K, 2006)	0.33
" We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37."	( Dose- and time-dependent antiplatelet effects of aspirin. Fitzgerald, D; Hjemdahl, P; Perneby, C; Rooney, C; Wallén, NH, 2006)	0.81
" Because acetaminophen has a different mechanism of action from the conventional NSAIDs, it does not inhibit peripheral PGs at recommended dosing and therefore appears to have a more favorable cardiovascular and gastrointestinal safety profile."	( Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease. Whelton, A, 2006)	0.33
" In the triple therapy group, the international normalized ratio or aspirin dosage did not influence the bleeding risk."	( Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006)	0.87
" We undertook a randomized, double-blind, placebo-controlled trial to evaluate which dosing regimens of ASA+MR-DP have better tolerance."	( Dose titration to reduce dipyridamole-related headache. Chang, YJ; Lee, TH; Ryu, SJ, 2006)	0.33
" Thirteen patients required a higher dosage of aspirin and/or an additional anti-platelet agent to achieve therapeutic adequacy."	( Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders. Gemmell, R; Hartwell, T; Manoharan, A, 2006)	0.59
"Variant CYP2C9 genotypes enhanced the protective effect of ibuprofen on the prevention of colorectal cancer, and a dose-response relationship with respect to increasing numbers of variant alleles was seen (P interaction = ."	( Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Andersen, K; Curtin, K; Levin, TR; Ma, KN; Samowitz, WS; Slattery, ML; Sweeney, C; Wolff, RK, 2006)	0.33
" Moreover, with no aspirin use as the referent category, there were no significant associations for duration of aspirin intake by category (< 1, 1- < 2, 2- < 3, 3- < 4, 4- < 5, and > or = 5 years) or for daily dosage by category (< 165, 165- < 300, 300- < 495, or > or = 495 mg)."	( The association between aspirin use and the incidence of colorectal cancer in women. Allison, M; Chlebowski, R; Criqui, M; Garland, C; Kuller, L; Langer, R; McTiernan, A; Roy, H; Wu, L, 2006)	0.97
" Data indicate that eptifibatide, at the current recommended dosing schedule, achieves the highest level of consistent platelet inhibition compared with current doses of abciximab and tirofiban."	( Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes. Jennings, LK, 2005)	0.33
"Establishing the dose-response relationship for clinically useful doses of aspirin, ibuprofen and paracetamol has been difficult."	( Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. McQuay, HJ; Moore, RA, 2007)	0.81
"Use of trials making direct comparison of two different doses of target drugs revealed the underlying dose-response curve for clinical analgesia."	( Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. McQuay, HJ; Moore, RA, 2007)	0.58
" However, having applied the polymer solution onto the dosage form's surface, the polymer should be converted to the nonionized form for delayed release action."	( A new solution for a chronic problem; aqueous enteric coating. Barzegar-Jalali, M; Ghassempour, A; Rafati, H, 2006)	0.33
" Since the optimal dose of ASA for primary and secondary prevention of events in the broad population is uncertain, dosing considerations should include an evaluation of a patient's individual clinical status as well as an overall cardiovascular and cerebrovascular benefit vs."	( The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Fisher, M; Knappertz, V, 2006)	0.71
" Subjects were eligible for inclusion in the study if they received an OTC dosage of naproxen (220 mg) or ibuprofen (200 mg)."	( Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. Biskupiak, JE; Brixner, DI; Howard, K; Oderda, GM, 2006)	0.33
" The physicians accepted 86% of the recommendations to initiate low dosage ASA and treatment was implemented for 63% of the patients."	( Drug-related problems in general practice: results from a development project in Denmark. Dinsen, C; Herborg, H; Kirkeby, B; Kjellberg, J; Soendergaard, B; Staehr, P, 2006)	0.33
" Oral aspirin has a repertoire of gastrointestinal side effects even at low doses and requires high frequent dosing because it undergoes extensive presystemic metabolism."	( Design of a transdermal delivery system for aspirin as an antithrombotic drug. Ammar, HO; El-Nahhas, SA; Ghorab, M; Kamel, R, 2006)	1.08
" A significant interpatient variation in response to the 4 dosing regimes was observed."	( Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Alberts, MJ; Coleman, JL, 2006)	0.74
" Examined a different way, the mean percentage of days that the correct aspirin dosage (1 pill per day for all patients) was taken was significantly lower in the persistently depressed patients (76."	( Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Burg, MM; Chaplin, WF; Davidson, KW; Gerin, W; Haas, D; Kronish, IM; Rieckmann, N; Vorchheimer, D, 2006)	0.84
" Two examples of this procedure would be the photodynamic treatment of choroidal neovasculature associated with exudative age-related macular degeneracy (AMD) where local delivery of an anti-angiogenic or an anti-inflammatory drug has been shown to be effective, or PDT of cancer where local dosing of a chemotherapeutic drug may well increase the treatment efficacy."	( Combination therapy using aspirin-enhanced photodynamic selective drug delivery. Ballini, JP; Debefve, E; Konan, YN; Pegaz, B; van den Bergh, H, 2007)	0.64
" Information on dosage and duration of use were not available for this analysis."	( Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women's health study. Anderson, KE; Folsom, AR; Hayes, JH, 2006)	0.33
"We sought to determine the optimal daily dosage of aspirin treatment."	( Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. Lee, JY; Simon, RA; Stevenson, DD, 2007)	0.96
" After 1 month, patients either increased or decreased their dosage based on their symptom control and continued that dosage for the remainder of the year."	( Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. Lee, JY; Simon, RA; Stevenson, DD, 2007)	0.71
"We recommend that patients begin daily aspirin therapy with 650 mg twice daily and subsequently decrease to the lowest effective dosage (usually 325 mg twice daily)."	( Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. Lee, JY; Simon, RA; Stevenson, DD, 2007)	0.98
" A greater aspirin resistance has been suggested in diabetic patents, which might lead to the use of a higher daily dosage of aspirin in diabetic than in non diabetic patients."	( [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. Legrand, DA; Scheen, AJ, 2006)	1.63
" The antinociceptive efficacies were evaluated using several dose-response curves and time courses."	( Evaluation of the antinociceptive effect of Rosmarinus officinalis L. using three different experimental models in rodents. Déciga-Campos, M; González-Trujano, ME; Guevara-Fefer, P; López-Muñoz, FJ; Martínez, AL; Moreno, J; Peña, EI, 2007)	0.34
" After adjustment for differences in definition, used dosage, and population, a statistically significant higher prevalence was found in studies with aspirin dosage < or =100 mg compared with > or =300 mg (36% [95% CI 28%-43%] vs 19% [95% CI 11%-26%], P < ."	( Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Eikenboom, JC; Hovens, MM; Huisman, MV; Mertens, BJ; Snoep, JD; van der Bom, JG, 2007)	0.78
" Both aspirin dosage and the method of defining aspirin resistance strongly influence estimated prevalence, which explains found heterogeneity among studies."	( Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Eikenboom, JC; Hovens, MM; Huisman, MV; Mertens, BJ; Snoep, JD; van der Bom, JG, 2007)	1.06
" To increase the probability of flushing, subjects received a single dose of reformulated niacin ER 2,000 mg, which is the upper limit of the approved dosage range."	( Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Cefali, EA; Kissling, CJ; McGovern, ME; Simmons, PD; Stanek, EJ, 2007)	1.78
" The described method was applied for the determination of these combinations in synthetic mixtures and dosage forms."	( Derivative-ratio spectrophotometric method for the determination of ternary mixture of aspirin, paracetamol and salicylic acid. Assi, SA; El-Yazbi, FA; Hammud, HH, 2007)	0.56
" QRT-PCR showed that the target gene cyclin D1 mRNA expression was gradually decreased with the dosage of aspirin."	( Down-regulation of beta-catenin nuclear localization by aspirin correlates with growth inhibition of Jurkat cell line. Hu, L; Shi, J; Wang, L, 2006)	0.79
" Within the limitations of the study, prasugrel was found to be well tolerated when dosed as LD followed by MD in the presence of ASA and provided greater platelet inhibition than ASA alone."	( Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ, 2007)	0.56
" Increasing dosage (trend P = ."	( Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Hancock, DB; Jewett, R; Martin, ER; Scott, BL; Scott, WK; Stacy, MA; Stajich, JM; Vance, JM, 2007)	0.34
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."	( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A, )	0.13
" It is probably due to drugs interaction, inadequate dosage and so on."	( [Pathogenesis and prevention tactics of aspirin resistance]. Zhang, JP; Zhang, RG, 2007)	0.61
" To analyze a possible interaction between both drugs a dose-response curve to ASA plus a fixed dose of CAF (5mg/kg) was obtained 3h after the injection of carrageenan, when the inflammatory pain peaked."	( Adjuvant effect of caffeine on acetylsalicylic acid anti-nociception: prostaglandin E2 synthesis determination in carrageenan-induced peripheral inflammation in rat. Fernández-Dueñas, V; Planas, E; Poveda, R; Sánchez, S, 2008)	0.35
" Dosing of aspirin in the first 24 hours was as follows: 17."	( Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007)	1.11
"We prospectively studied the effect of aspirin dosing on platelet function in 125 stable outpatients with coronary artery disease randomized in a double-blind, double-crossover investigation (81, 162, and 325 mg/d for 4 weeks each over a 12-week period)."	( Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Bliden, KP; Chaganti, SK; DiChiara, J; Etherington, A; Gesheff, T; Gurbel, PA; Neerchal, NK; Newcomer, J; Tantry, US; Weng, W, 2007)	0.88
" Present paper introduces the development and validation of analytical methods suitable for quantitative determination of paracetamol containing dosage forms in FoNo VII."	( [Current problems in the quality control of pharmaceutical preparations manufactured in pharmacies II. Paracetamol contraining preparations]. Horváth, P; Sinkó, B; Takaćsne, NK; Völgyi, G, 2006)	0.33
"Following orally dosing with 650 mg aspirin, saliva and urine samples were collected over a period of 24 h from healthy individuals with homozygous wild-type UGT1A6 *1/*1 (n=19) and homozygous variant UGT1A6 *2/*2 (T181A, R184S) (n=9) genotypes."	( UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Bigler, J; Chen, Y; Kuehl, GE; Lampe, JW; Rimorin, CF; Schwarz, Y; Shen, DD, 2007)	0.85
" We assessed the presence of duration-response and dose-response effects."	( Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Hennessy, S; Hwang, WT; Lewis, JD; Propert, K; Sedarat, A; Yang, YX, 2007)	0.34
" At the antithrombotic dosage they were free from prohemorrhagic side effect at variance with acetylsalicylic acid used as reference drug."	( Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis. Ballabeni, V; Barocelli, E; Bertoni, S; Bruni, R; Impicciatore, M; Tognolini, M, 2007)	0.34
" To investigate the effect of ASA, 10 dogs were dosed daily (75 or 250 mg ASA orally) for 4 consecutive days."	( Platelet function in dogs: breed differences and effect of acetylsalicylic acid administration. Nielsen, LA; Olsen, LH; Pedersen, HD; Tarnow, I; Zois, NE, 2007)	0.34
" In conclusion, FT-Raman spectroscopy is a fast and valuable tool for a quantitative determination of the extents of incompatibility in solid dosage forms."	( Compaction of lactose drug mixtures: quantification of the extent of incompatibility by FT-Raman spectroscopy. Flemming, A; Picker-Freyer, KM, 2008)	0.35
" Increased aspirin dosing resulted in similar rates of resistance and platelet function levels between groups."	( The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Antonino, MJ; Bailon, O; Bliden, KP; DiChiara, J; Gurbel, PA; Hamed, MS; Singla, A; Suarez, TA; Tantry, US, 2007)	1.09
" Platelet aggregation induced by ADP and dosing of prostanoid products 6-keto-PGF1alpha, TXB2, PGE2 and LTB4 were also performed."	( Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension. Aguejouf, O; Belon, P; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2007)	0.56
" For aspirin, the median dosage per week was 1300 mg and median ARU was 410."	( Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. Flaherty, CA; Lee, VH; Lopes, DK; Prabhakaran, S; Wells, KR, 2008)	1.14
" Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter."	( Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. Bates, V; Gengo, FM; Gengo, MF; Mager, DE; Rainka, M; Robson, M; Rubin, L, 2008)	0.83
" LMWH dosing was 'Prophylactic' (0."	( Primary thromboprophylaxis with heparins for arteriovenous fistula failure in pediatric patients. Adams, B; Crandell, C; Hirschl, R; Lin, JJ; Pipe, S; Sharathkumar, A, )	0.13
" We randomized 54 healthy subjects double-blind to 5-day treatment with a single daily oral dosage of either 100 mg aspirin plus 80 mg propranolol combined, 100 mg of aspirin, 80 mg of propranolol, or placebo medication."	( Effects of aspirin and propranolol on the acute psychological stress response in factor VIII coagulant activity: a randomized, double-blind, placebo-controlled experimental study. Cung, T; Fischer, JE; Haeberli, A; Helfricht, S; Kudielka, BM; Metzenthin, P; Preckel, D; von Känel, R, 2008)	0.95
"A mechanism-based pharmacodynamic model has been developed that characterizes the antiplatelet effects of aspirin and ibuprofen, alone and concomitantly, and predicts a significant inhibition of aspirin antiplatelet effects in the presence of a typical ibuprofen dosing regimen."	( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008)	0.83
"To determine, whether oral rabeprazole, administered 5 h before the initiation of therapeutic dosing of aspirin protects the gastroduodenal mucosa."	( Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole. Desipio, J; Fisher, RS; Irani, S; Kim-Jaffe, J; Krevsky, B; Maqbool, S, 2008)	0.81
" Subjects studied prior to therapy showed pronounced changes in AR parameters after aspirin dosing (e."	( Low prevalence and assay discordance of "aspirin resistance" in children. Bomgaars, L; Bray, PF; Dinu, BR; Edwards, RM; Justino, H; Sun, CW; Teruya, J; Yee, DL, 2008)	0.84
"The purpose of this study was to compare the ability of four commercial platelet function assays to detect aspirin response in normal individuals taking 81 or 325 mg aspirin in a single-dose response and then in a 7-day dosing regimen."	( Comparison of four laboratory methods to assess aspirin sensitivity. Fritsma, GA; McGlasson, DL, 2008)	0.81
" One hundred sixty-one patients on 100 mg of aspirin co-medication underwent elective coronary stenting and were given an initial dosage of 600 mg clopidogrel, followed by 75 mg clopidogrel daily."	( How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Engelhardt, A; Lask, S; Mügge, A; Neubauer, H, 2008)	0.61
" The specific dosing and its clinical usefulness of each medication are considered."	( [Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations]. Keltai, M, 2008)	0.35
"7%), all at low dosage levels."	( [Prescription patterns for antilipidemic drugs in a group of Colombian patients]. Machado, JE; Mesa, G; Moncada, JC, 2008)	0.35
" All of the antilipidemics are being used at lower-than-recommended dosage levels."	( [Prescription patterns for antilipidemic drugs in a group of Colombian patients]. Machado, JE; Mesa, G; Moncada, JC, 2008)	0.35
" Hyporesponsive patients might benefit from different dosing strategies or additional antiplatelet therapies."	( Investigating the mechanisms of hyporesponse to antiplatelet approaches. Angiolillo, D; Bates, E; Berger, PB; Bhatt, D; Braunwald, E; Cannon, CP; Furman, MI; Gurbel, P; Michelson, AD; Peterson, E; Wiviott, S, 2008)	0.35
" Aspirin, a widely used anti-thrombotic drug, achieved comparable activity in this model system at a dosage of ca."	( Synthesis, nano-scale assembly, and in vivo anti-thrombotic activity of novel short peptides containing L-Arg and L-Asp or L-Glu. Chen, Y; Cui, G; Lee, KH; Morris-Natschke, S; Peng, S; Qian, K; Wang, C; Zhao, M, 2008)	1.26
"A 4-year-old child with SWS, who was chronically treated with aspirin at an antiplatelet dosage of 3 mg/kg per day, presented with extensive SGH and significant anemia after a mild head trauma."	( Subgaleal hematoma in a child with Sturge-Weber syndrome: to prevent stroke-like episodes, is treatment with aspirin advisable? Fiumara, A; Greco, F; Pavone, L; Sorge, G, 2008)	0.8
" For example, increasing the dosage of aspirin or alternative antiplatelet drugs are potential therapeutic concepts, but these require careful future investigation."	( Aspirin "resistance". Hohlfeld, T; Weber, AA; Zimmermann, N, 2008)	2.06
" Clopidogrel at 3 mg kg(-1) was dosed orally once daily for three days, with the last dose given 2 h before injury."	( Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Crain, EJ; Watson, CA; Wong, PC, 2008)	0.35
" Endothelial function and beta(2)-adrenoceptor activity was tested by studying the dose-response relationship of acetylcholine and isoproterenol, respectively, on isolated aortic tissues in an organ bath setup."	( Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats. Fahim, M; Shahid, M; Sharma, KK; Tauseef, M, 2008)	0.65
"To achieve this goal, we have studied the effects of these two dosing regimens on platelet function in healthy women meeting the WHS inclusion criteria using a randomized design."	( Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study. Hillman, RS; Swaim, L, 2009)	1.8
"8%) compared to the patients who were using non-ASA NSAID, at therapeutic dosage (1."	( A new model of pharmacovigilance? A pilot study. Bacis, G; Locatelli, C; Manzo, L; Ramella, F; Tatoni, P; Vecchio, S; Zancan, A, 2009)	0.35
"Spontaneous spinal epidural hematoma (SEH) has not been reported under anti-thrombotic therapy with acetyl-salicylic acid (ASA) in a dosage of 50 mg/d."	( Recovery from acute paraplegia due to spontaneous spinal, epidural hematoma under minimal-dose acetyl-salicylic acid. Finsterer, J; Kleinpeter, G; Krugluger, W; Seywald, S; Stöllberger, C; Tscherney, R; Ulram, A, 2008)	0.35
" These adverse effects may be prevented by limiting NSAID dosage and duration and by performing individual risk assessments and treating patients accordingly."	( Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. van de Laar, MA; Vonkeman, HE, 2010)	0.36
" Decision to increase clopidogrel dosage may vary on the basis of the assay used, thus highlighting the need for unambiguous guidelines with respect to assay selection, as platelet function assays are not interchangeable."	( Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E, 2008)	0.35
" Thus, we investigated whether sP-selectin dosage might reflect platelet function in patients with risk factors for or with established cardiovascular diseases and whether its levels can be modulated by aspirin therapy."	( Soluble P-selectin as a marker of in vivo platelet activation. Ciatti, F; Ferroni, P; Guadagni, F; La Farina, F; Magnapera, A; Martini, F; Riondino, S, 2009)	0.54
"sP-selectin dosage could be proposed as a reliable marker of platelet activation in patients with major atherosclerotic risk factors either in the absence of clinically overt disease, and might represent a valid tool to asses in vivo platelet behavior."	( Soluble P-selectin as a marker of in vivo platelet activation. Ciatti, F; Ferroni, P; Guadagni, F; La Farina, F; Magnapera, A; Martini, F; Riondino, S, 2009)	0.35
" All patient groups were similar regarding age, gender distribution, dosage of antiplatelet drug, and medical condition for which the drug was prescribed."	( Exodontia and antiplatelet therapy. Alexander, M; Krishnan, B; Shenoy, NA, 2008)	0.35
"Glucose-6-phosphate dehydrogenase deficiency is commonly considered a contraindication to aspirin intake; however, this case shows that aspirin at low, antiplatelet dosage is well tolerated and should not be denied to patients with ischaemic heart disease and complex coronary anatomy."	( Drug-eluting stents in a patient with favism: is the aspirin administration safe? Capoluongo, E; Di Russo, C; Ferraiuolo, G; Giardina, B; Loschiavo, P; Minucci, A; Rigattieri, S; Silvestri, P, 2008)	0.82
" Due to lack of complete randomized investigation about the inclusion of antithrombotic prophylaxis in this group of pregnant women, common scheme of administration and optimal dosage is yet to be established."	( [Inherited thrombophilia in women with recurrent miscarriages and pregnancy loss in anamnesis--own experience]. Drews, K; Kaluba-Skotarczak, A; Puacz, P; Seremak-Mrozikiewicz, A, 2008)	0.35
" In all of these studies, lower dosage (50 or 100 microg/ml) exerted the best effect."	( Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Hua, Y; Sun, F; Xie, M; Xue, J; Zhu, L, 2009)	1.8
" The untested assumption was that exposure and the resultant pharmacological effects are similar for these two administration methods when dosing is normalized on the basis of mg/kg body weight/day."	( Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. Bauer, KS; Kapetanovic, IM; Lindeblad, MO; Lubet, R; Lyubimov, A; Tessier, DM; Zakharov, AD, 2009)	0.59
"Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy."	( Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Amarenco, P; Aronow, HD; Califf, RM; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, DJ; Graffagnino, C; Harrington, RA; Koudstaal, PJ; Shuaib, A; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F, 2008)	1.12
"The CURRENT-OASIS 7 trial will help to define optimal dosing regimens for clopidogrel and ASA in patients with ST and non-ST-segment-elevation ACS treated with an early invasive strategy."	( Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)	0.55
" In view of all this it is not surprising that in the past years the indications, application and dosage of anticoagulant and platelet aggregation inhibitor drugs have changed."	( [Current issues of anticoagulation therapy in the course of dental treatment and oral surgery]. Barabás, JB; Horváth, C; Joób-Fancsaly, A; Kalmár, G; Koppány, F, 2008)	0.35
"Most bronchial and naso-ocular reactions during oral aspirin challenges occurred within a narrow dosing range (45-100 mg)."	( Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. Hope, AP; Simon, RA; Stevenson, DD; Woessner, KA, 2009)	0.92
"To investigate the effect of small dosage aspirin on platelet biochemical indexes in patients with cardio-cerebrovascular diseases and the intervening action of Naoxintong (NXT)."	( [Intervening effect of naoxintong on anti-platelet treatment with aspirin]. Chen, DK; Zhang, HQ; Zhang, JH, 2008)	0.85
" In patients considered at moderate risk, the choice is now possible between VKA and aspirin, with a reduced dosage of aspirin (75 to 325 mg)."	( [Indications of vitamin K antagonists and aspirin in the atrial fibrillation of the elderly]. Estivin, S; Gentric, A; Jestin, C, 2009)	0.84
" While this may simplify dosing and monitoring, it will still be necessary to weigh the risks and benefits of therapy."	( Stroke prevention in atrial fibrillation--pharmacologic strategies. Goldbarg, SH; Mehta, D; Tiyyagura, SR, )	0.13
" No clear evidence exists regarding the ideal dosage of aspirin."	( Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: observations from the Ottawa Heart Institute PCI Registry. Cook, EF; Davies, R; Froeschl, M; Glover, C; Ha, A; Labinaz, M; Le May, M; Marquis, JF; O'Brien, E; So, D; Williams, W, 2009)	0.95
" The dose-response effect as studied by platelet aggregometry showed that the required molar concentration to block the interactive effect in the case of YH was less than that of MRS2179."	( Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome. Chakrabarti, P; Chaudhuri, U; Dasgupta, AK; Deb, S; Guha, P; Guha, S; Lahiri, P; Roy, S; Sardar, P, )	0.13
" The authors did not observe a dose-response relation with increased frequency or duration of regular use of any of these medications and ovarian cancer incidence."	( Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Cramer, DW; Hankinson, SE; Pinheiro, SP; Rosner, BA; Tworoger, SS, 2009)	0.35
" However, these studies are limited by varying antiplatelet drug dosing regimens, heterogeneous laboratory assessments for ex vivo platelet function, and wide interindividual variation in platelet responses."	( Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Fuster, V; Gorog, DA; Sweeny, JM, 2009)	0.35
" Although at discharge the patient was advised to permanently avoid triptans, she continued the use of oral sumatriptan at low dosage (25-50 mg) without any problems."	( Acute myocardial infarction with sumatriptan: a case report and review of the literature. Chalaupka, FD, 2009)	0.35
" The AGV values were estimated from IVIVCs of immediate release (IR) dosage forms in each apparatus and CFD simulations."	( Towards determining appropriate hydrodynamic conditions for in vitro in vivo correlations using computational fluid dynamics. Corrigan, OI; D'Arcy, DM; Healy, AM, 2009)	0.35
" In this setting, we assessed the safety and efficacy of rivaroxaban and aimed to select the most favourable dose and dosing regimen."	( Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009)	0.35
"The dose and dosing interval for leukotriene receptor antagonists montelukast and zafirlukast in adult asthmatic patients were determined by bronchoprovocation with exercise or leukotriene D4 inhalation."	( Dose selection and dosing interval determination for LTRA use in asthma. Hendeles, L, 2000)	0.31
" The steady-state trough MPA to ADP 20 micromol/L during 10-mg maintenance dosing was 30."	( Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial. Ernest, CS; Farid, NA; Li, YG; Ni, L; Payne, CD; Salazar, DE; Small, DS; Winters, KJ; Wrishko, RE, 2009)	0.35
" HCPR as measured with the novel INNOVANCE P2Y cartridge was associated with clinical determinants such as BMI, female gender, impaired LVEF (left ventricular ejection fraction), renal failure and dosing of clopidogrel."	( The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Berg, JM; Bouman, HJ; Elsenberg, EH; Hackeng, CM; van de Wal, RM; van Werkum, JW; Verheugt, FW; Zomer, AC, 2009)	0.35
" There is a need for further research in order to come to a clear conclusion regarding combined therapies of aspirin and laropiprant pretreatment, as well as exact dosage requirements."	( Mechanisms of flushing due to niacin and abolition of these effects. Arora, R; Sood, A, 2009)	0.57
" Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day."	( Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010)	0.84
" (2) Clopidogrel may be under dosed in obese patients."	( Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010)	0.36
" The improved efficacy of multiple-drug therapy is associated with an increased risk of bleeding, which raises the issue of the dosing of these drugs."	( Antiplatelet agents. Spectre, G; Varon, D, 2009)	0.35
"No clinically relevant changes were noted in the serum concentrations of tapentadol, and accordingly, no dosage adjustments with respect to the investigated pharmacokinetic mechanism of interaction are warranted for the administration of tapentadol given concomitantly with acetaminophen, naproxen, or acetylsalicylic acid."	( Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Mangold, B; Oh, C; Ravenstijn, PG; Rengelshausen, J; Smit, JW; Terlinden, R; Upmalis, D; Wang, SS, 2010)	0.36
" The improved efficacy of multiple drug therapy is associated with an increased risk of bleeding, which raises the issue of the dosing of these drugs."	( Frontiers in platelet inhibition. Shai, E; Spectre, G; Varon, D, 2009)	0.35
" The dose-response curve was shifted to the left in both cases, suggesting increased MK reactivity."	( Acetylsalicylic acid enhances purinergic receptor-mediated outward currents in rat megakaryocytes. Beckerman, J; Myers, A; Vicini, S; Young, JP, 2010)	0.36
" Five patients out of 32 developed CAA, with no statistical significance when analyzed for IVIG dosage or IVIG-resistance."	( Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Angelone, DF; Compagnone, A; De Nisco, A; De Rosa, G; Delogu, AB; Leo, A; Onesimo, R; Rigante, D; Rizzo, D; Valentini, P, 2010)	0.36
"To investigate whether sCD40L dosage might represent a useful tool to explore in vivo platelet function."	( Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Ferroni, P; Guadagni, F; La Farina, F; Martini, F; Riondino, S; Spila, A, 2010)	0.36
" All other treatments were continued with some dosage adjustments."	( Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB, 2009)	0.35
" Possible strategies for overcoming this decreased antiaggregant effect include increasing the aspirin dosage or dual therapy with another antiplatelet agent."	( [Resistance to aspirin: prevalence, mechanisms of action and association with thromboembolic events. A narrative review]. Cañivano Petreñas, L; García Yubero, C, )	0.7
" Results were analysed using dose-response modelling."	( Prostaglandins and radical oxygen species are involved in microvascular effects of hyperoxia. Henricson, J; Rousseau, A; Sjöberg, F; Tesselaar, E, 2010)	0.36
"Combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and cannabinoids are promising because of their potential synergistic effects in analgesia, resulting in a reduction in dosage and minimizing adverse reactions."	( The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats. Filaferro, M; Frigeri, C; Pini, LA; Ruggieri, V; Sandrini, M; Vitale, G, 2010)	0.36
" Aspirin therapy may decrease the level of inflammatory markers significantly, but increasing the dosage of aspirin from 100 mg to 1000 mg daily does not decrease the level of inflammatory markers and the clinical MACEs further."	( [The effect of different dosage of aspirin on inflammatory biomarkers and prognosis in acute coronary syndrome.]. Hu, DY; Li, RJ; Liang, YQ; Ren, WL; Song, LF; Xu, YY; Yin, ZN, 2009)	1.54
" Further research should consider increasing aspirin dosing frequency to twice daily, to allow sustained inhibition in such subjects."	( Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E, 2011)	0.88
" Identified areas of improvement were the standardization of treatment protocols, use of risk assessment scores, appropriate dosing of anticoagulants, and improvement in patient treatment times."	( Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program. Berry, CA; Cannon, CP; Carter, RD; Cornish, J; Hoekstra, JW; Karcher, RB; Larson, DM; Mencia, WA; Stowell, SA, 2010)	0.36
"A suppository dosage form has a rapid effect on therapeutics, because it dissolves in the rectum, is absorbed in the bloodstream, and passes the hepatic metabolism."	( Nondestructive prediction of the drug content of an aspirin suppository by near-infrared spectroscopy. Abe, H; Aburada, M; Otsuka, E; Otsuka, M, 2010)	0.61
" This paper studies the effect of the lower end of the aspirin dose-response curve, its possible mechanism and clinical implications."	( Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals. Aguejouf, O; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2010)	0.89
"Available evidence suggests that aspirin dosing must be individualized according to indication."	( Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010)	2.08
" Four meta-analyses described vascular events with dipyridamole using various dosing strategies."	( Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease. Crown, N; Mysak, T, 2010)	0.68
"Diabetic patients with CAD had significantly higher levels of both platelet aggregation and activation compared to non-diabetic patients with CAD despite treatment with the same dosage of aspirin."	( Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2010)	0.84
" We review the recent data on efficacy and safety of dosing strategies for antiplatelet therapy in PCI."	( Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A, 2010)	0.36
" The optimal drug therapies and dosing strategies for reducing VTE risk are not well defined for many clinical situations, despite the availability of evidence-based guidelines from authoritative sources."	( Issues in assessing and reducing the risk for venous thromboembolism. Dager, WE, 2010)	0.36
"Flavocoxid at a human equivalent dose (HED) of 569 mg (within the standard human dosing range of 500 mg) produced no significant increases in bleeding time in mice."	( Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Burnett, BP; Jia, Q; Levy, RM; Pillai, L; Yimam, M; Zhao, Y, 2010)	0.36
" Moreover, dosage and duration of postoperative low-molecular-weight heparin (LMWH) administration were associated with a higher risk of reoperation (Mann-Whitney U-test, p<0."	( The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. Forster, MT; Gerlach, R; Mathé, AK; Scharrer, I; Seifert, V; Senft, C, 2010)	0.36
" Related to the salicin content of the willow bark extract, a higher dosage of ASA was needed."	( In vitro anti-proliferative effects of the willow bark extract STW 33-I. Bonaterra, GA; Kelber, O; Kinscherf, R; Metz, J; Weiser, D, 2010)	0.36
" Additionally, it provides an overview of tirofiban's pharmacology and summary of the clinical efficacy and safety data of two dosing regimens."	( Safety evaluation of tirofiban. Tebaldi, M; Valgimigli, M, 2010)	0.36
" Multiple gastroduodenal biopsies were performed during 2 esophagogastroduodenoscopy in subjects dosed with aspirin enteric-coated 81 mg once daily or clopidogrel 75 mg once daily."	( Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?: a prospective, randomized study involving 630 biopsies. Aisenberg, J; Bamji, ND; Bodian, CA; Cohen, LB; Desai, JC; Dikman, AE; Harpaz, N; Kornacki, S; Miller, KM; Sanyal, S; von Althann, C; Whitson, MJ, 2011)	0.83
"The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients."	( Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Abderazek, F; Addad, F; Chakroun, T; Chouchene, S; Dridi, Z; Elalamy, I; Gamra, H; Gerotziafas, GT; Hassine, M; Hatmi, M, 2010)	0.85
" This case shows that, in such particular conditions, a change in dipyridamole dosage can induce a myocardial infarction even if its blood level remains in the therapeutic range."	( [Myocardial infarction after voluntary intoxication by drug interaction between dipyridamole and aspirin]. Amat, G; Brahic, H; Eschalier, A; Eschalier, R; Marcaggi, X; Ravan, R, 2010)	0.58
" However, evidence-based guidelines for dosing have not been established for either agent."	( Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010)	0.64
" When MMC and VIN were dosed by different routes at the same dose levels both compounds produced positive results in all three tissues by intraperitoneal injection but not oral administration."	( The rat gut micronucleus assay: a good choice for alternative in vivo genetic toxicology testing strategies. Coffing, S; Dickinson, D; Engel, M; Schuler, M; Shutsky, T; Spellman, R; Thiffeault, C, 2011)	0.37
" We investigated whether the dosage and adherence to aspirin was associated with the CRP level 3 months after ACS."	( Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Burg, M; Davidson, KW; Kronish, IM; Rieckmann, N; Shimbo, D, 2010)	2.05
" Until further reliable controlled data are available, this potential, but currently unproven, clinical interaction can be minimized by widely separating the dosing of clopidogrel and PPI."	( NSAID-induced gastrointestinal and cardiovascular injury. Chan, FK; Ng, SC, 2010)	0.36
" The dosage administrated were 250 mg niacin-ER plus 10 mg SV in the first two weeks, 500 mg/20 mg in the next two weeks, and 750 mg/20 mg in the final four weeks."	( Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010)	0.36
" Once-daily dosing of aspirin might not suffice to adequately inhibit platelet aggregation in patients with an increased platelet turnover."	( Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2011)	0.68
" If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended."	( [Dilemma between gastroprotection and cardiovascular prevention]. Kandulski, A; Malfertheiner, P; Venerito, M, 2010)	0.36
" Management is currently limited to dosing alteration and introduction of other antiplatelet agents."	( Resistance to aspirin and clopidogrel therapy. Alam, S; Assaad, S; Beresian, J; Bitar, A; Charafeddine, K; Khoury, M; Musallam, KM; Taher, AT, 2011)	0.73
" The present article reviews data on the clinical impact of enhanced P2Y12 inhibition with either higher clopidogrel dosing or new oral antiplatelet agents, including prasugrel and ticagrelor, in the setting of STEMI, focusing on results in the setting of primary PCI."	( Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C, 2010)	0.36
"Administration of the combination of zinc-L-carnosine and vitamin E at 1X or 2X dosing did not attenuate aspirin-induced gastroduodenal mucosal injury."	( Effects of zinc-L-carnosine and vitamin E on aspirin-induced gastroduodenal injury in dogs. Baan, M; Johnson, SE; Sherding, RG, )	0.61
"88) whereas neither, gender nor aspirin dosage (ranging from 75 and 325 mg) predicted the occurrence of UGS."	( Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. Cayla, G; Collet, JP; Montalescot, G; Silvain, J; Thiefin, G; Woimant, F, 2012)	0.88
"An HPLC method for the quantitative analysis of mebeverine HCl, 5-aminosalicylic acid (5-ASA), sulphasalazine and dispersible aspirin has been developed and then applied to these specific medicines when stored, with other medications, in Venalink blister packs (monitored dosage system) for periods of up to 35 days."	( Quantitative HPLC analysis of mebeverine, mesalazine, sulphasalazine and dispersible aspirin stored in a Venalink monitored dosage system with co-prescribed medicines. Blagbrough, IS; Elmasry, MS; Kheir, AA; Rogers, PJ; Rowan, MG; Saleh, HM, 2011)	0.8
" The effect of chronic aspirin and HCTZ dosing taken together upon the efficacy of chronic allopurinol therapy in patients with hyperuricaemia needs to be investigated."	( Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers. Day, RO; Graham, GG; Ng, DY; Stocker, SL; Williams, KM, 2011)	0.93
"If ASA resistance is detected by laboratory tests, replacement of ASA or its combination with other antiplatelet drugs as well as increased dosage may be considered."	( The assessment of aspirin resistance by using light transmission and multiple electrode aggregometry. Galuszka, J; Hutyra, M; Indrak, K; Krcova, V; Slavik, L; Ulehlova, J, 2011)	0.7
"A rapid, simple, and easy method for the simultaneous determination of clopidogrel and aspirin from bulk material and dosage formulations in the presence of meloxicam as internal standard has been developed."	( Simultaneous determination of clopidogrel and aspirin by RP-HPLC from bulk material and dosage formulations using multivariate calibration technique. Ali, KA; Arayne, MS; Nawaz, M; Sultana, N, 2011)	0.85
" Most studies were limited by lack of information on dosage and duration of use of the different classes of NSAIDs."	( Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. Aprikian, AG; Beck, P; Franco, EL; Mahmud, SM; Platt, RW; Sharpe, C; Skarsgard, D; Tonita, J; Turner, D, 2011)	0.37
" There was no clear evidence of dose-response or duration-response relationships for any of the examined NSAID classes."	( Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. Aprikian, AG; Beck, P; Franco, EL; Mahmud, SM; Platt, RW; Sharpe, C; Skarsgard, D; Tonita, J; Turner, D, 2011)	0.37
"In the recent PLATO trial, the daily aspirin dosages in the USA were split between 81 and 325 mg while the vast majority of dosing outside of the USA was 75 or 100 mg."	( Aspirin dose and ticagrelor benefit in PLATO: fact or fiction? Serebruany, VL, 2010)	2.08
" These preliminary data, while intriguing, require confirmation in poststroke patients receiving orally dosed ERD to determine whether these findings are clinically relevant."	( Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012)	0.38
" Our results identify the decreased expression of prostaglandin H synthase 1 and increased expression of leukotriene C(4) synthase as the key elements in AA metabolism that contribute to increased leukotriene C(4) and decreased anti-inflammatory prostaglandins after NSAID dosing in aspirin-intolerant patients."	( Role of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study. Brumen, M; Dobovišek, A; Fajmut, A, 2011)	0.77
" Strategies to improve the effectiveness of antithrombotic therapies include selecting the optimal drug and dosing regimen, the use of combinations of antiplatelet and anticoagulant drugs and the development of new more effective drugs to replace existing therapies."	( Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Eikelboom, JW; Paikin, JS; Wright, DS, 2011)	0.37
"Twenty-four hours after the last dosing on day 6 in volunteers receiving aspirin alone or aspirin before naproxen, serum TXB(2) was almost completely inhibited (median [range] 99."	( Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Anzellotti, P; Bruno, A; Capone, ML; Di Francesco, L; Di Gregorio, P; Garcia Rodriguez, LA; Grossi, L; Jeyam, A; Merciaro, G; Patrignani, P; Price, TS; Renda, G; Tacconelli, S; Tontodonati, P, 2011)	0.84
" This may be attributed to increased platelet turnover rates resulting in an increased proportion of non-aspirin-inhibited platelets during the daily dosing interval."	( Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	0.86
" When aspirin was administered once daily, there was no significant effect on platelet reactivity by increasing the once-daily dosing using aspirin-sensitive assays (collagen-induced aggregation and VerifyNow-Aspirin)."	( Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	1.12
"Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels."	( Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	2.08
" The objectives of the present study were to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model for simvastatin and to evaluate its usefulness in predicting the dose-response relationship of simvastatin in patients with hyperlipidaemia."	( A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Ahn, BJ; Chae, HS; Choi, J; Doh, K; Han, S; Jun, YK; Kim, J; Lee, YW; Yim, DS, 2011)	0.37
"To explore the clinical impact of aspirin dosage adjustment in pregnant women at high risk of hypertensive disorders."	( Is testing for aspirin response worthwhile in high-risk pregnancy? Rey, E; Rivard, GE, 2011)	1
"In this retrospective observational study including women with pre-existing hypertension, pre-gestational diabetes or previous placental-mediated complications, we compared the rates of pre-eclampsia, early-onset and severe pre-eclampsia between women who used 81 mg of aspirin (ASA) throughout pregnancy without platelet function analyser (PFA-100®) monitoring ("group ASA no PFA") and those in whom the aspirin dosage was adjusted according to PFA-100® results ("group ASA and PFA")."	( Is testing for aspirin response worthwhile in high-risk pregnancy? Rey, E; Rivard, GE, 2011)	0.9
" The rate of pre-eclampsia was higher in women who needed an increase in aspirin dosage (11/43, 25."	( Is testing for aspirin response worthwhile in high-risk pregnancy? Rey, E; Rivard, GE, 2011)	0.95
"Our results suggest that a strategy involving platelet function testing and individualized dosing is effective in preventing pre-eclampsia in high risk women."	( Is testing for aspirin response worthwhile in high-risk pregnancy? Rey, E; Rivard, GE, 2011)	0.72
" In order to achieve the desired results and, as with all medications, PPIs should always be used appropriately taking care never to exceed correct dosage and duration."	( Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections. Ferraccioli, GF; Gremese, E; Laria, A; Zoli, A, 2011)	0.37
" New and emerging oral alternatives to warfarin promise to combine the advantages of oral dosing and effective anticoagulation with improvements in safety, leading to reduced monitoring and dose adjustment."	( A pharmacoeconomic perspective on stroke prevention in atrial fibrillation. Fendrick, AM, 2010)	0.36
" Similar dose-response relationships were observed among short-term users (≤5 years; P(trend)<."	( Long-term use of aspirin and the risk of gastrointestinal bleeding. Chan, AT; Ho, WW; Huang, ES; Lee, SS; Strate, LL, 2011)	0.71
" We examined potential associations between high on treatment platelet reactivity and the risk of ST and assessed the effects of increased antiplatelet dosage on platelet inhibition."	( High on treatment platelet reactivity and stent thrombosis. French, JK; Juergens, CP; Parikh, D; Rajendran, S; Shugman, I, 2011)	0.37
" Using the PFA-100 system, reassessment of platelet function following oral administration of daily aspirin dosage significantly reduces the number of stable coronary disease patients considered to be non-responders to such treatment."	( Can resistance to aspirin be reversed after an additional dose? Angiolillo, DJ; Azcona, L; Bernardo, E; Fernández-Ortiz, A; García-Rubira, JC; González-Ferrer, JJ; Macaya, C; Núñez-Gil, I; Vivas, D, 2011)	0.92
" Collagen and U46619 caused in vivo thrombus formation with the former, but not latter, sensitive to oral dosing with aspirin."	( Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. Armstrong, PC; Emerson, M; Kirkby, NS; Mitchell, JA; Warner, TD; Zain, ZN, 2011)	0.58
" Most clinicians use a fixed dosage of LMWH in pregnant APS women despite the fact that there are no clinical trials establishing that fixed doses are more efficacious than adjusted ones in preventing pregnancy complications."	( Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study. Favaro, M; Gervasi, MT; Hoxha, A; Punzi, L; Ruffatti, A; Ruffatti, AT, )	0.38
" Although inclusion of cohort studies was a major source of heterogeneity, stratification by study design did not reveal a significant dose-response relationship."	( Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. Chambers, T; Gamble, JM; Mereu, L; Simpson, SH, 2011)	0.77
"This summary of available data does not support an aspirin dose-response effect for prevention of cardiovascular events in diabetic patients."	( Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. Chambers, T; Gamble, JM; Mereu, L; Simpson, SH, 2011)	1.02
" Nevertheless, VKAs do require frequent coagulation monitoring and dose adjustment because of their variable dose-response profile, narrow therapeutic window, increased risk for bleeding complications and numerous food and drug interactions."	( Challenges of stroke prevention in patients with atrial fibrillation in clinical practice. Hobbs, FD; Leach, I, 2011)	0.37
" Doubling clopidogrel dosage to 150 mg restored the basal response."	( Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Cerboni, P; Doyen, D; Ferrari, E; Moceri, P, 2011)	0.37
" A dose-response relation between the number of G alleles at rs12041331 and expression of PEAR1 protein in human platelets was confirmed by Western blotting and ELISA."	( Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Becker, DM; Becker, LC; Bray, PF; Chen, MH; Faraday, N; Friedman, AD; Gylfason, A; Herrera-Galeano, JE; Johnson, AD; Mathias, R; O'Donnell, CJ; Qayyum, R; Ruczinski, I; Suktitipat, B; Thorsteinsdottir, U; Tofler, GH; Yanek, LR; Yang, XP, 2011)	0.37
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing."	( Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011)	1.04
" We tested if twice daily dosing of aspirin would be more effective in T2DM, possibly due to increased platelet turnover."	( Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Arnetz, L; Brismar, K; Hjemdahl, P; Li, N; Östenson, CG; Spectre, G, 2011)	0.96
" Administration of aspirin at a dosage of 1 mg/kg, PO, every 24 hours for 7 days did not significantly decrease urinary 11-dehydroTXB(2) concentration, but administration of the single aspirin dose of 10 mg/kg did significantly decrease 11-dehydroTXB(2) concentration by a median of 45."	( Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. Byron, JK; Hoh, CM; McMichael, MA; Smith, SA, 2011)	0.98
" The study was designed to test the timing effect of aspirin dosing on 24-hour BP in treated hypertensive patients routinely taking aspirin for cardiovascular prevention."	( Is there a BP benefit of changing the time of aspirin administration in treated hypertensive patients? Baguet, JP; Dimitrov, Y; Ducher, M; Fauvel, JP; Hottelart, C; Marboeuf, P; Tartiere, JM, 2012)	0.89
"8 percent vomiting, which affected adherence to prescribed dosing regimens and, thus, is inversely associated with the level of pain relief."	( Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. Ackerman, SJ; Anastassopoulos, KP; Benson, C; Chow, W; Kim, MS; Tapia, C, )	0.13
" Facilitation of osteoblast apoptosis occurred regardless of IND dosage under hypoxic conditions."	( Facilitation of human osteoblast apoptosis by sulindac and indomethacin under hypoxic injury. Chang, CH; Chen, YC; Fan, SC; Huang, CH; Liu, C; Tsai, AL; Wu, CC, 2012)	0.38
"All patients received 325 mg of aspirin and a loading dose of 600 mg of clopidogrel followed by a maintenance dosage of 325 mg/d of aspirin and 75 mg/d of clopidogrel for at least 6 months."	( High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011)	0.65
"Floating dosage forms of acetylsalicylic acid, used for its antithrombotic effect, were developed to prolong gastric residence time and increase bioavailability."	( Effect of formulation parameters on the drug release and floating properties of gastric floating two-layer tablets with acetylsalicylic acid. Hasçiçek, C; Ozdemir, N; Türkmen, B; Yüksel-Tilkan, G, 2011)	0.37
"18), and no dose-response effects were present in either analysis."	( The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Green, AC; Pandeya, N; Smith, KJ; Thrift, AP; Webb, PM; Whiteman, DC, 2011)	0.37
" Adjusted dosing according to weight may help achieve adequate therapeutic platelet inhibition and reactivity while decreasing thromboembolic complications."	( Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. Alexander, MJ; Choulakian, A; Drazin, D; Kornbluth, P; Nuño, M, 2011)	0.37
" Initial responders to transfusion received a greater volume of platelets, suggesting a dose-response relationship."	( Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury. Bachelani, AM; Bautz, JT; Billiar, TR; Corcos, A; Marshall, GT; Peitzman, AB; Sperry, JL; Zenati, M, 2011)	0.62
" A dose-response relationship between quantity of platelets transfused and reversal of ASA inhibition was observed."	( Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury. Bachelani, AM; Bautz, JT; Billiar, TR; Corcos, A; Marshall, GT; Peitzman, AB; Sperry, JL; Zenati, M, 2011)	0.62
" A marked reduction in the antiplatelet effect of aspirin was also seen on the same schedule when the dosage of ibuprofen was 150 mg, which is the dose used in over-the-counter (OTC) preparations."	( Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. Awa, K; Hori, S; Satoh, H; Sawada, Y, 2012)	0.89
"15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily."	( Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012)	0.82
" The incidence of esophageal mucosal injury was reduced however with concomitant dosing of aspirin and famotidine (26."	( Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012)	0.83
" Newer aspirin dosing and scheduling, tailored at reducing the individual patient risk related to an incomplete inhibition of platelet function by a standard aspirin dose should now be defined."	( Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Buonauro, A; Di Minno, G; Di Minno, MN; Lupoli, R; Palmieri, NM; Russolillo, A, 2012)	2.28
" In the present study, we investigated the determinants of aspirin-insensitive platelet TXA(2) biosynthesis and whether it could be further suppressed by changing the aspirin dose, formulation, or dosing interval."	( Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Dragani, A; Habib, A; Pagliaccia, F; Pascale, S; Patrono, C; Petrucci, G; Pocaterra, D; Ragazzoni, E; Rocca, B; Rolandi, G; Zaccardi, F, 2012)	2.06
" The anti-platelet effect may be diminished by poor glycemic control or inadequate dosing of aspirin."	( The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. Bähler, L; Gerdes, VE; Hoekstra, JB; Holleman, F; Kamphuisen, PW; Lemkes, BA; Nieuwland, R; Stroobants, AK; Van Den Dool, EJ, 2012)	0.94
" In the management of bleeding ulcer patients with high-risk stigmata of recent hemorrhage, resuming antiplatelet agents at 3-5 days after the last dosing is a reasonable strategy."	( New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. Hsu, PI, 2012)	0.38
"Most conventional ophthalmic dosage forms, though simplistic are limited by poor bioavailability in the posterior chamber of the eye."	( Protein based nanoparticles as platforms for aspirin delivery for ophthalmologic applications. Banerjee, R; Bellare, JR; Das, S, 2012)	0.64
" Neither the concomitant use of an antacid nor the dosing period of NSAIDs affected the results."	( Endoscopic and clinical features of gastric ulcers in Japanese patients with or without Helicobacter pylori infection who were using NSAIDs or low-dose aspirin. Abe, T; Fukui, H; Hori, K; Kim, Y; Kondo, T; Matsumoto, T; Miwa, H; Okugawa, T; Oshima, T; Sakurai, J; Tanaka, J; Tomita, T; Toyoshima, F; Watari, J; Yamasaki, T; Yokoyama, S, 2012)	0.58
" Correlation analysis suggested that there was a negative correlation between clinical attachment loss and duration of aspirin intake but the clinical attachment loss was not significantly different in the two dosage groups."	( Association between long-term aspirin use and periodontal attachment level in humans: a cross-sectional investigation. Faizuddin, M; Korla, N; Swamy, S; Tarannum, F, 2012)	0.88
"This study sought to assess the presence of a dose-response effect of cigarette smoking and its impact on high on-treatment platelet reactivity (HPR) in patients with diabetes mellitus treated with clopidogrel."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
" If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"A dose-response effect was observed for all pharmacodynamic parameters tested."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"Cigarette smoking is associated with a dose-response effect on clopidogrel-induced antiplatelet effects and lower rates of HPR in diabetes mellitus patients."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"Testing platelet function makes clopidogrel dosing safer, and simplifies therapy adjustments in long-term treatment."	( Prophylactic use of clopidogrel in paediatric cardiac patients. Grohmann, J; Hanke, CA; Nakamura, L; Stiller, B; Zieger, B, 2012)	0.38
" We hypothesized that faster recovery of platelet cyclooxygenase-1 activity may explain incomplete thromboxane (TX) inhibition during the 24-h dosing interval."	( The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Cardillo, C; Davì, G; Del Ponte, A; Ferrante, E; Ghirlanda, G; Lattanzio, S; Liani, R; Martini, F; Mattoscio, D; Mirabella, M; Morosetti, R; Mucci, L; Patrono, C; Petrucci, G; Pitocco, D; Rocca, B; Santilli, F; Vazzana, N; Vitacolonna, E; Zaccardi, F, 2012)	0.59
" Interindividual variability in the recovery of platelet cyclooxygenase activity during the dosing interval may limit the duration of the antiplatelet effect of low-dose aspirin in patients with and without diabetes."	( The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Cardillo, C; Davì, G; Del Ponte, A; Ferrante, E; Ghirlanda, G; Lattanzio, S; Liani, R; Martini, F; Mattoscio, D; Mirabella, M; Morosetti, R; Mucci, L; Patrono, C; Petrucci, G; Pitocco, D; Rocca, B; Santilli, F; Vazzana, N; Vitacolonna, E; Zaccardi, F, 2012)	0.78
" Computational modeling of the brief ASA pulses experienced by PGHS-1 in circulating platelets during daily ASA dosing predicted that the 60% lower ASA reactivity in R108Q yields a 15-fold increase in surviving COX activity; smaller, approximately two-fold increases in surviving COX activity were predicted for L237M and V481I."	( Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1. Kulmacz, RJ; Liu, W; Poole, EM; Ulrich, CM, 2012)	0.65
"Aspirin at a dosage of 500 mg/d has an impact on vasoregulation in the microcirculation."	( Influence of acetylsalicylic acid (Aspirin) on cutaneous microcirculation. Jung, F; Leithäuser, B; Mrowietz, C; Park, JW, 2012)	2.1
"In patients undergoing elective PCI, using bivalirudin as a bolus only dosing may be as effective and less costly when compared with bolus followed by an infusion for the duration of the intervention."	( Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. Ghosn, S; Sheikh-Taha, M, 2012)	0.38
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."	( Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Halperin, JL; Varughese, CJ, 2012)	0.38
" Further study is needed to confirm these findings and to determine the optimal dosing and schedule, as well as the relative benefits and risks, of both therapies in combination with RT."	( Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Buyyounouski, MK; Horwitz, EM; Li, T; Zaorsky, NG, 2012)	1.82
" As a result, the BCS-based biowaiver procedure can be recommended for approval of new formulations of solid oral dosage forms containing ASA as the only API, including both multisource and reformulated products, under the following conditions: (1) excipients are chosen from those used in ASA products already registered in International Conference on Harmonization and associated countries and (2) the dissolution profiles of the test and the comparator products comply with the BE guidance."	( Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid. Abrahamsson, B; Barends, DM; Dressman, JB; Groot, DW; Kopp, S; Langguth, P; Nair, A; Polli, JE; Shah, VP; Zimmer, M, 2012)	0.38
"A new simple, rapid and sensitive reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of methocarbamol (MET) and aspirin (ASP) in their combined dosage form."	( Simultaneous determination of methocarbamol and aspirin by RP-HPLC using fluorescence detection with time programming: its application to pharmaceutical dosage form. Eid, M; El-Din, MS; Zeid, AM, )	0.58
" Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)."	( Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. Angiolillo, DJ; Ferreiro, JL, 2012)	0.38
"Six trials and one meta-analysis were identified; aspirin dosage was identified as a potential confounder."	( Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. Dewilde, S; Hawkins, N, 2012)	0.85
" We then discuss optimal dosing and diagnostic strategies for those populations at risk for aspirin resistance with a focus on tailored aspirin therapy for high-risk groups."	( Aspirin resistance: current status and role of tailored therapy. Cannon, CP; Grinstein, J, 2012)	2.04
"Twenty healthy female volunteers each received 600 mg aspirin or placebo in random sequence and were subsequently dosed with 10 g lactulose and 5 g mannitol, their urine collected every half hour for 6h."	( The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young women: toward a dynamic, aspirin augmented, test of gut mucosal permeability. Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2012)	0.99
" Hence, variation in sampling period and in method of dosage are likely to influence the result and it is preferable to examine the patterns of absorption of component sugars separately with due regard to the method of dosage."	( The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young women: toward a dynamic, aspirin augmented, test of gut mucosal permeability. Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2012)	0.74
"70), though an increase of similar magnitude among past users and lack of a dose-response effect did not support a pharmacologic mechanism."	( Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Alberts, DS; Feskanich, D; Han, J; Jeter, JM; Martinez, ME; Qureshi, AA, 2012)	0.38
" There was a significant inverse dose-response (p-trend <0."	( Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Nagle, CM; Neill, AS; Obermair, A; Protani, MM; Spurdle, AB; Webb, PM, 2013)	1.83
"This article is the second of a series of two articles detailing the application of mixing index to assess homogeneity distribution in oral pharmaceutical solid dosage forms by image analysis."	( A criterion for assessing homogeneity distribution in hyperspectral images. Part 2: application of homogeneity indices to solid pharmaceutical dosage forms. Blanco, M; Rosas, JG, 2012)	0.38
" Following first dosing on day 5, plasma samples were collected at different time points."	( Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin. Fung, KP; Lau, BS; Leung, PC; Wang, S; Zhang, Z; Zhou, L; Zuo, Z, 2012)	0.6
"Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support."	( Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012)	0.66
" Acetylsalicylic acid dosing was stratified into low- (<160 mg) and high- (≥ 160 mg) dose categories."	( Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012)	0.66
" Results did not vary appreciably by past or current use, days per week of use, or dosage of use."	( Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. Collins, LC; Hankinson, SE; Rosner, B; Smith-Warner, SA; Willett, WC; Zhang, X, 2012)	0.83
" Also, unlike the different dosage levels of aspirin, as a NSAIDs prototype, which differ by a factor of about ten, all these beneficial and counteracting effects of BPC 157 were obtained using the equipotent dosage (μg, ng/kg) in parenteral or peroral regimens."	( Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Aralica, G; Brcic, L; Drmic, D; Dzidic, S; Ilic, S; Klicek, R; Kolenc, D; Radic, B; Rak, D; Rokotov, DS; Rucman, R; Safic, H; Sebecic, B; Seiwerth, S; Sever, M; Sikiric, P; Suran, J; Turkovic, B; Vrcic, H, 2013)	0.65
" Ongoing studies are challenging the current one-size-fits-all dosing strategy, but the preceding evaluation of platelet function assays has not been adequate."	( Antiplatelet effect of aspirin in patients with coronary artery disease. Grove, EL, 2012)	0.69
"We investigated dosage regimens for aspirin therapy in regard to antiplatelet effects in patients without gastrointestinal lesions."	( Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions. Kitagawa, Y; Suzuki, Y; Tokuoka, K; Watanabe, M; Yaguchi, T; Yamada, Y; Yokoyama, H, 2012)	0.95
"Glucose metabolic changes in CM patients taking different dosage of analgesic during headache-free periods and clear distinctions in several brain regions were observed."	( Overuse of paracetamol caffeine aspirin powders affects cerebral glucose metabolism in chronic migraine patients. Di, W; Fang, Y; Luo, N; Miao, J; Qi, W; Shi, X; Tao, Y; Xiao, Z; Yi, C; Zhang, A; Zhang, X; Zhu, Y, 2013)	0.67
"The aim of this work was to measure the response to low-dose aspirin therapy (150 mg/day) among patients with unstable angina or non-ST-segment elevation myocardial infarction and to find out whether titrating aspirin dosage to 300 mg/day, would provide a better therapeutic response in the resistant cases."	( Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. ElSafady, LA; Morad, AR; Sabri, NA; Salama, MM; Saleh, MA; Zaki, MM, 2012)	0.93
" There was a nonsignificant decrease in thromboembolic complications in patients whose clopidogrel dosage was tailored to the assay."	( Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. Bennet, H; Berenstein, A; Brockington, C; Chong, J; Ewing, SL; Fifi, JT; Leesch, W; Narang, J, 2013)	0.39
" Both ASP and EGb reduced superoxide anion in HCAECs in a dosage dependent manner."	( Ginkgo biloba extract and aspirin synergistically attenuate activated platelet-induced ROS production and LOX-1 expression in human coronary artery endothelial cells. Li, C; Li, Z; Wang, J; Zhang, J; Zhu, X; Zou, Z, 2013)	0.69
" At steady-state ticagrelor (50 mg bid, or 200 mg bid), concomitant aspirin (300 mg qd) had no effect on mean maximum plasma concentration (Cmax), median time to Cmax (tmax), or mean area under the plasma concentration-time curve for the dosing interval (AUC0-τ) for ticagrelor and its primary metabolite, AR-C124910XX."	( Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Butler, K; Maya, J; Teng, R, 2013)	0.85
" Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation."	( Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014)	0.4
" The association showed a dose-response effect (multivariate-adjusted P = ."	( The association of aspirin use with age-related macular degeneration. Liew, G; Mitchell, P; Rochtchina, E; Wang, JJ; Wong, TY, 2013)	0.72
" Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)."	( Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013)	0.78
" An additional aim is to assess the effect of the polypill on LDL-c and BP compared to the administration of separate pills of identically dosed components of the polypill."	( The evening versus morning polypill utilization study: the TEMPUS rationale and design. Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014)	0.4
"5 mg) in the evening; (2) the polypill in the morning; and (3) the use of the identically dosed agents in separate pills taken at different time points during the day."	( The evening versus morning polypill utilization study: the TEMPUS rationale and design. Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014)	0.4
" The aspirin doses were chosen to span the clinical dosing range."	( Effect of aspirin on bone healing in a rabbit ulnar osteotomy model. Donovan, M; Femino, JE; Fredericks, D; George, M; Lack, WD; Nepola, J; Petersen, E; Smucker, J, 2013)	1.31
"Aspirin delayed bone healing, as demonstrated radiographically and with mechanical testing, in a dose-dependent fashion at salicylate levels equivalent to those resulting from typical human dosing (low-dose aspirin)."	( Effect of aspirin on bone healing in a rabbit ulnar osteotomy model. Donovan, M; Femino, JE; Fredericks, D; George, M; Lack, WD; Nepola, J; Petersen, E; Smucker, J, 2013)	2.23
" The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression."	( Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. Chen, S; Fu, J; Yang, Y; Ye, X, 2013)	0.64
" The dose-response meta-analysis showed that there was a 20% statistically significant decreased risk of colorectal cancer for 325 mg aspirin per day increment, 18% decreased risk for 7 times aspirin per week increment and 18% decreased risk for 10 years aspirin increment."	( Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. Chen, S; Fu, J; Yang, Y; Ye, X, 2013)	0.85
" The serial dosages were used in vivo: the low dosage, the medium dosage and the high dosage."	( Anti-inflammatory effects of essential oil in Echinacea purpurea L. Hu, F; Jiang, L; Tai, Y; Xie, Z; Yang, X; Yu, D; Yuan, Y, 2013)	0.39
" After the dosing of aspirin, hyperemia of lung tissue and the number of rats with infarction significantly decreased."	( [Effects of aspirin on CX3CL1 and CX3CR1 in acute pulmonary embolism rats]. Jiang, HF; Sun, C; Wang, LC; Yang, RH, 2013)	1.09
" The aim of this retrospective study was to measure the therapeutic response to standard dosing with LMWH (using anti-Xa) in patients after ablative and reconstructive surgery for head and neck cancer, and to review the associated risk of bleeding."	( Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications. Eley, KA; Parker, RJ; Watt-Smith, SR, 2013)	0.39
"When patients with NS are admitted to the hospital, develop an acute medical illness, or acquire an additional thrombotic events risk factor such as surgery, active malignancy, or pregnancy, consideration for primary pharmacologic prophylaxis with appropriately dosed low-molecular-weight heparin or other indicated anticoagulant should include the potential for increased thrombotic events risk in this patient population."	( Prophylaxis of thromboembolic events in patients with nephrotic syndrome. Hynicka, LM; Pincus, KJ, 2013)	0.39
" The present work has employed hot-melt mixing to prepare a modified enteric matrix, as a delayed-release dosage form."	( Properties of aspirin modified enteric polymer prepared by hot-melt mixing. Chomcharn, N; Xanthos, M, 2013)	0.75
" Despite substantial clinical heterogeneity across the studies, including types of H2 blockers, dosing of ASA and underlying conditions, no statistical heterogeneity was observed."	( Histamine H2 receptor antagonists for decreasing gastrointestinal harms in adults using acetylsalicylic acid: systematic review and meta-analysis. Al-Omran, M; Alateeq, A; Mamdani, M; Straus, SE; Tashkandi, M; Tricco, AC, 2012)	0.38
"This single-centre, open-label, randomised, two-way crossover study in healthy volunteers compared 7 days of once-daily dosing with PA32540 with 7 days of once-daily EC-ASA 325 mg + EC-omeprazole 40 mg dosed concomitantly."	( Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study Fort, JG; Miner, PB; Zhang, Y, 2013)	0.61
"Three hundred stable ischemic stroke patients, whose aspirin dosage varied between 60 to 325 mg/day for at least 14 days before enrollment were recruited in the present study."	( Aspirin non-responder in Thai ischemic stroke patients. Jongjaroenprasert, W; Mahasirimongkol, S; Suanprasert, N; Tantirithisak, T; Yadee, T, 2013)	2.08
" Dosage and duration of the aspirin therapy were the same in both groups."	( Aspirin non-responder in Thai ischemic stroke patients. Jongjaroenprasert, W; Mahasirimongkol, S; Suanprasert, N; Tantirithisak, T; Yadee, T, 2013)	2.13
" No association between duration and aspirin dosage with aspirin resistance was found."	( Aspirin non-responder in Thai ischemic stroke patients. Jongjaroenprasert, W; Mahasirimongkol, S; Suanprasert, N; Tantirithisak, T; Yadee, T, 2013)	2.11
" A review of data regarding aspirin use for secondary prevention of events in ACS demonstrated that low aspirin doses (75 to 160 mg/day) are consistently favored for short- and long-term use because of the lack of a dose-response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin dose."	( Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Berger, JS, 2013)	2.13
" The objectives of this study were to evaluate in Thai healthy volunteers: i) the inhibition of whole blood cyclooxygenase(COX)-2 and COX-1 activity by floctafenine and its metabolite floctafenic acid in vitro and ex vivo after dosing with floctafenine; ii) the possible interference of floctafenine administration with aspirin antiplatelet effects."	( Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. Archararit, N; Aryurachai, K; Del Boccio, P; Di Francesco, L; Maenthaisong, R; Patrignani, P; Sacchetta, P; Sritara, P; Suthisisang, C; Tacconelli, S, )	0.53
" In study 2, 35 healthy subjects were treated with LDA 100 mg (regimen A), and then 20 randomly selected subjects were dosed clopidogrel 75 mg (regimen C), LDA/clopidogrel (regimen AC), or LDA/clopidogrel/rabeprazole 10 mg for 7 days."	( Antiplatelet drugs are a risk factor for esophageal mucosal injury. Furuta, T; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2013)	0.39
" However, there are still open questions, regarding the benefit/risk ratio (bleedings) as well as dosage and duration of treatment during the probably long-term medication, before stringent recommendations regarding clinical use of aspirin can be made."	( [Aspirin and prevention of colorectal carcinomas]. Rauch, BH; Schrör, K, 2013)	1.48
" A combined formulation of ASA and clopidogrel has been developed to provide dosing convenience and improve adherence."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
" Serial blood samples were collected immediately before and after dosing for 24 hours."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
"Different aspirin dosing regimens have been suggested to impact outcomes when used in combination with adenosine diphosphate (ADP) P2Y12 receptor antagonists."	( Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Thano, E; Wilson, RE, 2013)	1.19
" The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression."	( Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. Chen, S; Fu, J; Gao, Y; Liu, L; Yang, Y; Ye, X, 2013)	0.64
" Median duration of aspirin usage was 48 months (range: 36-60) with dosage ranging from 75-325 mg/day."	( Chronic low-dose aspirin use does not alter colonic mucosa in asymptomatic individuals: a prospective cross-sectional study (STROBE 1a). Kaminski, MF; Kraszewska, E; Mroz, A; Regula, J; Rupinski, M; Zagorowicz, E, 2014)	1.07
" The aim of this study was to check the possibility of preparing a FDC product, containing individual dosage units of extended release DYP microparticles and fast release ASP, using the spray-drying technique as a practice compatible with pharmaceutical industries."	( Spray drying as a fast and simple technique for the preparation of extended release dipyridamole (DYP) microparticles in a fixed dose combination (FDC) product with aspirin. Alasty, P; Hamishehkar, H; Monajjemzadeh, F; Valizadeh, H, 2014)	0.6
"Findings proposed a new formulation (F7) as an alternative to innovative brand and proved spray drying as a practice compatible with pharmaceutical industries and as a successful method for sustaining the DYP release rate from prepared microparticles in a FDC dosage form."	( Spray drying as a fast and simple technique for the preparation of extended release dipyridamole (DYP) microparticles in a fixed dose combination (FDC) product with aspirin. Alasty, P; Hamishehkar, H; Monajjemzadeh, F; Valizadeh, H, 2014)	0.6
" The forms of these curves did not change significantly following dosing with aspirin."	( Differential trafficking of saccharidic probes following aspirin in clinical tests of intestinal permeability in young healthy women. Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2014)	0.88
" Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie."	( [Thrombocyte aggregation inhibitors: what are the risks?]. Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013)	0.39
" For warfarin, no significant sex difference was seen regarding bleeding event reports, suggesting individualised dosing being an important factor."	( Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. Holm, L; Loikas, D; Malmström, RE; Mejyr, S; Rydberg, DM; Schenck-Gustafsson, K; von Euler, M; Wettermark, B, 2014)	0.4
"Healthy volunteers (N = 56) were randomized to receive different dosing regimens of DR-DMF or matching placebo with or without pretreatment with 325 mg aspirin for 4 days."	( Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Dawson, KT; Huang, R; Milne, GL; Nestorov, I; Novas, M; O'Gorman, J; Russell, H; Scannevin, RH; Sheikh, SI, 2013)	0.8
"Optimal aspirin dosing after acute coronary syndromes remains uncertain."	( Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014)	1.24
" To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted."	( Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers. Chen, H; Chen, K; He, XM; Jia, MM; Li, J; Li, SF; Li, WY; Liu, MZ; Wang, YH; Wu, SL; Zhou, Y, 2013)	0.39
" In conclusion, in non-diabetic obese patients with CAD, standard prasugrel dosing achieved more potent PD effects than high-dose clopidogrel in the acute phase of treatment, but this was not sustained during maintenance phase treatment."	( Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014)	0.4
" Electronically compiled multidrug dosing histories allowed the concomitant intake of high-dose lipophilic statins to be identified as a risk factor of impaired response to clopidogrel and revealed that exposure to further potential drug-drug interactions (DDIs) was too low for analysis."	( Antiplatelet resistance in outpatients with monitored adherence. Arnet, I; Hersberger, KE; Romanens, M; Tsakiris, DA; Walter, PN, 2014)	0.4
" There was also no evidence of dose-response association after adjustments."	( Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cardwell, CR; Coleman, HG; Flahavan, EM; Hughes, CM; Murray, LJ; O'Sullivan, JM; Powe, DG, 2014)	0.82
" We used enrollment data from the Dual Antiplatelet Therapy Study, a randomized trial designed to compare 12 versus 30 months of dual antiplatelet therapy after PCI, to quantify the variation in ASA dosing after PCI in the US subjects and assess the extent to which dose variability was attributable to patient characteristics."	( Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Cutlip, DE; Kereiakes, D; Massaro, J; Matteau, A; Mauri, L; Normand, SL; Orav, EJ; Steg, PG; Yeh, RW, 2014)	0.66
" Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects."	( [Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber]. Dukát, A; Gašpar, L; Gavornik, P, 2013)	0.39
" This cohort study examines associations between pre-diagnostic aspirin use (overall and by dose and dosing intensity) and mortality in men with localised prostate cancer."	( A cohort study investigating aspirin use and survival in men with prostate cancer. Barron, TI; Bennett, K; Flahavan, EM; Sharp, L, 2014)	0.93
" Associations between prescribed dose and dosing intensity were examined."	( A cohort study investigating aspirin use and survival in men with prostate cancer. Barron, TI; Bennett, K; Flahavan, EM; Sharp, L, 2014)	0.69
" In this dosage the toxicity of the treatment is minimal."	( An aspirin a day. Majerus, PW, 2014)	1.02
" In addition, a dose-response curve (25-100 mg/kg) for compounds was carried out in the formalin test."	( Evaluation of the pharmacological properties of salicylic acid-derivative organoselenium: 2-hydroxy-5-selenocyanatobenzoic acid as an anti-inflammatory and antinociceptive compound. Braga, AL; Canto, RF; Chagas, PM; da Luz, SC; Nogueira, CW; Oliveira, CE; Rosa, SG; Sari, MH, 2014)	0.4
" Taken together, these findings identify a previously unrecognized role of TERT in improving the immunomodulatory capacity of BMMSCs, suggesting that aspirin treatment is a practical approach to significantly reduce cell dosage in BMMSC-based immunotherapies."	( Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression. Akiyama, K; Chen, C; Li, B; Shi, S; Xu, X; Yamaza, T; You, YO; Zhao, Y, 2014)	0.6
" Antiplatelet therapy dosing and resistance are poorly understood, leading to potential incorrect and ineffective dosing."	( Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. Forest, CR; Hotaling, NA; Ku, DN; Li, M, 2014)	0.4
" Treatment courses were from 3 to7 days, at a dosage of 60 mL."	( [Outcome study on parenterally administered shenfu in treatment of coronary heart disease]. Li, L; Shen, H; Xie, YM; Yang, J; Zhuang, Y, 2013)	0.39
" The suggested methods were successfully applied for the simultaneous analysis of the studied drugs in their co-formulated tablets as well as in their single dosage forms."	( Derivative spectrophotometric and liquid chromatographic methods for the simultaneous determination of metoclopramide hydrochloride and aspirin in pharmaceuticals. Belal, FF; Elmansi, H; Sharaf El-Din, MK; Tolba, MM, )	0.33
" This dosing is based at least in part on the platelet renewal rate, which is of only 10-15% a day."	( [Aspirin: once or twice a day?]. Boehlen, F; Casini, A; Fontana, P; Reny, JL, 2014)	1.31
" pylori-positive and 10-negative subjects) with 100 mg aspirin plus 75 mg clopidogrel (AC) once-daily dosing and AC plus 20 mg famotidine twice-daily dosing (ACH)."	( Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine. Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2014)	0.65
" The grade of gastric mucosal injuries was evaluated by esophagogastroduodenoscopy before and after dosing (on day 0 and day 14), and the grade of gastric mucosal injury was assessed according to the modified Lanza score."	( A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Fukui, H; Hida, N; Hori, K; Miwa, H; Nakamura, S; Ogawa, T; Ohda, Y; Okugawa, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J, 2014)	0.62
" A twice daily (bid) dosing is necessary to fully inhibit TXA2."	( In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. Barbieri, SS; Cavalca, V; Dragani, A; Pagliaccia, F; Patrono, C; Porro, B; Rocca, B; Squellerio, I; Tremoli, E; Veglia, F, 2014)	0.65
" The developed methods were applied for simultaneous analysis of aspirin, atorvastatin and clopedogrel in capsule dosage forms and results were in good concordance with alternative liquid chromatography."	( Comparative study of three modified numerical spectrophotometric methods: an application on pharmaceutical ternary mixture of aspirin, atorvastatin and clopedogrel. Hegazy, ND; Issa, MM; Nejem, RM; Shanab, AA; Stefan-van Staden, RI, 2014)	0.85
" Colesevelam (3750mg once daily) was dosed throughout the pharmacokinetic sampling period."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.63
" We investigated if the effect of aspirin declined during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes, and whether this correlated with increased platelet turnover."	( Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Christensen, KH; Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2015)	0.98
" Our data suggest that measurement of urinary 11-dTxB2 may be a useful method to optimise statin dosing in order to reduce thrombotic risk."	( Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. Bliden, KP; Ens, G; Franzese, CJ; Gesheff, MG; Gurbel, PA; Guyer, K; Singh, M; Singla, A; Stapleton, D; Tabrizchi, A; Tantry, US; Toth, PP, 2014)	0.62
" In conclusion, current statins use, particularly long-term use, has a dose-response protective effect on mortality in patients with CDI."	( Statins use and risk of mortality in patient with Clostridium difficile infection. Barnett-Griness, O; Elias, M; Rennert, G; Saliba, W, 2014)	0.4
"Once-daily aspirin is standard treatment, but recent studies point towards increased platelet function at the end of the dosing interval."	( 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Würtz, M, 2014)	1.08
"Platelet inhibition declined significantly during the 24-hour dosing interval in aspirin-treated patients with previous definite ST or stable coronary artery disease and in healthy individuals."	( 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Würtz, M, 2014)	0.91
" Medication use was compared between transfer and direct-arrival patients to determine if these therapies were delayed or dosed in excess."	( The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY, 2014)	0.4
"ST-segment elevation myocardial infarction patients transferred for primary PCI in community practice are at risk for delayed and excessively dosed antithrombotic therapy, highlighting the need for continued quality improvement to maximize the appropriate use of these important adjunctive therapies."	( The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY, 2014)	0.4
" Half-hourly lactulose excretions were generally increased after dosage with aspirin whilst those of mannitol were unchanged as was the temporal pattern and period of lowest between subject standard error for both sugars."	( Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability. Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2014)	0.63
" Even a 12-hour separation of dosing does not appear to prevent drug interactions between omeprazole and clopidogrel."	( Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Chilton, R; Johnson, DA; Liker, HR, 2014)	0.4
" At the end of the dosing interval on day 28, mean final-extent IPA was 10."	( Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Emanuelsson, H; Hiasa, Y; Teng, R, 2014)	0.4
" After chronic dosing with aspirin, the pharmacokinetics of acetylsalicylic acid was completely dissociated from pharmacodynamics."	( Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. Del Boccio, P; Di Francesco, L; Dovizio, M; Guillem-Llobat, P; Lanas, A; Marcantoni, E; Patrignani, P; Patrono, C; Piazuelo, E; Sostres, C; Tacconelli, S; Zucchelli, M, 2014)	0.95
" It is of great significance since these characteristics are closely related to the dose, dosage form, and effect of the drugs."	( Experimental and mathematical studies on the drug release properties of aspirin loaded chitosan nanoparticles. Chen, Y; Shi, Y; Wan, A; Zhang, Y, 2014)	0.63
" A loading dosage of aspirin (500 mg) and/or clopidogrel (300 mg) was given 24 hours before the procedure to patients naïve to antiplatelet agents, whereas the usual dosage (aspirin 100 mg and clopidogrel 75 mg) was continued for patients who had previously been taking these agents for more than a week."	( Association between silent embolic cerebral infarction and continuous increase of P2Y12 reaction units after neurovascular stenting. Jung, JM; Kang, DW; Kim, BJ; Kim, JS; Kwon, JY; Kwon, SU; Lee, DH, 2014)	0.72
"Biomarker testing for efficacy of therapy is an accepted way for clinicians to individualize dosing to genetic and/or environmental factors that may be influencing a treatment regimen."	( The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk. Berger, JS; Boone, JL; Jefferies, JL; Jesse, RL; Maisel, AS; McConnell, JP; McCullough, PA; Neath, SX; Wu, AH, 2014)	0.4
" The reference dose of Diclofenac used in all randomized controlled trials is 150 mg/die; this controlled release dosage allows to decrease the number of daily administrations, ensuring a better patient compliance, especially if elderly and/or in polytherapy."	( [Diclofenac: update on tolerableness and spinal anti-inflammatory action]. Sandri, A, 2014)	0.4
"To conduct a randomised, double-blind, triple-dummy, active-controlled, multicentre trial, named the PLANETARIUM study, to assess the efficacy, dose-response relationship and safety of rabeprazole for peptic ulcer recurrence in Japanese patients on long-term LDA therapy."	( Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014)	0.61
"Rabeprazole prevents the recurrence of peptic ulcers with no evidence of a major dose-response effect in subjects on low-dose aspirin therapy."	( Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014)	0.82
" However, before these agents are recommended for general use, large multicenter trials should be done exploring not only efficacy but also dose-response relationships and side effects."	( Novel preoperative pharmacologic methods of preventing postoperative sore throat due to tracheal intubation. Austin, PN; Kalil, DM; Silvestro, LS, 2014)	0.4
"Aspirin dosing from 221 199 patients with MI (40."	( Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Alexander, KP; Das, SR; de Lemos, JA; Desai, N; Enriquez, JR; Hall, HM; McGuire, DK; Peng, SA; Roe, MT; Wiviott, SD, 2014)	2.12
" Although aspirin dosing after percutaneous coronary intervention largely reflected prevailing guidelines before 2012, high-dose aspirin was prescribed with similar frequency in medically managed patients and to those in categories expected to be at high risk for bleeding."	( Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Alexander, KP; Das, SR; de Lemos, JA; Desai, N; Enriquez, JR; Hall, HM; McGuire, DK; Peng, SA; Roe, MT; Wiviott, SD, 2014)	1.08
" Although the dosage of aspirin administered in mice was higher than the therapeutic regimen against cardiovascular events, it is comparable with the recommended anti-inflammatory prescription."	( Aspirin delimits platelet life span by proteasomal inhibition. Dash, A; Dash, D; Nayak, MK; Singh, N, 2014)	2.15
" PD assessments included vasodilator-stimulated phosphoprotein, light transmission aggregometry, and VerifyNow P2Y12 ex vivo, before and after dosing and following in vitro incubation with escalating concentrations (1, 3, and 10 μM) of clopidogrel's active metabolite (Clop-AM)."	( Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014)	0.4
" Coagulation biomarkers in shed blood were assessed at 3 h after monotherapy with the medicines under study, at 3 h after triple therapy dosing and at steady state trough conditions."	( Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M, 2014)	0.4
" Moreover, light transmission aggregometry may detect impaired ristocetin-induced platelet agglutination, enabling dosage of aspirin to be adjusted."	( Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience. Barandon, L; Calderon, J; Fiore, M; James, C; Mouton, C; Ouattara, A; Picard, F, 2014)	0.61
"A 73-yr-old Korean man with permanent atrial fibrillation visited outpatient clinic with severely increased International Normalized Ratio (INR) values after taking a usual starting dosage of warfarin to prevent thromboembolism."	( Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis. Jeong, HJ; Jun, JE; Kim, JH; Kim, JS; Lee, JE; Lee, SY; Ryu, DH, 2014)	0.4
" The patients in the platelet function monitoring guided group received an antiplated therapy guided by a modified thromboelastography (TEG) platelet mapping: If inhibition of platelet aggregation (IPA) induced by arachidonic acid (AA) was less than 50% the aspirin dosage was raised to 200 mg/d; if IPA induced by adenosine diphosphate (ADP) was less than 30% the clopidogrel dosage was raised to 150 mg/d, for three months."	( Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions. Li, K; Li, W; Liu, Y; Ni, Z; Sun, H; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014)	0.58
" Objectives of the intervention were to (i) increase the identification of CKD, (ii) increase the use of aspirin and angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin II receptor blockers (ARBs) in patients with CKD, and (iii) ensure that all medications prescribed to patients with CKD were dosed appropriately based on renal function."	( Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home. Barnes, KD; Beatty, SJ; Lehman, AM; Tayal, NH, 2014)	0.62
"A pharmacist review of the electronic medical record was completed to confirm stage 3, 4, or 5 CKD based on estimated glomerular filtration rate, to ensure that ACE-Is/ARBs and aspirin were prescribed, and to ensure that all medications were dosed appropriately based on renal dosing adjustment recommendations."	( Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home. Barnes, KD; Beatty, SJ; Lehman, AM; Tayal, NH, 2014)	0.6
"These results demonstrate the impact of a pharmacist-driven renal medication dosing intervention within a PCMH on medication use and safety for patients with CKD."	( Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home. Barnes, KD; Beatty, SJ; Lehman, AM; Tayal, NH, 2014)	0.4
" However, data are lacking regarding optimal timing and dosing of ASA."	( Association Between Preoperative Aspirin-dosing Strategy and Mortality After Coronary Artery Bypass Graft Surgery. Collard, CD; Coselli, J; Deng, Y; Elayda, MA; Lee, VV; Pan, W; Pisklak, PV; Tolpin, DA, 2015)	0.7
" There was a significant dose-response relationship, with the risk increasing with longer duration of inhaled corticosteroids (P for trend < 0."	( Cohort study of corticosteroid use and risk of hospital admission for diverticular disease. Abraham-Nordling, M; Håkansson, N; Hjern, F; Mahmood, MW; Wolk, A, 2015)	0.42
" Aspirin "resistance," improved dosing regimens for personalized therapy, and chemoprevention of colorectal cancer are thoroughly discussed."	( Role of clinical pharmacology in the development of antiplatelet drugs. Patrono, C, 2014)	1.31
" Long-term dosage for patients with coronary artery aneurysms(CAA) is also important, however, there are few evidences of risk-benefit assessment for its long-term use especially for middle-aged and senior adults with KD and CAA."	( [Aspirin treatment for patients with Kawasaki disease]. Hamada, H, 2014)	1.31
" The injection is administered intravenously,with most patients receiving a dosage of 15-20 mL per dose for between 1 and 14 days."	( [Analysis of clinical use of shuxuening injection in treatment of cerebral infarction based on real world]. Luo, YH; Wang, YY; Xie, YM; Yang, W; You, L; Zhuang, Y, 2014)	0.4
" Current dosing guidelines recommend that the drug be administered over 30 minutes."	( The shortened infusion time of intravenous ibuprofen part 1: a multicenter, open-label, surveillance trial to evaluate safety and efficacy. Ayad, SS; Bergese, SD; Candiotti, K; Gan, TJ; Soghomonyan, S, 2015)	0.42
"5, and aspirin was administered at a dosage of 75 to 325 mg/d."	( Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Chen, KP; Zhang, JT; Zhang, S, 2015)	1.13
" The effects of administration of 600 mg aspirin alone, 500 mg ascorbic acid alone and simultaneous dosage of both agents were compared in a cross-over study in 28 healthy female volunteers."	( Ascorbic Acid may Exacerbate Aspirin-Induced Increase in Intestinal Permeability. Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2015)	0.97
" This reaction may be used as an important consideration to optimize the dosing regime of the two drugs and to help explain some pharmacological reactions between aspirin and biomolecules."	( A Reaction of Aspirin with Ferrous Gluconate. Zhang, J, 2015)	0.97
" Ex vivo platelet aggregation was analyzed on Day 1 (1 and 4h after administration), Day 4 (4h), and Day 7 (4h) under three different prasugrel dosing regimens: LD0/MD1 (1mg/kg/day), LD0/MD3 (3mg/kg/day), and LD10/MD1 (10mg/kg loading dose and 1mg/kg/day maintenance dose)."	( Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrel. Jakubowski, JA; Mizuno, M; Ohno, K; Sugidachi, A; Tomizawa, A, 2015)	0.61
" Therefore, aspirin dosage can be adjusted individually to reach maximum effect of platelet inhibition."	( Aspirin resistance in children and young adults with splenectomized thalassemia diseases. Chuansumrit, A; Kadegasem, P; Sirachainan, N; Soisamrong, A; Wijarn, P; Wongwerawattanakoon, P, 2015)	2.24
"The study group consisted of 92 postmenopausal women: 1) group G1 (n=30), treated with transdermal HT (17β-estradiol 50 μg/day plus NETA 170 μg/day); 2) group G2 (n=31), treated with the above transdermal HT and low dosage of acetylsalicylic acid (ASA); 3) control group P (n=31)."	( Effect of transdermal hormone therapy on platelet haemostasis in menopausal women. Pertyńska-Marczewska, M; Pertyński, T; Stachowiak, G, 2015)	0.42
"Among their beneficial effects, non-steroidal anti-inflammatory drugs may also exert several side effects which depend on the dosage and the type of these medications."	( [Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous]. Horváth, VJ; Koós, CG; Lakatos, P; Putz, Z; Szabó, G; Tabák, GÁ, 2015)	0.42
" Specifically, dosage and tablet-years of use were associated with lower risk (OR = 0."	( Regular aspirin use and stomach cancer risk in China. Duan, H; Ge, J; Shen, C; Wang, Y, 2015)	0.85
" Given the widespread use of nonsteroidal anti-inflammatory drugs and acetaminophen worldwide, further investigations of the possible role of analgesics in cervical cancer, using a larger sample size with better-defined dosing regimens, are warranted."	( Aspirin and Acetaminophen Use and the Risk of Cervical Cancer. Cannioto, RA; Friel, G; Hampras, SS; Kolomeyevskaya, NV; Kruszka, B; Lele, SB; Liu, CS; Moysich, KB; Odunsi, KO; Schmitt, K, 2015)	1.86
" This study aims to investigate whether calcium channel blockers plus low dosage aspirin therapy can reduce the incidence of complications during pregnancy with chronic hypertension and improve the prognosis of neonates."	( The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. Jiang, N; Liu, L; Liu, Q; Yang, WW; Zeng, Y, 2015)	0.64
" A once-daily, extended-release (ER) ASA formulation using ER microcapsule technology was developed to release ASA over the 24-h dosing interval and reduce maximal plasma concentrations to spare peripheral endogenous endothelial prostacyclin production."	( A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Armas, D; Dillaha, L; Patrick, J; Sessa, WC, 2015)	0.63
" Marked inhibition of TXB2 and 11-dehydro-TXB2 was maintained over the 24-h dosing interval after a dose of ≥81 mg ER-ASA or ≥40 mg IR-ASA."	( A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Armas, D; Dillaha, L; Patrick, J; Sessa, WC, 2015)	0.63
" The DMF without ASA group (n = 43) and the DMF with ASA group (n = 43) received placebo ASA or ASA, respectively, 30 minutes before DMF (weeks 1-4), then DMF alone (weeks 5-8); in both groups, DMF was dosed at 120 mg BID (week 1) and 240 mg BID (weeks 2-8)."	( Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. Kurukulasuriya, NC; Li, J; O'Gorman, J; Phillips, G; Russell, HK; Viglietta, V, 2015)	0.82
" The effect was less pronounced at 32 °C, with a significant reduction in EPICT obtained with a dosage of 5 microgram only (p = 0."	( The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin - a randomized controlled trial. Cheung, CW; Lee, Y; Leung, SW; Ng, KF; Tsui, PY, 2015)	0.62
" A higher dosage (5 microgram) further reduced the closure times below baseline."	( The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin - a randomized controlled trial. Cheung, CW; Lee, Y; Leung, SW; Ng, KF; Tsui, PY, 2015)	0.62
" Because increased platelet reactivity and/or turnover are postulated mechanisms, we examined whether higher and/or more frequent aspirin dosing might reduce platelet reactivity more effectively."	( Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016)	0.86
" Relationships between platelet reactivity and aspirin dosing were examined using generalized linear mixed models with random subject effects."	( Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016)	0.91
" Clinical outcome trials evaluating primary cardiovascular disease prevention with aspirin in Type 2 diabetes may need to consider using a more frequent dosing schedule."	( Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016)	0.88
" In the experiment, the following substances were used: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), dosed at 5 μg/kg BW and 12."	( Effect of tocopherol and acetylsalicylic acid on the biochemical indices of blood in dioxin-exposed rats. Całkosiński, I; Rosińczuk, J, 2015)	0.42
" In addition, the variability in benefit achievable from the prescription of aspirin has led to a growing interest in considering whether there are more effective aspirin regimens than once-daily dosing or whether effectiveness is influenced by the time of day aspirin is taken (chronotherapy)."	( Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. Bayliss, S; Bem, D; Dretzke, J; Fitzmaurice, D; Hodgkinson, J; Lordkipanidzé, M; Moore, D; Stevens, S, 2015)	0.91
" However, no systematic review to date has attempted to review the evidence pertaining to aspirin dosing regimens differing in frequency and/or in timing."	( Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. Bayliss, S; Bem, D; Dretzke, J; Fitzmaurice, D; Hodgkinson, J; Lordkipanidzé, M; Moore, D; Stevens, S, 2015)	0.9
" We sought to evaluate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and the pharmacokinetic profile of ticagrelor and its metabolite AR-C124910XX, in black patients with stable CAD taking low-dose aspirin (acetylsalicylic acid)."	( Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R, 2015)	0.6
" All patients received low-molecular-weight heparin in prophylactic dosage starting 24 hours after aneurysm treatment."	( Ventriculostomy-Related Hemorrhage After Treatment of Acutely Ruptured Aneurysms: The Influence of Anticoagulation and Antiplatelet Treatment. Bruder, M; El-Fiki, A; Güresir, E; Konczalla, J; Lescher, S; Schuss, P; Seifert, V; Vatter, H, 2015)	0.42
" AEE was administrated at the dosage of 18, 36 and 72 mg/kg."	( Preventive Effect of Aspirin Eugenol Ester on Thrombosis in κ-Carrageenan-Induced Rat Tail Thrombosis Model. Li, JY; Liu, GR; Liu, XW; Ma, N; Mohamed, I; Yang, YJ; Zhang, JY, 2015)	0.74
" A training data set of 2949 notes was created to develop a computer-based method to automatically extract aspirin use status and dosage information using natural language processing (NLP)."	( Medication Extraction from Electronic Clinical Notes in an Integrated Health System: A Study on Aspirin Use in Patients with Nonvalvular Atrial Fibrillation. An, J; Koblick, R; Rashid, N; Zheng, C, 2015)	0.85
" However, the use of these dosage forms has never been studied in the treatment of IP."	( Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. Schwier, NC, 2015)	0.42
" The majority of current desensitization protocols use 3-hour dosing intervals and often require 2 to 3 days to complete."	( An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated Respiratory Disease. Buchmiller, BL; Chen, JR; Khan, DA, )	0.38
"Data were unavailable on over-the-counter purchases of high-dose aspirin and low-dose ibuprofen or NSAID dosing schedules, there were several comparisons, and the authors were unable to adjust for confounding by some risk factors."	( Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. Baron, JA; Erichsen, R; Friis, S; Riis, AH; Sørensen, HT, 2015)	1.07
" However, its optimum dosing requirements have been up for debate especially in various settings of acute coronary syndrome and stable ischemic heart disease."	( Aspirin dosing in cardiovascular disease prevention and management: an update. Becker, RC; Ganjehei, L, 2015)	1.86
" However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours."	( Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers? Aradi, D; Gross, L; Sibbing, D, 2016)	0.65
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, cost, and place in therapy of vorapaxar in the secondary prevention of atherosclerotic events are reviewed."	( Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)	0.42
"We have used three dimensional (3D) extrusion printing to manufacture a multi-active solid dosage form or so called polypill."	( 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. Alexander, MR; Burley, JC; Khaled, SA; Roberts, CJ; Yang, J, 2015)	0.42
" This article reviews the importance of explaining the therapeutic and nontherapeutic effects of these agents, cautions, contraindications, dosing parameters, and the avoidance of acetaminophen/aspirin and multiple nonsteroidal anti-inflammatory drug use to patients and prescribers."	( Pharmacist's evolving role in the nonopioid, over-the-counter, analgesic selection process. Barkin, RL, )	0.32
"To investigate the effect of calcium ions on the disintegration of enteric-coated dosage forms, disintegration testing was performed on enteric-coated aspirin tablets in the presence and absence of calcium in the test media."	( Effect of Calcium Ions on the Disintegration of Enteric-Coated Solid Dosage Forms. Al-Gousous, J; Langguth, P, 2016)	0.63
"Barrier coatings are frequently employed on solid oral dosage forms under the assumption that they prevent moisture sorption into tablet cores thereby averting premature degradation of moisture-sensitive active ingredients."	( An investigation into moisture barrier film coating efficacy and its relevance to drug stability in solid dosage forms. Basit, AW; Mwesigwa, E, 2016)	0.43
" Careful attention must be paid to the dosing and potential teratogenicity of medications."	( Pregnancy and Lupus Nephritis. Garovic, VD; Kattah, AG, 2015)	0.42
"To analyze published studies about Aspirin use for preeclampsia prevention and about the more adequate dosage to be administered, Medline was used for searching the most relevant prospective research papers on this subject in order to evaluate current evidence about the use of aspirin in this context."	( [The Role of Aspirin in Preeclampsia Prevention: State of the Art]. Campos, A, )	0.78
"As we do not have other pharmacologic alternatives, low dosage of Aspirin between 80-150 mg a day in the first trimester and until 16 weeks, at evening time, is a possible choice in cases of risk, and is still contributing for an early preeclampsia risk reduction."	( [The Role of Aspirin in Preeclampsia Prevention: State of the Art]. Campos, A, )	0.74
"Daily generation of novel platelets may compromise aspirin's platelet inhibitory action, especially near the end of the regular 24-h dosing interval."	( Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake: a study in chronic aspirin users. Fuijkschot, WW; Smulders, YM; Thijs, A; van Diemen, JJ; Veen, G; Wessels, TJ, 2016)	1.02
" Despite the popularity of aspirin and its wide use, the proper dosing and frequency of aspirin has yet to be determined."	( Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. Becker, RC; Kim, J, 2016)	2.17
"The protocols varied widely in terms of medication and dosing choices, as well as listed contraindications to treatments."	( Chest Pain of Suspected Cardiac Origin: Current Evidence-based Recommendations for Prehospital Care. Barger, JA; Brown, JF; Gilbert, GH; Koenig, KL; Rudnick, EM; Salvucci, AA; Savino, PB; Sporer, KA, 2015)	0.42
" Increasing the aspirin dosage and/or shifting to uncoated preparations caused a change in aspirin sensitivity of 36-60%."	( Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. Ataç, BF; Bayraktar, N; Can, U; Çelikkol, C; Derle, E; Kibaroğlu, S; Öcal, R; Verdi, H, 2016)	2.22
" The critical attributes of the pellet dosage forms (dependent variables); disintegration time, sphericity and yield were predicted with adequate accuracy based on the regression model."	( Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion process using statistical tools. Gandra, S; Gurram, RK; Shastri, NR, 2016)	0.43
" We thus aimed to review main sources of evidence informing on daily dosage and preparation of aspirin for primary prevention of CVD and cancer."	( Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis. Biasucci, LM; Biondi-Zoccai, G; Frati, G; Giordano, A; Lotrionte, M; Peruzzi, M, )	0.83
" Suboptimal dosing was seen."	( Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation. Bell, AD; Deschaintre, Y; Gross, P; Heffernan, M; Purdham, DM; Roux, JF; Shuaib, A, 2016)	0.43
" Optimum type and dosage of NSAID for this purpose remains unclear."	( Do postoperative NSAIDs improve breast cancer outcomes? A Best Evidence Topic. Lambert, K; McGlone, E; Sutton, L, 2016)	0.43
"This study demonstrated that lower dosage of aspirin can promote ST2 cells growth, osteogenic activity and inhibit its apoptosis."	( [Effect of aspirin on cell biological activities in murine bone marrow stromal cells]. Du, M; Ge, S; Pan, W; Yang, P, 2016)	1.08
"Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups."	( Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016)	0.95
"In this contribution, the utility of sequential injection analysis in combination with surface-enhanced Raman spectroscopy (SERS) as a detection technique was investigated for simultaneous determination of aspirin and vitamin C in their pharmaceutical dosage forms and in spiked urine samples."	( Sequential SERS determination of aspirin and vitamin C using in situ laser-induced photochemical silver substrate synthesis in a moving flow cell. El-Zahry, MR; Lendl, B; Mohamed, HA; Refaat, IH, 2016)	0.9
" Dose-response relation was assessed by a two-stage linear dose-response model."	( Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Bai, B; Wang, T; Xi, Y; Zhang, D; Zhao, Y, 2016)	1.06
" The dose-response analysis showed an inverse significant association between aspirin use and the risk (RRper 1time/wk=0."	( Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Bai, B; Wang, T; Xi, Y; Zhang, D; Zhao, Y, 2016)	1.28
" In addition, we observed a possible dose-response relation between frequency of use and ovarian cancer risk, but further studies are needed to examine this association."	( Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Bai, B; Wang, T; Xi, Y; Zhang, D; Zhao, Y, 2016)	1.06
" Subgroup analysis was conducted based on obesity, hormone replacement therapy use, and cancer subtype; sensitivity analysis was conducted by pooling risk ratios of the highest dosage or longest duration of use."	( Can Aspirin Reduce the Risk of Endometrial Cancer?: A Systematic Review and Meta-analysis of Observational Studies. Bai, B; Xi, Y; Zhang, D; Zhao, Y, 2016)	0.99
" However, the evidence for its use is limited by the low quality of studies and variation in dose in dosing regimes."	( Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. An, VV; Bruce, WJ; Levy, YD; Phan, K, 2016)	1.88
" A dose-response relationship was observed between longer D2B and D2N times and shorter life expectancy after AMI."	( Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries. Bucholz, EM; Butala, NM; Krumholz, HM; Normand, ST; Wang, Y, 2016)	0.43
" To the best of our knowledge, this is the third reported case of takotsubo cardiomyopathy following appropriately dosed intramuscular administration of epinephrine for anaphylaxis."	( Rare case of stress cardiomyopathy due to intramuscular epinephrine administration. Lloyd, B; Lohani, S; Melnick, S; Nazir, S, 2016)	0.43
" However, there are no reports about the dose-response of loading aspirin in treating acute ischemic stroke."	( To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016)	0.98
" More recently, aspirin dosing has been thoroughly studied in the CAD population with concomitant therapy (such as P2Y12 inhibitors); however, patients in these studies were not randomized to aspirin dose."	( The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Hernandez, AF; Johnston, A; Jones, WS, 2016)	1.09
" Patients received a minimum dosage of aspirin of 2000 mg/day over at least 3 days."	( Gastrointestinal Safety of Aspirin for a High-Dose, Multiple-Day Treatment Regimen: A Meta-Analysis of Three Randomized Controlled Trials. Forder, S; Lanas, A; Voelker, M, 2016)	1
" We conducted a systematic review to evaluate the evidence on the effects of different aspirin regimens in terms of timing (chronotherapy) or frequency of dosing in the prevention of cardiovascular disease."	( The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. Bayliss, S; Bem, D; Dretzke, J; Fitzmaurice, D; Hodgkinson, J; Lordkipanidzé, M; Moore, D; Stevens, S, 2016)	0.96
" The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations."	( The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. Bolek, T; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016)	0.43
" Based on the results of this study, no signs of toxicity in acute, subacute, and subchronic studies following oral administration of ACS c-SLNs were found indicating that the oral dosing regimens were safe at the levels tested for long-term administration to prevent the onset of pancreatic cancer."	( Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Chenreddy, S; Khamas, W; Prabhu, S; Thakkar, A; Thio, A; Wang, J, 2016)	0.65
" A fixed-dose combination (FDC) capsule (HCP0911) has been developed to provide dosing convenience and improve adherence."	( Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Ahn, JH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, K; Koh, JS; Kwak, CH; Park, HW; Park, JR; Park, Y; Tantry, US, 2017)	0.7
" Also the accumulated loading dosage could be adjusted by the film thickness, and the sustained release of aspirin could ensure well anti-inflammatory effect."	( A novel porous aspirin-loaded (GO/CTS-HA)n nanocomposite films: Synthesis and multifunction for bone tissue engineering. Guo, H; He, J; Huang, F; Ji, M; Li, H; Li, S; Shen, Y; Wang, S; Xie, A, 2016)	1
"Guidelines from the American Heart Association/American College of Cardiology recommend a higher dosage of aspirin daily following Percutaneous Coronary Intervention (PCI), whereas guidelines from the European Society of Cardiology recommend a lower dosage."	( Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis. Bundhun, PK; Huang, WQ; Janoo, G; Teeluck, AR, 2016)	0.88
"To determine the efficacy of a novel and safer (for gastrointestinal tract) aspirin (aspirin-PC) in preclinical models of ovarian cancer, in vitro dose-response studies were performed to compare the growth-inhibitory effect of aspirin-PC versus aspirin on three human (A2780, SKOV3ip1, and HeyA8) and a mouse (ID8) ovarian cancer cell line over an 8-day culture period."	( Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Bottsford-Miller, JN; Dial, EJ; Dorniak, PL; Fang, D; Filant, J; Haemmerle, M; Hansen, JM; Hatakeyama, H; Hu, W; Huang, Y; Lichtenberger, LM; Lyons, Y; Pradeep, S; Previs, RA; Shen, F; Sood, AK; Taylor, M; Wagner, MJ, 2016)	0.93
"We sought to estimate the impact of aspirin dosage on the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction."	( The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Bujold, E; Chaillet, N; Demers, S; Hyett, J; Nicolaides, K; Roberge, S, 2017)	1.11
"Prevention of preeclampsia and fetal growth restriction using aspirin in early pregnancy is associated with a dose-response effect."	( The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Bujold, E; Chaillet, N; Demers, S; Hyett, J; Nicolaides, K; Roberge, S, 2017)	1.07
"To assess the consequences of switching aspirin dosage from 100 mg/d to 40 mg/d on cardiovascular benefit, bleeding risk and platelet aggregation in very elderly patients."	( [Dose-response of aspirin on platelet function in very elderly patients]. Fan, Y; Feng, XR; Liu, F; Liu, ML; Tian, QP, 2016)	1.04
"Switching aspirin dosage from 100 mg/d to 40 mg/d reduces the bleeding events and improves upper gastrointestinal symptoms, thus inhibiting platelet aggregation effectively in very elderly patients."	( [Dose-response of aspirin on platelet function in very elderly patients]. Fan, Y; Feng, XR; Liu, F; Liu, ML; Tian, QP, 2016)	1.17
" This paper investigates a new methodology for the control dosage of a polypill recently reported containing hydrochlorothiazide, amlodipine, losartan and simvastatin in a 12."	( Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill. Doadrio, AL; Doadrio, JC; Salinas, AJ; Sánchez-Montero, JM; Vallet-Regí, M, 2017)	0.46
" Based on individual weekly body weight (BW), AEE was intragastrically administrated at the dosage of 18, 36 and 54 mg/kg."	( Lowering effects of aspirin eugenol ester on blood lipids in rats with high fat diet. Karam, I; Kong, XJ; Li, JY; Liu, XW; Ma, N; Yang, YJ; Zhao, XL, 2016)	0.76
" AEE at the dosage of 54 mg/kg significantly decreased levels of TG, TCH and LDL (p < 0."	( Lowering effects of aspirin eugenol ester on blood lipids in rats with high fat diet. Karam, I; Kong, XJ; Li, JY; Liu, XW; Ma, N; Yang, YJ; Zhao, XL, 2016)	0.76
" The dose-response analysis and subgroup analysis were also performed."	( Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis. Chen, WJ; Chen, Y; Huang, XZ; Sun, SS; Wu, CC; Wu, J; Zhang, CY; Zhang, X, 2017)	1.9
" Moreover, the dose-response analysis indicated the risk of GC decreased by 11% and 5% for 2 years increment of any NSAIDs and aspirin use, respectively."	( Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis. Chen, WJ; Chen, Y; Huang, XZ; Sun, SS; Wu, CC; Wu, J; Zhang, CY; Zhang, X, 2017)	2.1
" The optimal dosage of ASA is not known."	( Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Ander, C; Dalén, M; Hjemdahl, P; Ivert, T; Lordkipanidzé, M; Näsman, P; Stålesen, R, 2017)	0.46
"Various strategies are emerging for dosing antiplatelet therapies in preparation for pipeline stent embolization in adults."	( Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature. Cobb, MIH; Fernando Gonzalez, L; Hauck, EF; Smith, TP; Zomorodi, AR, 2017)	0.46
" It is important to understand the bioavailability of aspirin and its major metabolite, salicylic acid, since dosage and route of administration can vary for treating differing diseases, and the major side-effects of aspirin, upper gastrointestinal ulceration and bleeding, are dose-dependent."	( Bioavailability of aspirin in rats comparing the drug's uptake into gastrointestinal tissue and vascular and lymphatic systems: implications on aspirin's chemopreventive action. Dial, EJ; Edler, S; Fang, D; Li-Geng, T; Lichtenberger, LM; Phan, T; Philip, J, 2016)	1.01
" We aimed to determine if aspirin administered at conventional dosing in shunted infants resulted in ≥50% arachidonic acid (AA) inhibition in short and midterm follow-up using thromboelastography with platelet mapping (TEG-PM) and to describe bleeding and thrombotic events during follow-up."	( Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up. Bailly, DK; Burch, PT; Clawson, JR; Johnson, JT; LuAnn Minich, L; Sheng, X; Truong, DT; Witte, MK, 2017)	1.02
" Dose escalation in initially nonresponsive patients to achieve responsiveness may confer a similar PT risk to patients initially responsive to standard aspirin dosing without increased bleeding risk."	( Assessment of Bleeding and Thrombosis Based on Aspirin Responsiveness after Continuous-Flow Left Ventricular Assist Device Placement. Brisco-Bacik, MA; Cook, JL; DeNino, WF; Floroff, CK; Heyward, DP; Lazarchick, J; Meadows, HB; Rieger, KL; Stroud, MR; Strout, SE; Toole, JM; Uber, WE; Veasey, TM, )	0.59
" Effects of ASA dosage on the metabolic profile have not been fully understood."	( Quantitative determination of five metabolites of aspirin by UHPLC-MS/MS coupled with enzymatic reaction and its application to evaluate the effects of aspirin dosage on the metabolic profile. Duan, JA; Guo, JM; Li, JP; Liu, Y; Shang, EX; Tang, ZS; Zhao, BC; Zhao, J; Zhu, ZH, 2017)	0.71
" GI bleeding was equally prevalent between the 2 dosing regimens, so patients need to be informed of this risk regardless of the ASA dose."	( A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties. Chen, AF; Feldstein, MJ; Hozack, WJ; Low, SL; Woodward, LA, 2017)	0.46
" Although there is evidence in the literature regarding specific OCS dosing protocols, it is not known to what extent these recommendations are being followed."	( Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership. Ernst, HM; Rotenberg, BW; Rudmik, L; Scott, JR; Sowerby, LJ, 2017)	0.46
" We tested whether more frequent dosing improves aspirin (ASA) response following CABG surgery."	( Once versus twice daily aspirin after coronary bypass surgery: a randomized trial. Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Pare, G; Weitz, JI; Whitlock, RP, 2017)	1.02
" Therefore, a randomized dosage adjustment trial should elucidate whether a tailored ASA treatment after CABG surgery represents a useful concept."	( The Prevalence and Clinical Relevance of ASA Nonresponse After Cardiac Surgery: A Prospective Bicentric Study. Adam, EH; Bauer, M; Kaiser, J; Kunze-Szikszay, N; Meybohm, P; Moldenhauer, L; Moritz, A; Popov, AF; Wand, S; Weber, CF; Wetz, AJ; Zacharowski, K, 2018)	0.48
" Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects."	( [Antiplatelet thromboprophylaxis of arterial vascular diseases and organovascular ischemic diseases]. Dukát, A; Gašpar, Ľ; Gašparová, I; Gavorník, P; Gavorníková, E; Gubo, G; Hučková, N; Petrášová, A; Sabolová, L, )	0.13
" The dosage varied from 50 to 650 mg/day across the studies."	( The effectiveness of aspirin for migraine prophylaxis: a systematic review. Baena, CP; Benseñor, I; Brunoni, AR; D'Amico, RC; Goulart, AC; Slongo, H, )	0.45
" However, the optimal dosage is unclear."	( The effectiveness of aspirin for migraine prophylaxis: a systematic review. Baena, CP; Benseñor, I; Brunoni, AR; D'Amico, RC; Goulart, AC; Slongo, H, )	0.45
"The reasons for this prospective experimental study were to determine a dosing scheme with loading and maintenance dose of aspirin inducing inhibition of platelet function measured by whole blood impedance aggregometry."	( Suspected aspirin resistance in individual healthy adult warmblood horses. Failing, K; Moritz, A; Roscher, KA; Schenk, I, 2017)	1.06
" The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression."	( Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. Lu, L; Shi, L; Wen, Z; Zeng, J, 2017)	1.9
"Our study confirmed a dose-response relationship between aspirin use and breast cancer risk."	( Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. Lu, L; Shi, L; Wen, Z; Zeng, J, 2017)	2.14
"Administration of aspirin with a dosage of 60 mg or 80 mg/kg initiated at 2 months after pilocarpine-induced status epilepticus significantly reduced the frequency and duration of spontaneous recurrent seizures."	( Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic mice. Hu, M; Liu, JX; Liu, Y; Yuan, B; Zhu, K, 2017)	2.23
"Our findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily was associated with a reduced risk of breast cancer in women with diabetes."	( Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. Chiou, JY; Huang, CN; Kornelius, E; Lai, YR; Lo, SC; Peng, CH; Yang, YS, 2017)	1.14
" A number of secondary analyses were performed, including lobe-specific analyses, subgroup analyses based on participants' overall risk of cerebrovascular disease, and a dose-response relationship analysis."	( Chronic Use of Aspirin and Total White Matter Lesion Volume: Results from the Women's Health Initiative Memory Study of Magnetic Resonance Imaging Study. Ammann, E; Espeland, MA; Holcombe, A; Kelley, BJ; Manson, JE; Robinson, J; Wallace, R, 2017)	0.81
"In formulation development, certain excipients, even though used in small quantities, can have a significant impact on the processability and performance of the dosage form."	( The Impact of Disintegrant Type, Surfactant, and API Properties on the Processability and Performance of Roller Compacted Formulations of Acetaminophen and Aspirin. Koo, O; Marin, A; Morkhade, D; Pan, D; Rana, S; Saha, P; Wu, Y; Zhao, J, 2017)	0.65
" There were also no evidence of a dose-response association between these drug groups and EC survival."	( Commonly used medications and endometrial cancer survival: a population-based cohort study. Cardwell, CR; Coleman, HG; Mc Menamin, ÚC; Murray, LJ; Sanni, OB; Sharp, L, 2017)	0.46
" Further, aspirin dosage did not impact growth outcomes or presenting tumor diameter."	( Vestibular Schwannoma Growth With Aspirin and Other Nonsteroidal Anti-inflammatory Drugs. Bennett, ML; Haynes, DS; Hunter, JB; O'Connell, BP; Rivas, A; Thompson, RC; Wanna, GB, 2017)	1.14
" If feasible, LMWH in therapeutic dosing should be avoided, and ASA should be discontinued."	( Influence of acetylsalicylic acid and low-molecular weight heparins on the formation of renal hematoma after shock wave lithotripsy. John, H; Keller, I; Randazzo, M; Schregel, C, 2017)	0.46
"The objective of this test series was to elucidate the importance of selecting the right media composition for a biopredictive in-vitro dissolution screening of enteric-coated dosage forms."	( Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets. Karkossa, F; Klein, S, 2017)	0.66
"Current practice of weight-based aspirin dosing may lead to subtherapeutic platelet inhibition in some children."	( Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery. DiNardo, JA; Emani, S; Emani, SM; Mulone, M; Trenor, CC; Zurakowski, D, 2017)	1.04
" Ninety-two percent had the dosage correct, 76% knew how long to take the medication, and 100% of the sample was still taking the ASA; 40% had forgotten to take 1 or more doses of the medication."	( Self-Reported Rates of Adherence to Aspirin Prescribed as an Antithrombotic Therapy Following Postoperative Total Joint Replacement. Carter, J; Higgins, M; Jacob, A; Johnson, I; Samms-McPherson, J; Shapiro, S; Winterboer, DS; Wittig-Wells, D, )	0.41
"The optimal dosing of novel oral P2Y12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians."	( A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Bang, J; Jin, C; Kim, MH; Serebruany, V, )	0.13
" There was no standardized dosing protocol, with respondents using ASA 325 mg once (46%) or twice daily (26%) or ASA 81 mg once (18%) or twice (10%) daily."	( Deep Venous Thrombosis Prophylaxis in Anterior Cruciate Ligament Reconstructive Surgery: What Is the Current State of Practice? Bush-Joseph, CA; Dines, JS; Keller, RA; Limpisvasti, O; Moutzouros, V, )	0.13
" Of those using ASA, there was no prevailing dosing protocol."	( Deep Venous Thrombosis Prophylaxis in Anterior Cruciate Ligament Reconstructive Surgery: What Is the Current State of Practice? Bush-Joseph, CA; Dines, JS; Keller, RA; Limpisvasti, O; Moutzouros, V, )	0.13
" Personalized dosing of DHA in those who take aspirin may be a beneficial option for patients with type 2 diabetes mellitus."	( Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus. Abdolahi, A; Block, RC; Holub, A; Mousa, SA; Oda, MN; Tu, XM, 2017)	1.1
" Screening modalities, target population, and aspirin dosage are still a matter of debate."	( Aspirin for Prevention of Preeclampsia. Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2017)	2.16
" Additional studies are needed to assess the relationship between caffeine dosing and clinical benefits in patients with TTH and migraine."	( Caffeine in the management of patients with headache. Diener, HC; Garas, SY; Lipton, RB; Patel, K; Robbins, MS, 2017)	0.46
" No duration of use or dose-response association was apparent."	( Low-dose aspirin and risk of intracranial bleeds: An observational study in UK general practice. Bromley, S; Cea Soriano, L; Gaist, D; García Rodríguez, LA; Soriano-Gabarró, M, 2017)	0.87
"Considering parachute as a "home-made" dosage form, we have applied the dissolution testing to characterize the dissolution performance of a substance wrapped into a parachute and to characterize whether a parachute represents an immediate-release form or not."	( Parachuting psychoactive substances: Pharmacokinetic clues for harm reduction. Baumevieille, M; Daveluy, A; Géniaux, H; Guéroult, P; Haramburu, F; Lazès-Charmetant, A; Létinier, L; Matta, MN, 2018)	0.48
" We investigated if platelet aggregation increased during the standard 24-hour aspirin dosing interval in patients with T2DM compared to non-diabetic controls."	( Antiplatelet effect of aspirin during 24h in patients with type 2 diabetes without cardiovascular disease. Baier, JM; Funck, KL; Grove, EL; Hvas, AM; Laugesen, E; Poulsen, PL; Vernstrøm, L, 2018)	1.02
"After 6days of treatment, platelet aggregation levels increased during the 24-hour aspirin dosing interval in both patients and controls (p<0."	( Antiplatelet effect of aspirin during 24h in patients with type 2 diabetes without cardiovascular disease. Baier, JM; Funck, KL; Grove, EL; Hvas, AM; Laugesen, E; Poulsen, PL; Vernstrøm, L, 2018)	1.02
"Patients with T2DM without a history of CVD and controls had increased platelet aggregation at the end of the standard 24-hour dosing interval of aspirin."	( Antiplatelet effect of aspirin during 24h in patients with type 2 diabetes without cardiovascular disease. Baier, JM; Funck, KL; Grove, EL; Hvas, AM; Laugesen, E; Poulsen, PL; Vernstrøm, L, 2018)	0.99
" Rats in AEE-treated group were fed with HFD for 8 weeks to induce hyperlipidemia, and then given AEE once daily by oral gavage for 5 weeks at the dosage of 54 mg/kg body weight."	( Feces and liver tissue metabonomics studies on the regulatory effect of aspirin eugenol eater in hyperlipidemic rats. Dong, P; Jiao, Z; Kong, X; Li, J; Li, S; Liu, X; Ma, N; Qin, Z; Yang, Y, 2017)	0.69
" The high-degree of variable and indeterminate aspirin response indicates suboptimal adherence and/or dosing are more pressing factors to address to optimise aspirin effectiveness."	( Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. Alfirevic, A; Alfirevic, Z; Jorgensen, A; Navaratnam, K, 2018)	2.18
" However, meta-analyses of randomized controlled trials that examined the effect of aspirin in relation to gestational age at onset of therapy and dosage of the drug reported that significant reduction in the risk of preeclampsia and small-for-gestational-age neonates is achieved only if the onset of treatment is at ≤16 weeks of gestation and the daily dosage of the drug is ≥100 mg."	( Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Bujold, E; Nicolaides, KH; Roberge, S, 2018)	0.99
"We aimed to estimate the effect of aspirin on the risk of placental abruption or antepartum hemorrhage in relation to gestational age at onset of therapy and the dosage of the drug."	( Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Bujold, E; Nicolaides, KH; Roberge, S, 2018)	1.04
" The bell/U-shaped dose-response curves seen with vitamin D and resveratrol might apply to other phytochemicals, shedding doubt on 'more is better'."	( Could Aspirin and Diets High in Fiber Act Synergistically to Reduce the Risk of Colon Cancer in Humans? Arnold, M; Huang, YW; Oshima, K; Pan, P; Wang, LS; Yearsley, M; Yu, J; Zhang, J, 2018)	0.96
" The genetic variants of vitamin K expoxide reductase might account for the universally lower warfarin dosage used in Chinese population."	( Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy. Chen, H, 2019)	0.77
" Direct oral anticoagulants (DOACs): For long-term secondary prevention, a reduced dosing regimen of DOACs was found to be effective with a low bleeding risk."	( [Prolonged Secondary Prevention After Venous Thromboembolism]. Bauersachs, R, 2018)	0.48
" Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant."	( Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. Chen, J; Gao, R; Huang, X; Qiao, S; Tang, YD; Wang, W; Wu, Y; Xu, B; Yan, H; Yang, M; Yang, Y; Zhang, K, 2018)	0.48
" Bivariate correlation and multivariate logistic regression were used to analyze associations between patient characteristics and need for repeated dosing of aspirin."	( Factors correlated with repeated aspirin dosing during aspirin desensitization. Baldwin, JL; Baptist, AP; Schuler, CF, 2018)	0.96
" Though there are a lot of trials about usage of ASA for first and secondary MACE prevention still there are unmet clinical needs - dosage choice, the therapy length, diagnostic and management of ASA resistance, and also the prophylaxis of gastro-enteric hemorrhages."	( [Selection of antiplatelet therapy for patients with stable angina]. Arkhipov, MV, )	0.13
"Many studies have found evidence that aspirin has protective effects against certain cancers, but quantitative dose-response data have been available only on a limited basis."	( Cumulative Dose Threshold for the Chemopreventive Effect of Aspirin Against Gastric Cancer. Banerjee, S; Chang, J; Kim, MH; Kim, WJ; Park, SM, 2018)	0.99
"The article presents a review of pharmacokinetics and pharmacodynamics of different acetylsalicylic acid (ASA) dosage forms."	( [Dosage forms and doses of acetylsalicylic acid: significance for clinical practice]. Tarlovskaya, EI, )	0.13
" This article focuses on physiopathological mechanisms and risk factors of pre-eclampsia and on the interest of early angiogenic biomarkers dosing during pregnancy, for the assessment of pre-eclampsia risk."	( [Pre-eclampsia prevention in 2018 in general population and in lupic women: At the dawn of a personalized medicine?] de Moreuil, C; Fauchais, AL; Lacut, K; Le Moigne, E; Merviel, P; Pan-Petesch, B; Pasquier, E; Tremouilhac, C, 2018)	0.48
"Metformin was associated with a reduced risk of HCC in a dose-response pattern."	( Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Tseng, CH, 2018)	0.48
" As the best ex vivo method of measuring ASA efficacy remains uncertain, we compared nine platelet function tests to assess responsiveness to three ASA dosing regimens in 24 T2D patients randomized in a three-treatment crossover design to ASA 100 mg/day, 200 mg/day, or 100 mg twice daily for 2-week treatment periods."	( Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes. Bethel, MA; Coleman, R; Dinsdale, R; Harrison, P; Holman, RR; Kennedy, I, 2019)	0.74
"A one-dose-fits-all approach to use of aspirin has yielded only modest benefits in long-term prevention of cardiovascular events, possibly due to underdosing in patients of large body size and excess dosing in patients of small body size, which might also affect other outcomes."	( Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Belch, JFF; Cook, NR; Gaziano, JM; Mehta, Z; Morimoto, T; Price, JF; Roncaglioni, MC; Rothwell, PM, 2018)	1.14
" Confounders included gender, age, smoking status, dosage of aspirin and clopidogrel, and BMI."	( Two common mutations within CYP2C19 affected platelet aggregation in Chinese patients undergoing PCI: a one-year follow-up study. Chen, W; Fu, Y; Li, W; Liu, Z; Tang, Y; Wang, W; Wang, Z; Zhang, X; Zhou, Z, 2019)	0.76
" Administration of ASA increased the infarct severity; however, concomitant dosing with NTG somewhat attenuated this effect."	( Nitroglycerin application and coronary arteriogenesis. Bramlage, P; Buschmann, IR; Dawid, R; Dülsner, A; Gatzke, N; Gorath, M; Güc, N; Hillmeister, P; Pagonas, N; Smith, KH, 2018)	0.48
"In this large case-control study, aspirin therapy at diagnosis was associated with a significantly decreased risk of subarachnoid hemorrhage, with an inverse dose-response relationship among aspirin users."	( Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: A case-control study. Cai, T; Can, A; Castro, VM; Dligach, D; Du, R; Finan, S; Gainer, V; Murphy, S; Rudy, RF; Savova, G; Shadick, NA; Weiss, ST; Yu, S, 2018)	1.08
" Targeted screening for subclinical coronary atherosclerosis with coronary artery calcium scores is prudent to guide appropriately dosed aspirin use to mitigate the increasing frequency of sports-related sudden cardiac death due to plaque rupture."	( Aspirin to Prevent Sudden Cardiac Death in Athletes with High Coronary Artery Calcium Scores. Noakes, TD; Siegel, AJ, 2019)	2.16
" As the drug has almost always to be formulated with excipients in the design of a dosage form, it is important to examine the implications of the choice of excipients on the dissolution of the drug, among others, especially in the case of an immediate release dosage form."	( A study of the impact of excipient shielding on initial drug release using UV imaging. Alaudin, MIB; Chua, SM; Heng, PWS; Hiew, TN, 2018)	0.48
" While the clinical significance of this interference is still unclear, this review sought to assess the body of literature which has evaluated the potential attenuation of the anti-platelet effect of aspirin when dosed concomitantly with an NSAID."	( A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. Gurbel, P; Tantry, U; Weisman, S, 2019)	0.93
" evening) dosing on the anti-aggregative effect of platelets in patients with CAD and arterial hypertension (AH)."	( The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial. Krasińska, B; Krasiński, M; Krasiński, Z; Miciak-Lawicka, E; Paluszkiewicz, L; Rzymski, P; Tykarski, A, 2019)	0.51
"In the group of patients with CAD and AH, bedtime ASA dosing is associated with a significant reduction in platelet aggregation."	( The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial. Krasińska, B; Krasiński, M; Krasiński, Z; Miciak-Lawicka, E; Paluszkiewicz, L; Rzymski, P; Tykarski, A, 2019)	0.51
" We used femtosecond laser ablation to rupture arterioles in the cortex of both young (2-5 months old) and aged (18-29 months old) mice dosed on aspirin in their drinking water and measured the extent of penetration of both red blood cells and blood plasma into the surrounding tissue."	( Aspirin treatment does not increase microhemorrhage size in young or aged mice. Brophy, M; Chan, S; Nishimura, N; Schaffer, CB, 2019)	2.16
"Long-term evidence supports a clustering of cardiovascular events in the early morning and smaller mechanistic studies in aspirin-treated patients have shown increased platelet reactivity at the end of the dosing interval."	( Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D, 2019)	0.72
"In order to mimic the standard dosing regimen for DAPT in human, various Sprague-Dawley rats treatment groups were received a bolus oral dose of DAPT on day 1 followed by DAPT for consecutive 13 days in absence and presence of orally co-administered four TCM herbs (Danshen, Gegen, Danggui and Chuanxiong) at their low and high doses."	( Impact of the Chinese herbal medicines on dual antiplatelet therapy with clopidogrel and aspirin: Pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats. Lee, P; Luo, X; Mok, C; Qian, C; Wu, C; Xiao, M; Yang, M; Zhang, Y; Zuo, Z, 2019)	0.74
" Dosing for neuroendovascular conditions is often extrapolated from the cardiac literature, although outcomes in cardiac patients may not be relevant to neurologic patients, making prophylactic treatment recommendations challenging for these patients."	( Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel-Hyporesponsive Patients. Barra, ME; Berger, K; Brophy, GM; Tesoro, EP, 2019)	0.51
" A randomised trial is needed to determine appropriate acetylsalicylic acid dosing in infants with modified Blalock-Taussig."	( High acetylsalicylic acid dosing in infants after modified Blalock-Taussig shunt. Allen, J; Boston, US; Cowan, KM; Jones, T; Joshi, AD; Knott-Craig, CJ; Kumar, STK; Nouer, SS; Saini, A; Shah, SH; Wayne Gatewood, C, 2019)	0.51
"Different dosage forms of ASA are characterized with similar efficacy in prevention of cardiovascular events and effects on the risk of bleeding."	( [Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease]. Erofeeva, SG; Karpukhina, EV; Nekrasov, AA; Timoshchenko, ES, 2019)	0.51
" We examined acute and chronic effects, and effects over the 24h dosing interval."	( Differential vascular effects of aspirin in people with Type 2 diabetes without cardiovascular disease and matched controls without diabetes. Baier, JM; Funck, KL; Grove, EL; Gullaksen, S; Hvas, AM; Laugesen, E; Poulsen, PL; Vernstrøm, L, 2019)	0.8
" Further, the effect of aspirin on endothelial function may be declining during a 24 h dosing interval in people with Type 2 diabetes."	( Differential vascular effects of aspirin in people with Type 2 diabetes without cardiovascular disease and matched controls without diabetes. Baier, JM; Funck, KL; Grove, EL; Gullaksen, S; Hvas, AM; Laugesen, E; Poulsen, PL; Vernstrøm, L, 2019)	1.1
" Pregnant women were in 1 of 4 groups (100 mg enteric coated, 100 mg non-enteric-coated, 150 mg non-enteric-coated morning dosing, and 150 mg non-enteric-coated evening dosing), whereas nonpregnant women undertook each of the 4 dosing schedules with at least a 30-day washout period."	( A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. Chau, K; Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Münch, G; Shanmugalingam, R; Wang, X; Xu, B, 2019)	0.74
" There was no difference in the total drug metabolite concentration of aspirin between enteric-coated and non-enteric-coated aspirin and between morning and evening dosing of aspirin."	( A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. Chau, K; Fulcher, I; Hennessy, A; Kumar, R; Lee, G; Makris, A; Münch, G; Shanmugalingam, R; Wang, X; Xu, B, 2019)	0.97
" In Part A, rivaroxaban pharmacokinetics, pharmacodynamics, safety, and tolerability are assessed to validate the pediatric dosing selected."	( Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). Bonnet, D; Dong, X; Harris, KC; Jefferies, J; Justino, H; Li, JS; McCrindle, BW; Michelson, AD; Pina, LM; Samtani, MN; Zhang, L, 2019)	0.51
" Avoidance of nephrotoxic and teratogenic medications is necessary, and renal dosing of commonly used medications must also be considered."	( Chronic Kidney Disease and Pregnancy. Hladunewich, MA; Hui, D, 2019)	0.51
"We did not find evidence to suggest aspirin dose-response differed by body composition measurements, including weight alone."	( Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. Ahnen, DJ; Baron, JA; Barry, EL; Mott, LA; Passarelli, MN; Rees, JR, 2019)	1.11
"Aspirin dosing strategies accounting for body weight suggested in previous trials of colorectal cancer may not apply to adenomas."	( Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. Ahnen, DJ; Baron, JA; Barry, EL; Mott, LA; Passarelli, MN; Rees, JR, 2019)	2.28
" In addition, most studies reported a decline in corticosteroid dosage (oral and inhaled)."	( Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. Li, R; Luo, F, 2020)	0.87
" However, the long-term adverse effects of Aspirin desensitization and optimal dosage of Aspirin merit further investigation."	( Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. Li, R; Luo, F, 2020)	1.13
" We took into account several criteria like statin dosage (low versus high intensity) and presence of contraindication for consideration of optimal therapy."	( Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study. Bruggmann, C; Fesselet, R; Gex-Fabry, M; Iglesias, JF; Sadeghipour, F; Vogt, P; Voirol, P, 2020)	0.56
" Postoperative outcomes of patients receiving ASA prior to TJA, dosing of ASA (81 mg or 325 mg) preoperatively and postoperatively, and the time of preoperative discontinuation (no ASA, <4 days, <7 days, and 7 or more days) were compared."	( Effect of Acetylsalicylic Acid Dose and Time Discontinued Preoperatively on Outcomes After Total Knee and Hip Arthroplasty. Charters, M; Kadri, OM; Les, CM; Shaw, JH, 2019)	0.51
" This information is vital if we are to deduce the suitability, optimal timing and dose of aspirin and/or a specific COX-2 inhibitor (most likely using modified forms that do not cross the placenta) that can then be tested in a randomized, controlled trial instead of the current practice of empirical dosing regimens."	( Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition? Danser, AHJ; Mirabito Colafella, KM; Neuman, RI; Versmissen, J; Visser, W, 2020)	2.22
" Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen."	( Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019)	1.03
" Key unresolved questions regarding the role of aspirin in primary prevention include the optimal drug formulation, dosing schedule, weight-based dose selection, and interplay between sex and treatment response."	( Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Harrington, RA; Hernandez, AF; Jones, WS; Marquis-Gravel, G; Muñoz, D; Roe, MT, 2019)	1.08
" Future studies should have clearly identified and comparable outcome measures, with direct comparisons and assessment of intervention combination, dosing and treatment duration."	( Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence. Fletcher, JP; Hitos, K; Seagrave, KG, 2019)	1.96
" On-demand, local delivery of anti-inflammatory drugs to target tissues provides an approach for more effective drug dosing while reducing the adverse effects of systemic drug delivery."	( Adaptive in vivo device for theranostics of inflammation: Real-time monitoring of interferon-γ and aspirin. Cao, C; Chen, X; Jin, R; Liu, G; Liu, GJ; Liu, Z; Ni, S; Wei, H; Young, HA, 2020)	0.77
" This article reviews landmark clinical trials of aspirin in primary prevention and highlights key changes in dosing strategies and demographics."	( Aspirin for the Primary Prevention of Cardiovascular Disease: A Review of the Literature and Considerations for Clinical Practice. Cicci, JD; Clarke, MM; Iyer, P; Mazzella, AJ, )	1.83
" Furthermore, the bioavailability of the APIs from the dosage form depends largely on these characteristics."	( Fiber-Array-Based Raman Hyperspectral Imaging for Simultaneous, Chemically-Selective Monitoring of Particle Size and Shape of Active Ingredients in Analgesic Tablets. Frosch, T; Popp, J; Wyrwich, E; Yan, D, 2019)	0.51
" At the same time, the dosage and duration of aspirin use had no statistical influence on the risk of PCSM in high/low risk PC."	( Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis. Li, T; Liu, R; Xia, S; Zhou, J, 2019)	1.25
" This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC."	( Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. Clark, C; Dang, M; Day, AS; Kontogiannis, V; Rahmani, J; Ryan, PM; Salehisahlabadi, A; Varkaneh, HK; Wang, S; Yu, Y; Zhang, Y, 2020)	1.14
" Oral dosing with vehicle, ticagrelor (300mg/kg/d), aspirin (20mg/kg/d), their combination or prasugrel (15mg/kg/d) started 7days after infarction."	( Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Birnbaum, Y; Chen, H; Nylander, S; Sampaio, LC; Tran, D; Ye, Y, 2019)	0.76
" We found no indication of a dose-response association according to increasing tablet strength, cumulative amount or duration of use, and the HRs were similar for pre-diagnostic and post-diagnostic low-dose aspirin use compared with non-use."	( Low-dose aspirin use and endometrial cancer mortality-a Danish nationwide cohort study. Aalborg, GL; Dehlendorff, C; Friis, S; Kjaer, SK; Sperling, CD; Verdoodt, F, 2020)	1.16
"We analysed hospitalized patients who ingested ASA at least 30 min prior to metamizole (recommended dosing group, n = 15), metamizole prior or simultaneously with ASA (not recommended dosing group, n = 16) and patients with unknown or mixed intake (mixed dosing group, n = 5)."	( Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity. Bertsche, T; Dietze, C; Gockel, I; Josten, C; Kaiser, T; Petros, S; Pfrepper, C; Remane, Y; Schiek, S, 2020)	0.96
"Maximum AA-induced LTA prior to the intake of ASA was significantly lower and the rate of high on treatment platelet reactivity (HTPR) higher in the recommended compared with the not recommended dosing group (19."	( Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity. Bertsche, T; Dietze, C; Gockel, I; Josten, C; Kaiser, T; Petros, S; Pfrepper, C; Remane, Y; Schiek, S, 2020)	0.96
" An initial dosing study performed in healthy mice indicates that aspirin at a dose of 25 mg/kg/d has a similar pharmacodynamic effect as low-dose aspirin treatment in human subjects (100 mg/d)."	( Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis. Hartung, NM; Kühl, AA; McDonald, FM; Ostermann, AI; Rohwer, N; Schebb, NH; Weylandt, KH; Zopf, D, 2020)	1.09
" Here we describe the results of 3 studies that evaluated the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects."	( Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)	0.98
"Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question."	( Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. Ahmad, FS; Alvarado, G; Benziger, CP; Berdan, LG; Bradley, SM; Daugherty, SE; Effron, MB; Farrehi, P; Faulkner, M; Fintel, DJ; Fonarow, GC; Ford, DE; Geary, C; Girotra, S; Goldberg, YH; Gupta, K; Hammill, BG; Harrington, RA; Haynes, K; Hernandez, AF; Jain, SK; Jones, WS; Kraschnewski, J; Kripalani, S; Lampert, BC; Marquis-Gravel, G; McClay, JC; McTigue, KM; Merritt, JG; Metkus, T; Muñoz, D; Nallamothu, BK; Nauman, E; Pencina, MJ; Re, RN; Robertson, HR; Roe, MT; Roger, VL; Rothman, R; Seifein, H; Shah, RC; VanWormer, JL; Whittle, J; Zhou, L, 2020)	1.14
"To report the rationale and design for a randomized clinical trial to determine the optimal dosage of aspirin to be used for secondary prevention of ASCVD, using an innovative research method."	( Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. Ahmad, FS; Alvarado, G; Benziger, CP; Berdan, LG; Bradley, SM; Daugherty, SE; Effron, MB; Farrehi, P; Faulkner, M; Fintel, DJ; Fonarow, GC; Ford, DE; Geary, C; Girotra, S; Goldberg, YH; Gupta, K; Hammill, BG; Harrington, RA; Haynes, K; Hernandez, AF; Jain, SK; Jones, WS; Kraschnewski, J; Kripalani, S; Lampert, BC; Marquis-Gravel, G; McClay, JC; McTigue, KM; Merritt, JG; Metkus, T; Muñoz, D; Nallamothu, BK; Nauman, E; Pencina, MJ; Re, RN; Robertson, HR; Roe, MT; Roger, VL; Rothman, R; Seifein, H; Shah, RC; VanWormer, JL; Whittle, J; Zhou, L, 2020)	1.07
"As a pragmatic study and the first interventional trial conducted within the PCORnet electronic data infrastructure, this trial is testing several unique and innovative operational approaches that have the potential to disrupt and transform the conduct of future patient-centered randomized clinical trials by evaluating treatments integrated in clinical practice while at the same time determining the optimal dosage of aspirin for secondary prevention of ASCVD."	( Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. Ahmad, FS; Alvarado, G; Benziger, CP; Berdan, LG; Bradley, SM; Daugherty, SE; Effron, MB; Farrehi, P; Faulkner, M; Fintel, DJ; Fonarow, GC; Ford, DE; Geary, C; Girotra, S; Goldberg, YH; Gupta, K; Hammill, BG; Harrington, RA; Haynes, K; Hernandez, AF; Jain, SK; Jones, WS; Kraschnewski, J; Kripalani, S; Lampert, BC; Marquis-Gravel, G; McClay, JC; McTigue, KM; Merritt, JG; Metkus, T; Muñoz, D; Nallamothu, BK; Nauman, E; Pencina, MJ; Re, RN; Robertson, HR; Roe, MT; Roger, VL; Rothman, R; Seifein, H; Shah, RC; VanWormer, JL; Whittle, J; Zhou, L, 2020)	1.02
" Therefore, the goal of this paper was to create a physiologically based pharmacokinetic (PBPK) model to offer a reasonable starting point for required total AT-RvD1 dosage to be administered in future mice and humans thereby eliminating the need for excessive use of animals and humans in preclinical and clinical trials, respectively."	( Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome. Baker, OJ; Yellepeddi, VK, 2020)	0.87
" Additionally, the controlled release of a high dose of drug allows for lower dosing over an extended period."	( A hybrid 3D-printed aspirin-laden liposome composite scaffold for bone tissue engineering. Bai, Y; Fu, X; Fuh, JYH; Li, H; Li, Q; Li, Y; Luo, Z; Pan, J; Shi, R; Wang, H; Wei, S; Xu, X, 2019)	0.84
" The antiplatelet response to low-dose aspirin can be markedly improved by shortening the dosing interval to 12 hours, with no improvement with further reductions (EudraCT 2016-002885-30)."	( A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Beggiato, E; Bertozzi, I; Betti, S; Bucelli, C; Carli, G; Carpenedo, M; Cattaneo, D; Cavalca, V; De Stefano, V; Di Ianni, M; Dragani, A; Elli, EM; Iurlo, A; Lanzarone, G; Palandri, F; Paoli, C; Patrono, C; Petrucci, G; Porro, B; Ranalli, P; Randi, ML; Ricco, A; Rocca, B; Rodeghiero, F; Rossi, E; Ruggeri, M; Soldati, D; Specchia, G; Timillero, A; Tosetto, A; Vannucchi, AM; Vianelli, N, 2020)	1.1
"The process of gastric emptying is of major importance for the in vivo performance of immediate release dosage forms."	( Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. Koziolek, M; Sager, M; Schick, P; Voelker, M; Weitschies, W, 2020)	0.77
" It has been proposed that shortening the ASA dosing interval may overcome the time-dependent renewal of the drug target, leading to a greater antiplatelet effect."	( Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis. Caldeira, D; Costa, J; Duarte, GS; Ferreira, J; Mainoli, B, 2021)	0.92
" Low-risk patients receive aspirin 81 mg twice daily for VTE prophylaxis; this dosing regimen has been reduced over the past few years from 325 mg to 162 mg to 81 mg twice daily."	( Interaction Between Low-Dose Aspirin and Nonsteroidal Anti-Inflammatory Drugs Can Compromise Aspirin's Efficacy in Preventing Venous Thrombosis Following Total Joint Arthroplasty. Cronin, M; Dengler, N; Krauss, E; Segal, A, )	0.72
" Notably, slow addition of any of the four therapeutics to cultured macrophages, mimicking the slowly increasing plasma concentration reported for standard oral dosage in patients, yielded no detectable change in pseudopod morphology."	( Rapid exposure of macrophages to drugs resolves four classes of effects on the leading edge sensory pseudopod: Non-perturbing, adaptive, disruptive, and activating. Buckles, TC; Djukovic, D; Falke, JJ; Ziemba, BP, 2020)	0.56
" The 200 mg/kg BW aspirin treatment was dosed as a 100 mg/kg BW aspirin oral bolus 36 and 24 h prior to Cr-ethylenediaminetetraacetic acid (EDTA) dosing (1 liter; 180 mM)."	( Use of aspirin to intentionally induce gastrointestinal tract barrier dysfunction in feedlot cattle. Brennan, KM; Briggs, NG; Funnell, BJ; Nicholls, GT; Schoonmaker, JP, 2020)	1.35
" These inconsistencies, however, can be largely explained by a high degree of heterogeneity regarding the selection of trial participants, baseline risk of the included women, dosage of aspirin, gestational age of prophylaxis initiation, and preeclampsia definition."	( Prevention of preeclampsia with aspirin. Nicolaides, KH; Poon, LC; Rolnik, DL, 2022)	1.2
" However, metformin use among patients with diabetes was associated with a reduction in gastric cancer mortality in a dose-response manner."	( Association of Aspirin, Metformin, and Statin Use with Gastric Cancer Incidence and Mortality: A Nationwide Cohort Study. Cho, MH; Jeong, SM; Shin, DW; Yoo, TG, 2021)	0.97
"001) in a dose-response fashion, and these associations were prominent among participants with a metformin cumulative defined daily dose of 547."	( The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data. Cho, JH; Cho, M; Jeong, SM; Kang, J; Kim, J; Shin, DW, 2021)	0.94
"Controlled studies are needed to confirm the clinical outcome value of twice-daily vs once-daily aspirin dosing and the therapeutic role of pegylated interferons and direct oral anticoagulants."	( Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Barbui, T; Tefferi, A, 2020)	0.78
"All available articles that compared different dosage of aspirin in the acute-phase of KD published until 20 September 2019 were included from the databases of PubMed, Embase and Cochrane Central Register of Controlled Trials Central without language restrictions."	( Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review. Chiang, MH; Liu, HE; Wang, JL, 2021)	1.22
" alternative dosing regimen, diet restriction, were seen as barriers to some patients and caregivers."	( Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study. Chiu, PKC; Jamieson, E; Kng, CPL; Lam, MPS; Ng, VWS; Siu, CW; Wong, ICK, 2020)	0.79
" It also reduced the dosage of levetiracetam and achieved better control of epilepsy compared to levetiracetam mono-treatment."	( Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020)	0.85
"Atorvastatin and aspirin co-treatment with levetiracetam can reduce epilepsy in PSE patients and reduce the dosage of levetiracetam required for effective control of PSE."	( Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020)	1.19
" Uncertainty about aspirin dosage and perceived strength of the evidence, precise wording of the recommendation, previous changes to guidelines about aspirin and conflicting findings from trials in older populations were barriers to implementation."	( Clinicians' opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50-70 years: a qualitative study. Alphonse, P; Emery, J; Karnchanachari, N; Lau, P; Macrae, F; McIntosh, J; Milton, S; Nguyen, P; Saya, S; Yogaparan, T, 2021)	1.22
" Patients received alternative drug dosing or antiplatelet agents other than clopidogrel only if this was prescribed for another diagnosis or they had a preexisting contraindication."	( Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. Hess, NR; Kilic, A; Sultan, I; Thoma, F; Wang, Y, 2021)	0.98
" A comparative analysis is also tabulated with different dosing regimens which shows that a combination of nutlin-3a and a low dose of aspirin provides better results than a high dose of aspirin."	( Effect of pharmacodynamical interaction between nutlin-3a and aspirin in the activation of p53. Aslam, M; Awan, MS; Bhatti, AI; Liaquat, A; Liaquat, M, 2021)	1.07
" Aspirin use was defined as one or more prescriptions, and the maximum defined daily dose was used to evaluate the dose-response relationship."	( Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort. Chan, C; Chen, CJ; Chen, YJ; Hsieh, RJ; Huang, C; Huang, CP; Huang, YH; Jackson, SS; Koshiol, J; Lee, MH; Liao, SF; Liu, PC; Lu, SN; Shen, CY, 2021)	1.89
" Dosing of 100 mg Aspirin was maintained if testing revealed a sufficient platelet inhibition."	( Low Dose Aspirin in high-risk pregnancies: The volatile effect of acetylsalicylic acid on the inhibition of platelets uncovered by G. Born's light transmission aggregometry. Cervar-Zivkovic, M; Eberhard, K; Kutllovci-Hasani, K; Mayer-Pickel, K; Nanda, M; Prüller, F; Stern, C; Weiss, EC, 2021)	1.37
"Previous studies have shown that aspirin is noninferior to other anticoagulation therapies in preventing postoperative venous thromboembolism following lower extremity arthroplasty or revision; however, its optimal dosing for this indication is less clear."	( A Retrospective Analysis Comparing Post-Operative Bleeding with Various Doses of Aspirin after Lower Extremity Joint Arthroplasty or Revision. Cornett, B; Dziadkowiec, O; Harkness, W; Hassan, S; Hicks, ME; Jenkins, P; Kopstein, M; Scherbak, D; Watts, PJ, 2021)	1.13
" Laboratory studies suggest that a twice-daily dosing regimen or evening intake may lead to more efficient platelet inhibition, and the potential clinical benefit of such strategies is currently being explored in ongoing clinical trials."	( Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. Christiansen, M; Grove, EL; Hvas, AM, 2021)	0.91
" From the beginning of the pregnancy to the end of the puerperium, the low dosage aspirin group (n = 129), the labetalol group (n = 127), and the drug-free or control group (n = 126) reported both mother and child results."	( Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020)	1.01
" The purpose of this study is to evaluate a weight-based aspirin dosing regimen for prevention of venous thromboembolism (VTE) following TJA."	( Weight-Based Aspirin Dosing May Further Reduce the Incidence of Venous Thromboembolism Following Primary Total Joint Arthroplasty. Brown, TS; Gulbrandsen, TR; Halbur, CR; Noiseux, NO; West, CR, 2021)	1.24
" A weight-based aspirin dosing regimen for VTE prophylaxis was administered to 1247 patients: patients weighing ≥120 kg received 325 mg aspirin twice daily (BID) and those weighing <120 kg received 81 mg aspirin BID for 4 weeks."	( Weight-Based Aspirin Dosing May Further Reduce the Incidence of Venous Thromboembolism Following Primary Total Joint Arthroplasty. Brown, TS; Gulbrandsen, TR; Halbur, CR; Noiseux, NO; West, CR, 2021)	1.34
" In the current work, two different high precision sensitive fluorescence spectroscopic methods were developed for quantitative analysis of the above drugs in pharmaceutical dosage form and spiked human plasma."	( Application of different spectrofluorimetric approaches for quantitative determination of acetylsalicylic acid and omeprazole in recently approved pharmaceutical preparation and human plasma. Abdelazim, AH; Almrasy, AA; El-Olemy, A; Hasan, MA; Madkour, AW; Ramzy, S; Shahin, M, 2021)	0.62
" To increase adherence to ASA and n3 PUFA supplementation, combination dosage form may be required to improve outcomes."	( Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022)	2.16
" Inadequate initial dosing appears to be the primary reason for aspirin resistance."	( Aspirin resistance in infants with shunt-dependent congenital heart disease. Cooper, DS; Henry, B; Koh, W; Nebbia, A; Rodts, M; Sawyer, J, 2022)	2.4
"A recent combination of aspirin (ASP) and omeprazole (OMP) has been presented in a fixed dosage form for the treatment of many cardiovascular diseases, particularly in patients with gastric diseases."	( Spectrophotometric Determination of Aspirin and Omeprazole in the Presence of Salicylic Acid as a Degradation Product: A Comparative Evaluation of Different Univariate/Multivariate Post Processing Algorithms. Badrawy, M; El-Mammli, MY; Elmasry, MS; Hassan, WS; Serag, A, 2022)	1.3
"A dosage of 100 mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation, did not reduce the incidence of preeclampsia in pregnant women with high-risk factors in China."	( A randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in women at high risk in China. Chen, D; Chen, J; Cui, S; Ding, H; Huai, J; Juan, J; Li, B; Li, G; Li, X; Lin, L; Ma, Y; Mi, Y; Qi, H; Sun, X; Yang, H; Yu, M; Zhang, H; Zhang, M; Zhang, W; Zhao, X; Zhao, Y; Zhu, Y, 2022)	1.3
"Although low-dose aspirin is well established in PV, its indications and dosing regimens are less clear in ET."	( Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. Hobbs, G; How, J, 2021)	0.96
" The UNIVERSE Study evaluated the efficacy and safety of a novel liquid rivaroxaban formulation, using a body weight-adjusted dosing regimen, versus acetylsalicylic acid (ASA) in children post-Fontan."	( Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. Harris, KC; Jefferies, JL; Justino, H; Li, JS; Lu, W; McCrindle, BW; Michelson, AD; Miriam Pina, L; Nessel, K; Pablo Sandoval, J; Peluso, C; Suzana Horowitz, E; Van Bergen, AH, 2021)	0.62
" Six smart and different spectrophotometric methods were developed for the analysis of omeprazole and aspirin in binary mixture and pharmaceutical dosage form."	( Earth friendly spectrophotometric methods based on different manipulation approaches for simultaneous determination of aspirin and omeprazole in binary mixture and pharmaceutical dosage form: Comparative statistical study. Badrawy, M; El-Mammli, MY; Elmasry, MS; Hassan, WS, 2022)	1.15
" The collection days (CD) were the second and seventh days after stable aspirin dosing and then a convalescent time point 2-9 months later."	( Urinary 11-dehydrothromboxane B2 aspirin efficacy testing is sensitive to perioperative inflammation in pediatric solid-organ transplant patients. Boucher, AA; Francisco, BJ; Luchtman-Jones, L; Martin, J; Martin, M; Nathan, JD; Pfeiffer, A; Shova, A; Tiao, GM, 2022)	1.23
" Using mRNA sequencing of purified platelets collected before and after each 4-week exposure, we identified 208 aspirin-responsive genes with no evidence for dosage effects."	( Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. Dave, S; Ginsburg, GS; Myers, RA; Ortel, TL; Voora, D; Waldrop, A, 2022)	2.38
"In patients with STEMI ischemia, giving nitroglycerin 10 min after aspirin dosing (compared to giving them simultaneously) leads to a greater than 20% reduction in need for additional nitroglycerin, a greater than 7% decrease in subjective pain experienced by the patient and reduced need for additional opioids."	( The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome. Todoroski, KB, 2021)	1.15
" After culture, embryo morphological and developmental parameters were documented using standardized scoring systems at each dosage concentration."	( Assessment of embryo morphology following perinatal exposure to aspirin, ibuprofen and paracetamol using whole embryo culture system. Leung, BW; Leung, TY; Moungmaithong, S; Poon, LC; Sahota, DS; Wang, CC, 2022)	0.96
" Aspirin, a key antiplatelet agent, has inconsistent effects on outcomes in diabetes and the best dosing regimen remains unclear."	( A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. Ajjan, RA; Grant, PJ; Hawkins, F; Kurdee, Z; Naseem, KM; Parker, WAE; Sagar, R; Storey, RF, 2021)	1.77
" When women at ≤ 16 gestational weeks started treatment with a dosage of < 100 mg/day aspirin, there was a significant reduction in the incidence of preeclampsia (RR = 0."	( The role of aspirin dose and initiation time in the prevention of preeclampsia and corresponding complications: a meta-analysis of RCTs. Dai, C; He, Q; Huang, X; Lee, W; Li, L; Li, R; Luo, Z; Mok, TN; Yip, KC; Zeng, W, 2022)	1.32
" A renal biopsy was not performed to identify the cause of the injury as it showed improvements after the start of the specific therapy for Kawasaki disease; intravenous immune globulin at a dose of 2 g/kg, aspirin at a high dosage of 80 mg/kg/day, and prednisolone at 2 mg/kg."	( Nontypical presentation of a common disease: a case report. Abdulrahman, A; Al Qahtani, F; Aldajani, A; Alhaji, M; Alshammasi, W; Bargawi, A, 2022)	0.91
"Following a cohort of 388,443 cancer patients diagnosed between October 2005 and December 2014 in Sweden, we ascertained dispense of aspirin or non-aspirin NSAIDs from 3 months before cancer diagnosis onward and defined the on-medication period as from date of drug dispense until the prescribed dosage was consumed."	( NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden. Fall, K; Fang, F; Shen, Q; Sjölander, A; Sloan, EK; Smedby, KE; Sparén, P; Valdimarsdottir, U; Walker, AK, 2022)	0.93
" However, the indications for the use of aspirin during pregnancy is currently controversial because the dosage of aspirin used and the sample sizes in various studies differ considerably."	( Aspirin in the prevention of preeclampsia: A protocol for systematic review and meta analysis. Dorsamy, V; Khaliq, OP; Mkhize, PZ; Moodley, J; Phoswa, WN, 2021)	2.33
" Previous pharmacokinetic and pharmacodynamic studies have suggested that the aspirin formulation (enteric-coated) and dosing schedule (once daily) studied in randomized trials for primary prevention of CV events defining contemporary clinical practice may not leverage the full potential of the drug, particularly in patients with diabetes."	( Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. Bloom, S; Del Bianco-Rondeau, M; Lordkipanidzé, M; Marquis-Gravel, G; Rabasa-Lhoret, R; Robert-Halabi, M; Tardif, JC, 2022)	2.39
" This is of particular importance as starch is a common excipient in solid dosage forms."	( Impact of Amylose-Amylopectin Ratio of Starches on the Mechanical Strength and Stability of Acetylsalicylic Acid Tablets. Heng, PWS; Liew, CV; Veronica, N, 2022)	0.72
" Results: the obtained\ results displayed that the serial concentration dose-response has a significant inhibition effect of blood vessels growth\ when compared to the negative control (DMSO 1%), the dose depended percentage of inhibition, sweet almond oil in\ combination with aspirin synergism effect to inhibition growth blood vessels as anti-angiogenic activity."	( Antiangiogenic Activity of Sweet Almond (Prunus dulcis) Oil Alone and in Combination with Aspirin in both in vivo and in vitro Assays. Ali, ZK; Sahib, HB, 2022)	1.12
" To better understand this apparent paradox, we measured ARS gene expression and score in volunteers to determine aspirin dose-response and ticagrelor relationships with ARS score and separately in patients to assess whether ARS is associated with incident bleeding."	( An antiplatelet response gene expression signature is associated with bleeding. Friede, KA; Gales, J; Ginsburg, GS; Kraus, WE; Myers, RA; Ortel, TL; Shah, SH; Voora, D; Zhbannikov, I, 2023)	1.12
"In the present work, we report a method based on micellar liquid chromatography coupled with ultraviolet detection (MLC/UV), for the simultaneous quantification of combined anti-platelet therapy namely, clopidogrel bisulfate (CPS), aspirin (ASP), together with salicylic acid (SA), in their pharmaceutical dosage form."	( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations. Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022)	0.9
"The MLC/UV method was successfully applied to the quantitative analysis of CPS, ASP together with SA-as a main degradation product of ASP-in their pharmaceutical dosage form."	( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations. Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022)	0.72
"The developed method was successfully applied for the determination of clopidogrel bisulfate (CPS), aspirin (ASP), together with salicylic acid (SA), in their pharmaceutical dosage form."	( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations. Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022)	0.94
" Dose-response and therapeutic window were investigated."	( Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window. Bazan, NG; Belayev, L; Khoutorova, L; Mukherjee, PK; Obenaus, A; Oria, RB; Petasis, NA; Reid, MM; Roque, CR, 2022)	0.72
"The presentation of 3D printing in drug innovation especially focuses on the advancement of patient-centered dosage forms based on the structural design."	( A Recent Review On 3D-Printing: Scope and Challenges with Special Focus on Pharmaceutical Field. Doolaanea, AA; Kumar, M; Mandal, UK; Singh, S, 2022)	0.72
" Optimal acetylsalicylic acid (ASA) dosage would facilitate antimicrobial effects while avoiding over-aggressive inhibition of platelet antimicrobial function."	( Low-Dose Aspirin for Venous Thromboembolism Prophylaxis is Associated With Lower Rates of Periprosthetic Joint Infection After Total Joint Arthroplasty. Bernthal, NM; Ciesielka, KA; Kendal, JK; Najafi, F; Parvizi, J; Peterson, NV; Restrepo, C, 2022)	1.14
"Combination therapy has become the hallmark of lung cancer treatment, as it reduces the dosage intensity of individual drugs while increasing their efficacy."	( The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer. Li, N; Song, B; Xu, M; Yang, X, 2022)	1
"A computational approach involving mathematical modeling and in silico experiments was used to characterize the determinants of extent and duration of platelet cyclooxygenase (COX)-1 inhibition by aspirin and design precision dosing in patients with accelerated platelet turnover or reduced drug bioavailability."	( Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing. Giaretta, A; Petrucci, G; Rocca, B; Toffolo, GM, 2022)	1.15
" We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets."	( Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G, 2022)	0.72
"The AXIOMATIC-SSP trial will evaluate the dose-response of milvexian for ischemic stroke occurrence in participants with ischemic stroke or TIA."	( Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G, 2022)	0.72
" The purpose of this study was to assess the effect of aspirin on clinical outcomes in patients with HCC in a meta-analysis and to explore the possible dose-response relationship."	( Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis. Bentley, R; Feng, L; Gao, J; Jiang, Y; Kim, NH; Li, N; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Q; Zhu, Y, 2023)	1.67
" A linear relationship was found for both dosage and duration of aspirin use."	( Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis. Bentley, R; Feng, L; Gao, J; Jiang, Y; Kim, NH; Li, N; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Q; Zhu, Y, 2023)	1.66
"10]), compared with never use, and there was no evidence of a dose-response relation."	( Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study. Cairat, M; Dossus, L; Fournier, A; Hicks, B; Olesen, M; Pottegård, A, 2023)	0.91
" Key consensus points include efforts to improve medical adherence through deprescribing and polypill use; adoption of universal risk definitions for bleeding, myocardial infarction, stroke and cause-specific death; multiple bleeding-avoidance strategies, ranging from gastroprotection with aspirin use to selection of antithrombotic-drug composition, dosing and duration tailored to multiple variables (setting, history, overall risk, age, weight, renal function, comedications, procedures) that need special consideration when managing older adults."	( Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis Andreotti, F; Collet, JP; Geisler, T; Gigante, B; Gorog, DA; Halvorsen, S; Lip, GYH; Morais, J; Navarese, EP; Patrono, C; Rocca, B; Rubboli, A; Sibbing, D; Storey, RF; Verheugt, FWA; Vilahur, G, 2023)	1.09
" In stratified analyses by COX2 status, significant associations of these medications with breast cancer risk were observed for dosage of aspirin among current users in COX2- tumors (OR for > 5 tablets per week vs."	( Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression. Colditz, G; Eliassen, AH; Rosner, B; Schedin, P; Tamimi, RM; Wijayabahu, A; Yaghjyan, L, 2022)	1.27
"Cardiovascular (CV) disease prevention with low-dose aspirin can be less effective in patients with a faster recovery of platelet (PLT) cyclooxygenase (COX)-1 activity during the 24-hour dosing interval."	( Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen. Abbonante, V; Auciello, R; Balduini, A; Bologna, G; Camera, M; Ciotti, S; Cipollone, F; Cufaro, MC; Del Boccio, P; Di Castelnuovo, A; Hoffmeister, KM; Lanuti, P; Lee-Sundlov, M; Liani, R; Luongo, M; Pieragostino, D; Porro, B; Recchiuti, A; Santilli, F; Simeone, P; Tremoli, E; Tripaldi, R, 2023)	1.37
" The 100 mg dosage was predominant in patients with ischemic heart disease with (64%) and without (64%) angina, as well as those with myocardial infarction (61."	( Adherence to European guidelines for the use of aspirin in primary health care. Corte-Real, S; Dantas, A; Ferreira Moita, C; Marau, G, 2023)	1.17
" In both primary and secondary prevention, the 150 mg dosage was predominant."	( Adherence to European guidelines for the use of aspirin in primary health care. Corte-Real, S; Dantas, A; Ferreira Moita, C; Marau, G, 2023)	1.17
"Analytical techniques must be sensitive, specific, and accurate to assess the active pharmaceutical ingredients in pharmaceutical dosage forms."	( An effective and stability-indicating method development and optimization utilizing the Box-Behnken design for the simultaneous determination of acetaminophen, caffeine, and aspirin in tablet formulation. Ettaboina, SK; Gundla, R; Katari, NK; Muchakayala, SK; Satheesh, B; Yenda, P, 2023)	1.1
" Guidelines are also inconsistent in the recommendation of routine ASA use for primary prevention of CVD, but advocate dosing as a "one-size-fits-all" approach."	( Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study). Hutchinson, D; Kim, K; Kirkham, A; Kroencke, R; Munger, M; Nay, I; Rondina, M; Tolley, ND; Trujillo, T, 2023)	0.91
"An intention-to-treat, double-blind, randomized, controlled, clinical trial comparing three treatment arms of ASA 81, 325, and 500 mg daily dosed for 14 days were evenly randomized across the dosing categories to measure the impact of dosing by body mass index (BMI) (20-24."	( Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study). Hutchinson, D; Kim, K; Kirkham, A; Kroencke, R; Munger, M; Nay, I; Rondina, M; Tolley, ND; Trujillo, T, 2023)	0.91
"Change in ASA reactivity unit (ARU), salicylate levels, and thromboxane B2 (TxB2) levels were measured across BMI dosing categories and time."	( Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study). Hutchinson, D; Kim, K; Kirkham, A; Kroencke, R; Munger, M; Nay, I; Rondina, M; Tolley, ND; Trujillo, T, 2023)	0.91
" In this limited series, apixaban paired with a level-based dosing regimen and low-dose aspirin provided safe and effective antithrombosis with only one hemocompatibility-related event related to medication non-adherence."	( Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device. Blume, ED; Cetatoiu, MA; Daly, KP; Esteso, P; Fynn-Thompson, F; Hawkins, B; Kobayashi, RL; VanderPluym, C; Ventresco, C, 2023)	1.13
" Finally, a spatially segmented antisolvent dosing method was also evaluated."	( Improvement of drug processability in a connected continuous crystallizer system using formulation additive. Galata, DL; Gyürkés, M; Marosi, G; Nagy, B; Nagy, ZK; Pataki, H; Pusztai, É; Stoffán, G; Szilágyi, B; Tacsi, K, 2023)	0.91
"In women with a history of pre-eclampsia, aspirin initiation during a second pregnancy and adherence to the prescribed dosage were largely insufficient, especially for women experiencing social deprivation."	( Aspirin for the Prevention of Early and Severe Pre-Eclampsia Recurrence: A Real-World Population-Based Study. Blacher, J; Deneux-Tharaux, C; Gabet, A; Grave, C; Kretz, S; Lailler, G; Olie, V; Plu-Bureau, G; Regnault, N; Tsatsaris, V, 2023)	2.62
"A dosage of 100 mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation, did not increase the risk of potential bleeding and PPH regardless of the maternal characteristic."	( Low-dose aspirin in the prevention of pre-eclampsia in China: postpartum hemorrhage in subgroups of women according to their characteristics and potential bleeding risk. Chen, J; Huai, J; Li, B; Lin, L; Yang, H; Zhu, Y, 2023)	1.64
" In age-adjusted analyses, aspirin plus LMWH regardless of dosage was associated with significantly higher odds of live birth compared with no antithrombotic use (OR = 7."	( Management and outcomes of women with antiphospholipid syndrome during pregnancy. Adurty, S; D'Angelo, D; DeSancho, MT; Tao, JJ, 2023)	1.21
" Therefore, clinical and computational studies have proposed optimizing antihypertensive medications' dosing time (Ta)."	( Understanding the dosing-time-dependent antihypertensive effect of valsartan and aspirin through mathematical modeling. Cortés-Ríos, J; Rodriguez-Fernandez, M, 2023)	1.14
" There were 8921 cases with available weight-based dosing information."	( Medical Outcomes of Acute Aspirin Single Substance Poisoning in Pediatric Patients. Anderson, BD; Biggs, JM; Daniel-McCalla, SN; Kishk, OA; Leonard, J; Morgan, JA; Parbuoni, KA, 2023)	1.21
" The AAS results showed that copper levels in rabbit blood plasma were increased with increasing the dosage of CAS, but still remains under the safer limit, which was twofold higher than the reported safe limit."	( Determination of Copper at Extended Dose Levels of Copper (II)-acetylsalicylate and Pharmacokinetics Applications. Amin, M; Hussain, MA; Khan, H; Khan, SH; Naeem-Ul-Hassan, M; Sher, M, 2023)	0.91
"To systematically investigate if aspirin (ASA), used as venous thromboembolism (VTE) prophylaxis, plays a role in the prevention of heterotopic ossification (HO) following total hip arthroplasty (THA) and if ASA dosage impacted the rate of HO."	( Role of aspirin in the prevention of heterotopic ossification following total hip replacement: a systematic review and meta-analysis. Chen, G; Li, H; Mao, Z; Wang, Y; Wang, Z; Yao, Q; Yu, M, )	0.85
" Additionally, combined HO incidences were compared according to ASA dosage (a regular dose of 325 bid vs."	( Role of aspirin in the prevention of heterotopic ossification following total hip replacement: a systematic review and meta-analysis. Chen, G; Li, H; Mao, Z; Wang, Y; Wang, Z; Yao, Q; Yu, M, )	0.57
" More well-designed trials with long-term follow-ups are encouraged to confirm the current findings and to investigate the effect of ASA dosage on HO reduction."	( Role of aspirin in the prevention of heterotopic ossification following total hip replacement: a systematic review and meta-analysis. Chen, G; Li, H; Mao, Z; Wang, Y; Wang, Z; Yao, Q; Yu, M, )	0.57
"The meta-analysis was conducted from February to May 2021 and comprised search on PubMed and Cochrane Library databases for randomised controlled trials consisting of previously hypertensive women aged 18-55 years, aspirin dosage range 60-100mg, and a comparison between aspirin and placebo groups."	( Role of aspirin in the prevention of preeclampsia in previously hypertensive pregnant women: A Meta-Analysis. Ashraf Jahangeer, SM; Khan, AA; Mansoor, M, 2023)	1.53
" The Royal College of Obstetricians and Gynaecologists recommends 150 mg of aspirin daily, and the National Institute of Health and Care Excellence guidelines suggest risk stratification with a dosage of 75 mg for those at moderate risk of preeclampsia and 150 mg for those at high risk of preeclampsia."	( Low-dose aspirin therapy for the prevention of preeclampsia: time to reconsider our recommendations? Abuhamad, A; Hage Diab, Y; Horgan, R; Saade, G; Waller, J, 2023)	1.56
" Large trials assessing use in the primary prevention setting and optimal dosing regimens were studied in the late 1990s and early 2000s."	( Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention. Bortfeld, KS; Brown, MT; Sperling, LS; Wenger, NK, 2023)	1.22
"The optimal dosing of aspirin (ASA) monotherapy for prophylaxis after total joint arthroplasty is debatable."	( Thirty day low-dose versus regular-dose aspirin for venous thromboembolism prophylaxis in primary total joint arthroplasty. Baig, S; Bowen, S; Cohen, D; Duke, AJ; Komatsu, DE; Nicholson, J, )	0.71
"This study aimed to compare 2 aspirin dosage regimens for the prevention of preterm preeclampsia (PE): 75 to 81 mg vs 150 to 162 mg taken daily starting in the first trimester of pregnancy."	( Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. Bujold, E; Foisy, MA; Ghesquiere, L; Guerby, P; Kumar, N; Marchant, I; Roberge, S; Zare, M, 2023)	1.6
"The inclusion criteria were randomized controlled trials that compared the effect of 2 aspirin dosage regimens during pregnancy for the prevention of PE initiated in the first trimester of pregnancy."	( Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. Bujold, E; Foisy, MA; Ghesquiere, L; Guerby, P; Kumar, N; Marchant, I; Roberge, S; Zare, M, 2023)	1.54
"When initiated in the first trimester of pregnancy, an aspirin dosage of 150 to 162 mg daily was associated with a lower risk of preterm PE than an aspirin dosage of 75 to 81 mg daily."	( Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. Bujold, E; Foisy, MA; Ghesquiere, L; Guerby, P; Kumar, N; Marchant, I; Roberge, S; Zare, M, 2023)	1.56
" This suggests that use of LDA outside the recommended guidelines should be cautioned and further investigation is needed to determine its ideal dosing and timing of discontinuation."	( Low-Dose Aspirin during Pregnancy and Postpartum Bleeding. Culhane, JF; Lundsberg, LS; Merriam, AA; Partridge, C; Reddy, UM; Son, M; White, KJ, 2023)	1.33
" In this secondary analysis from the ADAPTABLE trial, we studied the effectiveness and safety of ASA dosing in patients with a history of chronic kidney disease (CKD)."	( Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. Anderson, RD; Benziger, CP; Bradley, SM; DeWalt, DA; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kim, H; Knowlton, KU; Mehta, H; Muñoz, D; Pepine, CJ; Polonsky, TS; Rothman, RL; Stebbins, A; Whittle, J; Wruck, LM; Zhou, L, 2023)	1.17
" Coffee drinkers had fewer problems swallowing but dosage and duration of coffee intake were not associated with motor or non-motor symptoms."	( Lifestyle factors and clinical severity of Parkinson's disease. Gabbert, C; Grünewald, A; Kasten, M; Klein, C; König, IR; Lüth, T; Trinh, J, 2023)	0.91
" This study aimed to assess the relationship between aspirin use and BC risk, and to determine if there is a dose-response relationship between aspirin and BC risk."	( Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies. Bakierzynska, M; Corrigan, M; Cullinane, MC; Redmond, HP, 2023)	1.53
" The hazard of nonadherence to the assigned aspirin dosage was 46% higher in noninternet participants than internet participants."	( Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. Benziger, CP; Effron, MB; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jones, WS; Kripalani, S; Mulder, H; Muñoz, D; Polonsky, TS; Robertson, HR; Rothman, RL; Sharlow, AG; Shen, R; VanWormer, JJ; Weissler, EH; Whittle, J; Wruck, L, 2023)	1.17
" The purpose of this study was to assess the effect of aspirin on clinical outcomes in patients with PCa in a meta-analysis and to explore the possible dose-response relationship."	( Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies. Feng, L; Gao, J; Guo, X; Jiang, Y; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Z, 2023)	1.56
" Furthermore, the impact of aspirin on PCa occurrence was found to be dependent on both dosage and duration."	( Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies. Feng, L; Gao, J; Guo, X; Jiang, Y; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Z, 2023)	1.61
" Further studies assessing the optimum preoperative aspirin duration and dosage to meet the best benefit quantity for patients with planned joint arthroplasties are suggested."	( The impact of long-term aspirin use on the patients undergoing shoulder arthroplasty. Cui, Y; Li, X; Liang, C; Liang, F; Mao, X; Shi, D; Xie, H; Yang, Q, 2023)	1.47